Number O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
lymphocytes O O
and O O
their O O
sensitivity O O
to O O
hormone O O
action O O
. O O

The O O
study O O
demonstrated O O
a O O
decreased O O
level O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
GR B B_PROTEIN[GENE]/B_DISEASE
) O O
in O O
peripheral O O
blood O O
lymphocytes O O
from O O
hypercholesterolemic O O
subjects O O
, O O
and O O
an O O
elevated O O
level O O
in O O
patients O O
with O O
acute O O
myocardial O O
infarction O O
. O O

Treatment O O
with O O
I-hydroxyvitamin O O
D3 O O
( O O
1-1.5 O O
mg O O
daily O O
, O O
within O O
4 O O
weeks O O
) O O
led O O
to O O
normalization O O
of O O
total O O
and O O
ionized O O
form O O
of O O
Ca2+ O O
and O O
of O O
25 O O
( O O
OH O O
) O O
D O O
, O O
but O O
did O O
not O O
affect O O
the O O
PTH O O
content O O
in O O
blood O O
. O O

Concentration O O
of O O
the O O
receptors B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
1.25 O O
( O O
OH O O
) O O
2D3 O O
was O O
elevated O O
up O O
to O O
39.7 O O
fmole/mg O O
after O O
I O O
week O O
of O O
the O O
treatment O O
, O O
whereas O O
it O O
was O O
decreased O O
to O O
the O O
initial O O
level O O
24.8 O O
fmole/mg O O
within O O
4 O O
weeks O O
; O O
simultaneous O O
alteration O O
in O O
the O O
cAMP O O
content O O
was O O
observed O O
in O O
lymphocytes O O
. O O

To O O
investigate O O
whether O O
the O O
tumor O O
expression O O
of O O
beta-2-microglobulin B B_GENE
( O O
beta B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
could O O
serve O O
as O O
a O O
marker O O
of O O
tumor O O
biologic O O
behavior O O
, O O
the O O
authors O O
studied O O
specimens O O
of O O
breast O O
carcinomas O O
from O O
60 O O
consecutive O O
female O O
patients O O
. O O

Presence O O
of O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
analyzed O O
by O O
immunohistochemistry O O
. O O

No O O
significant O O
correlations O O
were O O
found O O
between O O
tumor B B_GENE
beta I I_GENE
2-M I I_GENE
expression O O
and O O
several O O
histologic O O
attributes O O
such O O
as O O
type O O
, O O
histologic O O
and O O
nuclear O O
grades O O
, O O
mitotic O O
index O O
, O O
necrosis O O
, O O
vascular O O
invasion O O
, O O
and O O
lymphocytic O O
infiltration O O
. O O

However O O
, O O
there O O
was O O
a O O
significantly O O
positive O O
association O O
between O O
tumor B B_GENE
beta I I_GENE
2-M I I_GENE
expression O O
and O O
the O O
degree O O
of O O
lymphocytic O O
infiltration O O
in O O
the O O
tumor O O
tissue O O
. O O

Beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum O O
levels O O
were O O
determined O O
by O O
an O O
enzyme-linked O O
immunosorbent O O
assay O O
in O O
samples O O
from O O
22 O O
of O O
the O O
above O O
women O O
. O O

[ O O
Preliminary O O
observation O O
of O O
level O O
free-form B B_GENE
E I I_GENE
receptor I I_GENE
levels O O
in O O
serum O O
of O O
normal O O
childbearing-aged O O
and O O
pregnant O O
women O O
] O O

The O O
level O O
of O O
sE B B_GENE/B_DISEASE
was O O
significantly O O
decreased O O
during O O
the O O
first O O
trimester O O
, O O
slightly O O
higher O O
in O O
the O O
second O O
trimester O O
, O O
and O O
recovered O O
to O O
normal O O
in O O
the O O
third O O
trimester O O
. O O

The O O
level O O
remained O O
lower O O
in O O
29 O O
PIH O O
women O O
but O O
appeared O O
higher O O
in O O
overdue O O
pregnancies O O
as O O
compared O O
with O O
the O O
normal O O
3rd O O
trimester O O
range O O
. O O

The O O
results O O
indicate O O
that O O
there O O
is O O
a O O
relationship O O
between O O
a O O
change O O
in O O
T O O
cell O O
function O O
and O O
pregnancy O O
. O O

Kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B-specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
role O O
in O O
the O O
regulation O O
of O O
human B B_GENE
interleukin-2 I I_GENE
gene I I_GENE
expression O O
. O O

Transcriptional O O
activation O O
of O O
the O O
human B B_GENE
interleukin-2 I I_GENE
( I I_GENE
IL-2 I I_GENE
) I I_GENE
gene I I_GENE
, O O
like O O
induction O O
of O O
the O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-2R I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
type O O
1 O O
human O O
immunodeficiency O O
virus O O
( O O
HIV-1 O O
) O O
, O O
is O O
shown O O
to O O
be O O
modulated O O
by O O
a O O
kappa B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B-like I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancer I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
kappa B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B-specific I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
80 O O
to O O
90 O O
and O O
50 O O
to O O
55 O O
kilodaltons O O
) O O
similarly O O
interact O O
with O O
the O O
functional O O
kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
enhancer I I_GENE/I_LOCATION
present O O
in O O
the O O
IL-2R B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
alpha I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
data O O
suggest O O
that O O
these O O
kappa B B_GENE/B_LOCATION
B-specific I I_GENE/I_LOCATION
proteins I I_GENE/I_LOCATION
have O O
a O O
role O O
in O O
the O O
coordinate O O
regulation O O
of O O
this O O
growth O O
factor-growth O O
factor O O
receptor O O
gene O O
system O O
that O O
controls O O
T O O
cell O O
proliferation O O
. O O

Novel O O
region O O
within O O
the O O
V B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
responsible O O
for O O
tissue O O
and O O
stage-specific O O
expression O O
of O O
immunoglobulin B B_GENE
genes I I_GENE
in O O
human O O
lymphoid O O
neoplasms O O
. O O

Immunoglobulin B B_PERSON/B_GENE
gene-specific I I_PERSON/I_GENE
transacting I I_PERSON/I_GENE
factors I I_PERSON/I_GENE
have O O
been O O
shown O O
to O O
play O O
a O O
role O O
in O O
lymphoid O O
tissue-specific O O
expression O O
of O O
immunoglobulin B B_GENE
genes I I_GENE
. O O

The O O
role O O
of O O
these O O
factors O O
in O O
B-cell O O
differentiation O O
and O O
stage-specific O O
expression O O
of O O
these O O
genes O O
is O O
, O O
however O O
, O O
not O O
fully O O
understood O O
. O O

We O O
have O O
used O O
a O O
model O O
of O O
human O O
lymphoid O O
neoplasia O O
to O O
address O O
this O O
question O O
. O O

Different O O
fragments O O
of O O
unrearranged B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
human I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variable I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
immunoglobulin B B_GENE
kappa I I_GENE
gene I I_GENE
( O O
V B B_GENE
kappa I I_GENE
) O O
were O O
used O O
for O O
cell-free O O
in O O
vitro O O
transcription O O
and O O
DNA O O
mobility O O
shift O O
assays O O
. O O

Previously O O
described O O
enhancement O O
of O O
in O O
vitro O O
transcription O O
that O O
was O O
only O O
seen O O
with O O
nuclear O O
extracts O O
derived O O
from O O
B-cell O O
neoplasms O O
corresponding O O
to O O
the O O
late O O
stages O O
of O O
B-cell O O
differentiation O O
was O O
shown O O
to O O
be O O
dependent O O
on O O
the O O
actions O O
of O O
these O O
factor O O
( O O
s O O
) O O
on O O
the O O
DNA O O
region O O
within O O
the O O
V B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
region O O
is O O
located O O
within O O
the O O
920 O O
bp O O
fragment O O
located O O
210 O O
bp O O
upstream O O
from O O
the O O
coding O O
region O O
and O O
this O O
fragment O O
represents O O
a O O
possible O O
novel O O
DNA O O
region O O
, O O
which O O
plays O O
a O O
role O O
in O O
the O O
stage- O O
and O O
tissue-specific O O
expression O O
of O O
immunoglobulin B B_GENE
genes I I_GENE
. O O

[ O O
Determination O O
of O O
the O O
sensitivity O O
to O O
glucocorticoids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
vitro O O
] O O

A O O
modified O O
method O O
for O O
the O O
determination O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
human O O
lymphocytes O O
is O O
suggested O O
. O O

The O O
modification O O
saves O O
time O O
and O O
money O O
, O O
limits O O
the O O
range O O
of O O
the O O
data O O
variations O O
, O O
and O O
makes O O
use O O
of O O
a O O
lesser O O
volume O O
of O O
blood O O
. O O

Dynamic O O
studies O O
have O O
not O O
shown O O
any O O
statistically O O
significant O O
changes O O
in O O
the O O
specific O O
binding O O
values O O
. O O

Octamer-binding B B_GENE
proteins I I_GENE
from O O
B O O
or O O
HeLa O O
cells O O
stimulate O O
transcription O O
of O O
the O O
immunoglobulin B B_GENE
heavy-chain I I_GENE
promoter I I_GENE
in O O
vitro O O
. O O

The O O
B-cell O O
-type O O
specificity O O
of O O
the O O
immunoglobulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Ig B B_PROTEIN[GENE]/B_LOCATION
) O O
heavy-chain O O
and O O
light-chain O O
promoters O O
is O O
mediated O O
by O O
an O O
octanucleotide B B_GENE
( I I_GENE
OCTA I I_GENE
) I I_GENE
element I I_GENE
, O O
ATGCAAAT O O
, O O
that O O
is O O
also O O
a O O
functional O O
component O O
of O O
other O O
RNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O O
as O O
snRNA O O
and O O
histone O O
H2B O O
promoters O O
. O O

NF-A1 B B_GENE
is O O
present O O
in O O
a O O
variety O O
of O O
cell O O
types O O
, O O
whereas O O
the O O
presence O O
of O O
NF-A2 B B_GENE
is O O
essentially O O
confined O O
to O O
B O O
cells O O
, O O
leading O O
to O O
the O O
hypothesis O O
that O O
NF-A2 B B_GENE
activates O O
cell-type-specific O O
transcription O O
of O O
the O O
Ig B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
and O O
NF-A1 B B_GENE/B_LOCATION
mediates O O
the O O
other O O
responses O O
of O O
the O O
OCTA B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
element I B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Extracts O O
of O O
the O O
B-cell O O
line O O
, O O
BJA-B O O
, O O
contain O O
high O O
levels O O
of O O
NF-A2 B B_GENE
and O O
specifically O O
transcribe O O
Ig B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O O
, O O
extracts O O
from O O
HeLa O O
cells O O
transcribed O O
the O O
Ig B B_GENE
promoter I I_GENE
poorly O O
. O O

Surprisingly O O
, O O
addition O O
of O O
either O O
affinity-enriched O O
NF-A2 O O
or O O
NF-A1 O O
to O O
either O O
a O O
HeLa O O
extract O O
or O O
a O O
partially O O
purified O O
reaction O O
system O O
specifically O O
stimulates O O
the O O
Ig B B_GENE
promoter I I_GENE
. O O

This O O
suggests O O
that O O
the O O
constitutive O O
OCTA-binding B B_GENE
factor I I_GENE
NF-A1 I I_GENE
can O O
activate O O
transcription O O
of O O
the O O
Ig B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
and O O
that O O
B-cell O O
-specific O O
transcription O O
of O O
this O O
promoter O O
, O O
at O O
least O O
in O O
vitro O O
, O O
is O O
partially O O
due O O
to O O
a O O
quantitative O O
difference O O
in O O
the O O
amount O O
of O O
OCTA-binding B B_GENE
protein I I_GENE
. O O

Because O O
NF-A1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
stimulate O O
Ig B B_GENE/B_DISEASE
transcription O O
, O O
the O O
inability O O
of O O
this O O
factor O O
to O O
activate O O
in O O
vivo O O
the O O
Ig B B_GENE
promoter I I_GENE
to O O
the O O
same O O
degree O O
as O O
the O O
snRNA B B_GENE/B_MEASURE
promoters I I_GENE/I_MEASURE
probably O O
reflects O O
a O O
difference O O
in O O
the O O
context O O
of O O
the O O
OCTA B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
element I B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
these O O
two O O
types O O
of O O
promoters B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Molecules O O
involved O O
in O O
the O O
antigen O O
receptor-dependent O O
regulation O O
of O O
early B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
T I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cell I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
investigated O O
with O O
the O O
use O O
of O O
functional O O
sequences O O
of O O
the O O
T B B_GENE/B_LOCATION
cell I I_GENE/I_LOCATION
activation-specific I I_GENE/I_LOCATION
enhancer I I_GENE/I_LOCATION
of O O
interleukin-2 B B_GENE
( O O
IL-2 B B_GENE
) O O
. O O

One O O
of O O
these O O
sequences O O
forms O O
a O O
protein O O
complex O O
, O O
NFAT-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
specifically O O
with O O
nuclear O O
extracts O O
of O O
activated O O
T O O
cells O O
. O O

This O O
complex O O
appeared O O
10 O O
to O O
25 O O
minutes O O
before O O
the O O
activation O O
of O O
the O O
IL-2 B B_GENE
gene I I_GENE
. O O

Studies O O
with O O
inhibitors O O
of O O
protein O O
synthesis O O
indicated O O
that O O
the O O
time O O
of O O
synthesis O O
of O O
the O O
activator O O
of O O
the O O
IL-2 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
in O O
Jurkat O O
T O O
cells O O
corresponds O O
to O O
the O O
time O O
of O O
appearance O O
of O O
NFAT-1 B B_GENE
. O O

NFAT-1 B B_GENE
, O O
or O O
a O O
very O O
similar O O
protein O O
, O O
bound O O
functional O O
sequences O O
of O O
the O O
long B B_GENE
terminal I I_GENE
repeat I I_GENE
( O O
LTR B B_GENE/B_DISEASE
) O O
of O O
the O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
; O O
the O O
LTR B B_GENE/B_DISEASE
of O O
this O O
virus O O
is O O
known O O
to O O
be O O
stimulated O O
during O O
early O O
T O O
cell O O
activation O O
. O O

The O O
binding B B_GENE
site I I_GENE
for O O
this O O
complex O O
activated O O
a O O
linked O O
promoter O O
after O O
transfection O O
into O O
antigen O O
receptor-activated O O
T O O
cells O O
but O O
not O O
other O O
cell O O
types O O
. O O

These O O
characteristics O O
suggest O O
that O O
NFAT-1 B B_GENE
transmits O O
signals O O
initiated O O
at O O
the O O
T B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
cell I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
antigen I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Characterization O O
of O O
thyroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
IM-9 O O
lymphocytes O O
. O O

Although O O
putatively O O
identified O O
more O O
than O O
10 O O
years O O
ago O O
, O O
thyroid B B_GENE/B_BIO
hormone I I_GENE/I_BIO
receptors I I_GENE/I_BIO
in O O
human O O
tissues O O
remain O O
poorly O O
characterized O O
. O O

As O O
a O O
first O O
step O O
towards O O
understanding O O
the O O
mechanism O O
of O O
thyroid O O
hormone O O
action O O
in O O
man O O
we O O
have O O
characterized O O
T3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
nuclei O O
of O O
the O O
human O O
lymphoblastoid O O
line O O
, O O
IM-9 O O
cells O O
. O O

In O O
whole O O
cell O O
experiments O O
at O O
37 O O
degrees O O
C O O
, O O
nuclear O O
binding O O
of O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
125I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
T3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
saturable O O
( O O
Kd O O
34 O O
+/- O O
6 O O
pmol/l O O
) O O
and O O
of O O
finite O O
capacity O O
( O O
approximately O O
equal O O
to O O
350 O O
sites/cell O O
) O O
. O O

The O O
binding B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
sites I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
were O O
extracted O O
from O O
a O O
nuclear O O
pellet O O
by O O
treatment O O
with O O
0.4 O O
mol/l O O
KCl O O
and O O
sonication O O
. O O

Rectilinear O O
Scatchard O O
plots O O
were O O
obtained O O
only O O
when O O
the O O
hydroxyapatite O O
was O O
washed O O
with O O
a O O
buffer O O
containing O O
0.5 O O
% O O
Triton O O
X-100 O O
. O O

The O O
same O O
assay O O
system O O
was O O
used O O
to O O
determine O O
the O O
hierarchy O O
of O O
affinities O O
for O O
a O O
range O O
of O O
natural O O
and O O
synthetic O O
analogues O O
. O O

Definition O O
of O O
T-cell B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
interact O O
with O O
a O O
3'-silencer B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
CD4+ B B_GENE
T-cell I I_GENE
gene I I_GENE
Rpt-1 I I_GENE
. O O

Analysis O O
of O O
the O O
region O O
3 O O
' O O
to O O
the O O
CD4+ B B_GENE/B_LOCATION
T-cell I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
Rpt-1 I I_GENE/I_LOCATION
( O O
encoding O O
regulatory O O
protein O O
T-lymphocyte B B_PROTEIN[GENE]/B_MEASURE
1 I I_PROTEIN[GENE]/I_MEASURE
) O O
led O O
to O O
the O O
definition O O
of O O
a O O
silencer B B_GENE
element I I_GENE
that O O
inhibits O O
heterologous B B_GENE
gene I I_GENE
expression O O
in O O
certain O O
CD4+ O O
T-cell O O
lines O O
but O O
not O O
in O O
B-cell O O
or O O
non-lymphoid O O
cell O O
lines O O
. O O

Functional O O
silencer B B_GENE
activity O O
in O O
vivo O O
was O O
associated O O
with O O
the O O
presence O O
of O O
a O O
specific O O
silencer-DNA-protein B B_GENE
complex I I_GENE
in O O
electrophoretic O O
mobility O O
shift O O
assays O O
with O O
T-cell O O
extracts O O
. O O

Formation O O
of O O
this O O
complex O O
was O O
selectively O O
inhibited O O
by O O
the O O
region O O
in O O
HIV-1 B B_BIO/B_GENE
containing O O
a O O
silencer B B_GENE
element I I_GENE
. O O

We O O
discuss O O
the O O
possibility O O
that O O
DNA-binding B B_DISEASE/B_GENE
factors I B_DISEASE/I_GENE
may O O
coregulate O O
HIV-1 O O
and O O
Rpt-1 O O
gene O O
expression O O
through O O
a O O
common O O
transcriptional B B_GENE/B_LOCATION
silencer I B_GENE/I_LOCATION
element I B_GENE/I_LOCATION
. O O

Congenital O O
immunodeficiencies O O
associated O O
with O O
absence O O
of O O
HLA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
lymphocytes O O
result O O
from O O
distinct O O
mutations O O
in O O
trans-acting B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Coordinate O O
regulation O O
of O O
HLA B B_GENE/B_BIO
class I I_GENE/I_BIO
II I I_GENE/I_BIO
gene I I_GENE/I_BIO
expression O O
during O O
development O O
and O O
coinduction O O
of O O
class B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
soluble B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggests O O
that O O
common O O
trans-acting B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
s O O
) O O
control O O
expression O O
of O O
these O O
genes O O
. O O

In O O
B-lymphoblastoid O O
cell O O
lines O O
derived O O
from O O
two O O
independent O O
class O O
II-deficient O O
bare O O
lymphocyte O O
syndrome O O
patients O O
, O O
we O O
observed O O
a O O
drastic O O
decrease O O
in O O
transcription O O
rates O O
of O O
the O O
class B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

When O O
these O O
cell O O
lines O O
are O O
fused O O
, O O
class B B_GENE/B_PERSON
II I I_GENE/I_PERSON
genes I I_GENE/I_PERSON
are O O
reexpressed O O
, O O
indicating O O
that O O
immunodeficiencies O O
in O O
bare O O
lymphocyte O O
syndrome O O
patients O O
are O O
the O O
result O O
of O O
two O O
distinct O O
mutations O O
. O O

Further O O
studies O O
show O O
that O O
genes O O
governing O O
the O O
expression O O
of O O
class B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fall O O
into O O
at O O
least O O
three O O
complementation O O
groups O O
; O O
two O O
of O O
these O O
were O O
previously O O
unidentified O O
in O O
mutant O O
cell O O
lines O O
generated O O
in O O
vitro O O
. O O

In O O
addition O O
, O O
we O O
report O O
the O O
identification O O
of O O
two O O
discrete O O
complexes O O
, O O
NFX1.1 B B_GENE
and O O
NFX1.2 B B_GENE
, O O
that O O
bind O O
to O O
the O O
DRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consensus I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Though O O
the O O
mutation O O
in O O
at O O
least O O
one O O
mutant O O
line O O
generated O O
in O O
vitro O O
( O O
RJ2.2.5 O O
) O O
affects O O
products O O
functioning O O
via O O
interaction O O
with O O
the O O
X B B_GENE
box I I_GENE
, O O
clear O O
alterations O O
in O O
either O O
NFX1.1 B B_GENE/B_DISEASE
or O O
NFX1.2 B B_GENE
are O O
not O O
found O O
in O O
any O O
of O O
the O O
mutant O O
cell O O
lines O O
. O O

In O O
vivo O O
responsiveness O O
to O O
glucocorticoid O O
correlated O O
with O O
glucocorticoid B B_GENE
receptor I I_GENE
content O O
in O O
peripheral O O
blood O O
leukocytes O O
in O O
normal O O
humans O O
. O O

Dexamethasone O O
loading O O
tests O O
( O O
0.1 O O
mg O O
dexamethasone/kg O O
, O O
iv O O
) O O
were O O
performed O O
in O O
18 O O
normal O O
males O O
to O O
evaluate O O
the O O
individual O O
responsiveness O O
to O O
glucocorticoid O O
. O O

There O O
were O O
inter-individual O O
differences O O
in O O
increase O O
in O O
peripheral O O
blood O O
polymorphonuclear O O
leukocyte O O
count O O
, O O
decrease O O
in O O
peripheral O O
blood O O
lymphocyte O O
count O O
, O O
and O O
increase O O
in O O
plasma O O
free O O
fatty O O
acids O O
levels O O
after O O
dexamethasone O O
injection O O
. O O

Simultaneous O O
measurements O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
content O O
by O O
whole-cell O O
assay O O
revealed O O
that O O
glucocorticoid B B_GENE
receptor I I_GENE
content O O
in O O
polymorphonuclear O O
leukocytes O O
linearly O O
correlated O O
with O O
that O O
in O O
the O O
corresponding O O
lymphocytes O O
( O O
r O O
= O O
0.9482 O O
, O O
p O O
less O O
than O O
0.0001 O O
) O O
. O O

There O O
were O O
also O O
significant O O
correlations O O
between O O
the O O
maximum O O
increase O O
in O O
polymorphonuclear O O
leukocytes O O
and O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O O
in O O
polymorphonuclear O O
leukocytes O O
( O O
r O O
= O O
0.7239 O O
, O O
p O O
less O O
than O O
0.0007 O O
) O O
, O O
and O O
between O O
the O O
maximum O O
decrease O O
in O O
lymphocytes O O
and O O
glucocorticoid B B_GENE
receptor I I_GENE
content O O
in O O
lymphocytes O O
( O O
r O O
= O O
0.7703 O O
, O O
p O O
less O O
than O O
0.0002 O O
) O O
. O O

These O O
results O O
suggest O O
that O O
individual O O
differences O O
are O O
preserved O O
both O O
in O O
glucocorticoid O O
responsiveness O O
and O O
in O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O O
in O O
peripheral O O
blood O O
leukocytes O O
in O O
normal O O
humans O O
. O O

The O O
level O O
of O O
estradiol B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
cytosol O O
of O O
mononuclear O O
cells O O
was O O
significantly O O
lower O O
in O O
asymptomatic O O
HBV O O
carriers O O
and O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
, O O
compared O O
to O O
normal O O
controls O O
. O O

This O O
low O O
level O O
of O O
cytosol O O
estradiol B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
was O O
increased O O
by O O
the O O
administration O O
of O O
IFN-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
addition O O
, O O
when O O
peripheral O O
blood O O
mononuclear O O
cells O O
from O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
were O O
incubated O O
with O O
IFN-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
vitro O O
, O O
the O O
level O O
of O O
cytosol O O
estradiol B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
increased O O
by O O
increasing O O
the O O
concentration O O
of O O
IFN-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

We O O
previously O O
reported O O
that O O
the O O
response O O
of O O
mononuclear O O
cells O O
to O O
estrogen O O
is O O
impaired O O
in O O
HBV O O
carriers O O
, O O
and O O
our O O
present O O
results O O
suggested O O
that O O
this O O
may O O
be O O
due O O
to O O
the O O
low O O
level O O
of O O
estradiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
cytosol O O
of O O
mononuclear O O
cells O O
. O O

Association O O
of O O
increased O O
lytic O O
effector O O
cell O O
function O O
with O O
high O O
estrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
tumor-bearing O O
patients O O
with O O
breast O O
cancer O O
. O O

Tumor-bearing O O
patients O O
with O O
breast O O
cancer O O
had O O
a O O
significant O O
increase O O
in O O
NK O O
activity O O
and O O
in O O
LDCC O O
, O O
as O O
compared O O
with O O
healthy O O
control O O
individuals O O
. O O

Thus O O
, O O
ER B B_GENE
levels O O
greater O O
than O O
31 O O
fmol/mg O O
might O O
be O O
associated O O
with O O
increased O O
cytotoxic O O
effector O O
cell O O
function O O
in O O
tumor-bearing O O
patients O O
with O O
breast O O
cancer O O
. O O

Properties O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
Epstein-Barr O O
virus-transformed O O
lymphocytes O O
from O O
patients O O
with O O
familial O O
cortisol O O
resistance O O
. O O

In O O
a O O
previous O O
report O O
of O O
two O O
patients O O
with O O
familial O O
glucocorticoid O O
resistance O O
due O O
to O O
reduced O O
numbers O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GR B B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
we O O
have O O
shown O O
decreased O O
numbers O O
of O O
GR B B_PROTEIN[GENE]/B_DISEASE
in O O
peripheral O O
mononuclear O O
cells O O
and O O
cultured O O
fibroblasts O O
but O O
normal O O
affinity O O
of O O
GR B B_PROTEIN[GENE]/B_DISEASE
in O O
both O O
patients O O
. O O

In O O
this O O
study O O
, O O
peripheral O O
lymphocytes O O
from O O
these O O
patients O O
, O O
one O O
patient O O
's O O
son O O
and O O
daughter O O
, O O
and O O
normal O O
subjects O O
were O O
transformed O O
with O O
Epstein-Barr O O
virus O O
. O O

Although O O
the O O
percentages O O
of O O
nuclear O O
bound O O
GR B B_PROTEIN[GENE]/B_DISEASE
were O O
similar O O
in O O
both O O
patients O O
and O O
normal O O
controls O O
, O O
the O O
absolute O O
amounts O O
of O O
nuclear O O
bound O O
GR B B_PROTEIN[GENE]/B_DISEASE
of O O
the O O
patients O O
were O O
about O O
one-half O O
that O O
of O O
normal O O
controls O O
. O O

Immunoglobulin B B_PERSON/B_GENE
heavy-chain I I_PERSON/I_GENE
genes I I_PERSON/I_GENE
contain O O
two O O
conserved B B_GENE/B_LOCATION
sequence I B_GENE/I_LOCATION
elements I B_GENE/I_LOCATION
5 O O
' O O
to O O
the O O
site O O
of O O
transcription O O
initiation O O
: O O
the O O
octamer O O
ATGCAAAT O O
and O O
the O O
heptamer O O
CTCATGA O O
. O O

Both O O
of O O
these O O
elements O O
are O O
required O O
for O O
normal B B_GENE
cell-specific I I_GENE
promoter I I_GENE
function O O
. O O

This O O
was O O
surprising O O
, O O
since O O
the O O
heptamer O O
and O O
octamer O O
sequence O O
motifs O O
bear O O
no O O
obvious O O
similarity O O
to O O
each O O
other O O
. O O

The O O
degeneracy O O
in O O
sequences O O
recognized O O
by O O
the O O
OTFs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
important O O
in O O
widening O O
the O O
range O O
over O O
which O O
gene O O
expression O O
can O O
be O O
modulated O O
and O O
in O O
establishing O O
cell O O
type O O
specificity O O
. O O

Identification O O
of O O
a O O
novel O O
lymphoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
octamer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
OTF-2B B B_GENE/B_LOCATION
) O O
by O O
proteolytic O O
clipping O O
bandshift O O
assay O O
( O O
PCBA O O
) O O
. O O

The O O
octamer O O
sequence O O
ATGCAAAT O O
is O O
found O O
in O O
the O O
promoters O O
of O O
immunoglobulin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ig I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heavy I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
the O O
heavy B B_GENE
chain I I_GENE
enhancer I I_GENE
and O O
is O O
a O O
major O O
determinant O O
of O O
the O O
cell O O
type O O
specific O O
expression O O
of O O
Ig B B_GENE
genes I I_GENE
in O O
B O O
cells O O
. O O

An O O
apparent O O
paradox O O
is O O
that O O
the O O
same O O
sequence O O
serves O O
as O O
an O O
upstream B B_GENE/B_TIME[MEASURE]
promoter I I_GENE/I_TIME[MEASURE]
or I I_GENE/I_TIME[MEASURE]
enhancer I I_GENE/I_TIME[MEASURE]
element I I_GENE/I_TIME[MEASURE]
in O O
a O O
variety O O
of O O
housekeeping B B_GENE/B_LOCATION
genes I I_GENE/I_LOCATION
such O O
as O O
the O O
histone B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
H2B I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
and I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
U I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
snRNA I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
genes I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
differential O O
usage O O
of O O
this O O
regulatory O O
sequence O O
motif O O
is O O
thought O O
to O O
be O O
mediated O O
by O O
different O O
species O O
of O O
octamer B B_GENE
binding I I_GENE
proteins I I_GENE
. O O

One O O
species O O
of O O
100 O O
kd O O
, O O
designated O O
OTF-1 B B_GENE
, O O
is O O
present O O
in O O
all O O
cell O O
types O O
and O O
may O O
exert O O
its O O
activating O O
function O O
only O O
when O O
it O O
can O O
interact O O
with O O
additional O O
adjacent O O
transcription B B_BIO/B_GENE
factors I I_BIO/I_GENE
. O O

The O O
lymphoid B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
specific I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
octamer I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
60 O O
kd O O
( O O
OTF-2A B B_GENE
) O O
specifically O O
stimulates O O
Ig B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
consist O O
essentially O O
of O O
a O O
TATA-box B B_GENE/B_MEASURE
and O O
an O O
octamer B B_GENE/B_LOCATION
sequence I I_GENE/I_LOCATION
upstream O O
of O O
it O O
. O O

Here O O
we O O
present O O
evidence O O
for O O
yet O O
another O O
B B B_GENE/B_MEASURE
cell I I_GENE/I_MEASURE
specific I I_GENE/I_MEASURE
octamer I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
of O O
75 O O
kd O O
( O O
OTF-2B B B_GENE
) O O
. O O

From O O
several O O
findings O O
, O O
including O O
the O O
absence O O
of O O
OTF-2B B B_GENE
( O O
but O O
not O O
OTF-2A B B_GENE
) O O
from O O
a O O
lymphocyte O O
line O O
that O O
can O O
not O O
respond O O
to O O
the O O
IgH B B_GENE
enhancer I I_GENE
, O O
we O O
propose O O
a O O
role O O
of O O
the O O
novel B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
octamer I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
long O O
range O O
activation O O
by O O
the O O
IgH B B_GENE/B_MEASURE
enhancer I I_GENE/I_MEASURE
. O O

We O O
have O O
used O O
the O O
proteolytic O O
clipping O O
bandshift O O
assay O O
( O O
PCBA O O
) O O
technique O O
to O O
distinguish O O
the O O
three O O
different O O
forms O O
found O O
in O O
B O O
cells O O
. O O

This O O
analysis O O
indicates O O
that O O
the O O
75 O O
kd-species O O
OTF-2B B B_GENE/B_MEASURE
is O O
closely O O
related O O
to O O
the O O
60 B B_MEASURE/B_GENE
kd I I_MEASURE/I_GENE
species I I_MEASURE/I_GENE
OTF-2A I I_MEASURE/I_GENE
. O O

Inhibition O O
of O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
proliferation O O
of O O
cloned O O
murine O O
T O O
cells O O
by O O
glucocorticoids O O
. O O

The O O
ability O O
of O O
glucocorticoids O O
to O O
inhibit O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IL B B_GENE
2 I I_GENE
) O O
-induced O O
T O O
cell O O
proliferation O O
in O O
two O O
cytotoxic O O
T O O
cell O O
( O O
CTL O O
) O O
clones O O
has O O
been O O
studied O O
. O O

No O O
significant O O
reduction O O
in O O
the O O
number O O
and O O
affinity O O
of O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
seen O O
after O O
6 O O
h O O
incubation O O
with O O
Dx O O
. O O

The O O
order O O
of O O
potency O O
observed O O
with O O
the O O
different O O
steroids O O
indicated O O
that O O
this O O
inhibitory O O
effect O O
was O O
mediated O O
through O O
binding O O
to O O
a O O
specific O O
glucocorticoid B B_PROTEIN[GENE]
receptor I I_PROTEIN[GENE]
. O O

Furthermore O O
, O O
supernatant O O
from O O
Dx-treated O O
CTL O O
contained O O
a O O
nondialyzable O O
factor O O
which O O
inhibited O O
DNA O O
synthesis O O
and O O
cell O O
growth O O
of O O
CTL O O
clones O O
induced O O
by O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Blocking O O
of O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O O
and O O
IL B B_GENE
2 I I_GENE
receptor I I_GENE
formation O O
have O O
been O O
proposed O O
as O O
one O O
of O O
the O O
major O O
mechanisms O O
of O O
glucocorticoid-induced O O
immunosuppression O O
. O O

Our O O
results O O
indicate O O
that O O
these O O
hormones B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
also O O
affect O O
T O O
cell O O
proliferation O O
by O O
inhibiting O O
IL B B_GENE
2 I I_GENE
activity O O
. O O

Identification O O
and O O
purification O O
of O O
a O O
human B B_GENE/B_MEASURE
immunoglobulin-enhancer-binding I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
( O O
NF-kappa B B_GENE/B_DISEASE
B I I_GENE/I_DISEASE
) O O
that O O
activates O O
transcription O O
from O O
a O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O O
. O O

The O O
enhancer-binding B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
NF-kappa I I_GENE/I_MEASURE
B I I_GENE/I_MEASURE
, O O
which O O
is O O
found O O
only O O
in O O
cells O O
that O O
transcribe O O
immunoglobulin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
light I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
has O O
been O O
purified O O
from O O
nuclear O O
extracts O O
of O O
Namalwa O O
cells O O
( O O
human O O
Burkitt O O
lymphoma O O
cells O O
) O O
by O O
sequence-specific O O
DNA O O
affinity O O
chromatography O O
. O O

The O O
purified O O
NF-kappa B B_GENE
B I I_GENE
has O O
been O O
identified O O
as O O
a O O
51-kDa B B_GENE
polypeptide I I_GENE
by O O
UV-crosslinking O O
analysis O O
. O O

`` O O
Footprint O O
'' O O
and O O
methylation-interference O O
analyses O O
have O O
shown O O
that O O
purified O O
NF-kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
has O O
a O O
binding O O
activity O O
specific O O
for O O
the O O
kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
light I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
purified O O
factor O O
activated O O
in O O
vitro O O
transcription O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
binding O O
to O O
an O O
upstream B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]

Lymphocyte O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
in O O
depression O O
: O O
normal O O
values O O
following O O
recovery O O
. O O

The O O
number O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
sites O O
in O O
lymphocytes O O
and O O
plasma O O
cortisol O O
concentrations O O
were O O
measured O O
in O O
20 O O
patients O O
who O O
had O O
recovered O O
from O O
major O O
depressive O O
disorder O O
and O O
20 O O
healthy O O
control O O
subjects O O
. O O

The O O
number O O
of O O
glucocorticoid B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O O
in O O
lymphocytes O O
from O O
the O O
recovered O O
depressed O O
group O O
was O O
not O O
significantly O O
different O O
from O O
that O O
of O O
the O O
control O O
group O O
. O O

Although O O
the O O
mean O O
plasma O O
cortisol O O
concentration O O
in O O
recovered O O
depressives O O
was O O
higher O O
than O O
in O O
control O O
subjects O O
, O O
the O O
difference O O
only O O
just O O
reached O O
significance O O
. O O

This O O
study O O
shows O O
that O O
the O O
reduction O O
in O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
numbers O O
which O O
occurs O O
during O O
acute O O
depressive O O
illness O O
does O O
not O O
persist O O
on O O
recovery O O
and O O
is O O
, O O
therefore O O
, O O
state-dependent O O
. O O

Identification O O
and O O
purification O O
of O O
a O O
human B B_PROTEIN[GENE]/B_MEASURE
lymphoid-specific I I_PROTEIN[GENE]/I_MEASURE
octamer-binding I I_PROTEIN[GENE]/I_MEASURE
protein I I_PROTEIN[GENE]/I_MEASURE
( O O
OTF-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
that O O
activates O O
transcription O O
of O O
an O O
immunoglobulin B B_GENE
promoter I I_GENE
in O O
vitro O O
. O O

It O O
is O O
of O O
particular O O
interest O O
in O O
immunoglobulin B B_SPECIES[BIO]/B_GENE
genes I I_SPECIES[BIO]/I_GENE
since O O
it O O
is O O
found O O
in O O
the O O
upstream B B_LOCATION/B_GENE
regions I I_LOCATION/I_GENE
of O O
all O O
heavy B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
light I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
the O O
heavy B B_GENE/B_LOCATION
chain I I_GENE/I_LOCATION
enhancer I I_GENE/I_LOCATION
, O O
both O O
of O O
which O O
are O O
known O O
to O O
be O O
necessary O O
for O O
cell-specific O O
expression O O
. O O

The O O
B B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
purified O O
to O O
homogeneity O O
using O O
affinity O O
chromatography O O
and O O
consists O O
of O O
three O O
peptides O O
of O O
62 O O
, O O
61 O O
, O O
and O O
58.5 O O
+/- O O
1.5 O O
kd O O
. O O

The O O
specific O O
DNA O O
binding O O
activity O O
of O O
the O O
pure O O
B B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
cell-specific I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O O
indistinguishable O O
from O O
that O O
of O O
the O O
affinity-purified B B_GENE/B_BIO
ubiquitous I I_GENE/I_BIO
factor I I_GENE/I_BIO
. O O

This O O
B B B_GENE
cell-specific I I_GENE
octamer-binding I I_GENE
factor I I_GENE
, O O
in O O
pure O O
form O O
, O O
activated O O
transcription O O
from O O
a O O
kappa B B_GENE
light I I_GENE
chain I I_GENE
promoter I I_GENE
in O O
vitro O O
, O O
thus O O
demonstrating O O
that O O
it O O
is O O
indeed O O
a O O
B B B_GENE/B_PERSON
cell-specific I I_GENE/I_PERSON
transcription I I_GENE/I_PERSON
factor I I_GENE/I_PERSON
for O O
this O O
gene O O
. O O

Decreased O O
deoxyribonucleic O O
acid O O
binding O O
of O O
glucocorticoid-receptor B B_GENE
complex I I_GENE
in O O
cultured O O
skin O O
fibroblasts O O
from O O
a O O
patient O O
with O O
the O O
glucocorticoid O O
resistance O O
syndrome O O
. O O

A O O
patient O O
with O O
the O O
syndrome O O
of O O
glucocorticoid O O
resistance O O
was O O
studied O O
. O O

A O O
27-yr-old O O
woman O O
initially O O
was O O
diagnosed O O
as O O
having O O
Cushing O O
's O O
disease O O
, O O
based O O
on O O
the O O
findings O O
of O O
high O O
plasma O O
ACTH O O
and O O
serum O O
cortisol O O
levels O O
, O O
increased O O
urinary O O
cortisol O O
secretion O O
, O O
resistance O O
to O O
adrenal O O
suppression O O
with O O
dexamethasone O O
, O O
and O O
bilateral O O
adrenal O O
hyperplasia O O
by O O
computed O O
tomography O O
and O O
scintigraphy O O
of O O
the O O
adrenal O O
glands O O
. O O

However O O
, O O
she O O
had O O
no O O
signs O O
or O O
symptoms O O
of O O
Cushing O O
's O O
syndrome O O
. O O

During O O
a O O
5-yr O O
follow-up O O
, O O
no O O
clinical O O
abnormalities O O
developed O O
, O O
although O O
hypercortisolism O O
persisted O O
. O O

End-organ O O
resistance O O
to O O
cortisol O O
was O O
suspected O O
. O O

To O O
explain O O
the O O
end-organ O O
resistance O O
to O O
cortisol O O
, O O
the O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
GR B B_PROTEIN[GENE]/B_DISEASE
) O O
in O O
peripheral O O
mononuclear O O
leukocytes O O
and O O
cultured O O
skin O O
fibroblasts O O
from O O
a O O
forearm O O
skin O O
biopsy O O
were O O
characterized O O
and O O
compared O O
with O O
the O O
results O O
of O O
similar O O
studies O O
in O O
normal O O
subjects O O
. O O

The O O
patient O O
's O O
GR B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O O
whole O O
cell O O
assays O O
had O O
an O O
increased O O
dissociation O O
constant O O
( O O
Kd O O
) O O
. O O

DNA B B_BIO/B_GENE
binding O O
of O O
the O O
GR B B_GENE
complex I I_GENE
after O O
temperature-induced O O
activation O O
was O O
lower O O
in O O
the O O
patient O O
than O O
in O O
normal O O
subjects O O
. O O

Nuclear O O
translocation O O
of O O
GR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
patient O O
was O O
also O O
slightly O O
decreased O O
. O O

Sensitive O O
and O O
receptor-mediated O O
regulation O O
by O O
1 O O
, O O
25-dihydroxyvitamin O O
D3 O O
in O O
normal O O
human O O
peripheral O O
blood O O
lymphocytes O O
. O O

We O O
show O O
that O O
1 O O
, O O
25-dihydroxyvitamin O O
D3 O O
( O O
1 O O
, O O
25 O O
[ O O
OH O O
] O O
2D3 O O
) O O
, O O
the O O
most O O
hormonally O O
active O O
metabolite O O
of O O
vitamin O O
D3 O O
, O O
modulates O O
sensitively O O
and O O
specifically O O
both O O
the O O
protein O O
and O O
messenger B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
accumulation O O
of O O
the O O
multilineage B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
granulocyte-macrophage B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

The O O
regulation O O
of O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O O
is O O
seen O O
in O O
both O O
normal O O
human O O
mitogen-activated O O
T O O
lymphocytes O O
and O O
T O O
lymphocytes O O
from O O
a O O
line O O
( O O
S-LB1 O O
) O O
transformed O O
with O O
human O O
T O O
cell O O
lymphotropic O O
virus O O
1 O O
( O O
HTLV-1 O O
) O O
. O O

Inhibition O O
of O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
can O O
occur O O
independently O O
of O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation O O
and O O
is O O
probably O O
mediated O O
through O O
cellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
25 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
OH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2D3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
conclude O O
that O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
may O O
be O O
important O O
in O O
the O O
physiology O O
of O O
hematopoiesis O O
. O O

Altered O O
interaction O O
between O O
triiodothyronine O O
and O O
its O O
nuclear B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
absence O O
of O O
cortisol O O
: O O
a O O
proposed O O
mechanism O O
for O O
increased O O
thyrotropin O O
secretion O O
in O O
corticosteroid O O
deficiency O O
states O O
. O O

Thyroid O O
hormones O O
occasionally O O
appear O O
less O O
effective O O
when O O
administered O O
alone O O
to O O
patients O O
with O O
panhypopituitarism O O
, O O
and O O
manifestations O O
suggestive O O
of O O
hypothyroidism O O
have O O
been O O
reported O O
in O O
patients O O
suffering O O
from O O
untreated O O
Addison O O
's O O
disease O O
. O O

In O O
the O O
latter O O
condition O O
, O O
thyrotropin O O
secretion O O
is O O
increased O O
: O O
this O O
occurs O O
already O O
after O O
as O O
little O O
as O O
2 O O
days O O
of O O
temporary O O
withdrawal O O
of O O
therapy O O
with O O
substitution O O
doses O O
of O O
corticosteroids O O
while O O
circulating O O
levels O O
of O O
thyroid O O
hormones O O
remain O O
within O O
normal O O
limits O O
. O O

Therefore O O
, O O
a O O
possible O O
role O O
of O O
cortisol O O
in O O
interaction O O
between O O
triiodothyronine O O
and O O
its O O
nuclear B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
examined O O
at O O
the O O
level O O
of O O
circulating O O
lymphocytes O O
obtained O O
from O O
patients O O
with O O
primary O O
or O O
secondary O O
adrenocortical O O
failure O O
. O O

This O O
change O O
was O O
promptly O O
corrected O O
upon O O
resumption O O
of O O
therapy O O
. O O

The O O
number O O
of O O
binding O O
sites O O
was O O
not O O
significantly O O
modified O O
. O O

Inhibition O O
by O O
cortisol O O
of O O
human O O
natural O O
killer O O
( O O
NK O O
) O O
cell O O
activity O O
. O O

Preincubation O O
for O O
20 O O
h O O
of O O
PBM O O
cells O O
drawn O O
from O O
healthy O O
donors O O
with O O
1 O O
X O O
10 O O
( O O
-8 O O
) O O
to O O
1 O O
X O O
10 O O
( O O
-5 O O
) O O
M O O
cortisol O O
resulted O O
in O O
a O O
significant O O
decrease O O
of O O
NK O O
cell O O
activity O O
. O O

The O O
magnitude O O
of O O
the O O
suppression O O
was O O
directly O O
related O O
to O O
the O O
steroid O O
concentration O O
and O O
inversely O O
related O O
to O O
the O O
number O O
of O O
effector O O
cells O O
. O O

A O O
significantly O O
higher O O
suppression O O
was O O
achieved O O
after O O
sequential O O
exposure O O
of O O
PBM O O
cells O O
to O O
cortisol O O
and O O
equimolar O O
levels O O
of O O
prostaglandin O O
E2 O O
( O O
PgE2 O O
) O O
. O O

The O O
concomitant O O
incubation O O
with O O
theophylline O O
and O O
isobutyl-methylxanthine O O
failed O O
to O O
enhance O O
the O O
cortisol-induced O O
suppression O O
, O O
whereas O O
PgE2-dependent O O
inhibition O O
significantly O O
increased O O
after O O
exposure O O
of O O
PBM O O
cells O O
to O O
methyl-xanthines O O
. O O

The O O
inhibitory O O
effect O O
of O O
cortisol O O
was O O
partially O O
or O O
totally O O
prevented O O
by O O
the O O
concomitant O O
incubation O O
with O O
equimolar O O
amounts O O
of O O
11-deoxycortisol O O
and O O
RU O O
486 O O
but O O
not O O
of O O
progesterone O O
. O O

Treatment O O
of O O
NK O O
effectors O O
with O O
a O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
anti-human I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
corticosteroid-binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
globulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CBG I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
produced O O
an O O
enhancement O O
of O O
the O O
spontaneous O O
NK O O
activity O O
and O O
a O O
partial O O
suppression O O
of O O
cortisol-mediated O O
effects O O
. O O

Our O O
results O O
suggest O O
that O O
endogenous O O
glucocorticoids O O
play O O
a O O
role O O
in O O
the O O
regulation O O
of O O
NK O O
cell-mediated O O
cytotoxicity O O
. O O

Since O O
the O O
effect O O
of O O
cortisol O O
was O O
additive O O
to O O
that O O
of O O
PgE2 O O
and O O
was O O
not O O
changed O O
by O O
phosphodiesterase B B_ENZYME[GENE]
inhibitors O O
, O O
it O O
is O O
conceivable O O
that O O
the O O
hormone O O
acts O O
at O O
a O O
level O O
different O O
from O O
the O O
adenylate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cyclase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
phosphodiesterase B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O O
. O O

Interaction O O
of O O
cell-type-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
immunoglobulin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
VH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

All O O
human B B_GENE/B_LOCATION
and I I_GENE/I_LOCATION
murine I I_GENE/I_LOCATION
immunoglobulin I I_GENE/I_LOCATION
heavy I I_GENE/I_LOCATION
chain I I_GENE/I_LOCATION
variable I I_GENE/I_LOCATION
region I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
VH I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
genes I I_GENE/I_LOCATION
contain O O
the O O
sequence O O
ATGCAAAT O O
approximately O O
70 O O
nucleotides O O
5 O O
' O O
from O O
the O O
site O O
of O O
transcription O O
initiation O O
. O O

This O O
octanucleotide O O
, O O
in O O
reverse O O
orientation O O
, O O
is O O
also O O
found O O
in O O
all O O
light B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
variable I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
VL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
in O O
the O O
immunoglobulin B B_GENE/B_BIO
heavy I I_GENE/I_BIO
chain I I_GENE/I_BIO
transcriptional I I_GENE/I_BIO
enhancer I I_GENE/I_BIO
. O O

Transfection O O
studies O O
have O O
established O O
that O O
this O O
octamer O O
is O O
involved O O
in O O
the O O
lymphoid-specific O O
transcription O O
of O O
immunoglobulin B B_GENE
genes I I_GENE
. O O

Here O O
we O O
establish O O
that O O
nuclear O O
extracts O O
from O O
distinct O O
cell O O
types O O
differ O O
in O O
their O O
ability O O
to O O
interact O O
with O O
octamer-containing B B_GENE
fragments I I_GENE
. O O

We O O
have O O
also O O
detected O O
a O O
DNA-protein O O
interaction O O
that O O
may O O
be O O
involved O O
in O O
the O O
cell-type O O
specificity O O
of O O
immunoglobulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
, O O
and O O
we O O
have O O
determined O O
that O O
a O O
sequence O O
upstream O O
of O O
the O O
octamer O O
participates O O
in O O
an O O
interaction O O
with O O
a O O
nuclear B B_GENE/B_BIO
protein I I_GENE/I_BIO
( O O
s O O
) O O
. O O

Preferential O O
transcription O O
of O O
HTLV-I B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
cell-free O O
extracts O O
of O O
human O O
T O O
cells O O
producing O O
HTLV-I B B_DISEASE/B_GENE
viral I B_DISEASE/I_GENE
proteins I B_DISEASE/I_GENE
. O O

The O O
promoters B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
adenovirus B B_GENE/B_DISEASE
2 I I_GENE/I_DISEASE
major I I_GENE/I_DISEASE
late I I_GENE/I_DISEASE
gene I I_GENE/I_DISEASE
, O O
the O O
mouse B B_GENE
beta-globin I I_GENE
gene I I_GENE
, O O
the O O
mouse B B_GENE
immunoglobulin I I_GENE
VH I I_GENE
gene I I_GENE
and O O
the O O
LTR B B_GENE/B_BIO
of O O
the O O
human O O
T-lymphotropic O O
retrovirus O O
type O O
I O O
were O O
tested O O
for O O
their O O
transcription O O
activities O O
in O O
cell-free O O
extracts O O
of O O
four O O
cell O O
lines O O
; O O
HeLa O O
, O O
CESS O O
( O O
Epstein-Barr O O
virus-transformed O O
human O O
B O O
cell O O
line O O
) O O
, O O
MT-1 O O
( O O
HTLV-I-infected O O
human O O
T O O
cell O O
line O O
without O O
viral O O
protein O O
synthesis O O
) O O
, O O
and O O
MT-2 O O
( O O
HTLV-I-infected O O
human O O
T O O
cell O O
line O O
producing O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

LTR B B_GENE/B_DISEASE
was O O
preferentially O O
transcribed O O
in O O
the O O
extracts O O
of O O
MT-2 O O
although O O
the O O
other O O
three O O
genes O O
were O O
transcribed O O
with O O
relatively O O
constant O O
efficiencies O O
in O O
different O O
extracts O O
. O O

The O O
results O O
agree O O
well O O
with O O
the O O
previous O O
in O O
vivo O O
studies O O
on O O
the O O
promoter O O
activity O O
of O O
HTLV-I B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
binds O O
to O O
a O O
conserved O O
sequence O O
motif O O
in O O
transcriptional B B_GENE/B_MEASURE
control I I_GENE/I_MEASURE
elements I I_GENE/I_MEASURE
of O O
immunoglobulin B B_GENE/B_SPECIES[BIO]
genes I B_GENE/I_SPECIES[BIO]
. O O

Two O O
B-cell-specific O O
, O O
cis-acting B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcriptional I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
regulatory I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
elements I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
have O O
been O O
identified O O
. O O

One O O
element O O
is O O
located O O
in O O
the O O
intron O O
between O O
the O O
variable O O
( O O
V O O
) O O
and O O
constant O O
( O O
C O O
) O O
regions O O
of O O
both O O
heavy B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light-chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
acts O O
as O O
a O O
transcriptional O O
enhancer O O
. O O

The O O
second O O
element B B_GENE/B_LOCATION
is O O
found O O
upstream O O
of O O
both O O
heavy B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light-chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
element O O
directs O O
lymphoid-specific O O
transcription O O
even O O
in O O
the O O
presence O O
of O O
viral B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
enhancers I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

We O O
have O O
sought O O
nuclear O O
factors O O
that O O
might O O
bind O O
specifically O O
to O O
these O O
two O O
regulatory B B_GENE/B_LOCATION
elements I I_GENE/I_LOCATION
by O O
application O O
of O O
a O O
modified O O
gel O O
electrophoresis O O
DNA O O
binding O O
assay O O
. O O

This O O
sequence-specific O O
binding O O
is O O
probably O O
mediated O O
by O O
a O O
highly O O
conserved O O
sequence O O
motif O O
, O O
ATTTGCAT O O
, O O
present O O
in O O
all O O
three O O
transcriptional B B_GENE/B_LOCATION
elements I I_GENE/I_LOCATION
. O O

Interestingly O O
, O O
a O O
factor O O
showing O O
similar O O
binding O O
specificity O O
to O O
IgNF-A B B_GENE
is O O
also O O
present O O
in O O
human O O
HeLa O O
cells O O
. O O

The O O
new O O
world O O
primates O O
as O O
animal O O
models O O
of O O
glucocorticoid O O
resistance O O
. O O

These O O
primates O O
also O O
have O O
high O O
levels O O
of O O
circulating O O
progesterone O O
, O O
estrogen O O
, O O
mineralocorticoid O O
, O O
androgen O O
and O O
vitamin O O
D O O
. O O

Transformation O O
of O O
B-lymphocytes O O
with O O
the O O
Epstein-Barr O O
virus O O
leads O O
to O O
glucocorticoid B B_GENE/B_DISEASE
receptor I I_GENE/I_DISEASE
induction O O
that O O
is O O
less O O
than O O
that O O
observed O O
with O O
cells O O
from O O
Old O O
World O O
primates O O
. O O

The O O
low O O
affinity O O
leads O O
to O O
an O O
increased O O
loss O O
of O O
specific O O
bound O O
ligand O O
during O O
thermal O O
activation O O
. O O

Meroreceptor O O
generation O O
is O O
normal O O
. O O

The O O
New O O
World O O
primates O O
, O O
unlike O O
men O O
with O O
the O O
syndrome O O
of O O
primary O O
cortisol O O
resistance O O
, O O
have O O
compensated O O
for O O
their O O
condition O O
with O O
intra-adrenal O O
and O O
mineralocorticoid O O
receptor O O
adaptations O O
. O O

Thus O O
, O O
unlike O O
Old O O
World O O
primates O O
, O O
cortisol O O
in O O
New O O
World O O
primates O O
has O O
only O O
weak O O
sodium-retaining O O
potency O O
because O O
the O O
aldosterone B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
a O O
low O O
affinity O O
for O O
cortisol O O
. O O

The O O
common O O
element O O
that O O
would O O
explain O O
the O O
apparent O O
resistance O O
to O O
six O O
steroid O O
hormones O O
in O O
New O O
World O O
primates O O

Acetylation O O
and O O
modulation O O
of O O
erythroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Kruppel-like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
activity O O
by O O
interaction O O
with O O
histone B B_GENE
acetyltransferases I I_GENE
. O O

EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
required O O
for O O
integrity O O
of O O
the O O
chromatin O O
structure O O
at O O
the O O
beta-like B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
globin I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
locus I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
it O O
interacts O O
with O O
a O O
positive-acting B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O O
. O O

We O O
find O O
that O O
EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
an O O
acetylated B B_GENE
transcription I I_GENE
factor I I_GENE
, O O
and O O
that O O
it O O
interacts O O
in O O
vivo O O
with O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
P/CAF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
functional O O
effects O O
of O O
these O O
interactions O O
are O O
that O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
p300 B B_GENE/B_LOCATION
, O O
but O O
not O O
P/CAF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
enhance O O
EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
's O O
transcriptional O O
activation O O
of O O
the O O
beta-globin B B_GENE
promoter I I_GENE
in O O
erythroid O O
cells O O
. O O

These O O
results O O
establish O O
EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
tissue-specific B B_GENE/B_MEASURE
transcription I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
that O O
undergoes O O
post-translational O O
acetylation O O
and O O
suggest O O
a O O
mechanism O O
by O O
which O O
EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
able O O
to O O
alter O O
chromatin O O
structure O O
and O O
induce O O
beta-globin O O
expression O O
within O O
the O O
beta-like B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
globin I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
cluster I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O O

The O O
local O O
cellular O O
immune O O
response O O
to O O
herpes O O
simplex O O
virus O O
( O O
HSV O O
) O O
is O O
important O O
in O O
the O O
control O O
of O O
recurrent O O
HSV O O
infection O O
. O O

The O O
antigens O O
recognized O O
by O O
many O O
HSV-specific O O
CD4 O O
T O O
cells O O
localizing O O
to O O
genital O O
HSV-2 O O
lesions O O
are O O
unknown O O
. O O

T O O
cells O O
recognizing O O
antigens O O
encoded O O
within O O
map O O
units O O
0.67 O O
to O O
0.73 O O
of O O
HSV B B_GENE/B_VIRUS[BIO]
DNA I I_GENE/I_VIRUS[BIO]
are O O
frequently O O
recovered O O
from O O
herpetic O O
lesions O O
. O O

Separate O O
epitopes B B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
VP22 B B_GENE/B_BIO
were O O
defined O O
for O O
T-cell O O
clones O O
from O O
each O O
of O O
three O O
patients O O
. O O

Reactivity O O
with O O
the O O
tegument B B_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
encoded O O
by O O
UL21 B B_GENE
was O O
identified O O
for O O
an O O
additional O O
patient O O
. O O

Some O O
tegument-specific O O
CD4 O O
T-cell O O
clones O O
exhibited O O
cytotoxic O O
activity O O
against O O
HSV-infected O O
cells O O
. O O

Fibrinogen B B_GENE
activates O O
NF-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mononuclear O O
phagocytes O O
. O O

Adhesion O O
to O O
extracellular O O
matrices O O
is O O
known O O
to O O
modulate O O
leukocyte O O
activation O O
, O O
although O O
the O O
mechanisms O O
are O O
not O O
fully O O
understood O O
. O O

U937 O O
cells O O
differentiated O O
with O O
PMA O O
in O O
nonadherent O O
culture O O
were O O
shown O O
to O O
express O O
two O O
fibrinogen-binding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
integrins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
predominately O O
CD11b/CD18 B B_GENE
, O O
and O O
to O O
a O O
lesser O O
extent O O
, O O
CD11c/CD18 B B_GENE
. O O

Cells O O
stimulated O O
with O O
fibrinogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
10-100 O O
microg/ml O O
) O O
/Mn2+ O O
( O O
50 O O
microM O O
) O O
for O O
2 O O
h O O
were O O
examined O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

NF-kappa B B_GENE
B I I_GENE
activation O O
, O O
minimal O O
in O O
unstimulated O O
cells O O
, O O
was O O
substantially O O
up-regulated O O
by O O
fibrinogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

Fibrinogen B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
caused O O
activation O O
of O O
AP-1 B B_GENE
, O O
but O O
not O O
SP1 B B_GENE
or O O
cAMP B B_GENE
response I I_GENE
element-binding I I_GENE
protein I I_GENE
( I I_GENE
CREB I I_GENE
) I I_GENE
factors I I_GENE
. O O

Blocking O O
mAbs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O O
CD18 B B_GENE
and O O
CD11b B B_GENE
abrogated O O
fibrinogen B B_GENE
-induced O O
NF-kappa B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
B I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
activation O O
. O O

To O O
determine O O
the O O
effects O O
on O O
transcriptional O O
regulation O O
, O O
U937 O O
cells O O
were O O
transfected O O
with O O
a O O
plasmid O O
containing O O
the O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
bearing O O
two O O
NF-kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
) O O
coupled O O
to O O
a O O
chloramphenicol B B_GENE
acetyltransferase I I_GENE
( I I_GENE
CAT I I_GENE
) I I_GENE
reporter I I_GENE
. O O

Cells O O
were O O
subsequently O O
stimulated O O
with O O
1 O O
) O O
PMA O O
for O O
24 O O
h O O
, O O
inducing O O
CAT O O
activity O O
by O O
2.6-fold O O
, O O
2 O O
) O O
fibrinogen B B_GENE
/Mn2+ O O
for O O
2 O O
h O O
, O O
inducing O O
CAT O O
activity O O
by O O
3.2-fold O O
, O O
or O O
3 O O
) O O
costimulation O O
with O O
fibrinogen B B_GENE
and O O
PMA O O
, O O
inducing O O
5.7-fold O O
the O O
CAT O O
activity O O
induced O O
by O O
PMA O O
alone O O
. O O

Peripheral O O
blood O O
T O O
cells O O
and O O
monocytes O O
and O O
B O O
cell O O
lines O O
derived O O
from O O
patients O O
with O O
lupus O O
express O O
estrogen O O
receptor O O
transcripts O O
similar O O
to O O
those O O
of O O
normal O O
cells O O
. O O

OBJECTIVE O O
: O O
To O O
identify O O
and O O
characterize O O
estrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ER I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expressed O O
in O O
immune O O
cells O O
of O O
patients O O
with O O
systemic O O
lupus O O
erythematosus O O
( O O
SLE O O
) O O
and O O
healthy O O
donors O O
. O O

METHODS O O
: O O
Peripheral O O
blood O O
monocytes O O
and O O
T O O
cells O O
were O O
prepared O O
from O O
patients O O
with O O
SLE O O
( O O
n O O
= O O
6 O O
) O O
and O O
healthy O O
donors O O
( O O
n O O
= O O
8 O O
) O O
. O O

Some O O
monocytes O O
and O O
T O O
cells O O
were O O
stimulated O O
with O O
estradiol O O
, O O
PMA O O
, O O
and O O
ionomycin O O
. O O

Epstein-Barr O O
virus-transformed O O
B O O
cell O O
lines O O
( O O
n O O
= O O
7 O O
) O O
and O O
B O O
cell O O
hybridomas O O
( O O
n O O
= O O
2 O O
) O O
established O O
from O O
patients O O
with O O
SLE O O
and O O
a O O
healthy O O
individual O O
were O O
used O O
as O O
a O O
B O O
cell O O
source O O
. O O

These O O
cells O O
were O O
examined O O
for O O
ER B B_GENE
mRNA I I_GENE
by O O
reverse O O
transcription O O
nested O O
polymerase O O
chain O O
reaction O O
. O O

Amplified O O
cDNA B B_GENE/B_LOCATION
were O O
sequenced O O
by O O
standard O O
methods O O
. O O

RESULTS O O
: O O
In O O
all O O
cells O O
tested O O
, O O
ER B B_GENE
mRNA I I_GENE
was O O
expressed O O
without O O
prior O O
in O O
vitro O O
stimulation O O
. O O

There O O
were O O
no O O
notable O O
differences O O
in O O
the O O
ER B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transcripts I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O O
patients O O
and O O
healthy O O
controls O O
. O O

Whether O O
the O O
detected O O
transcripts O O
are O O
translated O O
into O O
functional B B_GENE
receptor I I_GENE
proteins I I_GENE
remains O O
to O O
be O O
determined O O
. O O

In O O
vitro O O
stimulation O O
did O O
not O O
affect O O
ER B B_GENE
mRNA I I_GENE
expression O O
. O O

The O O
presence O O
of O O
variants O O
did O O
not O O
correlate O O
with O O
disease O O
activity O O
or O O
medication O O
. O O

CONCLUSION O O
: O O
Monocytes O O
, O O
T O O
cells O O
, O O
and O O
B O O
cells O O
in O O
patients O O
express O O
transcripts O O
of O O
the O O
normal O O
wild B B_GENE
type I I_GENE
ER I I_GENE
and O O
the O O
hormone B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
binding I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
domain I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variants I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
vivo O O
. O O

DNA O O
damaging O O
agents O O
induce O O
expression O O
of O O
Fas B B_GENE
ligand I I_GENE
and O O
subsequent O O
apoptosis O O
in O O
T O O
lymphocytes O O
via O O
the O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
and O O
AP-1 B B_GENE
. O O

Apoptosis O O
induced O O
by O O
DNA O O
damage O O
and O O
other O O
stresses O O
can O O
proceed O O
via O O
expression O O
of O O
Fas B B_GENE
ligand I I_GENE
( O O
FasL B B_GENE/B_LOCATION
) O O
and O O
ligation O O
of O O
its O O
receptor O O
, O O
Fas O O
( O O
CD95 O O
) O O
. O O

We O O
report O O
that O O
activation O O
of O O
the O O
two O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
crucially O O
involved O O
in O O
FasL B B_GENE
expression O O
induced O O
by O O
etoposide O O
, O O
teniposide O O
, O O
and O O
UV O O
irradiation O O
. O O

A O O
1.2 O O
kb O O
FasL B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
responded O O
to O O
DNA O O
damage O O
, O O
as O O
well O O
as O O
coexpression O O
with O O
p65 B B_GENE
Rel I I_GENE
or O O
Fos/Jun B B_GENE
. O O

Mutations O O
in O O
the O O
relevant O O
NF-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
eliminated O O
these O O
responses O O
. O O

Thus O O
, O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
and O O
AP-1 B B_GENE
contributes O O
to O O
stress-induced O O
apoptosis O O
via O O
the O O
expression O O
of O O
FasL B B_GENE
. O O

A O O
small O O
, O O
nonpeptidyl O O
mimic O O
of O O
granulocyte-colony-stimulating B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
see O O
commetns O O
] O O

A O O
nonpeptidyl O O
small O O
molecule O O
SB O O
247464 O O
, O O
capable O O
of O O
activating O O
granulocyte-colony-stimulating B B_GENE
factor I I_GENE
( O O
G-CSF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
signal O O
transduction O O
pathways O O
, O O
was O O
identified O O
in O O
a O O
high-throughput O O
assay O O
in O O
cultured O O
cells O O
. O O

Like O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
SB O O
247464 O O
induced O O
tyrosine O O
phosphorylation O O
of O O
multiple B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
stimulated O O
primary O O
murine O O
bone O O
marrow O O
cells O O
to O O
form O O
granulocytic O O
colonies O O
in O O
vitro O O
. O O

It O O
also O O
elevated O O
peripheral O O
blood O O
neutrophil O O
counts O O
in O O
mice O O
. O O

The O O
extracellular O O
domain O O
of O O
the O O
murine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G-CSF I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
required O O
for O O
the O O
activity O O
of O O
SB O O
247464 O O
, O O
suggesting O O
that O O
the O O
compound O O
acts O O
by O O
oligomerizing B B_MEASURE/B_GENE
receptor I I_MEASURE/I_GENE
chains I I_MEASURE/I_GENE
. O O

Minimal O O
residual O O
disease O O
in O O
acute O O
myelogenous O O
leukemia O O
with O O
PML/RAR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
AML1/ETO B B_GENE/B_DISEASE
mRNA I I_GENE/I_DISEASE
and O O
phenotypic O O
analysis O O
of O O
possible O O
T O O
and O O
natural O O
killer O O
cells O O
in O O
bone O O
marrow O O
. O O

Here O O
we O O
studied O O
minimal O O
residual O O
disease O O
( O O
MRD O O
) O O
of O O
patients O O
with O O
acute O O
myeloid O O
leukemia O O
( O O
AML O O
) O O
who O O
have O O
PML/RAR B B_DISEASE/B_GENE
alpha I I_DISEASE/I_GENE
or O O
AML1/ETO B B_DISEASE/B_GENE
as O O
well O O
as O O
the O O
phenotypic O O
analysis O O
of O O
lymphocyte O O
subsets O O
involved O O
in O O
antitumor O O
immunity O O
. O O

Using O O
the O O
reverse O O
transcription-polymerase O O
chain O O
reaction O O
( O O
RT O O
) O O
assay O O
, O O
the O O
limit O O
of O O
detection O O
was O O
10 O O
( O O
-5 O O
) O O
to O O
10 O O
( O O
-6 O O
) O O
for O O
PML/RAR B B_GENE
alpha I I_GENE
transcript I I_GENE
and O O
10 O O
( O O
-4 O O
) O O
to O O
10 O O
( O O
-5 O O
) O O
for O O
the O O
AML1/ETO B B_GENE/B_MEASURE
transcript I I_GENE/I_MEASURE
. O O

Simultaneously O O
, O O
T O O
lymphocyte O O
subsets O O
and O O
NK O O
cells O O
from O O
the O O
peripheral O O
blood O O
( O O
PB O O
) O O
and O O
bone O O
marrow O O
( O O
BM O O
) O O
were O O
investigated O O
by O O
flow O O
cytometric O O
analysis O O
. O O

Four O O
of O O
the O O
eight O O
patients O O
in O O
LT O O
and O O
7 O O
of O O
the O O
15 O O
patients O O
in O O
ST O O
remission O O
were O O
MRD-positive O O
. O O

The O O
total O O
populations O O
of O O
CD4 B B_GENE
+ O O
, O O
CD8 B B_GENE
+ O O
and O O
CD56 B B_GENE
+ O O
[ O O
possible O O
T-cell O O
and O O
natural O O
killer O O
( O O
T/NK O O
) O O
populations O O
] O O
in O O
the O O
BM O O
of O O
ST O O
patients O O
and O O
MRD+/LT O O
patients O O
were O O
significantly O O
( O O
p O O
< O O
.01 O O
) O O
low O O
. O O

The O O
CD8+ O O
CD28+ O O
population O O
showed O O
the O O
same O O
tendency O O
( O O
p O O
< O O
.01-.02 O O
) O O
. O O

The O O
T/NK O O
subsets O O
in O O
the O O
BM O O
of O O
MRD-negative O O
( O O
MRD- O O
) O O
LT O O
( O O
MRD-/LT O O
) O O
patients O O
showed O O
similar O O
numbers O O
of O O
cells O O
as O O
normal O O
volunteers O O
. O O

The O O
percentages O O
of O O
the O O
T/NK-cell O O
subsets O O
in O O
the O O
PB O O
were O O
not O O
significantly O O
different O O
among O O
these O O
groups O O
. O O

These O O
results O O
still O O
remain O O
to O O
be O O
confirmed O O
by O O
further O O
studies O O
of O O
the O O
functional O O
anti-tumor O O
immunity O O
of O O
T/NK O O
cells O O
of O O
AML O O
in O O
remission O O
. O O

Mycobacterium O O
tuberculosis O O
mannose-capped O O
lipoarabinomannan O O
can O O
induce O O
NF-kappaB B B_GENE
-dependent O O
activation O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
long I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeat I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
T O O
cells O O
. O O

Tuberculosis O O
has O O
emerged O O
as O O
an O O
epidemic O O
, O O
extended O O
by O O
the O O
large O O
number O O
of O O
individuals O O
infected O O
with O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
. O O

These O O
experiments O O
are O O
of O O
prime O O
importance O O
considering O O
that O O
CD4 B B_GENE
-expressing O O
T O O
lymphocytes O O
represent O O
the O O
major O O
virus O O
reservoir O O
in O O
the O O
peripheral O O
blood O O
of O O
infected O O
individuals O O
. O O

Using O O
the O O
1G5 O O
cell O O
line O O
harbouring O O
the O O
luciferase O O
reporter O O
gene O O
under O O
the O O
control O O
of O O
the O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
was O O
first O O
found O O
that O O
culture O O
protein O O
filtrates O O
( O O
CFP O O
) O O
from O O
M. O O
tuberculosis O O
or O O
purified O O
ManLAM O O
could O O
activate O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR-dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
unlike O O
similarly O O
prepared O O
CFP O O
extracts O O
devoid O O
of O O
ManLAM O O
. O O

The O O
implication O O
of O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
s I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
and/or O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
highlighted O O
by O O
the O O
abrogation O O
of O O
the O O
ManLAM-mediated O O
activation O O
of O O
HIV-1 O O
LTR-driven O O
gene O O
expression O O
using O O
herbimycin O O
A O O
and O O
H7 O O
. O O

It O O
was O O
also O O
determined O O
, O O
using O O
electrophoresis O O
mobility O O
shift O O
assays O O
, O O
that O O
M. O O
tuberculosis O O
ManLAM O O
led O O
to O O
the O O
nuclear O O
translocation O O
of O O
the O O
transcription B B_ENZYME[GENE]/B_BIO
factor I I_ENZYME[GENE]/I_BIO
NF-kappaB I I_ENZYME[GENE]/I_BIO
. O O

M. O O
tuberculosis O O
ManLAM O O
resulted O O
in O O
clear O O
induction O O
of O O
the O O
luciferase B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
placed O O
under O O
the O O
control O O
of O O
the O O
wild-type B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
but I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
not I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
the I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
kappaB-mutated I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
HIV-1 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
LTR I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Finally O O
, O O
the O O
ManLAM-mediated O O
activation O O
of O O
HIV-1 O O
LTR O O
transcription O O
was O O
found O O
to O O
be O O
independent O O
of O O
the O O
autocrine O O
or O O
paracrine O O
action O O
of O O
endogenous B B_GENE
TNF-alpha I I_GENE
. O O

To O O
gain O O
a O O
better O O
understanding O O
of O O
the O O
impact O O
of O O
long B B_GENE
terminal I I_GENE
repeat I I_GENE
( O O
LTR B B_PROTEIN[GENE]/B_DISEASE
) O O
sequence O O
diversity O O
on O O
LTR-directed B B_GENE
gene I I_GENE
expression O O
in O O
cells O O
of O O
the O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
and O O
immune O O
system O O
, O O
we O O
amplified O O
and O O
cloned O O
LTRs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O O
proviral O O
DNA O O
in O O
HIV-1-infected O O
peripheral O O
blood O O
. O O

These O O
findings O O
suggest O O
that O O
LTR B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequence I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
changes O O
can O O
significantly O O
affect O O
basal O O
LTR O O
function O O
and O O
transcription O O
factor O O
recruitment O O
, O O
which O O
may O O
, O O
in O O
turn O O
, O O
alter O O
the O O
course O O
of O O
viral O O
replication O O
in O O
cells O O
of O O
CNS O O
and O O
immune O O
system O O
origin O O
. O O

The O O
identification O O
of O O
the O O
mammalian B B_GENE/B_BIO
sex-determining I I_GENE/I_BIO
gene I I_GENE/I_BIO
Sry I I_GENE/I_BIO
has O O
led O O
to O O
the O O
discovery O O
of O O
a O O
large O O
family O O
of O O
related O O
( O O
' O O
HMG B B_GENE/B_PERSON
box I I_GENE/I_PERSON
' O O
) O O
transcription B B_GENE/B_BIO
factors I I_GENE/I_BIO
that O O
control O O
developmental O O
events O O
in O O
yeast O O
, O O
C. O O
elegans O O
, O O
Drosophila O O
and O O
vertebrates O O
. O O

In O O
lymphocyte O O
differentiation O O
, O O
several O O
HMG B B_GENE
box I I_GENE
proteins I I_GENE
play O O
a O O
decisive O O
role O O
. O O

In O O
flies O O
, O O
this O O
pathway O O
controls O O
segment O O
polarity O O
; O O
in O O
Xenopus O O
it O O
controls O O
the O O
definition O O
of O O
the O O
body O O
axis O O
. O O

Transcriptional O O
regulation O O
of O O
the O O
gene O O
for O O
the O O
myeloid B B_GENE
calcium I I_GENE
binding I I_GENE
protein I I_GENE
, O O
MRP14 B B_GENE
, O O
was O O
investigated O O
in O O
human O O
monocytic O O
leukemia O O
cell O O
lines O O
. O O

The O O
MRP14 B B_GENE/B_MEASURE
gene I I_GENE/I_MEASURE
was O O
not O O
expressed O O
in O O
monoblastic O O
ML-1 O O
cells O O
, O O
promonocytic O O
U-937 O O
cells O O
, O O
or O O
promyelocytic O O
HL-60 O O
cells O O
. O O

The O O
level O O
of O O
MRP14 B B_GENE
in O O
VD3-treated O O
HL-60 O O
cells O O
was O O
two-fold O O
higher O O
than O O
that O O
in O O
THP-1 O O
cells O O
. O O

Furthermore O O
, O O
to O O
examine O O
the O O
transcriptional O O
activity O O
of O O
the O O
C/EBP B B_GENE
motif I I_GENE
, O O
we O O
transfected O O
several O O
constructed O O
luciferase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
into O O
HL-60 O O
cells O O
and O O
THP-1 O O
cells O O
. O O

The O O
luciferase O O
activity O O
of O O
the O O
C/EBP B B_GENE
motif I I_GENE
in O O
HL-60 O O
cells O O
was O O
increased O O
by O O
VD3 O O
treatment O O
. O O

The O O
C/EBP B B_GENE/B_LOCATION
motif I I_GENE/I_LOCATION
in O O
the O O
MRP14 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
was O O
confirmed O O
to O O
function O O
as O O
a O O
regulatory O O
region O O
in O O
VD3-treated O O
HL-60 O O
cells O O
and O O
THP-1 O O
cells O O
by O O
the O O
assay O O
. O O

Since O O
C/EBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
also O O
detected O O
in O O
VD3-untreated O O
HL-60 O O
cells O O
by O O
immunoblotting O O
, O O
VD3 O O
activated O O
C/EBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
bind O O
to O O
the O O
motif O O
, O O
probably O O
through O O
post-translational O O
modification O O
. O O

Patients O O
with O O
high-risk O O
myelodysplastic O O
syndrome O O
can O O
have O O
polyclonal O O
or O O
clonal O O
haemopoiesis O O
in O O
complete O O
haematological O O
remission O O
. O O

The O O
clonality O O
of O O
mature O O
peripheral O O
blood-derived O O
myeloid O O
and O O
lymphoid O O
cells O O
and O O
bone O O
marrow O O
haemopoietic O O
progenitors O O
from O O
18 O O
females O O
with O O
myelodysplasia O O
( O O
MDS O O
) O O
( O O
five O O
refractory O O
anaemia O O
, O O
RA O O
; O O
one O O
RA O O
with O O
ringed O O
sideroblasts O O
, O O
RARS O O
; O O
three O O
chronic O O
myelomonocytic O O
leukaemia O O
, O O
CMML O O
; O O
four O O
RA O O
with O O
excess O O
of O O
blasts O O
, O O
RAEB O O
; O O
five O O
RAEB O O
in O O
transformation O O
, O O
RAEB-t O O
) O O
was O O
studied O O
by O O
X-chromosome B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inactivation O O
analysis O O
. O O

In O O
high-risk O O
patients O O
( O O
RAEB O O
, O O
RAEB-t O O
) O O
, O O
clonality O O
analysis O O
was O O
performed O O
before O O
and O O
after O O
intensive O O
remission-induction O O
treatment O O
. O O

All O O
patients O O
, O O
except O O
one O O
with O O
RA O O
, O O
had O O
predominance O O
of O O
a O O
single O O
clone O O
in O O
their O O
granulocytes O O
and O O
monocytes O O
. O O

The O O
same O O
clonal O O
pattern O O
was O O
found O O
in O O
CD34+ O O
progenitor O O
cells O O
. O O

In O O
contrast O O
, O O
CD3+ O O
T O O
lymphocytes O O
were O O
polyclonal O O
or O O
oligoclonal O O
in O O
14/18 O O
patients O O
. O O

X-chromosome B B_GENE/B_DISEASE
inactivation O O
patterns O O
of O O
CD19+ O O
B O O
cells O O
were O O
highly O O
concordant O O
with O O
CD3+ O O
T O O
cells O O
except O O
for O O
two O O
patients O O
( O O
one O O
RA O O
, O O
one O O
CMML O O
) O O
with O O
monoclonal O O
B O O
and O O
polyclonal O O
T O O
lymphocytes O O
, O O
therefore O O
suggesting O O
a O O
clonal O O
mutation O O
in O O
a O O
progenitor O O
common O O
to O O
the O O
myeloid O O
and O O
B-lymphoid O O
lineages O O
or O O
the O O
coexistence O O
of O O
MDS O O
and O O
a O O
B-cell O O
disorder O O
in O O
these O O
particular O O
patients O O
. O O

After O O
high-dose O O
non-myeloablative O O
chemotherapy O O
, O O
polyclonal O O
haemopoiesis O O
was O O
reinstalled O O
in O O
the O O
mature O O
myeloid O O
cells O O
and O O
immature O O
and O O
committed O O
marrow O O
progenitors O O
in O O
three O O
of O O
four O O
patients O O
achieving O O
complete O O
haematological O O
remission O O
. O O

Therefore O O
we O O
conclude O O
that O O
most O O
haematological O O
remissions O O
in O O
MDS O O
are O O
associated O O
with O O
restoration O O
of O O
polyclonal O O
haemopoiesis O O
. O O

Prominent O O
sex O O
steroid O O
metabolism O O
in O O
human O O
lymphocytes O O
. O O

B-LCL O O
, O O
but O O
not O O
T O O
and O O
B O O
cells O O
, O O
expressed O O
CYP11B B B_GENE
. O O

There O O
was O O
minimal O O
expression O O
of O O
HSD3B1 B B_GENE/B_LOCATION
and O O
HSD3B2 B B_GENE/B_DISEASE
( O O
3beta-hydroxysteroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
B-LCL O O
and O O
T O O
cells O O
. O O

Transcripts O O
for O O
CYP19 B B_GENE/B_DISEASE
and O O
HSD11K B B_GENE
were O O
not O O
detected O O
. O O

Corresponding O O
enzymatic O O
activity O O
was O O
detectable O O
only O O
for O O
17-hydroxysteroid B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
5alpha-reductase B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
producing O O
testosterone O O
and O O
5alpha-dihydrotestosterone O O
. O O

Steroid O O
identities O O
were O O
confirmed O O
by O O
gas O O
chromatography/mass O O
spectrometry O O
( O O
GC/MS O O
) O O
. O O

One O O
metabolite O O
thought O O
to O O
be O O
deoxycorticosterone O O
was O O
identified O O
by O O
GC/MS O O
as O O
6alpha-hydroxypregnanolone O O
. O O

It O O
was O O
concluded O O
that O O
sex O O
hormone O O
metabolism O O
, O O
including O O
androgen O O
synthesis O O
, O O
occurs O O
in O O
lymphocytes O O
, O O
and O O
may O O
modulate O O
immune O O
response O O
. O O

Pterin B B_PROTEIN[GENE]/B_TIME[MEASURE]
carbinolamine I I_PROTEIN[GENE]/I_TIME[MEASURE]
dehydratase/dimerization I I_PROTEIN[GENE]/I_TIME[MEASURE]
cofactor I I_PROTEIN[GENE]/I_TIME[MEASURE]
of O O
HNF1 B B_GENE/B_DISEASE
( O O
PCD/DCoH B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
a O O
protein O O
that O O
has O O
a O O
dual O O
function O O
. O O

In O O
addition O O
, O O
it O O
is O O
the O O
dimerization O O
cofactor O O
of O O
HNF1 B B_GENE
that O O
is O O
able O O
to O O
activate O O
the O O
transcriptional O O
activity O O
of O O
HNF1 B B_GENE
. O O

Deficiencies O O
in O O
the O O
gene O O
for O O
this O O
dual B B_GENE
functional I I_GENE
protein I I_GENE
result O O
in O O
hyperphenylalaninemia O O
. O O

Here O O
we O O
report O O
for O O
the O O
first O O
time O O
that O O
the O O
PCD/DCoH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
present O O
in O O
human O O
white O O
blood O O
cells O O
and O O
hair O O
follicles O O
. O O

Copyright O O
1998 O O
Academic O O
Press O O
. O O

Biochemical O O
characterization O O
of O O
the O O
NF-Y B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
transcription I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
factor I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
complex I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
during O O
B O O
lymphocyte O O
development O O
. O O

The O O
transcription B B_GENE
factor I I_GENE
, O O
NF-Y B B_GENE
, O O
plays O O
a O O
critical O O
role O O
in O O
tissue-specific O O
major B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O O
. O O

In O O
this O O
report O O
the O O
biochemical O O
properties O O
of O O
the O O
heterotrimeric B B_GENE
NF-Y I I_GENE
complex I I_GENE
have O O
been O O
characterized O O
during O O
stage-specific O O
B-cell O O
development O O
, O O
and O O
in O O
several O O
class O O
II- O O
mutant O O
B-cell O O
lines O O
, O O
which O O
represent O O
distinct O O
bare O O
lymphocyte O O
syndrome O O
class O O
II O O
genetic O O
complementation O O
groups O O
. O O

Recombination O O
of O O
the O O
native B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NF-YA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
transcriptional B B_GENE/B_PERSON
cofactor I I_GENE/I_PERSON
, O O
PC4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
likewise O O
conferred O O
high B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
affinity I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
NF-Y I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
binding O O
to O O
anion B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exchangers I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
stabilized O O
NF-Y B B_GENE/B_PERSON
interaction O O
with O O
CCAAT-box B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O O
. O O

These O O
results O O
suggest O O
that O O
in O O
class O O
II+ O O
mature O O
B-cells O O
NF-Y B B_GENE
is O O
associated O O
with O O
the O O
protein O O
cofactor O O
, O O
PC4 B B_GENE
, O O
which O O
may O O
play O O
an O O
important O O
role O O
in O O
NF-Y-mediated O O
transcriptional O O
control O O
of O O
class B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Despite O O
extensive O O
research O O
, O O
the O O
role O O
of O O
CD40 B B_GENE
signaling O O
in O O
B O O
cell O O
terminal O O
differentiation O O
remains O O
controversial O O
. O O

Here O O
we O O
show O O
that O O
CD40 B B_GENE/B_LOCATION
engagement O O
arrests O O
B O O
cell O O
differentiation O O
prior O O
to O O
plasma O O
cell O O
formation O O
. O O

This O O
arrest O O
is O O
manifested O O
at O O
a O O
molecular O O
level O O
as O O
a O O
reduction O O
in O O
mRNA O O
levels O O
of O O
secretory O O
immunoglobulin O O
gene O O
products O O
such O O
as O O
mu O O
( O O
s O O
) O O
and O O
J O O
chain O O
as O O
well O O
as O O
the O O
loss O O
of O O
the O O
transcriptional B B_GENE
regulator I I_GENE
BLIMP-1 B I_GENE
. O O

A O O
positively O O
charged O O
alpha-lipoic O O
acid O O
analogue O O
with O O
increased O O
cellular O O
uptake O O
and O O
more O O
potent O O
immunomodulatory O O
activity O O
. O O

To O O
improve O O
retention O O
in O O
cells O O
, O O
the O O
LA O O
molecule O O
was O O
modified O O
to O O
confer O O
a O O
positive O O
charge O O
at O O
physiological O O
pH O O
. O O

N O O
, O O
N-dimethyl O O
, O O
N'-2-amidoethyl-lipoate O O
was O O
synthesized O O
. O O

The O O
protonated O O
form O O
of O O
the O O
new O O
molecule O O
is O O
referred O O
to O O
as O O
LA-Plus O O
. O O

The O O
uptake O O
of O O
LA-Plus O O
by O O
human O O
Wurzburg O O
T O O
cells O O
was O O
higher O O
compared O O
to O O
that O O
of O O
LA O O
. O O

Several-fold O O
higher O O
amounts O O
of O O
DHLA-Plus O O
, O O
the O O
corresponding O O
reduced O O
form O O
of O O
LA-Plus O O
, O O
were O O
detected O O
in O O
LA-Plus O O
treated O O
cells O O
compared O O
to O O
the O O
amount O O
of O O
DHLA O O
found O O
in O O
cells O O
treated O O
with O O
LA O O
. O O

At O O
100 O O
microM O O
, O O
LA O O
did O O
not O O
but O O
LA-Plus O O
inhibited O O
H2O2 O O
induced O O
NF-kappaB B B_GENE
activation O O
and O O
NF-kappaB B B_GENE
directed O O
IL-2 B B_GENE
receptor I I_GENE
expression O O
. O O

Both O O
LA O O
and O O
LA-Plus O O
synergised O O
with O O
selenium O O
in O O
inhibiting O O
H2O2 O O
induced O O
NF-kappaB B B_GENE
activation O O
. O O

At O O
150 O O
microM O O
LA-Plus O O
, O O
but O O
not O O
LA O O
, O O
inhibited O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
NF-kappaB B B_GENE
activation O O
. O O

LA-Plus O O
is O O
thus O O
an O O
improved O O
form O O
of O O
LA O O
with O O
increased O O
therapeutic O O
potential O O
. O O

Copyright O O
1998 O O
Academic O O
Press O O
. O O

Carrier O O
identification O O
in O O
X-linked O O
immunodeficiency O O
diseases O O
. O O

OBJECTIVE O O
: O O
Carrier O O
identification O O
in O O
X-linked O O
immunodeficiency O O
disorders O O
can O O
be O O
based O O
on O O
the O O
demonstration O O
of O O
non-random O O
X O O
inactivation O O
( O O
NRXI O O
) O O
in O O
affected O O
blood O O
cell O O
lineages O O
when O O
growth O O
is O O
impaired O O
in O O
cells O O
expressing O O
the O O
abnormal B B_GENE
gene I I_GENE
. O O

We O O
examined O O
the O O
utility O O
of O O
seeking O O
evidence O O
of O O
NRXI O O
to O O
test O O
the O O
carrier O O
status O O
of O O
women O O
in O O
families O O
affected O O
by O O
X-linked O O
severe O O
combined O O
immunodeficiency O O
( O O
XSCID O O
) O O
and O O
X-linked O O
hypogammaglobulinaemia O O
( O O
XLH O O
) O O
, O O
to O O
identify O O
as O O
carriers O O
the O O
mothers O O
of O O
boys O O
with O O
SCID O O
or O O
hypogammaglobulinaemia O O
whose O O
phenotype O O
suggested O O
X-linkage O O
and O O
to O O
infer O O
X-linkage O O
in O O
boys O O
with O O
SCID O O
or O O
hypogammaglobulinaemia O O
whose O O
disease O O
was O O
not O O
clearly O O
X-linked O O
on O O
the O O
basis O O
either O O
of O O
family O O
history O O
or O O
clinical O O
and O O
immunological O O
characteristics O O
. O O

RESULTS O O
: O O
Heterozygosity O O
was O O
found O O
in O O
24 O O
of O O
31 O O
female O O
subjects O O
( O O
77 O O
% O O
) O O
. O O

The O O
finding O O
of O O
NRXI O O
in O O
the O O
mother O O
of O O
a O O
boy O O
with O O
a O O
SCID O O
variant O O
showed O O
her O O
to O O
be O O
a O O
carrier O O
of O O
XSCID O O
and O O
establishes O O
that O O
her O O
son O O
has O O
XSCID O O
, O O
not O O
otherwise O O
evident O O
from O O
available O O
data O O
. O O

CONCLUSIONS O O
: O O
This O O
PCR O O
assay O O
provides O O
a O O
rapid O O
method O O
for O O
carrier O O
detection O O
of O O
X-linked O O
immunodeficiencies O O
, O O
and O O
has O O
allowed O O
us O O
to O O
expand O O
the O O
phenotype O O
of O O
XSCID O O

Leukocyte-endothelial O O
interaction O O
is O O
augmented O O
by O O
high O O
glucose O O
concentrations O O
and O O
hyperglycemia O O
in O O
a O O
NF-kB-dependent O O
fashion O O
. O O

At O O
the O O
end O O
of O O
incubation O O
endothelial O O
cells O O
were O O
perfused O O
with O O
total O O
leukocyte O O
suspension O O
in O O
a O O
parallel O O
plate O O
flow O O
chamber O O
under O O
laminar O O
flow O O
( O O
1.5 O O
dyn/cm2 O O
) O O
. O O

Rolling O O
and O O
adherent O O
cells O O
were O O
evaluated O O
by O O
digital O O
image O O
processing O O
. O O

Results O O
showed O O
that O O
30 O O
mM O O
glucose O O
significantly O O
( O O
P O O
< O O
0.01 O O
) O O
increased O O
the O O
number O O
of O O
adherent O O
leukocytes O O
to O O
endothelial O O
cells O O
in O O
respect O O
to O O
control O O
( O O
5 O O
mM O O
glucose O O
; O O
151+/-19 O O
versus O O
33+/-8 O O
cells/mm2 O O
) O O
. O O

A O O
similar O O
response O O
was O O
induced O O
by O O
endothelial O O
stimulation O O
with O O
IL-1beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
here O O
used O O
as O O
positive O O
control O O
( O O
195+/-20 O O
cells/mm2 O O
) O O
. O O

The O O
number O O
of O O
rolling O O
cells O O
on O O
endothelial O O
surface O O
was O O
not O O
affected O O
by O O
high O O
glucose O O
level O O
. O O

Stable O O
adhesion O O
of O O
leukocytes O O
to O O
glucose-treated O O
as O O
well O O
as O O
to O O
IL-1beta-stimulated O O
endothelial O O
cells O O
was O O
preceded O O
by O O
short O O
interaction O O
of O O
leukocytes O O
with O O
the O O
endothelial O O
surface O O
. O O

Functional O O
blocking O O
of O O
E-selectin B B_GENE
, O O
intercellular B B_GENE
cell I I_GENE
adhesion I I_GENE
molecule-1 I I_GENE
, O O
and O O
vascular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecule-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
endothelial O O
cells O O
with O O
the O O
corresponding O O
mouse B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mAb I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
significantly O O
inhibited O O
glucose-induced O O
increase O O
in O O
leukocyte O O
adhesion O O
( O O
67+/-16 O O
, O O
83+/-12 O O
, O O
62+/-8 O O
versus O O
144+/-21 O O
cells/ O O
mm2 O O
) O O
. O O

Confocal O O
fluorescence O O
microscopy O O
studies O O
showed O O
that O O
30 O O
mM O O
glucose O O
induced O O
an O O
increase O O
in O O
endothelial O O
surface O O
expression O O
of O O
E-selectin B B_GENE
, O O
intercellular B B_GENE
cell I I_GENE
adhesion I I_GENE
molecule-1 I I_GENE
, O O
and O O
vascular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecule-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Electrophoretic O O
mobility O O
shift O O
assay O O
of O O
nuclear O O
extracts O O
of O O
human O O
umbilical O O
vein O O
endothelial O O
cells O O
( O O
HUVEC O O
) O O
exposed O O
for O O
1 O O
h O O
to O O
30 O O
mM O O
glucose O O
revealed O O
an O O
intense O O
NF-kB B B_GENE
activation O O
. O O

A O O
significant O O
( O O
P O O
< O O
0.01 O O
) O O
inhibitory O O
effect O O
on O O
glucose-induced O O
leukocyte O O
adhesion O O
was O O
observed O O
after O O
blocking O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
with O O
staurosporine O O
( O O
5 O O
nM O O
) O O
. O O

When O O
HUVEC O O
were O O
treated O O
with O O
specific O O
antisense O O
oligodesoxynucleotides O O
against O O
PKCalpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PKCepsilon I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
before O O
the O O
addition O O
of O O
30 O O
mM O O
glucose O O
, O O
a O O
significant O O
( O O
P O O
< O O
0.05 O O
) O O
reduction O O
in O O
the O O
adhesion O O
was O O
also O O
seen O O
. O O

Sera O O
from O O
diabetic O O
patients O O
significantly O O
( O O
P O O
< O O
0.01 O O
) O O
enhanced O O
leukocyte O O
adhesion O O
as O O
compared O O
with O O
controls O O
, O O
despite O O
normal O O
levels O O
of O O
IL-1beta B B_GENE
and O O
TNFalpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
sera O O
. O O

These O O
data O O
indicate O O
that O O
high O O
glucose O O
concentration O O
and O O
hyperglycemia O O
promote O O
leukocyte O O
adhesion O O
to O O
the O O
endothelium O O
through O O
upregulation O O
of O O
cell O O
surface O O
expression O O
of O O
adhesive O O
proteins O O
, O O
possibly O O
depending O O
on O O
NF-kB B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
. O O

Studies O O
on O O
the O O
molecular O O
mechanisms O O
that O O
control O O
hemopoietic O O
differentiation O O
have O O
focused O O
on O O
signaling O O
cascades O O
and O O
nuclear O O
effectors O O
that O O
drive O O
this O O
complex O O
developmental O O
system O O
in O O
a O O
regulated O O
fashion O O
. O O

Here O O
we O O
review O O
the O O
role O O
of O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
founding O O
member O O
of O O
a O O
unique O O
family O O
of O O
zinc B B_GENE/B_BIO
finger I I_GENE/I_BIO
transcription I I_GENE/I_BIO
factors I I_GENE/I_BIO
in O O
this O O
developmental O O
process O O
. O O

Studies O O
on O O
an O O
Ikaros B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
null O O
mutation O O
have O O
revealed O O
an O O
essential O O
role O O
for O O
this O O
factor O O
in O O
lymphoid O O
cell O O
fate O O
determination O O
and O O
at O O
subsequent O O
branch O O
points O O
of O O
the O O
T O O
cell O O
differentiation O O
pathway O O
. O O

Differences O O
in O O
the O O
phenotypes O O
of O O
a O O
null O O
and O O
a O O
dominant B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
negative I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DN I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Ikaros I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
provide O O
insight O O
into O O
a O O
regulatory O O
network O O
through O O
which O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exert O O
their O O
effects O O
in O O
development O O
. O O

The O O
transcription B B_GENE
factors I I_GENE
encoded O O
by O O
the O O
E2A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
early B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
B I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
cell I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EBF B B_PROTEIN[GENE]/B_LOCATION
) O O
genes O O
are O O
required O O
for O O
the O O
proper O O
development O O
of O O
B O O
lymphocytes O O
. O O

However O O
, O O
the O O
absence O O
of O O
B O O
lineage O O
cells O O
in O O
E2A- O O
and O O
EBF-deficient O O
mice O O
has O O
made O O
it O O
difficult O O
to O O
determine O O
the O O
function O O
or O O
relationship O O
between O O
these O O
proteins O O
. O O

We O O
report O O
the O O
identification O O
of O O
a O O
novel O O
model O O
system O O
in O O
which O O
the O O
role O O
of O O
E2A B B_LOCATION/B_GENE
and O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
regulation O O
of O O
multiple O O
B O O
lineage O O
traits O O
can O O
be O O
studied O O
. O O

We O O
found O O
that O O
the O O
conversion O O
of O O
70Z/3 O O
pre-B O O
lymphocytes O O
to O O
cells O O
with O O
a O O
macrophage-like O O
phenotype O O
is O O
associated O O
with O O
the O O
loss O O
of O O
E2A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Activation O O
of O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
one O O
of O O
the O O
critical O O
functions O O
of O O
E12 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
regulating O O
the O O
B O O
lineage O O
phenotype O O
since O O
expression O O
of O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
leads O O
to O O
the O O
activation O O
of O O
a O O
subset O O
of O O
E12 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-inducible O O
traits O O
. O O

Activation-induced O O
down-regulation O O
of O O
retinoid B B_GENE
receptor I I_GENE
RXRalpha I I_GENE
expression O O
in O O
human O O
T O O
lymphocytes O O
. O O

Role O O
of O O
cell O O
cycle O O
regulation O O
. O O

A O O
5.4-kilobase B B_GENE
mRNA I I_GENE
, O O
the O O
expression O O
of O O
which O O
is O O
down-regulated O O
after O O
treatment O O
of O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMCs O O
) O O
with O O
various O O
T O O
cell-activating O O
agents O O
, O O
was O O
isolated O O
using O O
an O O
mRNA O O
differential O O
display O O
method O O
. O O

Activated O O
PBMCs O O
also O O
expressed O O
lower O O
levels O O
of O O
RXRalpha B B_GENE/B_LOCATION
protein O O
, O O
and O O
a O O
DNA O O
binding O O
assay O O
showed O O
that O O
the O O
activation-induced O O
loss O O
of O O
RXRalpha B B_GENE
mRNA I I_GENE
and O O
protein O O
expression O O
correlated O O
with O O
the O O
loss O O
of O O
DNA O O
binding O O
activity O O
of O O
this O O
protein O O
. O O

We O O
present O O
evidence O O
that O O
the O O
transition O O
from O O
G0/G1 O O
to O O
S O O
phase O O
of O O
the O O
cell O O
cycle O O
results O O
in O O
the O O
down-regulation O O
of O O
RXRalpha B B_GENE
expression O O
and O O
that O O
cell O O
cycle O O
inhibitors O O
, O O
which O O
block O O
the O O
cells O O
in O O
G1 O O
phase O O
, O O
prevent O O
this O O
down-regulation O O
. O O

The O O
decrease O O
in O O
the O O
levels O O
of O O
RXRalpha B B_GENE
mRNA I I_GENE
was O O
found O O
to O O
be O O
regulated O O
at O O
the O O
post-transcriptional O O
level O O
and O O
involved O O
new O O
protein O O
synthesis O O
. O O

These O O
observations O O
indicate O O
that O O
the O O
levels O O
of O O
RXRalpha B B_GENE/B_LOCATION
expression O O
in O O
T O O
lymphocytes O O
are O O
coupled O O
to O O
cell O O
cycle O O
progression O O
, O O
and O O
there O O
is O O
tight O O
regulatory O O
control O O
of O O
RXRalpha B B_GENE/B_BIO
expression O O
during O O
the O O
transition O O
from O O
G0/G1 O O
to O O
S O O
phase O O
of O O
the O O
cell O O
cycle O O
. O O

Epidemiology O O
and O O
pathogenesis O O
of O O
AIDS-related O O
lymphomas O O
. O O

Among O O
patients O O
with O O
congenital O O
and O O
acquired O O
immunodeficiencies O O
, O O
non-Hodgkin O O
's O O
lymphoma O O
( O O
NHLs O O
) O O
are O O
the O O
most O O
common O O
tumors O O
of O O
the O O
immune O O
system O O
. O O

In O O
the O O
setting O O
of O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
infection O O
, O O
as O O
many O O
as O O
10 O O
% O O
to O O
20 O O
% O O
of O O
people O O
ultimately O O
developed O O
NHLs O O
. O O

These O O
tumors O O
are O O
clinically O O
aggressive O O
, O O
frequently O O
involve O O
extranodal O O
sites O O
, O O
and O O
often O O
exhibit O O
unique O O
features O O
that O O
distinguish O O
them O O
from O O
NHL O O
arising O O
in O O
individuals O O
with O O
other O O
forms O O
of O O
immunosuppression O O
. O O

Elucidation O O
of O O
the O O
factors O O
that O O
contribute O O
to O O
the O O
high O O
incidence O O
of O O
NHL O O
among O O
patients O O
infected O O
with O O
HIV O O
provides O O
insights O O
into O O
important O O
elements O O
of O O
lymphomagenesis O O
. O O

Matrix B B_GENE/B_PERSON
metalloproteinase I I_GENE/I_PERSON
expression O O
in O O
human O O
breast O O
cancer O O
: O O
an O O
immunohistochemical O O
study O O
including O O
correlation O O
with O O
cathepsin B B_GENE
D I I_GENE
, O O
type B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
collagen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
laminin B B_GENE
, O O
fibronectin B B_GENE
, O O
EGFR B B_GENE
, O O
c-erbB-2 B B_GENE/B_LOCATION
oncoprotein I I_GENE/I_LOCATION
, O O
p53 B B_GENE
, O O
steroid O O
receptors O O
status O O
and O O
proliferative O O
indices O O
. O O

Matrix B B_GENE/B_PERSON
metalloproteinase I I_GENE/I_PERSON
s O O
( O O
MMPs B B_GENE/B_BACTERIUM[BIO]
) O O
are O O
a O O
group O O
of O O
enzymes O O
thought O O
to O O
be O O
responsible O O
for O O
both O O
normal O O
connective O O
tissue O O
matrix O O
remodelling O O
and O O
accelerated O O
breakdown O O
associated O O
with O O
tumour O O
development O O
. O O

The O O
current O O
study O O
aimed O O
to O O
investigate O O
the O O
immunohistochemical O O
expression O O
of O O
matrix B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
metalloproteinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MMP-3 B B_GENE/B_LOCATION
, O O
stromelysin-1 B B_GENE/B_MEASURE
) O O
in O O
correlation O O
with O O
the O O
expression O O
of O O
Basement B B_GENE
Membrane I I_GENE
( I I_GENE
BM I I_GENE
) I I_GENE
antigen I I_GENE
( O O
type B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
collagen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
laminin B B_GENE
) O O
, O O
fibronectin B B_GENE
, O O
cathepsin B B_GENE
D I I_GENE
, O O
p53 B B_GENE
, O O
c-erbB-2 B B_GENE
, O O
proliferative O O
activity O O
( O O
Ki-67 B B_GENE/B_LOCATION
, O O
PCNA B B_GENE/B_MEASURE
) O O
, O O
steroid O O
receptor O O
content O O
as O O
well O O
as O O
to O O
the O O
other O O
conventional O O
clinicopathological O O
parameters O O
in O O
breast O O
cancer O O
. O O

This O O
study O O
was O O
performed O O
on O O
a O O
series O O
of O O
frozen O O
and O O
paraffin O O
sections O O
from O O
84 O O
breast O O
cancer O O
specimens O O
by O O
immunohistochemistry O O
using O O
the O O
monoclonal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibody I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MMP-3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Ab-1 B B_GENE/B_MEASURE
) O O
. O O

Stromelysin-1 B B_GENE/B_DISEASE
( O O
ST1 B B_GENE/B_DISEASE
) O O
was O O
observed O O
in O O
about O O
10 O O
% O O
of O O
epithelial O O
cells O O
in O O
the O O
control O O
groups O O
( O O
cases O O
of O O
fibrocystic O O
and O O
benign O O
proliferative O O
breast O O
disease O O
) O O
, O O
while O O
expression O O
( O O
> O O
10 O O
% O O
of O O
expression O O
) O O
was O O
detected O O
in O O
89.7 O O
% O O
of O O
tumours O O
. O O

The O O
expression O O
of O O
ST1 B B_GENE
in O O
carcinoma O O
cells O O
was O O
strongly O O
associated O O
with O O
its O O
presence O O
in O O
the O O
stroma O O
( O O
p O O
< O O
0.001 O O
) O O
. O O

A O O
significantly O O
positive O O
correlation O O
was O O
found O O
between O O
ST1 B B_GENE
expression O O
, O O
and O O
p53 B B_GENE/B_PERSON
tumour O O
suppressor O O
gene O O
product O O
( O O
p O O
= O O
0.004 O O
) O O
, O O
and O O
a O O
relationship O O
with O O
c-erbB-2 B B_GENE
protein O O
and O O
progesterone O O
receptor O O
status O O
was O O
also O O
indicated O O
. O O

These O O
findings O O
suggest O O
that O O
ST1 B B_GENE
expression O O
in O O
breast O O
cancer O O
tissue O O
is O O
irrespective O O
of O O
the O O
expression O O
of O O
the O O
extracellular O O
matrix O O
component O O
, O O
the O O
proteolytic B B_ENZYME[GENE]/B_MEASURE
enzyme I B_ENZYME[GENE]/I_MEASURE
cathepsin B B_ENZYME[GENE]/I_MEASURE
D I B_ENZYME[GENE]/I_MEASURE
and O O
the O O
growth O O
fraction O O
of O O
the O O
tumour O O
, O O
and O O
that O O
it O O
could O O
be O O
a O O
potential O O
new O O
prognostic O O
marker O O
in O O
breast O O
cancer O O
. O O

Use O O
of O O
transfected O O
liver O O
cells O O
to O O
evaluate O O
potential O O
mechanisms O O
of O O
alcohol-induced O O
liver O O
injury O O
[ O O
see O O
comments O O
] O O

Hepatic O O
neutrophil O O
infiltration O O
is O O
a O O
principal O O
injurious O O
manifestation O O
of O O
ALD O O
. O O

TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O O
induce O O
cellular O O
oxidative O O
injury O O
directly O O
, O O
and O O
indirectly O O
by O O
inducing O O
neutrophil O O
chemotactic O O
factor O O
( O O
IL-8 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
production O O
by O O
hepatocytes O O
. O O

IL-8 B B_DISEASE/B_GENE
activates O O
and O O
chemotactically O O
attracts O O
neutrophils O O
to O O
the O O
liver O O
where O O
they O O
release O O
oxidizing O O
substances O O
. O O

Manganous B B_ENZYME[GENE]
superoxide I I_ENZYME[GENE]
dismutase I I_ENZYME[GENE]
( O O
MnSOD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
is O O
an O O
antioxidant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
protective I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
. O O

Inactivation O O
of O O
the O O
NF-kappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3'NF-IL-6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
decreased O O
IL-8 B B_GENE/B_PERSON
gene I I_GENE/I_PERSON
transcriptional O O
activation O O
in O O
response O O
to O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
while O O
inactivation O O
of O O
the O O
5'NF-IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
increased O O
IL-8 B B_GENE/B_BIO
gene I I_GENE/I_BIO
transcriptional O O
activity O O
in O O
response O O
to O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

This O O
system O O
may O O
be O O
useful O O
to O O
assess O O
the O O
effects O O
of O O
ethanol O O
on O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
hepatocyte O O
IL-8 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O O
. O O

In O O
the O O
second O O
set O O
of O O
experiments O O
, O O
HepG2 O O
cells O O
were O O
cultured O O
in O O
25 O O
to O O
100 O O
mmol O O
concentrations O O
of O O
ethanol O O
. O O

Further O O
studies O O
are O O
needed O O
to O O
assess O O
the O O
effect O O
of O O
this O O
diminished O O
induction O O
of O O
MnSOD B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
chronic O O
ethanol O O
culture O O
on O O
HepG2 O O
cell O O
susceptibility O O
to O O
TNF O O
cytotoxicity O O
. O O

Local O O
hypoxemia O O
and O O
stasis O O
trigger O O
thrombosis O O
. O O

We O O
now O O
show O O
that O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
early-growth-response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
product I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Egr-1 B B_GENE/B_DISEASE
) O O
is O O
rapidly O O
activated O O
in O O
hypoxia O O
, O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
, O O
and O O
is O O
responsible O O
for O O
transcription O O
and O O
expression O O
of O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
hypoxic O O
lung O O
. O O

Using O O
32P-labeled O O
Egr O O
consensus O O
oligonucleotide O O
, O O
we O O
observed O O
induction O O
of O O
DNA-binding O O
activity O O
in O O
nuclear O O
extracts O O
from O O
hypoxic O O
lung O O
and O O
HeLa O O
cells O O
because O O
of O O
activation O O
of O O
Egr-1 B B_GENE
, O O
by O O
means O O
of O O
supershift O O
analysis O O
. O O

Transient O O
transfection O O
of O O
HeLa O O
cells O O
with O O
chimeric B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plasmids I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
wild-type B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SRR I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
tissue B B_GENE/B_BIO
factor I I_GENE/I_BIO
promoter I I_GENE/I_BIO
showed O O
that O O
intact B B_GENE/B_MEASURE
Sp1 I I_GENE/I_MEASURE
sites I I_GENE/I_MEASURE
are O O
necessary O O
for O O
basal O O
promoter O O
activity O O
, O O
whereas O O
the O O
integrity O O
of O O
Egr-1 B B_GENE/B_MEASURE
sites I I_GENE/I_MEASURE
was O O
required O O
for O O
hypoxia-enhanced O O
expression O O
. O O

Kinetics O O
of O O
cytokine O O
and O O
NFAT O O
gene O O
expression O O
in O O
human O O
interleukin-2-dependent O O
T O O
lymphoblasts O O
stimulated O O
via O O
T-cell B B_GENE
receptor I I_GENE
. O O

T O O
cells O O
respond O O
to O O
mitogenic O O
or O O
antigenic O O
stimulation O O
by O O
proliferation O O
and O O
by O O
turning O O
on O O
cytokine O O
gene O O
expression O O
. O O

Anti-CD3-restimulated O O
T O O
cells O O
( O O
mainly O O
CD8+ O O
) O O
produced O O
IL-2 B B_GENE
, O O
interferon-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IFN-gamma B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
tumour B B_GENE
necrosis I I_GENE
factor-alpha I I_GENE
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
low O O
levels O O
of O O
IL-4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-10 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
proteins O O
. O O

No O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
was O O
observed O O
. O O

In O O
LCL-stimulated O O
cells O O
the O O
cytokine O O
production O O
pattern O O
was O O
very O O
similar O O
. O O

Steady-state O O
mRNA O O
levels O O
of O O
IL-2 B B_GENE
, O O
IL-10 B B_GENE
and O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
peaked O O
at O O
3 O O
hr O O
after O O
anti-CD3 O O
stimulation O O
and O O
declined O O
rapidly O O
thereafter O O
. O O

The O O
kinetics O O
of O O
TNF-alpha B B_GENE
mRNA I I_GENE
expression O O
was O O
faster O O
, O O
being O O
at O O
its O O
peak O O
level O O
1 O O
hr O O
after O O
stimulation O O
. O O

Anti-CD3-stimulated O O
IL-2 B B_GENE
gene I I_GENE
expression O O
was O O
down-regulated O O
by O O
protein O O
synthesis O O
inhibitor O O
, O O
whereas O O
IL-10 B B_GENE/B_PERSON
, I I_GENE/I_PERSON
IFN-gamma I I_GENE/I_PERSON
and I I_GENE/I_PERSON
TNF-alpha I I_GENE/I_PERSON
genes I I_GENE/I_PERSON
were O O
readily O O
induced O O
independent O O
of O O
ongoing O O
protein O O
synthesis O O
. O O

T-cell B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O O
also O O
induced O O
a O O
very O O
rapid O O
expression O O
of O O
c-jun B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-fos I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NFATc1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NFATc I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
gene O O
products O O
of O O
which O O
are O O
involved O O
in O O
cytokine O O
gene O O
expression O O
. O O

In O O
conclusion O O
, O O
the O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesized O O
by O O
IL-2-dependent O O
T O O
cells O O
were O O
predominantly O O
IL-2 B B_GENE
, O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

An O O
animal O O
model O O
to O O
study O O
local O O
oxidation O O
of O O
LDL O O
and O O
its O O
biological O O
effects O O
in O O
the O O
arterial O O
wall O O
. O O

Mainly O O
on O O
the O O
basis O O
of O O
cell O O
culture O O
studies O O
, O O
oxLDL O O
has O O
been O O
shown O O
to O O
produce O O
many O O
biological O O
effects O O
that O O
influence O O
the O O
atherosclerotic O O
process O O
. O O

To O O
study O O
LDL O O
oxidation O O
in O O
vivo O O
, O O
we O O
have O O
established O O
a O O
model O O
in O O
which O O
Sprague-Dawley O O
rats O O
are O O
given O O
a O O
single O O
injection O O
of O O
unmodified O O
human O O
LDL O O
( O O
> O O
or O O
= O O
4 O O
mg/kg O O
body O O
weight O O
) O O
. O O

Within O O
6 O O
hours O O
, O O
an O O
accumulation O O
of O O
apolipoprotein O O
B O O
and O O
epitopes B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
present O O
on O O
oxLDL O O
are O O
detected O O
in O O
the O O
arterial O O
endothelium O O
and O O
media O O
. O O

The O O
presence O O
of O O
oxLDL O O
is O O
associated O O
with O O
activation O O
of O O
the O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
nuclear B I_GENE/I_LOCATION
factor-kappaB I I_GENE/I_LOCATION
in O O
the O O
endothelium O O
as O O
well O O
as O O
endothelial O O
expression O O
of O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
. O O

Thus O O
, O O
this O O
simple O O
model O O
has O O
the O O
potential O O
to O O
analyze O O
the O O
mechanisms O O
behind O O
and O O
biological O O
effects O O
of O O
LDL O O
oxidation O O
in O O
vivo O O
. O O

Molecular O O
mechanisms O O
of O O
promoter O O
regulation O O
of O O
the O O
gp34 B B_GENE
gene I I_GENE
that O O
is O O
trans-activated O O
by O O
an O O
oncoprotein B B_GENE/B_DISEASE
Tax I I_GENE/I_DISEASE
of O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
I O O
. O O

We O O
investigated O O
the O O
molecular O O
mechanism O O
of O O
transcriptional O O
activation O O
of O O
the O O
gp34 B B_GENE
gene I I_GENE
by O O
the O O
Tax B B_GENE
oncoprotein I I_GENE
of O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV-I O O
) O O
. O O

gp34 B B_GENE
is O O
a O O
type B B_GENE
II I I_GENE
transmembrane I I_GENE
molecule I I_GENE
belonging O O
to O O
the O O
tumor O O
necrosis O O
factor O O
family O O
and O O
is O O
constitutively O O
expressed O O
on O O
HTLV-I-producing O O
cells O O
but O O
not O O
normal O O
resting O O
T O O
cells O O
. O O

The O O
transcriptional O O
regulatory O O
region O O
of O O
the O O
gp34 B B_GENE
gene I I_GENE
was O O
activated O O
by O O
HTLV-I O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
human O O
T O O
cell O O
line O O
Jurkat O O
, O O
in O O
which O O
endogenous O O
gp34 B B_GENE
is O O
induced O O
by O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

NF-kappaB B B_GENE/B_LOCATION
-like O O
element O O
2 O O
elevated O O
promoter O O
activity O O
when O O
combined O O
with O O
NF-kappaB-like B B_GENE
element I I_GENE
1 I I_GENE
, O O
indicating O O
cooperative O O
function O O
of O O
the O O
elements O O
for O O
maximum O O
promoter O O
function O O
. O O

Unlike O O
typical O O
NF-kappaB B B_GENE/B_BIO
elements I I_GENE/I_BIO
, O O
the O O
NF-kappaB-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
gp34 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
not O O
activated O O
by O O
treatment O O
of O O
Jurkat O O
cells O O
with O O
phorbol O O
ester O O
despite O O
induction O O
of O O
the O O
NF-kappaB B B_GENE
-like O O
binding O O
activity O O
. O O

Chloramphenicol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acetyltransferase I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter O O
assays O O
using O O
the O O
region O O
upstream O O
of O O
the O O
NF-kappaB-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
identified O O
an O O
upstream O O
region O O
that O O
reduced O O
transcription O O
from O O
cognate B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
noncognate I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
core I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
promoters I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
a O O
Tax-independent O O
manner O O
. O O

Our O O
results O O
imply O O
complex O O
regulation O O
of O O
expression O O
of O O
the O O
gp34 B B_GENE
gene I I_GENE
and O O
suggest O O
implication O O
of O O
gp34 B B_GENE
in O O
proliferation O O
of O O
HTLV-I O O
infected O O
T O O
cells O O
. O O

Abeta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
the O O
rapid O O
, O O
transient O O
activation O O
of O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ERK1 B B_GENE
) O O
and O O
ERK2 B B_GENE
in O O
microglia O O
and O O
ERK2 B B_GENE
in O O
THP1 O O
monocytes O O
. O O

A O O
second O O
superfamily B B_GENE/B_PERSON
member I I_GENE/I_PERSON
, O O
p38 B B_GENE
MAPK I I_GENE
, O O
was O O
also O O
activated O O
with O O
similar O O
kinetics O O
. O O

Scavenger B B_GENE
receptor I I_GENE
and O O
receptor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
for I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
advanced I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
end I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
RAGE B B_GENE/B_DISEASE
) O O
ligands O O
failed O O
to O O
activate O O
ERK B B_GENE
and O O
p38 B B_GENE
MAPK I I_GENE
in O O
the O O
absence O O
of O O
significant O O
increases O O
in O O
protein O O
tyrosine O O
phosphorylation O O
, O O
demonstrating O O
that O O
scavenger B B_GENE
receptors I I_GENE
and O O
RAGE B B_GENE
are O O
not O O
linked O O
to O O
these O O
pathways O O
. O O

Importantly O O
, O O
the O O
stress-activated B B_GENE/B_BIO
protein I I_GENE/I_BIO
kinases I I_GENE/I_BIO
( O O
SAPKs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
not O O
significantly O O
activated O O
in O O
response O O
to O O
Abeta B B_DISEASE/B_GENE
. O O

Downstream O O
effectors O O
of O O
the O O
MAPK O O
signal O O
transduction O O
cascades O O
include O O
MAPKAP B B_ENZYME[GENE]/B_BIO
kinases I I_ENZYME[GENE]/I_BIO
, O O
such O O
as O O
RSK1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
RSK2 B B_GENE
, O O
as O O
well O O
as O O
transcription B B_GENE
factors I I_GENE
. O O

Exposure O O
of O O
microglia O O
and O O
THP1 O O
monocytes O O
to O O
Abeta B B_GENE
resulted O O
in O O
the O O
activation O O
of O O
RSK1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
RSK2 B B_GENE
and O O
phosphorylation O O
of O O
cAMP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
at O O
Ser133 O O
, O O
providing O O
a O O
mechanism O O
for O O
Abeta B B_GENE/B_DISEASE
-induced O O
changes O O
in O O
gene O O
expression O O

Regulation O O
of O O
cellular B B_GENE/B_DISEASE
retinoic I I_GENE/I_DISEASE
acid I I_GENE/I_DISEASE
binding I I_GENE/I_DISEASE
protein I I_GENE/I_DISEASE
( O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
during O O
human O O
monocyte O O
differentiation O O
in O O
vitro O O
. O O

Cellular B B_GENE/B_PERSON
retinoic I I_GENE/I_PERSON
acid I I_GENE/I_PERSON
binding I I_GENE/I_PERSON
proteins I I_GENE/I_PERSON
( O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
are O O
low B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecular I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
weight I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
whose O O
precise O O
function O O
remains O O
unknown O O
. O O

They O O
bind O O
retinoids O O
and O O
may O O
thereby O O
modulate O O
the O O
intracellular O O
steady-state O O
concentration O O
of O O
retinoids O O
. O O

By O O
representative O O
difference O O
analysis O O
we O O
found O O
that O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
also O O
strongly O O
expressed O O
in O O
human O O
monocyte-derived O O
macrophages O O
( O O
MAC O O
) O O
but O O
not O O
in O O
freshly O O
isolated O O
monocytes O O
( O O
MO O O
) O O
. O O

The O O
CRABP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
gradually O O
upregulated O O
during O O
differentiation O O
from O O
MO O O
to O O
MAC O O
in O O
the O O
presence O O
of O O
2 O O
% O O
serum O O
. O O

As O O
MO O O
can O O
differentiate O O
along O O
the O O
classical O O
pathway O O
not O O
only O O
to O O
MAC O O
but O O
also O O
to O O
dendritic O O
cells O O
we O O
analyzed O O
the O O
expression O O
of O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
MO-derived O O
dendritic O O
cells O O
cultured O O
with O O
10 O O
% O O
FCS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
IL-4 B B_GENE/B_LOCATION
, O O
and O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
contrast O O
to O O
MAC O O
, O O
MO-derived O O
dendritic O O
cells O O
showed O O
an O O
extremely O O
low O O
expression O O
of O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
paired B B_GENE
box I I_GENE
containing I I_GENE
gene I I_GENE
PAX-5 B I_GENE
encodes O O
the O O
transcription B B_GENE/B_DISEASE
factor I I_GENE/I_DISEASE
BSAP B I_GENE/I_DISEASE
( O O
B-cell-specific B B_PROTEIN[GENE]/B_DISEASE
activator I I_PROTEIN[GENE]/I_DISEASE
protein I I_PROTEIN[GENE]/I_DISEASE
) O O
, O O
which O O
plays O O
a O O
key O O
role O O
in O O
B-lymphocyte O O
development O O
. O O

Despite O O
its O O
known O O
involvement O O
in O O
a O O
rare O O
subtype O O
of O O
non-Hodgkin O O
's O O
lymphoma O O
( O O
NHL O O
) O O
, O O
a O O
detailed O O
examination O O
of O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
in O O
NHL O O
has O O
not O O
been O O
previously O O
reported O O
. O O

In O O
this O O
study O O
, O O
we O O
analyzed O O
normal O O
and O O
malignant O O
lymphoid O O
tissues O O
and O O
cell O O
lines O O
, O O
including O O
102 O O
cases O O
of O O
B-cell O O
NHL O O
, O O
23 O O
cases O O
of O O
T- O O
and O O
null-cell O O
NHL O O
, O O
and O O
18 O O
cases O O
of O O
Hodgkin O O
's O O
disease O O
. O O

Normal O O
lymphoid O O
tissues O O
showed O O
strong O O
nuclear O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
in O O
mantle O O
zone O O
B O O
cells O O
, O O
less O O
intense O O
reactivity O O
in O O
follicular O O
center O O
B O O
cells O O
, O O
and O O
no O O
expression O O
in O O
cells O O
of O O
the O O
T-cell-rich O O
zones O O
. O O

Monocytoid O O
B O O
cells O O
showed O O
weak O O
expression O O
, O O
whereas O O
plasma O O
cells O O
and O O
extrafollicular O O
large O O
transformed O O
B O O
cells O O
were O O
negative O O
. O O

Of O O
the O O
102 O O
B-cell O O
NHLs O O
, O O
83 O O
( O O
81 O O
% O O
) O O
demonstrated O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
. O O

Eight O O
of O O
12 O O
( O O
67 O O
% O O
) O O
marginal O O
zone O O
lymphoma O O
cases O O
showed O O
negative O O
or O O
low O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
, O O
and O O
17 O O
of O O
24 O O
( O O
71 O O
% O O
) O O
large O O
B-cell O O
lymphomas O O
displayed O O
moderate O O
to O O
strong O O
expression O O
. O O

Western O O
blot O O
analysis O O
showed O O
a O O
52-kD O O
BSAP B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
band O O
in O O
B-cell O O
lines O O
, O O
but O O
not O O
in O O
non-B-cell O O
or O O
plasma O O
cell O O
lines O O
. O O

We O O
conclude O O
that O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
is O O
largely O O
restricted O O
to O O
lymphomas O O
of O O
B-cell O O
lineage O O
and O O
that O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
varies O O
in O O
B-cell O O
subsets O O
and O O
subtypes O O
of O O
B-cell O O
NHL O O
. O O

The O O
high O O
levels O O
of O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
especially O O
those O O
found O O
in O O
large-cell O O
lymphomas O O
and O O
in O O
some O O
follicular O O
lymphomas O O
, O O
may O O
be O O
a O O
consequence O O
of O O
deregulated O O
gene O O
expression O O
and O O
suggest O O
a O O
possible O O
involvement O O
of O O
PAX-5 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
certain O O
B-cell O O
malignancies O O
. O O

This O O
is O O
a O O
US O O
government O O
work O O
. O O

There O O
are O O
no O O
restrictions O O
on O O
its O O
use O O
. O O

Mitogen O O
and O O
growth O O
factor-induced O O
activation O O
of O O
a O O
STAT-like B B_GENE/B_LOCATION
molecule I I_GENE/I_LOCATION
in O O
channel O O
catfish O O
lymphoid O O
cells O O
. O O

This O O
article O O
describes O O
the O O
identification O O
of O O
a O O
putative B B_GENE
STAT I I_GENE
molecule I I_GENE
in O O
the O O
channel O O
catfish O O
( O O
Ictalurus O O
punctatus O O
) O O
, O O
the O O
first O O
report O O
of O O
such O O
a O O
molecule O O
in O O
a O O
'lower O O
' O O
vertebrate O O
. O O

These O O
results O O
suggest O O
that O O
STAT B B_GENE/B_BIO
molecules I I_GENE/I_BIO
have O O
been O O
highly O O
conserved O O
in O O
vertebrate O O
evolution O O
. O O

Isolation O O
and O O
analysis O O
of O O
a O O
T O O
cell O O
clone O O
variant O O
exhibiting O O
constitutively O O
phosphorylated B B_GENE
Ser133 I I_GENE
cAMP I I_GENE
response I I_GENE
element-binding I I_GENE
protein I I_GENE
. O O

In O O
driving O O
T O O
cell O O
proliferation O O
, O O
IL-2 B B_GENE
stimulates O O
a O O
new O O
program O O
of O O
gene O O
expression O O
that O O
includes O O
proliferating B B_GENE/B_DISEASE
cell I I_GENE/I_DISEASE
nuclear I I_GENE/I_DISEASE
antigen I I_GENE/I_DISEASE
( O O
PCNA B B_GENE
) O O
, O O
a O O
requisite O O
processivity O O
factor O O
for O O
DNA B B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
polymerase I B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
delta I B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

PCNA B B_GENE
transcription O O
is O O
regulated O O
in O O
part O O
through O O
tandem O O
CRE B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
promoter B B_GENE
and I I_GENE
CRE I I_GENE
binding I I_GENE
proteins I I_GENE
; O O
IL-2 B B_GENE
stimulates O O
CREB O O
phosphorylation O O
in O O
the O O
resting O O
cloned O O
T O O
lymphocyte O O
, O O
L2 O O
. O O

After O O
culturing O O
L2 O O
cells O O
for O O
greater O O
than O O
91 O O
days O O
, O O
we O O
consistently O O
isolate O O
a O O
stable O O
variant O O
that O O
exhibits O O
constitutive O O
CREB O O
phosphorylation O O
. O O

L2 O O
and O O
L2 O O
variant O O
cells O O
were O O
tested O O
for O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
responsiveness O O
and O O
rapamycin O O
sensitivity O O
with O O
respect O O
to O O
specific O O
kinase O O
activity O O
, O O
PCNA O O
expression O O
and O O
proliferation O O
. O O

In O O
L2 O O
cells O O
, O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulated O O
and O O
rapamycin O O
inhibited O O
the O O
following O O
: O O
cAMP-independent O O
CREB B B_GENE/B_LOCATION
kinase I I_GENE/I_LOCATION
activity O O
, O O
PCNA O O
expression O O
and O O
proliferation O O
. O O

In O O
L2 O O
variant O O
cells O O
, O O
CREB B B_GENE
kinase I I_GENE
activity O O
was O O
constitutively O O
high O O
; O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulated O O
and O O
rapamycin O O
blocked O O
PCNA O O
expression O O
and O O
proliferation O O
. O O

These O O
results O O
indicate O O
that O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
a O O
rapamycin-sensitive O O
, O O
cAMP-independent O O
CREB B B_GENE/B_DISEASE
kinase I I_GENE/I_DISEASE
activity O O
in O O
L2 O O
cells O O
. O O

However O O
, O O
phosphorylation O O
of O O
CREB B B_GENE
alone O O
is O O
not O O
sufficient O O
to O O
drive O O
PCNA B B_GENE
expression O O
and O O
L2 O O
cell O O
proliferation O O
in O O
the O O
absence O O
of O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Serotonin O O
derivative O O
, O O
N- O O
( O O
p-coumaroyl O O
) O O
serotonin O O
, O O
inhibits O O
the O O
production O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IL-1alpha B B_GENE
, O O
IL-1beta B B_GENE
, O O
and O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
by O O
endotoxin-stimulated O O
human O O
blood O O
monocytes O O
. O O

We O O
have O O
reported O O
that O O
N- O O
( O O
p-coumaroyl O O
) O O
serotonin O O
( O O
CS O O
) O O
and O O
its O O
derivatives O O
with O O
antioxidative O O
activity O O
are O O
present O O
in O O
safflower O O
seeds O O
. O O

As O O
reactive O O
oxygen O O
species O O
( O O
ROS O O
) O O
are O O
implicated O O
in O O
the O O
signaling O O
of O O
lipopolysaccharide O O
( O O
LPS O O
) O O
, O O
we O O
examined O O
whether O O
CS O O
has O O
a O O
suppressive O O
effect O O
on O O
inflammatory B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokine I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generation O O
from O O
human O O
monocyte O O
s O O
in O O
vitro O O
. O O

CS O O
at O O
50-200 O O
microM O O
reduced O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
necrosis I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factor I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
TNF B B_GENE/B_LOCATION
) O O
, O O
interleukin-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-1 B B_GENE
) O O
, O O
and O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activities O O
in O O
the O O
culture O O
supernatants O O
from O O
LPS-stimulated O O
human O O
blood O O
monocytes O O
without O O
cytotoxicity O O
. O O

ELISA O O
assay O O
revealed O O
that O O
the O O
production O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IL-1alpha B B_GENE
, O O
IL-1beta B B_GENE
, O O
and O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
inhibited O O
by O O
CS O O
. O O

Northern O O
blot O O
analysis O O
showed O O
that O O
LPS-induced O O
expression O O
of O O
these O O
cytokine B B_GENE
mRNA I I_GENE
in O O
monocytes O O
was O O
suppressed O O
by O O
CS O O
. O O

These O O
findings O O
indicate O O
that O O
CS O O
has O O
a O O
suppressive O O
effect O O
on O O
proinflammatory O O
cytokine O O
production O O
from O O
monocytes O O
, O O
and O O
this O O
effect O O
is O O
based O O
in O O
part O O
on O O
the O O
suppression O O
of O O
cytokine B B_GENE
mRNA I I_GENE
expression O O
through O O
inhibition O O
of O O
NF-kappaB B B_GENE
activation O O
. O O

Elevated O O
expression O O
of O O
differentiation B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nm23 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
monoblastic O O
crisis O O
of O O
a O O
patient O O
with O O
chronic O O
myelogenous O O
leukemia O O
. O O

Differentiation B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nm23 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
found O O
to O O
be O O
expressed O O
in O O
high O O
quantities O O
in O O
acute O O
myelogenous O O
leukemia O O
( O O
AML O O
) O O
, O O
especially O O
in O O
acute O O
monocytic O O
leukemia O O
( O O
AML-M5 O O
) O O
and O O
is O O
suggested O O
as O O
a O O
new O O
prognostic O O
factor O O
in O O
AML-M5 O O
. O O

We O O
report O O
an O O
example O O
of O O
elevated O O
expression O O
of O O
nm23 B B_GENE
mRNA I I_GENE
in O O
a O O
patient O O
with O O
chronic O O
myelogenous O O
leukemia O O
( O O
CML O O
) O O
who O O
developed O O
monoblastic O O
crisis O O
. O O

Relative O O
levels O O
of O O
nm23-H1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-H2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
extracted O O
from O O
the O O
patient O O
's O O
peripheral O O
blood O O
mononuclear O O
cells O O
and O O
bone O O
marrow O O
mononuclear O O
cells O O
were O O
measured O O
by O O
quantitative O O
reverse O O
transcriptase O O
polymerase O O
chain O O
reaction O O
. O O

The O O
level O O
of O O
nm23-H1 B B_GENE
mRNA I I_GENE
in O O
CML O O
cells O O
at O O
the O O
chronic O O
phase O O
was O O
as O O
high O O
as O O
that O O
in O O
bone O O
marrow O O
cells O O
from O O
healthy O O
volunteers O O
. O O

The O O
mRNA O O
level O O
of O O
nm23-H2 B B_GENE
was O O
slightly O O
below O O
the O O
normal O O
level O O
. O O

At O O
blastic O O
crisis O O
, O O
however O O
, O O
expression O O
of O O
both O O
nm23-H1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-H2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
elevated O O
to O O
about O O
three O O
to O O
nine O O
times O O
of O O
that O O
at O O
the O O
chronic O O
phase O O
. O O

Proliferated O O
blastic O O
cells O O
were O O
positive O O
for O O
non-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
esterase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
the O O
serum O O
lysozyme O O
level O O
was O O
elevated O O
and O O
diagnosed O O
as O O
monoblastic O O
crisis O O
. O O

The O O
patient O O
received O O
combined O O
chemotherapy O O
but O O
response O O
was O O
partial O O
. O O

These O O
findings O O
are O O
compatible O O
with O O
our O O
previous O O
report O O
that O O
nm23 B B_GENE
gene I I_GENE
is O O
overexpressed O O
in O O
monocytic O O
leukemia O O
. O O

Increased O O
transcription O O
decreases O O
the O O
spontaneous O O
mutation O O
rate O O
at O O
the O O
thymidine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
cells O O
. O O

Furthermore O O
, O O
increased O O
transcription O O
level O O
stimulates O O
spontaneous O O
mutation O O
rate O O
in O O
yeast O O
. O O

We O O
explored O O
whether O O
transcription O O
level O O
affects O O
spontaneous O O
mutation O O
rate O O
in O O
human O O
cells O O
. O O

In O O
our O O
TK6i-G3 O O
and O O
G9 O O
tk O O
heterozygous O O
cell O O
lines O O
, O O
the O O
active O O
tk B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
allele I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
linked O O
to O O
an O O
inducible O O
promoter B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
. O O

Copyright O O
1998 O O
Elsevier O O
Science O O
B.V O O
. O O

All O O
rights O O
reserved O O
. O O

Mutation O O
of O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
normal O O
B O O
cells O O
by O O
the O O
process O O
of O O
somatic O O
hypermutation O O
of O O
Ig B B_GENE
genes I I_GENE
. O O

Immunoglobulin B B_PERSON/B_GENE
( I I_PERSON/I_GENE
Ig I I_PERSON/I_GENE
) I I_PERSON/I_GENE
genes I I_PERSON/I_GENE
are O O
hypermutated O O
in O O
B O O
lymphocytes O O
that O O
are O O
the O O
precursors O O
to O O
memory O O
B O O
cells O O
. O O

Significant O O
mutations O O
were O O
not O O
observed O O
in O O
c-MYC B B_DISEASE/B_GENE
, I I_DISEASE/I_GENE
S14 I I_DISEASE/I_GENE
, I I_DISEASE/I_GENE
or I I_DISEASE/I_GENE
alpha-fetoprotein I I_DISEASE/I_GENE
( I I_DISEASE/I_GENE
AFP I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
genes I I_DISEASE/I_GENE
, O O
but O O
BCL-6 B B_GENE
was O O
highly O O
mutated O O
in O O
a O O
large O O
proportion O O
of O O
memory O O
B O O
cells O O
of O O
normal O O
individuals O O
. O O

The O O
mutation O O
pattern O O
was O O
similar O O
to O O
that O O
of O O
Ig B B_GENE/B_BIO
genes I I_GENE/I_BIO
. O O

We O O
have O O
analyzed O O
the O O
effect O O
of O O
complete O O
T O O
cell O O
activation O O
( O O
anti-CD3 O O
plus O O
anti-CD28 O O
) O O
on O O
the O O
activation O O
of O O
NF-kappaB B B_GENE
in O O
CD45RA+ O O
( O O
naive O O
) O O
and O O
CD45RO+ O O
( O O
memory/effector O O
) O O
T O O
cells O O
. O O

Long O O
exposure O O
( O O
24 O O
h O O
) O O
induced O O
stronger O O
NF-kappaB B B_GENE
DNA O O
binding O O
in O O
CD45RA+ O O
cells O O
than O O
in O O
CD45RO+ O O
cells O O
. O O

Analysis O O
of O O
the O O
nuclear B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
c-Rel I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
after O O
anti-CD3+anti-CD28 O O
stimulation O O
the O O
level O O
of O O
c-Rel B B_GENE
was O O
higher O O
in O O
CD45RA+ O O
cells O O
. O O

Analysis O O
of O O
the O O
cytoplasmic B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
inhibitor I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
IkappaBalpha B I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
indicated O O
that O O
anti-CD3+anti-CD28 O O
stimulation O O
induced O O
a O O
long-lasting O O
degradation O O
in O O
CD45RA+ O O
cells O O
but O O
in O O
CD45RO+ O O
cells O O
the O O
degradation O O
process O O
was O O
more O O
rapid O O
. O O

Because O O
the O O
CD28 B B_GENE
costimulus O O
is O O
known O O
to O O
induce O O
the O O
production O O
of O O
reactive O O
oxygen O O
intermediates O O
( O O
ROIs O O
) O O
, O O
the O O
intracellular O O
ROI O O
levels O O
in O O
CD45RA+ O O
and O O
CD45RO+ O O
cells O O
were O O
compared O O
by O O
flow O O
cytometry O O
. O O

ROIs O O
were O O
produced O O
in O O
both O O
cell O O
types O O
, O O
but O O
more O O
strongly O O
in O O
CD45RA+ O O
cells O O
. O O

Non-Hodgkin O O
's O O
lymphoma O O
involving O O
bilateral O O
breasts O O
[ O O
see O O
comments O O
] O O

We O O
describe O O
here O O
two O O
cases O O
of O O
diffuse O O
large O O
cell O O
type O O
non-Hodgkin O O
's O O
lymphoma O O
affecting O O
the O O
bilateral O O
breasts O O
. O O

The O O
contralateral O O
tumor O O
in O O
one O O
case O O
appeared O O
17 O O
months O O
after O O
the O O
first O O
mastectomy O O
, O O
whereas O O
the O O
bilateral O O
tumors O O
occurred O O
concurrently O O
in O O
the O O
other O O
patient O O
who O O
was O O
pregnant O O
and O O
showed O O
widespread O O
dissemination O O
at O O
initial O O
presentation O O
. O O

Lymphoma O O
cells O O
from O O
both O O
cases O O
showed O O
the O O
mature O O
B-cell O O
immunophenotype O O
and O O
had O O
rearrangements O O
of O O
the O O
BCL6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Both O O
patients O O
developed O O
progressive O O
disease O O
despite O O
chemo-radiotherapy O O
and O O
died O O
of O O
leukemic O O
manifestations O O
. O O

There O O
were O O
no O O
apparent O O
pathological O O
features O O
of O O
lymphomas O O
of O O
mucosa-associated O O
lymphoid O O
tissue O O
origin O O

A O O
family O O
of O O
hematopoietic B B_GENE/B_NUMBER[MEASURE]
specific I I_GENE/I_NUMBER[MEASURE]
transcription I I_GENE/I_NUMBER[MEASURE]
factors I I_GENE/I_NUMBER[MEASURE]
, O O
MIP-1 B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
nuclear I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
MNP I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
family I I_GENE/I_LOCATION
, O O
has O O
recently O O
been O O
identified O O
. O O

They O O
are O O
intimately O O
involved O O
in O O
regulating O O
the O O
transcription O O
of O O
the O O
huMIP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
monocytes O O
, O O
T-cells O O
, O O
and O O
transformed O O
B-cells O O
. O O

One O O
member O O
of O O
the O O
family O O
( O O
MNP-1 B B_GENE/B_DISEASE
) O O
is O O
essential O O
for O O
promoter O O
activity O O
in O O
monocytes O O
and O O
B-cells O O
, O O
while O O
another O O
( O O
MNP-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
required O O
for O O
full O O
promotor O O
activity O O
in O O
T-cells O O
. O O

A O O
third O O
member O O
of O O
the O O
family O O
( O O
MNP-3 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
expressed O O
in O O
PMA O O
induced O O
HL60 O O
cells O O
and O O
probably O O
has O O
a O O
role O O
in O O
monocyte O O
differentiation O O
. O O

In O O
this O O
communication O O
we O O
demonstrate O O
by O O
two O O
techniques O O
that O O
MNP-1 B B_GENE
and O O
MNP-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
distinct O O
but O O
related O O
factors O O
, O O
and O O
we O O
present O O
further O O
evidence O O
to O O
show O O
that O O
MNP-1 B B_GENE/B_PERSON
acts O O
as O O
a O O
heterodimer B B_GENE
. O O

Bcl-3 B B_GENE
expression O O
and O O
nuclear O O
translocation O O
are O O
induced O O
by O O
granulocyte-macrophage B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
erythropoietin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
proliferating O O
human O O
erythroid O O
precursors O O
. O O

Bcl-3 B B_GENE
is O O
a O O
proto-oncogene B B_GENE/B_BIO
involved O O
in O O
the O O
chromosomal O O
translocation O O
t B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
14 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
; I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
19 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
found O O
in O O
some O O
patients O O
with O O
chronic O O
lymphocytic O O
leukemia O O
. O O

It O O
shares O O
structural O O
similarities O O
with O O
and O O
is O O
a O O
member O O
of O O
the O O
IkappaB B B_GENE/B_PERSON
family I I_GENE/I_PERSON
of O O
proteins O O
. O O

In O O
this O O
report O O
, O O
involvement O O
of O O
Bcl-3 B B_GENE
in O O
hematopoietic O O
growth O O
factor-stimulated O O
erythroid O O
proliferation O O
and O O
differentiation O O
was O O
examined O O
. O O

Bcl-3 B B_GENE
protein O O
was O O
also O O
highly O O
expressed O O
in O O
early O O
burst-forming O O
unit-erythroid O O
( O O
BFU-E O O
) O O
-derived O O
erythroid O O
precursors O O
( O O
day O O
7 O O
) O O
and O O
decreased O O
during O O
maturation O O
( O O
days O O
10 O O
and O O
14 O O
) O O
, O O
suggesting O O
that O O
Bcl-3 B B_GENE
is O O
involved O O
in O O
normal O O
erythroid O O
proliferation O O
. O O

In O O
these O O
hematopoietic O O
cells O O
, O O
Bcl-3 B B_GENE
was O O
hyperphosphorylated O O
. O O

GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
Epo B B_GENE
modulated O O
the O O
subcellular O O
localization O O
of O O
Bcl-3 B B_GENE
. O O

Upon O O
stimulation O O
of O O
TF-1 O O
cells O O
with O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
Epo B B_GENE
, O O
the O O
nuclear O O
translocation O O
of O O
Bcl-3 B B_GENE
was O O
dramatically O O
enhanced O O
. O O

Overexpression O O
of O O
Bcl-3 B B_GENE
in O O
TF-1 O O
cells O O
by O O
transient O O
transfection O O
along O O
with O O
the O O
NF-kappaB B B_GENE
factors I I_GENE
p50 I I_GENE
or I I_GENE
p52 I I_GENE
resulted O O
in O O
significant O O
induction O O
of O O
an O O
human B B_GENE
immunodeficiency I I_GENE
virus-type I I_GENE
1 I I_GENE
( I I_GENE
HIV-1 I I_GENE
) I I_GENE
kappaB-TATA-luceriferase I I_GENE
reporter I I_GENE
plasmid I I_GENE
, O O
demonstrating O O
that O O
Bcl-3 B B_GENE
has O O
a O O
positive O O
role O O
in O O
transactivation O O
of O O
kappaB-containing B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
erythroid O O
cells O O
. O O

Stimulation O O
with O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
enhanced O O
c-myb B B_GENE
mRNA I I_GENE
expression O O
in O O
these O O
cells O O
. O O

Furthermore O O
, O O
cotransfection O O
of O O
Bcl-3 B B_GENE
with O O
p52 B B_GENE
or O O
p50 B B_GENE
in O O
TF-1 O O
cells O O
resulted O O
in O O
significant O O
activation O O
of O O
a O O
c-myb B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappaB-TATA-luceriferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Copyright O O
1998 O O
by O O
The O O
American O O
Society O O
of O O
Hematology O O
. O O

5-Lipoxygenase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
compartmentalization O O
in O O
granulocytic O O
cells O O
is O O
modulated O O
by O O
an O O
internal B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bipartite I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclear I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localizing I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
nuclear B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
factor I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
kappa I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
B I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
complex I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
formation O O
. O O

A O O
region O O
of O O
basic O O
amino O O
acids O O
spanning O O
residues B B_NUMBER[MEASURE]/B_GENE
639-656 I I_NUMBER[MEASURE]/I_GENE
in O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
5-lipoxygenase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resembles O O
a O O
consensus B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bipartite I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclear I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localizing I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
synthetic O O
peptide O O
consisting O O
of O O
the O O
Kaposi B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
fibroblast I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
signal I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
fused O O
to O O
the O O
5-lipoxygenase639-656 B B_GENE
bipartite I I_GENE
nuclear I I_GENE
localizing I I_GENE
sequence I I_GENE
has O O
a O O
prominent O O
inhibitory O O
effect O O
on O O
5-lipoxygenase B B_GENE
catalysis O O
in O O
granulocytic O O
HL-60 O O
cells O O
activated O O
by O O
calcium O O
ionophor O O
A23187 O O
. O O

Recombinant O O
5-lipoxygenase B B_GENE
was O O
not O O
affected O O
by O O
the O O
peptide O O
. O O

The O O
peptide O O
also O O
inhibited O O
redistribution O O
of O O
5-lipoxygenase B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
cytosol O O
to O O
the O O
nuclear O O
membrane O O
of O O
HL-60 O O
cells O O
stimulated O O
by O O
A23187 O O
. O O

5-Lipoxygenase B B_GENE
protein I I_GENE
was O O
detected O O
in O O
nuclear B B_GENE/B_NUMBER[MEASURE]
factor I B_GENE/I_NUMBER[MEASURE]
kappaB I B_GENE/I_NUMBER[MEASURE]
( I B_GENE/I_NUMBER[MEASURE]
NF-kappaB I B_GENE/I_NUMBER[MEASURE]
) I B_GENE/I_NUMBER[MEASURE]
p65 I B_GENE/I_NUMBER[MEASURE]
subunit I B_GENE/I_NUMBER[MEASURE]
immunoprecipitate O O
fractions O O
prepared O O
from O O
HL-60 O O
cell O O
lysates O O
. O O

The O O
amount O O
of O O
5-lipoxygenase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coimmunoprecipitated O O
by O O
NF-kappaB O O
antiserum O O
was O O
increased O O
following O O
A23187 O O
stimulation O O
. O O

In O O
cells O O
treated O O
with O O
agents O O
that O O
block O O
5-lipoxygenase B B_GENE
translocation O O
to O O
the O O
nucleus O O
, O O
5-lipoxygenase B B_GENE
protein O O
appearing O O
in O O
the O O
NF-kappaB B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
immunoprecipitate O O
was O O
diminished O O
. O O

Our O O
results O O
implicate O O
an O O
internal B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
bipartite I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
localizing I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
regulatory O O
domain O O
that O O
modulates O O
5-lipoxygenase B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
redistribution O O
and O O
catalysis O O
in O O
granulocytic O O
cells O O
. O O

Copyright O O
1998 O O
Academic O O
Press O O
. O O

Inhibition O O
of O O
CD28/CD3-mediated O O
costimulation O O
of O O
naive O O
and O O
memory O O
human O O
T O O
lymphocytes O O
by O O
intracellular O O
incorporation O O
of O O
polyclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
specific O O
for O O
the O O
activator B B_GENE
protein-1 I I_GENE
transcriptional I I_GENE
complex I I_GENE
. O O

A O O
number O O
of O O
indirect O O
methods O O
have O O
been O O
utilized O O
in O O
demonstrating O O
activator B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein-1 I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O O
factor O O
function O O
in O O
IL-2 O O
promoter O O
activity O O
. O O

However O O
, O O
there O O
has O O
been O O
no O O
direct O O
demonstration O O
that O O
activator B B_GENE
protein-1 I I_GENE
is O O
involved O O
in O O
CD28-dependent O O
costimulation O O
of O O
IL-2 B B_GENE
gene I I_GENE
transcription O O
in O O
freshly O O
isolated O O
naive O O
and O O
memory O O
human O O
T O O
lymphocytes O O
. O O

To O O
address O O
this O O
issue O O
, O O
the O O
method O O
of O O
scrape O O
loading O O
was O O
applied O O
to O O
purified O O
peripheral O O
blood O O
T O O
lymphocytes O O
. O O

Cells O O
scraped O O
off O O
poly-L-lysine O O
in O O
the O O
presence O O
of O O
Ig B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
FITC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
efficiently O O
incorporated O O
Ig O O
, O O
with O O
relatively O O
uniform O O
fluorescence O O
. O O

T O O
cells O O
retained O O
their O O
physical O O
parameters O O
as O O
measured O O
by O O
forward O O
and O O
side O O
light O O
scatter O O
, O O
and O O
functional O O
activity O O
as O O
measured O O
by O O
costimulation O O
of O O
proliferation O O
and O O
IL-2 B B_GENE
production O O
after O O
being O O
scraped O O
off O O
this O O
substrate O O
. O O

CD28/CD3-costimulated O O
T O O
cells O O
produced O O
intracellular O O
IL-2 B B_GENE
from O O
all O O
subsets O O
measured O O
( O O
CD4+ O O
, O O
CD4- O O
, O O
CD45RO+ O O
, O O
and O O
CD45RO- O O
) O O
. O O

IL-2 B B_GENE
production O O
and O O
intracellular O O
accumulation O O
in O O
nonscraped O O
PB-T O O
cells O O
activated O O
with O O
CD28/CD3 O O
coligation O O
were O O
skewed O O
favoring O O
CD45RO+ O O
and O O
CD4+ O O
subsets O O
, O O
as O O
was O O
IL-2 B B_GENE
production O O
in O O
scraped O O
PB-T O O
cells O O
. O O

The O O
intracellular O O
incorporation O O
of O O
Abs O O
specific O O
for O O
c-Fos B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
members I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
scrape O O
loading O O
inhibited O O
the O O
production O O
and O O
intracellular O O
accumulation O O
of O O
IL-2 B B_GENE
within O O
6 O O
h O O
of O O
costimulation O O
with O O
PMA/ionomycin O O
, O O
or O O
costimulation O O
by O O
CD28 O O
and O O
CD3 O O
ligation O O
. O O

Scrape O O
loading O O
thus O O
provides O O
an O O
efficient O O
mechanism O O
for O O
intracellular O O
incorporation O O
of O O
macromolecules O O
, O O
and O O
the O O
first O O
direct O O
evidence O O
that O O
c-Fos B B_GENE
and O O
c-Jun B B_GENE
are O O
involved O O
in O O
transcription O O
of O O
the O O
IL-2 B B_GENE
gene I I_GENE
within O O
its O O
correct O O
chromosomal O O
context O O
, O O
in O O
resting O O
human O O
T O O
lymphocyte O O
subpopulations O O
. O O

Differential O O
expression O O
of O O
Nur77 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O O
T-lymphotropic O O
virus O O
type O O
1-infected O O
cells O O
: O O
transactivation O O
of O O
the O O
TR3/nur77 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
Tax B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
analyzed O O
the O O
differential O O
expression O O
and O O
regulation O O
of O O
three O O
members O O
of O O
the O O
Nur77 B B_GENE/B_BIO
transcription I I_GENE/I_BIO
factor I I_GENE/I_BIO
family I I_GENE/I_BIO
by O O
the O O
human O O
T-lymphotropic O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
Tax B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
demonstrated O O
that O O
in O O
both O O
HTLV-1-infected O O
cells O O
and O O
Tax-expressing O O
JPX-9 O O
cells O O
, O O
TR3/nur77 B B_GENE
is O O
highly O O
expressed O O
, O O
whereas O O
neither O O
NOR-1 O O
nor O O
NOT O O
expression O O
is O O
detectable O O
. O O

Furthermore O O
, O O
expression O O
of O O
a O O
luciferase B B_GENE
reporter I I_GENE
gene I I_GENE
driven O O
by O O
the O O
NGFI-B B B_GENE
( I I_GENE
rat I I_GENE
homolog I I_GENE
of I I_GENE
TR3/Nur77 I I_GENE
) I I_GENE
response I I_GENE
element I I_GENE
( O O
NBRE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
provided O O
evidence O O
that O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-mediated O O
transactivation O O
resulted O O
in O O
the O O
induction O O
of O O
a O O
functional O O
protein O O
. O O

Cotransfection O O
assays O O
with O O
the O O
TR3/nur77 B B_GENE
promoter I I_GENE
sequence I I_GENE
or O O
the O O
NBRE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O O
motif O O
together O O
with O O
a O O
series O O
of O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants O O
have O O
shown O O
that O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
TR3/nur77 B B_GENE
expression O O
is O O
mediated O O
by O O
CREB/ATF-related B B_GENE
transcription I I_GENE
factors I I_GENE
. O O

Negative O O
regulation O O
of O O
the O O
heat O O
shock O O
transcriptional O O
response O O
by O O
HSBP1 B B_GENE
. O O

In O O
response O O
to O O
stress O O
, O O
heat B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
shock I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HSF1 B B_GENE
) O O
acquires O O
rapid O O
DNA O O
binding O O
and O O
transient O O
transcriptional O O
activity O O
while O O
undergoing O O
conformational O O
transition O O
from O O
an O O
inert O O
non-DNA-binding B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monomer I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
active O O
functional O O
trimers O O
. O O

Attenuation O O
of O O
the O O
inducible O O
transcriptional O O
response O O
occurs O O
during O O
heat O O
shock O O
or O O
upon O O
recovery O O
at O O
non-stress O O
conditions O O
and O O
involves O O
dissociation O O
of O O
the O O
HSF1 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trimer I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
loss O O
of O O
activity O O
. O O

We O O
have O O
used O O
the O O
hydrophobic B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
repeats I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
the O O
HSF1 B B_GENE/B_DISEASE
trimerization O O
domain O O
in O O
the O O
yeast O O
two-hybrid O O
protein O O
interaction O O
assay O O
to O O
identify O O
heat B B_GENE
shock I I_GENE
factor I I_GENE
binding I I_GENE
protein I I_GENE
1 I I_GENE
( O O
HSBP1 B B_GENE
) O O
, O O
a O O
novel O O
, O O
conserved O O
, O O
76-amino-acid B B_PROTEIN[GENE]/B_PERSON
protein I I_PROTEIN[GENE]/I_PERSON
that O O
contains O O
two O O
extended O O
arrays O O
of O O
hydrophobic B B_PROTEIN[GENE]/B_LOCATION
repeats I I_PROTEIN[GENE]/I_LOCATION
that O O
interact O O
with O O
the O O
HSF1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
heptad I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeats I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

HSBP1 B B_GENE/B_DISEASE
is O O
nuclear-localized O O
and O O
interacts O O
in O O
vivo O O
with O O
the O O
active O O
trimeric O O
state O O
of O O
HSF1 B B_GENE
that O O
appears O O
during O O
heat O O
shock O O
. O O

During O O
attenuation O O
of O O
HSF1 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
inert O O
monomer O O
, O O
HSBP1 B B_GENE
associates O O
with O O
Hsp70 O O
. O O

HSBP1 B B_GENE/B_DISEASE
negatively O O
affects O O
HSF1 B B_GENE/B_BIO
DNA-binding O O
activity O O
, O O
and O O
overexpression O O
of O O
HSBP1 B B_GENE
in O O
mammalian O O
cells O O
represses O O
the O O
transactivation O O
activity O O
of O O
HSF1 B B_GENE
. O O

To O O
establish O O
a O O
biological O O
role O O
for O O
HSBP1 B B_GENE
, O O
the O O
homologous O O
Caenorhabditis B B_GENE/B_LOCATION
elegans I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
was O O
overexpressed O O
in O O
body O O
wall O O
muscle O O
cells O O
and O O
was O O
shown O O
to O O
block O O
activation O O
of O O
the O O
heat O O
shock O O
response O O
from O O
a O O
heat B B_GENE/B_DISEASE
shock I I_GENE/I_DISEASE
promoter-reporter I I_GENE/I_DISEASE
construct I I_GENE/I_DISEASE
. O O

Alteration O O
in O O
the O O
level O O
of O O
HSBP1 B B_GENE
expression O O
in O O
C. O O
elegans O O
has O O
severe O O
effects O O
on O O
survival O O
of O O
the O O
animals O O
after O O
thermal O O
and O O
chemical O O
stress O O
, O O
consistent O O
with O O
a O O
role O O
for O O
HSBP1 B B_GENE
as O O
a O O
negative O O
regulator O O
of O O
the O O
heat O O
shock O O
response O O
. O O

Most O O
studies O O
on O O
the O O
control O O
of O O
cytokine O O
gene O O
expression O O
have O O
involved O O
the O O
functional O O
analysis O O
of O O
proximal B B_GENE
promoters I I_GENE
. O O

These O O
studies O O
have O O
begun O O
to O O
elucidate O O
the O O
basis O O
for O O
cell-specificity O O
and O O
high-level O O
expression O O
of O O
cytokine B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
. O O

A O O
signaling O O
complex O O
of O O
Ca2+-calmodulin-dependent B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
see O O
comments O O
] O O

Stimulation O O
of O O
T O O
lymphocytes O O
results O O
in O O
a O O
rapid O O
increase O O
in O O
intracellular O O
calcium O O
concentration O O
( O O
[ O O
Ca2+ O O
] O O
i O O
) O O
that O O
parallels O O
the O O
activation O O
of O O
Ca2+-calmodulin-dependent B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CaMKIV B B_GENE
) O O
, O O
a O O
nuclear B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
can O O
phosphorylate O O
and O O
activate O O
the O O
cyclic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adenosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
monophosphate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cAMP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CREB B B_GENE/B_DISEASE
) O O
. O O

However O O
, O O
inactivation O O
of O O
CaMKIV B B_GENE
occurs O O
despite O O
the O O
sustained O O
increase O O
in O O
[ O O
Ca2+ O O
] O O
i O O
that O O
is O O
required O O
for O O
T O O
cell O O
activation O O
. O O

A O O
stable O O
and O O
stoichiometric O O
complex O O
of O O
CaMKIV B B_GENE
with O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serine-threonine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PP2A B B_GENE
) O O
was O O
identified O O
in O O
which O O
PP2A B B_GENE
dephosphorylates O O
CaMKIV B B_GENE
and O O
functions O O
as O O
a O O
negative O O
regulator O O
of O O
CaMKIV B B_GENE
signaling O O
. O O

In O O
Jurkat O O
T O O
cells O O
, O O
inhibition O O
of O O
PP2A B B_GENE
activity O O
by O O
small O O
t O O
antigen O O
enhanced O O
activation O O
of O O
CREB B B_GENE
-mediated O O
transcription O O
by O O
CaMKIV B B_GENE
. O O

These O O
findings O O
reveal O O
an O O
intracellular O O
signaling O O
mechanism O O
whereby O O
a O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serine-threonine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CaMKIV B B_GENE/B_LOCATION
) O O
is O O
regulated O O
by O O
a O O
tightly O O
associated O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
serine-threonine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PP2A B B_GENE/B_LOCATION
) O O
. O O

Hypoxia O O
down-regulates O O
MCP-1 B B_GENE
expression O O
: O O
implications O O
for O O
macrophage O O
distribution O O
in O O
tumors O O
. O O

Monocyte B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chemoattractant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MCP-1 B B_GENE
) O O
is O O
likely O O
to O O
contribute O O
to O O
the O O
macrophage O O
infiltrate O O
in O O
human O O
ovarian O O
carcinomas O O
. O O

Although O O
MCP-1 B B_GENE
is O O
predominantly O O
expressed O O
by O O
the O O
tumor O O
parenchyma O O
, O O
macrophages O O
accumulate O O
at O O
highest O O
density O O
in O O
necrotic O O
regions O O
, O O
which O O
are O O
associated O O
with O O
low O O
oxygen O O
tensions O O
. O O

Tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
can O O
stimulate O O
MCP-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
and O O
is O O
also O O
present O O
within O O
ovarian O O
carcinomas O O
. O O

We O O
have O O
investigated O O
the O O
effect O O
of O O
hypoxia O O
both O O
on O O
MCP-1 B B_GENE
expression O O
in O O
ovarian O O
cancer O O
cell O O
lines O O
and O O
monocyte O O
migration O O
. O O

Hypoxia O O
down-regulated O O
TNF-alpha-induced B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MCP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
protein O O
production O O
by O O
ovarian O O
cancer O O
cells O O
. O O

The O O
effect O O
was O O
mimicked O O
by O O
cobalt O O
chloride O O
and O O
desferrioxamine O O
, O O
consistent O O
with O O
a O O
specific O O
oxygen-sensing O O
mechanism O O
. O O

Monocyte O O
migration O O
in O O
response O O
to O O
MCP-1 B B_GENE
was O O
also O O
diminished O O
under O O
hypoxic O O
conditions O O
. O O

Down-regulation O O
of O O
MCP-1 B B_GENE
expression O O
and O O
the O O
inhibition O O
of O O
monocyte O O
migration O O
are O O
independent O O
effects O O
of O O
hypoxia O O
that O O
may O O
contribute O O
to O O
the O O
distribution O O
of O O
macrophages O O
within O O
ovarian O O
tumors O O
. O O

Activation O O
of O O
nuclear B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
factor I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
kappa I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
B I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
inflammatory O O
bowel O O
disease O O
[ O O
see O O
comments O O
] O O

BACKGROUND O O
: O O
Expression O O
of O O
pro-inflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
increased O O
in O O
the O O
intestinal O O
lamina O O
propria O O
of O O
patients O O
with O O
inflammatory O O
bowel O O
disease O O
( O O
IBD O O
) O O
. O O

Nuclear B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
kappa I I_GENE/I_MEASURE
B I I_GENE/I_MEASURE
( O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
) O O
controls O O
transcription O O
of O O
inflammation B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
. O O

On O O
activation O O
, O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
is O O
rapidly O O
released O O
from O O
its O O
cytoplasmic B B_ENZYME[GENE]/B_PERSON
inhibitor I I_ENZYME[GENE]/I_PERSON
( O O
I B B_GENE/B_DISEASE
kappa I I_GENE/I_DISEASE
B I I_GENE/I_DISEASE
) O O
, O O
transmigrates O O
into O O
the O O
nucleus O O
, O O
and O O
binds O O
to O O
DNA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elements I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
gene O O
promoter O O
regions O O
. O O

AIMS O O
: O O
To O O
investigate O O
whether O O
increased O O
activation O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
is O O
important O O
in O O
IBD O O
and O O
may O O
be O O
down-regulated O O
by O O
anti-inflammatory O O
treatment O O
. O O

METHODS O O
: O O
Activation O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
was O O
determined O O
by O O
western O O
blot O O
assessment O O
and O O
electrophoretic O O
mobility O O
shift O O
assay O O
in O O
nuclear O O
extracts O O
of O O
colonic O O
biopsy O O
samples O O
as O O
well O O
as O O
lamina O O
propria O O
mononuclear O O
cells O O
. O O

RESULTS O O
: O O
Nuclear O O
levels O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
p65 B I_GENE
are O O
increased O O
in O O
lamina O O
propria O O
biopsy O O
specimens O O
from O O
patients O O
with O O
Crohn O O
's O O
disease O O
in O O
comparison O O
with O O
patients O O
with O O
ulcerative O O
colitis O O
and O O
controls O O
. O O

Increased O O
activation O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
was O O
detected O O
in O O
lamina O O
propria O O
mononuclear O O
cells O O
from O O
patients O O
with O O
active O O
IBD O O
. O O

Corticosteroids O O
strongly O O
inhibit O O
intestinal O O
NF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kappa I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
in O O
IBD O O
in O O
vivo O O
and O O
in O O
vitro O O
by O O
stabilising O O
the O O
cytosolic B B_GENE
inhibitor I I_GENE
I B I_GENE
kappa I I_GENE
B I I_GENE
alpha O O
against O O
activation O O
induced O O
degradation O O
. O O

CONCLUSIONS O O
: O O
In O O
both O O
IBDs O O
, O O
but O O
particularly O O
Crohn O O
's O O
disease O O
, O O
increased O O
activation O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
may O O
be O O
involved O O
in O O
the O O
regulation O O
of O O
the O O
inflammatory O O
response O O
. O O

Inhibition O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
activation O O
may O O
represent O O
a O O
mechanism O O
by O O
which O O
steroids O O
exert O O
an O O
anti-inflammatory O O
effect O O
in O O
IBD O O

Insufficient O O
glycemic O O
control O O
increases O O
nuclear B B_GENE
factor-kappa I I_GENE
B I I_GENE
binding O O
activity O O
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
isolated O O
from O O
patients O O
with O O
type O O
1 O O
diabetes O O
. O O

OBJECTIVE O O
: O O
The O O
redox-sensitive B B_GENE
transcription I I_GENE
factor I I_GENE
nuclear I I_GENE
factor-kappa I I_GENE
B I I_GENE
( O O
NF-kappa B B_GENE
B I I_GENE
) O O
is O O
believed O O
to O O
contribute O O
to O O
late O O
diabetic O O
complications O O
. O O

It O O
is O O
unknown O O
whether O O
NF-kappa B B_GENE/B_DISEASE
B I B_GENE/I_DISEASE
is O O
influenced O O
by O O
glycemic O O
control O O
. O O

RESEARCH O O
DESIGN O O
AND O O
METHODS O O
: O O
To O O
determine O O
whether O O
NF-kappa B B_GENE
B I I_GENE
is O O
activated O O
in O O
patients O O
with O O
insufficient O O
glycemic O O
control O O
( O O
HbA1c O O
> O O
10 O O
% O O
) O O
, O O
we O O
developed O O
a O O
tissue O O
culture-independent O O
electrophoretic O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
-based O O
semiquantitative O O
detection O O
system O O
that O O
allowed O O
us O O
to O O
determine O O
NF-kappa B B_GENE
B I I_GENE
activation O O
in O O
ex O O
vivo-isolated O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMCs O O
) O O
. O O

We O O
included O O
43 O O
patients O O
with O O
type O O
1 O O
diabetes O O
in O O
this O O
cross-sectional O O
study O O
. O O

10 O O
of O O
those O O
received O O
the O O
antioxidant O O
thioctic O O
acid O O
( O O
600 O O
mg/day O O
p.o. O O
) O O
for O O
2 O O
weeks O O
. O O

RESULTS O O
: O O
Monocytes O O
of O O
patients O O
with O O
HbA1c O O
levels O O
> O O
10 O O
% O O
demonstrated O O
significantly O O
higher O O
NF-kappa B B_GENE
B I I_GENE
binding O O
activity O O
in O O
an O O
EMSA O O
and O O
a O O
stronger O O
NF-kappa B B_GENE
B I I_GENE
staining O O
in O O
immunohistochemistry O O
than O O
monocytes O O
of O O
patients O O
with O O
HbA1c O O
levels O O
of O O
6-8 O O
% O O
. O O

The O O
increase O O
in O O
NF-kappa B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
correlated O O
with O O
an O O
increase O O
in O O
plasmatic O O
markers O O
of O O
lipid O O
peroxidation O O
. O O

Treatment O O
with O O
the O O
antioxidant O O
thioctic O O
acid O O
decreased O O
NF-kappa B B_GENE
B I I_GENE
binding O O
activity O O
. O O

CONCLUSIONS O O
: O O
Hyperglycemia O O
induces O O
activation O O
of O O
the O O
transcription O O
factor O O
NF-kappa B B_GENE
B I I_GENE
in O O
ex O O
vivo-isolated O O
PBMCs O O
of O O
patients O O
with O O
type O O
1 O O
diabetes O O
. O O

NF-kappa B B_GENE
B I I_GENE
activation O O
is O O
at O O
least O O
partially O O
dependent O O
on O O
oxidative O O
stress O O
, O O
since O O
the O O
antioxidant O O
thioctic O O
acid O O
significantly O O
lowered O O
the O O
extent O O
of O O
NF-kappa B B_GENE
B I I_GENE
binding O O
activity O O
. O O

Synergistic O O
activation O O
of O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ERK1/2 B B_GENE/B_LOCATION
) O O
by O O
erythropoietin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
stem B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
essential O O
for O O
expanded O O
erythropoiesis O O
. O O

Treatment O O
of O O
the O O
cells O O
with O O
PD98059 O O
and O O
wortmannin O O
, O O
inhibitors O O
of O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
PI-3 B B_GENE
kinase I I_GENE
, O O
respectively O O
, O O
inhibited O O
the O O
synergistic O O
activation O O
of O O
MAPK B B_GENE
and O O
also O O
the O O
cell O O
growth O O
, O O
further O O
supporting O O
this O O
conclusion O O
. O O

Wortmannin O O
only O O
inhibits O O
MAPK B B_GENE
activation O O
induced O O
by O O
EPO B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
not O O
that O O
by O O
SCF B B_GENE/B_BIO
, O O
suggesting O O
that O O
SCF B B_GENE/B_BIO
and O O
EPO B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
activate O O
MAPK B B_GENE
through O O
different O O
pathways O O
, O O
which O O
would O O
facilitate O O
synergy O O
. O O

Together O O
, O O
the O O
data O O
suggest O O
that O O
synergistic O O
activation O O
of O O
MAPK B B_GENE
by O O
SCF B B_GENE/B_BIO
and O O
EPO B B_GENE/B_LOCATION
is O O
essential O O
for O O
expanded O O
erythropoiesis O O
. O O

Copyright O O
1998 O O
by O O
The O O
American O O
Society O O
of O O
Hematology O O
. O O

The O O
molecular O O
and O O
phenotypic O O
profile O O
of O O
primary O O
central O O
nervous O O
system O O
lymphoma O O
identifies O O
distinct O O
categories O O
of O O
the O O
disease O O
and O O
is O O
consistent O O
with O O
histogenetic O O
derivation O O
from O O
germinal O O
center-related O O
B O O
cells O O
. O O

Primary O O
central O O
nervous O O
system O O
lymphoma O O
( O O
PCNSL O O
) O O
is O O
a O O
major O O
cause O O
of O O
morbidity O O
and O O
mortality O O
among O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
-infected O O
individuals O O
. O O

The O O
precise O O
histogenetic O O
derivation O O
and O O
the O O
molecular O O
pathogenesis O O
of O O
PCNSL O O
is O O
poorly O O
understood O O
. O O

In O O
an O O
attempt O O
to O O
clarify O O
the O O
histogenesis O O
and O O
pathogenesis O O
of O O
these O O
lymphomas O O
, O O
49 O O
PCNSL O O
( O O
26 O O
acquired O O
immunodeficiency O O
syndrome O O
[ O O
AIDS O O
] O O
-related O O
and O O
23 O O
AIDS-unrelated O O
) O O
were O O
analyzed O O
for O O
multiple O O
biologic O O
markers O O
, O O
which O O
are O O
known O O
to O O
bear O O
histogenetic O O
and O O
pathogenetic O O
significance O O
for O O
mature O O
B-cell O O
neoplasms O O
. O O

PCNSL O O
associated O O
frequently O O
( O O
50.0 O O
% O O
) O O
with O O
mutations O O
of O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
noncoding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
are O O
regarded O O
as O O
a O O
marker O O
of O O
B-cell O O
transition O O
through O O
the O O
germinal O O
center O O
( O O
GC O O
) O O
. O O

Expression O O
of O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
is O O
restricted O O
to O O
GC O O
B O O
cells O O
throughout O O
physiologic O O
B-cell O O
maturation O O
, O O
was O O
detected O O
in O O
100 O O
% O O
AIDS-unrelated O O
PCNSL O O
and O O
in O O
56.2 O O
% O O
AIDS-related O O
cases O O
. O O

Notably O O
, O O
among O O
AIDS-related O O
PCNSL O O
, O O
expression O O
of O O
BCL-6 B B_GENE
was O O
mutually O O
exclusive O O
with O O
expression O O
of O O
Epstein-Barr B B_GENE
virus I I_GENE
( I I_GENE
EBV I I_GENE
) I I_GENE
-encoded I I_GENE
latent I I_GENE
membrane I I_GENE
protein I I_GENE
( I I_GENE
LMP I I_GENE
) I I_GENE
-1 I I_GENE
and O O
, O O
with O O
few O O
exceptions O O
, O O
also O O
of O O
BCL-2 B B_GENE
. O O

These O O
data O O
suggest O O
that O O
PCNSL O O
may O O
be O O
frequently O O
related O O
to O O
GC O O
B O O
cells O O
and O O
may O O
be O O
segregated O O
into O O
two O O
major O O
biologic O O
categories O O
based O O
on O O
the O O
expression O O
pattern O O
of O O
BCL-6 B B_GENE
, O O
LMP-1 B B_GENE/B_DISEASE
, O O
and O O
BCL-2 B B_GENE
. O O

BCL-6 B B_GENE/B_DISEASE
( O O
+ O O
) O O
/ O O
LMP-1 B B_GENE
( O O
- O O
) O O
/ O O
BCL-2 B B_GENE
( O O
- O O
) O O
PCNSL O O
occur O O
both O O
in O O
the O O
presence O O
and O O
in O O
the O O
absence O O
of O O
HIV O O
infection O O
and O O
consistently O O
display O O
a O O
large O O
noncleaved O O
cell O O
morphology O O
. O O

Conversely O O
, O O
BCL-6 B B_GENE
( O O
- O O
) O O
/ O O
LMP-1 B B_GENE
( O O
+ O O
) O O
/ O O
BCL-2 B B_GENE
( O O
+ O O
) O O
PCNSL O O
are O O
restricted O O
to O O
HIV-infected O O
hosts O O
and O O
are O O
represented O O
by O O
lymphomas O O
with O O
immunoblastic O O
features O O
. O O

These O O
data O O
are O O
relevant O O
for O O
the O O
pathogenesis O O
and O O
histogenesis O O
of O O
PCNSL O O
and O O
may O O
be O O
helpful O O
to O O
segregate O O
distinct O O
biologic O O
and O O
prognostic O O
categories O O
of O O
these O O
lymphomas O O
. O O

Copyright O O
1998 O O
by O O
The O O
American O O
Society O O
of O O
Hematology O O
. O O

The O O
effect O O
was O O
significant O O
for O O
ICAM-1 B B_GENE
( O O
p O O
< O O
.01 O O
) O O
and O O
VCAM-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
p O O
< O O
.01 O O
) O O
expression O O
in O O
cells O O
pretreated O O
with O O
100 O O
microM O O
alpha-lipoate O O
compared O O
to O O
PMA-activated O O
untreated O O
cells O O
. O O

Inhibition O O
of O O
PMA-induced O O
adhesion O O
molecule O O
expression O O
and O O
cell-cell O O
adhesion O O
was O O
more O O
pronounced O O
when O O
a O O
combination O O
of O O
antioxidants O O
, O O
alpha-lipoate O O
and O O
alpha-tocopherol O O
, O O
were O O
used O O
compared O O
to O O
the O O
use O O
of O O
either O O
of O O
these O O
antioxidant O O
alone O O
. O O

The O O
regulation O O
of O O
adhesion O O
molecule O O
expression O O
and O O
function O O
by O O
low O O
concentration O O
of O O
antioxidants O O
investigated O O
does O O
not O O
appear O O
to O O
be O O
NF-kappaB B B_GENE
regulated O O
or O O
transcription O O
dependent O O
because O O
no O O
change O O
in O O
the O O
mRNA O O
response O O
was O O
observed O O
. O O

Protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PKC B B_GENE
) O O
has O O
been O O
suggested O O
to O O
regulate O O
PMA-induced O O
adhesion O O
molecule O O
expression O O
by O O
post-transcriptional O O
stabilization O O
of O O
adhesion B B_GENE
molecule I I_GENE
mRNA I I_GENE
. O O

Alpha-lipoate O O
pretreatment O O
did O O
not O O
influence O O
the O O
response O O
of O O
PKC B B_GENE
activity O O
to O O
PMA O O
. O O

Oxidants O O
are O O
known O O
to O O
be O O
involved O O
in O O
the O O
regulation O O
of O O
cell O O
adhesion O O
processes O O
. O O

Treatment O O
of O O
ECV O O
cells O O
with O O
PMA O O
induced O O
generation O O
of O O
intracellular O O
oxidants O O
. O O

Alpha-lipoate O O
( O O
100 O O
or O O
250 O O
microM O O
) O O
treatment O O
decreased O O
PMA-induced O O
generation O O
of O O
intracellular O O
oxidants O O
. O O

The O O
inhibitory O O
effect O O
of O O
low O O
concentration O O
of O O
alpha-lipaote O O
alone O O
or O O
in O O
combination O O
with O O
alpha-tocopherol O O
on O O
agonist-induced O O
adhesion O O
processes O O
observed O O
in O O
this O O
study O O
may O O
be O O
of O O
potential O O
therapeutic O O
value O O
. O O

Binding O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
to O O
CD4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CXCR4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
differentially O O
regulates O O
expression O O
of O O
inflammatory B B_GENE
genes I I_GENE
and O O
activates O O
the O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ERK O O
signaling O O
pathway O O
. O O

We O O
have O O
previously O O
shown O O
that O O
binding O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
virions O O
to O O
CD4 B B_GENE
receptors I I_GENE
stimulates O O
association O O
of O O
Lck B B_GENE/B_BACTERIUM[BIO]
with O O
Raf-1 B B_GENE
and O O
results O O
in O O
the O O
activation O O
of O O
Raf-1 B B_GENE
kinase O O
in O O
a O O
Ras-independent O O
manner O O
. O O

The O O
activation O O
of O O
this O O
signaling O O
pathway O O
requires O O
functional O O
CD4 B B_GENE
receptors I I_GENE
and O O
is O O
independent O O
of O O
binding O O
to O O
CXCR4 B B_GENE
. O O

Binding O O
of O O
the O O
natural O O
ligand O O
stromal B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell-derived I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
SDF-1 B B_GENE
) O O
to O O
CXCR4 B B_GENE
, O O
which O O
inhibits O O
entry O O
of O O
T-cell-tropic O O
HIV-1 O O
, O O
activates O O
also O O
the O O
ERK/ O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathway O O
. O O

However O O
, O O
SDF-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
did O O
not O O
affect O O
the O O
CD4-mediated O O
expression O O
of O O
cytokine B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemokine I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
results O O
provide O O
firm O O
molecular O O
evidence O O
that O O
binding O O
of O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
envelope I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycoproteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
CD4 B B_GENE
receptor I I_GENE
initiates O O
a O O
signaling O O
pathway O O
( O O
s O O
) O O
independent O O
of O O
the O O
binding O O
to O O
the O O
chemokine B B_GENE
receptor I I_GENE
that O O
leads O O
to O O
the O O
aberrant O O
expression O O
of O O
inflammatory B B_GENE
genes I I_GENE
and O O
may O O
contribute O O
significantly O O
to O O
HIV-1 O O
replication O O
as O O
well O O
as O O
to O O
deregulation O O
of O O
the O O
immune O O
system O O
. O O

Antigen O O
receptor O O
signaling O O
induces O O
MAP O O
kinase-mediated O O
phosphorylation O O
and O O
degradation O O
of O O
the O O
BCL-6 B B_GENE
transcription B I_GENE
factor I I_GENE
. O O

The O O
bcl-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proto-oncogene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O O
a O O
POZ/zinc B B_GENE/B_MEASURE
finger I I_GENE/I_MEASURE
transcriptional I I_GENE/I_MEASURE
repressor I I_GENE/I_MEASURE
expressed O O
in O O
germinal O O
center O O
( O O
GC O O
) O O
B O O
and O O
T O O
cells O O
and O O
required O O
for O O
GC O O
formation O O
and O O
antibody O O
affinity O O
maturation O O
. O O

Deregulation O O
of O O
bcl-6 B B_GENE
expression O O
by O O
chromosomal O O
rearrangements O O
and O O
point O O
mutations O O
of O O
the O O
bcl-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
B-cell O O
lymphoma O O
. O O

The O O
signals O O
regulating O O
bcl-6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
are O O
not O O
known O O
. O O

Here O O
we O O
show O O
that O O
antigen O O
receptor O O
activation O O
leads O O
to O O
BCL-6 B B_GENE
phosphorylation O O
by O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE
) O O
. O O

Phosphorylation O O
, O O
in O O
turn O O
, O O
targets O O
BCL-6 B B_GENE
for O O
rapid O O
degradation O O
by O O
the O O
ubiquitin B B_GENE
/ O O
proteasome B B_GENE
pathway O O
. O O

These O O
findings O O
indicate O O
that O O
BCL-6 B B_GENE
expression O O
is O O
directly O O
controlled O O
by O O
the O O
antigen O O
receptor O O
via O O
MAPK B B_GENE
activation O O
. O O

This O O
signaling O O
pathway O O
may O O
be O O
crucial O O
for O O
the O O
control O O
of O O
B-cell O O
differentiation O O
and O O
antibody O O
response O O
and O O
has O O
implications O O
for O O
the O O
regulation O O
of O O
other O O
POZ/zinc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finger I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcription I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
other O O
tissues O O
. O O

Glucocorticoid B B_PERSON/B_GENE
receptors I I_PERSON/I_GENE
are O O
differentially O O
expressed O O
in O O
the O O
cells O O
and O O
tissues O O
of O O
the O O
immune O O
system O O
. O O

To O O
address O O
these O O
inconsistencies O O
, O O
GR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
assessed O O
in O O
immune O O
cells O O
and O O
tissues O O
using O O
cytosolic O O
radioligand O O
binding O O
. O O

Western O O
blot O O
analysis O O
, O O
and O O
immunocytochemistry O O
. O O

Consistent O O
with O O
previous O O
cytosolic O O
receptor O O
binding O O
studies O O
on O O
immune O O
tissue O O
homogenates O O
, O O
thymic O O
T O O
cells O O
were O O
found O O
to O O
have O O
higher O O
levels O O
of O O
GR B B_GENE/B_DISEASE
than O O
T O O
cells O O
isolated O O
from O O
the O O
spleen O O
. O O

These O O
results O O
indicate O O
a O O
meaningful O O
relationship O O
between O O
receptor O O
expression O O
and O O
known O O
sensitivity O O
to O O
glucocorticoids O O
. O O

The O O
mammalian B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
E2A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HEB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E2-2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encode O O
a O O
unique O O
class O O
of O O
basic B B_GENE
helix-loop-helix I I_GENE
( I I_GENE
bHLH I I_GENE
) I I_GENE
transcription I I_GENE
factors I I_GENE
that O O
are O O
evolutionarily O O
conserved O O
and O O
essential O O
for O O
embryonic O O
and O O
postnatal O O
development O O
. O O

While O O
the O O
structural O O
and O O
functional O O
similarities O O
among O O
the O O
gene B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
products I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
well O O
demonstrated O O
, O O
it O O
is O O
not O O
clear O O
why O O
deletion O O
of O O
E2A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
HEB B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
E2-2 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
leads O O
to O O
a O O
complete O O
arrest O O
in O O
B-lymphocyte O O
development O O
. O O

We O O
find O O
that O O
the O O
alternatively O O
spliced O O
E12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E47 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
E2A B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
gene I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
play O O
similar O O
and O O
additive O O
roles O O
in O O
supporting O O
B O O
lymphopoiesis O O
. O O

Further O O
, O O
we O O
find O O
that O O
HEB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
driven O O
by O O
the O O
endogenous B B_GENE/B_LOCATION
E2A I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
can O O
functionally O O
replace O O
E2A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
supporting O O
B-cell O O
commitment O O
and O O
differentiation O O
toward O O
completion O O
. O O

This O O
study O O
suggests O O
that O O
the O O
functional O O
divergence O O
among O O
E12 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
E47 B B_GENE
, O O
and O O
HEB B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
different O O
cell O O
types O O
is O O
partially O O
defined O O
by O O
the O O
context O O
of O O
gene O O
expression O O
. O O

Biased O O
dependency O O
of O O
CD80 B B_GENE
versus O O
CD86 B B_GENE
in O O
the O O
induction O O
of O O
transcription B B_GENE
factors I I_GENE
regulating O O
the O O
human B B_GENE/B_DISEASE
IL-2 I I_GENE/I_DISEASE
promoter I I_GENE/I_DISEASE
. O O

One O O
such O O
co-stimulatory O O
signal O O
is O O
delivered O O
when O O
CD28 B B_GENE
on O O
T O O
cells O O
binds O O
to O O
CD80 B B_GENE
or O O
CD86 B B_GENE
on O O
antigen-presenting O O
cells O O
( O O
APC O O
) O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
analyzed O O
the O O
ability O O
of O O
CD80 B B_GENE
and O O
CD86 B B_GENE
to O O
co-stimulate O O
human O O
T O O
cells O O
activated O O
by O O
superantigen O O
. O O

Using O O
the O O
Raji O O
B O O
cell O O
lymphoma O O
, O O
which O O
express O O
similar O O
levels O O
of O O
CD80 B B_GENE
and O O
CD86 B B_GENE
, O O
it O O
was O O
found O O
that O O
T O O
cell O O
proliferation O O
was O O
mainly O O
co-stimulated O O
by O O
CD80 B B_GENE
. O O

To O O
further O O
characterize O O
the O O
consequences O O
of O O
this O O
biased O O
co-stimulatory O O
dependency O O
, O O
we O O
employed O O
a O O
well-defined O O
system O O
of O O
transfected O O
CHO O O
cells O O
expressing O O
human B B_GENE
MHC I I_GENE
class I I_GENE
II I I_GENE
together O O
with O O
CD80 B B_GENE
, O O
CD86 B B_GENE
or O O
CD80 B B_GENE
and O O
CD86 B B_GENE
. O O

Proliferation O O
of O O
freshly O O
prepared O O
CD4+ O O
T O O
cells O O
required O O
the O O
presence O O
of O O
either O O
CD80 B B_GENE
or O O
CD86 B B_GENE
. O O

However O O
, O O
IL-2 B B_GENE
production O O
reached O O
only O O
suboptimal O O
levels O O
in O O
the O O
presence O O
of O O
CD86 B B_GENE
but O O
optimal O O
levels O O
with O O
CD80 B B_GENE
. O O

To O O
analyze O O
IL-2 B B_GENE
transcriptional O O
activity O O
in O O
CD80 B B_GENE
and O O
CD86 B B_GENE
co-stimulated O O
T O O
cells O O
we O O
used O O
Jurkat O O
T O O
cells O O
transfected O O
with O O
luciferase B B_GENE
reporter I I_GENE
gene I I_GENE
constructs I I_GENE
. O O

CD80 B B_GENE
induced O O
higher O O
levels O O
of O O
IL-2 B B_GENE/B_DISEASE
promoter I I_GENE/I_DISEASE
-enhancer O O
activity O O
compared O O
to O O
CD86 B B_GENE
. O O

Furthermore O O
, O O
the O O
activity O O
of O O
transcription B B_GENE
factors I I_GENE
regulating O O
the O O
IL-2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
promoter-enhancer I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
including O O
activation B B_GENE
protein-1 I I_GENE
, O O
CD28 B B_GENE
response I I_GENE
element I I_GENE
and O O
nuclear B B_GENE
factor I I_GENE
kappaB I I_GENE
were O O
4-8 O O
times O O
higher O O
after O O
CD80 B B_GENE
compared O O
to O O
CD86 B B_GENE
ligation O O
. O O

Our O O
results O O
suggest O O
that O O
the O O
eventual O O
appearance O O
of O O
CD80 B B_GENE
on O O
recently O O
activated O O
CD86+ O O
APC O O
is O O
important O O
for O O
the O O
superinduction O O
of O O
IL-2 B B_GENE
production O O
and O O
to O O
support O O
vigorous O O
T O O
cell O O
proliferation O O
. O O

Duplication O O
of O O
the O O
DR3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
human B B_GENE/B_MEASURE
chromosome I B_GENE/I_MEASURE
1p36 I B_GENE/I_MEASURE
and O O
its O O
deletion O O
in O O
human O O
neuroblastoma O O
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DR3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
whose O O
product O O
is O O
also O O
known O O
as O O
Wsl-1/APO-3/TRAMP/LARD B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
encodes O O
a O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
is O O
expressed O O
primarily O O
on O O
the O O
surface O O
of O O
thymocytes O O
and O O
lymphocytes O O
. O O

DR3 B B_GENE
is O O
capable O O
of O O
inducing O O
both O O
NF-kappa B B_GENE
B I I_GENE
activation O O
and O O
apoptosis O O
when O O
overexpressed O O
in O O
mammalian O O
cells O O
, O O
although O O
its O O
ligand O O
has O O
not O O
yet O O
been O O
identified O O
. O O

We O O
report O O
here O O
that O O
the O O
DR3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
tandemly O O
duplicated O O
on O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chromosome I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
band I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1p36.2-p36.3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
that O O
these O O
genes O O
are O O
hemizygously O O
deleted O O
and/or O O
translocated O O
to O O
another O O
chromosome O O
in O O
neuroblastoma O O
( O O
NB O O
) O O
cell O O
lines O O
with O O
amplified O O
MYCN O O
. O O

In O O
most O O
NB O O
cell O O
lines O O
, O O
both O O
the O O
DR3 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
the I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DR3L I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
simultaneously O O
deleted O O
and/or O O
translocated O O
to O O
another O O
chromosome B B_GENE/B_LOCATION
. O O

Finally O O
, O O
DR3/ B B_GENE
Wsl-1 I I_GENE
protein I I_GENE
expression O O
is O O
quite O O
variable O O
among O O
these O O
NB O O
cell O O
lines O O
, O O
with O O
very O O
low O O
or O O
undetectable O O
levels O O
in O O
7 O O
of O O
17 O O
NB O O
cell O O
lines O O

Differential O O
protection O O
of O O
normal O O
and O O
malignant O O
human O O
myeloid O O
progenitors O O
( O O
CFU-GM O O
) O O
from O O
Ara-C O O
toxicity O O
using O O
cycloheximide O O
. O O

Cycloheximide O O
, O O
a O O
reversible O O
protein O O
synthesis O O
inhibitor O O
, O O
is O O
thought O O
to O O
block O O
DNA O O
replication O O
in O O
normal O O
cells O O
by O O
preventing O O
synthesis O O
of O O
a O O
labile B B_GENE
protein I I_GENE
. O O

In O O
animal O O
systems O O
, O O
cycloheximide O O
protects O O
normal O O
cells O O
from O O
cytotoxic O O
S-phase O O
specific O O
agents O O
, O O
such O O
as O O
cytosine O O
arabinoside O O
( O O
Ara-C O O
) O O
. O O

Malignant O O
cells O O
appear O O
not O O
to O O
be O O
susceptible O O
to O O
cycloheximide-induced O O
cycle O O
arrest O O
and O O
, O O
subsequently O O
, O O
may O O
not O O
be O O
protected O O
from O O
Ara-C O O
cytotoxicity O O
. O O

Mononuclear O O
or O O
clonogenic O O
cells O O
were O O
incubated O O
for O O
one O O
hour O O
with O O
cycloheximide O O
, O O
followed O O
by O O
the O O
addition O O
, O O
for O O
three O O
or O O
17 O O
hours O O
, O O
of O O
Ara-C O O
before O O
being O O
plated O O
in O O
a O O
methylcellulose O O
culture O O
system O O
. O O

CFU-GM O O
survival O O
was O O
significantly O O
increase O O
if O O
normal O O
cells O O
were O O
treated O O
with O O
cycloheximide O O
before O O
Ara-C O O
exposure O O
. O O

Similar O O
cycloheximide O O
pretreatment O O
of O O
CML O O
progenitors O O
and O O
clonogenic O O
HL-60 O O
and O O
KG-1 O O
cells O O
failed O O
to O O
protect O O
CFU-GM O O
from O O
Ara-C-induced O O
cytotoxicity O O
. O O

Primary O O
cortisol O O
resistance O O
accompanied O O
by O O
a O O
reduction O O
in O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
two O O
members O O
of O O
the O O
same O O
family O O
. O O

This O O
report O O
describes O O
studies O O
of O O
a O O
man O O
suspected O O
of O O
having O O
primary O O
cortisol O O
resistance O O
. O O

This O O
conclusion O O
is O O
based O O
on O O
his O O
high O O
plasma O O
cortisol O O
levels O O
and O O
high O O
24-h O O
urinary O O
17-hydroxycorticosteroid O O
and O O
cortisol O O
excretion O O
, O O
plus O O
the O O
fact O O
that O O
he O O
had O O
no O O
manifestations O O
of O O
Cushing O O
's O O
syndrome O O
. O O

Among O O
family O O
members O O
tested O O
, O O
his O O
mother O O
also O O
had O O
hypercortisolemia O O
. O O

Both O O
mother O O
and O O
son O O
had O O
high O O
levels O O
of O O
unbound O O
plasma O O
cortisol O O
, O O
but O O
their O O
plasma O O
ACTH O O
concentrations O O
were O O
within O O
the O O
normal O O
range O O
. O O

Both O O
were O O
partially O O
resistant O O
to O O
dexamethasone O O
adrenal O O
suppression O O
, O O
and O O
both O O
had O O
mild O O
hypertension O O
without O O
hypokalemia O O
. O O

To O O
study O O
this O O
apparent O O
end-organ O O
resistance O O
to O O
cortisol O O
, O O
we O O
examined O O
the O O
glucocorticoid B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
peripheral O O
mononuclear O O
cells O O
. O O

The O O
subsequent O O
achievement O O
of O O
complete O O
remission O O
after O O
combination O O
chemotherapy O O
was O O
correlated O O
with O O
high O O
receptor O O
levels O O
. O O

Forty-seven O O
of O O
50 O O
patients O O
with O O
leukemic O O
cells O O
containing O O
more O O
than O O
6 O O
, O O
000 O O
receptor O O
sites O O
and O O
22 O O
of O O
36 O O
patients O O
with O O
cells O O
containing O O
less O O
than O O
6 O O
, O O
000 O O
receptor O O
sites O O
achieved O O
remission O O
. O O

The O O
study O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
leukemic O O
cells O O
may O O
predict O O
response O O
to O O
combination O O
chemotherapy O O
in O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
. O O

Specific O O
uptake O O
of O O
1 O O
, O O
25-dihydroxycholecalciferol O O
by O O
human O O
chronic O O
myeloid O O
leukemia O O
cells O O
. O O

Whole O O
cells O O
specifically O O
took O O
up O O
[ O O
3H O O
] O O
-1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
with O O
high O O
affinity O O
( O O
Kd O O
3.6 O O
X O O
10 O O
( O O
-11 O O
) O O
M O O
) O O
and O O
low O O
capacity O O
. O O

Subcellular O O
fractionation O O
of O O
labeled O O
cells O O
showed O O
that O O
binding O O
was O O
restricted O O
to O O
cytosols O O
and O O
nuclei O O
. O O

Sucrose O O
gradient O O
centrifugation O O
of O O
cells O O
preincubated O O
with O O
[ O O
3H O O
] O O
-1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
revealed O O
a O O
single O O
3.6S O O
peak O O
which O O
was O O
totally O O
displaced O O
with O O
100-fold O O
excess O O
nonradioactive O O
hormone O O
. O O

However O O
, O O
we O O
were O O
unable O O
to O O
demonstrate O O
specific O O
binding O O
of O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
by O O
postlabeling O O
standard O O
cytosol O O
preparations O O
. O O

However O O
, O O
the O O
levels O O
of O O
binding O O
in O O
T47D O O
cytosols O O
were O O
not O O
reduced O O
if O O
the O O
receptors O O
were O O
occupied O O
with O O
[ O O
3H O O
] O O
-1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
prior O O
to O O
the O O
addition O O
of O O
the O O
CML O O
cytosols O O
. O O

Cells O O
from O O
patients O O
with O O
CML O O
in O O
the O O
chronic O O
phase O O
specifically O O
bound O O
more O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
[ O O
18.0 O O
+/- O O
3.2 O O
( O O
S.E. O O
) O O
fmol/10 O O
( O O
7 O O
) O O
cells O O
] O O
than O O
did O O
those O O
in O O
acute O O
myeloid O O
transformation O O
[ O O
7.2 O O
+/- O O
1.5 O O
] O O
or O O
than O O
did O O
cells O O
from O O
patients O O
with O O
acute O O
myeloid O O
leukemia O O
[ O O
2.6 O O
+/- O O
0.8 O O
] O O
. O O

Only O O
cells O O
from O O
the O O
first O O
group O O
of O O
patients O O
responded O O
to O O
the O O
addition O O
of O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
by O O
differentiating O O
along O O
the O O
monocyte-macrophage O O
pathway O O
. O O

Effect O O
of O O
cell O O
cycle O O
position O O
on O O
dexamethasone O O
binding O O
by O O
mouse O O
and O O
human O O
lymphoid O O
cell O O
lines O O
: O O
correlation O O
between O O
an O O
increase O O
in O O
dexamethasone O O
binding O O
during O O
S O O
phase O O
and O O
dexamethasone O O
sensitivity O O
. O O

We O O
determined O O
the O O
effect O O
of O O
cell O O
cycle O O
position O O
on O O
the O O
amount O O
of O O
dexamethasone O O
that O O
was O O
specifically O O
bound O O
by O O
mouse O O
and O O
human O O
lymphoid O O
cell O O
lines O O
. O O

Cell O O
lines O O
that O O
were O O
either O O
sensitive O O
or O O
resistant O O
to O O
growth O O
inhibition O O
by O O
dexamethasone O O
were O O
compared O O
. O O

Exponentially O O
growing O O
cells O O
were O O
separated O O
by O O
centrifugal O O
elutriation O O
into O O
fractions O O
that O O
corresponded O O
to O O
different O O
positions O O
in O O
the O O
cell O O
cycle O O
. O O

The O O
cell O O
cycle O O
phase O O
distribution O O
of O O
each O O
fraction O O
was O O
estimated O O
by O O
flow O O
cytometry O O
and O O
autoradiography O O
. O O

The O O
amount O O
of O O
dexamethasone O O
bound O O
per O O
cell O O
in O O
each O O
fraction O O
was O O
measured O O
by O O
a O O
whole O O
cell O O
binding O O
assay O O
. O O

In O O
three O O
dexamethasone-sensitive O O
cell O O
lines O O
( O O
two O O
mouse O O
and O O
one O O
human O O
) O O
, O O
we O O
found O O
that O O
the O O
amount O O
of O O
dexamethasone O O
bound O O
per O O
cell O O
increased O O
2-4-fold O O
between O O
G1 O O
phase O O
and O O
S O O
phase O O
, O O
and O O
then O O
decreased O O
during O O
G2/M O O
phase O O
. O O

Results O O
were O O
the O O
same O O
when O O
the O O
amount O O
of O O
dexamethasone O O
bound O O
per O O
milligram O O
of O O
cell B B_PROTEIN[GENE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
protein I B_PROTEIN[GENE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
was O O
measured O O
. O O

Binding O O
affinity O O
was O O
the O O
same O O
during O O
G1 O O
phase O O
and O O
S O O
phase O O
, O O
but O O
the O O
proportion O O
of O O
bound O O
dexamethasone O O
that O O
translocated O O
to O O
the O O
nucleus O O
was O O
greater O O
during O O
S O O
phase O O
. O O

In O O
contrast O O
, O O
we O O
found O O
that O O
the O O
amount O O
of O O
dexamethasone O O
bound O O
per O O
cell O O
by O O
three O O
dexamethasone-resistant O O
cell O O
lines O O
( O O
two O O
mouse O O
and O O
one O O
human O O
) O O
did O O
not O O
increase O O
during O O
S O O
phase O O
. O O

Our O O
results O O
indicate O O
that O O
cell O O
cycle O O
changes O O
in O O
dexamethasone O O
binding O O
are O O
not O O
simply O O
related O O
to O O
changes O O
in O O
cell B B_GENE/B_MEASURE
protein I B_GENE/I_MEASURE
or O O
cell O O
volume O O
during O O
the O O
cell O O
cycle O O
. O O

An O O
increase O O
in O O
dexamethasone O O
binding O O
during O O
S O O
phase O O
may O O
be O O
required O O
for O O
dexamethasone O O
to O O
inhibit O O
cell O O
growth O O
, O O
and O O
a O O
failure O O
of O O
dexamethasone O O
binding O O
to O O
increase O O
during O O
S O O
phase O O
might O O
represent O O
a O O
new O O
mechanism O O
of O O
dexamethasone O O
resistance O O
in O O
lymphoid O O
cells O O
. O O

Presence O O
and O O
steroid O O
inducibility O O
of O O
glutamine B B_GENE/B_LOCATION
synthetase I I_GENE/I_LOCATION
in O O
human O O
leukemic O O
cells O O
. O O

Glutamine B B_GENE
synthetase I I_GENE
( O O
EC O O
6.3.1.2 O O
; O O
GS O O
) O O
is O O
present O O
in O O
lymphoblasts O O
from O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
( O O
ALL O O
) O O
as O O
well O O
as O O
in O O
normal O O
peripheral O O
blood O O
lymphocytes O O
. O O

In O O
16 O O
out O O
of O O
20 O O
ALL O O
patients O O
studied O O
exposure O O
of O O
the O O
cells O O
to O O
physiological O O
concentrations O O
of O O
dexamethasone O O
in O O
vitro O O
increased O O
enzyme B B_GENE
activity O O
above O O
the O O
control O O
levels O O
. O O

A O O
direct O O
correlation O O
was O O
found O O
between O O
the O O
magnitude O O
of O O
glucocorticoid-mediated O O
increase O O
of O O
GS O O
activity O O
and O O
the O O
cellular O O
levels O O
of O O
specific O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assayed O O
in O O
the O O
same O O
cell O O
specimen O O
. O O

Moreover O O
, O O
the O O
basal O O
levels O O
of O O
the O O
enzyme B B_GENE
measured O O
in O O
cells O O
prior O O
to O O
exposure O O
to O O
dexamethasone O O
correlated O O
negatively O O
with O O
receptor O O
density O O
. O O

It O O
is O O
suggested O O
that O O
the O O
presence O O
of O O
steroid-inducible B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GS I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
ALL O O
cells O O
may O O
prove O O
to O O
be O O
a O O
marker O O
for O O
functional B B_DISEASE/B_GENE
receptor I I_DISEASE/I_GENE
sites I I_DISEASE/I_GENE
. O O

Binding O O
of O O
progestins O O
to O O
the O O
glucocorticoid B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
receptor I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O O

Correlation O O
to O O
their O O
glucocorticoid-like O O
effects O O
on O O
in O O
vitro O O
functions O O
of O O
human O O
mononuclear O O
leukocytes O O
. O O

A O O
number O O
of O O
physiological O O
and O O
synthetic O O
progestins O O
were O O
tested O O
for O O
their O O
ability O O
to O O
compete O O
with O O
[ O O
3H O O
] O O
dexamethasone O O
for O O
the O O
binding O O
to O O
the O O
glucocorticoid B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
of O O
human O O
mononuclear O O
leukocytes O O
and O O
their O O
ability O O
to O O
elicit O O
glucocorticoid-like O O
effects O O
on O O
the O O
same O O
cells O O
. O O

The O O
effective O O
binding O O
of O O
medroxyprogesterone O O
acetate O O
to O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
was O O
confirmed O O
by O O
direct O O
binding O O
studies O O
utilizing O O
a O O
tritiated O O
derivative O O
of O O
this O O
steroid O O
. O O

No O O
evidence O O
for O O
the O O
existence O O
of O O
a O O
specific O O
progesterone B B_PROTEIN[GENE]
receptor I I_PROTEIN[GENE]
in O O
human O O
mononuclear O O
leukocytes O O
was O O
obtained O O
as O O
judged O O
by O O
the O O
results O O
of O O
competition O O
experiments O O
where O O
a O O
progesterone O O
receptor-specific O O
ligand O O
[ O O
3H O O
] O O
Org O O
2058 O O
was O O
used O O
. O O

Medroxyprogesterone O O
acetate O O
and O O
megestrol O O
acetate O O
also O O
induced O O
glucocorticoid-like O O
effects O O
on O O
the O O
lymphocyte O O
functions O O
. O O

The O O
progestin O O
effect O O
appears O O
to O O
be O O
mediated O O
through O O
a O O
radiosensitive O O
( O O
suppressor O O
) O O
subpopulation O O
of O O
T O O
lymphocytes O O
. O O

In O O
contrast O O
, O O
the O O
synthetic O O
progestins O O
related O O
structurally O O
to O O
19-nortestosterone O O
, O O
norethisterone O O
and O O
d-norgestrel O O
, O O
were O O
virtually O O
devoid O O
of O O
binding O O
affinity O O
towards O O
the O O
glucocorticoid B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
nor O O
did O O
they O O
measurably O O
influence O O
the O O
in O O
vitro O O
lymphocyte O O
functions O O
. O O

These O O
studies O O
demonstrate O O
that O O
certain O O
progestins O O
in O O
common O O
clinical O O
use O O
probably O O
possess O O
inherent O O
glucocorticoid O O
activity O O
and O O
suggest O O
that O O
side O O
effects O O
attributable O O
to O O
this O O
character O O
( O O
e.g. O O
suppression O O
of O O
the O O
pituitary-adrenal O O
axis O O
) O O
might O O
be O O
expected O O
when O O
these O O
compounds O O
are O O
used O O
in O O
pharmacological O O
doses O O
. O O

Metabolic O O
and O O
ultrastructural O O
aspects O O
of O O
the O O
in O O
vitro O O
lysis O O
of O O
chronic O O
lymphocytic O O
leukemia O O
cells O O
by O O
glucocorticoids O O
. O O

In O O
this O O
study O O
, O O
metabolic O O
and O O
ultrastructural O O
aspects O O
of O O
the O O
cortisol-induced O O
killing O O
process O O
of O O
CLL O O
cells O O
are O O
recorded O O
. O O

In O O
vitro O O
lysis O O
was O O
found O O
to O O
be O O
temperature O O
dependent O O
and O O
was O O
detected O O
only O O
after O O
6 O O
to O O
8 O O
hr O O
incubation O O
with O O
cortisol O O
by O O
means O O
of O O
the O O
trypan O O
blue O O
exclusion O O
test O O
. O O

However O O
, O O
30 O O
min O O
of O O
incubation O O
with O O
cortisol O O
at O O
either O O
37 O O
degrees O O
or O O
4 O O
degrees O O
followed O O
by O O
the O O
removal O O
of O O
the O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
still O O
sufficient O O
to O O
induce O O
the O O
lytic O O
process O O
. O O

Addition O O
of O O
metabolic O O
inhibitors O O
including O O
actinomycin O O
D O O
, O O
puromycin O O
, O O
and O O
cycloheximide O O
following O O
administration O O
of O O
cortisol O O
resulted O O
in O O
inhibition O O
of O O
the O O
cell O O
lysis O O
. O O

An O O
excess O O
of O O
an O O
antagonist O O
such O O
as O O
cortexolone O O
was O O
found O O
to O O
inhibit O O
the O O
cortisol-induced O O
cytolysis O O
of O O
the O O
CLL O O
cells O O
. O O

It O O
is O O
suggested O O
that O O
the O O
glucocorticoid-induced O O
lysis O O
of O O
human O O
CLL O O
cells O O
is O O
similar O O
to O O
the O O
phenomenon O O
observed O O
in O O
rat O O
or O O
murine O O
lymphocytes O O
and O O
is O O
mediated O O
by O O
interaction O O
of O O
the O O
steroid O O
molecule O O
with O O
the O O
cytoplasmic B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
resulting O O
complex O O
appears O O
to O O
activate O O
specific O O
gene B B_GENE
( O O
s O O
) O O
the O O
products O O
of O O
which O O
eventually O O
cause O O
cytolysis O O
. O O

There O O
is O O
a O O
range O O
of O O
levels O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
numbers O O
seen O O
in O O
the O O
various O O
subclasses O O
of O O
acute O O
lymphatic O O
leukemia O O
( O O
ALL O O
) O O
. O O

This O O
variability O O
can O O
not O O
be O O
explained O O
by O O
the O O
known O O
correlation O O
between O O
active O O
cell O O
proliferation O O
and O O
an O O
increase O O
in O O
the O O
number O O
of O O
receptors O O
, O O
since O O
the O O
tumors O O
with O O
the O O
highest O O
growth O O
fraction O O
( O O
i.e. O O
, O O
Burkitt O O
's O O
lymphoma O O
and O O
T-cell O O
leukemia O O
) O O
tend O O
to O O
have O O
lower O O
average O O
receptor O O
numbers O O
than O O
do O O
tumors O O
with O O
lower O O
growth O O
fractions O O
such O O
as O O
common O O
ALL O O
. O O

However O O
, O O
there O O
has O O
been O O
a O O
positive O O
correlation O O
, O O
in O O
our O O
hands O O
, O O
with O O
receptor O O
level O O
and O O
prognosis O O
. O O

This O O
greater O O
genetic O O
variability O O
in O O
the O O
low-receptor O O
lines O O
could O O
account O O
for O O
the O O
earlier O O
emergence O O
of O O
clinical O O
glucocorticoid O O
resistance O O
in O O
these O O
patients O O
. O O

A O O
strong O O
sinushistiocytosis O O
and O O
T-cellreaction O O
could O O
be O O
verified O O
mainly O O
in O O
metastases O O
in O O
free O O
lymphnodes O O
. O O

The O O
steroid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O O
does O O
not O O
correlate O O
with O O
histological O O
parameters O O

Aldosterone-receptor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deficiency O O
in O O
pseudohypoaldosteronism O O
. O O

Pseudohypoaldosteronism O O
, O O
a O O
syndrome O O
characterized O O
by O O
salt O O
wasting O O
and O O
failure O O
to O O
thrive O O
, O O
usually O O
presents O O
in O O
infancy O O
as O O
high O O
urinary O O
levels O O
of O O
sodium O O
despite O O
hyponatremia O O
, O O
hyperkalemia O O
, O O
hyperreninemia O O
, O O
and O O
elevated O O
aldosterone O O
levels O O
. O O

We O O
have O O
studied O O
three O O
patients O O
with O O
pseudohypoaldosteronism O O
: O O
the O O
28-year-old O O
index O O
case O O
in O O
Melbourne O O
( O O
Patient O O
1 O O
) O O
and O O
two O O
siblings O O
in O O
Munich O O
, O O
eight O O
and O O
two O O
years O O
of O O
age O O
( O O
Patients O O
2 O O
and O O
3 O O
) O O
; O O
clinically O O
, O O
Patient O O
3 O O
had O O
a O O
less O O
severe O O
case O O
than O O
his O O
sister O O
. O O

On O O
repeated O O
examination O O
, O O
no O O
[ O O
3H O O
] O O
aldosterone O O
binding O O
was O O
found O O
in O O
monocytes O O
from O O
Patients O O
1 O O
and O O
2 O O
; O O
in O O
Patient O O
3 O O
, O O
the O O
levels O O
were O O
62 O O
sites O O
per O O
cell O O
, O O
more O O
than O O
2 O O
S.D. O O
below O O
those O O
of O O
the O O
control O O
. O O

Levels O O
in O O
the O O
parents O O
of O O
the O O
Munich O O
patients O O
( O O
first O O
cousins O O
) O O
were O O
normal O O
. O O

It O O
appears O O
that O O
pseudohypoaldosteronism O O
is O O
caused O O
by O O
a O O
Type O O
I O O
receptor O O
defect O O
, O O
that O O
the O O
defect O O
may O O
be O O
complete O O
or O O
partial O O
, O O
that O O
transmission O O
may O O
be O O
autosomal O O
recessive O O
, O O
and O O
that O O
the O O
study O O
of O O
patients O O
with O O
pseudohypoaldosteronism O O
may O O
indicate O O
physiologic O O
roles O O
for O O
Type B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
nonepithelial O O
tissues O O
. O O

Glucocorticoid O O
inhibition O O
of O O
urokinase-like B B_DISEASE/B_GENE
plasminogen I B_DISEASE/I_GENE
activators I B_DISEASE/I_GENE
in O O
cultured O O
human O O
lymphoblasts O O
. O O

Treatment O O
of O O
both O O
HMy2 O O
and O O
GM4672A O O
cells O O
with O O
Dex O O
for O O
1-4 O O
days O O
inhibits O O
extracellular O O
PA B B_GENE/B_DISEASE
activity O O
in O O
a O O
concentration-dependent O O
manner O O
, O O
being O O
half-maximal O O
at O O
approximately O O
1 O O
X O O
10 O O
( O O
-9 O O
) O O
M O O
. O O

Inhibition O O
of O O
PA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
both O O
cell O O
types O O
is O O
specific O O
for O O
active O O
glucocorticoids O O
, O O
and O O
this O O
specificity O O
parallels O O
the O O
ability O O
of O O
various O O
steroids O O
to O O
bind O O
to O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
conditioned O O
media O O
from O O
Dex-treated O O
GM4672A O O
cells O O
inhibits O O
a O O
portion O O
of O O
the O O
homologous O O
cellular O O
activator O O
in O O
conditioned O O
media O O
from O O
control O O
GM4672A O O
cells O O
. O O

Glucocorticoid-inducible B B_GENE/B_TIME[MEASURE]
inhibitors I I_GENE/I_TIME[MEASURE]
in O O
HMy2 O O
cells O O
are O O
either O O
totally O O
absent O O
or O O
are O O
present O O
at O O
undetectable O O
levels O O
. O O

After O O
washing O O
and O O
resuspension O O
in O O
RPMI-1640 O O
medium O O
, O O
cells O O
were O O
incubated O O
at O O
37 O O
degrees O O
C O O
for O O
1 O O
h O O
with O O
different O O
concentrations O O
of O O
[ O O
3H O O
] O O
aldosterone O O
plus O O
a O O
100-fold O O
concentration O O
of O O
RU-26988 O O
( O O
11 O O
alpha O O
, O O
17 O O
alpha-dihydroxy-17 O O
beta-propynylandrost-1 O O
, O O
4 O O
, O O
6-trien-3-one O O
) O O
, O O
with O O
or O O
without O O
an O O
excess O O
of O O
unlabeled O O
aldosterone O O
. O O

The O O
specificity O O
data O O
show O O
a O O
hierarchy O O
of O O
affinity O O
of O O
desoxycorticosterone O O
= O O
corticosterone O O
= O O
aldosterone O O
greater O O
than O O
hydrocortisone O O
greater O O
than O O
dexamethasone O O
. O O

The O O
results O O
indicate O O
that O O
mononuclear O O
leukocytes O O
could O O
be O O
useful O O
for O O
studying O O
the O O
physiological O O
significance O O
of O O
these O O
mineralocorticoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
their O O
regulation O O
in O O
humans O O
. O O

Mineralocorticoid B B_GENE/B_PERSON
and I I_GENE/I_PERSON
glucocorticoid I I_GENE/I_PERSON
receptors I I_GENE/I_PERSON
were O O
measured O O
in O O
circulating O O
mononuclear O O
leukocytes O O
in O O
5 O O
patients O O
affected O O
by O O
Conn O O
's O O
syndrome O O
( O O
3 O O
cases O O
of O O
bilateral O O
adrenal O O
hyperplasia O O
and O O
2 O O
cases O O
of O O
adenoma O O
plus O O
unilateral O O
hyperplasia O O
) O O
. O O

The O O
number O O
of O O
the O O
binding O O
sites O O
per O O
cell O O
resulted O O
significantly O O
lower O O
( O O
189 O O
+/- O O
114 O O
, O O
mean O O
+/- O O
SD O O
) O O
, O O
as O O
compared O O
with O O
the O O
normal O O
controls O O
( O O
298 O O
+/- O O
105 O O
) O O
. O O

The O O
capacity O O
and O O
the O O
affinity O O
of O O
dexamethasone O O
for O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ranged O O
in O O
the O O
normal O O
values O O
. O O

These O O
data O O
suggest O O
a O O
possible O O
down-regulation O O
of O O
mineralocorticoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
humans O O
. O O

Short-term O O
and O O
long-term O O
effects O O
of O O
estrogen O O
on O O
lymphoid O O
tissues O O
and O O
lymphoid O O
cells O O
with O O
some O O
remarks O O
on O O
the O O
significance O O
for O O
carcinogenesis O O
. O O

Estrogens O O
have O O
long O O
been O O
thought O O
to O O
play O O
a O O
role O O
in O O
regulating O O
the O O
immune O O
system O O
. O O

The O O
difference O O
in O O
some O O
types O O
of O O
immune O O
responses O O
between O O
males O O
and O O
females O O
is O O
well-known O O
, O O
as O O
is O O
the O O
pronounced O O
thymic O O
involution O O
induced O O
by O O
exogenous O O
estrogens O O
. O O

Another O O
example O O
is O O
the O O
estrogen O O
effect O O
on O O
the O O
delayed O O
type O O
hypersensitivity O O
response O O
. O O

A O O
broad O O
review O O
is O O
given O O
of O O
such O O
estrogen O O
effects O O
on O O
lymphoid O O
tissue O O
and O O
immune O O
response O O
. O O

Most O O
of O O
the O O
studies O O
published O O
so O O
far O O
are O O
phenomenological O O
. O O

However O O
, O O
the O O
recent O O
description O O
of O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
thymus O O
and O O
in O O
some O O
lymphocyte O O
subpopulations O O
, O O
as O O
well O O
as O O
a O O
deeper O O
understanding O O
of O O
regulating O O
factors O O
in O O
the O O
immune O O
system O O
, O O
open O O
the O O
possibility O O
of O O
a O O
more O O
detailed O O
understanding O O
of O O
the O O
estrogen O O
mechanism O O
of O O
interference O O
. O O

Estrogen O O
effects O O
in O O
adults O O
are O O
reversible O O
. O O

After O O
treating O O
neonatal O O
mice O O
with O O
the O O
synthetic O O
estrogen O O
diethylstilbestrol O O
( O O
DES O O
) O O
, O O
disturbances O O
are O O
induced O O
in O O
lymphocyte O O
populations O O
and O O
lymphocyte O O
functions O O
which O O
are O O
permanent O O
and O O
irreversible O O
. O O

A O O
detailed O O
analysis O O
demonstrated O O
a O O
decreased O O
T O O
helper O O
cell O O
population O O
. O O

The O O
same O O
animals O O
have O O
an O O
increased O O
sensitivity O O
to O O
chemical O O
carcinogens O O
( O O
methylcholanthrene O O
) O O
and O O
they O O
spontaneously O O
develop O O
epithelial O O
changes O O
in O O
the O O
uterine O O
cervix O O
which O O
morphologically O O
are O O
similar O O
to O O
adenocarcinoma O O
. O O

The O O
association O O
between O O
estrogen-associated O O
malignancy O O
and O O
estrogen O O
effects O O
in O O
lymphocyte O O
functions O O
deserves O O
further O O
study O O
. O O

Drugs O O
affecting O O
the O O
hormonal O O
receptors O O
of O O
normal O O
and O O
leukaemic O O
peripheral O O
leucocytes O O
. O O

The O O
authors O O
investigated O O
the O O
behaviour O O
of O O
steroid O O
hormone O O
uptake O O
in O O
leukaemic O O
cells O O
( O O
CML O O
, O O
CLL O O
, O O
AML O O
, O O
ALL O O
) O O
, O O
in O O
basal O O
conditions O O
and O O
after O O
incubation O O
with O O
drugs O O
which O O
modify O O
the O O
cellular O O
concentration O O
of O O
cAMP O O
, O O
PGE O O
and O O
PGF O O
. O O

The O O
results O O
demonstrated O O
the O O
presence O O
in O O
leukaemic O O
cells O O
of O O
an O O
alteration O O
in O O
the O O
incorporation O O
of O O
steroid O O
hormones O O
. O O

This O O
alteration O O
was O O
scarcely O O
modified O O
by O O
incubation O O
with O O
theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
which O O
increases O O
cellular O O
concentration O O
of O O
cAMP O O
. O O

On O O
the O O
other O O
hand O O
, O O
it O O
was O O
moderately O O
counteracted O O
by O O
thioproline O O
and O O
was O O
evidently O O
inhibited O O
by O O
flurbiprofen O O
, O O
which O O
also O O
reduced O O
cellular O O
concentrations O O
of O O
prostaglandins O O
, O O
particularly O O
PGE2 O O
, O O
with O O
the O O
exception O O
of O O
PGF2 O O
which O O
showed O O
a O O
poor O O
response O O
. O O

Differences O O
were O O
observed O O
in O O
the O O
behavior O O
of O O
hormonal O O
uptake O O
of O O
CML O O
, O O
in O O
contrast O O
to O O
that O O
of O O
AML O O
, O O
CLL O O
and O O
ALL O O
peripheral O O
leucocytes O O
. O O

Human O O
breast O O
cancer O O
and O O
impaired O O
NK O O
cell O O
function O O
. O O

Recent O O
advances O O
in O O
tumor O O
immunology O O
have O O
led O O
to O O
the O O
discovery O O
of O O
a O O
new O O
lymphoid O O
cell O O
with O O
unique O O
antitumor O O
activity O O
. O O

We O O
studied O O
NK O O
activity O O
in O O
patients O O
with O O
benign O O
and O O
malignant O O
breast O O
disease O O
, O O
using O O
a O O
chromium-51 O O
release O O
microtiter O O
cytotoxicity O O
assay O O
with O O
K562 O O
cells O O
as O O
targets O O
. O O

Compared O O
with O O
benign O O
controls O O
, O O
patients O O
with O O
malignancies O O
had O O
significantly O O
depressed O O
NK O O
-mediated O O
lysis O O
( O O
P O O
less O O
than O O
0.01 O O
) O O
. O O

Furthermore O O
, O O
lysis O O
in O O
those O O
with O O
advanced O O
disease O O
( O O
stages O O
II O O
, O O
III O O
, O O
and O O
IV O O
) O O
was O O
significantly O O
less O O
than O O
in O O
those O O
with O O
limited O O
disease O O
( O O
stage O O
I O O
) O O
( O O
P O O
less O O
than O O
0.01 O O
) O O
. O O

NK O O
activity O O
was O O
not O O
correlated O O
to O O
estrogen O O
or O O
progesterone O O
receptor O O
states O O
. O O

Positive O O
correlation O O
of O O
a O O
depressed O O
natural O O
killer O O
activity O O
with O O
the O O
extent O O
of O O
tumor O O
spread O O
supports O O
the O O
concept O O
of O O
an O O
NK O O
cell O O
immune O O
surveillance O O
system O O
in O O
breast O O
cancer O O
and O O
emphasizes O O
its O O
importance O O
in O O
this O O
malignancy O O
. O O

Immunosuppressive O O
effect O O
of O O
serum O O
progesterone O O
during O O
pregnancy O O
depends O O
on O O
the O O
progesterone O O
binding O O
capacity O O
of O O
the O O
lymphocytes O O
. O O

Cytotoxic O O
activity O O
and O O
progesterone O O
binding O O
capacity O O
of O O
the O O
lymphocytes O O
, O O
together O O
with O O
serum O O
progesterone O O
concentrations O O
, O O
were O O
determined O O
in O O
women O O
with O O
normal O O
pregnancy O O
or O O
with O O
a O O
clinical O O
diagnosis O O
of O O
threatened O O
abortion O O
or O O
threatened O O
premature O O
labour O O
. O O

The O O
lymphocytes O O
of O O
women O O
with O O
threatened O O
abortion O O
or O O
threatened O O
premature O O
labour O O
showed O O
significantly O O
higher O O
cytotoxic O O
activity O O
( O O
P O O
less O O
than O O
0.001 O O
) O O
and O O
significantly O O
lower O O
progesterone O O
binding O O
capacity O O
( O O
P O O
less O O
than O O
0.001 O O
) O O
than O O
did O O
lymphocytes O O
obtained O O
from O O
the O O
healthy O O
pregnant O O
women O O
. O O

Significant O O
inverse O O
correlation O O
was O O
found O O
between O O
progesterone O O
binding O O
capacity O O
and O O
cytotoxic O O
activity O O
of O O
the O O
lymphocytes O O
( O O
P O O
less O O
than O O
0.001 O O
) O O
, O O
but O O
the O O
progesterone O O
concentration O O
of O O
the O O
pregnancy O O
serum O O
appeared O O
to O O
have O O
no O O
influence O O
on O O
the O O
other O O
two O O
parameters O O
. O O

The O O
findings O O
indicate O O
that O O
intact O O
progesterone O O
binding O O
capacity O O
of O O
the O O
lymphocytes O O
is O O
an O O
essential O O
factor O O
for O O
the O O
manifestation O O
of O O
the O O
blocking O O
effect O O
exerted O O
by O O
pregnancy O O
serum O O
on O O
lymphocyte O O
cytotoxicity O O
in O O
vitro O O
. O O

In O O
addition O O
, O O
an O O
extensive O O
monitoring O O
of O O
clinical O O
chemical O O
and O O
hematological O O
tests O O
from O O
the O O
blood O O
samples O O
were O O
performed O O
. O O

Serum O O
estradiol O O
and O O
progesterone O O
concentrations O O
were O O
significantly O O
decreased O O
during O O
the O O
treatment O O
cycle O O
, O O
suggesting O O
that O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interacts O O
in O O
vivo O O
with O O
the O O
function O O
of O O
both O O
FSH O O
and O O
LH O O
. O O

These O O
results O O
suggest O O
that O O
one O O
of O O
the O O
mechanisms O O
by O O
which O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O O
may O O
affect O O
the O O
growth O O
of O O
hormone-dependent O O
neoplasms O O
could O O
be O O
the O O
interaction O O
with O O
production O O
and/or O O
function O O
of O O
circulating O O
hormonal O O
compounds O O
. O O

[ O O
Glucocorticoid B B_GENE
receptor I I_GENE
level O O
in O O
the O O
blood O O
leukocytes O O
in O O
different O O
acute O O
diseases O O
] O O

Content O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
cytosol O O
of O O
blood O O
leukocytes O O
, O O
concentration O O
of O O
cortisol O O
and O O
amount O O
of O O
leukocytes O O
in O O
blood O O
were O O
studied O O
in O O
20 O O
patients O O
with O O
acute O O
impairments O O
within O O
the O O
second O O
day O O
of O O
the O O
disease O O
. O O

Content O O
of O O
receptors O O
in O O
cytosol O O
of O O
blood O O
leukocytes O O
was O O
studied O O
using O O
3H-triamcinolone O O
acetonide O O
. O O

Distinct O O
increase O O
in O O
amount O O
of O O
the O O
leukocyte B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
in O O
patients O O
with O O
poisoning O O
by O O
dichlorethane O O
and O O
hypnotic O O
drugs O O
under O O
conditions O O
of O O
acute O O
myocardial O O
infarction O O
. O O

In O O
acute O O
pancreatitis O O
content O O
of O O
the O O
leukocyte B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
receptors I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
not O O
altered O O
as O O
compared O O
with O O
controls O O
. O O

Concentration O O
of O O
endogenous O O
cortisol O O
was O O
increased O O
in O O
blood O O
of O O
all O O
the O O
patients O O
, O O
except O O
of O O
the O O
cases O O
of O O
acetate O O
intoxication O O
. O O

Reverse O O
correlation O O
was O O
observed O O
between O O
concentration O O
of O O
cortisol O O
in O O
blood O O
and O O
content O O
of O O
glucocorticoid O O
receptors O O
in O O
leukocytes O O
. O O

By O O
exposing O O
human O O
blood-derived O O
macrophages O O
and O O
alveolar O O
macrophages O O
in O O
vitro O O
to O O
dexamethasone O O
, O O
we O O
showed O O
in O O
these O O
studies O O
that O O
glucocorticoids O O
markedly O O
suppress O O
the O O
antimicrobial O O
activity O O
of O O
macrophages O O
but O O
not O O
macrophage O O
activation O O
by O O
lymphokines O O
. O O

As O O
little O O
as O O
2.5 O O
X O O
10 O O
( O O
-8 O O
) O O
mol/liter O O
of O O
dexamethasone O O
prevented O O
macrophages O O
from O O
inhibiting O O
germination O O
of O O
Aspergillus O O
spores O O
or O O
from O O
eliminating O O
ingested O O
bacteria O O
such O O
as O O
Listeria O O
, O O
Nocardia O O
, O O
or O O
Salmonella O O
. O O

Damage O O
to O O
macrophage O O
function O O
was O O
inhibited O O
by O O
progesterone O O
and O O
appeared O O
to O O
be O O
receptor-mediated O O
. O O

In O O
accordance O O
with O O
in O O
vivo O O
observations O O
, O O
dexamethasone O O
required O O
24-36 O O
h O O
to O O
suppress O O
antimicrobial O O
activity O O
. O O

While O O
glucocorticoids O O
interfered O O
with O O
base-line O O
activity O O
of O O
macrophages O O
, O O
dexamethasone O O
concentrations O O
comparable O O
to O O
drug O O
levels O O
in O O
patients O O
had O O
no O O
effect O O
on O O
macrophage O O
activation O O
. O O

The O O
lymphokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enhanced O O
the O O
antimicrobial O O
activity O O
of O O
dexamethasone-treated O O
macrophages O O
against O O
Listeria O O
and O O
Salmonella O O
but O O
not O O
against O O
Aspergillus O O
or O O
Nocardia O O
. O O

Dexamethasone-induced O O
damage O O
to O O
the O O
antimicrobial O O
activity O O
of O O
human O O
macrophages O O
in O O
vitro O O
parallels O O
observations O O
that O O
glucocorticoids O O
render O O
laboratory O O
animals O O
susceptible O O
to O O
listeriosis O O
and O O
aspergillosis O O
by O O
damaging O O
resident O O
macrophages O O
. O O

Interleukin B B_GENE
2 I I_GENE
receptor I I_GENE
( O O
Tac B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
expression O O
in O O
HTLV-I-associated O O
adult O O
T-cell O O
leukemia O O
. O O

Interleukin-2 B B_GENE
( O O
IL-2 B B_GENE
) O O
is O O
a O O
lymphokine B B_GENE
synthesized O O
by O O
some O O
T-cells O O
following O O
activation O O
. O O

Resting O O
T-cells O O
do O O
not O O
express O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
receptors O O
are O O
rapidly O O
expressed O O
on O O
T-cells O O
following O O
interaction O O
of O O
antigens O O
, O O
mitogens O O
, O O
or O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
the O O
antigen-specific B B_GENE
T-cell I I_GENE
receptor I I_GENE
complex I I_GENE
. O O

Normal O O
resting O O
T-cells O O
and O O
most O O
leukemic O O
T-cell O O
populations O O
do O O
not O O
express O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
however O O
, O O
the O O
leukemic O O
cells O O
of O O
the O O
11 O O
patients O O
examined O O
who O O
had O O
human O O
T-cell O O
lymphotropic O O
virus-associated O O
adult O O
T-cell O O
leukemia O O
expressed O O
the O O
Tac B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
human O O
T-cell O O
lymphotropic O O
virus-I O O
infected O O
cells O O
, O O
the O O
Mr O O
42 O O
, O O
000 O O
long O O
open B B_GENE
reading I I_GENE
frame I I_GENE
protein I I_GENE
encoded O O
in O O
part O O
by O O
the O O
pX B B_GENE
region I I_GENE
of O O
this O O
virus O O
may O O
act O O
as O O
a O O
transacting B B_GENE
transcriptional I I_GENE
activator I I_GENE
that O O
induces O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O O
, O O
thus O O
providing O O
an O O
explanation O O
for O O
the O O
constant O O
association O O
of O O
IL-2 B B_GENE
receptor I I_GENE
expression O O
with O O
adult O O
T-cell O O
lymphotropic O O
virus-I O O
infection O O
of O O
lymphoid O O
cells O O
. O O

The O O
constant O O
expression O O
of O O
large O O
numbers O O
of O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
may O O
be O O
aberrant O O
may O O
play O O
a O O
role O O
in O O
the O O
uncontrolled O O
growth O O
of O O
adult O O
T-cell O O
leukemia O O
cells O O
. O O

Lymphocyte O O
glucocorticoid B B_GENE
receptor I I_GENE
binding O O
in O O
depressed O O
patients O O
with O O
hypercortisolemia O O
. O O

Despite O O
elevated O O
levels O O
of O O
serum O O
and O O
urinary O O
cortisol O O
, O O
patients O O
with O O
depressive O O
illness O O
manifest O O
none O O
of O O
the O O
clinical O O
stigmata O O
of O O
glucocorticoid O O
excess O O
. O O

This O O
hypercortisolemia O O
in O O
the O O
absence O O
of O O
clinical O O
effects O O
suggests O O
a O O
state O O
of O O
hormone O O
resistance O O
and O O
could O O
be O O
mediated O O
by O O
alterations O O
in O O
the O O
glucocorticoid B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
receptor I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O O

Earlier O O
studies O O
have O O
shown O O
that O O
small O O
doses O O
of O O
glucocorticoids O O
cause O O
a O O
decrease O O
in O O
glucocorticoid B B_GENE
receptor I I_GENE
binding O O
in O O
normal O O
human O O
lymphocytes O O
. O O

White O O
cells O O
from O O
depressed O O
patients O O
with O O
significant O O
hypercortisolemia O O
would O O
be O O
expected O O
to O O
show O O
a O O
similar O O
change O O
in O O
receptor O O
concentration O O
if O O
peripheral O O
tissues O O
are O O
adequately O O
exposed O O
to O O
and O O
sensitive O O
to O O
the O O
hormone O O
. O O

In O O
this O O
study O O
we O O
compared O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
dexamethasone O O
to O O
lymphocytes O O
from O O
normal O O
subjects O O
and O O
depressed O O
patients O O
with O O
hypercortisolemia O O
. O O

Lymphocytes O O
from O O
normal O O
subjects O O
had O O
a O O
mean O O
receptor O O
concentration O O
of O O
10.2 O O
+/- O O
0.66 O O
fm/10 O O
( O O
6 O O
) O O
cells O O
( O O
S.E.M. O O
) O O
and O O
a O O
dissociation O O
constant O O
of O O
4.8 O O
+/- O O
0.47 O O
nM O O
. O O

Lymphocytes O O
from O O
depressed O O
patients O O
with O O
abnormal O O
0800 O O
h O O
serum O O
cortisol O O
after O O
dexamethasone O O
had O O
a O O
mean O O
receptor O O
concentration O O
of O O
8.8 O O
+/- O O
0.75 O O
fm/10 O O
( O O
6 O O
) O O
cells O O
, O O
which O O
was O O
not O O
significantly O O
different O O
from O O
that O O
in O O
lymphocytes O O
from O O
normal O O
subjects O O
or O O
from O O
depressed O O
subjects O O
with O O
normal O O
post-dexamethasone O O
cortisol O O
levels O O
( O O
9.4 O O
+/- O O
0.95 O O
fm/10 O O
( O O
6 O O
) O O
cells O O
) O O
. O O

Lymphocytes O O
from O O
depressed O O
patients O O
with O O
elevated O O
urinary O O
free O O
cortisol O O
excretion O O
( O O
UFC O O
) O O
also O O
had O O
normal O O
receptor O O
concentration O O
and O O
binding O O
affinity O O
for O O
dexamethasone O O
. O O

The O O
lack O O
of O O
a O O
change O O
in O O
lymphocyte O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
concentration O O
in O O
the O O
presence O O
of O O
cortisol O O
excess O O
suggests O O
the O O
possibility O O
that O O
hypercortisolemia O O
in O O
depressive O O
illness O O
represents O O
a O O
state O O
of O O
peripheral O O
glucocorticoid O O
resistance O O
. O O

Structure O O
and O O
regulation O O
of O O
the O O
glucocorticoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
glucocorticoid B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
is O O
an O O
intracellular B B_PROTEIN[GENE]/B_BIO
protein I I_PROTEIN[GENE]/I_BIO
which O O
possesses O O
three O O
distinct O O
domains O O
, O O
one O O
that O O
binds O O
agonist O O
and O O
antagonist O O
steroids O O
, O O
one O O
that O O
binds O O
DNA O O
, O O
and O O
one O O
that O O
binds O O
anti-receptor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
is O O
required O O
for O O
glucocorticoid O O
modulation O O
of O O
gene O O
expression O O
. O O

Although O O
substituent O O
groups O O
that O O
confer O O
agonist O O
or O O
antagonist O O
activity O O
to O O
the O O
steroid O O
have O O
been O O
identified O O
, O O
the O O
molecular O O
determinants O O
of O O
this O O
difference O O
at O O
the O O
receptor O O
level O O
remain O O
unknown O O
. O O

Thermodynamics O O
of O O
steroid O O
binding O O
to O O
the O O
human B B_GENE
glucocorticoid I I_GENE
receptor I I_GENE
. O O

The O O
rate O O
and O O
affinity O O
constants O O
of O O
dexamethasone O O
and O O
cortisol O O
between O O
0 O O
degree O O
and O O
25 O O
degrees O O
C O O
were O O
calculated O O
by O O
curve-fitting O O
from O O
time-course O O
and O O
equilibrium O O
kinetics O O
. O O

The O O
data O O
were O O
consistent O O
with O O
a O O
simple O O
reversible O O
bimolecular O O
interaction O O
. O O

Arrhenius O O
and O O
Va O O
n't O O
Hoff O O
plots O O
were O O
curvilinear O O
for O O
both O O
steroids O O
. O O

At O O
equilibrium O O
, O O
the O O
solution O O
for O O
the O O
equation O O
delta O O
G O O
= O O
delta O O
H O O
- O O
T O O
X O O
delta O O
S O O
( O O
eqn. O O
1 O O
) O O
was O O
( O O
in O O
kJ O O
X O O
mol-1 O O
) O O
-47 O O
= O O
36 O O
- O O
83 O O
( O O
dexamethasone O O
) O O
and O O
-42 O O
= O O
-9 O O
- O O
33 O O
( O O
cortisol O O
) O O
at O O
0 O O
degree O O
C O O
. O O

Enthalpy O O
and O O
entropy O O
changes O O
decreased O O
quasi-linearly O O
with O O
temperature O O
such O O
that O O
, O O
at O O
25 O O
degrees O O
C O O
, O O
the O O
respective O O
values O O
were O O
-50 O O
= O O
-75 O O
+ O O
25 O O
and O O
-43 O O
= O O
-48 O O
+ O O
5 O O
. O O

Thus O O
, O O
for O O
both O O
steroids O O
, O O
the O O
interaction O O
was O O
entropy-driven O O
at O O
low O O
temperature O O
and O O
became O O
entirely O O
enthalpy-driven O O
at O O
20 O O
degrees O O
C O O
. O O

Thermodynamic O O
values O O
for O O
the O O
transition O O
state O O
were O O
calculated O O
from O O
the O O
rate O O
constants O O
. O O

For O O
the O O
forward O O
reaction O O
, O O
eqn. O O
( O O
1 O O
) O O
gave O O
45 O O
= O O
84 O O
- O O
39 O O
( O O
dexamethasone O O
) O O
and O O
46 O O
= O O
60 O O
- O O
14 O O
( O O
cortisol O O
) O O
at O O
0 O O
degree O O
C O O
, O O
and O O
44 O O
= O O
24 O O
+ O O
20 O O
( O O
dexamethasone O O
) O O
and O O
46 O O
= O O
28 O O
+ O O
18 O O
( O O
cortisol O O
) O O
at O O
25 O O
degrees O O
C O O
. O O

These O O
data O O
fit O O
quite O O
well O O
with O O
a O O
two-step O O
model O O
[ O O
Ross O O
& O O
Subramanian O O
( O O
1981 O O
) O O
Biochemistry O O
20 O O
, O O
3096-3102 O O
] O O
proposed O O
for O O
ligand-protein O O
interactions O O
, O O
which O O
involves O O
a O O
partial O O
immobilization O O
of O O
the O O
reacting O O
species O O
governed O O
by O O
hydrophobic O O
forces O O
, O O
followed O O
by O O
stabilization O O
of O O
the O O
complex O O
by O O
short-range O O
interactions O O
. O O

On O O
the O O
basis O O
of O O
this O O
model O O
, O O
an O O
analysis O O
of O O
the O O
transition-state O O
thermodynamics O O
led O O
to O O
the O O
conclusion O O
that O O
no O O
more O O
than O O
half O O
of O O
the O O
steroid O O
molecular O O
area O O
is O O
engaged O O
in O O
the O O
binding O O
process O O
. O O

Cell O O
cycle-related O O
changes O O
in O O
number O O
of O O
T-lymphocyte B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
glucocorticoids O O
and O O
insulin O O
. O O

Enriched O O
human O O
peripheral O O
T-lymphocytes O O
were O O
stimulated O O
with O O
PHA O O
and O O
examined O O
for O O
variations O O
in O O
insulin O O
and O O
glucocorticoid O O
( O O
dexamethasone O O
) O O
receptor O O
numbers O O
during O O
the O O
early O O
phases O O
of O O
the O O
cell O O
cycle O O
. O O

Cells O O
in O O
G0 O O
, O O
G1a O O
and O O
G1b O O
phases O O
, O O
where O O
the O O
G1a O O
- O O
G1b O O
transition O O
is O O
an O O
Interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent O O
event O O
, O O
were O O
quantitated O O
by O O
flow O O
cytometry O O
. O O

Although O O
the O O
specific O O
binding O O
further O O
increased O O
as O O
T-cells O O
entered O O
the O O
G1b O O
phase O O
( O O
as O O
measured O O
at O O
44 O O
h O O
of O O
incubation O O
and O O
using O O
hydroxyurea-treated O O
cells O O
) O O
, O O
the O O
major O O
changes O O
in O O
the O O
specific O O
binding O O
of O O
dexamethasone O O
took O O
place O O
during O O
the O O
period O O
16 O O
- O O
20 O O
h O O
after O O
stimulation O O
. O O

Based O O
on O O
these O O
findings O O
, O O
it O O
is O O
concluded O O
that O O
both O O
receptor O O
types O O
( O O
cell B B_PROTEIN[GENE]/B_LOCATION
membrane I I_PROTEIN[GENE]/I_LOCATION
and I I_PROTEIN[GENE]/I_LOCATION
cytoplasmic I I_PROTEIN[GENE]/I_LOCATION
receptors I I_PROTEIN[GENE]/I_LOCATION
) O O
are O O
being O O
formed O O
and O O
increased O O
at O O
G1 O O
phase O O
prior O O
to O O
cell O O
proliferation O O
, O O
indicating O O
the O O
importance O O
of O O
G1 O O
phase O O
in O O
immunoregulation O O
. O O

CM-SM O O
is O O
a O O
clonal O O
line O O
of O O
human O O
precursor O O
mononuclear O O
phagocytes O O
inducible O O
to O O
macrophage O O
differentiation O O
in O O
response O O
to O O
the O O
tumor O O
promoter O O
phorbol O O
ester O O
12-O-tetradecanoyl-phorbol-13-acetate O O
( O O
TPA O O
) O O
. O O

Exposure O O
of O O
CM-SM O O
to O O
dexamethasone O O
( O O
DEX O O
) O O
produced O O
a O O
progressive O O
, O O
dose- O O
and O O
time-related O O
series O O
of O O
changes O O
in O O
CM-SM O O
cell O O
growth O O
, O O
saturation O O
density O O
, O O
morphology O O
, O O
and O O
functional O O
properties O O
, O O
with O O
half-maximal O O
effects O O
at O O
about O O
10 O O
( O O
-9 O O
) O O
M O O
for O O
DEX O O
. O O

After O O
5 O O
days O O
in O O
culture O O
with O O
a O O
saturating O O
concentration O O
( O O
3.6 O O
X O O
10 O O
( O O
-8 O O
) O O
M O O
) O O
of O O
hormone O O
, O O
the O O
cells O O
reached O O
a O O
saturation O O
density O O
of O O
about O O
9.0 O O
X O O
10 O O
( O O
6 O O
) O O
viable O O
cells/ml O O
( O O
about O O
4.0 O O
X O O
10 O O
( O O
6 O O
) O O
viable O O
cells/ml O O
in O O
the O O
controls O O
) O O
, O O
while O O
the O O
modal O O
volume O O
of O O
the O O
resulting O O
cell O O
population O O
was O O
approximately O O
60 O O
% O O
, O O
as O O
compared O O
to O O
the O O
volume O O
of O O
untreated O O
cells O O
. O O

DEX-treated O O
cells O O
appeared O O
less O O
differentiated O O
than O O
controls O O
, O O
as O O
assessed O O
by O O
combined O O
morphologic O O
, O O
antigenic O O
, O O
and O O
cytoenzymatic O O
analyses O O
. O O

After O O
removal O O
of O O
DEX O O
, O O
the O O
cells O O
, O O
within O O
a O O
few O O
passages O O
, O O
returned O O
to O O
a O O
state O O
apparently O O
identical O O
to O O
the O O
untreated O O
controls O O
and O O
could O O
be O O
induced O O
to O O
macrophage O O
differentiation O O
in O O
response O O
to O O
TPA O O
. O O

Acute O O
lymphoblastic O O
leukemia O O
in O O
children O O
: O O
current O O
status O O
, O O
controversies O O
, O O
and O O
future O O
perspective O O
. O O

Additional O O
immunological O O
, O O
morphological O O
, O O
biochemical O O
, O O
cytokinetic O O
, O O
and O O
cytogenetic O O
factors O O
have O O
been O O
identified O O
, O O
illustrating O O
the O O
heterogeneity O O
of O O
ALL O O
and O O
its O O
derivation O O
from O O
malignant O O
clones O O
at O O
various O O
stages O O
of O O
differentiation O O
and O O
with O O
varying O O
rates O O
of O O
proliferation O O
. O O

Of O O
biologic O O
importance O O
, O O
these O O
factors O O
may O O
refine O O
further O O
the O O
characteristic O O
features O O
of O O
clinically-determined O O
prognostic O O
groups O O
. O O

Multivariate O O
analysis O O
of O O
large O O
prospective O O
trials O O
with O O
homogeneous O O
therapy O O
will O O
be O O
required O O
to O O
determine O O
the O O
independent O O
prognostic O O
importance O O
of O O
these O O
factors O O
. O O

Current O O
treatment O O
strategies O O
in O O
ALL O O
include O O
( O O
1 O O
) O O
tailoring O O
therapy O O
and O O
its O O
intensity O O
to O O
prognostic O O
groups O O
; O O
( O O
2 O O
) O O
multiple-drug O O
combinations O O
in O O
induction O O
; O O
( O O
3 O O
) O O
early O O
use O O
of O O
intrathecal O O
( O O
IT O O
) O O
methotrexate O O
( O O
MTX O O
) O O
; O O
( O O
4 O O
) O O
CNS O O
prophylaxis O O
with O O
IT O O
MTX O O
alone O O
in O O
good O O
prognosis O O
patients O O
and O O
combined O O
cranial O O
radiation O O
( O O
CXRT O O
) O O
, O O
1800 O O
rads O O
plus O O
IT O O
MTX O O
, O O
in O O
average O O
and O O
poor O O
prognosis O O
patients O O
. O O

Current O O
studies O O
show O O
a O O
CNS O O
relapse O O
rate O O
of O O
5 O O
% O O
in O O
all O O
prognostic O O
groups O O
. O O

Late O O
neuropsychological O O
defects O O
caused O O
by O O
cranial O O
XRT O O
and O O
IT O O
MTX O O
have O O
prompted O O
programs O O
designed O O
to O O
reduce O O
the O O
potential O O
late O O
toxicity O O
of O O
CNS O O
prophylaxis O O
. O O

More O O
pronounced O O
in O O
younger O O
children O O
, O O
these O O
abnormalities O O
include O O
decreased O O
IQ O O
, O O
visual-motor O O
incoordination O O
, O O
poor O O
performance O O
in O O
mathematics O O
, O O
and O O
memory O O
dysfunction O O
. O O

Until O O
1980 O O
, O O
more O O
intensive O O
induction O O
, O O
consolidation O O
, O O
and O O
maintenance O O
therapy O O
had O O
failed O O
to O O
prolong O O
DFS O O
in O O
children O O
with O O
a O O
poor O O
prognosis O O
. O O

In O O
West O O
Germany O O
( O O
Berlin-Frankfurt-Muenster O O
protocol O O
) O O
a O O
70 O O
to O O
75 O O
% O O
DFS O O
is O O
seen O O
in O O
all O O
patients O O
regardless O O
of O O
initial O O
WBC O O
, O O
suggesting O O
that O O
effective O O
therapy O O
will O O
override O O
prognostic O O
factors O O
. O O

Ultra-high-dose O O
MTX O O
, O O
without O O
cranial O O
radiation O O
, O O
is O O
also O O
showing O O
promise O O
in O O
poor O O
prognosis O O
patients O O
. O O

Other O O
issues O O
include O O
the O O
optimal O O
duration O O
of O O
therapy O O
, O O
the O O
role O O
of O O
testicular O O
biopsies O O
, O O
and O O
prophylactic O O
testicular O O
radiation O O
. O O

Recent O O
studies O O
suggest O O
that O O
prognostic O O
factors O O
lose O O
their O O
significance O O
after O O
2 O O
years O O
of O O
continuous O O
complete O O
remission O O
and O O
that O O
2 O O
years O O
of O O
maintenance O O
therapy O O
is O O
adequate O O
. O O

Bilateral O O
open-wedge O O
testicular O O
biopsies O O
have O O
identified O O
occult O O
testicular O O
disease O O
in O O
8 O O
to O O
10 O O
% O O
of O O
males O O
. O O

A O O
unified O O
approach O O
to O O
children O O
with O O
leukemia/lymphoma O O
, O O
a O O
group O O
with O O
a O O
particularly O O
poor O O
prognosis O O
, O O
utilizing O O
NHL-type O O
therapy O O
may O O
be O O
more O O
effective O O
than O O
conventional O O
ALL O O
therapy O O
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

The O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GR B B_PROTEIN[GENE]/B_DISEASE
) O O
quantitation O O
by O O
a O O
whole-cell O O
assay O O
and/or O O
cytosol O O
technique O O
and O O
the O O
in O O
vitro O O
sensitivity O O
to O O
steroids O O
have O O
been O O
assessed O O
in O O
peripheral O O
blood O O
cells O O
from O O
normal O O
donors O O
and O O
patients O O
with O O
chronic O O
lymphatic O O
leukemia O O
( O O
CLL O O
) O O
, O O
acute O O
lymphoblastic O O
leukemia O O
( O O
ALL O O
) O O
, O O
lymphosarcoma O O
cell O O
leukemia O O
( O O
LSCL O O
) O O
, O O
acute O O
nonlymphatic O O
leukemia O O
( O O
ANLL O O
) O O
, O O
and O O
chronic O O
myeloid O O
leukemia O O
( O O
CML O O
) O O
. O O

On O O
the O O
contrary O O
, O O
CLL O O
cells O O
presented O O
the O O
highest O O
sensitivity O O
to O O
glucocorticoids O O
in O O
PHA-stimulated O O
cell O O
cultures O O
. O O

Cells O O
from O O
the O O
only O O
two O O
ALL O O
patients O O
who O O
did O O
not O O
undergo O O
a O O
remission O O
after O O
glucocorticoid-inclusive O O
chemotherapy O O
had O O
both O O
the O O
lowest O O
in O O
vitro O O
sensitivity O O
to O O
dexamethasone O O
and O O
the O O
lowest O O
GR O O
concentration O O
with O O
whole-cell O O
assay O O
. O O

CML O O
cells O O
exhibited O O
an O O
inhibition O O
degree O O
by O O
in O O
vitro O O
glucocorticoids O O
significantly O O
higher O O
than O O
that O O
of O O
ANLL O O
cells O O
but O O
not O O
different O O
from O O
that O O
of O O
lymphoproliferative O O
diseases O O
. O O

No O O
clear O O
relationship O O
among O O
GR O O
pattern O O
, O O
in O O
vitro O O
cell O O
sensitivity O O
to O O
glucocorticoids O O
, O O
and O O
clinicohematologic O O
parameters O O
was O O
observed O O
in O O
myeloid O O
leukemia-bearing O O
patients O O
. O O

In O O
6 O O
human O O
thymus O O
glands O O
, O O
the O O
immature O O
subset O O
of O O
thymocytes O O
was O O
separated O O
from O O
the O O
more O O
mature O O
one O O
, O O
by O O
differential O O
peanut O O
lectin O O
agglutination O O
. O O

These O O
2 O O
cell O O
subpopulations O O
were O O
analyzed O O
for O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O O
by O O
using O O
a O O
whole O O
cell O O
assay O O
, O O
with O O
( O O
3H O O
) O O
-triamcinolone O O
acetonide O O
as O O
tracer O O
. O O

Despite O O
the O O
greater O O
number O O
of O O
glucocorticoid B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
receptor I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
sites O O
, O O
the O O
peanut-negative O O
thymocyte O O
subpopulation O O
did O O
not O O
differ O O
from O O
the O O
peanut-positive O O
one O O
in O O
its O O
sensitivity O O
to O O
the O O
inhibitory O O
effects O O
of O O
triamcinolone O O
acetonide O O
, O O
as O O
determined O O
by O O
measurements O O
of O O
the O O
incorporation O O
of O O
radiolabeled O O
precursors O O
of O O
protein O O
and O O
DNA O O
. O O

Moreover O O
, O O
the O O
peanut-negative O O
subset O O
appeared O O
more O O
resistant O O
in O O
vitro O O
to O O
the O O
steroid-induced O O
cell O O
lysis O O
as O O
compared O O
to O O
the O O
peanut-positive O O
one O O
. O O

Thus O O
, O O
our O O
data O O
suggest O O
that O O
glucocorticoid O O
receptor O O
density O O
and O O
corticosensitivity O O
are O O
not O O
directly O O
correlated O O
and O O
that O O
the O O
number O O
of O O
glucocorticoid B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O O
may O O
be O O
dependent O O
on O O
the O O
degree O O
of O O
immunologic O O
maturation O O

Defective O O
binding O O
and O O
function O O
of O O
1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
25-dihydroxyvitamin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
D3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
peripheral O O
mononuclear O O
cells O O
of O O
patients O O
with O O
end-organ O O
resistance O O
to O O
1 O O
, O O
25-dihydroxyvitamin O O
D O O
. O O

Lectin-induced O O
DNA O O
synthesis O O
by O O
peripheral O O
mononuclear O O
cells O O
from O O
17 O O
normal O O
donors O O
was O O
inhibited O O
( O O
40-60 O O
% O O
) O O
by O O
1 O O
, O O
25-dihydroxyvitamin O O
D3 O O
( O O
1 O O
, O O
25 O O
[ O O
OH O O
] O O
2D3 O O
) O O
at O O
physiological O O
concentrations O O
( O O
10 O O
( O O
-10 O O
) O O
-10 O O
( O O
-9 O O
) O O
M O O
) O O
. O O

The O O
lymphocytes O O
acquire O O
specific O O
receptors O O
for O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
upon O O
activation O O
by O O
the O O
lectins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

This O O
process O O
precedes O O
the O O
inhibitory O O
effect O O
of O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
. O O

In O O
five O O
patients O O
( O O
three O O
kindreds O O
) O O
peripheral O O
blood O O
mononuclear O O
cells O O
did O O
not O O
acquire O O
receptors O O
for O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
upon O O
phytohemagglutinin-induced O O
activation O O
. O O

Activated O O
lymphocytes O O
of O O
the O O
sixth O O
patient O O
from O O
a O O
fourth O O
kindred O O
exhibited O O
normal O O
binding O O
of O O
[ O O
3H O O
] O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
but O O
the O O
hormone O O
failed O O
to O O
inhibit O O
the O O
mitogenic O O
stimulation O O
. O O

A O O
similar O O
pattern O O
of O O
the O O
vitamin O O
D O O
effector O O
system O O
was O O
previously O O
observed O O
in O O
fibroblasts O O
cultured O O
from O O
skin O O
biopsies O O
of O O
the O O
same O O
group O O
of O O
patients O O
. O O

The O O
conclusions O O
from O O
these O O
findings O O
are O O
: O O
( O O
a O O
) O O
the O O
inhibition O O
of O O
mitogenic O O
stimulation O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
is O O
mediated O O
by O O
specific B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
functional I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
the O O
hormone O O
; O O
and O O
( O O
b O O
) O O
the O O
receptors O O
for O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
in O O
mononuclear O O
cells O O
are O O
probably O O
controlled O O
genetically O O
by O O
the O O
same O O
mechanisms O O
as O O
the O O
effector O O
system O O
in O O
well-characterized O O
target O O
organs O O
of O O
the O O
hormone O O
, O O
such O O
as O O
intestine O O
and O O
kidney O O
. O O

A O O
whole O O
cell O O
binding O O
assay O O
with O O
3 O O
( O O
H O O
) O O
dexamethasone O O
was O O
used O O
. O O

Sex O O
, O O
age O O
or O O
clinical O O
forms O O
of O O
illness O O
did O O
not O O
influence O O
the O O
results O O
. O O

In O O
patients O O
receiving O O
prednisone O O
( O O
Pd O O
) O O
the O O
GR B B_GENE/B_DISEASE
values O O
were O O
significantly O O
lower O O
than O O
in O O
MG O O
patients O O
without O O
Pd O O
therapy O O
, O O
independent O O
of O O
Pd O O
dose O O
or O O
time O O
of O O
administration O O
. O O

No O O
differences O O
in O O
receptor O O
binding O O
between O O
normal O O
subjects O O
and O O
MG O O
patients O O
receiving O O
Pd O O
have O O
been O O
found O O
. O O

Immunological O O
interference O O
of O O
high O O
dose O O
corticosteroids O O
. O O

High-dose O O
corticosteroids O O
( O O
HDC O O
) O O
will O O
influence O O
cellular O O
as O O
well O O
as O O
humoral O O
participants O O
of O O
the O O
immune O O
response O O
. O O

The O O
lymphoid O O
tissue O O
will O O
decrease O O
in O O
size O O
and O O
weight O O
after O O
prolonged O O
treatment O O
with O O
HDC O O
. O O

Lymphocyte O O
functions O O
will O O
be O O
impaired O O
. O O

The O O
inhibitory O O
effect O O
on O O
B-cell O O
function O O
can O O
be O O
observed O O
both O O
as O O
decreased O O
serum O O
levels O O
of O O
immunoglobulins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
as O O
impaired O O
binding O O
of O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
complement O O
to O O
the O O
cellular O O
surface O O
. O O

Reduced O O
lymphocyte O O
adherence O O
to O O
antigen O O
and O O
suppressed O O
lymphocyte O O
reaction O O
have O O
also O O
been O O
observed O O
. O O

Humoral O O
factors O O
involved O O
in O O
chemotaxis O O
, O O
opsonisation O O
, O O
phagocytosis O O
, O O
vascular O O
permeability O O
leading O O
to O O
leakage O O
of O O
fluid O O
and O O
cells O O
and O O
factors O O
involved O O
in O O
lysis O O
of O O
antigens O O
are O O
impaired O O
. O O

This O O
can O O
be O O
explained O O
partly O O
by O O
the O O
observed O O
reduced O O
complement O O
activation O O
via O O
the O O
alternative O O
as O O
well O O
as O O
the O O
classical O O
pathway O O
in O O
association O O
with O O
HDC O O
therapy O O
. O O

Acute O O
processes O O
with O O
increased O O
vascular O O
permeability O O
and O O
accumulation O O
of O O
leukocytes O O
as O O
impairing O O
factors O O
could O O
be O O
influenced O O
beneficially O O
by O O
HDC O O
therapy O O
. O O

This O O
positive O O
effect O O
can O O
be O O
seen O O
in O O
treatment O O
of O O
septic O O
shock O O
or O O
rejection O O
of O O
a O O
transplant O O
. O O

However O O
, O O
if O O
sepsis O O
or O O
rejection O O
is O O
not O O
rapidly O O
reversed O O
, O O
complications O O
such O O
as O O
multisystem O O
organ O O
failure O O
and O O
bacteremia O O
are O O
prone O O
to O O
appear O O
. O O

Antisera O O
raised O O
against O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lymphoid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
glucocorticoid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
used O O
in O O
combination O O
with O O
the O O
glucocorticoid O O
receptor O O
affinity O O
label O O
[ O O
3H O O
] O O
dexamethasone O O
21-mesylate O O
[ O O
( O O
3H O O
] O O
DM O O
) O O
to O O
identify O O
the O O
glucocorticoid B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
human O O
B-lymphoblastoid O O
cell O O
line O O
IM-9 O O
and O O
the O O
human O O
T-cell O O
leukemic O O
cell O O
line O O
CEM-C7 O O
. O O

Antisera O O
were O O
obtained O O
following O O
immunization O O
of O O
New O O
Zealand O O
White O O
rabbits O O
with O O
[ B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3H I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
triamcinolone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acetonide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3H I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-glucocorticoid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
partially O O
purified O O
by O O
two-stage O O
DNA-cellulose O O
chromatography O O
. O O

Sodium O O
dodecyl O O
sulfate-polyacrylamide O O
gel O O
electrophoresis O O
of O O
[ O O
3H O O
] O O
DM-labeled O O
IM-9 O O
cytosol O O
identified O O
a O O
major O O
competable O O
band O O
with O O
a O O
molecular O O
weight O O
of O O
approximately O O
90 O O
, O O
000 O O
, O O
three O O
minor O O
competable O O
components O O
with O O
molecular O O
weights O O
of O O
approximately O O
78 O O
, O O
000 O O
, O O
approximately O O
51 O O
, O O
000 O O
, O O
and O O
approximately O O
38 O O
, O O
500 O O
, O O
and O O
at O O
least O O
21 O O
other O O
noncompetable O O
components O O
. O O

Following O O
immunoprecipitation O O
of O O
[ O O
3H O O
] O O
DM-labeled O O
cytosol O O
with O O
immune O O
serum O O
, O O
only O O
the O O
Mr O O
90 O O
, O O
000 O O
and O O
78 O O
, O O
000 O O
components O O
were O O
seen O O
. O O

Sodium O O
dodecyl O O
sulfate-polyacrylamide O O
gel O O
electrophoresis O O
of O O
[ O O
3H O O
] O O
DM-labeled O O
CEM-C7 O O
cytosol O O
revealed O O
a O O
larger O O
number O O
of O O
[ O O
3H O O
] O O
DM-labeled O O
components O O
. O O

However O O
, O O
after O O
immunoprecipitation O O
of O O
[ O O
3H O O
] O O
DM-labeled O O
CEM-C7 O O
cytosol O O
, O O
a O O
predominant O O
competable O O
component O O
with O O
a O O
molecular O O
weight O O
of O O
90 O O
, O O
000 O O
was O O
easily O O
identified O O
. O O

This O O
component O O
was O O
markedly O O
diminished O O
when O O
cytosols O O
from O O
the O O
glucocorticoid O O
receptor-deficient O O
cell O O
line O O
ICR-27 O O
were O O
used O O
. O O

Effect O O
of O O
thymosin O O
on O O
glucocorticoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
and O O
glucocorticoid O O
sensitivity O O
of O O
human O O
thymocytes O O
. O O

The O O
glucocorticoid B B_PROTEIN[GENE]/B_MEASURE
receptor I I_PROTEIN[GENE]/I_MEASURE
activity O O
in O O
normal O O
infant O O
thymocytes O O
was O O
found O O
to O O
be O O
2 O O
, O O
146 O O
+/- O O
726 O O
( O O
s.d. O O
) O O
sites O O
per O O
cell O O
with O O
dissociation O O
constant O O
of O O
1.4 O O
+/- O O
0.6 O O
X O O
10 O O
( O O
-8 O O
) O O
M O O
. O O

TMS O O
F5 O O
also O O
increased O O
the O O
resistance O O
of O O
human O O
thymocytes O O
to O O
the O O
cytolytic O O
effect O O
of O O
dexamethasone O O
( O O
2.5 O O
X O O
10 O O
( O O
-8 O O
) O O
M O O
) O O
to O O
168.6 O O
+/- O O
30.2 O O
% O O
of O O
control O O
( O O
P O O
less O O
than O O
0.01 O O
) O O
. O O

In O O
animals O O
, O O
medullary O O
and O O
peripheral O O
blood O O
T O O
cells O O
are O O
more O O
resistant O O
to O O
glucocorticoids O O
than O O
immature O O
thymic O O
T O O
cells O O
. O O

Incubation O O
of O O
a O O
human O O
malignant O O
thymus O O
derived O O
T O O
cell O O
line O O
( O O
MOLT O O
3 O O
) O O
with O O
TMS O O
F5 O O
also O O
resulted O O
in O O
a O O
significant O O
reduction O O
of O O
the O O
number O O
of O O
steroid O O
binding O O
sites O O
to O O
44.2 O O
+/- O O
15.3 O O
% O O
of O O
control O O
( O O
P O O
less O O
than O O
0.05 O O
) O O
, O O
but O O
TMS O O
F5 O O
did O O
not O O
significantly O O
reduce O O
the O O
glucocorticoid O O
sensitivity O O
of O O
MOLT O O
3 O O
cells O O
. O O

Specific B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
high-affinity I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
1 O O
, O O
25-dihydroxyvitamin O O
D3 O O
in O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
: O O
presence O O
in O O
monocytes O O
and O O
induction O O
in O O
T O O
lymphocytes O O
following O O
activation O O
. O O

Resting O O
human O O
peripheral O O
blood O O
T O O
lymphocytes O O
, O O
however O O
, O O
do O O
not O O
have O O
a O O
demonstrable O O
1 B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
25- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
OH I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2D3 I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

After O O
activation O O
with O O
phytohemagglutinin B B_BIO/B_GENE
the O O
T O O
cells O O
exhibit O O
the O O
receptor O O
within O O
24 O O
h O O
, O O
and O O
this O O
expression O O
is O O
blocked O O
by O O
cycloheximide O O
. O O

Effects O O
of O O
chronic O O
glucocorticoid O O
excess O O
in O O
man O O
on O O
insulin O O
binding O O
to O O
circulating O O
cells O O
: O O
differences O O
between O O
endogenous O O
and O O
exogenous O O
hypercorticism O O
. O O

We O O
measured O O
[ O O
125I O O
] O O
insulin O O
binding O O
to O O
circulating O O
monocytes O O
or O O
erythrocytes O O
from O O
16 O O
patients O O
with O O
chronic O O
glucocorticoid O O
excess O O
, O O
9 O O
chronically O O
treated O O
with O O
prednisone O O
and O O
7 O O
with O O
adrenocortical O O
hyperfunction O O
. O O

With O O
monocytes O O
, O O
[ O O
125I O O
] O O
insulin O O
binding O O
was O O
iincreased O O
in O O
all O O
patients O O
. O O

With O O
erythrocytes O O
from O O
patients O O
with O O
adrenocortical O O
hyperfunction O O
there O O
was O O
an O O
increase O O
in O O
receptor O O
affinity O O
and O O
a O O
decrease O O
in O O
receptor O O
concentration O O
, O O
so O O
that O O
the O O
binding O O
of O O
[ O O
125I O O
] O O
insulin O O
was O O
normal O O
. O O

The O O
disparity O O
of O O
results O O
between O O
endogenous O O
and O O
exogenous O O
hypercorticism O O
, O O
between O O
the O O
two O O
cell O O
types O O
, O O
and O O
between O O
the O O
present O O
studies O O
and O O
previous O O
studies O O
suggest O O
that O O
the O O
effects O O
of O O
glucocorticoid O O
excess O O
on O O
the O O
insulin B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
receptor I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
are O O
extremely O O
complex O O
and O O
wide-ranging O O
and O O
that O O
in O O
this O O
condition O O
, O O
extrapolations O O
in O O
humans O O
from O O
data O O
with O O
circulating O O
cells O O
to O O
liver O O
and O O
muscle O O
may O O
not O O
be O O
appropriate O O
. O O

Specific O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
measured O O
in O O
circulating O O
mononuclear O O
leukocytes O O
from O O
12 O O
patients O O
with O O
anorexia O O
nervosa O O
and O O
21 O O
healthy O O
control O O
subjects O O
. O O

Cells O O
from O O
patients O O
were O O
found O O
to O O
contain O O
a O O
significantly O O
( O O
p O O
less O O
than O O
0.01 O O
) O O
lower O O
level O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
( O O
3830 O O
+/- O O
210 O O
sites/cell O O
, O O
mean O O
+/- O O
SE O O
) O O
than O O
those O O
from O O
controls O O
( O O
4930 O O
+/- O O
250 O O
sites/cell O O
) O O
. O O

A O O
partial O O
glucocorticoid B B_GENE
receptor I I_GENE
defect O O
may O O
well O O
explain O O
the O O
abnormal O O
cortisol O O
metabolism O O
and O O
glucocorticoid O O
resistance O O
commonly O O
found O O
in O O
patients O O
with O O
anorexia O O
nervosa O O
. O O

Regulation O O
of O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
in O O
human O O
lymphocytes O O
. O O

The O O
presence O O
of O O
a O O
glucocorticoid B B_GENE
receptor I I_GENE
in O O
human O O
lymphocytes O O
is O O
well O O
established O O
, O O
but O O
factors O O
affecting O O
its O O
regulation O O
have O O
not O O
been O O
described O O
. O O

At O O
24 O O
degrees O O
C O O
normal O O
human O O
lymphocytes O O
had O O
6000 O O
binding O O
sites/cell O O
and O O
a O O
dissociation O O
constant O O
of O O
4 O O
x O O
10 O O
( O O
-9 O O
) O O
M O O
. O O

The O O
administration O O
of O O
1 O O
mg O O
of O O
dexamethasone O O
, O O
5 O O
mg O O
of O O
prednisone O O
, O O
and O O
37.5 O O
mg O O
of O O
cortisone O O
acetate O O
resulted O O
in O O
a O O
30 O O
% O O
decrease O O
in O O
binding O O
sites O O
after O O
1 O O
week O O
with O O
no O O
change O O
in O O
binding O O
affinity O O
. O O

No O O
changes O O
in O O
the O O
number O O
of O O
binding O O
sites O O
was O O
noted O O
before O O
1 O O
week O O
and O O
the O O
diminished O O
number O O
persisted O O
for O O
1 O O
week O O
after O O
discontinuation O O
of O O
glucocorticoid O O
treatment O O
. O O

Lymphocytes O O
from O O
hospitalized O O
patients O O
taking O O
40-60 O O
mg O O
of O O
dexamethasone O O
daily O O
demonstrated O O
the O O
same O O
change O O
in O O
number O O
of O O
binding O O
sites O O
that O O
was O O
seen O O
in O O
normal O O
subjects O O
taking O O
1 O O
mg O O
of O O
dexamethasone O O
. O O

When O O
binding O O
assays O O
were O O
carried O O
out O O
at O O
physiologic O O
temperature O O
there O O
was O O
the O O
same O O
decrease O O
in O O
number O O
of O O
binding O O
sites O O
after O O
dexamethasone O O
administration O O
, O O
and O O
in O O
addition O O
, O O
there O O
was O O
a O O
two-fold O O
increase O O
in O O
binding O O
affinity O O
. O O

Glucocorticoid O O
administration O O
results O O
in O O
a O O
time-dependent O O
decrease O O
in O O
the O O
number O O
of O O
lymphocyte O O
glucocorticoid O O
binding O O
sites O O
that O O
is O O
independent O O
of O O
the O O
type O O
of O O
glucocorticoid O O
administered O O
. O O

This O O
is O O
the O O
first O O
in O O
vivo O O
demonstration O O
that O O
glucocorticoids O O
modulate O O
their O O
own O O
receptors O O
in O O
man O O
. O O

Immunoglobulin O O
localization O O
in O O
benign O O
and O O
malignant O O
lesions O O
of O O
the O O
human O O
mammary O O
gland O O
. O O

The O O
lesions O O
included O O
benign O O
elements O O
from O O
66 O O
subcutaneous O O
mastectomy O O
specimens O O
in O O
which O O
the O O
absence O O
of O O
simultaneous O O
breast O O
malignancy O O
was O O
documented O O
, O O
primary O O
breast O O
carcinomas O O
from O O
153 O O
mastectomy O O
specimens O O
, O O
and O O
47 O O
biopsies O O
containing O O
metastatic O O
breast O O
cancer O O
. O O

A O O
statistically O O
significant O O
association O O
of O O
IgA B B_GENE/B_DISEASE
and O O
IgM B B_GENE
with O O
benign O O
lesions O O
was O O
contrasted O O
to O O
the O O
association O O
of O O
IgG B B_GENE
with O O
malignant O O
lesions O O
. O O

In O O
both O O
primary O O
and O O
metastatic O O
lesions O O
, O O
IgG B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
localization O O
was O O
associated O O
with O O
estrogen-receptor-poor O O
primary O O
cancers O O
as O O
compared O O
with O O
estrogen-receptor-rich O O
primary O O
cancers O O
. O O

Among O O
primary O O
breast O O
cancer O O
patients O O
, O O
IgG B B_GENE/B_DISEASE
localization O O
in O O
the O O
tumor O O
correlated O O
with O O
relative O O
lymphopenia O O
. O O

A O O
shorter O O
disease-free O O
interval O O
was O O
noted O O
in O O
association O O
with O O
IgG B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
localization O O
among O O
the O O
metastatic O O
breast O O
lesions O O
. O O

No O O
statistically O O
significant O O
association O O
between O O
stage O O
of O O
disease O O
and O O
immunoglobulin O O
presence O O
was O O
demonstrable O O
. O O

Moderate-to-severe O O
intraductal O O
epithelial O O
hyperplasias O O
were O O
more O O
often O O
associated O O
with O O
immunoglobulin B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
G I I_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
localization O O
that O O
were O O
other O O
benign O O
lesions O O

Correlation O O
of O O
steroid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
histologic O O
differentiation O O
in O O
mammary O O
carcinoma O O
. O O

A O O
Singapore O O
experience O O
. O O

Cancer O O
of O O
the O O
breast O O
is O O
the O O
most O O
common O O
tumor O O
in O O
females O O
in O O
Singapore O O
, O O
with O O
the O O
rate O O
of O O
20.7 O O
per O O
100 O O
, O O
000 O O
per O O
year O O
( O O
1977 O O
estimate O O
) O O
, O O
which O O
is O O
predicted O O
to O O
increase O O
to O O
29.8 O O
per O O
100 O O
, O O
000 O O
women O O
per O O
year O O
by O O
1995 O O
. O O

Cytosol O O
was O O
incubated O O
with O O
3H-estradiol O O
in O O
the O O
presence O O
and O O
absence O O
of O O
cold O O
diethylstilbestrol O O
, O O
and O O
bound O O
and O O
free O O
hormone O O
were O O
separated O O
by O O
Dextran-coated O O
charcoal O O
method O O
. O O

Tumors O O
binding O O
more O O
than O O
5 O O
fmol/mg O O
cytosol B B_GENE
protein I I_GENE
were O O
classified O O
as O O
ER B B_GENE
-positive O O
. O O

Progesterone B B_GENE
receptor I I_GENE
( O O
PR B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
level O O
was O O
analyzed O O
in O O
some O O
specimens O O
with O O
the O O
use O O
of O O
a O O
similar O O
method O O
. O O

Most O O
of O O
the O O
patients O O
were O O
Chinese O O
( O O
90 O O
% O O
) O O
. O O

Three O O
patients O O
were O O
Malays O O
, O O
one O O
was O O
Indian O O
, O O
and O O
one O O
was O O
European O O
in O O
this O O
series O O
. O O

Results O O
indicated O O
that O O
there O O
was O O
strong O O
correlation O O
between O O
ER B B_GENE
level O O
, O O
age O O
, O O
and O O
histologic O O
grade O O
of O O
the O O
tumors O O
. O O

No O O
correlation O O
existed O O
between O O
absence O O
or O O
presence O O
of O O
lymph O O
node O O
metastases O O
and O O
ER B B_GENE/B_DISEASE
. O O

Although O O
there O O
was O O
a O O
trend O O
for O O
ER B B_GENE
-positive O O
tumors O O
to O O
have O O
a O O
low-grade O O
lymphocytic O O
infiltration O O
, O O
the O O
difference O O
was O O
not O O
statistically O O
significant O O
. O O

Mononuclear O O
cells O O
infiltrating O O
human O O
mammary O O
carcinomas O O
: O O
immunohistochemical O O
analysis O O
with O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Sixty-four O O
per O O
cent O O
of O O
the O O
patients O O
had O O
a O O
moderate O O
or O O
strong O O
mononuclear O O
cell O O
infiltration O O
, O O
77 O O
% O O
of O O
the O O
patients O O
without O O
mononuclear O O
cell O O
infiltration O O
had O O
receptors O O
for O O
estrogens O O
as O O
compared O O
to O O
51 O O
% O O
of O O
the O O
patients O O
with O O
infiltration O O
. O O

The O O
majority O O
of O O
the O O
infiltrating O O
mononuclear O O
cells O O
were O O
T O O
cells O O
; O O
generally O O
the O O
OKT8 O O
cells O O
were O O
predominant O O
. O O

The O O
Leu O O
3A/OKT8 O O
cell O O
ratio O O
was O O
not O O
related O O
to O O
histological O O
type O O
, O O
tumor O O
size O O
, O O
age O O
of O O
the O O
patient O O
or O O
presence O O
of O O
metastases O O
. O O

Some O O
of O O
the O O
T O O
cells O O
had O O
the O O
Ia B B_GENE
antigen I I_GENE
and O O
were O O
thus O O
probably O O
activated O O
. O O

The O O
B O O
cells O O
were O O
either O O
absent O O
or O O
less O O
numerous O O
than O O
the O O
T O O
cells O O
. O O

There O O
was O O
no O O
relation O O
between O O
their O O
distribution O O
and O O
the O O
various O O
parameters O O
studied O O
. O O

A O O
few O O
monocytes O O
were O O
heterogeneous O O
according O O
to O O
their O O
markers O O
( O O
OKM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
acid O O
phosphatase O O
) O O
. O O

In O O
6 O O
cases O O
only O O
there O O
was O O
a O O
strong O O
infiltration O O
of O O
mononuclear O O
cells O O
positive O O
for O O
acid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
number O O
of O O
the O O
natural O O
killer O O
cells O O
was O O
also O O
low O O
. O O

There O O
was O O
a O O
positive O O
correlation O O
between O O
the O O
inflammatory O O
infiltration O O
and O O
the O O
presence O O
of O O
HLA B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
class-I I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
antigens I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
on O O
tumor O O
cell O O
s O O
. O O

The O O
great O O
variations O O
in O O
the O O
subsets O O
of O O
mononuclear O O
cells O O
in O O
breast O O
carcinomas O O
may O O
correspond O O
to O O
various O O
systems O O
of O O
defense O O
against O O
neoplasm O O
. O O

A O O
case O O
of O O
male O O
pseudohermaphroditism O O
with O O
47 O O
, O O
XYY O O
karyotype O O
in O O
blood O O
and O O
cutaneous O O
fibroblasts O O
is O O
described O O
. O O

The O O
plasma O O
testosterone O O
response O O
to O O
HCG O O
stimulation O O
was O O
slightly O O
below O O
the O O
normal O O
range O O
on O O
two O O
occasions O O
suggesting O O
a O O
deficit O O
of O O
gonadal O O
function O O
. O O

A O O
study O O
of O O
the O O
receptors O O
for O O
dihydrotestosterone O O
in O O
fibroblasts O O
of O O
genital O O
and O O
nongenital O O
skin O O
showed O O
a O O
normal O O
concentration O O
of O O
receptors O O
in O O
genital O O
skin O O
; O O
5-alpha-reductase B B_GENE/B_PERSON
activity O O
in O O
fibroblasts O O
of O O
the O O
genital O O
skin O O
was O O
low O O
, O O
but O O
the O O
plasma O O
relationship O O
testosterone/dihydrotestosterone O O
under O O
HCG O O
stimulation O O
was O O
normal O O
. O O

The O O
diagnostic O O
possibility O O
of O O
a O O
complete O O
testicular O O
feminization O O
syndrome O O
with O O
normal O O
receptors O O
for O O
dihydrotestosterone O O
is O O
commented O O
on O O
. O O

1 O O
, O O
25-Dihydroxyvitamin O O
D3 O O
inhibits O O
antigen-induced O O
T O O
cell O O
activation O O
. O O

The O O
proliferative O O
response O O
of O O
murine O O
spleen O O
and O O
thymus O O
cells O O
to O O
antigen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
but O O
not O O
to O O
lectin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
inhibited O O
by O O
the O O
active O O
metabolite O O
of O O
vitamin O O
D3 O O
, O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
. O O

To O O
directly O O
examine O O
the O O
effect O O
of O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
on O O
T O O
cell O O
activation O O
in O O
the O O
absence O O
of O O
other O O
complicating O O
interactions O O
, O O
we O O
utilized O O
a O O
panel O O
of O O
cloned O O
Ia-restricted O O
T O O
cell O O
hybridomas O O
that O O
secrete O O
IL B B_GENE
2 I I_GENE
on O O
activation O O
by O O
cloned O O
Ia-bearing O O
stimulator O O
cells O O
( O O
TA3 O O
) O O
or O O
when O O
stimulated O O
by O O
mitogen O O
. O O

This O O
inhibition O O
was O O
dependent O O
on O O
the O O
concentration O O
of O O
the O O
free O O
hormone O O
and O O
could O O
be O O
overcome O O
by O O
increasing O O
the O O
number O O
of O O
Ia-bearing O O
stimulator O O
cells O O
used O O
. O O

1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
failed O O
, O O
however O O
, O O
to O O
inhibit O O
the O O
activation O O
of O O
the O O
T O O
cell O O
hybridomas O O
by O O
lectin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
by O O
an O O
anti-Thy-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

This O O
system O O
should O O
prove O O
useful O O
in O O
studying O O
the O O
molecular O O
mechanisms O O
by O O
which O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
acts O O
to O O
inhibit O O
T O O
cell O O
activation O O
and O O
subsequent O O
IL B B_GENE
2 I I_GENE
production O O
. O O

Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
steroid O O
sensitivity O O
in O O
normal O O
and O O
neoplastic O O
human O O
lymphoid O O
tissues O O
: O O
a O O
review O O
. O O

The O O
determination O O
of O O
estrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
progesterone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
breast O O
cancer O O
has O O
been O O
shown O O
to O O
be O O
useful O O
in O O
predicting O O
the O O
response O O
to O O
endocrine O O
therapy O O
. O O

Given O O
their O O
well-known O O
inhibitory O O
effects O O
on O O
lymphoid O O
tissue O O
, O O
glucocorticoids O O
have O O
been O O
used O O
widely O O
in O O
the O O
treatment O O
of O O
leukemia O O
. O O

No O O
clear O O
correlation O O
could O O
be O O
established O O
between O O
the O O
level O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
and O O
the O O
in O O
vitro O O
action O O
of O O
steroids O O
in O O
normal O O
and O O
neoplastic O O
lymphoid O O
tissue O O
. O O

In O O
contrast O O
, O O
attempts O O
to O O
correlate O O
glucocorticoid B B_GENE
receptor I I_GENE
levels O O
in O O
acute O O
lymphocytic O O
leukemia O O
to O O
in O O
vivo O O
steroid O O
responsiveness O O
and O O
immunological O O
type O O
using O O
the O O
whole-cell-binding O O
assay O O
for O O
receptor O O
determination O O
and O O
selecting O O
the O O
patients O O
according O O
to O O
age O O
and O O
immunological O O
criteria O O
have O O
been O O
more O O
successful O O
. O O

GC O O
binding O O
parameters O O
were O O
found O O
to O O
be O O
highly O O
reproducible O O
in O O
repeated O O
experiments O O
with O O
lymphocytes O O
. O O

It O O
was O O
shown O O
that O O
GC B B_GENE
receptors I I_GENE
in O O
donors O O
' O O
lymphocytes O O
could O O
be O O
distributed O O
into O O
two O O
different O O
classes O O
similarly O O
to O O
the O O
pattern O O
seen O O
in O O
skin O O
fibroblasts O O
. O O

Human O O
lymphocytes O O
are O O
an O O
adequate O O
object O O
for O O
studying O O
genetically O O
determined O O
variability O O
of O O
GC B B_DISEASE/B_GENE
receptors I I_DISEASE/I_GENE
and O O
its O O
clinical O O
importance O O
. O O

Specific O O
estrogen B B_GENE
binding I I_GENE
sites I I_GENE
in O O
human O O
lymphoid O O
cells O O
and O O
thymic O O
cells O O
. O O

Scatchard O O
's O O
analysis O O
of O O
[ O O
3H O O
] O O
-moxestrol O O
( O O
R2858 O O
) O O
and O O
[ O O
3H O O
] O O
-estradiol O O
binding O O
proves O O
the O O
existence O O
of O O
a O O
single O O
class O O
of O O
receptor B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O O
a O O
dissociation O O
constant O O
of O O
0.18-2.4 O O
X O O
10 O O
( O O
-9 O O
) O O
M O O
. O O

The O O
injections O O
did O O
not O O
cause O O
local O O
irritation O O
or O O
inflammation O O
. O O

Fever O O
occurred O O
in O O
only O O
1 O O
of O O
the O O
11 O O
patients O O
. O O

Although O O
several O O
types O O
of O O
metastases O O
were O O
monitored O O
, O O
only O O
skin O O
nodules O O
consistently O O
( O O
10 O O
out O O
of O O
11 O O
patients O O
) O O
exhibited O O
changes O O
that O O
were O O
suggestive O O
of O O
a O O
therapeutic O O
effect O O
of O O
the O O
treatment O O
regimen O O
: O O
either O O
a O O
simple O O
decrease O O
in O O
size O O
of O O
some O O
nodules O O
or O O
central O O
necrosis O O
accompanied O O
by O O
an O O
inflammatory O O
reaction O O
. O O

NK-activity O O
of O O
peripheral O O
blood O O
leukocytes O O
was O O
significantly O O
increased O O
after O O
administration O O
of O O
the O O
first O O
dose O O
; O O
the O O
effect O O
of O O
subsequent O O
injections O O
was O O
less O O
clear O O
. O O

Receptors O O
for O O
estrogens O O
and O O
progestogens O O
were O O
increased O O
in O O
the O O
tumor O O
biopsies O O
of O O
2 O O
out O O
of O O
2 O O
and O O
5 O O
out O O
of O O
6 O O
patients O O
tested O O
respectively O O
. O O

Decreased O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
in O O
adrenal O O
insufficiency O O
. O O

To O O
examine O O
the O O
effect O O
of O O
glucocorticoid O O
deficiency O O
on O O
the O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
we O O
examine O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
dexamethasone O O
to O O
lymphocytes O O
in O O
normal O O
subjects O O
and O O
patients O O
with O O
adrenal O O
insufficiency O O
before O O
and O O
after O O
glucocorticoid O O
replacement O O
therapy O O
. O O

Using O O
a O O
whole O O
cell O O
competitive O O
binding O O
assay O O
, O O
normal O O
human O O
lymphocytes O O
had O O
5977 O O
+/- O O
1487 O O
( O O
mean O O
+/- O O
SD O O
) O O
binding O O
sites/cell O O
and O O
a O O
dissociation O O
constant O O
of O O
10 O O
+/- O O
2 O O
nM O O
. O O

The O O
administration O O
of O O
conventional O O
replacement O O
doses O O
of O O
cortisone O O
acetate O O
for O O
6 O O
months O O
caused O O
no O O
change O O
in O O
receptor O O
number O O
, O O
but O O
was O O
associated O O
with O O
a O O
decrease O O
in O O
binding O O
affinity O O
toward O O
normal O O
. O O

After O O
long O O
term O O
glucocorticoid O O
replacement O O
therapy O O
, O O
binding O O
parameters O O
were O O
similar O O
to O O
those O O
in O O
patients O O
before O O
treatment O O
. O O

The O O
physiological O O
implications O O
of O O
the O O
decreased O O
receptor O O
number O O
and O O
increased O O
binding O O
affinity O O
in O O
adrenal O O
insufficiency O O
remain O O
to O O
be O O
elucidated O O
. O O

Glucocorticoid B B_GENE
receptor I I_GENE
concentrations O O
and O O
terminal O O
transferase B B_ENZYME[GENE]/B_DISEASE
activity O O
as O O
indicators O O
of O O
prognosis O O
in O O
acute O O
non-lymphocytic O O
leukaemia O O
. O O

Activity O O
of O O
terminal B B_ENZYME[GENE]
deoxynucleotidyl I I_ENZYME[GENE]
transferase I I_ENZYME[GENE]
( O O
TdT B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
adenosine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deaminase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
5'nucleotidase B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
cellular O O
concentration O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dexamethasone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
determined O O
in O O
25 O O
patients O O
with O O
acute O O
non-lymphocytic O O
leukaemia O O
. O O

All O O
patients O O
were O O
treated O O
according O O
to O O
a O O
common O O
protocol O O
. O O

Increased O O
activity O O
of O O
TdT B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
greater O O
than O O
0.1 O O
unit/microgram O O
DNA O O
) O O
was O O
found O O
in O O
11 O O
patients O O
. O O

This O O
group O O
of O O
patients O O
was O O
shown O O
to O O
have O O
higher O O
remission O O
and O O
survival O O
rates O O
( O O
p O O
= O O
0.06 O O
) O O
compared O O
with O O
patients O O
with O O
low O O
activity O O
of O O
TdT O O
. O O

The O O
glucocorticoid B B_MEASURE/B_GENE
receptor I I_MEASURE/I_GENE
concentration O O
of O O
the O O
leukaemic O O
blast O O
cells O O
ranged O O
from O O
0 O O
to O O
0.94 O O
fmol/microgram O O
DNA O O
. O O

Thirteen O O
patients O O
had O O
blast O O
cells O O
with O O
a O O
glucocorticoid B B_MEASURE/B_GENE
receptor I I_MEASURE/I_GENE
concentration O O
over O O
0.22 O O
fmol/microgram O O
DNA O O
. O O

These O O
patients O O
had O O
significantly O O
increased O O
remission O O
and O O
survival O O
rates O O
( O O
p O O
= O O
0.006 O O
) O O
compared O O
with O O
those O O
with O O
a O O
low O O
receptor O O
concentration O O
. O O

This O O
finding O O
can O O
not O O
be O O
explained O O
by O O
a O O
difference O O
in O O
sensitivity O O
to O O
glucocorticoids O O
since O O
these O O
were O O
not O O
used O O
as O O
therapeutic O O
agents O O
. O O

Adenosine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deaminase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
5'nucleotidase B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
activities O O
both O O
varied O O
within O O
two O O
orders O O
of O O
magnitude O O
. O O

These O O
results O O
show O O
that O O
measurements O O
of O O
TdT B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
and O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
concentration O O
yield O O
valuable O O
prognostic O O
information O O
in O O
acute O O
non-lymphocytic O O
leukaemia O O

[ O O
3H O O
] O O
cortivazol O O
: O O
a O O
unique O O
high O O
affinity O O
ligand O O
for O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
. O O

Cortivazol O O
( O O
CVZ O O
) O O
and O O
deacylcortivazol O O
( O O
DAC O O
) O O
are O O
pyrazolosteroids O O
with O O
potent O O
glucocorticoid O O
activity O O
. O O

In O O
previous O O
work O O
we O O
showed O O
that O O
DAC O O
is O O
40-fold O O
more O O
potent O O
than O O
dexamethasone O O
( O O
DEX O O
) O O
in O O
lysing O O
leukemic O O
lymphoblasts O O
. O O

To O O
assess O O
the O O
interaction O O
between O O
these O O
atypical O O
steroids O O
and O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
, O O
we O O
examined O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
CVZ O O
to O O
cytosol O O
from O O
glucocorticoid-sensitive O O
and O O
-resistant O O
variants O O
of O O
the O O
human O O
leukemic O O
cell O O
line O O
CEM O O
C7 O O
. O O

In O O
glucocorticoid-sensitive O O
cells O O
[ O O
3H O O
] O O
CVZ O O
causes O O
a O O
2-fold O O
induction O O
of O O
glutamine B B_ENZYME[GENE]
synthetase I I_ENZYME[GENE]
and O O
binds O O
to O O
a O O
protein O O
in O O
the O O
4.6 O O
S O O
region O O
of O O
high O O
salt O O
sucrose O O
gradients O O
. O O

CVZ O O
competes O O
for O O
a O O
97 O O
, O O
000-dalton O O
protein O O
labeled O O
by O O
[ O O
3H O O
] O O
dexamethasone O O
mesylate O O
. O O

Scatchard O O
analysis O O
of O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
CVZ O O
in O O
glucocorticoid-sensitive O O
cells O O
revealed O O
a O O
curvilinear O O
plot O O
which O O
resolved O O
into O O
high O O
( O O
0.4 O O
nM O O
) O O
and O O
low O O
( O O
11 O O
nM O O
) O O
affinity O O
components O O
. O O

The O O
receptor O O
concentration O O
of O O
the O O
low O O
affinity O O
site O O
( O O
0.30 O O
pmol/mg O O
protein O O
) O O
was O O
approximately O O
twice O O
that O O
of O O
the O O
high B B_GENE/B_MEASURE
affinity I I_GENE/I_MEASURE
site I I_GENE/I_MEASURE
( O O
0.14 O O
pmol/mg O O
protein O O
) O O
. O O

Dissociation O O
experiments O O
with O O
dilution O O
and/or O O
excess O O
unlabeled O O
CVZ O O
supported O O
the O O
presence O O
of O O
independent O O
sites O O
. O O

In O O
cytosol O O
from O O
a O O
glucocorticoid-resistant O O
cell O O
line O O
with O O
virtually O O
no O O
[ O O
3H O O
] O O
DEX O O
binding O O
, O O
[ O O
3H O O
] O O
CVZ O O
detected O O
a O O
single O O
high B B_PROTEIN[GENE]/B_LOCATION
affinity I I_PROTEIN[GENE]/I_LOCATION
binding I I_PROTEIN[GENE]/I_LOCATION
site I I_PROTEIN[GENE]/I_LOCATION
that O O
was O O
similar O O
in O O
dissociation O O
constant O O
( O O
0.8 O O
nM O O
) O O
and O O
receptor O O
concentration O O
( O O
0.13 O O
pmol/mg O O
protein O O
) O O
to O O
the O O
high B B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity I B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O O
in O O
the O O
glucocorticoid-sensitive O O
cell O O
line O O
C7 O O
. O O

A O O
controlled O O
pore O O
glass O O
bead O O
assay O O
for O O
the O O
measurement O O
of O O
cytoplasmic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Excess O O
labeled O O
steroid O O
as O O
well O O
as O O
most O O
non-specifically O O
bound O O
steroid O O
is O O
easily O O
washed O O
away O O
, O O
leaving O O
the O O
hormone-receptor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complex I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
retained O O
by O O
the O O
beads O O
. O O

Bound O O
3H-steroid O O
is O O
eluted O O
with O O
ethanol O O
and O O
measured O O
for O O
radioactivity O O
. O O

This O O
procedure O O
which O O
is O O
simple O O
, O O
rapid O O
, O O
and O O
highly O O
reproducible O O
is O O
carried O O
out O O
using O O
frozen O O
samples O O
( O O
stable O O
for O O
many O O
months O O
) O O
containing O O
as O O
few O O
as O O
1 O O
X O O
10 O O
( O O
7 O O
) O O
cells O O
. O O

A O O
comparison O O
of O O
the O O
CPG O O
assay O O
to O O
dextran O O
coated O O
charcoal O O
and O O
a O O
whole O O
cell O O
assay O O
demonstrates O O
that O O
CPG O O
and O O
dextran O O
coated O O
charcoal O O
give O O
equivalent O O
measurements O O
of O O
cytosolic B B_GENE
receptor I I_GENE
concentration O O
, O O
while O O
the O O
CPG O O
and O O
whole O O
cell O O
assays O O
provide O O
equivalent O O
values O O
for O O
total O O
receptor O O
content O O
. O O

Plasmacytoid O O
blast O O
crisis O O
in O O
B-cell O O
chronic O O
lymphocytic O O
leukemia O O
: O O
effect O O
of O O
estradiol O O
on O O
growth O O
and O O
differentiation O O
in O O
vitro O O
. O O

Evolution O O
of O O
a O O
case O O
of O O
chronic O O
lymphocytic O O
leukemia O O
( O O
CLL O O
) O O
into O O
blast O O
crisis O O
was O O
found O O
to O O
be O O
characterized O O
by O O
three O O
unusual O O
features O O
( O O
1 O O
) O O
the O O
phenotype O O
of O O
the O O
emerging O O
blast O O
cells O O
was O O
that O O
of O O
pre-plasmacytoid O O
cells O O
as O O
shown O O
by O O
plasma O O
cell O O
morphology O O
and O O
an O O
immunological O O
phenotype O O
corresponding O O
partially O O
with O O
CLL- O O
or O O
intermediate O O
B-cells O O
, O O
partially O O
with O O
plasma O O
cells O O
( O O
terminal B B_GENE/B_LOCATION
transferase I I_GENE/I_LOCATION
- O O
, O O
common O O
acute B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leukemia I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
, O O
Ia+ B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
surface B B_GENE
immunoglobulin I I_GENE
heavy I I_GENE
chains I I_GENE
- O O
, O O
surface B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ O O
, O O
intracytoplasmic B B_GENE/B_DISEASE
immunoglobulin I I_GENE/I_DISEASE
A+ I I_GENE/I_DISEASE
and I I_GENE/I_DISEASE
G+ I I_GENE/I_DISEASE
, O O
BA-1+ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
polyclonal O O
gammaglobulin O O
production O O
) O O
; O O
( O O
2 O O
) O O
cytogenetic O O
analysis O O
of O O
spontaneous O O
metaphases O O
revealed O O
that O O
in O O
addition O O
to O O
the O O
typical O O
CLL O O
abnormality O O
, O O
trisomy O O
12 O O
, O O
in O O
all O O
of O O
the O O
cells O O
, O O
an O O
additional O O
translocation O O
between O O
chromosomes B B_DISEASE/B_GENE
14 I I_DISEASE/I_GENE
and I I_DISEASE/I_GENE
17 I I_DISEASE/I_GENE
was O O
present O O
in O O
40 O O
% O O
with O O
a O O
presumptive O O
breakpoint O O
on O O
chromosome B B_GENE/B_MEASURE
14 I I_GENE/I_MEASURE
( O O
q12-3 O O
) O O
never O O
described O O
before O O
( O O
commonly O O
q32 O O
) O O
and O O
( O O
3 O O
) O O
the O O
progression O O
of O O
the O O
disease O O
was O O
associated O O
with O O
a O O
striking O O
increase O O
in O O
the O O
expression O O
by O O
the O O
transformed O O
cells O O
of O O
specific O O
binding O O
sites O O
for O O
estradiol O O
( O O
E2 O O
) O O
due O O
to O O
an O O
actual O O
increase O O
in O O
total O O
cellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
not O O
to O O
a O O
change O O
in O O
receptor O O
affinity O O
for O O
E2 O O
. O O

The O O
functional O O
status O O
of O O
the O O
steroid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
confirmed O O
by O O
nuclear O O
transfer O O
of O O
the O O
cytoplasmic B B_GENE
hormone-receptor I I_GENE
complex I I_GENE
upon O O
temperature O O
activation O O
. O O

Since O O
the O O
rise O O
in O O
E2-receptor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
display O O
paralleled O O
a O O
large O O
increase O O
in O O
the O O
proliferative O O
activity O O
of O O
the O O
cells O O
as O O
well O O
as O O
a O O
change O O
in O O
their O O
maturation O O
status O O
the O O
question O O
was O O
raised O O
as O O
to O O
whether O O
the O O
E2-receptor B B_PROTEIN[GENE]/B_MEASURE
should O O
be O O
considered O O
as O O
a O O
physiological O O
marker O O
of O O
growth O O
rate O O
or O O
of O O
cellular O O
differentiation O O
. O O

Exposure O O
of O O
the O O
patient O O
's O O
blast O O
cells O O
to O O
E2 O O
in O O
vitro O O
resulted O O
in O O
cessation O O
of O O
cell O O
growth O O
following O O
at O O
least O O
one O O
mitosis O O
after O O
addition O O
of O O
the O O
inducer O O
as O O
seen O O
from O O
the O O
replacement O O
of O O
the O O
large O O
blasts O O
by O O
small O O
CLL-like O O
cells O O
without O O
definite O O
signs O O
of O O
alteration O O
of O O
the O O
differentiation O O
status O O
. O O

This O O
suggests O O
the O O
association O O
of O O
E2-receptor B B_GENE
expression O O
with O O
control O O
of O O
growth O O
rather O O
than O O
cell O O
maturation O O
. O O

Multiple O O
forms O O
and O O
fragments O O
of O O
cytosolic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
human O O
leukemic O O
cells O O
and O O
normal O O
lymphocytes O O
. O O

Therapy O O
with O O
glucocorticoids O O
is O O
generally O O
more O O
effective O O
in O O
acute O O
lymphoblastic O O
leukemia O O
than O O
in O O
other O O
types O O
of O O
human O O
leukemia O O
. O O

The O O
objectives O O
of O O
this O O
study O O
were O O
to O O
determine O O
whether O O
there O O
are O O
intrinsic O O
structural O O
differences O O
among O O
the O O
glucocorticoid B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
various O O
types O O
of O O
leukemic O O
cells O O
and O O
normal O O
lymphocytes O O
and O O
to O O
investigate O O
the O O
role O O
of O O
endogenous B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptidases I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
receptor O O
degradation O O
. O O

Cytosols O O
were O O
prepared O O
from O O
fresh O O
or O O
rapidly O O
frozen O O
leukocytes O O
from O O
6 O O
healthy O O
adults O O
and O O
35 O O
high-risk O O
leukemia O O
patients O O
( O O
median O O
white O O
blood O O
cell O O
count O O
, O O
150 O O
, O O
000 O O
cells/microliter O O
; O O
median O O
age O O
, O O
13 O O
years O O
) O O
. O O

Receptors O O
were O O
labeled O O
with O O
[ O O
3H O O
] O O
triamcinolone O O
acetonide O O
and O O
quantitated O O
by O O
charcoal-dextran O O
treatment O O
or O O
Sephadex O O
LH-20 O O
chromatography O O
. O O

No O O
other O O
consistent O O
differences O O
in O O
receptor O O
content O O
were O O
observed O O
. O O

Agarose O O
filtration O O
and O O
ultracentrifugation O O
in O O
hypotonic O O
buffers O O
containing O O
20 O O
mM O O
Na2MoO4 O O
revealed O O
complexes O O
of O O
similar O O
size O O
and O O
shape O O
in O O
all O O
clinical O O
specimens O O
tested O O
and O O
two O O
established O O
leukemic O O
cell O O
lines O O
. O O

Fragmentation O O
of O O
the O O
oligomer B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
subunit B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
evident O O
in O O
some O O
cytosols O O
. O O

High O O
activities O O
of O O
peptidases B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
various O O
specificities O O
were O O
detected O O
in O O
leukemic O O
cell O O
cytosols O O
, O O
as O O
in O O
other O O
cytosols O O
, O O
by O O
fluorometric O O
assays O O
with O O
derivatives O O
of O O
7-amino-4-methylcoumarin O O
. O O

Receptor O O
cleavage O O
by O O
these O O
and O O
other O O
endogenous B B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzymes I I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
account O O
for O O
previous O O
observations O O
of O O
`` O O
abnormal O O
'' O O
receptors O O
in O O
cytosols O O
from O O
some O O
leukemic O O
specimens O O
. O O

Glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
number O O
and O O
intracellular O O
water O O
space O O
. O O

The O O
cellular O O
water O O
space O O
was O O
measured O O
with O O
3H2O O O
, O O
and O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
number O O
was O O
measured O O
in O O
a O O
whole-cell O O
binding O O
assay O O
with O O
[ O O
3H O O
] O O
dexamethasone O O
at O O
30 O O
and O O
37 O O
degrees O O
C O O
. O O

The O O
intracellular O O
water O O
phase O O
concentration O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
around O O
40 O O
nmol/l O O
cell O O
water O O
) O O
, O O
and O O
the O O
dependence O O
of O O
receptor O O
affinity O O
on O O
temperature O O
were O O
similar O O
in O O
normal O O
and O O
malignant O O
rodent O O
and O O
human O O
cells O O
. O O

It O O
is O O
concluded O O
that O O
comparisons O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
are O O
best O O
made O O
on O O
the O O
basis O O
of O O
intracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
concentrations O O
. O O

Covalent O O
labeling O O
of O O
rat O O
thymocyte O O
and O O
human B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
lymphoid I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
glucocorticoid I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
receptor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

Lymphoid O O
cells O O
contain O O
specific O O
receptors B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
glucocorticoids O O
. O O

We O O
have O O
used O O
[ O O
3H O O
] O O
dexamethasone-21-mesylate O O
to O O
label O O
covalently O O
glucocorticoid B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rat O O
thymic O O
lymphocytes O O
and O O
in O O
neoplastic O O
cells O O
obtained O O
from O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
and O O
malignant O O
lymphoma O O
. O O

The O O
covalently O O
labeled O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
identified O O
by O O
polyacrylamide O O
gel O O
electrophoresis O O
( O O
in O O
the O O
presence O O
of O O
0.1 O O
% O O
sodium O O
dodecyl O O
sulfate O O
) O O
. O O

In O O
cytosolic O O
fractions O O
prepared O O
from O O
rat O O
thymic O O
lymphocytes O O
, O O
[ O O
3H O O
] O O
-dexamethasone-21-mesylate O O
labels O O
a O O
protein O O
( O O
Mr O O
approximately O O
equal O O
to O O
95 O O
, O O
000 O O
) O O
which O O
was O O
identified O O
as O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
by O O
the O O
following O O
criteria O O
: O O
( O O
a O O
) O O
labeling O O
of O O
this O O
moiety O O
is O O
inhibited O O
by O O
treatment O O
with O O
a O O
100-fold O O
molar O O
excess O O
of O O
glucocorticoids O O
, O O
such O O
as O O
dexamethasone O O
and O O
triamcinolone O O
acetonide O O
; O O
and O O
( O O
b O O
) O O
the O O
covalently O O
labeled O O
Mr O O
approximately O O
equal O O
to O O
95 O O
, O O
000 O O
protein O O
is O O
activated O O
( O O
by O O
heating O O
at O O
20 O O
degrees O O
for O O
30 O O
min O O
) O O
to O O
a O O
form O O
that O O
binds O O
to O O
DNA-cellulose O O
. O O

Neoplastic O O
cells O O
from O O
acute O O
lymphoblastic O O
leukemia O O
and O O
malignant O O
lymphoma O O
were O O
treated O O
with O O
[ O O
3H O O
] O O
dexamethasone-21-mesylate O O
. O O

Thus O O
, O O
in O O
rat O O
and O O
human O O
lymphoid O O
cells O O
, O O
[ O O
3H O O
] O O
dexamethasone-21-mesylate O O
can O O
be O O
used O O
to O O
label O O
covalently O O
the O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Two O O
hundred O O
and O O
eighty-eight O O
primary O O
breast O O
tumours O O
were O O
examined O O
for O O
the O O
presence O O
or O O
absence O O
of O O
oestrogen B B_DISEASE/B_GENE
( I I_DISEASE/I_GENE
REc I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
and I I_DISEASE/I_GENE
progesterone I I_DISEASE/I_GENE
( I I_DISEASE/I_GENE
RPc I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
receptors I I_DISEASE/I_GENE
. O O

Analysis O O
has O O
shown O O
a O O
relative O O
interdependence O O
between O O
the O O
steroid B B_GENE
receptor I I_GENE
status O O
of O O
primary O O
breast O O
cancer O O
and O O
other O O
prognostic O O
variables O O
such O O
as O O
histological O O
grade O O
, O O
lymphocytic O O
infiltration O O
and O O
tumour O O
elastosis O O
. O O

There O O
were O O
significant O O
associations O O
between O O
epithelial O O
cellularity O O
, O O
stromal O O
fibrosis O O
and O O
the O O
value O O
of O O
REc B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
those O O
tumours O O
in O O
which O O
the O O
receptor O O
was O O
present O O
. O O

Cellularity O O
and O O
fibrosis O O
were O O
unrelated O O
to O O
the O O
presence O O
or O O
absence O O
of O O
oestrogen B B_DISEASE/B_GENE
receptor I I_DISEASE/I_GENE
. O O

By O O
contrast O O
, O O
neither O O
the O O
presence O O
or O O
absence O O
nor O O
the O O
value O O
of O O
RPc B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
related O O
to O O
cellularity O O
or O O
fibrosis O O
. O O

There O O
was O O
no O O
difference O O
in O O
RFS O O
of O O
receptor O O
positive O O
and O O
negative O O
tumours O O
when O O
the O O
axillary O O
node O O
status O O
was O O
taken O O
into O O
account O O
. O O

Clinical O O
implications O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O O
leukemia O O
. O O

Normal O O
lymphoid O O
cells O O
contain O O
glucocorticoid B B_GENE
receptor I I_GENE
. O O

A O O
variety O O
of O O
stimuli O O
that O O
activate O O
these O O
cells O O
also O O
induce O O
increases O O
in O O
receptor O O
concentration O O
. O O

Absence O O
of O O
the O O
glucocorticoid B B_GENE/B_DISEASE
receptor I I_GENE/I_DISEASE
( O O
usually O O
found O O
in O O
treated O O
patients O O
) O O
predicts O O
lack O O
of O O
glucocorticoid O O
responsiveness O O
. O O

Furthermore O O
, O O
in O O
our O O
hands O O
, O O
glucocorticoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
correlate O O
with O O
the O O
duration O O
of O O
complete O O
remission O O
in O O
ALL O O
( O O
though O O
not O O
in O O
other O O
forms O O
of O O
leukemia O O
) O O
. O O

This O O
association O O
is O O
independent O O
of O O
cell O O
type O O
, O O
age O O
, O O
sex O O
, O O
or O O
initial O O
leukocyte O O
count O O
. O O

Corticosteroid-mediated O O
immunoregulation O O
in O O
man O O
. O O

Glucocorticoids O O
have O O
profound O O
and O O
complex O O
effects O O
on O O
the O O
human O O
immune O O
response O O
. O O

However O O
, O O
the O O
precise O O
mechanisms O O
of O O
the O O
corticosteroid-induced O O
immunoregulation O O
in O O
man O O
have O O
not O O
been O O
precisely O O
defined O O
. O O

Human O O
circulating O O
mononuclear O O
cells O O
redistribute O O
out O O
of O O
the O O
intravascular O O
compartment O O
following O O
treatment O O
with O O
corticosteroids O O
. O O

Although O O
certain O O
components O O
at O O
this O O
redistribution O O
phenomenon O O
have O O
been O O
well-characterized O O
, O O
the O O
importance O O
of O O
this O O
compartmental O O
cellular O O
shift O O
with O O
respect O O
to O O
the O O
mechanisms O O
of O O
corticosteroid-induced O O
immunoregulation O O
are O O
less O O
well-defined O O
. O O

Recent O O
observations O O
that O O
activated O O
lymphocytes O O
may O O
be O O
sensitive O O
to O O
the O O
lytic O O
effects O O
of O O
glucocorticoids O O
suggest O O
that O O
under O O
certain O O
situations O O
the O O
elimination O O
of O O
selected O O
subsets O O
of O O
cells O O
may O O
be O O
a O O
relevant O O
mechanism O O
of O O
corticosteroid-mediated O O
immunoregulation O O
in O O
man O O
. O O

Corticosteroid-mediated O O
effects O O
on O O
monocyte O O
function O O
may O O
be O O
an O O
important O O
mechanism O O
of O O
drug-induced O O
immunoregulation O O
in O O
monocyte-dependent O O
responses O O
. O O

In O O
some O O
experimental O O
conditions O O
, O O
corticosteroids O O
inhibit O O
Interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
by O O
monocytes O O
. O O

The O O
immunoregulatory O O
effects O O
of O O
corticosteroids O O
on O O
lymphocyte O O
immune O O
responses O O
are O O
complex O O
. O O

In O O
vitro O O
corticosteroids O O
appear O O
to O O
selectively O O
affect O O
early O O
immunoregulatory O O
events O O
as O O
opposed O O
to O O
altering O O
an O O
established O O
response O O
. O O

Multiple O O
sites O O
of O O
steroid-induced O O
modulations O O
of O O
human O O
B O O
cell O O
responses O O
have O O
been O O
defined O O
. O O

Human O O
lymphoid O O
cell O O
lines O O
and O O
glucocorticoids O O
: O O
II O O
. O O

Whole O O
cell O O
and O O
cytoplasmic O O
binding O O
properties O O
of O O
lymphoblastoid O O
, O O
leukaemia O O
and O O
lymphoma O O
lines O O
. O O

The O O
glucocorticoid O O
binding O O
properties O O
of O O
18 O O
human O O
lymphoid O O
cell O O
lines O O
( O O
HLCL O O
) O O
have O O
been O O
investigated O O
. O O

The O O
specificity O O
of O O
steroid O O
binding O O
was O O
confirmed O O
with O O
various O O
glucocorticoid O O
agonists O O
and O O
antagonists O O
. O O

A O O
gradation O O
in O O
whole O O
cell O O
and O O
cytoplasmic O O
glucocorticoid O O
binding O O
capacity O O
was O O
observed O O
in O O
the O O
different O O
cell O O
line O O
types O O
: O O
lymphoblastoid O O
greater O O
than O O
lymphoma O O
greater O O
than O O
leukaemia O O
. O O

The O O
cytoplasmic B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptors I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
of O O
leukaemia O O
and O O
lymphoblastoid O O
lines O O
appeared O O
to O O
contain O O
both O O
proteinaceous O O
and O O
phospholipid O O
components O O
. O O

Cytoplasmic B B_PERSON/B_GENE
steroid-receptor I I_PERSON/I_GENE
complexes I I_PERSON/I_GENE
exhibited O O
a O O
wide O O
range O O
of O O
sedimentation O O
coefficients O O
( O O
8.5-11.3S O O
) O O
in O O
low O O
ionic O O
strength O O
buffer O O
but O O
there O O
was O O
no O O
correlation O O
with O O
cell O O
line O O
type O O
or O O
glucocorticoid O O
sensitivity O O
. O O

Activation O O
of O O
these O O
complexes O O
by O O
heat O O
( O O
37 O O
degrees O O
C O O
) O O
or O O
exposure O O
to O O
high O O
ionic O O
strength O O
buffer O O
( O O
0.3 O O
M O O
NaCl O O
) O O
induced O O
nuclear O O
binding O O
of O O
steroid O O
but O O
only O O
complexes O O
in O O
high O O
ionic O O
strength O O
buffer O O
manifested O O
changes O O
in O O
sedimentation O O
coefficient O O
. O O

No O O
correlation O O
was O O
observed O O
between O O
the O O
level O O
or O O
nature O O
of O O
glucocorticoid O O
binding O O
and O O
the O O
cytolethal O O
or O O
cytostatic O O
responsiveness O O
of O O
HLCL O O
to O O
glucocorticoid O O
treatment O O
in O O
vitro O O
. O O

The O O
resistance O O
to O O
cytolethal O O
effects O O
can O O
not O O
be O O
ascribed O O
to O O
a O O
failure O O
of O O
cells O O
to O O
take O O
up O O
and O O
bind O O
steroid O O
or O O
to O O
significant O O
differences O O
in O O
the O O
molecular O O
species O O
of O O
cytoplasmic B B_PROTEIN[GENE]
receptors I I_PROTEIN[GENE]
present O O
. O O

The O O
molecular O O
mechanisms O O
by O O
which O O
glucocorticoids O O
achieve O O
cytolethal O O
responses O O
in O O
human O O
lymphoid O O
cells O O

CD28 B B_GENE
-mediated O O
activation O O
in O O
CD45RA+ O O
and O O
CD45RO+ O O
T O O
cells O O
: O O
enhanced O O
levels O O
of O O
reactive O O
oxygen O O
intermediates O O
and O O
c-Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear O O
translocation O O
in O O
CD45RA+ O O
cells O O
. O O

We O O
have O O
analyzed O O
the O O
effect O O
of O O
complete O O
T O O
cell O O
activation O O
( O O
anti-CD3 B B_GENE
plus O O
anti-CD28 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
on O O
the O O
activation O O
of O O
NF-kappaB B B_GENE
in O O
CD45RA+ O O
( O O
naive O O
) O O
and O O
CD45RO+ O O
( O O
memory/effector O O
) O O
T O O
cells O O
. O O

Long O O
exposure O O
( O O
24 O O
h O O
) O O
induced O O
stronger O O
NF-kappaB B B_GENE
DNA O O
binding O O
in O O
CD45RA+ O O
cells O O
than O O
in O O
CD45RO+ O O
cells O O
. O O

Analysis O O
of O O
the O O
nuclear B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
c-Rel I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
after O O
anti-CD3+anti-CD28 O O
stimulation O O
the O O
level O O
of O O
c-Rel B B_GENE
was O O
higher O O
in O O
CD45RA+ O O
cells O O
. O O

Analysis O O
of O O
the O O
cytoplasmic O O
inhibitor O O
IkappaBalpha B B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
anti-CD3+anti-CD28 O O
stimulation O O
induced O O
a O O
long-lasting O O
degradation O O
in O O
CD45RA+ O O
cells O O
but O O
in O O
CD45RO+ O O
cells O O
the O O
degradation O O
process O O
was O O
more O O
rapid O O
. O O

ROIs O O
were O O
produced O O
in O O
both O O
cell O O
types O O
, O O
but O O
more O O
strongly O O
in O O
CD45RA+ O O
cells O O
. O O

Studies O O
on O O
the O O
molecular O O
mechanisms O O
that O O
control O O
hemopoietic O O
differentiation O O
have O O
focused O O
on O O
signaling O O
cascades O O
and O O
nuclear O O
effectors O O
that O O
drive O O
this O O
complex O O
developmental O O
system O O
in O O
a O O
regulated O O
fashion O O
. O O

Here O O
we O O
review O O
the O O
role O O
of O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
founding O O
member O O
of O O
a O O
unique O O
family O O
of O O
zinc B B_GENE/B_BIO
finger I I_GENE/I_BIO
transcription I I_GENE/I_BIO
factors I I_GENE/I_BIO
in O O
this O O
developmental O O
process O O
. O O

Studies O O
on O O
an O O
Ikaros B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
null O O
mutation O O
have O O
revealed O O
an O O
essential O O
role O O
for O O
this O O
factor O O
in O O
lymphoid O O
cell O O
fate O O
determination O O
and O O
at O O
subsequent O O
branch O O
points O O
of O O
the O O
T O O
cell O O
differentiation O O
pathway O O
. O O

Differences O O
in O O
the O O
phenotypes O O
of O O
a O O
null O O
and O O
a O O
dominant O O
negative O O
( O O
DN O O
) O O
Ikaros O O
mutation O O
provide O O
insight O O
into O O
a O O
regulatory O O
network O O
through O O
which O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exert O O
their O O
effects O O
in O O
development O O
. O O

Overexpression O O
of O O
p65 O O
and O O
c-Jun O O
substitutes O O
for O O
B7-1 O O
costimulation O O
by O O
targeting O O
the O O
CD28RE B B_GENE/B_LOCATION
within O O
the O O
IL-2 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
role O O
of O O
Rel B B_GENE/B_DISEASE
and O O
activation B B_GENE
protein-1 I I_GENE
( O O
AP-1 B B_GENE/B_DISEASE
) O O
in O O
IL-2 B B_GENE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoter I B_GENE/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
in O O
B7-1- O O
and O O
leukocyte O O
function-associated O O
Ag-3 O O
( O O
LFA. O O
3 O O
) O O
-costimulated O O
T O O
cells O O
has O O
been O O
evaluated O O
. O O

We O O
demonstrate O O
that O O
overexpression O O
of O O
c-Jun B B_GENE
but O O
not O O
c-Fos B B_GENE
increases O O
IL-2 B B_GENE
promoter I I_GENE
activity O O
in O O
both O O
B7-1- O O
and O O
LFA-3-costimulated O O
Jurkat O O
T O O
cells O O
. O O

Cotransfection O O
of O O
both O O
c-Jun O O
and O O
c-Fos O O
substitutes O O
for O O
B7-1 O O
costimulation O O
in O O
driving O O
an O O
activation B B_GENE/B_LOCATION
protein-1 I I_GENE/I_LOCATION
response I I_GENE/I_LOCATION
element I I_GENE/I_LOCATION
but O O
not O O
for O O
the O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Overexpression O O
of O O
Rel B B_GENE
proteins I I_GENE
demonstrated O O
that O O
p65-expressing O O
Jurkat O O
cells O O
transcribed O O
equally O O
well O O
a O O
nuclear B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
kappabeta I I_GENE/I_MEASURE
reporter I I_GENE/I_MEASURE
construct I I_GENE/I_MEASURE
when O O
costimulated O O
with O O
B7-1 B B_GENE
or O O
LFA-3 B B_GENE
, O O
but O O
transcription O O
of O O
IL-2 B B_GENE
promoter I I_GENE
or O O
CD28 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CD28RE I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-driven I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
superior O O
in O O
B7-1-costimulated O O
cells O O
. O O

Combined O O
expression O O
of O O
c-Jun B B_GENE
and O O
p65 B B_GENE
induced O O
vigorous O O
transcription O O
of O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CD28RE-driven I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
both O O
LFA-3- O O
and O O
B7-1-costimulated O O
Jurkat O O
cells O O
. O O

Mutating O O
the O O
CD28RE B B_GENE/B_LOCATION
but O O
not O O
the O O
upstream B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappabeta-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
reduced O O
B7-1 B B_GENE
-driven O O
transcription O O
> O O
90 O O
% O O
. O O

The O O
results O O
implicates O O
a O O
major O O
role O O
of O O
the O O
CD28RE B B_GENE/B_LOCATION
in O O
the O O
integration O O
of O O
p65 B B_GENE
/ O O
c-Jun B B_GENE
-mediated O O
transcription O O
within O O
the O O
IL-2 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
suggest O O
that O O
the O O
transition O O
from O O
an O O
autocrine O O
LFA-3 B B_GENE
-driven O O
immune O O
response O O
to O O
a O O
B7 O O
-- O O
induced O O
paracrine O O
immune O O
response O O
involves O O
the O O
activation O O
of O O
c-Jun B B_GENE
and O O
p65 B B_GENE
, O O
which O O
target O O
the O O
CD28RE B B_GENE
region O O
of O O
the O O
IL-2 B B_GENE
promoter I I_GENE
. O O

Defects O O
in O O
actin-cap O O
formation O O
in O O
Vav-deficient O O
mice O O
implicate O O
an O O
actin O O
requirement O O
for O O
lymphocyte O O
signal O O
transduction O O
. O O

We O O
have O O
studied O O
the O O
events O O
underlying O O
cap O O
formation O O
using O O
mice O O
bearing O O
a O O
null O O
mutation O O
in O O
vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-/- O O
) O O
, O O
a O O
gene O O
that O O
encodes O O
a O O
guanine-nucleotide B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
exchange I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
GTPase B B_GENE
Rac I I_GENE
. O O

RESULTS O O
: O O
Lymphocytes O O
from O O
vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-/- O O
mice O O
failed O O
to O O
form O O
T-cell O O
receptor O O
caps O O
following O O
activation O O
and O O
had O O
a O O
defective O O
actin O O
cytoskeleton O O
. O O

Activation O O
of O O
Jun B B_GENE/B_DISEASE
N-terminal I I_GENE/I_DISEASE
kinase I I_GENE/I_DISEASE
or O O
stress-activated B B_GENE
kinase I I_GENE
( O O
JNK B B_GENE/B_LOCATION
or O O
SAPK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE/B_LOCATION
) O O
and O O
the O O
induction O O
of O O
the O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-ATc1 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
egr-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
normal O O
. O O

Despite O O
the O O
reduced O O
Ca2+ O O
mobilization O O
, O O
translocation O O
of O O
cytoplasmic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NF-ATc I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
nucleus O O
was O O
normal O O
, O O
reflecting O O
that O O
the O O
lower O O
levels O O
of O O
Ca2+ O O
in O O
vav-/- O O
cells O O
were O O
still O O
sufficient O O
to O O
activate O O
calcineurin B B_GENE
. O O

In O O
transfection O O
studies O O
, O O
either O O
constitutively O O
active O O
Vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
Rac B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
complement O O
constitutively O O
active O O
calcineurin B B_GENE
to O O
activate O O
NF-AT-dependent O O
transcription O O
. O O

CONCLUSIONS O O
: O O
These O O
results O O
indicate O O
that O O
Vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
required O O
for O O
cap O O
formation O O
in O O
lymphocytes O O
. O O

Furthermore O O
, O O
the O O
correlation O O
between O O
cap O O
formation O O
, O O
IL-2 O O
production O O
and O O
proliferation O O
supports O O
the O O
hypothesis O O
that O O
an O O
actin-dependent O O
pathway O O
is O O
a O O
source O O
of O O
specialized O O
growth O O
regulatory O O
signals O O
. O O

CD14 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O O
activation O O
of O O
human O O
endothelial O O
cells O O
by O O
Bacteroides O O
fragilis O O
outer O O
membrane O O
. O O

We O O
studied O O
the O O
capacity O O
of O O
isolated O O
Bacteriodes O O
fragilis O O
outer O O
membrane O O
, O O
B. O O
fragilis O O
NCTC9343 O O
lipopolysaccharide O O
( O O
LPS O O
; O O
endotoxin O O
) O O
, O O
and O O
B. O O
fragilis O O
NCTC9343 O O
capsular O O
polysaccharides O O
to O O
activate O O
human O O
umbilical O O
vein O O
endothelial O O
cell O O
( O O
HUVEC O O
) O O
monolayers O O
. O O

To O O
assess O O
HUVEC O O
activation O O
, O O
E-selectin B B_GENE
expression O O
was O O
measured O O
by O O
enzyme-linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
, O O
Northern O O
blot O O
analysis O O
for O O
E-selectin-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
electrophoretic O O
gel O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
for O O
NF-kappa B B_GENE
B I I_GENE
, O O
a O O
transcription B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
necessary O O
for O O
E-selectin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
gene I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
activation O O
. O O

Exposure O O
of O O
HUVECs O O
to O O
B. O O
fragilis O O
outer O O
membrane O O
fractions O O
, O O
separated O O
from O O
other O O
components O O
of O O
the O O
B. O O
fragilis O O
cell O O
wall O O
by O O
isopycnic O O
, O O
sucrose O O
gradient O O
centrifugation O O
, O O
significantly O O
increased O O
surface O O
expression O O
of O O
E-selectin B B_GENE
and O O
induced O O
functional O O
endothelial O O
cell O O
-dependent O O
leukocyte O O
adhesion O O
. O O

B. O O
fragilis O O
outer O O
membranes O O
induced O O
translocation O O
of O O
NF-kappa B B_GENE
B I I_GENE
to O O
HUVEC O O
nuclei O O
and O O
accumulation O O
of O O
E-selectin B B_GENE
mRNA I I_GENE
in O O
HUVEC O O
cytoplasm O O
. O O

Neither O O
purified O O
B. O O
fragilis O O
LPS O O
, O O
a O O
prominent O O
constituent O O
of O O
the O O
outer O O
membrane O O
, O O
nor O O
purified O O
B. O O
fragilis O O
capsular O O
polysaccharides O O
induced O O
HUVEC O O
activation O O
. O O

We O O
conclude O O
that O O
the O O
outer O O
membrane O O
component O O
of O O
the O O
B. O O
fragilis O O
cell O O
wall O O
contains O O
a O O
proinflammatory O O
factor O O
( O O
s O O
) O O
, O O
that O O
is O O
not O O
LPS O O
, O O
which O O
induces O O
human O O
endothelial O O
cell O O
activation O O
by O O
a O O
soluble O O
CD14 B B_GENE
-dependent O O
mechanism O O
. O O

NF-kappaB B B_GENE
protects O O
HIV-1-infected O O
myeloid O O
cells O O
from O O
apoptosis O O
. O O

HIV-1 O O
infection O O
of O O
primary O O
monocytic O O
cells O O
and O O
myeloid O O
cell O O
lines O O
results O O
in O O
sustained O O
NF-kappaB O O
activation O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
sought O O
to O O
investigate O O
whether O O
constitutive O O
NF-kappaB B B_GENE
activity O O
in O O
chronically O O
HIV-1-infected O O
promonocytic O O
U937 O O
( O O
U9-IIIB O O
) O O
and O O
myeloblastic O O
PLB-985 O O
( O O
PLB-IIIB O O
) O O
cells O O
affects O O
apoptotic O O
signaling O O
. O O

TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
cycloheximide O O
caused O O
infected O O
cells O O
to O O
undergo O O
apoptosis O O
more O O
rapidly O O
than O O
parental O O
U937 O O
and O O
PLB-985 O O
cells O O
. O O

Inhibition O O
of O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
NF-kappaB O O
activation O O
using O O
the O O
antioxidant O O
N-acetylcysteine O O
( O O
NAC O O
) O O
resulted O O
in O O
increased O O
apoptosis O O
in O O
both O O
U937 O O
and O O
U9-IIIB O O
cells O O
, O O
while O O
preactivation O O
of O O
NF-kappaB B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
the O O
non-apoptotic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inducer I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IL-1beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
caused O O
a O O
relative O O
decrease O O
in O O
apoptosis O O
. O O

Inhibition O O
of O O
constitutive O O
NF-kappaB B B_GENE
activity O O
in O O
U9-IIIB O O
and O O
PLB-IIIB O O
cells O O
also O O
induced O O
apoptosis O O
, O O
suggesting O O
that O O
NF-kappaB O O
protects O O
cells O O
from O O
a O O
persistent O O
apoptotic O O
signal O O
. O O

TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O O
NAC O O
treatment O O
resulted O O
in O O
a O O
marked O O
decrease O O
in O O
Bcl-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
HIV-1-infected O O
cells O O
, O O
coupled O O
with O O
an O O
increase O O
in O O
Bax B B_GENE/B_DISEASE
protein I I_GENE/I_DISEASE
compared O O
to O O
uninfected O O
cells O O
, O O
suggesting O O
that O O
the O O
difference O O
in O O
susceptibility O O
to O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
apoptosis O O
may O O
relate O O
to O O
the O O
differences O O
in O O
relative O O
levels O O
of O O
Bcl-2 B B_GENE
and O O
Bax B B_GENE
. O O

The O O
protective O O
role O O
of O O
NF-kappaB B B_GENE
in O O
blocking O O
TNFalpha- O O
and O O
HIV-1-induced O O
apoptosis O O
was O O
supported O O
by O O
studies O O
in O O
Jurkat O O
T O O
cells O O
engineered O O
to O O
express O O
IkappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repressor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutants I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TD-IkappaB B B_PROTEIN[GENE]/B_LOCATION
) O O
under O O
the O O
control O O
of O O
a O O
tetracycline-responsive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cells O O
underwent O O
apoptosis O O
in O O
response O O
to O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
only O O
when O O
NF-kappaB O O
activation O O
was O O
inhibited O O
by O O
TD-IkappaB B B_GENE
expression O O
. O O

Human O O
normal O O
peripheral O O
blood O O
B-lymphocytes O O
are O O
deficient O O
in O O
DNA-dependent O O
protein O O
kinase O O
activity O O
due O O
to O O
the O O
expression O O
of O O
a O O
variant O O
form O O
of O O
the O O
Ku86 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
heterodimeric O O
Ku B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
comprises O O
a O O
86 B B_MEASURE/B_PROTEIN[GENE]
kDa I I_MEASURE/I_PROTEIN[GENE]
( I I_MEASURE/I_PROTEIN[GENE]
Ku86 I I_MEASURE/I_PROTEIN[GENE]
) I I_MEASURE/I_PROTEIN[GENE]
amd O O
a O O
70 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kDa I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ku70 I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunits I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
an O O
abundant O O
nuclear B B_GENE
DNA-binding I I_GENE
protein I I_GENE
which O O
binds O O
in O O
vitro O O
to O O
DNA B B_GENE
termini I I_GENE
without O O
sequence O O
specificity O O
. O O

The O O
presence O O
of O O
this O O
faster B B_GENE
migrating I I_GENE
complex I I_GENE
was O O
restricted O O
to O O
B O O
cells O O
among O O
the O O
circulating O O
lymphocyte O O
population O O
. O O

Western O O
blot O O
analysis O O
revealed O O
that O O
B O O
cells O O
express O O
a O O
variant O O
form O O
of O O
the O O
Ku86 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
an O O
apparent O O
molecular O O
weight O O
of O O
69 O O
kDa O O
, O O
and O O
not O O
the O O
86 B B_GENE/B_MEASURE
kDa- I I_GENE/I_MEASURE
full-length I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
. O O

These O O
data O O
provide O O
a O O
molecular O O
basis O O
for O O
the O O
increased O O
sensitivity O O
of O O
B O O
cells O O
to O O
ionizing O O
radiation O O
and O O
identify O O
a O O
new O O
mechanism O O
of O O
regulation O O
of O O
DNA-PK O O
activity O O
that O O
operates O O
in O O
vivo O O
. O O

Co-stimulation O O
of O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
with O O
IL-2 B B_GENE
and O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
monoclonal I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibodies I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
induces O O
phosphorylation O O
of O O
CREB B B_GENE
. O O

Phosphorylation O O
of O O
the O O
cAMP-response B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CREB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
within O O
1 O O
h O O
of O O
CD2 B B_GENE
but O O
not O O
CD3 B B_GENE/B_MEASURE
cross-linking O O
of O O
human O O
PBMC O O
was O O
recently O O
demonstrated O O
. O O

The O O
absence O O
of O O
P-CREB B B_GENE
following O O
CD3 O O
cross-linking O O
was O O
unexpected O O
, O O
as O O
other O O
laboratories O O
reported O O
increased O O
phosphorylation O O
of O O
CREB B B_GENE
following O O
CD3 O O
cross-linking O O
of O O
the O O
Jurkat O O
lymphocyte O O
cell O O
line O O
. O O

Due O O
to O O
Jurkat O O
T-cells O O
being O O
IL-2-independent O O
, O O
it O O
was O O
postulated O O
that O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O O
provide O O
a O O
necessary O O
co-stimulus O O
for O O
phosphorylation O O
of O O
CREB B B_GENE
in O O
primary O O
lymphocytes O O
. O O

Therefore O O
, O O
P-CREB B B_GENE/B_DISEASE
was O O
evaluated O O
following O O
co-stimulation O O
of O O
human O O
PBMC O O
through O O
the O O
IL-2 B B_GENE
and I I_GENE
CD2 I I_GENE
or I I_GENE
CD3 I I_GENE
receptors I I_GENE
. O O

IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
further O O
augment O O
phosphorylation O O
of O O
CREB B B_GENE
following O O
CD2 O O
cross-linking O O
. O O

However O O
, O O
while O O
neither O O
IL-2 B B_GENE
nor O O
CD3 O O
cross-linking O O
alone O O
induced O O
P-CREB B B_GENE/B_DISEASE
, O O
a O O
4.5-fold O O
increase O O
in O O
phosphorylation O O
of O O
CREB B B_GENE
within O O
1 O O
h O O
of O O
IL-2/CD3 O O
co-stimulation O O
was O O
observed O O
. O O

Phosphorylation O O
was O O
not O O
associated O O
with O O
the O O
induction O O
of O O
cAMP O O
, O O
and O O
inhibition O O
of O O
PKA O O
signaling O O
had O O
no O O
effect O O
on O O
P-CREB B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Consistent O O
with O O
signal O O
transduction O O
through O O
p56lck B B_GENE
or O O
p59fyn B B_GENE
, O O
inhibition O O
of O O
PTK O O
signaling O O
reduced O O
phosphorylation O O
50 O O
% O O
. O O

In O O
contrast O O
to O O
previous O O
studies O O
performed O O
in O O
the O O
absence O O
of O O
exogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
IL-2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
no O O
increase O O
in O O
binding O O
of O O
CREB B B_GENE
to O O
a O O
32P-labeled O O
oligonucleotide O O
probe O O
was O O
observed O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

These O O
data O O
suggest O O
that O O
the O O
IL-2 B B_GENE
and O O
CD3 B B_GENE
signaling O O
pathways O O
provide O O
a O O
necessary O O
and O O
co-operative O O
stimulus O O
promoting O O
phosphorylation O O
of O O
CREB B B_GENE
following O O
receptor O O
cross-linking O O
. O O

Loss O O
of O O
immune O O
function O O
in O O
HIV O O
patients O O
is O O
usually O O
associated O O
with O O
a O O
profound O O
dysregulation O O
of O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
. O O

To O O
investigate O O
whether O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
defects O O
occur O O
during O O
HIV O O
infection O O
, O O
PHA O O
blasts O O
from O O
healthy O O
human O O
donors O O
were O O
infected O O
with O O
two O O
strains O O
of O O
HIV-1 O O
and O O
screened O O
for O O
the O O
expression O O
of O O
STAT B B_GENE/B_BIO
proteins I I_GENE/I_BIO
used O O
in O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
. O O

A O O
selective O O
decrease O O
in O O
STAT5B B B_GENE/B_DISEASE
was O O
seen O O
8 O O
days O O
after O O
infection O O
with O O
the O O
BZ167 O O
dual-tropic O O
HIV O O
isolate O O
, O O
but O O
not O O
with O O
the O O
Ba-L O O
, O O
M-tropic O O
strain O O
. O O

Based O O
on O O
these O O
findings O O
, O O
purified O O
T O O
cells O O
from O O
HIV-infected O O
patients O O
in O O
different O O
stages O O
of O O
disease O O
were O O
also O O
tested O O
for O O
STAT O O
expression O O
; O O
decreases O O
in O O
STAT5A B B_GENE
, O O
STAT5B B B_GENE
, O O
and O O
STAT1alpha B B_GENE
were O O
observed O O
in O O
all O O
patients O O
. O O

The O O
reduction O O
in O O
STATs B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
seen O O
in O O
vivo O O
and O O
in O O
vitro O O
after O O
HIV O O
infection O O
may O O
contribute O O
to O O
the O O
loss O O
of O O
T O O
cell O O
function O O
in O O
HIV O O
disease O O
. O O

Transcription B B_GENE/B_LOCATION
factors I I_GENE/I_LOCATION
that O O
regulate O O
monocyte O O
/ O O
macrophage O O
differentiation O O
. O O

Although O O
all O O
the O O
cells O O
in O O
an O O
organism O O
contain O O
the O O
same O O
genetic O O
information O O
, O O
differences O O
in O O
the O O
cell O O
phenotype O O
arise O O
from O O
the O O
expression O O
of O O
lineage-specific B B_GENE/B_MEASURE
genes I I_GENE/I_MEASURE
. O O

During O O
myelopoiesis O O
, O O
external O O
differentiating O O
signals O O
regulate O O
the O O
expression O O
of O O
a O O
set O O
of O O
transcription B B_GENE
factors I I_GENE
. O O

The O O
combined O O
action O O
of O O
these O O
transcription B B_GENE
factors I I_GENE
subsequently O O
determines O O
the O O
expression O O
of O O
myeloid-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
generation O O
of O O
monocytes O O
and O O
macrophages O O
. O O

In O O
particular O O
, O O
the O O
transcription B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
factor I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
PU.1 I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
has O O
a O O
critical O O
role O O
in O O
this O O
process O O
. O O

We O O
review O O
the O O
contribution O O
of O O
several O O
transcription B B_GENE
factors I I_GENE
to O O
the O O
control O O
of O O
macrophage O O
development O O

Transcription B B_GENE
factor I I_GENE
LKLF I I_GENE
is O O
sufficient O O
to O O
program O O
T O O
cell O O
quiescence O O
via O O
a O O
c-Myc O O
-- O O
dependent O O
pathway O O
. O O

T O O
lymphocytes O O
circulate O O
in O O
a O O
quiescent O O
state O O
until O O
they O O
encounter O O
cognate B B_PROTEIN[GENE]
antigen I I_PROTEIN[GENE]
bound O O
to O O
the O O
surface O O
of O O
an O O
antigen-presenting O O
cell O O
. O O

The O O
molecular O O
pathways O O
that O O
regulate O O
T O O
cell O O
quiescence O O
remain O O
largely O O
unknown O O
. O O

Here O O
we O O
show O O
that O O
forced O O
expression O O
of O O
the O O
lung B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Kruppel-like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
Jurkat O O
T O O
cells O O
is O O
sufficient O O
to O O
program O O
a O O
quiescent O O
phenotype O O
characterized O O
by O O
decreased O O
proliferation O O
, O O
reduced O O
cell O O
size O O
and O O
protein O O
synthesis O O
and O O
decreased O O
surface O O
expression O O
of O O
activation O O
markers O O
. O O

Forced O O
expression O O
of O O
LKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
associated O O
with O O
markedly O O
decreased O O
c-Myc B B_GENE
expression O O
. O O

In O O
addition O O
, O O
many O O
effects O O
of O O
LKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
were O O
mimicked O O
by O O
expression O O
of O O
the O O
dominant-negative B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MadMyc I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
rescued O O
by O O
overexpression O O
of O O
c-Myc B B_GENE
. O O

Thus O O
, O O
LKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
both O O
necessary O O
and O O
sufficient O O
to O O
program O O
quiescence O O
in O O
T O O
cells O O
and O O
functions O O
, O O
in O O
part O O
, O O
by O O
negatively O O
regulating O O
a O O
c-Myc O O
-- O O
dependent O O
pathway O O
. O O

HTLV-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p12 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhances O O
STAT5 O O
activation O O
and O O
decreases O O
the O O
interleukin-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
requirement O O
for O O
proliferation O O
of O O
primary O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
. O O

The O O
p12 B B_GENE
( I I_GENE
I I I_GENE
) I I_GENE
protein I I_GENE
, O O
encoded O O
by O O
the O O
pX B B_GENE
open I I_GENE
reading I I_GENE
frame I I_GENE
I I I_GENE
of O O
the O O
human O O
T-lymphotropic O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
, O O
is O O
a O O
hydrophobic B B_ENZYME[GENE]/B_MEASURE
protein I I_ENZYME[GENE]/I_MEASURE
that O O
localizes O O
to O O
the O O
endoplasmic O O
reticulum O O
and O O
the O O
Golgi O O
. O O

Although O O
p12 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
I I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
contains O O
4 O O
minimal O O
proline-rich O O
, O O
src B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
homology I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
3-binding I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
motifs I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PXXP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
a O O
characteristic O O
commonly O O
found O O
in O O
proteins O O
involved O O
in O O
signaling O O
pathways O O
, O O
it O O
has O O
not O O
been O O
known O O
whether O O
p12 B B_GENE/B_MEASURE
( I I_GENE/I_MEASURE
I I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
has O O
a O O
role O O
in O O
modulating O O
intracellular O O
signaling O O
pathways O O
. O O

As O O
a O O
result O O
of O O
this O O
interaction O O
, O O
p12 B B_GENE
( I I_GENE
I I I_GENE
) I I_GENE
increases O O
signal B B_GENE
transducers I I_GENE
and I I_GENE
activators I I_GENE
of I I_GENE
transcription I I_GENE
5 I I_GENE
( O O
STAT5 B B_GENE
) O O
DNA O O
binding O O
and O O
transcriptional O O
activity O O
and O O
this O O
effect O O
depends O O
on O O
the O O
presence O O
of O O
both O O
IL-2R B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Jak3 B B_GENE
. O O

Transduction O O
of O O
primary O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMCs O O
) O O
with O O
a O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
immunodeficiency I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
virus I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
type I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1-based I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
retroviral I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
vector I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
expressing O O
p12 B B_GENE/B_DISEASE
( I I_GENE/I_DISEASE
I I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
also O O
resulted O O
in O O
increased O O
STAT5 B B_GENE
phosphorylation O O
and O O
DNA O O
binding O O
. O O

In O O
addition O O
, O O
the O O
proliferative O O
advantage O O
of O O
p12 O O
( O O
I O O
) O O
-transduced O O
PBMCs O O
was O O
evident O O
mainly O O
at O O
low O O
concentrations O O
of O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Together O O
, O O
these O O
data O O
indicate O O
that O O
p12 B B_GENE
( I I_GENE
I I I_GENE
) I I_GENE
may O O
confer O O
a O O
proliferative O O
advantage O O
on O O
HTLV-1-infected O O
cells O O
in O O
the O O
presence O O
of O O
suboptimal O O
antigen O O
stimulation O O
and O O
that O O
this O O
event O O
may O O
account O O
for O O
the O O
clonal O O
proliferation O O
of O O
infected O O
T O O
cells O O
in O O
vivo O O
. O O

( O O
Blood. O O
2001 O O
; O O
98 O O
: O O
823-829 O O
) O O

To O O
further O O
unravel O O
underlying O O
mechanisms O O
the O O
authors O O
wished O O
to O O
determine O O
, O O
firstly O O
, O O
the O O
kinetics O O
of O O
antigen O O
delivery O O
and O O
, O O
secondly O O
, O O
the O O
early O O
cellular O O
responses O O
involved O O
in O O
the O O
initial O O
stages O O
of O O
nasal O O
mucosal O O
tolerance O O
induction O O
. O O

Significant O O
proliferative O O
responses O O
to O O
IRBP O O
were O O
elicited O O
by O O
48 O O
hours O O
indicating O O
that O O
systemic O O
priming O O
of O O
naive O O
T O O
cells O O
to O O
retinal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
had O O
occurred O O
. O O

Cell O O
activation O O
was O O
further O O
confirmed O O
by O O
immunoprecipitation O O
studies O O
, O O
which O O
demonstrated O O
phosphorylation O O
of O O
STAT4 B B_GENE
but O O
not O O
STAT6 B B_GENE
in O O
both O O
lymph O O
nodes O O
and O O
spleen O O
. O O

However O O
, O O
at O O
24 O O
hours O O
, O O
STAT4 O O
heterodimerisation O O
with O O
STAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
only O O
observed O O
in O O
spleen O O
. O O

Further O O
understanding O O
of O O
these O O
underlying O O
cellular O O
mechanisms O O
, O O
in O O
particular O O
as O O
is O O
inferred O O
by O O
the O O
results O O
the O O
contribution O O
of O O
local O O
versus O O
systemic O O
tolerance O O
induction O O
, O O
may O O
assist O O
in O O
strategies O O
to O O
clinically O O
apply O O
mucosal O O
tolerance O O
therapy O O
successfully O O
. O O

Regulation O O
of O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-18 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
on O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
during O O
T O O
helper O O
( O O
Th O O
) O O
1/Th2 O O
differentiation O O
. O O

Critical O O
downregulatory O O
role O O
of O O
IL-4 B B_PERSON/B_ENT
. O O

To O O
determine O O
the O O
mechanisms O O
by O O
which O O
IL-18 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
might O O
regulate O O
these O O
diametrically O O
distinct O O
immune O O
responses O O
, O O
we O O
have O O
analyzed O O
the O O
role O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
regulation O O
of O O
IL-18 B B_GENE
receptor I I_GENE
alpha I I_GENE
chain I I_GENE
( O O
IL-18Ralpha B B_PROTEIN[GENE]/B_LOCATION
) O O
expression O O
. O O

The O O
majority O O
of O O
peripheral O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
constitutively O O
expressed O O
the O O
IL-18Ralpha B B_GENE
. O O

Upon O O
antigen O O
stimulation O O
in O O
the O O
presence O O
of O O
IL-12 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
marked O O
enhancement O O
of O O
IL-18Ralpha B B_GENE
expression O O
was O O
observed O O
. O O

IL-12 B B_GENE
-mediated O O
upregulation O O
of O O
IL-18Ralpha B B_GENE
required O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Activated O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
that O O
expressed O O
low O O
levels O O
of O O
IL-18Ralpha B B_GENE
could O O
produce O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
when O O
stimulated O O
with O O
the O O
combination O O
of O O
IL-12 B B_GENE
and O O
IL-18 B B_GENE
, O O
while O O
CD4 O O
( O O
+ O O
) O O
cells O O
which O O
expressed O O
high O O
levels O O
of O O
IL-18Ralpha B B_GENE
could O O
respond O O
to O O
IL-18 B B_GENE
alone O O
. O O

In O O
contrast O O
, O O
T O O
cell O O
stimulation O O
in O O
the O O
presence O O
of O O
IL-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
a O O
downregulation O O
of O O
IL-18Ralpha B B_GENE
expression O O
. O O

Both O O
IL-4 O O
( O O
-/ O O
) O O
- O O
and O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
( O O
Stat O O
) O O
6 O O
( O O
-/ O O
) O O
- O O
T O O
cells O O
expressed O O
higher O O
levels O O
of O O
IL-18Ralpha B B_GENE
after O O
TCR O O
stimulation O O
. O O

Furthermore O O
, O O
activated O O
T O O
cells O O
from O O
Stat6 O O
( O O
-/ O O
) O O
- O O
mice O O
produced O O
more O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
response O O
to O O
IL-18 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
wild-type O O
controls O O
. O O

Glucocorticoids O O
are O O
the O O
most O O
effective O O
antiinflammatory O O
drugs O O
used O O
in O O
the O O
treatment O O
of O O
asthma O O
. O O

They O O
act O O
by O O
binding O O
to O O
a O O
specific O O
receptor O O
( O O
GR B B_GENE/B_DISEASE
) O O
that O O
, O O
upon O O
activation O O
, O O
translocates O O
to O O
the O O
nucleus O O
and O O
either O O
increases O O
( O O
transactivates O O
) O O
or O O
decreases O O
( O O
transrepresses O O
) O O
gene O O
expression O O
. O O

Inhibition O O
of O O
pro-inflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
such O O
as O O
activator B B_GENE
protein I I_GENE
( I I_GENE
AP I I_GENE
) I I_GENE
-1 I I_GENE
, O O
signal B B_GENE
transducers I I_GENE
and I I_GENE
activators I I_GENE
of I I_GENE
transcription I I_GENE
( O O
STATs B B_GENE/B_LOCATION
) O O
, O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NFAT B B_GENE/B_ORGANIZATION
) O O
and O O
nuclear B B_GENE
factor I I_GENE
( I I_GENE
NF I I_GENE
) I I_GENE
-kappa I I_GENE
B I I_GENE
is O O
thought O O
to O O
be O O
a O O
major O O
action O O
of O O
glucocorticoids O O
. O O

Acetylation O O
of O O
histones B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allows O O
unwinding O O
of O O
the O O
local B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
structure I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
enables O O
RNA B B_GENE
polymerase I I_GENE
II I I_GENE
to O O
enhance O O
gene O O
transcription O O
. O O

A O O
sub-group O O
of O O
patients O O
with O O
glucocorticoid-insensitive O O
asthma O O
have O O
an O O
inability O O
to O O
induce O O
histone O O
acetylation O O
in O O
response O O
to O O
dexamethasone O O
suggesting O O
reduced O O
expression O O
of O O
a O O
GR-specific B B_GENE/B_MEASURE
HAT I I_GENE/I_MEASURE
. O O

Identification O O
of O O
the O O
precise O O
mechanism O O
by O O
which O O
activated B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GR I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recruits O O
HDAC2 B B_GENE
may O O
reveal O O
new O O
targets O O
for O O
the O O
development O O
of O O
drugs O O
that O O
may O O
dissociate O O
the O O
antiinflammatory O O
actions O O
of O O
glucocorticoids O O
from O O
their O O
side O O
effects O O
that O O
are O O
largely O O
due O O
to O O
gene O O
induction O O
. O O

Copyright O O
Academic O O
Press O O
. O O

Differential O O
ultraviolet-B-induced O O
immunomodulation O O
in O O
XPA O O
, O O
XPC O O
, O O
and O O
CSB O O
DNA O O
repair-deficient O O
mice O O
. O O

Ultraviolet O O
B O O
irradiation O O
has O O
serious O O
consequences O O
for O O
cellular O O
immunity O O
and O O
can O O
suppress O O
the O O
rejection O O
of O O
skin O O
tumors O O
and O O
the O O
resistance O O
to O O
infectious O O
diseases O O
. O O

DNA O O
damage O O
plays O O
a O O
crucial O O
role O O
in O O
these O O
immunomodulatory O O
effects O O
of O O
ultraviolet O O
B O O
, O O
as O O
impaired O O
repair O O
of O O
ultraviolet-B-induced O O
DNA O O
damage O O
has O O
been O O
shown O O
to O O
cause O O
suppression O O
of O O
cellular O O
immunity O O
. O O

In O O
this O O
study O O
the O O
immunologic O O
consequences O O
of O O
specific O O
nucleotide O O
excision O O
repair O O
defects O O
in O O
three O O
mouse O O
models O O
, O O
XPA O O
, O O
XPC O O
, O O
and O O
CSB O O
mutant O O
mice O O
, O O
were O O
investigated O O
. O O

This O O
may O O
indicate O O
that O O
the O O
reported O O
altered O O
cellular O O
responses O O
in O O
xeroderma O O
pigmentosum O O
patients O O
are O O
not O O
constitutive O O
but O O
could O O
be O O
due O O
to O O
external O O
factors O O
, O O
such O O
as O O
ultraviolet O O
B O O
. O O

Upon O O
exposure O O
to O O
ultraviolet O O
B O O
, O O
only O O
XPA O O
mice O O
are O O
very O O
sensitive O O
to O O
ultraviolet-B-induced O O
inhibition O O
of O O
Th1-mediated O O
contact O O
hypersensitivity O O
responses O O
and O O
interferon-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O O
in O O
skin O O
draining O O
lymph O O
nodes O O
. O O

Lipopolysaccharide-stimulated O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
necrosis I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factor I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
alpha I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
interleukin-10 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
are O O
significantly O O
augmented O O
in O O
both O O
XPA O O
and O O
CSB O O
mice O O
after O O
ultraviolet O O
B O O
exposure O O
. O O

Lymph O O
node O O
cell O O
numbers O O
were O O
increased O O
very O O
significantly O O
in O O
XPA O O
, O O
mildly O O
increased O O
in O O
CSB O O
, O O
and O O
not O O
in O O
XPC O O
mice O O
. O O

In O O
general O O
XPC O O
mice O O
do O O
not O O
exhibit O O
any O O
indication O O
of O O
enhanced O O
ultraviolet O O
B O O
susceptibility O O
with O O
regard O O
to O O
the O O
immune O O
parameters O O
analyzed O O
. O O

Biomechanical O O
strain O O
induces O O
class O O
a O O
scavenger B B_GENE
receptor I I_GENE
expression O O
in O O
human O O
monocyte/macrophages O O
and O O
THP-1 O O
cells O O
: O O
a O O
potential O O
mechanism O O
of O O
increased O O
atherosclerosis O O
in O O
hypertension O O
. O O

BACKGROUND O O
: O O
Although O O
hypertension O O
is O O
an O O
important O O
risk O O
factor O O
for O O
the O O
development O O
of O O
atherosclerosis O O
, O O
the O O
mechanisms O O
for O O
this O O
interaction O O
are O O
incompletely O O
described O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Human O O
monocyte/macrophages O O
or O O
THP-1 O O
cells O O
were O O
cultured O O
in O O
a O O
device O O
that O O
imposes O O
uniform O O
biaxial O O
cyclic O O
1-Hz O O
strains O O
of O O
0 O O
% O O
, O O
1 O O
% O O
, O O
2 O O
% O O
, O O
or O O
3 O O
% O O
, O O
and O O
SRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
was O O
analyzed O O
. O O

Mechanical O O
strains O O
induced O O
SRA B B_GENE
mRNA I I_GENE
( O O
3.5+/-0.6-fold O O
at O O
3 O O
% O O
strain O O
for O O
48 O O
hours O O
, O O
P O O
< O O
0.01 O O
) O O
and O O
SRA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
THP-1 O O
cells O O
in O O
an O O
amplitude-dependent O O
manner O O
. O O

This O O
induction O O
was O O
accompanied O O
by O O
augmented O O
expression O O
of O O
the O O
class B B_GENE
B I I_GENE
scavenger I I_GENE
receptor I I_GENE
CD36 I I_GENE
( O O
2.8+/-0.3-fold O O
, O O
P O O
< O O
0.001 O O
) O O
but O O
not O O
by O O
increased O O
peroxisome B B_GENE
proliferator-activated I I_GENE
receptor-gamma I I_GENE
expression O O
. O O

Immunohistochemistry O O
revealed O O
that O O
among O O
macrophages O O
in O O
atherosclerotic O O
lesions O O
of O O
the O O
aorta O O
, O O
the O O
proportion O O
of O O
macrophages O O
with O O
SRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
was O O
highest O O
in O O
hypertensive O O
animals O O
on O O
a O O
high-cholesterol O O
diet O O
( O O
43.9+/-0.7 O O
% O O
, O O
versus O O
12.0+/-2.0 O O
% O O
for O O
normotensive O O
animals O O
on O O
a O O
high-cholesterol O O
diet O O
and O O
4.7+/-4.7 O O
% O O
for O O
animals O O
on O O
standard O O
chow O O
; O O
P O O
< O O
0.001 O O
) O O
. O O

CONCLUSIONS O O
: O O
Biomechanical O O
strain O O
induces O O
SRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
by O O
monocyte/macrophages O O
, O O
suggesting O O
a O O
novel O O
mechanism O O
for O O
promotion O O
of O O
atherosclerosis O O
in O O
hypertensive O O
patients O O
. O O

BACKGROUND O O
: O O
High O O
glucose O O
in O O
peritoneal O O
dialysis O O
solutions O O
has O O
been O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
peritoneal O O
fibrosis O O
in O O
chronic O O
ambulatory O O
peritoneal O O
dialysis O O
( O O
CAPD O O
) O O
patients O O
. O O

However O O
, O O
the O O
mechanisms O O
are O O
not O O
very O O
clear O O
. O O

Peritoneal O O
macrophages O O
seem O O
to O O
participate O O
in O O
the O O
process O O
of O O
peritoneal O O
fibrosis O O
and O O
monocyte B B_GENE
chemoattractant I I_GENE
protein-1 I I_GENE
( O O
MCP-1 B B_GENE/B_DISEASE
) O O
plays O O
a O O
key O O
role O O
in O O
the O O
recruitment O O
of O O
monocytes O O
toward O O
the O O
peritoneal O O
cavity O O
. O O

However O O
, O O
little O O
is O O
known O O
about O O
the O O
effect O O
of O O
high O O
glucose O O
on O O
MCP-1 B B_GENE
expression O O
and O O
its O O
signal O O
transduction O O
pathway O O
in O O
human O O
peritoneal O O
mesothelial O O
cells O O
. O O

METHODS O O
: O O
Mesothelial O O
cells O O
were O O
cultured O O
with O O
glucose O O
( O O
5 O O
to O O
100 O O
mmol/L O O
) O O
or O O
mannitol O O
chronically O O
for O O
up O O
to O O
seven O O
days O O
. O O

MCP-1 B B_GENE/B_MEASURE
expression O O
of O O
mRNA O O
and O O
protein O O
was O O
measured O O
by O O
Northern O O
blot O O
analysis O O
and O O
enzyme-linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
. O O

Chemotactic O O
activity O O
of O O
high-glucose-conditioned O O
culture O O
supernatant O O
was O O
measured O O
by O O
chemotactic O O
assay O O
. O O

To O O
examine O O
the O O
roles O O
of O O
the O O
transcription B B_GENE
factors I I_GENE
activator B I_GENE
protein-1 I I_GENE
( O O
AP-1 B B_GENE/B_DISEASE
) O O
and O O
nuclear B B_GENE
factor-kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
, O O
electrophoretic O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
was O O
performed O O
. O O

RESULTS O O
: O O
Glucose O O
induced O O
MCP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
a O O
time- O O
and O O
dose-dependent O O
manner O O
. O O

Equivalent O O
concentrations O O
of O O
mannitol O O
had O O
no O O
significant O O
effect O O
. O O

High-glucose-conditioned O O
supernatant O O
possessed O O
an O O
increased O O
chemotactic O O
activity O O
for O O
monocytes O O
, O O
which O O
was O O
neutralized O O
by O O
anti-MCP-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

EMSA O O
revealed O O
that O O
glucose O O
increased O O
the O O
AP-1 B B_GENE
binding O O
activity O O
in O O
a O O
time- O O
and O O
dose-dependent O O
manner O O
, O O
but O O
not O O
NF-kappaB B B_GENE
. O O

Curcumin O O
, O O
an O O
inhibitor O O
of O O
AP-1 B B_GENE
, O O
dose-dependently O O
suppressed O O
the O O
induction O O
of O O
MCP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
high O O
glucose O O
. O O

Tyrosine O O
kinase O O
inhibitors O O
such O O
as O O
genistein O O
( O O
12.5 O O
to O O
50 O O
micromol/L O O
) O O
and O O
herbimycin O O
A O O
( O O
0.1 O O
to O O
1 O O
micromol/L O O
) O O
inhibited O O
the O O
high-glucose-induced O O
MCP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
a O O
dose-dependent O O
manner O O
, O O
and O O
also O O
suppressed O O
the O O
high-glucose-induced O O
AP-1 B B_GENE
binding O O
activity O O
. O O

CONCLUSIONS O O
: O O
: O O
High O O
glucose O O
induced O O
mesothelial O O
MCP-1 B B_GENE
expression O O
partly O O
via O O
the O O
tyrosine O O
kinase- O O
AP-1 B B_GENE
pathway O O
. O O

We O O
analyzed O O
intracellular O O
pathways O O
modulating O O
surface O O
densities O O
of O O
CD80 B B_GENE
and O O
CD86 B B_GENE
in O O
B O O
cells O O
activated O O
through O O
ligation O O
of O O
the O O
Ag B B_GENE
receptor I I_GENE
, O O
and O O
the O O
adhesion B B_GENE
molecule I I_GENE
CD54 B I_GENE
. O O

Whereas O O
B B B_GENE
cell I I_GENE
Ag I I_GENE
receptor I I_GENE
( O O
BCR B B_GENE/B_LOCATION
) O O
cross-linking O O
alone O O
stimulated O O
increased O O
expression O O
of O O
CD86 B B_GENE
, O O
up-regulation O O
of O O
CD80 B B_GENE
required O O
dual O O
stimulation O O
with O O
anti-IgM B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
anti-CD54 B B_GENE
. O O

The O O
principal O O
downstream O O
component O O
contributed O O
by O O
BCR B B_GENE
signaling O O
, O O
toward O O
both O O
CD80 B B_GENE
and O O
CD86 B B_GENE
induction O O
, O O
was O O
the O O
elevated O O
concentration O O
of O O
free O O
cytoplasmic O O
Ca O O
( O O
2+ O O
) O O
, O O
recruited O O
by O O
way O O
of O O
capacitative O O
influx O O
. O O

This O O
alone O O
was O O
sufficient O O
to O O
generate O O
an O O
increase O O
in O O
CD86 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
. O O

However O O
, O O
CD80 B B_GENE/B_LOCATION
enhancement O O
required O O
the O O
concerted O O
action O O
of O O
both O O
intracellular O O
Ca O O
( O O
2+ O O
) O O
concentration O O
and O O
CD54-initiated O O
pathways O O
. O O

The O O
nexus O O
between O O
anti-IgM O O
and O O
anti-CD54 O O
stimulation O O
, O O
in O O
the O O
context O O
of O O
CD80 B B_GENE
regulation O O
, O O
was O O
identified O O
to O O
involve O O
a O O
self-propagating O O
process O O
of O O
sequential O O
synergy O O
. O O

The O O
first O O
step O O
involved O O
amplified O O
accumulation O O
of O O
intracellular O O
cAMP O O
, O O
as O O
a O O
result O O
of O O
cross-talk O O
between O O
BCR B B_GENE
-mobilized O O
Ca O O
( O O
2+ O O
) O O
and O O
CD54-derived O O
signals O O
. O O

This O O
then O O
facilitated O O
a O O
second O O
synergistic O O
interaction O O
between O O
Ca O O
( O O
2+ O O
) O O
and O O
cAMP O O
, O O
culminating O O
in O O
CD80 B B_GENE
expression O O
. O O

Importantly O O
, O O
these O O
results O O
also O O
reveal O O
how O O
concentration O O
threshold O O
barriers O O
for O O
recruitment O O
of O O
individual O O
second O O
messengers O O
can O O
be O O
overcome O O
by O O
constructive O O
convergence O O
of O O
signaling O O
modules O O
. O O

The O O
role O O
of O O
Epstein-Barr O O
virus O O
in O O
neoplastic O O
transformation O O
. O O

In O O
this O O
review O O
, O O
we O O
focus O O
on O O
new O O
data O O
from O O
basic O O
, O O
translational O O
and O O
clinical O O
research O O
relating O O
to O O
the O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
. O O

Beside O O
its O O
well-known O O
tropism O O
for O O
B O O
lymphocytes O O
and O O
epithelial O O
cells O O
, O O
EBV O O
also O O
infects O O
T O O
lymphocytes O O
, O O
monocytes O O
and O O
granulocytes O O
. O O

After O O
primary O O
infection O O
, O O
EBV O O
persists O O
throughout O O
the O O
life O O
span O O
in O O
resting O O
memory O O
B O O
cells O O
, O O
from O O
where O O
it O O
is O O
reactivated O O
upon O O
breakdown O O
of O O
cellular O O
immunity O O
. O O

TRAF2 B B_GENE
-mediated O O
NF-kappaB B B_GENE
activation O O
, O O
AP-1 B B_GENE
induction O O
and O O
JAK3 B B_GENE/B_LOCATION
/ O O
STAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O O
may O O
result O O
in O O
sustained O O
proliferation O O
leading O O
to O O
lymphoma O O
. O O

The O O
ability O O
of O O
LMP1 B B_GENE
to O O
suppress O O
germinal O O
center O O
formation O O
and O O
its O O
capacity O O
to O O
mediate O O
its O O
own O O
transcriptional O O
activation O O
shed O O
new O O
light O O
on O O
the O O
pathogenesis O O
of O O
EBV-associated O O
latency O O
type O O
II O O
lymphoproliferations O O
like O O
Hodgkin O O
's O O
disease O O
and O O
angioimmunoblastic O O
lymphadenopathy O O
. O O

Interferon-alpha B B_DISEASE/B_GENE
drives O O
T O O
cell-mediated O O
immunopathology O O
in O O
the O O
intestine O O
. O O

We O O
have O O
recently O O
described O O
enhanced O O
expression O O
of O O
IFN-alpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
mucosa O O
of O O
patients O O
with O O
celiac O O
disease O O
( O O
CD O O
) O O
, O O
a O O
gluten-sensitive O O
Th1-mediated O O
enteropathy O O
, O O
characterized O O
by O O
villous O O
atrophy O O
and O O
crypt O O
cell O O
hyperplasia O O
. O O

Previous O O
studies O O
from O O
this O O
laboratory O O
have O O
shown O O
that O O
T O O
cell O O
activation O O
in O O
explant O O
cultures O O
of O O
human O O
fetal O O
gut O O
can O O
also O O
result O O
in O O
villous O O
atrophy O O
and O O
crypt O O
cell O O
hyperplasia O O
. O O

We O O
have O O
, O O
therefore O O
, O O
examined O O
changes O O
that O O
take O O
place O O
in O O
explant O O
cultures O O
of O O
human O O
fetal O O
gut O O
after O O
activation O O
of O O
T O O
cells O O
with O O
anti-CD3 B B_GENE
and/or O O
IFN-alpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
show O O
that O O
activation O O
of O O
T O O
cells O O
with O O
anti-CD3 B B_GENE
alone O O
elicits O O
a O O
small O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response O O
with O O
no O O
tissue O O
injury O O
. O O

Similarly O O
, O O
no O O
changes O O
are O O
seen O O
in O O
explants O O
cultured O O
with O O
IFN-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alone O O
. O O

This O O
is O O
associated O O
with O O
enhanced O O
phosphorylation O O
of O O
STAT1 B B_GENE
, O O
STAT3 B B_GENE
, O O
and O O
Fyn B B_GENE
, I I_GENE
a I I_GENE
Src I I_GENE
homology I I_GENE
tyrosine I I_GENE
kinase I I_GENE
, O O
which O O
interacts O O
with O O
both O O
TCR O O
and O O
IFN-alpha O O
signal O O
components O O
. O O

Suppression O O
of O O
tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
necrosis I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
production O O
by O O
cAMP O O
in O O
human O O
monocytes O O
: O O
dissociation O O
with O O
mRNA O O
level O O
and O O
independent O O
of O O
interleukin-10 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BACKGROUND O O
: O O
Elevation O O
of O O
cellular O O
cAMP O O
inhibits O O
lipopolysaccharide O O
( O O
LPS O O
) O O
-stimulated O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF-alpha B B_GENE/B_LOCATION
) O O
production O O
and O O
increases O O
the O O
expression O O
of O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-10 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mononuclear O O
cells O O
. O O

TNF-alpha B B_GENE
gene I I_GENE
expression O O
obligates O O
activation O O
of O O
the O O
transcription B B_GENE
factor I I_GENE
nuclear B I_GENE
factor I I_GENE
kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
. O O

Exogenous O O
IL-10 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibits O O
NF-kappaB B B_GENE
in O O
monocytes O O
and O O
thus O O
attenuates O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O O
. O O

We O O
examined O O
the O O
role O O
of O O
endogenous O O
IL-10 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
regulation O O
of O O
NF-kappaB B B_GENE
activation O O
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O O
in O O
human O O
monocytes O O
by O O
cAMP O O
. O O

Cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
IL-10 B B_GENE
) O O
release O O
was O O
measured O O
by O O
immunoassay O O
. O O

TNF-alpha B B_GENE
mRNA I I_GENE
was O O
measured O O
by O O
reverse O O
transcription O O
polymerase O O
chain O O
reaction O O
, O O
and O O
NF-kappaB B B_GENE
DNA O O
binding O O
activity O O
was O O
assessed O O
by O O
gel O O
mobility O O
shift O O
assay O O
. O O

RESULTS O O
: O O
cAMP-elevating O O
agents O O
inhibited O O
LPS-stimulated O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
release O O
( O O
0.77 O O
+/- O O
0.13 O O
ng/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
+ O O
dbcAMP O O
and O O
0.68 O O
+/- O O
0.19 O O
ng/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
+ O O
FSK O O
, O O
both O O
P O O
< O O
0.05 O O
vs O O
1.61 O O
+/- O O
0.34 O O
ng/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
alone O O
) O O
. O O

Conversely O O
, O O
cAMP O O
enhanced O O
LPS-stimulated O O
IL-10 B B_GENE
release O O
( O O
100 O O
+/- O O
21.5 O O
pg/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
+ O O
dbcAMP O O
and O O
110 O O
+/- O O
25.2 O O
pg/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
+ O O
FSK O O
, O O
both O O
P O O
< O O
0.05 O O
vs O O
53.3 O O
+/- O O
12.8 O O
pg/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
alone O O
) O O
. O O

Neither O O
TNF-alpha B B_GENE
mRNA I I_GENE
expression O O
nor O O
NF-kappaB B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
stimulated O O
by O O
LPS O O
was O O
inhibited O O
by O O
the O O
cAMP-elevating O O
agents O O
. O O

CONCLUSION O O
: O O
The O O
results O O
indicate O O
that O O
cAMP O O
inhibits O O
LPS-stimulated O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O O
through O O
a O O
posttranscriptional O O
mechanism O O
that O O
is O O
independent O O
of O O
endogenous O O
IL-10 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

We O O
have O O
previously O O
reported O O
that O O
BMP-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O O
the O O
growth O O
of O O
HS-72 O O
mouse O O
hybridoma O O
cells O O
by O O
inducing O O
p21 O O
( O O
CIP1/WAF1 O O
) O O
expression O O
. O O

Furthermore O O
, O O
an O O
oligonucleotide O O
containing O O
the O O
29-b B B_GENE/B_LOCATION
region I I_GENE/I_LOCATION
was O O
found O O
to O O
be O O
associated O O
with O O
Smad4 B B_GENE
and O O
phosphorylated B B_GENE/B_MEASURE
Smad1 I I_GENE/I_MEASURE
in O O
the O O
nuclear O O
extract O O
of O O
BMP-2 B B_GENE
-stimulated O O
HS-72 O O
cells O O
. O O

Dendritic O O
cell O O
development O O
from O O
common O O
myeloid O O
progenitors O O
. O O

It O O
has O O
been O O
suggested O O
that O O
these O O
different O O
effects O O
on O O
responder O O
cells O O
depend O O
on O O
subsets O O
of O O
DCs O O
arising O O
from O O
either O O
myeloid O O
or O O
lymphoid O O
hematopoietic O O
origins O O
. O O

In O O
this O O
model O O
, O O
CD8 O O
alpha+ O O
Mac-1- O O
DCs O O
are O O
supposed O O
to O O
be O O
of O O
lymphoid O O
while O O
CD8 O O
alpha- O O
Mac-1+ O O
DCs O O
are O O
supposed O O
to O O
be O O
of O O
myeloid O O
origin O O
. O O

Therefore O O
CD8 B B_GENE/B_MEASURE
alpha I I_GENE/I_MEASURE
expression O O
DCs O O
does O O
not O O
indicate O O
a O O
lymphoid O O
origin O O
and O O
differences O O
among O O
CD8 O O
alpha+ O O
and O O
CD8 O O
alpha- O O
DCs O O
might O O
rather O O
reflect O O
maturation O O
status O O
than O O
ontogeny O O
. O O

On O O
the O O
basis O O
of O O
transplantation O O
studies O O
, O O
it O O
seems O O
likely O O
that O O
most O O
of O O
the O O
DCs O O
in O O
secondary O O
lymphoid O O
organs O O
and O O
a O O
substantial O O
fraction O O
of O O
thymic O O
DCs O O
are O O
myeloid-derived O O
. O O

Macrophage O O
stimulation O O
with O O
Murabutide O O
, O O
an O O
HIV-suppressive O O
muramyl O O
peptide O O
derivative O O
, O O
selectively O O
activates O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
C/EBPbeta B B_GENE
and O O
STAT1 B B_GENE
: O O
role O O
of O O
CD14 B B_GENE
and O O
Toll-like B B_GENE
receptors I I_GENE
2 I I_GENE
and I I_GENE
4 I I_GENE
. O O

We O O
have O O
addressed O O
the O O
signaling O O
events O O
activated O O
in O O
MDM O O
following O O
stimulation O O
with O O
either O O
MB O O
or O O
the O O
potent O O
immunostimulant O O
LPS O O
. O O

We O O
demonstrate O O
that O O
, O O
unlike O O
LPS O O
, O O
the O O
safe O O
immunomodulator O O
MB O O
selectively O O
activates O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Erk I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1/2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
the O O
absence O O
of O O
detectable O O
Jun B B_GENE
N-terminal I I_GENE
kinase I I_GENE
( O O
JNK B B_GENE/B_LOCATION
) O O
or O O
p38 B B_GENE
mitogen-activated I I_GENE
kinase I I_GENE
activation O O
. O O

Furthermore O O
, O O
STAT1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation O O
but O O
weak O O
or O O
no O O
activation O O
of O O
STAT3 B B_GENE
or O O
STAT5 B B_GENE
respectively O O
, O O
could O O
be O O
detected O O
in O O
MB-stimulated O O
MDM O O
. O O

Using O O
MonoMac6 O O
cells O O
, O O
we O O
observed O O
high O O
C/EBPbeta B B_GENE
and O O
AP-1 B B_GENE
but O O
weaker O O
and O O
transient O O
NF-kappaB B B_GENE
activation O O
by O O
MB O O
. O O

Moreover O O
, O O
the O O
truncated O O
form O O
of O O
C/EBPbeta B B_GENE/B_LOCATION
, O O
known O O
to O O
repress O O
HIV-1 O O
transcription O O
, O O
was O O
detected O O
in O O
extracts O O
from O O
MB-treated O O
THP-1 O O
cells O O
. O O

Surprisingly O O
, O O
neither O O
MB O O
nor O O
MDP O O
were O O
able O O
to O O
transduce O O
signals O O
via O O
CD14 B B_GENE/B_LOCATION
and O O
TLR2 B B_GENE
or I I_GENE
4 I I_GENE
. O O

These O O
findings O O
present O O
major O O
differences O O
in O O
the O O
early O O
cell O O
activation O O
process O O
between O O
LPS O O
and O O
muramyl O O
peptides O O
, O O
and O O
strongly O O
argue O O
for O O
the O O
implication O O
of O O
co-receptors B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
other O O
than O O
TLR2 B B_GENE
and O O
TLR4 B B_GENE
in O O
mediating O O
the O O
signaling O O
events O O
induced O O
by O O
defined O O
subunits O O
of O O
bacterial O O
peptidoglycans O O
. O O

Nuclear B B_PERSON/B_GENE
peroxisome I I_PERSON/I_GENE
proliferator-activated I I_PERSON/I_GENE
receptors I I_PERSON/I_GENE
alpha I I_PERSON/I_GENE
and I I_PERSON/I_GENE
gamma I I_PERSON/I_GENE
have O O
opposing O O
effects O O
on O O
monocyte O O
chemotaxis O O
in O O
endometriosis O O
. O O

The O O
peroxisome B B_GENE
proliferator-activated I I_GENE
receptors I I_GENE
( I I_GENE
PPARs I I_GENE
) I I_GENE
alpha I I_GENE
and I I_GENE
gamma I I_GENE
are O O
nuclear B B_GENE
receptors I I_GENE
that O O
play O O
important O O
roles O O
in O O
inflammatory O O
diseases O O
like O O
ulcerative O O
colitis O O
and O O
arthritis O O
. O O

In O O
this O O
study O O
, O O
we O O
examined O O
the O O
possible O O
role O O
of O O
PPARs B B_GENE
in O O
macrophage O O
attraction O O
into O O
the O O
peritoneal O O
cavity O O
of O O
patients O O
with O O
endometriosis O O
. O O

We O O
identified O O
PPAR-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
messenger O O
RNA O O
by O O
RT-PCR O O
and O O
protein O O
by O O
immunoblotting O O
of O O
lysates O O
of O O
peritoneal O O
macrophages O O
and O O
monocytic O O
U937 O O
cells O O
. O O

Using O O
immunocytochemistry O O
, O O
we O O
localized O O
PPAR-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
nuclei O O
of O O
both O O
cell O O
types O O
. O O

Monocyte O O
chemotactic O O
activity O O
of O O
peritoneal O O
fluid O O
from O O
patients O O
with O O
endometriosis O O
was O O
quantified O O
in O O
Boyden O O
chambers O O
. O O

Migration O O
of O O
U937 O O
cells O O
was O O
increased O O
by O O
WY O O
14643 O O
and O O
reduced O O
by O O
rosiglitazone O O
. O O

Peritoneal O O
fluid O O
from O O
patients O O
with O O
endometriosis O O
activated O O
U937 O O
cells O O
transiently O O
transfected O O
with O O
a O O
PPAR-alpha/GAL4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
luciferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

By O O
contrast O O
, O O
peritoneal O O
fluid O O
did O O
not O O
cause O O
significant O O
activation O O
of O O
PPAR-gamma/GAL4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
constructs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
U937 O O
cells O O
transiently O O
transfected O O
with O O
a O O
PPAR B B_GENE
response I I_GENE
element I I_GENE
luciferase I I_GENE
reporter I I_GENE
showed O O
disease O O
stage-dependent O O
up-regulation O O
when O O
treated O O
with O O
peritoneal O O
fluid O O
from O O
patients O O
with O O
endometriosis O O
. O O

We O O
conclude O O
that O O
peritoneal O O
fluid O O
of O O
endometriosis O O
patients O O
contains O O
activators O O
of O O
PPAR-alpha B B_GENE
that O O
stimulate O O
macrophage O O
chemotaxis O O
. O O

Inhibitors O O
of O O
PPAR-alpha B B_GENE/B_DISEASE
or O O
activators O O
of O O
PPAR-gamma B B_GENE
could O O
be O O
developed O O
for O O
the O O
treatment O O
of O O
inflammation O O
associated O O
with O O
endometriosis O O
. O O

Long-term-impaired O O
expression O O
of O O
nuclear B B_GENE
factor-kappa I I_GENE
B I I_GENE
and O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
of O O
trauma O O
patients O O
. O O

Nuclear B B_GENE
factor I I_GENE
( I I_GENE
NF I I_GENE
) I I_GENE
-kappa I I_GENE
B I I_GENE
expression O O
and O O
dimer O O
characteristics O O
were O O
studied O O
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMCs O O
) O O
of O O
major-trauma O O
patients O O
and O O
healthy O O
controls O O
. O O

Analysis O O
of O O
PBMCs O O
on O O
days O O
1 O O
, O O
3 O O
, O O
5 O O
, O O
and O O
10 O O
after O O
trauma O O
revealed O O
that O O
expression O O
of O O
both O O
p65p50 B B_GENE
heterodimers I I_GENE
and O O
p50p50 B B_GENE
homodimers I I_GENE
was O O
significantly O O
reduced O O
compared O O
with O O
that O O
in O O
controls O O
. O O

In O O
vitro O O
lipopolysaccharide O O
( O O
LPS O O
) O O
stimulation O O
of O O
PBMCs O O
induced O O
NF-kappa O O
B O O
translocation O O
. O O

However O O
, O O
throughout O O
the O O
survey O O
, O O
p65p50 O O
activation O O
remained O O
significantly O O
lower O O
in O O
trauma O O
patients O O
than O O
in O O
controls O O
. O O

After O O
LPS O O
stimulation O O
in O O
vitro O O
, O O
the O O
p65p50/p50p50 O O
ratio O O
was O O
significantly O O
lower O O
in O O
PBMCs O O
from O O
trauma O O
patients O O
than O O
from O O
healthy O O
controls O O
. O O

The O O
ex O O
vivo O O
expression O O
of O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
higher O O
in O O
PBMCs O O
of O O
controls O O
than O O
of O O
trauma O O
patients O O
. O O

LPS O O
did O O
not O O
induce O O
I O O
kappa O O
B O O
expression O O
in O O
PBMCs O O
from O O
trauma O O
patients O O
, O O
but O O
strong O O
induction O O
was O O
obtained O O
with O O
staphylococci O O
, O O
suggesting O O
that O O
this O O
defect O O
is O O
not O O
universal O O
and O O
depends O O
on O O
the O O
nature O O
of O O
the O O
activating O O
signal O O
. O O

Although O O
no O O
direct O O
correlation O O
was O O
found O O
between O O
levels O O
of O O
interleukin-10 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
transforming B B_GENE/B_MEASURE
growth I B_GENE/I_MEASURE
factor-beta I B_GENE/I_MEASURE
and O O
NF-kappa B B_GENE/B_DISEASE
B I B_GENE/I_DISEASE
, O O
these O O
immunosuppressive B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokines I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
significantly O O
elevated O O
in O O
trauma O O
patients O O
by O O
10 O O
days O O
after O O
admission O O
. O O

The O O
long-term O O
low-basal O O
and O O
LPS-induced O O
nuclear O O
translocation O O
of O O
NF-kappa B B_GENE
B I I_GENE
recalled O O
long-term O O
immunoparalysis O O
observed O O
in O O
patients O O
with O O
severe O O
inflammatory O O
stress O O
such O O
as O O
trauma O O
. O O

Hepatic O O
ischemia-reperfusion O O
injury O O
. O O

BACKGROUND O O
: O O
The O O
morbidity O O
associated O O
with O O
liver O O
transplantation O O
and O O
major O O
hepatic O O
resections O O
is O O
partly O O
a O O
result O O
of O O
ischemia-reperfusion O O
injury O O
. O O

DATA O O
SOURCES O O
: O O
The O O
entire O O
world O O
literature O O
on O O
the O O
subject O O
was O O
searched O O
via O O
Medline O O
. O O

Keywords O O
included O O
reperfusion O O
injury O O
, O O
transplantation O O
, O O
liver O O
resection O O
, O O
nitric O O
oxide O O
, O O
endothelin O O
, O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
Kupffer O O
cells O O
, O O
ischemic/ischaemic O O
preconditioning O O
, O O
and O O
nuclear B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factor-kappa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

CONCLUSIONS O O
: O O
An O O
imbalance O O
between O O
endothelin O O
and O O
nitric O O
oxide O O
levels O O
results O O
in O O
failure O O
of O O
the O O
hepatic O O
microcirculation O O
at O O
the O O
onset O O
of O O
reperfusion O O
. O O

Activation O O
of O O
nuclear B B_GENE
factor-kappa I I_GENE
B I I_GENE
in O O
the O O
liver O O
promotes O O
proinflammatory B B_DISEASE/B_GENE
cytokine I I_DISEASE/I_GENE
and O O
adhesion B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
molecule I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
synthesis O O
. O O

These O O
result O O
in O O
oxygen-derived O O
free O O
radical O O
production O O
and O O
neutrophil O O
recruitment O O
, O O
further O O
contributing O O
to O O
cellular O O
injury O O
. O O

Various O O
therapeutic O O
modalities O O
acting O O
on O O
the O O
above O O
mediators O O
have O O
been O O
successfully O O
used O O
to O O
attenuate O O
reperfusion O O
injury O O
in O O
animal O O
models O O
of O O
hepatic O O
transplantation O O
and O O
resection O O
. O O

Application O O
of O O
the O O
knowledge O O
gained O O
from O O
animal O O
models O O
of O O
hepatic O O
ischemia-reperfusion O O
to O O
the O O
clinical O O
setting O O
will O O
improve O O
the O O
outcome O O
of O O
hepatic O O
surgery O O
. O O

Down-regulation O O
of O O
IL-12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p40 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Plasmodium O O
berghei-infected O O
mice O O
. O O

We O O
analyzed O O
the O O
mechanism O O
that O O
causes O O
suppression O O
of O O
IL-12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p40 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induction O O
during O O
Plasmodium O O
berghei O O
infection O O
. O O

Although O O
IL-12 B B_GENE
together O O
with O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plays O O
an O O
important O O
role O O
in O O
protection O O
against O O
pathogenic O O
infection O O
, O O
the O O
IL-12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p70 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
production O O
of O O
infected O O
macrophages O O
is O O
lower O O
than O O
that O O
by O O
the O O
uninfected O O
macrophages O O
. O O

We O O
showed O O
in O O
the O O
present O O
study O O
that O O
the O O
induction O O
of O O
IL-12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p40 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
but O O
not O O
IL-12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p35 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
macrophages O O
of O O
P. O O
berghei-infected O O
mice O O
was O O
profoundly O O
inhibited O O
. O O

The O O
inhibition O O
was O O
induced O O
by O O
interaction O O
with O O
macrophages O O
that O O
had O O
contacted O O
with O O
P. O O
berghei-infected O O
erythrocytes O O
and O O
was O O
mediated O O
by O O
a O O
soluble O O
factor O O
, O O
IL-10 B B_GENE
. O O

There O O
was O O
comparable O O
activation O O
of O O
NF-kappaB B B_GENE
in O O
uninfected O O
and O O
infected O O
cells O O
. O O

The O O
induction O O
of O O
IFN-regulatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
comparable O O
in O O
transcription O O
level O O
in O O
uninfected O O
and O O
infected O O
cells O O
, O O
while O O
the O O
unidentified O O
complex O O
formation O O
of O O
IFN-regulatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
in O O
infected O O
cells O O
. O O

Therefore O O
, O O
the O O
inhibition O O
of O O
the O O
IL-12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p40 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induction O O
appeared O O
to O O
be O O
regulated O O
at O O
transcriptional O O
regulation O O
level O O
of O O
the O O
gene O O
. O O

The O O
Friend B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GATA I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
U-shaped O O
, O O
FOG-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
FOG-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O O
as O O
negative O O
regulators O O
of O O
blood O O
, O O
heart O O
, O O
and O O
eye O O
development O O
in O O
Drosophila O O
. O O

Friend B B_PERSON/B_GENE
of I I_PERSON/I_GENE
GATA I I_PERSON/I_GENE
( I I_PERSON/I_GENE
FOG I I_PERSON/I_GENE
) I I_PERSON/I_GENE
proteins I I_PERSON/I_GENE
regulate O O
GATA O O
factor-activated O O
gene O O
transcription O O
. O O

During O O
vertebrate O O
hematopoiesis O O
, O O
FOG B B_BIO/B_GENE
and I I_BIO/I_GENE
GATA I I_BIO/I_GENE
proteins I I_BIO/I_GENE
cooperate O O
to O O
promote O O
erythrocyte O O
and O O
megakaryocyte O O
differentiation O O
. O O

The O O
Drosophila B B_GENE
FOG I I_GENE
homologue I I_GENE
U-shaped I I_GENE
( O O
Ush B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
expressed O O
similarly O O
in O O
the O O
blood O O
cell O O
anlage O O
during O O
embryogenesis O O
. O O

During O O
hematopoiesis O O
, O O
the O O
acute O O
myeloid O O
leukemia O O
1 O O
homologue O O
Lozenge O O
and O O
Glial O O
cells O O
missing O O
are O O
required O O
for O O
the O O
production O O
of O O
crystal O O
cells O O
and O O
plasmatocytes O O
, O O
respectively O O
. O O

However O O
, O O
additional O O
factors O O
have O O
been O O
predicted O O
to O O
control O O
crystal O O
cell O O
proliferation O O
. O O

Furthermore O O
, O O
loss O O
of O O
ush O O
function O O
results O O
in O O
an O O
overproduction O O
of O O
crystal O O
cells O O
, O O
whereas O O
forced O O
expression O O
of O O
Ush B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O O
this O O
cell O O
population O O
. O O

Murine B B_PERSON/B_GENE
FOG-1 I I_PERSON/I_GENE
and I I_PERSON/I_GENE
FOG-2 I I_PERSON/I_GENE
also O O
can O O
repress O O
crystal O O
cell O O
production O O
, O O
but O O
a O O
mutant O O
version O O
of O O
FOG-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacking O O
a O O
conserved O O
motif O O
that O O
binds O O
the O O
corepressor B B_GENE/B_LOCATION
C-terminal I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
fails O O
to O O
affect O O
the O O
cell O O
lineage O O
. O O

The O O
GATA B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Pannier I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Pnr B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
required O O
for O O
eye O O
and O O
heart O O
development O O
in O O
Drosophila O O
. O O

When O O
Ush B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O O
FOG-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
FOG-2 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
or O O
mutant B B_GENE/B_PERSON
FOG-2 I I_GENE/I_PERSON
is O O
coexpressed O O
with O O
Pnr B B_GENE/B_PERSON
during O O
these O O
developmental O O
processes O O
, O O
severe O O
eye O O
and O O
heart O O
phenotypes O O
result O O
, O O
consistent O O
with O O
a O O
conserved O O
negative O O
regulation O O
of O O
Pnr B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
function O O
. O O

These O O
results O O
indicate O O
that O O
the O O
fly O O
and O O
mouse O O
FOG B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
function O O
similarly O O
in O O
three O O
distinct O O
cellular O O
contexts O O
in O O
Drosophila O O
, O O
but O O
may O O
use O O
different O O
mechanisms O O
to O O
regulate O O
genetic O O
events O O
in O O
blood O O
vs O O
. O O
cardial O O
or O O
eye O O
cell O O
lineages O O

The O O
RING B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finger I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Siah-1 B I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulates O O
the O O
level O O
of O O
the O O
transcriptional B B_GENE
coactivator I I_GENE
OBF-1 B I_GENE
. O O

The O O
transcriptional B B_GENE/B_MEASURE
coactivator I I_GENE/I_MEASURE
OBF-1 B I_GENE/I_MEASURE
, O O
which O O
interacts O O
with O O
Oct-1 B B_GENE
and O O
Oct-2 B B_GENE
and O O
the O O
octamer B B_GENE/B_BIO
site I I_GENE/I_BIO
DNA I I_GENE/I_BIO
, O O
has O O
been O O
shown O O
to O O
be O O
critical O O
for O O
development O O
of O O
a O O
normal O O
immune O O
response O O
and O O
the O O
formation O O
of O O
germinal O O
centers O O
in O O
secondary O O
lymphoid O O
organs O O
. O O

Here O O
we O O
have O O
identified O O
the O O
RING B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finger I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Siah-1 B I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
protein O O
interacting O O
specifically O O
with O O
OBF-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Interaction O O
between O O
Siah-1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
OBF-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leads O O
to O O
downregulation O O
of O O
OBF-1 O O
protein O O
level O O
but O O
not O O
mRNA O O
, O O
and O O
to O O
a O O
corresponding O O
reduction O O
in O O
octamer O O
site-dependent O O
transcription O O
activation O O
. O O

Inhibition O O
of O O
the O O
ubiquitin-proteasome O O
pathway O O
in O O
B O O
cells O O
leads O O
to O O
elevated O O
levels O O
of O O
OBF-1 B B_GENE
protein I I_GENE
. O O

Furthermore O O
, O O
in O O
immunized O O
mice O O
, O O
OBF-1 B B_GENE/B_MEASURE
protein I I_GENE/I_MEASURE
amounts O O
are O O
dramatically O O
increased O O
in O O
primary O O
activated O O
B O O
cells O O
, O O
without O O
concomitant O O
increase O O
in O O
OBF-1 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mRNA I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
data O O
suggest O O
that O O
Siah-1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
part O O
of O O
a O O
novel O O
regulatory O O
loop O O
controlling O O
the O O
level O O
of O O
OBF-1 B B_GENE
protein I I_GENE
in O O
B O O
cells O O
. O O

The O O
association O O
of O O
trans-acting B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TCFs B B_GENE/B_LOCATION
) O O
or O O
lymphoid B B_GENE/B_BIO
enhancer I I_GENE/I_BIO
factor I I_GENE/I_BIO
1 I I_GENE/I_BIO
( O O
LEF-1 B B_GENE/B_LOCATION
) O O
with O O
their O O
coactivator O O
beta-catenin O O
mediates O O
transient O O
transcriptional O O
responses O O
to O O
extracellular O O
Wnt O O
signals O O
. O O

We O O
show O O
here O O
that O O
T O O
cell O O
maturation O O
depends O O
on O O
the O O
presence O O
of O O
the O O
beta-catenin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Accelerated O O
spontaneous O O
thymocyte O O
death O O
in O O
the O O
absence O O
of O O
TCF-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
correlates O O
with O O
aberrantly O O
low O O
expression O O
of O O
the O O
anti-apoptotic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Bcl-x B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
L I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Increasing O O
anti-apoptotic O O
effectors O O
in O O
thymocytes O O
by O O
the O O
use O O
of O O
a O O
Bcl-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transgene I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rescued O O
TCF-1-deficient O O
DP O O
thymocytes O O
from O O
apoptosis O O
. O O

Thus O O
, O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
upon O O
association O O
with O O
beta-catenin O O
, O O
transiently O O
ensures O O
the O O
survival O O
of O O
immature O O
T O O
cells O O
, O O
which O O
enables O O
them O O
to O O
generate O O
and O O
edit O O
T B B_GENE
cell I I_GENE
receptor I I_GENE
( I I_GENE
TCR I I_GENE
) I I_GENE
alpha I I_GENE
chains I I_GENE
and O O
attempt O O
TCR B B_GENE
-mediated O O
positive O O
selection O O
. O O

TRAIL/Apo2L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligand I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
selectively O O
induces O O
apoptosis O O
and O O
overcomes O O
drug O O
resistance O O
in O O
multiple O O
myeloma O O
: O O
therapeutic O O
applications O O
. O O

Multiple O O
myeloma O O
( O O
MM O O
) O O
remains O O
incurable O O
and O O
novel O O
treatments O O
are O O
urgently O O
needed O O
. O O

Preclinical O O
in O O
vitro O O
and O O
in O O
vivo O O
evaluations O O
were O O
performed O O
to O O
assess O O
the O O
potential O O
therapeutic O O
applications O O
of O O
human O O
recombinant O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TNF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
apoptosis-inducing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ligand/Apo2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ligand I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TRAIL/Apo2L B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
MM O O
. O O

TRAIL/Apo2L B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
potently O O
induced O O
apoptosis O O
of O O
MM O O
cells O O
from O O
patients O O
and O O
the O O
majority O O
of O O
MM O O
cell O O
lines O O
, O O
including O O
cells O O
sensitive O O
or O O
resistant O O
to O O
dexamethasone O O
( O O
Dex O O
) O O
, O O
doxorubicin O O
( O O
Dox O O
) O O
, O O
melphalan O O
, O O
and O O
mitoxantrone O O
. O O

The O O
status O O
of O O
the O O
TRAIL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
assessed O O
by O O
immunoblotting O O
and O O
flow O O
cytometry O O
) O O
could O O
not O O
predict O O
TRAIL O O
sensitivity O O
of O O
MM O O
cells O O
. O O

The O O
anti-MM O O
activity O O
of O O
TRAIL/Apo2L B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
confirmed O O
in O O
nu/xid/bg O O
mice O O
xenografted O O
with O O
human O O
MM O O
cells O O
; O O
TRAIL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
500 O O
microg O O
intraperitoneally O O
daily O O
for O O
14 O O
days O O
) O O
was O O
well O O
tolerated O O
and O O
significantly O O
suppressed O O
the O O
growth O O
of O O
plasmacytomas O O
. O O

Dox O O
up-regulated O O
the O O
expression O O
of O O
the O O
TRAIL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
death B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DR5 B B_GENE
) O O
and O O
synergistically O O
enhanced O O
the O O
effect O O
of O O
TRAIL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
not O O
only O O
against O O
MM O O
cells O O
sensitive O O
to O O
, O O
but O O
also O O
against O O
those O O
resistant O O
to O O
, O O
Dex- O O
or O O
Dox-induced O O
apoptosis O O
. O O

Importantly O O
, O O
normal O O
B O O
lymphocytes O O
were O O
not O O
sensitized O O
to O O
TRAIL B B_GENE/B_DISEASE
by O O
either O O
Dox O O
, O O
SN50 O O
, O O
or O O
PS-341 O O
. O O

( O O
Blood. O O
2001 O O
; O O
98 O O
: O O
795-804 O O
) O O

CD28 B B_GENE
costimulation O O
is O O
required O O
not O O
only O O
to O O
induce O O
IL-12 B B_GENE/B_DISEASE
receptor I I_GENE/I_DISEASE
but O O
also O O
to O O
render O O
janus B B_PERSON/B_GENE
kinases/STAT4 I I_PERSON/I_GENE
responsive O O
to O O
IL-12 B B_GENE
stimulation O O
in O O
TCR-triggered O O
T O O
cells O O
. O O

Here O O
, O O
we O O
investigated O O
how O O
CD28 O O
costimulation O O
functions O O
to O O
allow O O
TCR B B_GENE/B_DISEASE
-triggered O O
resting O O
T O O
cells O O
to O O
acquire O O
IL-12 B B_GENE/B_MEASURE
responsiveness O O
. O O

When O O
T O O
cells O O
are O O
stimulated O O
with O O
low O O
doses O O
of O O
anti-CD3 B B_GENE
mAb I I_GENE
, O O
CD28 O O
costimulation O O
was O O
required O O
for O O
the O O
optimal O O
levels O O
of O O
IL-12 B B_GENE
receptor I I_GENE
( O O
IL-12R B B_PROTEIN[GENE]/B_LOCATION
) O O
expression O O
. O O

However O O
, O O
stimulation O O
of O O
T O O
cells O O
with O O
high O O
doses O O
of O O
anti-CD3 B B_GENE
alone O O
induced O O
comparable O O
levels O O
of O O
IL-12R B B_GENE
expression O O
to O O
those O O
induced O O
upon O O
CD28 O O
costimulation O O
. O O

Nevertheless O O
, O O
there O O
was O O
a O O
substantial O O
difference O O
in O O
IL-12 B B_GENE/B_PERSON
responsiveness O O
between O O
these O O
two O O
groups O O
of O O
T O O
cells O O
: O O
compared O O
to O O
anti-CD28-costimulated O O
T O O
cells O O
, O O
T O O
cells O O
that O O
were O O
not O O
costimulated O O
with O O
anti-CD28 B B_GENE
exhibited O O
decreased O O
levels O O
of O O
Janus B B_GENE
kinases I I_GENE
( O O
JAK B B_GENE
) O O
JAK2/TYK2 B B_GENE/B_MEASURE
and O O
STAT4 B B_GENE
phosphorylation O O
and O O
IFN-y O O
production O O
following O O
IL-12 B B_GENE
stimulation O O
. O O

Constitutively O O
activated O O
Akt-1 B B_GENE
is O O
vital O O
for O O
the O O
survival O O
of O O
human O O
monocyte-differentiated O O
macrophages O O
. O O

Role O O
of O O
Mcl-1 B B_GENE
, O O
independent O O
of O O
nuclear B B_GENE
factor I I_GENE
( I I_GENE
NF I I_GENE
) I I_GENE
-kappaB I I_GENE
, O O
Bad B B_GENE
, O O
or O O
caspase O O
activation O O
. O O

Here O O
, O O
we O O
focused O O
on O O
the O O
role O O
of O O
the O O
PI3K-regulated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serine/threonine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Akt-1 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
modulating O O
macrophage O O
survival O O
. O O

Akt-1 B B_GENE
was O O
constitutively O O
activated O O
in O O
human O O
macrophages O O
and O O
addition O O
of O O
the O O
PI3K B B_GENE
inhibitor O O
, O O
LY294002 O O
, O O
suppressed O O
the O O
activation O O
of O O
Akt-1 B B_GENE
and O O
induced O O
cell O O
death O O
. O O

Furthermore O O
, O O
suppression O O
of O O
Akt-1 B B_GENE
by O O
inhibition O O
of O O
PI3K B B_GENE
or O O
a O O
dominant B B_GENE
negative I I_GENE
( I I_GENE
DN I I_GENE
) I I_GENE
Akt-1 I I_GENE
resulted O O
in O O
loss O O
of O O
mitochondrial O O
transmembrane O O
potential O O
, O O
activation O O
of O O
caspases-9 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
DNA O O
fragmentation O O
. O O

The O O
effects O O
of O O
PI3K B B_GENE
inhibition O O
were O O
reversed O O
by O O
the O O
ectopic O O
expression O O
of O O
constitutively O O
activated O O
Akt-1 B B_GENE
or O O
Bcl-x B B_GENE
( I I_GENE
L I I_GENE
) I I_GENE
. O O

Inhibition O O
of O O
PI3K B B_GENE
/Akt-1 O O
pathway O O
either O O
by O O
LY294002 O O
or O O
DN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Akt-1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
had O O
no O O
effect O O
on O O
the O O
constitutive O O
or O O
inducible O O
activation O O
of O O
nuclear B B_GENE
factor I I_GENE
( I I_GENE
NF I I_GENE
) I I_GENE
-kappaB I I_GENE
in O O
human O O
macrophages O O
. O O

Further O O
, O O
inhibition O O
of O O
Mcl-1 B B_GENE
by O O
antisense O O
oligonucleotides O O
, O O
also O O
resulted O O
in O O
macrophage O O
apoptosis O O
. O O

Thus O O
, O O
our O O
findings O O
demonstrate O O
that O O
the O O
constitutive O O
activation O O
of O O
Akt-1 B B_GENE
regulates O O
macrophage O O
survival O O
through O O
Mcl-1 B B_GENE/B_DISEASE
, O O
which O O
is O O
independent O O
of O O
caspases B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
NF-kappaB B B_GENE
, O O
or O O
Bad B B_GENE
. O O

BACKGROUND O O
: O O
Nasal O O
polyposis O O
disease O O
is O O
an O O
inflammatory O O
disorder O O
with O O
intense O O
eosinophilic O O
infiltration O O
of O O
respiratory O O
mucosa O O
that O O
is O O
often O O
difficult O O
to O O
control O O
with O O
topical O O
steroids O O
. O O

Recent O O
evidence O O
suggests O O
that O O
overexpression O O
of O O
the O O
glucocorticoid B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
splice I I_GENE/I_LOCATION
variant I I_GENE/I_LOCATION
GRbeta B I_GENE/I_LOCATION
in O O
inflammatory O O
cells O O
might O O
contribute O O
to O O
steroid O O
insensitivity O O
in O O
diseases O O
such O O
as O O
asthma O O
. O O

OBJECTIVE O O
: O O
The O O
purposes O O
of O O
this O O
investigation O O
were O O
to O O
determine O O
whether O O
nasal O O
polyp O O
( O O
NP O O
) O O
inflammatory O O
cells O O
overexpress O O
GRbeta B B_GENE
and O O
to O O
examine O O
whether O O
GRbeta B B_GENE/B_PERSON
overexpression O O
is O O
associated O O
with O O
insensitivity O O
to O O
the O O
potent O O
topical O O
steroid O O
fluticasone O O
propionate O O
( O O
FP O O
) O O
. O O

METHODS O O
: O O
Biopsies O O
were O O
obtained O O
from O O
10 O O
subjects O O
with O O
NPs O O
before O O
and O O
4 O O
weeks O O
after O O
treatment O O
with O O
intranasal O O
FP O O
. O O

Middle O O
turbinates O O
biopsies O O
from O O
6 O O
healthy O O
, O O
nonallergic O O
subjects O O
served O O
as O O
normal O O
controls O O
. O O

Biopsies O O
were O O
immunostained O O
for O O
inflammatory O O
cell O O
markers O O
as O O
well O O
as O O
GRbeta B B_GENE
and O O
probed O O
for O O
various O O
cytokine B B_GENE
mRNA I I_GENE
. O O

RESULTS O O
: O O
The O O
total O O
numbers O O
of O O
inflammatory O O
cells O O
were O O
increased O O
in O O
NPs O O
. O O

The O O
percentage O O
of O O
inflammatory O O
cells O O
expressing O O
GRbeta B B_GENE
was O O
also O O
increased O O
( O O
40.5 O O
% O O
+/- O O
19.2 O O
% O O
vs O O
16.1 O O
% O O
+/- O O
4.0 O O
% O O
, O O
P O O
=.009 O O
) O O
. O O

GRbeta B B_GENE
expression O O
in O O
NPs O O
was O O
almost O O
exclusive O O
to O O
T O O
lymphocytes O O
, O O
eosinophils O O
, O O
and O O
macrophages O O
. O O

An O O
inverse O O
correlation O O
was O O
observed O O
between O O
the O O
baseline O O
inflammatory O O
cell O O
GRbeta B B_GENE/B_MEASURE
expression O O
and O O
the O O
reduction O O
after O O
FP O O
treatment O O
in O O
EG2-positive O O
eosinophils O O
, O O
CD4-positive O O
T O O
lymphocytes O O
, O O
endothelial O O
VCAM-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
, O O
and O O
IL-4 O O
mRNA-positive O O
cells O O
. O O

NPs O O
that O O
were O O
`` O O
FP-insensitive O O
'' O O
in O O
terms O O
of O O
suppression O O
of O O
eosinophil O O
numbers O O
( O O
major B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
basic I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
-positive O O
) O O
had O O
a O O
significantly O O
greater O O
percentage O O
of O O
GRbeta-positive O O
inflammatory O O
cells O O
, O O
a O O
higher O O
ratio O O
of O O
GRbeta-positive/GRalpha-positive O O
cells O O
, O O
and O O
increased O O
numbers O O
of O O
GRbeta-positive O O
eosinophils O O
and O O
macrophages O O
in O O
comparison O O
with O O
those O O
that O O
were O O
`` O O
FP-sensitive. O O
'' O O

`` O O
FP-insensitive O O
'' O O
NPs O O
also O O
demonstrated O O
a O O
higher O O
percentage O O
of O O
IL-5-positive O O
inflammatory O O
cells O O
expressing O O
GRbeta B B_GENE
before O O
and O O
after O O
FP O O
treatment O O
. O O

CONCLUSION O O
: O O
GRbeta B B_GENE/B_LOCATION
expression O O
appears O O
to O O
be O O
a O O
marker O O
of O O
steroid O O
insensitivity O O
in O O
NPs O O
. O O

Expression O O
of O O
GRbeta B B_GENE
by O O
NP O O
inflammatory O O
cells O O
, O O
particularly O O
T O O
cells O O
and O O
eosinophils O O
, O O
might O O
render O O
them O O
resistant O O
to O O
suppression O O
by O O
topical O O
steroids O O
and O O
thereby O O
contribute O O
to O O
persistent O O
NP O O
inflammation O O
. O O

Transcriptional O O
regulation O O
of O O
galectin-10 B B_GENE/B_DISEASE
( O O
eosinophil B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Charcot-Leyden I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
crystal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
: O O
a O O
GC B B_GENE/B_LOCATION
box I B_GENE/I_LOCATION
( O O
-44 O O
to O O
-50 O O
) O O
controls O O
butyric O O
acid O O
induction O O
of O O
gene O O
expression O O
. O O

To O O
gain O O
a O O
better O O
understanding O O
of O O
galectin O O
gene O O
expression O O
, O O
we O O
present O O
an O O
analysis O O
of O O
the O O
transcriptional O O
regulation O O
of O O
the O O
gene O O
encoding O O
gal-10 B B_GENE
. O O

By O O
supershift O O
analysis O O
, O O
we O O
demonstrate O O
binding O O
of O O
the O O
transcription B B_GENE
factors I I_GENE
Sp1 B I_GENE
and O O
Oct1 B B_GENE/B_LOCATION
to O O
the O O
consensus B B_GENE/B_LOCATION
GC I I_GENE/I_LOCATION
box I I_GENE/I_LOCATION
and O O
the O O
Oct B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
. O O

Similar O O
to O O
gal-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
gal-10 O O
expression O O
is O O
induced O O
by O O
butyric O O
acid O O
, O O
an O O
effect O O
that O O
is O O
lost O O
upon O O
ablation O O
of O O
the O O
GC B B_GENE
box I I_GENE
. O O

Additionally O O
, O O
we O O
demonstrate O O
AML3 O O
binding O O
to O O
the O O
consensus B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AML I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
YY1 B B_TIME[MEASURE]/B_GENE
binding I I_TIME[MEASURE]/I_GENE
to O O
the O O
Inr B B_LOCATION/B_GENE
sequence I I_LOCATION/I_GENE
, O O
both O O
elements O O
functioning O O
as O O
silencers O O
in O O
the O O
gal-10 B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
promoter I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Tumour-stromal O O
interactions O O
. O O

Role O O
of O O
the O O
stroma O O
in O O
mammary O O
development O O
. O O

Because O O
breast O O
carcinomas O O
are O O
overwhelmingly O O
ductal O O
in O O
origin O O
, O O
this O O
review O O
focuses O O
on O O
stromal O O
influences O O
guiding O O
postnatal O O
ductal O O
development O O
and O O
there O O
is O O
only O O
the O O
briefest O O
account O O
of O O
the O O
role O O
of O O
embryonic O O
stroma O O
( O O
mesenchyme O O
) O O
. O O

The O O
stroma O O
as O O
the O O
necessary O O
target O O
for O O
endocrine O O
mammogens O O
and O O
the O O
source O O
of O O
stimulatory O O
growth O O
factors O O
is O O
described O O
and O O
the O O
importance O O
of O O
mammary O O
epithelium-induced O O
modifications O O
of O O
the O O
periductal O O
stroma O O
is O O
emphasized O O
. O O

The O O
induction O O
of O O
a O O
fibrous O O
stromal O O
tunic O O
around O O
the O O
end O O
bud O O
is O O
described O O
and O O
its O O
likely O O
role O O
as O O
a O O
complex O O
ductal O O
morphogen O O
is O O
discussed O O
; O O
a O O
possible O O
role O O
in O O
growth O O
inhibition O O
is O O
also O O
considered O O
. O O

Although O O
the O O
signals O O
governing O O
fibrotic O O
induction O O
, O O
ductal O O
morphogenesis O O
, O O
and O O
growth O O
inhibition O O
are O O
unknown O O
, O O
a O O
role O O
for O O
transforming O O
growth B B_GENE
factor-beta I I_GENE
is O O
highly O O
likely O O
and O O
is O O
discussed O O
. O O

Finally O O
, O O
a O O
need O O
for O O
new O O
conceptual O O
and O O
experimental O O
approaches O O
to O O
understanding O O
stromal-epithelial O O
signaling O O
is O O
discussed O O
. O O

Adipophilin B B_GENE
is O O
a O O
sensitive O O
marker O O
for O O
lipid O O
loading O O
in O O
human O O
blood O O
monocytes O O
. O O

Adipophilin B B_GENE
, O O
a O O
marker O O
of O O
lipid O O
accumulation O O
initially O O
described O O
in O O
adipocytes O O
, O O
was O O
recently O O
shown O O
to O O
be O O
induced O O
in O O
macrophage O O
foam O O
cells O O
. O O

We O O
found O O
that O O
even O O
freshly O O
isolated O O
blood O O
monocytes O O
express O O
adipophilin B B_GENE
and O O
that O O
the O O
amount O O
of O O
adipophilin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
variable O O
in O O
monocytes O O
from O O
different O O
healthy O O
individuals O O
. O O

However O O
, O O
the O O
physiological O O
expression O O
of O O
adipophilin B B_GENE/B_DISEASE
does O O
not O O
correlate O O
with O O
the O O
levels O O
of O O
free O O
fatty O O
acids O O
, O O
cholesterylesters O O
or O O
free O O
cholesterol O O
. O O

Enzymatically B B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
modified I I_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
low-density I I_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
lipoprotein I I_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
( O O
E-LDL B B_PROTEIN[GENE]/B_LOCATION
) O O
induces O O
rapid O O
foam O O
cell O O
formation O O
in O O
monocytes O O
and O O
upregulates O O
adipophilin B B_GENE
mRNA O O
and O O
protein O O
within O O
2 O O
h O O
of O O
incubation O O
. O O

This O O
rapid O O
induction O O
of O O
adipophilin B B_GENE
is O O
accompanied O O
by O O
a O O
significant O O
increase O O
of O O
free O O
fatty O O
acids O O
in O O
monocytes O O
incubated O O
with O O
E-LDL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Adipophilin B B_GENE/B_DISEASE
facilitates O O
the O O
uptake O O
of O O
free O O
fatty O O
acids O O
, O O
and O O
here O O
we O O
demonstrate O O
that O O
free O O
fatty O O
acids O O
increase O O
is O O
related O O
to O O
the O O
early O O
upregulation O O
of O O
adipophilin O O
expression O O
in O O
blood O O
monocytes O O
. O O

Fatty O O
acids O O
are O O
ligands O O
for O O
peroxisome B B_GENE/B_LOCATION
proliferator-activated I I_GENE/I_LOCATION
receptor-gamma I I_GENE/I_LOCATION
( O O
PPARgamma B B_GENE
) O O
, O O
and O O
the O O
upregulation O O
of O O
adipophilin B B_GENE
mRNA I I_GENE
by O O
PPARgamma B B_GENE
agonists O O
like O O
15d-PGJ O O
( O O
2 O O
) O O
and O O
ciglitazone O O
indicates O O
that O O
PPARgamma B B_GENE/B_PERSON
may O O
mediate O O
the O O
induction O O
of O O
adipophilin O O
expression O O
in O O
human O O
blood O O
monocytes O O
. O O

Constitutive O O
expression O O
of O O
MHC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
melanoma O O
cell O O
lines O O
results O O
from O O
the O O
transcription O O
of O O
class B B_GENE/B_LOCATION
II I I_GENE/I_LOCATION
transactivator I I_GENE/I_LOCATION
abnormally O O
initiated O O
from O O
its O O
B B B_GENE/B_PERSON
cell-specific I I_GENE/I_PERSON
promoter I I_GENE/I_PERSON
. O O

In O O
melanoma O O
cell O O
lines O O
, O O
two O O
different O O
patterns O O
of O O
MHC O O
class O O
II O O
expression O O
have O O
been O O
described O O
, O O
either O O
an O O
IFN O O
gamma-inducible O O
expression O O
of O O
HLA-DR B B_GENE
and O O
HLA-DP B B_PROTEIN[GENE]/B_LOCATION
, O O
with O O
a O O
faint O O
or O O
null O O
expression O O
of O O
HLA-DQ B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
resembling O O
that O O
described O O
for O O
melanocytes O O
, O O
or O O
a O O
constitutive O O
expression O O
, O O
i.e. O O
, O O
IFN-gamma O O
independent O O
, O O
of O O
all O O
three O O
HLA-D B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isotypes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
this O O
latter O O
phenotype O O
has O O
been O O
associated O O
with O O
a O O
more O O
rapid O O
progression O O
of O O
melanoma O O
tumors O O
, O O
we O O
have O O
analyzed O O
in O O
different O O
melanoma O O
cell O O
lines O O
the O O
molecular O O
mechanisms O O
leading O O
to O O
this O O
abnormal O O
pattern O O
of O O
MHC O O
class O O
II O O
expression O O
. O O

Unexpectedly O O
, O O
these O O
transcripts O O
initiate O O
from O O
promoter B B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_LOCATION
III I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_LOCATION
of O O
the O O
CIITA B B_GENE
gene I I_GENE
, O O
a O O
promoter O O
that O O
is O O
mainly O O
used O O
constitutively O O
in O O
B O O
lymphocytes O O
. O O

This O O
expression O O
was O O
further O O
shown O O
to O O
occur O O
through O O
factor O O
( O O
s O O
) O O
acting O O
on O O
the O O
enhancer O O
located O O
upstream O O
of O O
CIITA B B_GENE
promoter I I_GENE
III I I_GENE
, O O
which O O
was O O
previously O O
described O O
in O O
epithelioid O O
cells O O
as O O
an O O
IFN-gamma-response O O
sequence O O
. O O

The O O
hypothesis O O
of O O
a O O
general O O
abnormality O O
of O O
the O O
IFN-gamma O O
transduction O O
pathway O O
was O O
dismissed O O
. O O

Constitutive O O
transcription O O
of O O
CIITA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
promoter B B_GENE
III I I_GENE
having O O
been O O
observed O O
in O O
unrelated O O
melanoma O O
cell O O
lines O O
, O O
we O O
propose O O
the O O
hypothesis O O
that O O
this O O
phenomenon O O
might O O
not O O
be O O
a O O
random O O
event O O
, O O
but O O
could O O
be O O
linked O O
to O O
the O O
neoplasic O O
state O O
of O O
the O O
melanoma O O
cells O O

Caspase B B_GENE
-mediated O O
calcineurin O O
activation O O
contributes O O
to O O
IL-2 B B_GENE
release O O
during O O
T O O
cell O O
activation O O
. O O

Calcineurin B B_GENE
, O O
a O O
Ca B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2+ I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/calmodulin-dependent I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Ser/Thr I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2B I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
plays O O
a O O
critical O O
role O O
in O O
IL-2 O O
production O O
during O O
T O O
cell O O
activation O O
. O O

It O O
has O O
been O O
previously O O
reported O O
that O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release O O
in O O
activated O O
Jurkat O O
T O O
requires O O
caspase-like O O
activity O O
( O O
Posmantur O O
et O O
al. O O
( O O
1998 O O
) O O
Exp. O O
Cell. O O
Res. O O
244 O O
, O O
302-309 O O
) O O
. O O

We O O
report O O
here O O
that O O
the O O
60-kDa B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
catalytic I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
calcineurin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Cn B B_LOCATION/B_PROTEIN[GENE]
A I I_LOCATION/I_PROTEIN[GENE]
) O O
was O O
partially O O
cleaved O O
to O O
a O O
45-kDa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
form O O
in O O
phytohemagglutinin O O
A O O
( O O
PHA O O
) O O
or O O
phorbol O O
ester O O
+ O O
ionomycin O O
( O O
P O O
+ O O
I O O
) O O
-activated O O
Jurkat O O
cells O O
. O O

In O O
parallel O O
, O O
proteolytic O O
activation O O
of O O
upstream O O
caspases B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
caspase-8 O O
and O O
-9 O O
) O O
as O O
well O O
as O O
effector B B_GENE
caspase-3 I I_GENE
was O O
also O O
observed O O
. O O

Cn B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cleavage O O
was O O
caspase O O
mediated O O
, O O
since O O
it O O
was O O
inhibitable O O
by O O
pan-caspase O O
inhibitor O O
Cbz-Asp-CH O O
( O O
2 O O
) O O
OC O O
( O O
O O O
) O O
-2 O O
, O O
6-dichlorobenzene O O
( O O
Z-D-DCB O O
) O O
. O O

Cn B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
A I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cleavage O O
was O O
also O O
observed O O
when O O
purified O O
calcineurin B B_GENE/B_DISEASE
was O O
digested O O
in O O
vitro O O
with O O
caspase-3 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
in O O
PHA O O
or O O
P O O
+ O O
I-activated O O
Jurkat O O
cells O O
, O O
dephosphorylation O O
of O O
calcineurin B B_GENE
substrate O O
NFATc B B_GENE
( O O
a O O
transcription B B_ENZYME[GENE]/B_MEASURE
factor I I_ENZYME[GENE]/I_MEASURE
known O O
to O O
be O O
involved O O
in O O
transactivation O O
of O O
the O O
IL-2 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
) O O
, O O
was O O
also O O
suppressed O O
by O O
Z-D-DCB O O
. O O

Taken O O
together O O
, O O
our O O
results O O
suggest O O
that O O
caspase-mediated O O
cleavage O O
of O O
Cn B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contributes O O
to O O
IL-2 O O
production O O
during O O
T O O
cell O O
activation O O
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

AIM O O
: O O
Sulfasalazine O O
, O O
a O O
nonsteroidal O O
anti-inflammatory O O
drug O O
, O O
is O O
effective O O
in O O
treating O O
some O O
autoimmune O O
diseases O O
, O O
but O O
its O O
mechanism O O
of O O
action O O
is O O
unclear O O
. O O

METHODS O O
: O O
We O O
prepared O O
immature O O
dendritic O O
cells O O
by O O
incubating O O
CD14-positive O O
cells O O
in O O
the O O
presence O O
of O O
granulocyte- B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
macrophage I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IL I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
cells O O
were O O
matured O O
by O O
addition O O
of O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TNF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-a I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
IL-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
presence O O
of O O
sulfasalazine O O
or O O
its O O
metabolites O O
-- O O
aminosalicylate O O
and O O
sulfapyridine O O
, O O
or O O
their O O
combinations O O
. O O

We O O
quantified O O
the O O
effect O O
of O O
drugs O O
on O O
the O O
dendritic O O
cell O O
characteristics O O
, O O
such O O
as O O
stimulation O O
of O O
autologous O O
and O O
allogeneic O O
pan-T O O
cell O O
proliferation O O
, O O
surface O O
marker O O
phenotype O O
, O O
IL-12 O O
p40 O O
subunit O O
secretion O O
, O O
and O O
activation O O
of O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O O
: O O
Dendritic O O
cells O O
treated O O
with O O
sulfasalazine O O
( O O
1.25 O O
micromol/L O O
or O O
2.5 O O
micromol/L O O
) O O
could O O
not O O
stimulate O O
T O O
cells O O
( O O
p O O
< O O
0.028 O O
, O O
two-sided O O
paired O O
t-test O O
) O O
. O O

In O O
distinction O O
to O O
drug-free O O
maturing O O
dendritic O O
cells O O
, O O
2.5 O O
micromol/L O O
sulfasalazine O O
upregulated O O
the O O
levels O O
of O O
CD14 B B_GENE
and O O
CD68 B B_GENE
and O O
downregulated O O
the O O
levels O O
of O O
CD40 B B_GENE
, O O
CD80 B B_GENE
, O O
and O O
CD83 B B_GENE
( O O
for O O
all O O
CD O O
markers O O
, O O
p O O
< O O
0.03 O O
for O O
difference O O
between O O
measurements O O
in O O
the O O
absence O O
and O O
the O O
presence O O
of O O
sulfasalazine O O
) O O
. O O

The O O
apparent O O
ID50 O O
value O O
for O O
aminosalicylate-inhibited O O
maturation O O
was O O
4 O O
micromol/L O O
. O O

Sulfapyridine O O
had O O
no O O
effect O O
. O O

At O O
1.25 O O
micromol/L O O
, O O
sulfasalazine O O
largely O O
inhibited O O
NF-kB O O
activation O O
in O O
dendritic O O
cells O O
. O O

CONCLUSION O O
: O O
Maturing O O
human O O
dendritic O O
cells O O
are O O
hundred-fold O O
more O O
sensitive O O
to O O
sulfasalazine O O
than O O
T O O
cells O O
and O O
NK O O
cells O O
and O O
the O O
most O O
sensitive O O
human O O
cells O O
described O O
so O O
far O O
. O O

Because O O
of O O
the O O
role O O
of O O
dendritic O O
cells O O
in O O
( O O
auto O O
) O O
immunity O O
, O O
inhibition O O
of O O
their O O
maturation O O
might O O
provide O O
a O O
target O O
for O O
further O O
optimization O O
of O O
sulfasalazine O O
therapy O O
. O O

Defective O O
function O O
of O O
the O O
proteasome B B_GENE
in O O
autoimmunity O O
: O O
involvement O O
of O O
impaired O O
NF-kappaB O O
activation O O
. O O

The O O
novel O O
role O O
of O O
the O O
proteasome B B_BODY_PART_OR_ORGAN_COMPONENT/B_ENZYME[GENE]
in O O
dysfunction O O
in O O
autoimmunity O O
is O O
presented O O
and O O
documented O O
to O O
be O O
both O O
tissue O O
and O O
developmental O O
stage O O
specific O O
. O O

We O O
propose O O
a O O
role O O
of O O
the O O
proteasome B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
as O O
a O O
step O O
in O O
disease O O
pathogenesis O O
and O O
tissue O O
targeting O O
. O O

Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
unique O O
regulator O O
of O O
lymphopoiesis O O
that O O
associates O O
with O O
pericentromeric B B_GENE
heterochromatin I I_GENE
and O O
has O O
been O O
implicated O O
in O O
heritable O O
gene O O
inactivation O O
. O O

Binding O O
and O O
competition O O
experiments O O
demonstrate O O
that O O
Ikaros B B_PERSON/B_GENE
dimers I I_PERSON/I_GENE
compete O O
with O O
an O O
Ets B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
occupancy O O
of O O
the O O
lymphocyte-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
TdT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mutations O O
that O O
selectively O O
disrupt O O
Ikaros O O
binding O O
to O O
an O O
integrated B B_GENE/B_MEASURE
TdT I I_GENE/I_MEASURE
promoter I I_GENE/I_MEASURE
had O O
no O O
effect O O
on O O
promoter O O
function O O
in O O
a O O
CD4 O O
( O O
+ O O
) O O
CD8 O O
( O O
+ O O
) O O
thymocyte O O
line O O
. O O

However O O
, O O
these O O
mutations O O
abolished O O
down-regulation O O
on O O
differentiation O O
, O O
providing O O
evidence O O
that O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plays O O
a O O
direct O O
role O O
in O O
repression O O
. O O

The O O
Ikaros-dependent O O
down-regulation O O
event O O
and O O
the O O
observed O O
chromatin O O
alterations O O
appear O O
to O O
precede O O
pericentromeric O O
repositioning O O
. O O

Current O O
models O O
propose O O
that O O
the O O
functions O O
of O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
should O O
be O O
disrupted O O
by O O
a O O
small O O
isoform B B_GENE/B_LOCATION
that O O
retains O O
the O O
dimerization B B_GENE
domain I I_GENE
and O O
lacks O O
the O O
DNA-binding B B_GENE
domain I I_GENE
. O O

Surprisingly O O
, O O
in O O
the O O
CD4 O O
( O O
+ O O
) O O
CD8 O O
( O O
+ O O
) O O
thymocyte O O
line O O
, O O
overexpression O O
of O O
a O O
small B B_GENE
Ikaros I I_GENE
isoform I I_GENE
had O O
no O O
effect O O
on O O
differentiation O O
or O O
on O O
the O O
pericentromeric O O
targeting O O
and O O
DNA-binding O O
properties O O
of O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
capacity O O
for O O
in O O
vivo O O
multimer O O
formation O O
suggests O O
that O O
interactions O O
between O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bound O O
to O O
the O O
TdT B B_GENE
promoter I I_GENE
and O O
those O O
bound O O
to O O
pericentromeric B B_GENE/B_MEASURE
repeat I I_GENE/I_MEASURE
sequences I I_GENE/I_MEASURE
may O O
contribute O O
to O O
the O O
pericentromeric O O
repositioning O O
of O O
the O O
inactive B B_GENE
gene I I_GENE
. O O

Many O O
of O O
the O O
diverse O O
diseases O O
targeted O O
are O O
marked O O
by O O
pathogenetic O O
abnormalities O O
in O O
cell-mediated O O
immunity O O
( O O
CMI O O
) O O
, O O
these O O
cellular O O
immune O O
responses O O
either O O
causing O O
injury O O
to O O
the O O
host O O
, O O
lacking O O
sufficient O O
vigor O O
for O O
virus O O
or O O
tumor O O
clearance O O
, O O
or O O
both O O
. O O

In O O
general O O
, O O
therapeutic O O
efficacy O O
is O O
limited O O
. O O

Type B B_PERSON/B_GENE
I I I_PERSON/I_GENE
IFN I I_PERSON/I_GENE
have O O
previously O O
been O O
shown O O
to O O
be O O
able O O
to O O
substitute O O
for O O
IL-12 B B_GENE
in O O
driving O O
IFN-gamma O O
production O O
from O O
T O O
and O O
NK O O
cells O O
. O O

Nuclear B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
factor-kappaB I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
suppressive O O
and O O
inhibitor-kappaB B B_GENE
stimulatory O O
effects O O
of O O
troglitazone O O
in O O
obese O O
patients O O
with O O
type O O
2 O O
diabetes O O
: O O
evidence O O
of O O
an O O
antiinflammatory O O
action O O
? O O

It O O
has O O
been O O
shown O O
recently O O
that O O
troglitazone O O
exerts O O
an O O
anti-inflammatory O O
effect O O
, O O
in O O
vitro O O
, O O
and O O
in O O
experimental O O
animals O O
. O O

To O O
test O O
these O O
properties O O
in O O
humans O O
, O O
we O O
investigated O O
the O O
effect O O
of O O
troglitazone O O
on O O
the O O
proinflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-kappaB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
inhibitory B B_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
IkappaB I I_PROTEIN[GENE]
in O O
mononuclear O O
cells O O
( O O
MNC O O
) O O
and O O
plasma B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
soluble I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
intracellular I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
adhesion I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
molecule-1 I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
monocyte B B_GENE
chemoattractant I I_GENE
protein-1 I I_GENE
, O O
plasminogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
C-reactive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Blood O O
samples O O
were O O
obtained O O
at O O
weekly O O
intervals O O
. O O

Nuclear B B_GENE
factor-kappaB I I_GENE
binding O O
activity O O
in O O
MNC O O
nuclear O O
extracts O O
was O O
significantly O O
inhibited O O
after O O
troglitazone O O
treatment O O
at O O
week O O
1 O O
and O O
continued O O
to O O
be O O
inhibited O O
up O O
to O O
week O O
4 O O
. O O

On O O
the O O
other O O
hand O O
, O O
IkappaB O O
protein O O
levels O O
increased O O
significantly O O
after O O
troglitazone O O
treatment O O
at O O
week O O
1 O O
, O O
and O O
this O O
increase O O
persisted O O
throughout O O
the O O
study O O
. O O

13-HODE/linoleic O O
acid O O
and O O
9-HODE/linoleic O O
acid O O
ratios O O
also O O
decreased O O
after O O
troglitazone O O
intake O O
. O O

However O O
, O O
o-tyrosine/phenylalanine O O
and O O
m-tyrosine/phenylalanine O O
ratios O O
did O O
not O O
change O O
significantly O O
. O O

These O O
data O O
show O O
that O O
troglitazone O O
has O O
profound O O
antiinflammatory O O
effects O O
in O O
addition O O
to O O
antioxidant O O
effects O O
in O O
obese O O
type O O
2 O O
diabetics O O
; O O
these O O
effects O O
may O O
be O O
relevant O O
to O O
the O O
recently O O
described O O
beneficial O O
antiatherosclerotic O O
effects O O
of O O
troglitazone O O
at O O
the O O
vascular O O
level O O
. O O

OX40 O O
stimulation O O
by O O
gp34/OX40 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ligand I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhances O O
productive O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
infection O O
. O O

OX40 B B_GENE
is O O
a O O
member O O
of O O
the O O
tumor B B_GENE/B_PERSON
necrosis I I_GENE/I_PERSON
factor I I_GENE/I_PERSON
( I I_GENE/I_PERSON
TNF I I_GENE/I_PERSON
) I I_GENE/I_PERSON
receptor I I_GENE/I_PERSON
superfamily I I_GENE/I_PERSON
and O O
known O O
to O O
be O O
an O O
important O O
costimulatory B B_GENE
molecule I I_GENE
expressed O O
on O O
activated O O
T O O
cells O O
. O O

To O O
investigate O O
the O O
role O O
of O O
costimulation O O
of O O
OX40 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
infection O O
by O O
its O O
natural O O
ligand O O
, O O
gp34 B B_GENE
, O O
the O O
OX40-transfected O O
ACH-2 O O
cell O O
line O O
, O O
ACH-2/OX40 O O
, O O
chronically O O
infected O O
with O O
HIV-1 O O
, O O
was O O
cocultured O O
with O O
paraformaldehyde O O
( O O
PFA O O
) O O
-fixed O O
gp34-transfected O O
mouse O O
cell O O
line O O
, O O
SV-T2/gp34 O O
. O O

This O O
was O O
followed O O
by O O
apparent O O
apoptosis O O
, O O
and O O
both O O
processes O O
were O O
specifically O O
inhibited O O
by O O
the O O
gp34 B B_GENE
-specific O O
neutralizing B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
monoclonal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5A8 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Endogenous O O
TNF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TNF-alpha B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
TNF-beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O O
were O O
not O O
involved O O
in O O
the O O
enhanced O O
HIV-1 O O
production O O
. O O

The O O
present O O
study O O
first O O
shows O O
that O O
OX40-gp34 O O
interaction O O
stimulates O O
HIV-1 O O
expression O O
and O O
suggests O O
that O O
OX40 O O
triggering O O
by O O
gp34 B B_GENE
may O O
play O O
an O O
important O O
role O O
in O O
enhancing O O
HIV-1 O O
production O O
in O O
both O O
acutely O O
and O O
latently O O
infected O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
in O O
vivo O O
. O O

Troglitazone O O
, O O
a O O
PPARgamma O O
ligand O O
, O O
inhibits O O
osteopontin O O
gene O O
expression O O
in O O
human O O
monocytes/macrophage O O
THP-1 O O
cells O O
. O O

Peroxizome B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proliferator-activated I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor-gamma I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PPARgamma B B_GENE
) O O
is O O
a O O
member O O
of O O
the O O
nuclear B B_GENE/B_PERSON
receptor I I_GENE/I_PERSON
family I I_GENE/I_PERSON
of O O
transcription B B_GENE/B_BIO
factors I I_GENE/I_BIO
that O O
regulate O O
adipocyte O O
differentiation O O
. O O

Recent O O
studies O O
indicate O O
that O O
liganded B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PPARgamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
not O O
only O O
promotes O O
differentiation O O
but O O
also O O
inhibits O O
the O O
activation O O
of O O
macrophages O O
. O O

Osteopontin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
component O O
of O O
extracellular O O
matrix O O
, O O
is O O
synthesized O O
by O O
macrophages O O
in O O
atherosclerotic O O
plaques O O
. O O

In O O
this O O
study O O
, O O
we O O
examined O O
whether O O
PPARgamma B B_GENE
ligand O O
regulates O O
osteopontin O O
gene O O
expression O O
in O O
THP-1 O O
cells O O
, O O
a O O
cell O O
line O O
derived O O
from O O
human O O
monocytic O O
leukemia O O
cells O O
which O O
can O O
differentiate O O
to O O
macrophage O O
upon O O
stimulation O O
with O O
phorbol O O
ester O O
PMA O O
. O O

Troglitazone O O
, O O
a O O
PPARgamma B B_GENE/B_DISEASE
ligand O O
, O O
dramatically O O
attenuated O O
the O O
PMA-induced O O
osteopontin O O
expression O O
. O O

These O O
data O O
indicate O O
that O O
troglitazone O O
reduces O O
osteopontin O O
gene O O
expression O O
at O O
transcriptional O O
level O O
through O O
PPARgamma B B_GENE
activation O O
, O O
and O O
suggest O O
the O O
role O O
of O O
troglitazone O O
in O O
inhibiting O O
the O O
ability O O
of O O
macrophages O O
to O O
produce O O
extracellular O O
matrix O O
, O O
which O O
is O O
particularly O O
relevant O O
to O O
atherosclerotic O O
plaque O O
formation O O
. O O

Transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulates O O
Ig B B_GENE
lambda I I_GENE
light O O
chain O O
gene O O
rearrangement O O
. O O

The O O
tissue- O O
and O O
stage-specific O O
assembly O O
of O O
Ig B B_GENE
and I I_GENE
TCR I I_GENE
genes I I_GENE
is O O
mediated O O
by O O
a O O
common O O
V B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
D I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
J I I_GENE/I_LOCATION
recombinase I I_GENE/I_LOCATION
complex I I_GENE/I_LOCATION
in O O
precursor O O
lymphocytes O O
. O O

Directed O O
alterations O O
in O O
the O O
accessibility O O
of O O
V B B_GENE/B_LOCATION
, I I_GENE/I_LOCATION
D I I_GENE/I_LOCATION
, I I_GENE/I_LOCATION
and I I_GENE/I_LOCATION
J I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
segments I I_GENE/I_LOCATION
target O O
the O O
recombinase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
specific O O
Ag B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
loci I I_GENE/I_LOCATION
. O O

Accessibility O O
within O O
a O O
given O O
locus B B_GENE/B_LOCATION
is O O
regulated O O
by O O
the O O
functional O O
interaction O O
of O O
transcription B B_GENE
factors I I_GENE
with O O
cognate B B_GENE
enhancer I I_GENE
elements I I_GENE
and O O
correlates O O
with O O
the O O
transcriptional O O
activity O O
of O O
unrearranged O O
gene B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
segments I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
demonstrated O O
in O O
our O O
prior O O
studies O O
, O O
rearrangement O O
of O O
the O O
Igkappa B B_GENE
locus I I_GENE
is O O
regulated O O
by O O
the O O
inducible B B_GENE
transcription I I_GENE
factor I I_GENE
NF-kappaB B I_GENE
. O O

In O O
contrast O O
to O O
the O O
Igkappa B B_GENE/B_BIO
locus I I_GENE/I_BIO
, O O
known O O
transcriptional B B_GENE
control I I_GENE
elements I I_GENE
in O O
the O O
Iglambda B B_GENE/B_LOCATION
locus I I_GENE/I_LOCATION
lack O O
functional O O
NF-kappaB B B_GENE/B_MEASURE
binding I I_GENE/I_MEASURE
sites I I_GENE/I_MEASURE
. O O

Consistent O O
with O O
this O O
observation O O
, O O
the O O
expression O O
of O O
assembled O O
Iglambda B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mature O O
B O O
cells O O
has O O
been O O
shown O O
to O O
be O O
NF-kappaB B B_GENE
independent O O
. O O

Nonetheless O O
, O O
we O O
now O O
show O O
that O O
specific O O
repression O O
of O O
NF-kappaB B B_GENE
inhibits O O
germline O O
transcription O O
and O O
recombination O O
of O O
Iglambda B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
segments I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
precursor O O
B O O
cells O O
. O O

Molecular O O
analyses O O
indicate O O
that O O
the O O
block O O
in O O
NF-kappaB B B_GENE
impairs O O
Iglambda O O
rearrangement O O
at O O
the O O
level O O
of O O
recombinase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
accessibility O O
. O O

In O O
contrast O O
, O O
the O O
activities O O
of O O
known O O
Iglambda B B_GENE/B_BIO
promoter I I_GENE/I_BIO
and O O
enhancer B B_GENE
elements I I_GENE
are O O
unaffected O O
in O O
the O O
same O O
cellular O O
background O O
. O O

These O O
findings O O
expand O O
the O O
range O O
of O O
NF-kappaB B B_GENE
action O O
in O O
precursor O O
B O O
cells O O
beyond O O
Igkappa B B_GENE/B_DISEASE
to O O
include O O
the O O
control O O
of O O
recombinational O O
accessibility O O
at O O
both O O
L B B_GENE/B_LOCATION
chain I I_GENE/I_LOCATION
loci I I_GENE/I_LOCATION
. O O

Moreover O O
, O O
our O O
results O O
strongly O O
suggest O O
the O O
existence O O
of O O
a O O
novel O O
Iglambda B B_GENE/B_LOCATION
regulatory I I_GENE/I_LOCATION
element I I_GENE/I_LOCATION
that O O
is O O
either O O
directly O O
or O O
indirectly O O
activated O O
by O O
NF-kappaB B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
early O O
stages O O
of O O
B O O
cell O O
development O O
. O O

Transcription B B_GENE
factor I I_GENE
STAT5A B I_GENE
is O O
a O O
substrate O O
of O O
Bruton B B_GENE
's I I_GENE
tyrosine I I_GENE
kinase I I_GENE
in O O
B O O
cells O O
. O O

STAT5A B B_GENE
is O O
a O O
molecular O O
regulator O O
of O O
proliferation O O
, O O
differentiation O O
, O O
and O O
apoptosis O O
in O O
lymphohematopoietic O O
cells O O
. O O

Here O O
we O O
show O O
that O O
STAT5A B B_GENE
can O O
serve O O
as O O
a O O
functional O O
substrate O O
of O O
Bruton B B_GENE
's I I_GENE
tyrosine I I_GENE
kinase I I_GENE
( O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Purified B B_GENE/B_PERSON
recombinant I I_GENE/I_PERSON
BTK I I_GENE/I_PERSON
was O O
capable O O
of O O
directly O O
binding O O
purified B B_GENE
recombinant I I_GENE
STAT5A I I_GENE
with O O
high O O
affinity O O
( O O
K O O
( O O
d O O
) O O
= O O
44 O O
nm O O
) O O
, O O
as O O
determined O O
by O O
surface O O
plasmon O O
resonance O O
using O O
a O O
BIAcore O O
biosensor O O
system O O
. O O

BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
also O O
capable O O
of O O
tyrosine-phosphorylating O O
ectopically O O
expressed O O
recombinant B B_GENE
STAT5A I I_GENE
on O O
Tyr O O
( O O
694 O O
) O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
in O O
a O O
Janus B B_GENE
kinase I I_GENE
3 I I_GENE
-independent O O
fashion O O
. O O

BTK B B_PERSON/B_GENE
phosphorylated O O
the O O
Y665F B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
, I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
Y668F I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
, I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
Y682F I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
, I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
Y683F I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
but O O
not O O
the O O
Y694F B B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutant I I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
of O O
STAT5A B B_GENE
. O O

STAT5A O O
mutations O O
in O O
the O O
Src B B_GENE/B_BIO
homology I I_GENE/I_BIO
2 I I_GENE/I_BIO
( I I_GENE/I_BIO
SH2 I I_GENE/I_BIO
) I I_GENE/I_BIO
and I I_GENE/I_BIO
SH3 I I_GENE/I_BIO
domains I I_GENE/I_BIO
did O O
not O O
alter O O
the O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-mediated O O
tyrosine O O
phosphorylation O O
. O O

In O O
pull-down O O
experiments O O
, O O
only O O
full-length B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
BTK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
SH1/kinase B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
( O O
but O O
not O O
the O O
pleckstrin O O
homology O O
, O O
SH2 B B_PROTEIN[GENE]/B_LOCATION
, I I_PROTEIN[GENE]/I_LOCATION
or I I_PROTEIN[GENE]/I_LOCATION
SH3 I I_PROTEIN[GENE]/I_LOCATION
domains I I_PROTEIN[GENE]/I_LOCATION
) O O
were O O
capable O O
of O O
binding O O
STAT5A B B_GENE
. O O

Ectopically O O
expressed O O
BTK B B_GENE
kinase I I_GENE
domain I I_GENE
was O O
capable O O
of O O
tyrosine-phosphorylating O O
STAT5A B B_GENE
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-mediated O O
tyrosine O O
phosphorylation O O
of O O
ectopically O O
expressed O O
wild O O
type O O
( O O
but O O
not O O
Tyr B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
694 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) O O
STAT5A B B_GENE/B_LOCATION
enhanced O O
its O O
DNA O O
binding O O
activity O O
. O O

In O O
BTK B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
-competent O O
chicken O O
B O O
cells O O
, O O
anti-IgM-stimulated O O
tyrosine O O
phosphorylation O O
of O O
STAT5 B B_GENE
protein I I_GENE
was O O
prevented O O
by O O
pretreatment O O
with O O
the O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
LFM-A13 O O
but O O
not O O
by O O
pretreatment O O
with O O
the O O
JAK3 O O
inhibitor O O
HI-P131 O O
. O O

Similarly O O
, O O
anti-IgM O O
stimulation O O
resulted O O
in O O
enhanced O O
tyrosine O O
phosphorylation O O
of O O
STAT5A B B_GENE
in O O
BTK B B_DISEASE/B_GENE
-competent O O
B O O
cells O O
from O O
wild O O
type O O
mice O O
but O O
not O O
in O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-deficient O O
B O O
cells O O
from O O
XID O O
mice O O
. O O

In O O
contrast O O
to O O
B O O
cells O O
from O O
XID O O
mice O O
, O O
B O O
cells O O
from O O
JAK3 O O
knockout O O
mice O O
showed O O
a O O
normal O O
STAT5A O O
phosphorylation O O
response O O
to O O
anti-IgM O O
stimulation O O
. O O

These O O
findings O O
provide O O
unprecedented O O
experimental O O
evidence O O
that O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plays O O
a O O
nonredundant O O
and O O
pivotal O O
role O O
in O O
B O O
cell O O
antigen O O
receptor-mediated O O
STAT5A O O
activation O O
in O O
B O O
cells O O

Role O O
of O O
T-bet B B_GENE
in O O
commitment O O
of O O
TH1 O O
cells O O
before O O
IL-12 B B_GENE
-dependent O O
selection O O
. O O

We O O
show O O
that O O
T-bet B B_GENE
, O O
without O O
apparent O O
assistance O O
from O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
12 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-12 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
STAT4 B B_GENE/B_MEASURE
, O O
specifies O O
TH1 O O
effector O O
fate O O
by O O
targeting O O
chromatin O O
remodeling O O
to O O
individual O O
interferon-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IFN-gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alleles I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
inducing O O
IL-12 B B_GENE
receptor I I_GENE
beta2 I I_GENE
expression O O
. O O

Subsequently O O
, O O
it O O
appears O O
that O O
IL-12 B B_GENE/B_LOCATION
/ O O
STAT4 B B_MEASURE/B_GENE
serves O O
two O O
essential O O
functions O O
in O O
the O O
development O O
of O O
TH1 O O
cells O O
: O O
as O O
growth B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
inducing O O
survival O O
and O O
cell O O
division O O
; O O
and O O
as O O
trans-activator B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
prolonging O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthesis O O
through O O
a O O
genetic O O
interaction O O
with O O
the O O
coactivator B B_GENE/B_PERSON
, O O
CREB-binding B B_GENE
protein I I_GENE
. O O

These O O
results O O
suggest O O
that O O
a O O
cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O O
not O O
simply O O
induce O O
TH O O
fate O O
choice O O
but O O
instead O O
may O O
act O O
as O O
an O O
essential O O
secondary O O
stimulus O O
that O O
mediates O O
selective O O
survival O O
of O O
a O O
lineage O O
. O O

Stat6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
necessary O O
and O O
sufficient O O
for O O
IL-4 O O
's O O
role O O
in O O
Th2 O O
differentiation O O
and O O
cell O O
expansion O O
. O O

IL-4 B B_GENE
plays O O
a O O
critical O O
role O O
in O O
the O O
differentiation O O
of O O
T O O
CR-stimulated O O
naive O O
CD4 O O
T O O
cells O O
to O O
the O O
Th2 O O
phenotype O O
. O O

In O O
response O O
to O O
IL-4 B B_GENE/B_DISEASE
, O O
the O O
IL-4R B B_GENE
activates O O
a O O
set O O
of O O
phosphotyrosine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain-containing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
insulin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
substrate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1/2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
IL-4R B B_GENE
interacting I I_GENE
protein I I_GENE
, O O
as O O
well O O
as O O
Stat6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Stat6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
shown O O
to O O
be O O
required O O
for O O
Th2 O O
differentiation O O
. O O

To O O
determine O O
the O O
roles O O
of O O
the O O
phosphotyrosine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adaptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Th2 O O
differentiation O O
, O O
we O O
prepared O O
a O O
retrovirus O O
containing O O
a O O
mutant O O
of O O
the O O
human B B_GENE
( I I_GENE
h I I_GENE
) I I_GENE
IL-4R I I_GENE
alpha-chain I I_GENE
, O O
Y497F B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
unable O O
to O O
recruit O O
these O O
adaptors O O
. O O

The O O
mutant B B_GENE
hIL-4Ralpha I I_GENE
, O O
as O O
well O O
as O O
the O O
wild-type B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
WT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hIL-4Ralpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
introduced O O
into O O
naive O O
CD4 O O
T O O
cells O O
. O O

Upon O O
hIL-4 O O
stimulation O O
, O O
Y497F B B_GENE/B_PERSON
worked O O
as O O
well O O
as O O
the O O
WT B B_GENE
hIL-4Ralpha I I_GENE
in O O
driving O O
Th2 O O
differentiation O O
, O O
as O O
measured O O
by O O
Gata3 O O
up-regulation O O
and O O
IL-4 O O
production O O
. O O

These O O
results O O
suggest O O
that O O
the O O
signal O O
pathway O O
mediated O O
by O O
Y497 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
dispensable O O
for O O
both O O
IL-4 B B_GENE
-driven O O
Th2 O O
differentiation O O
and O O
cell O O
expansion O O
. O O

Both O O
WT B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Y497F I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hIL-4Ralpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lose O O
the O O
ability O O
to O O
drive O O
Th2 O O
differentiation O O
and O O
cell O O
expansion O O
in O O
Stat6-knockout O O
CD4 O O
T O O
cells O O
. O O

A O O
constitutively O O
activated O O
form O O
of O O
Stat6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introduced O O
into O O
CD4 O O
T O O
cells O O
resulted O O
in O O
both O O
Th2 O O
differentiation O O
and O O
enhanced O O
cell O O
expansion O O
. O O

Thus O O
, O O
activated B B_GENE
Stat6 I I_GENE
is O O
necessary O O
and O O
sufficient O O
to O O
mediate O O
both O O
IL-4 B B_GENE
-driven O O
Th2 O O
differentiation O O
and O O
cell O O
expansion O O
in O O
CD4 O O
T O O
cells O O
. O O

The O O
effect O O
of O O
HIV-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulatory I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
cellular O O
genes O O
: O O
derepression O O
of O O
the O O
IL-2 B B_GENE
promoter I I_GENE
by O O
Tat B B_GENE
. O O

In O O
HIV-infected O O
individuals O O
dysregulation O O
of O O
the O O
immune O O
system O O
is O O
characterized O O
by O O
severe O O
disorders O O
of O O
the O O
cytokine O O
network O O
. O O

We O O
demonstrate O O
that O O
increased O O
IL-2 O O
secretion O O
is O O
due O O
to O O
Tat B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-enhanced O O
IL-2 B B_GENE
promoter I I_GENE
activation O O
. O O

Tat B B_GENE
derepresses O O
and O O
activates O O
the O O
distal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
AP-1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
position B B_LOCATION/B_PROTEIN[GENE]
-185 I I_LOCATION/I_PROTEIN[GENE]
to I I_LOCATION/I_PROTEIN[GENE]
-177 I I_LOCATION/I_PROTEIN[GENE]
) O O
in O O
the O O
IL-2 B B_GENE
promoter I I_GENE
. O O

In O O
nonstimulated O O
T O O
cells O O
a O O
repressor O O
complex O O
containing O O
NF-IL6 B B_GENE
, O O
JunB B B_GENE/B_BACTERIUM[BIO]
, O O
c-Fos B B_GENE
and O O
Fra-1 B B_GENE
is O O
formed O O
on O O
the O O
AP-1 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
( I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
IL-2/d I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
) I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
site I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
represses O O
IL-2 B B_GENE
promoter I I_GENE
activity O O
. O O

HIV B B_GENE/B_DISEASE
Tat I I_GENE/I_DISEASE
enhances O O
activation O O
of O O
NF-kappaB B B_GENE
and O O
consequently O O
, O O
activates O O
the O O
AP-1 B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
IL-2/d I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
site I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Transforming B B_GENE
growth I I_GENE
factor-beta1 I I_GENE
interferes O O
with O O
thrombopoietin-induced O O
signal O O
transduction O O
in O O
megakaryoblastic O O
and O O
erythroleukemic O O
cells O O
. O O

OBJECTIVE O O
: O O
Thrombopoietin B B_GENE
( O O
TPO B B_PROTEIN[GENE]/B_DISEASE
) O O
and O O
transforming B B_GENE
growth I I_GENE
factor-beta I I_GENE
( I I_GENE
1 I I_GENE
) I I_GENE
( O O
TGF-beta B B_GENE/B_MEASURE
( I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
) O O
have O O
been O O
shown O O
to O O
exert O O
opposite O O
effects O O
on O O
proliferation O O
and O O
megakaryocytic O O
differentiation O O
of O O
hematopoietic O O
cells O O
. O O

To O O
determine O O
whether O O
TGF-beta B B_GENE
( I I_GENE
1 I I_GENE
) I I_GENE
interferes O O
directly O O
with O O
TPO B B_GENE
-induced O O
signal O O
transduction O O
in O O
hematopoietic O O
cells O O
, O O
we O O
compared O O
the O O
regulatory O O
effects O O
in O O
the O O
TPO B B_GENE
-responsive O O
cell O O
lines O O
Mo-7e O O
and O O
HEL O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
The O O
cells O O
were O O
stimulated O O
by O O
100 O O
ng/mL O O
TPO B B_GENE
and/or O O
100 O O
ng/mL O O
TGF-beta1 B B_GENE
and O O
analyzed O O
for O O
proliferation O O
( O O
3H O O
thymidine O O
incorporation O O
) O O
, O O
viability O O
( O O
trypan O O
blue O O
exclusion O O
) O O
, O O
and O O
protein O O
expression O O
and O O
phosphorylation O O
( O O
Western O O
blot O O
) O O
. O O

RESULTS O O
: O O
TPO B B_GENE/B_DISEASE
enhanced O O
the O O
proliferation O O
of O O
Mo-7e O O
cells O O
as O O
determined O O
by O O
3H-thymidine O O
incorporation O O
, O O
whereas O O
TGF-beta1 B B_GENE
suppressed O O
baseline O O
cell O O
growth O O
and O O
antagonized O O
the O O
proliferative O O
effect O O
of O O
TPO B B_GENE
. O O

TPO B B_PROTEIN[GENE]/B_DISEASE
-induced O O
proliferation O O
also O O
was O O
reduced O O
by O O
a O O
specific O O
inhibitor O O
of O O
the O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE
) O O
pathway O O
( O O
PD098059 O O
) O O
, O O
which O O
inhibits O O
activation O O
of O O
the O O
MAPK B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
extracellular I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
signal-regulated I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
kinases I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
ERK B B_GENE/B_LOCATION
) O O
ERK1 B B_GENE
and O O
ERK2 B B_GENE/B_LOCATION
, O O
and O O
AG490 O O
, O O
an O O
inhibitor O O
of O O
Janus B B_GENE
kinase-2 I I_GENE
, O O
which O O
completely O O
blocked O O
TPO B B_GENE
-induced O O
proliferation O O
. O O

As O O
demonstrated O O
by O O
Western O O
blotting O O
, O O
TGF-beta1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduced O O
the O O
TPO B B_GENE
-stimulated O O
ERK1 B B_GENE
/ O O
ERK2 B B_GENE
and O O
STAT5 O O
phosphorylation O O
in O O
Mo-7e O O
and O O
HEL O O
cells O O
. O O

This O O
effect O O
was O O
completely O O
reversed O O
by O O
preincubation O O
with O O
a O O
tyrosine O O
phosphatase O O
inhibitor O O
( O O
Na3VO4 O O
) O O
, O O
which O O
suggests O O
that O O
TGF-beta1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activated O O
a O O
phosphatase B B_GENE/B_LOCATION
. O O

Although O O
STAT3 B B_GENE
also O O
was O O
activated O O
by O O
TPO B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
STAT3 B B_GENE/B_MEASURE
activation O O
remained O O
unaltered O O
by O O
TGF-beta1 B B_GENE
. O O

CONCLUSION O O
: O O
Taken O O
together O O
, O O
these O O
data O O
suggest O O
that O O
TGF-beta1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
modulates O O
TPO B B_GENE
-mediated O O
effects O O
on O O
megakaryocytic O O
proliferation O O
by O O
interfering O O
with O O
TPO B B_GENE
-induced O O
signal O O
transduction O O
, O O
particularly O O
by O O
reducing O O
the O O
activities O O
of O O
MAPK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ERK1/ERK2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
STAT5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Invariant B B_GENE
chain I I_GENE
induces O O
B O O
cell O O
maturation O O
by O O
activating O O
a O O
TAF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
105-NF-kappaB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-dependent O O
transcription O O
program O O
. O O

Early O O
stages O O
of O O
B O O
cell O O
development O O
occur O O
in O O
the O O
bone O O
marrow O O
, O O
resulting O O
in O O
formation O O
of O O
immature O O
B O O
cells O O
. O O

From O O
there O O
these O O
immature O O
cells O O
migrate O O
to O O
the O O
spleen O O
where O O
they O O
differentiate O O
to O O
mature O O
cells O O
. O O

Recently O O
, O O
invariant B B_GENE
chain I I_GENE
( O O
Ii B B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
a O O
major B B_GENE
histocompatibility I I_GENE
complex I I_GENE
class I I_GENE
II I I_GENE
chaperone I I_GENE
, O O
as O O
well O O
as O O
the O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Rel B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
p65/RelA B B_GENE
, O O
were O O
found O O
to O O
play O O
a O O
role O O
in O O
the O O
final O O
antigen-independent O O
differentiation O O
stage O O
of O O
B O O
cells O O
in O O
the O O
spleen O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
a O O
possible O O
link O O
between O O
Ii B B_GENE/B_DISEASE
-dependent O O
B O O
cell O O
maturation O O
and O O
the O O
NF-kappaB O O
pathway O O
. O O

Our O O
studies O O
indicate O O
that O O
Ii B B_DISEASE/B_GENE
-induced O O
B O O
cell O O
maturation O O
involves O O
activation O O
of O O
transcription O O
mediated O O
by O O
the O O
NF-kappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p65/RelA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homodimer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
requires O O
the O O
B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell-enriched I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coactivator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TBP-associated B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
105 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Androgens O O
indirectly O O
accelerate O O
thymocyte O O
apoptosis O O
. O O

Apoptotic O O
processes O O
, O O
or O O
the O O
disturbance O O
of O O
the O O
natural O O
regulation O O
of O O
these O O
processes O O
, O O
may O O
be O O
involved O O
in O O
the O O
pathogenesis O O
of O O
autoimmune O O
diseases O O
( O O
AID O O
) O O
. O O

Women O O
are O O
, O O
in O O
general O O
, O O
more O O
susceptible O O
than O O
men O O
to O O
develop O O
AID O O
like O O
rheumatoid O O
arthritis O O
. O O

Androgens O O
and O O
glucocorticoids O O
, O O
in O O
contrast O O
to O O
oestrogens O O
, O O
have O O
favourable O O
effects O O
in O O
AID O O
models O O
as O O
well O O
as O O
in O O
human O O
AID O O
. O O

It O O
is O O
known O O
that O O
glucocorticoids O O
( O O
GC O O
) O O
, O O
used O O
for O O
treatment O O
of O O
AID O O
, O O
increase O O
apoptosis O O
in O O
the O O
thymus O O
resulting O O
in O O
decreased O O
numbers O O
of O O
CD4+ O O
CD8+ O O
thymocytes O O
. O O

It O O
was O O
asked O O
whether O O
androgens O O
, O O
in O O
contrast O O
to O O
oestrogens O O
, O O
exert O O
their O O
favourable O O
effects O O
in O O
the O O
treatment O O
of O O
AID O O
by O O
a O O
mechanism O O
comparable O O
to O O
that O O
described O O
for O O
GC O O
by O O
eliminating O O
the O O
apoptosis O O
prone O O
CD4+ O O
CD8+ O O
population O O
in O O
the O O
thymus O O
. O O

Although O O
both O O
androgens O O
and O O
oestrogens O O
proved O O
thymolytic O O
, O O
a O O
significantly O O
decreased O O
percentage O O
of O O
CD4+ O O
CD8+ O O
thymocytes O O
was O O
observed O O
by O O
flow O O
cytometry O O
after O O
treatment O O
of O O
mice O O
with O O
the O O
androgen O O
methyltestosterone O O
, O O
but O O
not O O
with O O
the O O
oestrogen O O
ethinylestradiol O O
. O O

To O O
investigate O O
whether O O
the O O
observed O O
thymolytic O O
effects O O
were O O
due O O
to O O
the O O
presence O O
of O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
thymocytes O O
, O O
cells O O
were O O
isolated O O
from O O
the O O
thymus O O
and O O
incubated O O
with O O
androgens O O
or O O
oestrogens O O
to O O
measure O O
apoptosis O O
. O O

Several O O
techniques O O
were O O
used O O
to O O
determine O O
thymocyte O O
apoptosis O O
in O O
vitro O O
, O O
but O O
no O O
enhanced O O
apoptotic O O
signal O O
was O O
observed O O
. O O

Using O O
the O O
very O O
sensitive O O
TUNEL O O
assay O O
, O O
no O O
direct O O
effect O O
of O O
androgens O O
on O O
thymocytes O O
in O O
vitro O O
could O O
be O O
observed O O
. O O

This O O
is O O
in O O
sharp O O
contrast O O
to O O
the O O
high O O
signal O O
observed O O
with O O
GC O O
. O O

Thus O O
, O O
it O O
is O O
concluded O O
that O O
androgens O O
indirectly O O
accelerate O O
thymocyte O O
apoptosis O O
in O O
vivo O O
. O O

The O O
peroxisome B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PPARgamma B B_GENE
) O O
, O O
a O O
member O O
of O O
the O O
nuclear B B_GENE/B_BIO
hormone I I_GENE/I_BIO
receptor I I_GENE/I_BIO
superfamily I I_GENE/I_BIO
, O O
is O O
essential O O
for O O
adipocyte O O
differentiation O O
and O O
glucose O O
homeostasis O O
. O O

Our O O
study O O
shows O O
PPARgamma B B_GENE
to O O
be O O
preferentially O O
expressed O O
in O O
the O O
nuclei O O
of O O
resting O O
T O O
cells O O
and O O
to O O
increase O O
upon O O
activation O O
of O O
T O O
cells O O
by O O
either O O
anti-CD3 B B_GENE
and O O
anti-CD28 B B_GENE
or O O
phorbol O O
myristyl O O
acetate O O
( O O
PMA O O
) O O
. O O

We O O
also O O
found O O
the O O
PPARgamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligand I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ciglitizone O O
to O O
attenuate O O
the O O
activation O O
of O O
T O O
cells O O
by O O
inhibiting O O
cytokine O O
gene O O
expression O O
and O O
anti-CD3 B B_GENE
and O O
anti-CD28 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
PMA-induced O O
proliferative O O
responses O O
. O O

Inhibition O O
of O O
both O O
the O O
proliferative O O
response O O
and O O
inflammatory O O
cytokine O O
expression O O
in O O
CD4 O O
T O O
cells O O
was O O
correlated O O
with O O
suppression O O
of O O
the O O
activated O O
transcription B B_GENE/B_LOCATION
factors I I_GENE/I_LOCATION
AP1 B I_GENE/I_LOCATION
and O O
NF-kappaB B B_GENE
. O O

These O O
results O O
, O O
together O O
with O O
previous O O
findings O O
of O O
the O O
inhibitory O O
effect O O
of O O
PPARgamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligands I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
activated O O
macrophages O O
, O O
provide O O
clear O O
evidence O O
for O O
PPARgamma B B_GENE
as O O
a O O
negative B B_GENE/B_PERSON
regulator I I_GENE/I_PERSON
of O O
the O O
inflammatory O O
activation O O
of O O
both O O
macrophage O O
and O O
T O O
cells O O
. O O

PPARgamma B B_GENE
may O O
thus O O
be O O
a O O
potential O O
therapeutic O O
target O O
for O O
the O O
treatment O O
of O O
autoimmunity O O
. O O

A O O
prominent O O
role O O
for O O
activator B B_GENE
protein-1 I I_GENE
in O O
the O O
transcription O O
of O O
the O O
human B B_GENE
2B4 I I_GENE
( I I_GENE
CD244 I I_GENE
) I I_GENE
gene I I_GENE
in O O
NK O O
cells O O
. O O

The O O
cell B B_GENE/B_PERSON
surface I I_GENE/I_PERSON
glycoprotein I I_GENE/I_PERSON
2B4 I I_GENE/I_PERSON
( O O
CD244 B B_GENE
) O O
of O O
the O O
Ig B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
superfamily I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
is O O
involved O O
in O O
the O O
regulation O O
of O O
NK O O
and O O
T O O
lymphocyte O O
functions O O
. O O

We O O
have O O
recently O O
identified O O
CD48 B B_GENE
as O O
the O O
high B B_GENE/B_PERSON
affinity I I_GENE/I_PERSON
counterreceptor I I_GENE/I_PERSON
for O O
2B4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
both O O
mice O O
and O O
humans O O
. O O

The O O
cytoplasmic B B_GENE
domain I I_GENE
of O O
2B4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associates O O
with O O
src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homology I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain-containing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
signaling B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphocyte I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecule-associated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
whose O O
mutation O O
is O O
the O O
underlying O O
genetic O O
defect O O
in O O
the O O
X-linked O O
lymphoproliferative O O
syndrome O O
. O O

In O O
this O O
study O O
, O O
we O O
report O O
the O O
molecular O O
cloning O O
and O O
characterization O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2B4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
h2B4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Through O O
primer O O
extension O O
analysis O O
, O O
we O O
found O O
that O O
the O O
transcription O O
of O O
the O O
h2B4 B B_GENE
gene I I_GENE
initiates O O
at O O
multiple O O
start O O
sites O O
. O O

We O O
isolated O O
h2B4 B B_GENE
genomic I I_GENE
clones I I_GENE
and O O
PCR O O
amplified O O
the O O
5 B B_GENE/B_LOCATION
' I I_GENE/I_LOCATION
untranslated I I_GENE/I_LOCATION
region I I_GENE/I_LOCATION
containing O O
the O O
promoter B B_GENE
elements I I_GENE
. O O

We O O
have O O
identified O O
a O O
functional O O
AP-1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O O
lies O O
between O O
( O O
-106 O O
to O O
-100 O O
) O O
through O O
transient O O
transfection O O
analysis O O
in O O
YT O O
cells O O
, O O
a O O
human O O
NK O O
cell O O
line O O
. O O

Mutation O O
of O O
the O O
AP-1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
not O O
only O O
abolishes O O
protein/DNA O O
interactions O O
but O O
also O O
promoter O O
activity O O
. O O

These O O
results O O
demonstrate O O
a O O
significant O O
role O O
for O O
AP-1 B B_GENE
in O O
the O O
transcriptional O O
regulation O O
of O O
the O O
h2B4 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
. O O

Functional O O
correction O O
of O O
FA-C O O
cells O O
with O O
FANCC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
suppresses O O
the O O
expression O O
of O O
interferon B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gamma-inducible I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
an O O
attempt O O
to O O
clarify O O
mechanisms O O
by O O
which O O
FA-C O O
cells O O
overexpress O O
IFNgamma-inducible B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
face O O
of O O
defective O O
STAT1 O O
phosphorylation O O
, O O
it O O
was O O
reasoned O O
that O O
decreased O O
levels O O
of O O
activated B B_GENE
STAT1 I I_GENE
might O O
result O O
in O O
reduced O O
expression O O
of O O
a O O
hematopoietic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IFNgamma-responsive I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
normally O O
modulates O O
expression O O
of O O
other O O
IFNgamma-responsive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Levels O O
of O O
the O O
IFNgamma B B_GENE
-inducible O O
factor O O
IFN B B_PROTEIN[GENE]/B_MEASURE
consensus I I_PROTEIN[GENE]/I_MEASURE
sequence I I_PROTEIN[GENE]/I_MEASURE
binding I I_PROTEIN[GENE]/I_MEASURE
protein I I_PROTEIN[GENE]/I_MEASURE
( O O
ICSBP B B_DISEASE/B_GENE
) O O
, O O
a O O
negative B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
trans-acting I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
some O O
IFNgamma-inducible B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
were O O
quantified O O
. O O

ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
levels O O
were O O
reduced O O
in O O
FA-C O O
B O O
lymphoblasts O O
and O O
MEFs O O
. O O

However O O
, O O
enforced O O
expression O O
of O O
ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
failed O O
to O O
down-regulate O O
IRF-1 B B_GENE
, O O
ISGF3gamma B B_GENE
, O O
and O O
p21 B B_GENE
( I I_GENE
WAF1 I I_GENE
) I I_GENE
. O O

Thus O O
, O O
the O O
FANCC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
functions O O
to O O
modulate O O
expression O O
of O O
a O O
family O O
of O O
genes O O
that O O
in O O
normal O O
cells O O
are O O
inducible O O
only O O
by O O
specific O O
environmental O O
cues O O
for O O
apoptosis O O
or O O
mitogenic O O
inhibition O O
, O O
but O O
it O O
does O O
so O O
independently O O
of O O
the O O
classic O O
IFN-STAT1 O O
pathway O O
and O O
is O O
not O O
the O O
direct O O
result O O
of O O
reduced O O
ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
. O O

A O O
genetic O O
investigation O O
of O O
E2A O O
function O O
in O O
lymphocyte O O
development O O
. O O

Lymphocytes O O
are O O
derived O O
from O O
hematopoietic O O
stem O O
cells O O
( O O
HSC O O
) O O
following O O
a O O
series O O
of O O
regulated O O
differentiation O O
events O O
. O O

Multipotent O O
HSCs O O
become O O
committed O O
to O O
the O O
B O O
cell O O
lineage O O
in O O
bone O O
marrow O O
and O O
the O O
T O O
cell O O
lineage O O
in O O
the O O
thymus O O
after O O
receiving O O
appropriate O O
signals O O
from O O
the O O
corresponding O O
microenvironment O O
. O O

These O O
committed O O
lymphoid O O
cells O O
must O O
then O O
undergo O O
V O O
( O O
D O O
) O O
J O O
recombination O O
at O O
the O O
immunoglobulin B B_GENE
gene I I_GENE
or O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resulting O O
in O O
clonal O O
production O O
of O O
functional O O
B O O
or O O
T O O
lymphocytes O O
, O O
respectively O O
. O O

Lymphocyte O O
commitment O O
and O O
differentiation O O
are O O
accompanied O O
by O O
programmed O O
gene O O
expression O O
or O O
repression O O
events O O
which O O
are O O
driven O O
by O O
lineage B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stage I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
basic-helix-loop-helix B B_GENE
( I I_GENE
bHLH I I_GENE
) I I_GENE
transcription I I_GENE
factors I I_GENE
encoded O O
by O O
the O O
E2A B B_GENE
gene I I_GENE
are O O
involved O O
in O O
several O O
differentiation O O
events O O
during O O
B O O
and O O
T O O
cell O O
development O O
, O O
including O O
lineage O O
commitment O O
, O O
initiation O O
of O O
V O O
( O O
D O O
) O O
J O O
recombination O O
, O O
and O O
antigen O O
receptor O O
mediated O O
proliferation O O
and O O
differentiation O O
. O O

Several O O
recent O O
reviews O O
have O O
provided O O
a O O
comprehensive O O
discussion O O
of O O
biochemical O O
, O O
cellular O O
, O O
and O O
genetic O O
research O O
on O O
E2A O O
function O O
in O O
lymphocyte O O
development O O
( O O
1 O O
, O O
2 O O
) O O
. O O

Here O O
, O O
we O O
only O O
discuss O O
some O O
of O O
the O O
genetic O O
approaches O O
our O O
laboratory O O
( O O
except O O
where O O
it O O
is O O
noted O O
) O O
has O O
undertaken O O
to O O
investigate O O
the O O
molecular O O
pathways O O
mediated O O
by O O
E2A B B_GENE
transcription I I_GENE
factors I I_GENE
in O O
lymphocyte O O
development O O

D609 O O
inhibits O O
ionizing O O
radiation-induced O O
oxidative O O
damage O O
by O O
acting O O
as O O
a O O
potent O O
antioxidant O O
. O O

Tricyclodecan-9-yl-xanthogenate O O
( O O
D609 O O
) O O
has O O
been O O
extensively O O
studied O O
in O O
biological O O
systems O O
and O O
exhibits O O
a O O
variety O O
of O O
biological O O
functions O O
, O O
including O O
antiviral O O
, O O
antitumor O O
, O O
and O O
anti-inflammatory O O
activities O O
. O O

Most O O
of O O
these O O
activities O O
have O O
been O O
largely O O
attributed O O
to O O
the O O
inhibitory O O
effect O O
of O O
D609 O O
on O O
phosphatidylcholine-specific O O
phospholipase B B_ENZYME[GENE]
C I I_ENZYME[GENE]
. O O

However O O
, O O
as O O
a O O
xanthate O O
derivative O O
, O O
D609 O O
is O O
a O O
strong O O
electrolyte O O
and O O
readily O O
dissociates O O
to O O
xanthate O O
anions O O
and O O
cations O O
of O O
alkali O O
metals O O
in O O
solution O O
. O O

Xanthate O O
anions O O
and O O
protonated O O
xanthic O O
acid O O
contain O O
a O O
free O O
thiol O O
moiety O O
and O O
are O O
highly O O
reductive O O
. O O

This O O
implies O O
that O O
D609 O O
and O O
other O O
xanthate O O
derivatives O O
may O O
function O O
as O O
potent O O
antioxidants O O
. O O

Indeed O O
, O O
we O O
found O O
that O O
D609 O O
inhibited O O
the O O
Fenton O O
reaction-induced O O
oxidation O O
of O O
dihydrorhodamine O O
123 O O
in O O
a O O
dose-dependent O O
manner O O
similar O O
to O O
that O O
of O O
pyrrolidinedithiocarbamate O O
, O O
a O O
well O O
known O O
antioxidant O O
. O O

Furthermore O O
, O O
preincubation O O
of O O
lymphocytes O O
with O O
D609 O O
resulted O O
in O O
a O O
significant O O
diminution O O
of O O
ionizing O O
radiation O O
( O O
IR O O
) O O
-induced O O
1 O O
) O O
production O O
of O O
reactive O O
oxygen O O
species O O
; O O
2 O O
) O O
decrease O O
in O O
intracellular O O
reduced O O
glutathione O O
; O O
3 O O
) O O
oxidative O O
damage O O
to O O
proteins O O
and O O
lipids O O
; O O
and O O
4 O O
) O O
activation O O
of O O
nuclear B B_GENE
factor-kappaB I I_GENE
. O O

Moreover O O
, O O
when O O
D609 O O
( O O
50 O O
mg/kg O O
i.v. O O
) O O
was O O
administered O O
to O O
mice O O
10 O O
min O O
prior O O
to O O
total O O
body O O
IR O O
( O O
6.5 O O
and O O
8.5 O O
Gy O O
) O O
, O O
it O O
protected O O
the O O
mice O O
from O O
IR-induced O O
lethality O O
. O O

Thus O O
, O O
these O O
results O O
indicate O O
that O O
D609 O O
is O O
a O O
potent O O
antioxidant O O
and O O
has O O
the O O
ability O O
to O O
inhibit O O
IR-induced O O
cellular O O
oxidative O O
stress O O
. O O

Inhibition O O
of O O
AP-1 B B_GENE
by O O
the O O
glucocorticoid-inducible O O
protein B B_GENE/B_LOCATION
GILZ I I_GENE/I_LOCATION
. O O

The O O
immunosuppressive O O
effects O O
of O O
glucocorticoids O O
arise O O
largely O O
by O O
inhibition O O
of O O
cytokine O O
gene O O
expression O O
, O O
which O O
has O O
been O O
ascribed O O
to O O
interference O O
between O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
and O O
transcription B B_GENE
factors I I_GENE
such O O
as O O
AP-1 B B_GENE
and O O
NF-kappa B B_GENE
B I I_GENE
as O O
well O O
as O O
by O O
competition O O
for O O
common O O
coactivators O O
. O O

Here O O
we O O
show O O
that O O
glucocorticoid-induced O O
inhibition O O
of O O
interleukin-2 O O
mRNA O O
expression O O
in O O
activated O O
normal O O
T O O
cells O O
required O O
new O O
protein O O
synthesis O O
, O O
suggesting O O
that O O
this O O
phenomenon O O
is O O
secondary O O
to O O
expression O O
of O O
glucocorticoid-regulated O O
genes B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

One O O
of O O
the O O
most O O
prominent O O
glucocorticoid-induced O O
genes B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
glucocorticoid-induced B B_GENE
leucine I I_GENE
zipper I I_GENE
( O O
GILZ B B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
which O O
has O O
been O O
reported O O
to O O
inhibit O O
activation-induced O O
up-regulation O O
of O O
Fas B B_GENE
ligand I I_GENE
( I I_GENE
FasL I I_GENE
) I I_GENE
mRNA I I_GENE
. O O

Indeed O O
, O O
transient O O
expression O O
of O O
GILZ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Jurkat O O
T O O
cells O O
blocked O O
induction O O
of O O
a O O
reporter B B_GENE/B_LOCATION
construct I I_GENE/I_LOCATION
driven O O
by O O
the O O
FasL B B_GENE
promoter I I_GENE
. O O

This O O
could O O
be O O
accounted O O
for O O
by O O
GILZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-mediated O O
inhibition O O
of O O
Egr-2 B B_GENE
and O O
Egr-3 B B_GENE
, O O
NFAT/AP-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-inducible O O
transcription B B_GENE
factors I I_GENE
that O O
bind O O
a O O
regulatory B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
in O O
the O O
FasL B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
and O O
up-regulate O O
FasL O O
expression O O
. O O

Whereas O O
homodimerization O O
of O O
GILZ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O O
the O O
presence O O
of O O
its O O
leucine B B_GENE/B_PERSON
zipper I I_GENE/I_PERSON
, O O
the O O
interaction O O
with O O
c-Fos B B_GENE
and O O
c-Jun B B_GENE
occurred O O
through O O
the O O
N-terminal B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
60-amino B B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
GILZ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thus O O
, O O
GILZ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represents O O
a O O
glucocorticoid-induced O O
gene O O
product O O
that O O
can O O
inhibit O O
a O O
variety O O
of O O
activation-induced O O
events O O
, O O
at O O
least O O
in O O
part O O
by O O
direct O O
interference O O
with O O
AP-1 B B_GENE
, O O
and O O
is O O
therefore O O
a O O
candidate O O
for O O
a O O
mediator O O
of O O
glucocorticoid-induced O O
immunosuppression O O
. O O

Pharmacokinetic O O
differences O O
between O O
a O O
T O O
cell-tolerizing O O
and O O
a O O
T O O
cell-activating O O
peptide O O
. O O

Vaccination O O
with O O
a O O
peptide O O
representing O O
a O O
CTL O O
epitope O O
from O O
the O O
human O O
papillomavirus O O
( O O
HPV O O
) O O
16 O O
E7 B B_GENE
protein I I_GENE
induces O O
a O O
specific O O
CTL O O
response O O
that O O
prevents O O
the O O
outgrowth O O
of O O
HPV16 O O
E7-expressing O O
tumors O O
. O O

It O O
is O O
unclear O O
why O O
these O O
peptides O O
induce O O
such O O
opposite O O
effects O O
. O O

Results O O
show O O
that O O
the O O
tolerizing O O
peptide O O
spread O O
through O O
the O O
body O O
16 O O
times O O
faster O O
than O O
the O O
activating O O
peptide O O
and O O
was O O
cleared O O
at O O
least O O
2 O O
times O O
faster O O
. O O

The O O
HPV16 O O
E7 O O
peptide O O
kinetics O O
correlated O O
with O O
the O O
kinetics O O
of O O
HPV16 B B_VIRUS[BIO]/B_PROTEIN[GENE]
E7 I B_VIRUS[BIO]/I_PROTEIN[GENE]
-specific O O
CTL O O
induction O O
. O O

In O O
contrast O O
, O O
Ad5 O O
E1A O O
peptide O O
injection O O
resulted O O
in O O
physical O O
deletion O O
of O O
preexisting O O
Ad5 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
E1A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-specific O O
CTLs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
within O O
24 O O
h O O
after O O
injection O O
. O O

This O O
tolerization O O
occurred O O
at O O
the O O
time O O
when O O
the O O
peptide O O
reached O O
its O O
maximum O O
peptide O O
concentration O O
in O O
the O O
organs O O
. O O

Therefore O O
, O O
information O O
on O O
the O O
pharmacokinetics O O
of O O
peptides O O
is O O
vital O O
for O O
the O O
safety O O
and O O
efficacy O O
of O O
peptide-based O O
vaccines O O
. O O

Smad3 B B_GENE
and O O
Smad4 B B_GENE
mediate O O
transforming B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor-beta1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
IgA O O
expression O O
in O O
murine O O
B O O
lymphocytes O O
. O O

We O O
examined O O
the O O
involvement O O
of O O
Smad B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
TGF-beta1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
IgA O O
expression O O
. O O

To O O
investigate O O
its O O
signaling O O
mechanisms O O
, O O
the O O
lymphoma O O
cell O O
line O O
was O O
transfected O O
with O O
pFL3 B B_GENE
that O O
contains O O
the O O
TGF-beta-responsive B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
of O O
the O O
GLalpha B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
and O O
stimulated O O
with O O
TGF-beta1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Similar O O
to O O
endogenous B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GLalpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
TGF-beta1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
GLalpha B B_GENE/B_MEASURE
promoter I I_GENE/I_MEASURE
activity O O
and O O
overexpression O O
of O O
Smad3 B B_GENE
markedly O O
enhances O O
the O O
promoter O O
activity O O
. O O

This O O
activity O O
is O O
further O O
augmented O O
by O O
cotransfected B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Smad4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

On O O
the O O
other O O
hand O O
, O O
Smad7 B B_GENE
substantially O O
abrogates O O
the O O
synergistic O O
effect O O
of O O
Smad3/4 B B_GENE
on O O
GLalpha B B_GENE
promoter I I_GENE
activity O O
. O O

In O O
addition O O
, O O
overexpression O O
of O O
Smad3/4 B B_GENE
enhances O O
TGF-beta1 B B_GENE
-induced O O
endogenous B B_DISEASE/B_GENE
GLalpha I I_DISEASE/I_GENE
transcripts I I_DISEASE/I_GENE
in O O
normal O O
spleen O O
B O O
cell O O
s O O
. O O

Finally O O
, O O
in O O
the O O
presence O O
of O O
TGF-beta1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
overexpression O O
of O O
Smad3/4 B B_GENE
selectively O O
increases O O
both O O
surface O O
IgA O O
expression O O
and O O
IgA O O
production O O
. O O

The O O
results O O
from O O
the O O
present O O
study O O
indicate O O
that O O
Smad3 B B_GENE
, O O
Smad4 B B_GENE
, O O
and O O
Smad7 B B_GENE
, O O
at O O
least O O
in O O
part O O
, O O
serve O O
as O O
mediators O O
linking O O
TGF-beta1 B B_GENE/B_LOCATION
to O O
transcriptional O O
regulation O O
of O O
IgA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
switching I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
regulation O O
of O O
IgA O O
class O O
switching O O
. O O

The O O
translesion B B_GENE
DNA I I_GENE
polymerase I I_GENE
zeta I I_GENE
plays O O
a O O
major O O
role O O
in O O
Ig O O
and O O
bcl-6 O O
somatic O O
hypermutation O O
. O O

Ig O O
somatic O O
mutations O O
would O O
be O O
introduced O O
by O O
a O O
polymerase B B_GENE
( O O
pol B B_PROTEIN[GENE]/B_DISEASE
) O O
while O O
repairing O O
DNA O O
outside O O
main O O
DNA O O
replication O O
. O O

We O O
show O O
that O O
human O O
B O O
cells O O
constitutively O O
express O O
the O O
translesion B B_GENE/B_DISEASE
pol I I_GENE/I_DISEASE
zeta I I_GENE/I_DISEASE
, O O
which O O
effectively O O
extends O O
DNA O O
past O O
mismatched O O
bases O O
( O O
mispair O O
extender O O
) O O
, O O
and O O
pol B B_PROTEIN[GENE]
eta I I_PROTEIN[GENE]
, O O
which O O
bypasses O O
DNA O O
lesions O O
in O O
an O O
error-free O O
fashion O O
. O O

Upon O O
B B B_GENE
cell I I_GENE
receptor I I_GENE
( O O
BCR B B_PROTEIN[GENE]/B_LOCATION
) O O
engagement O O
and O O
coculture O O
with O O
activated O O
CD4+ O O
T O O
cells O O
, O O
these O O
lymphocytes O O
upregulated O O
pol B B_GENE
zeta I I_GENE
, O O
downregulated O O
pol B B_GENE
eta I I_GENE
, O O
and O O
mutated O O
the O O
Ig B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bcl-6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Inhibition O O
of O O
the O O
pol B B_GENE
zeta I I_GENE
REV3 B I_GENE
catalytic I I_GENE
subunit I I_GENE
by O O
specific O O
phosphorothioate-modified O O
oligonucleotides O O
impaired O O
Ig O O
and O O
bcl-6 O O
hypermutation O O
and O O
UV O O
damage-induced O O
DNA O O
mutagenesis O O
, O O
without O O
affecting O O
cell O O
cycle O O
or O O
viability O O
. O O

Thus O O
, O O
pol B B_GENE
zeta I I_GENE
plays O O
a O O
critical O O
role O O
in O O
Ig O O
and O O
bcl-6 O O
hypermutation O O
, O O
perhaps O O
facilitated O O
by O O
the O O
downregulation O O
of O O
pol B B_GENE
eta I I_GENE
. O O

Molecular O O
mechanism O O
of O O
cell O O
cycle O O
progression O O
induced O O
by O O
the O O
oncogene B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
product I B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Tax I B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
human O O
T-cell O O
leukemia O O
virus O O
type O O
I O O
. O O

The O O
trans-activator B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Tax I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
human O O
T-cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV-I O O
) O O
plays O O
an O O
important O O
role O O
in O O
the O O
development O O
of O O
adult O O
T-cell O O
leukemia O O
through O O
, O O
at O O
least O O
in O O
part O O
, O O
its O O
ability O O
to O O
stimulate O O
cell O O
growth O O
. O O

We O O
previously O O
reported O O
that O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
cell O O
cycle O O
progression O O
from O O
G0/G1 O O
phase O O
to O O
S O O
and O O
G2/M O O
phases O O
in O O
human O O
T-cell O O
line O O
Kit O O
225 O O
cells O O
. O O

Introduction O O
of O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O O
resting O O
Kit O O
225 O O
cells O O
induced O O
activation O O
of O O
the O O
G1/S O O
transition O O
regulation O O
cascade O O
consisting O O
of O O
activation O O
of O O
cyclin B B_GENE
dependent I I_GENE
kinase I I_GENE
2 I I_GENE
( O O
CDK2 B B_GENE
) O O
and O O
CDK4 B B_GENE
, O O
phosphorylation O O
of O O
the O O
Rb B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
an O O
increase O O
in O O
free O O
E2F B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
kinase O O
activation O O
was O O
found O O
to O O
result O O
from O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
expression O O
of O O
genes O O
for O O
cell B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cycle I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
regulatory I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
molecules I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
including O O
cyclin B B_GENE
D2 I I_GENE
, O O
cyclin B B_GENE
E I I_GENE
, O O
E2F1 B B_GENE
, O O
CDK2 B B_GENE
, O O
CDK4 B B_GENE
and O O
CDK6 B B_GENE/B_MEASURE
, O O
and O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
reduction O O
of O O
CDK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p19 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
INK4d B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
p27 B B_GENE
( I I_GENE
Kip1 I I_GENE
) I I_GENE
. O O

These O O
modulations O O
by O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
always O O
paralleled O O
the O O
ability O O
of O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
activate O O
the O O
NF-kappaB O O
transcription O O
pathway O O
. O O

These O O
results O O
indicate O O
the O O
important O O
role O O
of O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-mediated O O
trans-activation O O
of O O
the O O
genes O O
for O O
cell B B_GENE/B_ORGANIZATION
cycle I I_GENE/I_ORGANIZATION
regulatory I I_GENE/I_ORGANIZATION
molecules I I_GENE/I_ORGANIZATION
in O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
cell O O
cycle O O
progression O O
. O O

Cot B B_GENE
kinase I I_GENE
induces O O
cyclooxygenase-2 O O
expression O O
in O O
T O O
cells O O
through O O
activation O O
of O O
the O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cyclooxygenase-2 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
COX-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
induced O O
in O O
human O O
T O O
lymphocytes O O
upon O O
T B B_GENE/B_DISEASE
cell I I_GENE/I_DISEASE
receptor I I_GENE/I_DISEASE
triggering O O
. O O

Here O O
we O O
report O O
that O O
Cot B B_GENE
kinase I I_GENE
, O O
a O O
mitogen-activated B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
involved O O
in O O
T O O
cell O O
activation O O
, O O
up-regulates O O
COX-2 B B_GENE
gene I I_GENE
expression O O
in O O
Jurkat O O
T O O
cells O O
. O O

Induction O O
of O O
COX-2 O O
promoter O O
activity O O
by O O
Cot B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
occurred O O
mainly O O
through O O
activation O O
of O O
the O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NFAT B B_GENE/B_LOCATION
) O O
. O O

Even O O
more O O
, O O
coexpression O O
of O O
a O O
dominant O O
negative O O
version O O
of O O
NFAT B B_GENE
inhibited O O
Cot B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-mediated O O
COX-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O O
, O O
whereas O O
cotransfection O O
of O O
a O O
constitutively O O
active O O
version O O
of O O
the O O
calcium-dependent B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
calcineurin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synergizes O O
with O O
Cot B B_GENE
kinase I I_GENE
in O O
the O O
up-regulation O O
of O O
COX-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-driven O O
transcription O O
. O O

Strikingly O O
, O O
Cot B B_GENE/B_PERSON
kinase I I_GENE/I_PERSON
increased O O
transactivation O O
mediated O O
by O O
a O O
GAL4-NFAT B B_GENE/B_LOCATION
fusion I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
containing O O
the O O
N-terminal B B_GENE/B_LOCATION
transactivation I I_GENE/I_LOCATION
domain I I_GENE/I_LOCATION
of O O
NFATp B B_GENE
. O O

In O O
contrast O O
to O O
phorbol O O
ester O O
plus O O
calcium O O
ionophore O O
A23187 O O
, O O
Cot B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
increases O O
both O O
COX-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
and O O
NFAT B B_GENE
-mediated O O
transactivation O O
in O O
a O O
cyclosporin O O
A-independent O O
manner O O
. O O

These O O
data O O
indicate O O
that O O
Cot B B_GENE
kinase I I_GENE
up-regulates O O
COX-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-driven O O
transcription O O
through O O
the O O
NFAT B B_GENE/B_LOCATION
response I I_GENE/I_LOCATION
elements I I_GENE/I_LOCATION
, O O
being O O
the O O
Cot B B_GENE
kinase I I_GENE
-induced O O
NFAT B B_GENE
-dependent O O
transactivation O O
presumably O O
implicated O O
in O O
this O O
up-regulation O O
. O O

Positive O O
and O O
negative O O
roles O O
of O O
the O O
trans-acting B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
T I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
cell I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
factor-1 I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
for O O
the O O
acquisition O O
of O O
distinct O O
Ly-49 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MHC I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
NK O O
cells O O
. O O

Members O O
of O O
the O O
Ly-49 B B_GENE/B_PERSON
gene I I_GENE/I_PERSON
family I I_GENE/I_PERSON
code O O
for O O
class B B_GENE
I I I_GENE
MHC-specific I I_GENE
receptors I I_GENE
that O O
regulate O O
NK O O
cell O O
function O O
. O O

Due O O
to O O
a O O
combinatorial O O
distribution O O
of O O
Ly-49 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
NK O O
cells O O
display O O
considerable O O
clonal O O
heterogeneity O O
. O O

The O O
acquisition O O
of O O
one O O
Ly-49 B B_GENE
receptor I I_GENE
, O O
Ly-49A B B_GENE/B_MEASURE
is O O
strictly O O
dependent O O
on O O
the O O
transcriptional B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
trans-acting I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cell-specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Indeed O O
, O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binds O O
to O O
two O O
sites O O
in O O
the O O
Ly-49a B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
and O O
regulates O O
its O O
activity O O
, O O
suggesting O O
that O O
the O O
Ly-49a B B_GENE/B_PERSON
gene I I_GENE/I_PERSON
is O O
a O O
direct O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O O
. O O

We O O
show O O
in O O
this O O
study O O
, O O
using O O
TCF-1 B B_GENE/B_NUMBER[MEASURE]
beta I I_GENE/I_NUMBER[MEASURE]
( I I_GENE/I_NUMBER[MEASURE]
2 I I_GENE/I_NUMBER[MEASURE]
) I I_GENE/I_NUMBER[MEASURE]
-microglobulin I I_GENE/I_NUMBER[MEASURE]
double-deficient O O
mice O O
, O O
that O O
these O O
repertoire O O
alterations O O
are O O
not O O
due O O
to O O
Ly-49/MHC O O
class O O
I O O
interactions O O
. O O

Our O O
findings O O
rather O O
suggest O O
a O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O O
, O O
cell O O
autonomous O O
effect O O
on O O
the O O
acquisition O O
of O O
multiple O O
Ly-49 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Besides O O
reduced O O
receptor O O
usage O O
( O O
Ly-49A B B_PROTEIN[GENE]/B_LOCATION
and I I_PROTEIN[GENE]/I_LOCATION
D I I_PROTEIN[GENE]/I_LOCATION
) O O
, O O
we O O
also O O
observed O O
no O O
effect O O
( O O
Ly-49C B B_PROTEIN[GENE]/B_LOCATION
) O O
and O O
significantly O O
expanded O O
( O O
Ly-49G B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
receptor O O
usage O O
in O O
the O O
absence O O
of O O
TCF-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

These O O
effects O O
did O O
not O O
in O O
all O O
cases O O
correlate O O
with O O
the O O
presence O O
of O O
TCF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
respective O O
proximal B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
findings O O
reveal O O
an O O
important O O
role O O
of O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
formation O O
of O O
the O O
NK B B_GENE
cell I I_GENE
receptor I I_GENE
repertoire O O
. O O

Ligation O O
of O O
CD11b B B_GENE
and O O
CD11c B B_GENE
beta I I_GENE
( I I_GENE
2 I I_GENE
) I I_GENE
integrins B I_GENE
by O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
soluble B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CD23 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
macrophage B B_GENE
inflammatory I I_GENE
protein I I_GENE
1alpha I I_GENE
( O O
MIP-1alpha B B_GENE
) O O
and O O
MIP-1beta B B_GENE
production O O
in O O
primary O O
human O O
monocytes O O
through O O
a O O
pathway O O
dependent O O
on O O
nuclear B B_GENE
factor-kappaB I I_GENE
. O O

We O O
found O O
that O O
ligation O O
of O O
CD11b B B_GENE
or O O
CD11c B B_GENE
but O O
not O O
CD11a B B_GENE/B_MEASURE
alpha I I_GENE/I_MEASURE
chains I I_GENE/I_MEASURE
of O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
integrins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
soluble B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CD23 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sCD23 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rapidly O O
induced O O
transcription O O
and O O
secretion O O
of O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
macrophage B B_MEASURE/B_GENE
inflammatory I I_MEASURE/I_GENE
protein I I_MEASURE/I_GENE
( I I_MEASURE/I_GENE
MIP I I_MEASURE/I_GENE
) I I_MEASURE/I_GENE
1alpha I I_MEASURE/I_GENE
, O O
and O O
MIP-1beta B B_GENE
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
showed O O
that O O
sCD23 B B_GENE
or O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
CD11b B B_GENE
or O O
to O O
CD11c B B_GENE
up-regulated O O
DNA-binding O O
activity O O
of O O
NF-kappaB B B_GENE
. O O

Activation O O
of O O
NF-kappaB B B_GENE
was O O
accompanied O O
by O O
degradation O O
of O O
its O O
cytosolic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IkappaB-alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Blockade O O
of O O
depletion O O
of O O
IkappaB-alpha B B_GENE
by O O
proteasome O O
inhibitors O O
( O O
proteasome O O
inhibitor O O
I O O
or O O
acetyl-leucinyl-leucinyl-norleucinal O O
) O O
led O O
to O O
concomitant O O
inhibition O O
of O O
NF-kappaB O O
DNA-binding O O
activity O O
and O O
expression O O
of O O
MIP-1alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MIP-1beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
messenger I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
beta O O
( O O
2 O O
) O O
integrin O O
ligation O O
. O O

These O O
results O O
suggest O O
that O O
triggering O O
of O O
CD11b B B_GENE
or O O
CD11c B B_GENE
beta I I_GENE
( I I_GENE
2 I I_GENE
) I I_GENE
integrin O O
on O O
primary O O
human O O
monocytes O O
provides O O
activation O O
signals O O
leading O O
to O O
nuclear O O
translocation O O
of O O
NF-kappaB B B_GENE
and O O
subsequent O O
secretion O O
of O O
MIP-1alpha B B_GENE
and O O
MIP-1beta B B_GENE
that O O
may O O
have O O
an O O
important O O
role O O
in O O
recruitment O O
of O O
other O O
inflammatory O O
cells O O
during O O
initiation O O
of O O
an O O
inflammatory O O
response O O

Interferon-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IFN-gamma B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
a O O
cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
exerts O O
many O O
pro-atherosclerotic O O
effects O O
in O O
vivo O O
, O O
causes O O
up-regulation O O
of O O
ACAT-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
blood O O
monocyte-derived O O
macrophages O O
and O O
macrophage-like O O
cells O O
but O O
not O O
in O O
other O O
cell O O
types O O
. O O

To O O
examine O O
the O O
molecular O O
nature O O
of O O
this O O
observation O O
, O O
we O O
identified O O
within O O
the O O
ACAT-1 B B_GENE/B_MEASURE
P1 I I_GENE/I_MEASURE
promoter I I_GENE/I_MEASURE
a O O
159-base B B_GENE/B_MEASURE
pair I I_GENE/I_MEASURE
core I I_GENE/I_MEASURE
region I I_GENE/I_MEASURE
. O O

This O O
region O O
contains O O
4 O O
Sp1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
an O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GAS B B_GENE/B_BACTERIUM[BIO]
) O O
that O O
overlaps O O
with O O
the O O
second O O
Sp1 B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
. O O

Inhaled O O
nitric O O
oxide O O
down-regulates O O
intrapulmonary O O
nitric O O
oxide O O
production O O
in O O
lipopolysaccharide-induced O O
acute O O
lung O O
injury O O
. O O

OBJECTIVE O O
: O O
To O O
examine O O
whether O O
inhaled O O
nitric O O
oxide O O
( O O
NO O O
) O O
affected O O
the O O
intrapulmonary O O
production O O
of O O
NO O O
, O O
reactive O O
oxygen O O
species O O
, O O
and O O
nuclear B B_GENE
factor-kappaB I I_GENE
in O O
a O O
lipopolysaccharide O O
( O O
LPS O O
) O O
-induced O O
model O O
of O O
acute O O
lung O O
injury O O
. O O

DESIGN O O
: O O
Prospective O O
, O O
randomized O O
, O O
laboratory O O
study O O
. O O

SETTING O O
: O O
Experimental O O
laboratory O O
at O O
a O O
biomedical O O
institute O O
. O O

SUBJECTS O O
: O O
Twenty O O
male O O
rabbits O O
weighing O O
2.5-3.5 O O
kg O O
. O O

INTERVENTIONS O O
: O O
Saline O O
or O O
LPS O O
( O O
5 O O
mg/kg O O
of O O
body O O
weight O O
) O O
was O O
administered O O
intravenously O O
with O O
or O O
without O O
NO O O
inhalation O O
( O O
10 O O
ppm O O
) O O
in O O
each O O
group O O
of O O
five O O
rabbits O O
. O O

MEASUREMENTS O O
AND O O
MAIN O O
RESULTS O O
: O O
LPS O O
increased O O
the O O
lung O O
leak O O
index O O
, O O
the O O
neutrophils O O
and O O
NO O O
levels O O
in O O
bronchoalveolar O O
lavage O O
fluid O O
, O O
and O O
NO O O
levels O O
produced O O
by O O
resting O O
and O O
stimulated O O
alveolar O O
macrophages O O
. O O

Inhaled O O
NO O O
decreased O O
the O O
lung O O
leak O O
index O O
, O O
the O O
neutrophils O O
and O O
NO O O
levels O O
as O O
measured O O
by O O
nitrite O O
levels O O
in O O
the O O
lavage O O
fluid O O
, O O
and O O
NO O O
produced O O
by O O
the O O
resting O O
and O O
stimulated O O
alveolar O O
macrophages O O
. O O

Inhaled O O
NO O O
also O O
blocked O O
the O O
activities O O
of O O
reactive O O
oxygen O O
species O O
and O O
nuclear B B_GENE
factor-kappaB I I_GENE
binding O O
to O O
DNA O O
in O O
lavage O O
cells O O
and O O
in O O
alveolar O O
macrophages O O
. O O

CONCLUSION O O
: O O
Inhaled O O
NO O O
attenuates O O
LPS-induced O O
acute O O
lung O O
injury O O
, O O
possibly O O
by O O
decreasing O O
NO O O
production O O
in O O
the O O
lungs O O
. O O

The O O
mechanism O O
of O O
reducing O O
NO O O
production O O
resulting O O
from O O
inhaled O O
NO O O
may O O
involve O O
, O O
in O O
part O O
, O O
the O O
activities O O
of O O
reactive O O
oxygen O O
species O O
and/or O O
nuclear B B_GENE
factor-kappaB I I_GENE
. O O

Treatment O O
of O O
allergic O O
airway O O
inflammation O O
and O O
hyperresponsiveness O O
by O O
antisense-induced O O
local O O
blockade O O
of O O
GATA-3 B B_GENE
expression O O
. O O

Recent O O
studies O O
in O O
transgenic O O
mice O O
have O O
revealed O O
that O O
expression O O
of O O
a O O
dominant O O
negative O O
form O O
of O O
the O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
GATA-3 I I_GENE/I_LOCATION
in O O
T O O
cells O O
can O O
prevent O O
T O O
helper O O
cell O O
type O O
2 O O
( O O
Th2 O O
) O O
-mediated O O
allergic O O
airway O O
inflammation O O
in O O
mice O O
. O O

However O O
, O O
it O O
remains O O
unclear O O
whether O O
GATA-3 B B_GENE
plays O O
a O O
role O O
in O O
the O O
effector O O
phase O O
of O O
allergic O O
airway O O
inflammation O O
and O O
whether O O
antagonizing O O
the O O
expression O O
and/or O O
function O O
of O O
GATA-3 B B_GENE
can O O
be O O
used O O
for O O
the O O
therapy O O
of O O
allergic O O
airway O O
inflammation O O
and O O
hyperresponsiveness O O
. O O

Here O O
, O O
we O O
analyzed O O
the O O
effects O O
of O O
locally O O
antagonizing O O
GATA-3 B B_GENE
function O O
in O O
a O O
murine O O
model O O
of O O
asthma O O
. O O

In O O
a O O
murine O O
model O O
of O O
asthma O O
associated O O
with O O
allergic O O
pulmonary O O
inflammation O O
and O O
hyperresponsiveness O O
in O O
ovalbumin O O
( O O
OVA O O
) O O
-sensitized O O
mice O O
, O O
local O O
intranasal O O
administration O O
of O O
fluorescein O O
isothiocyanate-labeled O O
GATA-3 O O
antisense O O
oligonucleotides O O
led O O
to O O
DNA O O
uptake O O
in O O
lung O O
cells O O
associated O O
with O O
a O O
reduction O O
of O O
intracellular O O
GATA-3 O O
expression O O
. O O

These O O
data O O
indicate O O
a O O
critical O O
role O O
for O O
GATA-3 B B_GENE
in O O
the O O
effector O O
phase O O
of O O
a O O
murine O O
asthma O O
model O O
and O O
suggest O O
that O O
local O O
delivery O O
of O O
GATA-3 O O
antisense O O
oligonucleotides O O
may O O
be O O
a O O
novel O O
approach O O
for O O
the O O
treatment O O
of O O
airway O O
hyperresponsiveness O O
such O O
as O O
in O O
asthma O O
. O O

This O O
approach O O
has O O
the O O
potential O O
advantage O O
of O O
suppressing O O
the O O
expression O O
of O O
various O O
proinflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Th2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
simultaneously O O
rather O O
than O O
suppressing O O
the O O
activity O O
of O O
a O O
single O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODS O O
AND O O
RESULTS O O
: O O
BALB/c O O
mice O O
, O O
making O O
a O O
CD4+ O O
Th2 O O
( O O
IL-4+ O O
) O O
cell O O
response O O
, O O
express O O
both O O
MHC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
d I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
IE B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
d I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
are O O
atherosclerosis-resistant O O
. O O

C57Bl/6 O O
mice O O
produce O O
a O O
CD4+ O O
Th1 O O
( O O
interferon O O
[ O O
IFN O O
] O O
gamma+ O O
) O O
response O O
, O O
express O O
IA B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
b I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
no O O
IE B B_DISEASE/B_GENE
, O O
and O O
are O O
atherosclerosis-prone O O
. O O

Immunohistology O O
revealed O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
IL-4 B B_GENE
, O O
colocalized O O
with O O
activated O O
macrophages O O
. O O

CONCLUSIONS O O
: O O
In O O
mildly O O
hypercholesterolemic O O
C57Bl/6 O O
mice O O
, O O
presence O O
of O O
IA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
b I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O O
absence O O
of O O
IE B B_DISEASE/B_GENE
regulated O O
CD4+ O O
T O O
helper-cell O O
phenotype O O
; O O
fatty O O
lesions O O
were O O
proportional O O
to O O
IFNgamma+ O O
Th1 O O
cells O O
in O O
both O O
C57Bl/6 O O
and O O
BALB/c O O
strains O O
. O O

IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
may O O
participate O O
through O O
macrophage O O
activation O O
, O O
whereas O O
IL-4 B B_GENE
may O O
act O O
to O O
limit O O
Th1-cell O O
response O O
. O O

Requirement O O
for O O
p38 B B_GENE
and O O
p44/p42 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
RAGE B B_GENE
-mediated O O
nuclear B B_GENE
factor-kappaB I I_GENE
transcriptional O O
activation O O
and O O
cytokine O O
secretion O O
. O O

Advanced O O
glycation O O
end O O
product O O
( O O
AGE O O
) O O
activation O O
of O O
the O O
signal-transducing B B_GENE/B_DISEASE
receptor I I_GENE/I_DISEASE
for I I_GENE/I_DISEASE
AGE I I_GENE/I_DISEASE
( O O
RAGE B B_GENE/B_DISEASE
) O O
has O O
been O O
linked O O
to O O
a O O
proinflammatory O O
phenotypic O O
change O O
within O O
cells O O
. O O

However O O
, O O
the O O
precise O O
intracellular O O
signaling O O
pathways O O
involved O O
have O O
not O O
been O O
elucidated O O
. O O

We O O
demonstrate O O
here O O
that O O
human O O
serum O O
albumin O O
modified O O
with O O
N O O
( O O
varepsilon O O
) O O
- O O
( O O
carboxymethyl O O
) O O
lysine O O
( O O
CML O O
) O O
, O O
a O O
major O O
AGE O O
adduct O O
that O O
progressively O O
accumulates O O
with O O
aging O O
, O O
diabetes O O
, O O
and O O
renal O O
failure O O
, O O
induced O O
nuclear B B_GENE/B_DISEASE
factor I I_GENE/I_DISEASE
( I I_GENE/I_DISEASE
NF I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
-kappaB I I_GENE/I_DISEASE
-driven O O
reporter O O
gene O O
expression O O
in O O
human O O
monocytic O O
THP-1 O O
cells O O
. O O

Signal O O
transduction O O
from O O
RAGE B B_GENE
to O O
NF-kappaB B B_GENE
involved O O
the O O
generation O O
of O O
reactive O O
oxygen O O
species O O
, O O
since O O
reporter O O
gene O O
expression O O
was O O
blocked O O
with O O
the O O
antioxidant O O
N-acetyl-L-cysteine O O
. O O

CML-modified B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
albumin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
produced O O
rapid O O
transient O O
activation O O
of O O
tyrosine O O
phosphorylation O O
, O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE
) O O
, O O
but O O
not O O
c-Jun B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RAGE B B_GENE
-mediated O O
NF-kappaB O O
activation O O
was O O
suppressed O O
by O O
the O O
selective O O
p38 B B_GENE
MAPK I I_GENE
inhibitor O O
SB203580 O O
and O O
by O O
coexpression O O
of O O
a O O
kinase-dead O O
p38 O O
dominant-negative O O
mutant O O
. O O

These O O
results O O
indicate O O
that O O
p38 B B_GENE
MAPK I I_GENE
activation O O
mediates O O
RAGE B B_GENE
-induced O O
NF-kappaB B B_GENE
-dependent O O
secretion O O
of O O
proinflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
suggest O O
that O O
accelerated O O
inflammation O O
may O O
be O O
a O O
consequence O O
of O O
cellular O O
activation O O
induced O O
by O O
this O O
receptor O O
. O O

Antigen-receptor O O
cross-linking O O
and O O
lipopolysaccharide O O
trigger O O
distinct O O
phosphoinositide B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3-kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-dependent O O
pathways O O
to O O
NF-kappa O O
B O O
activation O O
in O O
primary O O
B O O
cells O O
. O O

The O O
NF-kappaB/Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
play O O
an O O
important O O
role O O
in O O
the O O
expression O O
of O O
genes O O
involved O O
in O O
B O O
cell O O
development O O
, O O
differentiation O O
and O O
function O O
. O O

Nuclear B B_GENE
NF-kappaB I I_GENE
is O O
induced O O
in O O
B O O
cells O O
by O O
engagement O O
of O O
either O O
the O O
BCR B B_GENE
or O O
CD40 B B_GENE/B_LOCATION
or O O
by O O
stimulation O O
with O O
lipopolysaccharide O O
( O O
LPS O O
) O O
. O O

Despite O O
the O O
importance O O
of O O
NF-kappaB B B_GENE
to O O
B O O
cell O O
function O O
, O O
little O O
is O O
known O O
about O O
the O O
signaling O O
pathways O O
leading O O
to O O
NF-kappaB O O
activation O O
. O O

In O O
this O O
report O O
we O O
address O O
the O O
role O O
of O O
phosphoinositide B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3'-kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI B B_GENE/B_LOCATION
3-kinase I I_GENE/I_LOCATION
) O O
in O O
BCR B B_GENE
- O O
and O O
LPS-induced O O
NF-kappaB O O
activation O O
using O O
populations O O
of O O
primary O O
murine O O
resting O O
B O O
cells O O
. O O

Using O O
the O O
specific O O
pharmacological O O
inhibitors O O
of O O
PI B B_GENE
3-kinase I I_GENE
, O O
Wortmannin O O
and O O
LY294002 O O
, O O
we O O
demonstrate O O
that O O
PI B B_GENE
3-kinase I I_GENE
activity O O
is O O
vital O O
for O O
BCR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
NF-kappaB B B_GENE
DNA-binding O O
activity O O
. O O

Furthermore O O
, O O
we O O
show O O
that O O
this O O
is O O
achieved O O
via O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-dependent O O
degradation O O
of O O
IkappaBalpha B B_GENE
. O O

Similar O O
analyses O O
reveal O O
that O O
PI B B_GENE
3-kinase I I_GENE
is O O
also O O
critical O O
in O O
triggering O O
NF-kappaB B B_GENE
DNA-binding O O
activity O O
and O O
IkappaBalpha B B_GENE
degradation O O
following O O
LPS O O
stimulation O O
. O O

Interestingly O O
, O O
a O O
PKC O O
inhibitor O O
which O O
blocked O O
the O O
BCR B B_GENE
-induced O O
IkappaBalpha B B_GENE
degradation O O
had O O
no O O
effect O O
on O O
the O O
degradation O O
of O O
IkappaBalpha B B_GENE
after O O
LPS O O
stimulation O O
. O O

Taken O O
together O O
, O O
our O O
results O O
indicate O O
the O O
involvement O O
of O O
PI B B_GENE
3-kinase I I_GENE
in O O
at O O
least O O
two O O
distinct O O
signaling O O
pathways O O
leading O O
to O O
activation O O
of O O
NF-kappaB B B_GENE
in O O
B O O
cells O O
. O O

Although O O
DRA1*0101/DRB1*0401 O O
and O O
DRA1*0101/DRB1*0404 O O
are O O
structurally O O
very O O
similar O O
, O O
nonoverlapping O O
VP16 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
epitopes I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
identified O O
, O O
illustrating O O
high O O
selectivity O O
of O O
individual O O
allele O O
polymorphisms O O
within O O
common O O
MHC O O
variants O O
. O O

Localized O O
pancreatic O O
NF-kappaB O O
activation O O
and O O
inflammatory O O
response O O
in O O
taurocholate-induced O O
pancreatitis O O
. O O

Transcription B B_GENE
factor I I_GENE
nuclear I I_GENE
factor-kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
is O O
activated O O
in O O
cerulein O O
pancreatitis O O
and O O
mediates O O
cytokine O O
expression O O
. O O

Here O O
we O O
report O O
upregulation O O
of O O
NF-kappaB B B_GENE
and O O
inflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
their O O
correlation O O
with O O
local O O
pancreatic O O
injury O O
, O O
in O O
a O O
model O O
of O O
severe O O
pancreatitis O O
. O O

Rats O O
received O O
intraductal O O
infusion O O
of O O
taurocholate O O
or O O
saline O O
, O O
and O O
the O O
pancreatic O O
head O O
and O O
tail O O
were O O
analyzed O O
separately O O
. O O

NF-kappaB B B_GENE
and O O
activator B B_GENE/B_LOCATION
protein-1 I I_GENE/I_LOCATION
( O O
AP-1 B B_GENE
) O O
activation O O
were O O
assessed O O
by O O
gel O O
shift O O
assay O O
, O O
and O O
mRNA O O
expression O O
of O O
interleukin-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
tumor B B_GENE/B_LOCATION
necrosis I I_GENE/I_LOCATION
factor-alpha I I_GENE/I_LOCATION
, O O
KC O O
, O O
monocyte B B_GENE/B_LOCATION
chemoattractant I I_GENE/I_LOCATION
protein-1 I I_GENE/I_LOCATION
, O O
and O O
inducible B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nitric I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oxide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
assessed O O
by O O
semiquantitative O O
RT-PCR O O
. O O

Morphological O O
damage O O
and O O
trypsin O O
activation O O
were O O
much O O
greater O O
in O O
the O O
pancreatic O O
head O O
than O O
tail O O
, O O
in O O
parallel O O
with O O
a O O
stronger O O
activation O O
of O O
NF-kappaB B B_GENE
and I I_GENE
cytokine I I_GENE
mRNA I I_GENE
. O O

Saline O O
infusion O O
mildly O O
affected O O
these O O
parameters O O
. O O

AP-1 B B_GENE
was O O
strongly O O
activated O O
in O O
both O O
pancreatic O O
segments O O
after O O
either O O
taurocholate O O
or O O
saline O O
infusion O O
. O O

NF-kappaB B B_GENE
inhibition O O
with O O
N-acetylcysteine O O
ameliorated O O
the O O
local O O
inflammatory O O
response O O
. O O

Correlation O O
between O O
localized O O
NF-kappaB B B_GENE
activation O O
, O O
cytokine O O
upregulation O O
, O O
and O O
tissue O O
damage O O
suggests O O
a O O
key O O
role O O
for O O
NF-kappaB B B_GENE
in O O
the O O
development O O
of O O
the O O
inflammatory O O
response O O
of O O
acute O O
pancreatitis O O
. O O

CD45 B B_GENE
tyrosine I I_GENE
phosphatase I I_GENE
controls O O
common O O
gamma-chain B B_GENE
cytokine I I_GENE
-mediated O O
STAT B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
extracellular O O
signal-related O O
kinase O O
phosphorylation O O
in O O
activated O O
human O O
lymphoblasts O O
: O O
inhibition O O
of O O
proliferation O O
without O O
induction O O
of O O
apoptosis O O
. O O

In O O
experiments O O
with O O
the O O
CD45R0 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mAb I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
UCHL-1 I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
control B B_GENE/B_TIME[MEASURE]
CD45 I I_GENE/I_TIME[MEASURE]
mAbs I I_GENE/I_TIME[MEASURE]
, O O
we O O
found O O
significant O O
inhibition O O
of O O
proliferation O O
. O O

Interestingly O O
, O O
the O O
pan-CD45 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mAb I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GAP8.3 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
most O O
effective O O
in O O
inhibition O O
of O O
OKT-3-mediated O O
proliferation O O
in O O
quiescent O O
lymphocytes O O
, O O
was O O
ineffective O O
in O O
lymphoblasts O O
. O O

In O O
contrast O O
, O O
after O O
addition O O
of O O
OKT-3 B B_GENE
to O O
IL-4 B B_GENE
- O O
and O O
IL-7 B B_GENE
-stimulated O O
proliferation O O
assays O O
, O O
UCHL-1 B B_GENE/B_PERSON
signals O O
could O O
not O O
significantly O O
alter O O
cellular O O
proliferation O O
. O O

In O O
Western O O
blots O O
using O O
mAbs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
detecting O O
phosphorylated B B_GENE
STAT-3 I I_GENE
, I I_GENE
STAT-5 I I_GENE
, I I_GENE
STAT-6 I I_GENE
, O O
or O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1/2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
found O O
that O O
CD45R0 O O
signaling O O
could O O
effectively O O
diminish O O
phosphorylation O O
of O O
these O O
intracellular O O
signaling O O
components O O
. O O

Using O O
RT-PCR O O
, O O
we O O
found O O
that O O
CD45R0 O O
signaling O O
inhibited O O
IL-2 O O
mRNA O O
production O O
without O O
major O O
influence O O
on O O
IL-13 B B_GENE
, O O
IL-5 B B_GENE
, O O
or O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
. O O

Costimulation O O
with O O
OKT-3 B B_GENE
and O O
IL-2 B B_GENE/B_LOCATION
optimally O O
induced O O
secretion O O
of O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
IL-5 B B_GENE
, O O
which O O
was O O
not O O
decreased O O
by O O
CD45 O O
signals O O
. O O

Furthermore O O
, O O
we O O
show O O
the O O
existence O O
of O O
CD45 B B_GENE/B_BIO
epitopes I I_GENE/I_BIO
( O O
GAP8.3 B B_GENE/B_LOCATION
) O O
, O O
which O O
are O O
active O O
and O O
critical O O
for O O
signaling O O
in O O
quiescent O O
lymphocytes O O
, O O
but O O
are O O
nonfunctional O O
in O O
activated O O
human O O
lymphoblasts O O
. O O

Pax5 B B_GENE/B_LOCATION
determines O O
the O O
identity O O
of O O
B O O
cells O O
from O O
the O O
beginning O O
to O O
the O O
end O O
of O O
B-lymphopoiesis O O
. O O

Despite O O
being O O
one O O
of O O
the O O
most O O
intensively O O
studied O O
cell O O
types O O
, O O
the O O
molecular O O
basis O O
of O O
B O O
cell O O
specification O O
is O O
largely O O
unknown O O
. O O

The O O
Pax5 B B_GENE
gene I I_GENE
encoding O O
the O O
transcription B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
BSAP I I_GENE/I_MEASURE
is O O
required O O
for O O
progression O O
of O O
B-lymphopoiesis O O
beyond O O
the O O
pro-B O O
cell O O
stage O O
. O O

Pax5-deficient O O
pro-B O O
cells O O
are O O
, O O
however O O
, O O
not O O
yet O O
committed O O
to O O
the O O
B-lymphoid O O
lineage O O
, O O
but O O
instead O O
have O O
a O O
broad O O
lymphomyeloid O O
developmental O O
potential O O
. O O

Pax5 B B_GENE
appears O O
to O O
mediate O O
B-lineage O O
commitment O O
by O O
repressing O O
the O O
transcription O O
of O O
non-B-lymphoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
simultaneously O O
activating O O
the O O
expression O O
of O O
B-lineage-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Once O O
committed O O
to O O
the O O
B-lineage O O
, O O
B O O
cells O O
require O O
Pax5 B B_GENE/B_MEASURE
function O O
to O O
maintain O O
their O O
B-lymphoid O O
identity O O
throughout O O
B O O
cell O O
development O O

Partners O O
in O O
transcription O O
: O O
NFAT B B_GENE
and O O
AP-1 B B_GENE
. O O

Combinatorial O O
regulation O O
is O O
a O O
powerful O O
mechanism O O
that O O
enables O O
tight O O
control O O
of O O
gene O O
expression O O
, O O
via O O
integration O O
of O O
multiple O O
signaling O O
pathways O O
that O O
induce O O
different O O
transcription B B_GENE/B_LOCATION
factors I I_GENE/I_LOCATION
required O O
for O O
enhanceosome O O
assembly O O
. O O

The O O
four O O
calcium-regulated O O
transcription B B_GENE/B_BIO
factors I I_GENE/I_BIO
of O O
the O O
NFAT B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
family I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
act O O
synergistically O O
with O O
AP-1 B B_GENE/B_BIO
( I I_GENE/I_BIO
Fos/Jun I I_GENE/I_BIO
) I I_GENE/I_BIO
proteins I I_GENE/I_BIO
on O O
composite O O
DNA O O
elements O O
which O O
contain O O
adjacent O O
NFAT B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
where O O
they O O
form O O
highly O O
stable O O
ternary O O
complexes O O
to O O
regulate O O
the O O
expression O O
of O O
diverse O O
inducible O O
genes O O
. O O

A O O
fifth O O
member O O
of O O
the O O
NFAT B B_GENE/B_BIO
family I I_GENE/I_BIO
, O O
NFAT5 B B_GENE/B_LOCATION
, O O
controls O O
the O O
cellular O O
response O O
to O O
osmotic O O
stress O O
, O O
by O O
a O O
mechanism O O
that O O
requires O O
dimer O O
formation O O
and O O
is O O
independent O O
of O O
calcineurin B B_GENE
or O O
of O O
interaction O O
with O O
AP-1 B B_GENE
. O O

Balanced O O
activation O O
of O O
NFAT B B_GENE
and O O
AP-1 B B_GENE
is O O
known O O
to O O
be O O
required O O
for O O
productive O O
immune O O
responses O O
, O O
but O O
the O O
role O O
of O O
NFAT O O
: O O
AP-1 O O
interactions O O
in O O
other O O
cell O O
types O O
and O O
biological O O
processes O O
remains O O
to O O
be O O
understood O O
. O O

Two O O
coxsackievirus O O
B3 O O
( O O
CVB3 O O
) O O
variants O O
( O O
H3 O O
and O O
H310A1 O O
) O O
differ O O
by O O
a O O
single O O
amino O O
acid O O
mutation O O
in O O
the O O
VP2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
capsid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

H3 O O
induces O O
severe O O
myocarditis O O
in O O
BALB/c O O
mice O O
, O O
but O O
H310A1 O O
is O O
amyocarditic O O
. O O

Infection O O
with O O
H3 O O
, O O
but O O
not O O
H310A1 O O
, O O
preferentially O O
activates O O
Vgamma4 O O
Vdelta4 O O
cells O O
, O O
which O O
are O O
strongly O O
positive O O
for O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interferon I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IFN-gamma B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
whereas O O
Vgamma1 O O
Vdelta4 O O
cells O O
are O O
increased O O
in O O
both O O
H3 O O
and O O
H310A1 O O
virus-infected O O
animals O O
. O O

Depletion O O
of O O
Vgamma1 O O
( O O
+ O O
) O O
cells O O
using O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
anti-Vgamma1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
enhanced O O
myocarditis O O
and O O
CD4 O O
( O O
+ O O
) O O
- O O
, O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
+ O O
) O O
-cell O O
responses O O
in O O
both O O
H3- O O
and O O
H310A1-infected O O
mice O O
yet O O
decreased O O
the O O
CD4 O O
( O O
+ O O
) O O
- O O
, O O
IL-4 O O
( O O
+ O O
) O O
-cell O O
response O O
. O O

The O O
role O O
of O O
cytokine O O
production O O
by O O
Vgamma1 O O
( O O
+ O O
) O O
and O O
Vgamma4 O O
( O O
+ O O
) O O
T O O
cells O O
was O O
investigated O O
by O O
adoptively O O
transferring O O
these O O
cells O O
isolated O O
from O O
H3-infected O O
BALB/c O O
Stat4 O O
knockout O O
( O O
Stat4ko O O
) O O
( O O
defective O O
in O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
) O O
or O O
BALB/c O O
Stat6ko O O
( O O
defective O O
in O O
IL-4 O O
expression O O
) O O
mice O O
into O O
H3 O O
virus-infected O O
wild-type O O
BALB/c O O
recipients O O
. O O

Vgamma4 O O
and O O
Vgamma1 O O
( O O
+ O O
) O O
T O O
cells O O
from O O
Stat4ko O O
mice O O
expressed O O
IL-4 B B_GENE
but O O
no O O
or O O
minimal O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
these O O
cell O O
populations O O
derived O O
from O O
Stat6ko O O
mice O O
expressed O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
but O O
no O O
IL-4 B B_GENE
. O O

Plasmin B B_GENE
-induced O O
expression O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
monocytes O O
involves O O
AP-1 B B_GENE
and O O
IKKbeta B B_GENE
-mediated O O
NF-kappaB O O
activation O O
. O O

It O O
was O O
previously O O
shown O O
that O O
plasmin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activates O O
human O O
peripheral O O
monocytes O O
in O O
terms O O
of O O
lipid O O
mediator O O
release O O
and O O
chemotactic O O
migration O O
. O O

Here O O
it O O
is O O
demonstrated O O
that O O
plasmin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
proinflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
release O O
and O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TF B B_PROTEIN[GENE]
) O O
expression O O
by O O
monocytes O O
. O O

Plasmin B B_GENE/B_MEASURE
0.043 O O
to O O
1.43 O O
CTA O O
U/mL O O
, O O
but O O
not O O
active B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
site-blocked I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
triggered O O
concentration-dependent O O
expression O O
of O O
mRNA O O
for O O
interleukin-1alpha B B_GENE
( O O
IL-1alpha B B_GENE
) O O
, O O
IL-1beta B B_GENE
, O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
and O O
TF B B_GENE
with O O
maximum O O
responses O O
after O O
4 O O
hours O O
. O O

Plasmin B B_GENE
-mediated O O
mRNA O O
expression O O
was O O
inhibited O O
in O O
a O O
concentration-dependent O O
manner O O
by O O
the O O
lysine O O
analogue O O
trans-4- O O
( O O
aminomethyl O O
) O O
cyclohexane-1-carboxylic O O
acid O O
( O O
t-AMCA O O
) O O
. O O

Increases O O
in O O
mRNA O O
levels O O
were O O
followed O O
by O O
concentration- O O
and O O
time-dependent O O
release O O
of O O
IL-1alpha B B_GENE
, O O
IL-1beta B B_GENE
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
TF B B_GENE
expression O O
on O O
monocyte O O
surfaces O O
. O O

Neither O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nor O O
TF B B_GENE
could O O
be O O
detected O O
when O O
monocytes O O
were O O
preincubated O O
with O O
actinomycin O O
D O O
or O O
cycloheximide O O
. O O

Nuclear O O
translocation O O
of O O
NF-kappaB/Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coincided O O
with O O
IkappaBalpha O O
degradation O O
. O O

At O O
variance O O
with O O
endotoxic O O
lipopolysaccharide O O
, O O
plasmin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elicited O O
the O O
rapid O O
degradation O O
of O O
another O O
cytoplasmic B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
NF-kappaB I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
p105 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Proteolysis O O
of O O
NF-kappaB O O
inhibitors O O
was O O
apparently O O
due O O
to O O
transient O O
activation O O
of O O
IkappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IKK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
reached O O
maximum O O
activity O O
at O O
1 O O
hour O O
after O O
plasmin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O O
. O O

In O O
addition O O
, O O
AP-1 O O
binding O O
was O O
increased O O
in O O
plasmin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-treated O O
monocytes O O
, O O
with O O
most O O
complexes O O
composed O O
of O O
JunD B B_GENE/B_DISEASE
, O O
c-Fos B B_GENE/B_LOCATION
, O O
and O O
FosB B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
findings O O
further O O
substantiate O O
the O O
role O O
of O O
plasmin B B_GENE
as O O
a O O
proinflammatory O O
activator O O
of O O
human O O
monocytes O O
and O O
reveal O O
an O O
important O O
new O O
link O O
between O O
the O O
plasminogen-plasmin O O
system O O
and O O
inflammation O O
. O O

( O O
Blood. O O
2001 O O
; O O
97 O O
: O O
3941-3950 O O
) O O

STAT3 B B_GENE
is O O
constitutively O O
active O O
in O O
some O O
patients O O
with O O
Polycythemia O O
rubra O O
vera O O
. O O

OBJECTIVE O O
: O O
Polycythemia O O
vera O O
is O O
a O O
clonal O O
stem O O
cell O O
disorder O O
characterized O O
by O O
hyperproliferation O O
of O O
the O O
erythroid O O
, O O
myeloid O O
, O O
and O O
megakaryocytic O O
lineages O O
. O O

While O O
it O O
has O O
been O O
shown O O
that O O
progenitor O O
cells O O
of O O
P. O O
vera O O
patients O O
are O O
hypersensitive O O
to O O
several O O
growth O O
factors O O
including O O
erythropoietin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
insulin-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
thrombopoietin B B_GENE
, O O
interleukin-3 B B_GENE
, O O
and O O
granulocyte/monocyte B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
molecular O O
pathogenesis O O
of O O
this O O
disease O O
remains O O
unknown O O
. O O

Growth O O
factor O O
hypersensitivity O O
could O O
be O O
mediated O O
by O O
changes O O
in O O
signal O O
transduction O O
pathways O O
. O O

We O O
therefore O O
investigated O O
a O O
common O O
downstream O O
effector O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
signal B B_GENE
transducers I I_GENE
and I I_GENE
activators I I_GENE
of I I_GENE
transcription I I_GENE
( O O
STATs B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

A O O
constitutive O O
activation O O
of O O
STAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
explain O O
the O O
increased O O
proliferation O O
of O O
P. O O
vera O O
cells O O
even O O
in O O
the O O
absence O O
of O O
growth O O
factor O O
stimulation O O
. O O

METHODS O O
: O O
Peripheral O O
granulocytes O O
from O O
patients O O
with O O
P. O O
vera O O
and O O
from O O
healthy O O
volunteers O O
were O O
assayed O O
for O O
STAT1 B B_GENE
, I I_GENE
3 I I_GENE
, I I_GENE
and I I_GENE
5 I I_GENE
DNA O O
binding O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

RESULTS O O
: O O
Four O O
of O O
14 O O
P. O O
vera O O
patients O O
analyzed O O
showed O O
constitutive O O
STAT3 O O
DNA O O
binding O O
in O O
unstimulated O O
peripheral O O
granulocytes O O
, O O
while O O
none O O
of O O
the O O
17 O O
healthy O O
volunteers O O
tested O O
did O O
. O O

None O O
of O O
the O O
subjects O O
showed O O
constitutive O O
STAT1 B B_GENE
or O O
STAT5 B B_GENE
activity O O
. O O

Western O O
blotting O O
demonstrated O O
that O O
, O O
in O O
the O O
three O O
patients O O
, O O
STAT3 B B_GENE
is O O
constitutively O O
phosphorylated O O
on O O
Tyr O O
705 O O
, O O
whereas O O
it O O
is O O
unphosphorylated O O
in O O
the O O
other O O
patients O O
and O O
in O O
controls O O
. O O

Interestingly O O
, O O
constitutive O O
STAT3 B B_GENE
activity O O
did O O
not O O
correlate O O
with O O
the O O
duration O O
of O O
disease O O
or O O
the O O
treatment O O
regimen O O
. O O

It O O
was O O
observed O O
in O O
a O O
recently O O
diagnosed O O
patient O O
and O O
in O O
two O O
patients O O
treated O O
only O O
with O O
phlebotomy O O
. O O

CONCLUSION O O
: O O
Our O O
data O O
suggest O O
that O O
constitutive O O
phosphorylation O O
and O O
activation O O
of O O
STAT3 B B_GENE
is O O
not O O
a O O
secondary O O
event O O
induced O O
by O O
mutagenizing O O
agents O O
or O O
by O O
prolonged O O
hyperproliferation O O
of O O
hematopoietic O O
cells O O
, O O
but O O
rather O O
represents O O
a O O
primary O O
molecular O O
aberration O O
. O O

Constitutively B B_GENE/B_PERSON
active I I_GENE/I_PERSON
STAT3 I I_GENE/I_PERSON
may O O
contribute O O
to O O
the O O
growth O O
factor O O
hypersensitivity O O
of O O
P. O O
vera O O
cells O O
. O O

Identification O O
of O O
phosphorylation B B_ENZYME[GENE]/B_LOCATION
sites I I_ENZYME[GENE]/I_LOCATION
for O O
Bruton B B_GENE
's I I_GENE
tyrosine I I_GENE
kinase I I_GENE
within O O
the O O
transcriptional B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
regulator I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
BAP/TFII-I I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

BAP/TFII-I B B_GENE
, O O
a O O
protein O O
implicated O O
in O O
transcriptional O O
regulation O O
, O O
is O O
associated O O
with O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
B O O
cells O O
and O O
is O O
transiently O O
phosphorylated O O
on O O
tyrosine O O
following O O
B O O
cell O O
receptor O O
engagement O O
. O O

BAP/TFII-I B B_GENE
is O O
a O O
substrate O O
for O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vitro O O
and O O
is O O
hyperphosphorylated O O
on O O
tyrosine O O
upon O O
coexpression O O
with O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mammalian O O
cells O O
. O O

In O O
an O O
effort O O
to O O
understand O O
the O O
physiologic O O
consequences O O
of O O
BAP/TFII-I B B_GENE
tyrosine O O
phosphorylation O O
following O O
B O O
cell O O
receptor O O
stimulation O O
, O O
site-directed O O
mutagenesis O O
and O O
phosphopeptide O O
mapping O O
were O O
used O O
to O O
locate O O
the O O
predominant O O
sites O O
of O O
BAP/TFII-I B B_GENE
phosphorylation O O
by O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vitro O O
. O O

These O O
residues O O
, O O
Tyr248 O O
, O O
Tyr357 O O
, O O
and O O
Tyr462 O O
, O O
were O O
also O O
found O O
to O O
be O O
the O O
major O O
sites O O
for O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O O
phosphorylation O O
of O O
BAP/TFII-I B B_GENE
in O O
vivo O O
. O O

Mutation O O
of O O
either O O
Tyr248 O O
, O O
Tyr357 O O
, O O
or O O
Tyr462 O O
to O O
phenylalanine O O
reduced O O
transcription O O
from O O
a O O
c-fos B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
relative O O
to O O
wild-type B B_GENE/B_TIME[MEASURE]
BAP/TFII-I I I_GENE/I_TIME[MEASURE]
in O O
transfected O O
COS-7 O O
cells O O
, O O
consistent O O
with O O
the O O
interpretation O O
that O O
phosphorylation O O
at O O
these O O
sites O O
contributes O O
to O O
transcriptional O O
activation O O
. O O

Phosphorylation O O
of O O
BAP/TFII-I B B_GENE
by O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
link O O
engagement O O
of O O
receptors O O
such O O
as O O
surface O O
immunoglobulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
modulation O O
of O O
gene O O
expression O O
. O O

Expression O O
of O O
interferon B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
consensus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
potent O O
immunity O O
against O O
BCR/ABL-induced O O
leukemia O O
. O O

Mice O O
deficient O O
in O O
the O O
interferon B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
consensus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
develop O O
a O O
disease O O
resembling O O
chronic O O
myeloid O O
leukemia O O
( O O
CML O O
) O O
, O O
which O O
in O O
humans O O
is O O
caused O O
by O O
the O O
BCR/ABL B B_GENE/B_DISEASE
oncoprotein I I_GENE/I_DISEASE
. O O

Interferon-alpha B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IFN-alpha B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
induces O O
ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
and O O
is O O
an O O
effective O O
therapy O O
for O O
CML O O
. O O

This O O
study O O
examined O O
whether O O
enforced O O
expression O O
of O O
ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
might O O
antagonize O O
BCR/ABL-induced O O
leukemia O O
; O O
results O O
demonstrated O O
that O O
ICSBP-modified O O
cells O O
generated O O
a O O
protective O O
CD8 O O
( O O
+ O O
) O O
cytotoxic O O
T-cell O O
response O O
against O O
BCR/ABL-transformed O O
BaF3 O O
cells O O
in O O
a O O
murine O O
leukemia O O
model O O
. O O

ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
represents O O
a O O
novel O O
means O O
of O O
stimulating O O
a O O
host O O
immune O O
response O O
to O O
BCR/ABL O O
( O O
+ O O
) O O
leukemia O O
cells O O
and O O
a O O
potential O O
strategy O O
for O O
immunotherapy O O
of O O
CML O O
. O O

( O O
Blood. O O
2001 O O
; O O
97 O O
: O O
3491-3497 O O
) O O

A O O
transcriptional O O
block O O
in O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
at O O
the O O
-150 B B_GENE/B_MEASURE
AP-1 I I_GENE/I_MEASURE
site I I_GENE/I_MEASURE
in O O
effector O O
CD8+ O O
T O O
cells O O
. O O

Both O O
CD4+ O O
and O O
CD8+ O O
T O O
cells O O
that O O
produce O O
IL-2 B B_GENE
in O O
response O O
to O O
Ag O O
recognition O O
have O O
been O O
isolated O O
. O O

To O O
evaluate O O
transcriptional O O
regulation O O
of O O
the O O
IL-2 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
in O O
CD8+ O O
T O O
cells O O
, O O
we O O
stably O O
transfected O O
reporter B B_GENE/B_PERSON
genes I I_GENE/I_PERSON
into O O
Ag B B_VIRUS[BIO]/B_GENE
-specific O O
CD8+ O O
T O O
cell O O
clones O O
. O O

CD28+ O O
CD8 O O
( O O
+ O O
) O O
T O O
cells O O
unable O O
to O O
transcribe O O
the O O
IL-2 B B_GENE
gene I I_GENE
in O O
response O O
to O O
antigenic O O
stimulation O O
had O O
a O O
block O O
in O O
transactivation O O
of O O
the O O
-150 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CD28 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CD28RE I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
IL-2 B B_GENE
promoter I I_GENE
, O O
but O O
did O O
transactivate O O
the O O
composite O O
NFAT/AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
OCT/AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
a O O
consensus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motif I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mutation O O
of O O
the O O
nonconsensus B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-150 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AP-1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
consensus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
AP-1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
or O O
insertion O O
of O O
a O O
CD28RE/AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
consensus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
upstream O O
of O O
the O O
native O O
-150 B B_GENE/B_LOCATION
CD28RE/AP-1 I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
restored O O
transactivation O O
of O O
the O O
altered O O
promoter B B_GENE/B_LOCATION
. O O

These O O
results O O
suggest O O
that O O
the O O
defect O O
at O O
the O O
-150 B B_PERSON/B_GENE
site I B_PERSON/I_GENE
may O O
reflect O O
the O O
absence O O
or O O
inactivity O O
of O O
a O O
required O O
factor O O
rather O O
than O O
repression O O
of O O
the O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Stem B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
interleukin-3 B B_GENE
induce O O
stepwise O O
generation O O
of O O
erythroid O O
precursor O O
cells O O
from O O
a O O
basic O O
fibroblast B B_GENE
growth I I_GENE
factor I I_GENE
-dependent O O
hematopoietic O O
stem O O
cell O O
line O O
, O O
A-6 O O
. O O

Those O O
cells O O
were O O
positive O O
for O O
stem B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
markers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
c-kit B B_GENE
and O O
CD34 B B_GENE
, O O
and O O
a O O
myeloid B B_GENE/B_MEASURE
cell I I_GENE/I_MEASURE
marker I I_GENE/I_MEASURE
, I I_GENE/I_MEASURE
F4/80 I I_GENE/I_MEASURE
. O O

Some O O
cell O O
fractions O O
were O O
also O O
positive O O
for O O
Mac-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
a I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
macrophage I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
marker I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
Gr-1 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
a I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
granulocytic I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
maker I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
negative O O
for O O
an O O
erythroid B B_GENE
marker I I_GENE
TER119 I I_GENE
. O O

They O O
also O O
showed O O
the O O
expression O O
of O O
mRNA O O
for O O
the O O
myeloid-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PU.1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
but O O
did O O
not O O
that O O
for O O
the O O
erythroid-specific B B_GENE
GATA-1 I I_GENE
. O O

The O O
quantitative O O
analysis O O
showed O O
that O O
erythroid O O
precursor O O
cells O O
were O O
newly O O
produced O O
from O O
the O O
immature O O
myeloid O O
cells O O
by O O
cultivation O O
with O O
IL-3 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

SCF B B_GENE/B_BIO
and O O
IL-3 B B_GENE/B_LOCATION
induced O O
stepwise O O
generation O O
of O O
erythroid O O
precursor O O
cells O O
from O O
an O O
A-6 O O
hematopoietic O O
stem O O
cell O O
line O O
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

Distinct O O
BMI-1 B B_GENE
and O O
EZH2 B B_GENE
expression O O
patterns O O
in O O
thymocytes O O
and O O
mature O O
T O O
cells O O
suggest O O
a O O
role O O
for O O
Polycomb B B_GENE/B_MEASURE
genes I I_GENE/I_MEASURE
in O O
human O O
T O O
cell O O
differentiation O O
. O O

BMI-1 B B_GENE/B_DISEASE
and O O
EZH2 B B_GENE/B_DISEASE
Polycomb-group B I_GENE/I_DISEASE
( I I_GENE/I_DISEASE
PcG I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
proteins I I_GENE/I_DISEASE
belong O O
to O O
two O O
distinct O O
protein O O
complexes O O
involved O O
in O O
the O O
regulation O O
of O O
hematopoiesis O O
. O O

Using O O
unique O O
PcG-specific O O
antisera O O
and O O
triple O O
immunofluorescence O O
, O O
we O O
found O O
that O O
mature O O
resting O O
peripheral O O
T O O
cells O O
expressed O O
BMI-1 B B_GENE
, O O
whereas O O
dividing O O
blasts O O
were O O
EZH2 O O
( O O
+ O O
) O O
. O O

By O O
contrast O O
, O O
subcapsular O O
immature O O
double-negative O O
( O O
DN O O
) O O
( O O
CD4 O O
( O O
- O O
) O O
/CD8 O O
( O O
- O O
) O O
) O O
T O O
cells O O
in O O
the O O
thymus O O
coexpressed O O
BMI-1 B B_GENE
and O O
EZH2 B B_GENE
or O O
were O O
BMI-1 O O
single O O
positive O O
. O O

Maturation O O
of O O
DP O O
cortical O O
thymocytes O O
to O O
single-positive O O
( O O
CD4 O O
( O O
+ O O
) O O
/CD8 O O
( O O
- O O
) O O
or O O
CD8 O O
( O O
+ O O
) O O
/CD4 O O
( O O
- O O
) O O
) O O
medullar O O
thymocytes O O
correlated O O
with O O
decreased O O
detectability O O
of O O
EZH2 B B_GENE
and O O
continued O O
relative O O
absence O O
of O O
BMI-1 B B_GENE
. O O

Our O O
data O O
show O O
that O O
BMI-1 B B_GENE
and O O
EZH2 B B_GENE
expression O O
in O O
mature O O
peripheral O O
T O O
cells O O
is O O
mutually O O
exclusive O O
and O O
linked O O
to O O
proliferation O O
status O O
, O O
and O O
that O O
this O O
pattern O O
is O O
not O O
yet O O
established O O
in O O
thymocytes O O
of O O
the O O
cortex O O
and O O
medulla O O
. O O

T O O
cell O O
stage-specific O O
PcG O O
expression O O
profiles O O
suggest O O
that O O
PcG B B_GENE/B_BIO
genes I I_GENE/I_BIO
contribute O O
to O O
regulation O O
of O O
T O O
cell O O
differentiation O O
. O O

They O O
probably O O
reflect O O
stabilization O O
of O O
cell O O
type-specific O O
gene O O
expression O O
and O O
irreversibility O O
of O O
lineage O O
choice O O
. O O

The O O
difference O O
in O O
PcG O O
expression O O
between O O
medullar O O
thymocytes O O
and O O
mature O O
interfollicular O O
T O O
cells O O
indicates O O
that O O
additional O O
maturation O O
processes O O
occur O O
after O O
thymocyte O O
transportation O O
from O O
the O O
thymus O O
. O O

Stepwise O O
lineage O O
restriction O O
of O O
progenitors O O
in O O
lympho-myelopoiesis O O
. O O

It O O
has O O
long O O
been O O
controversial O O
whether O O
hematopoiesis O O
progresses O O
through O O
ordered O O
stages O O
of O O
determination O O
as O O
in O O
embryonic O O
development O O
. O O

This O O
is O O
due O O
to O O
the O O
absence O O
of O O
a O O
methodology O O
capable O O
of O O
exactly O O
determining O O
the O O
developmental O O
potential O O
of O O
hematopoietic O O
stem/progenitor O O
cells O O
. O O

Among O O
these O O
seven O O
types O O
, O O
the O O
p-TB O O
type O O
progenitor O O
was O O
found O O
to O O
be O O
absent O O
. O O

These O O
findings O O
indicate O O
that O O
the O O
process O O
of O O
lineage O O
commitment O O
proceeds O O
through O O
an O O
ordered O O
but O O
not O O
random O O
process O O
. O O

By O O
extending O O
the O O
area O O
of O O
investigation O O
to O O
include O O
the O O
erythroid O O
lineage O O
, O O
more O O
convincing O O
evidence O O
for O O
the O O
ordered O O
process O O
was O O
obtained O O
. O O

Detailed O O
and O O
exact O O
illustration O O
of O O
the O O
process O O
of O O
hematopoiesis O O
will O O
provide O O
an O O
opportunity O O
to O O
revive O O
hematopoiesis O O
as O O
one O O
of O O
the O O
most O O
fascinating O O
targets O O
of O O
research O O
in O O
developmental O O
biology O O

Epstein-Barr O O
Virus O O
and O O
its O O
glycoprotein-350 B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
upregulate O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
B-lymphocytes O O
via O O
CD21 B B_GENE/B_LOCATION
, O O
involving O O
activation O O
of O O
NF-kappaB B B_GENE/B_DISEASE
and O O
different O O
signaling O O
pathways O O
. O O

Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
is O O
a O O
ubiquitous O O
and O O
highly O O
immunotropic O O
gamma O O
herpesvirus O O
that O O
infects O O
more O O
than O O
90 O O
% O O
of O O
humans O O
worldwide O O
. O O

Its O O
pathogenicity O O
leads O O
to O O
a O O
number O O
of O O
diseases O O
including O O
tumors O O
that O O
result O O
from O O
EBV O O
's O O
ability O O
to O O
readily O O
transform O O
B-lymphocytes O O
and O O
, O O
to O O
a O O
lesser O O
extent O O
, O O
epithelial O O
cells O O
. O O

EBV O O
utilizes O O
CD21/CR2 B B_GENE
as O O
its O O
receptor O O
on O O
B O O
cells O O
to O O
initiate O O
the O O
infection O O
process O O
. O O

We O O
had O O
previously O O
shown O O
that O O
EBV O O
is O O
capable O O
of O O
modulating O O
the O O
synthesis O O
of O O
a O O
number O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
now O O
show O O
that O O
while O O
both O O
purified O O
recombinant B B_GENE/B_VIRUS[BIO]
gp350 I B_GENE/I_VIRUS[BIO]
( O O
rgp350 B B_GENE
) O O
and O O
EBV O O
upregulate O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthesis O O
in O O
B O O
cells O O
, O O
EBV-induced O O
IL-6 O O
gene O O
activation O O
occurs O O
for O O
a O O
significantly O O
longer O O
period O O
of O O
time O O
( O O
i.e. O O
12 O O
hours O O
for O O
EBV O O
as O O
compared O O
to O O
6 O O
hours O O
for O O
rgp350 B B_GENE/B_VIRUS[BIO]
) O O
. O O

Moreover O O
, O O
the O O
half-life O O
of O O
EBV-induced O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
also O O
significantly O O
longer O O
( O O
10 O O
hours O O
) O O
than O O
that O O
of O O
mRNA O O
induced O O
by O O
rgp350 B B_GENE/B_VIRUS[BIO]
( O O
about O O
6 O O
hours O O
) O O
. O O

Both O O
EBV O O
and O O
gp350 B B_GENE/B_VIRUS[BIO]
enhance O O
the O O
binding O O
of O O
the O O
NF-kappaB B B_GENE
transcription I I_GENE
factor I I_GENE
, O O
as O O
determined O O
by O O
band-shift O O
and O O
augment O O
NF-kappaB B B_GENE/B_MEASURE
-mediated O O
activation O O
of O O
a O O
CAT B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
we O O
demonstrate O O
that O O
while O O
the O O
activation O O
of O O
IL-6 O O
gene O O
expression O O
by O O
gp350 B B_GENE/B_VIRUS[BIO]
is O O
mediated O O
primarily O O
by O O
the O O
protein O O
kinase O O
C O O
pathway O O
, O O
EBV O O
can O O
mediate O O
its O O
effects O O
through O O
multiple O O
signaling O O
pathways O O
. O O

To O O
our O O
knowledge O O
this O O
is O O
the O O
first O O
report O O
showing O O
that O O
the O O
binding O O
of O O
a O O
herpesvirus B B_GENE
envelope I I_GENE
glycoprotein I I_GENE
to O O
CR2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
human O O
B O O
cells O O
results O O
in O O
the O O
activation O O
of O O
the O O
NF-kappaB B B_GENE
transcription I I_GENE
factor I I_GENE
leading O O
to O O
the O O
upregulation O O
of O O
IL-6 O O
gene O O
expression O O
in O O
these O O
lymphocytes O O
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

Gene- O O
and O O
tissue-specificity O O
of O O
mutation O O
in O O
Big O O
Blue O O
rats O O
treated O O
with O O
the O O
hepatocarcinogen O O
N-hydroxy-2-acetylaminofluorene O O
. O O

In O O
the O O
present O O
study O O
, O O
sequence O O
analysis O O
was O O
conducted O O
on O O
lacI B B_SPECIES[BIO]/B_GENE
DNA I B_SPECIES[BIO]/I_GENE
and O O
hprt B B_GENE
cDNA I I_GENE
from O O
the O O
mutants O O
, O O
to O O
determine O O
the O O
mutational O O
specificity O O
of O O
N-OH-AAF O O
in O O
the O O
rat O O
. O O

All O O
the O O
mutation O O
spectra O O
from O O
N-OH-AAF-treated O O
rats O O
differed O O
significantly O O
from O O
corresponding O O
mutation O O
profiles O O
from O O
untreated O O
animals O O
( O O
P O O
= O O
0.02 O O
to O O
P O O
< O O
0.0001 O O
) O O
. O O

Also O O
, O O
multiplex O O
PCR O O
analysis O O
of O O
genomic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
hprt O O
mutants O O
indicated O O
that O O
12 O O
% O O
of O O
mutants O O
from O O
treated O O
rats O O
had O O
major O O
deletions O O
in O O
the O O
hprt B B_GENE
gene I I_GENE
; O O
no O O
corresponding O O
incidence O O
of O O
large O O
deletions O O
was O O
evident O O
among O O
lacI O O
mutations O O
. O O

All O O
the O O
mutation O O
profiles O O
reflect O O
the O O
general O O
mutational O O
specificity O O
of O O
the O O
major O O
DNA O O
adduct O O
formed O O
by O O
N-OH-AAF O O
. O O

The O O
differences O O
between O O
N-OH-AAF O O
mutation O O
in O O
the O O
endogenous B B_GENE/B_BIO
gene I I_GENE/I_BIO
and O O
transgene B B_GENE
can O O
be O O
partially O O
explained O O
by O O
the O O
structures O O
of O O
the O O
two O O
genes O O
. O O

The O O
tissue-specificity O O
of O O
the O O
mutation O O
spectra O O
may O O
contribute O O
to O O
targeting O O
tumor O O
formation O O
to O O
the O O
liver O O
. O O

Environ. O O
Mol. O O
Mutagen. O O
37 O O
: O O
203-214 O O
, O O
2001 O O
. O O

Published O O
2001 O O
Wiley-Liss O O
, O O
Inc O O
. O O

Caspase B B_GENE
-dependent O O
cleavage O O
of O O
the O O
hematopoietic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adaptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Gads I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alters O O
signalling O O
from O O
the O O
T B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
cell I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Gads B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
SH2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
SH3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
domain I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-containing O O
, O O
hematopoietic-specific B B_GENE
adaptor I I_GENE
protein I I_GENE
that O O
functions O O
in O O
signalling O O
from O O
the O O
T B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
cell I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
receptor I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Gads B B_PERSON/B_GENE
acts O O
by O O
linking O O
SLP-76 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
bound O O
by O O
the O O
carboxy-terminal B B_GENE
Gads I I_GENE
SH3 I I_GENE
domain I I_GENE
, O O
to O O
tyrosine B B_GENE/B_LOCATION
phosphorylated I I_GENE/I_LOCATION
LAT I I_GENE/I_LOCATION
which O O
contains O O
binding O O
sites O O
for O O
the O O
Gads B B_PROTEIN[GENE]
SH2 I I_PROTEIN[GENE]
domain I I_PROTEIN[GENE]
. O O

Here O O
we O O
demonstrate O O
that O O
the O O
unique O O
region O O
of O O
Gads B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
contains O O
a O O
capase B B_LOCATION/B_GENE
cleavage I I_LOCATION/I_GENE
site I I_LOCATION/I_GENE
. O O

Induction O O
of O O
apoptosis O O
in O O
lymphocytes O O
results O O
in O O
detectable O O
Gads B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cleavage O O
by O O
60 O O
min O O
. O O

Gads B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cleavage O O
is O O
blocked O O
in O O
vivo O O
by O O
treating O O
cells O O
with O O
a O O
caspase O O
3 O O
inhibitor O O
. O O

A O O
putative B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
caspase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cleavage I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
identified O O
within O O
the O O
unique O O
region O O
and O O
mutation O O
of O O
this O O
site O O
prevented O O
Gads B B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
cleavage O O
in O O
vitro O O
, O O
and O O
in O O
vivo O O
. O O

The O O
Gads B B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
cleavage O O
products O O
retained O O
the O O
predicted O O
binding O O
specificity O O
for O O
SLP-76 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
LAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Expression O O
of O O
the O O
Gads B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cleavage O O
products O O
in O O
Jurkat O O
T O O
cells O O
inhibited O O
NFAT O O
activation O O
following O O
TCR O O
cross O O
linking O O
. O O

These O O
findings O O
indicate O O
that O O
cleavage O O
of O O
Gads B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O O
could O O
function O O
to O O
alter O O
signalling O O
downstream O O
of O O
the O O
T B B_GENE/B_LOCATION
cell I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
by O O
disrupting O O
cross O O
talk O O
between O O
SLP-76 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
LAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
report O O
, O O
we O O
explore O O
the O O
mechanisms O O
of O O
targeting O O
of O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
interleukin-2 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
( I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
IL-2 I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
) I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O O
response O O
to O O
mitogenic O O
and O O
oncogenic O O
molecular O O
signals O O
. O O

Mutational O O
analysis O O
of O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O O
differential O O
structural O O
requirements O O
for O O
the O O
N-terminal O O
p300 O O
module O O
by O O
individual O O
cis-elements B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
. O O

Regulation O O
of O O
cytokine O O
production O O
in O O
T-cell O O
responses O O
to O O
inhalant O O
allergen O O
: O O
GATA-3 B B_GENE/B_PERSON
expression O O
distinguishes O O
between O O
Th1- O O
and O O
Th2-polarized O O
immunity O O
. O O

BACKGROUND O O
: O O
The O O
precise O O
nature O O
of O O
allergen-specific O O
cytokine O O
responses O O
in O O
atopics O O
versus O O
non-atopics O O
, O O
in O O
particular O O
the O O
'Th1 O O
polarity O O
' O O
of O O
responses O O
in O O
non-atopics O O
, O O
remains O O
controversial O O
. O O

This O O
is O O
due O O
in O O
part O O
to O O
the O O
relative O O
insensitivity O O
of O O
cytokine O O
detection O O
systems O O
, O O
and O O
associated O O
variations O O
in O O
kinetics O O
of O O
cytokine O O
production O O
and O O
catabolism O O
in O O
in O O
vitro O O
culture O O
systems O O
. O O

As O O
an O O
alternative O O
to O O
cytokine O O
measurement O O
, O O
this O O
study O O
focuses O O
on O O
expression O O
of O O
the O O
transcription B B_GENE
factor I I_GENE
GATA-3 I I_GENE
for O O
analysis O O
of O O
allergen-specific O O
Th O O
cell O O
responses O O
. O O

METHODS O O
: O O
Cord O O
blood O O
mononuclear O O
cells O O
were O O
Th1- O O
or O O
Th2-polarized O O
by O O
culture O O
in O O
IL-12- O O
or O O
IL-4-employing O O
established O O
methods O O
; O O
PBMC O O
from O O
house O O
dust O O
mite O O
( O O
HDM O O
) O O
-sensitive O O
atopics O O
and O O
controls O O
were O O
stimulated O O
overnight O O
with O O
HDM O O
; O O
cytokine O O
production O O
was O O
measured O O
by O O
ELISA O O
and O O
GATA-3 B B_GENE/B_DISEASE
mRNA I I_GENE/I_DISEASE
expression O O
by O O
PCR O O
. O O

RESULTS O O
: O O
Cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-driven O O
Th2 O O
polarization O O
of O O
naive O O
T O O
cells O O
is O O
associated O O
with O O
marked O O
upregulation O O
of O O
GATA-3 B B_GENE
expression O O
, O O
whereas O O
a O O
reciprocal O O
expression O O
pattern O O
accompanies O O
differentiation O O
towards O O
the O O
Th1 O O
cytokine O O
phenotype O O
. O O

In O O
T O O
cells O O
from O O
HDM O O
skin O O
prick O O
test-positive O O
( O O
HDM-SPT+/HDM-IgE+ O O
) O O
volunteers O O
, O O
overnight O O
stimulation O O
results O O
in O O
marked O O
upregulation O O
of O O
GATA-3 B B_GENE
expression O O
, O O
compared O O
to O O
an O O
equally O O
marked O O
downregulation O O
of O O
expression O O
in O O
T O O
cells O O
from O O
SPT-/IgE- O O
subjects O O
. O O

In O O
subjects O O
who O O
are O O
HDM-SPT+ O O
but O O
IgE- O O
, O O
GATA-3 B B_GENE/B_DISEASE
expression O O
levels O O
remained O O
relatively O O
stable O O
during O O
culture O O
with O O
HDM O O
. O O

CONCLUSIONS O O
: O O
Upregulation O O
of O O
GATA-3 B B_GENE
expression O O
in O O
PBMC O O
is O O
a O O
hallmark O O
of O O
the O O
early O O
phase O O
of O O
Th2 O O
recall O O
responses O O
to O O
specific O O
allergen O O
in O O
atopics O O
. O O

The O O
reciprocal O O
expression O O
pattern O O
observed O O
in O O
HDM-specific O O
recall O O
responses O O
of O O
non-atopics O O
provides O O
independent O O
confirmation O O
of O O
the O O
presence O O
of O O
underlying O O
Th1-like O O
immunity O O
in O O
these O O
subjects O O
. O O

The O O
parallel O O
findings O O
in O O
neonatal O O
T O O
cells O O
suggest O O
that O O
the O O
same O O
approach O O
may O O
be O O
utilized O O
for O O
monitoring O O
the O O
progress O O
of O O
allergen-specific O O
Th1/Th2 O O
memory O O
development O O
during O O
early O O
childhood O O
, O O
and O O
hence O O
in O O
assessment O O
of O O
risk O O
for O O
future O O
allergic O O
disease O O
. O O

Copyright O O
2001 O O
S. O O
Karger O O
AG O O
, O O
Basel O O

The O O
heat O O
shock O O
response O O
reduces O O
myelin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
oligodendrocyte I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
glycoprotein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
-induced O O
experimental O O
autoimmune O O
encephalomyelitis O O
in O O
mice O O
. O O

The O O
stress O O
response O O
( O O
SR O O
) O O
can O O
block O O
inflammatory O O
gene O O
expression O O
by O O
preventing O O
activation O O
of O O
transcription B B_GENE
factor I I_GENE
nuclear B I_GENE
factor-kappa I I_GENE
B I I_GENE
( O O
NF-kappaB B B_GENE
) O O
. O O

EAE O O
was O O
actively O O
induced O O
in O O
C57BL/6 O O
mice O O
using O O
an O O
encephalitogenic O O
myelin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oligodendrocyte I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glycoprotein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MOG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
35-55 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
peptide O O
. O O

Whole O O
body O O
hyperthermia O O
was O O
used O O
to O O
induce O O
a O O
heat O O
shock O O
response O O
( O O
HSR O O
) O O
in O O
immunized O O
mice O O
2 O O
days O O
after O O
the O O
booster O O
MOG O O
( O O
35-55 O O
) O O
peptide O O
injection O O
. O O

The O O
HSR O O
reduced O O
the O O
incidence O O
of O O
EAE O O
by O O
70 O O
% O O
, O O
delayed O O
disease O O
onset O O
by O O
6 O O
days O O
, O O
and O O
attenuated O O
disease O O
severity O O
. O O

The O O
HSR O O
attenuated O O
leukocyte O O
infiltration O O
into O O
CNS O O
assessed O O
by O O
quantitation O O
of O O
perivascular O O
infiltrates O O
, O O
and O O
by O O
reduced O O
staining O O
for O O
CD4 B B_GENE
and O O
CD25 B B_GENE
immunopositive O O
T-cells O O
. O O

The O O
early O O
activation O O
of O O
transcription B B_GENE
factor I I_GENE
NF-kappaB B I_GENE
was O O
also O O
blocked O O
by O O
the O O
HSR O O
. O O

The O O
finding O O
that O O
the O O
SR O O
reduces O O
inflammation O O
in O O
the O O
brain O O
and O O
the O O
clinical O O
severity O O
of O O
EAE O O
opens O O
a O O
novel O O
therapeutic O O
approach O O
for O O
prevention O O
of O O
autoimmune O O
diseases O O
. O O

Information O O
regarding O O
the O O
intracellular O O
signaling O O
processes O O
that O O
occur O O
during O O
the O O
development O O
of O O
T O O
cells O O
has O O
largely O O
been O O
obtained O O
with O O
the O O
use O O
of O O
transgenic O O
mouse O O
models O O
, O O
which O O
although O O
providing O O
invaluable O O
information O O
are O O
time O O
consuming O O
and O O
costly O O
. O O

This O O
approach O O
uses O O
reporter-plasmids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
the O O
detection O O
of O O
intracellular O O
signals O O
mediated O O
by O O
the O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
cyclic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AMP-dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Reporter-plasmids B B_PERSON/B_GENE
are O O
transfected O O
into O O
thymocytes O O
in O O
fetal O O
thymic O O
organ O O
culture O O
by O O
accelerated O O
DNA/particle O O
bombardment O O
( O O
gene O O
gun O O
) O O
, O O
and O O
the O O
activation O O
of O O
a O O
signaling O O
pathway O O
is O O
determined O O
in O O
the O O
form O O
of O O
a O O
standard O O
luciferase O O
assay O O
. O O

Thus O O
, O O
this O O
method O O
allows O O
for O O
the O O
monitoring O O
of O O
signals O O
that O O
occur O O
in O O
a O O
biological O O
time O O
frame O O
, O O
such O O
as O O
during O O
differentiation O O
, O O
and O O
within O O
the O O
natural O O
environment O O
of O O
differentiating O O
cells O O
. O O

Core-binding B B_GENE
factor I I_GENE
beta I I_GENE
( O O
CBFbeta B B_GENE
) O O
, O O
but O O
not O O
CBFbeta-smooth B B_GENE
muscle I I_GENE
myosin I I_GENE
heavy I I_GENE
chain I I_GENE
, O O
rescues O O
definitive O O
hematopoiesis O O
in O O
CBFbeta B B_GENE
-deficient O O
embryonic O O
stem O O
cells O O
. O O

Core-binding B B_PROTEIN[GENE]
factor I I_PROTEIN[GENE]
beta I I_PROTEIN[GENE]
( O O
CBFbeta B B_GENE/B_DISEASE
) O O
is O O
the O O
non-DNA-binding B B_GENE/B_MEASURE
subunit I I_GENE/I_MEASURE
of O O
the O O
heterodimeric B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
CBFs I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Genes B B_GENE/B_DISEASE
encoding I I_GENE/I_DISEASE
CBFbeta I I_GENE/I_DISEASE
( O O
CBFB B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
one O O
of O O
the O O
DNA-binding B B_GENE/B_NUMBER[MEASURE]
CBFalpha I I_GENE/I_NUMBER[MEASURE]
subunits I I_GENE/I_NUMBER[MEASURE]
, I I_GENE/I_NUMBER[MEASURE]
Runx1 I I_GENE/I_NUMBER[MEASURE]
( O O
also O O
known O O
as O O
CBFalpha2 B B_GENE/B_DISEASE
, O O
AML1 B B_GENE
, O O
and O O
PEBP2alphaB B B_GENE/B_DISEASE
) O O
, O O
are O O
required O O
for O O
normal O O
hematopoiesis O O
and O O
are O O
also O O
frequent O O
targets O O
of O O
chromosomal O O
translocations O O
in O O
acute O O
leukemias O O
in O O
humans O O
. O O

Homozygous O O
disruption O O
of O O
either O O
the O O
Runx1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Cbfb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mice O O
results O O
in O O
embryonic O O
lethality O O
at O O
midgestation O O
due O O
to O O
hemorrhaging O O
in O O
the O O
central O O
nervous O O
system O O
, O O
and O O
severely O O
impairs O O
fetal O O
liver O O
hematopoiesis O O
. O O

Results O O
of O O
this O O
study O O
show O O
that O O
Cbfb-deficient O O
mouse O O
embryonic O O
stem O O
( O O
ES O O
) O O
cells O O
can O O
differentiate O O
into O O
primitive O O
erythroid O O
colonies O O
in O O
vitro O O
, O O
but O O
are O O
impaired O O
in O O
their O O
ability O O
to O O
produce O O
definitive O O
erythroid O O
and O O
myeloid O O
colonies O O
, O O
mimicking O O
the O O
in O O
vivo O O
defect O O
. O O

Definitive O O
hematopoiesis O O
is O O
restored O O
by O O
ectopic O O
expression O O
of O O
full-length B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Cbfb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transgenes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
well O O
as O O
by O O
a O O
transgene O O
encoding O O
only O O
the O O
heterodimerization B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
of O O
CBFbeta B B_GENE
. O O

In O O
contrast O O
, O O
the O O
CBFbeta B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
smooth B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
muscle I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
myosin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heavy I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
SMMHC I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fusion I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generated O O
by O O
the O O
inv B B_GENE/B_DISEASE
( I B_GENE/I_DISEASE
16 I B_GENE/I_DISEASE
) I B_GENE/I_DISEASE
associated O O
with O O
acute O O
myeloid O O
leukemias O O
( O O
M4Eo O O
) O O
can O O
not O O
rescue O O
definitive O O
hematopoiesis O O
by O O
Cbfb-deficient O O
ES O O
cells O O
. O O

Results O O
also O O
show O O
that O O
the O O
CBFbeta-SMMHC B B_GENE
fusion I I_GENE
protein I I_GENE
transdominantly O O
inhibits O O
definitive O O
hematopoiesis O O
, O O
but O O
not O O
to O O
the O O
same O O
extent O O
as O O
homozygous O O
loss O O
of O O
Runx1 B B_GENE
or O O
Cbfb B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CBFbeta-SMMHC B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preferentially O O
inhibits O O
the O O
differentiation O O
of O O
myeloid O O
lineage O O
cells O O
, O O
while O O
increasing O O
the O O
number O O
of O O
blastlike O O
cells O O
in O O
culture O O
. O O

The O O
latency O O
pattern O O
of O O
Epstein-Barr O O
virus O O
infection O O
and O O
viral O O
IL-10 B B_GENE
expression O O
in O O
cutaneous O O
natural O O
killer/T-cell O O
lymphomas O O
. O O

In O O
order O O
to O O
elucidate O O
the O O
EBV O O
gene O O
expression O O
patterns O O
in O O
vivo O O
, O O
we O O
examined O O
eight O O
patients O O
with O O
cutaneous O O
EBV-related O O
NK/T-cell O O
lymphomas O O
, O O
including O O
six O O
patients O O
with O O
a O O
NK-cell O O
phenotype O O
and O O
two O O
patients O O
with O O
a O O
T-cell O O
phenotype O O
. O O

The O O
expression O O
of O O
EBV-related B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
examined O O
by O O
immunostaining O O
using O O
paraffin-embedded O O
tissue O O
sections O O
and O O
cell O O
pellets O O
of O O
EBV-positive O O
cell O O
lines O O
. O O

Our O O
study O O
demonstrated O O
that O O
all O O
samples O O
from O O
the O O
patients O O
contained O O
EBV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
was O O
transcribed O O
using O O
the O O
Q B B_GENE
promoter I I_GENE
, O O
whereas O O
both O O
the O O
Q B B_PROTEIN[GENE]/B_LOCATION
promoter I I_PROTEIN[GENE]/I_LOCATION
and O O
another O O
upstream B B_GENE
promoter I I_GENE
( O O
Cp/Wp B B_PROTEIN[GENE]
) O O
were O O
used O O
in O O
EBV-positive O O
cell O O
lines O O
, O O
B95.8 O O
, O O
Raji O O
and O O
Jiyoye O O
. O O

Latent B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
membrane I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LMP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
detected O O
in O O
seven O O
of O O
eight O O
patients O O
and O O
all O O
cell O O
lines O O
, O O
whereas O O
EBNA-2 B B_GENE/B_PERSON
transcripts I I_GENE/I_PERSON
were O O
found O O
only O O
in O O
the O O
cell O O
lines O O
. O O

Latent B B_GENE/B_PERSON
BHRF1 I I_GENE/I_PERSON
transcripts I I_GENE/I_PERSON
encoding O O
bcl-2 B B_GENE/B_VIRUS[BIO]
homologue I B_GENE/I_VIRUS[BIO]
and O O
BCRF1 B B_GENE/B_BIO
transcripts I I_GENE/I_BIO
encoding O O
viral B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interleukin I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vIL I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-10 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
detected O O
in O O
one O O
and O O
two O O
of O O
eight O O
patients O O
, O O
respectively O O
. O O

Our O O
results O O
indicate O O
that O O
the O O
restricted O O
expression O O
of O O
the O O
latency-associated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
EBV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
production O O
of O O
vIL-10 B B_GENE
and I I_GENE
bcl-2 I I_GENE
homologue I I_GENE
may O O
favour O O
tumour O O
growth O O
, O O
evading O O
the O O
host O O
immune O O
surveillance O O
. O O

Copyright O O
2001 O O
Cancer O O
Research O O
Campaign O O
. O O

Oxidized O O
alkyl O O
phospholipids O O
are O O
specific O O
, O O
high O O
affinity O O
peroxisome O O
proliferator-activated O O
receptor O O
gamma O O
ligands O O
and O O
agonists O O
. O O

Oxidized B B_PROTEIN[GENE]
low I I_PROTEIN[GENE]
density I I_PROTEIN[GENE]
lipoprotein I I_PROTEIN[GENE]
( O O
oxLDL B B_GENE/B_LOCATION
) O O
is O O
inflammatory O O
and O O
signals O O
through O O
PPARs B B_GENE
. O O

We O O
showed O O
, O O
by O O
phospholipase O O
A O O
( O O
1 O O
) O O
digestion O O
, O O
that O O
PPARgamma O O
agonists O O
in O O
oxLDL B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
arise O O
from O O
the O O
small O O
pool O O
of O O
alkyl O O
phosphatidylcholines O O
in O O
LDL B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

We O O
identified O O
an O O
abundant O O
oxidatively O O
fragmented O O
alkyl O O
phospholipid O O
in O O
oxLDL B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
hexadecyl O O
azelaoyl O O
phosphatidylcholine O O
( O O
azPC O O
) O O
, O O
as O O
a O O
high O O
affinity O O
ligand O O
and O O
agonist O O
for O O
PPARgamma B B_GENE/B_LOCATION
. O O

azPC O O
induced O O
PPRE O O
reporter O O
gene O O
expression O O
, O O
as O O
did O O
rosiglitazone O O
, O O
with O O
a O O
half-maximal O O
effect O O
at O O
100 O O
nm O O
. O O

Overexpression O O
of O O
PPARalpha B B_GENE/B_LOCATION
or O O
PPARgamma B B_GENE
revealed O O
that O O
azPC O O
was O O
a O O
specific O O
PPARgamma O O
agonist O O
. O O

The O O
scavenger B B_GENE/B_MEASURE
receptor I I_GENE/I_MEASURE
CD36 I I_GENE/I_MEASURE
is O O
encoded O O
by O O
a O O
PPRE-responsive B B_GENE
gene I I_GENE
, O O
and O O
azPC O O
enhanced O O
expression O O
of O O
CD36 B B_GENE
in O O
primary O O
human O O
monocytes O O
. O O

We O O
found O O
that O O
anti-CD36 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O O
azPC O O
uptake O O
, O O
and O O
it O O
inhibited O O
PPRE O O
reporter O O
induction O O
. O O

Thus O O
, O O
certain O O
alkyl O O
phospholipid O O
oxidation O O
products O O
in O O
oxLDL B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
are O O
specific O O
, O O
high O O
affinity O O
extracellular O O
ligands O O
and O O
agonists O O
for O O
PPARgamma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
induce O O
PPAR-responsive B B_DISEASE/B_GENE
genes I B_DISEASE/I_GENE

Regulation O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MAT2B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O O
the O O
regulatory B B_PROTEIN[GENE]/B_PERSON
beta I I_PROTEIN[GENE]/I_PERSON
subunit I I_PROTEIN[GENE]/I_PERSON
of O O
methionine B B_GENE
adenosyltransferase I I_GENE
, O O
MAT B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
II I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
MAT B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
II I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
isozyme I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
consists O O
of O O
a O O
catalytic B B_PROTEIN[GENE]
alpha2 I I_PROTEIN[GENE]
and I I_PROTEIN[GENE]
a I I_PROTEIN[GENE]
regulatory I I_PROTEIN[GENE]
beta I I_PROTEIN[GENE]
subunit I I_PROTEIN[GENE]
. O O

Down-regulation O O
of O O
the O O
MAT B B_GENE
II I I_GENE
beta I I_GENE
subunit I I_GENE
expression O O
causes O O
a O O
6-10-fold O O
increase O O
in O O
intracellular O O
AdoMet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
. O O

To O O
understand O O
the O O
mechanism O O
by O O
which O O
the O O
beta B B_GENE
subunit I I_GENE
expression O O
is O O
regulated O O
, O O
we O O
cloned O O
the O O
MAT2B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
determined O O
its O O
organization O O
, O O
characterized O O
its O O
5'-flanking B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
elucidated O O
the O O
in O O
vitro O O
and O O
in O O
vivo O O
regulation O O
of O O
its O O
promoter B B_GENE
. O O

The O O
inclusion O O
of O O
sequences O O
up O O
to O O
position O O
-115 O O
provided O O
full O O
activity O O
; O O
this O O
was O O
attributed O O
to O O
a O O
TATA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
-32 O O
. O O

The O O
Sp1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O O
position O O
+9 O O
was O O
key O O
for O O
the O O
formation O O
of O O
protein.DNA O O
complexes O O
. O O

Mutation O O
of O O
both O O
the O O
Sp1 B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
at O O
+9 O O
and O O
the O O
TATA B B_GENE/B_MEASURE
at O O
-32 O O
reduced O O
promoter O O
activity O O
to O O
its O O
minimal O O
level O O
. O O

Chromatin O O
immunoprecipitation O O
assays O O
supported O O
the O O
involvement O O
of O O
both O O
Sp1 B B_GENE/B_DISEASE
and O O
Sp3 B B_GENE
in O O
complexes O O
formed O O
on O O
the O O
MAT2B B B_GENE
promoter I I_GENE
. O O

The O O
data O O
show O O
that O O
the O O
5'-untranslated B B_GENE
sequences I I_GENE
play O O
an O O
important O O
role O O
in O O
regulating O O
the O O
MAT2B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
identifies O O
the O O
Sp1 B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
at O O
+9 O O
as O O
a O O
potential O O
target O O
for O O
modulating O O
MAT2B O O
expression O O
, O O
a O O
process O O
that O O
can O O
have O O
a O O
major O O
effect O O
on O O
intracellular O O
AdoMet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
. O O

Molecular O O
pathogenesis O O
of O O
influenza O O
A O O
virus O O
infection O O
and O O
virus-induced O O
regulation O O
of O O
cytokine B B_GENE
gene I I_GENE
expression O O
. O O

Despite O O
vaccines O O
and O O
antiviral O O
substances O O
influenza O O
still O O
causes O O
significant O O
morbidity O O
and O O
mortality O O
world O O
wide O O
. O O

Better O O
understanding O O
of O O
the O O
molecular O O
mechanisms O O
of O O
influenza O O
virus O O
replication O O
, O O
pathogenesis O O
and O O
host O O
immune O O
responses O O
is O O
required O O
for O O
the O O
development O O
of O O
more O O
efficient O O
means O O
of O O
prevention O O
and O O
treatment O O
of O O
influenza O O
. O O

Cytokine O O
gene O O
expression O O
is O O
associated O O
with O O
the O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
, O O
AP-1 B B_GENE
, O O
STAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IRF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transducing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
influenza O O
A O O
virus-infected O O
cells O O
. O O

In O O
addition O O
of O O
upregulating O O
cytokine B B_GENE
gene I I_GENE
expression O O
, O O
influenza O O
A O O
virus O O
infection O O
activates O O
caspase-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
is O O
involved O O
in O O
the O O
proteolytic O O
processing O O
of O O
proIL-1 B B_GENE
beta I I_GENE
and O O
proIL-18 B B_GENE
into O O
their O O
biologically O O
active O O
forms O O
. O O

IFN-alpha/beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O O
prolongs O O
T O O
cell O O
survival O O
, O O
upregulates O O
IL-12 O O
and O O
IL-18 O O
receptor O O
gene O O
expression O O
and O O
together O O
with O O
IL-18 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulates O O
NK O O
and O O
T O O
cell O O
IFN-gamma O O
production O O
and O O
the O O
development O O
of O O
Th1-type O O
immune O O
response O O
. O O

N-Hydroxy-2-acetylaminofluorene O O
( O O
N-OH-AAF O O
) O O
is O O
the O O
proximate O O
carcinogenic O O
metabolite O O
of O O
the O O
powerful O O
rat O O
liver O O
carcinogen O O
2-acetylaminofluorene O O
. O O

In O O
this O O
study O O
, O O
transgenic O O
Big O O
Blue O O
( O O
R O O
) O O
rats O O
were O O
used O O
to O O
examine O O
the O O
relationship O O
between O O
in O O
vivo O O
mutagenicity O O
and O O
DNA O O
adduct O O
formation O O
by O O
N-OH-AAF O O
in O O
the O O
target O O
liver O O
compared O O
with O O
that O O
in O O
nontarget O O
tissues O O
. O O

Male O O
rats O O
were O O
given O O
one O O
, O O
two O O
, O O
or O O
four O O
doses O O
of O O
25 O O
mg O O
N-OH-AAF/kg O O
body O O
weight O O
by O O
i.p. O O
injection O O
at O O
4-day O O
intervals O O
, O O
and O O
groups O O
of O O
treated O O
and O O
control O O
rats O O
were O O
euthanized O O
up O O
to O O
10 O O
weeks O O
after O O
beginning O O
the O O
dosing O O
. O O

Mutant O O
frequencies O O
were O O
measured O O
in O O
the O O
spleen B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
lymphocyte I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
hprt I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
gene I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
, O O
and O O
lacI O O
mutant O O
frequencies O O
were O O
determined O O
in O O
the O O
liver O O
and O O
spleen O O
lymphocytes O O
. O O

At O O
6 O O
weeks O O
after O O
beginning O O
the O O
dosing O O
, O O
the O O
hprt O O
mutant O O
frequency O O
in O O
spleen O O
lymphocytes O O
from O O
the O O
four-dose O O
group O O
was O O
16.5 O O
x O O
10 O O
( O O
-6 O O
) O O
compared O O
with O O
3.2 O O
x O O
10 O O
( O O
-6 O O
) O O
in O O
control O O
animals O O
. O O

Also O O
at O O
6 O O
weeks O O
, O O
rats O O
given O O
one O O
, O O
two O O
, O O
or O O
four O O
doses O O
of O O
N-OH-AAF O O
had O O
lacI O O
mutant O O
frequencies O O
in O O
the O O
liver O O
of O O
97.6 O O
, O O
155.6 O O
, O O
and O O
406.8 O O
x O O
10 O O
( O O
-6 O O
) O O
, O O
respectively O O
, O O
compared O O
with O O
a O O
control O O
frequency O O
of O O
25.7 O O
x O O
10 O O
( O O
-6 O O
) O O
; O O
rats O O
given O O
four O O
doses O O
had O O
lacI O O
mutant O O
frequencies O O
in O O
spleen O O
lymphocytes O O
of O O
55.8 O O
x O O
10 O O
( O O
-6 O O
) O O
compared O O
with O O
a O O
control O O
frequency O O
of O O
20.4 O O
x O O
10 O O
( O O
-6 O O
) O O
. O O

Additional O O
rats O O
were O O
evaluated O O
for O O
DNA O O
adduct O O
formation O O
in O O
the O O
liver O O
, O O
spleen O O
lymphocytes O O
, O O
and O O
bone O O
marrow O O
by O O
( O O
32 O O
) O O
P-postlabeling O O
. O O

Adduct O O
analysis O O
was O O
conducted O O
1 O O
day O O
after O O
one O O
, O O
two O O
, O O
and O O
four O O
treatments O O
with O O
N-OH-AAF O O
, O O
5 O O
days O O
after O O
one O O
treatment O O
, O O
and O O
9 O O
days O O
after O O
two O O
treatments O O
. O O

N- O O
( O O
Deoxyguanosin-8-yl O O
) O O
-2-aminofluorene O O
was O O
the O O
major O O
DNA O O
adduct O O
identified O O
in O O
all O O
the O O
tissues O O
examined O O
. O O

Adduct O O
concentrations O O
increased O O
with O O
total O O
dose O O
to O O
maximum O O
values O O
in O O
samples O O
taken O O
1 O O
day O O
after O O
two O O
doses O O
, O O
and O O
remained O O
essentially O O
the O O
same O O
after O O
four O O
doses O O
. O O

The O O
results O O
indicate O O
that O O
the O O
extent O O
of O O
both O O
DNA O O
adduct O O
formation O O
and O O
mutant O O
induction O O
correlates O O
with O O
the O O
organ O O
specificity O O
for O O
N-OH-AAF O O
carcinogenesis O O
in O O
the O O
rat O O
. O O

Environ. O O
Mol. O O
Mutagen. O O
37 O O
: O O
195-202 O O
, O O
2001 O O
. O O

Published O O
2001 O O
Wiley-Liss O O
, O O
Inc O O
. O O

Expression O O
of O O
Mad1 B B_GENE/B_BIO
in O O
T O O
cells O O
leads O O
to O O
reduced O O
thymic O O
cellularity O O
and O O
impaired O O
mitogen-induced O O
proliferation O O
. O O

To O O
investigate O O
Mad1 B B_GENE/B_PERSON
function O O
in O O
vivo O O
, O O
transgenic O O
mice O O
were O O
generated O O
that O O
express O O
a O O
Mad1 B B_GENE
transgene I I_GENE
in O O
T O O
lineage O O
cells O O
under O O
the O O
control O O
of O O
the O O
proximal B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
lck I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
promoter I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Thymus O O
size O O
in O O
lck-Mad1 O O
transgenic O O
mice O O
is O O
drastically O O
reduced O O
although O O
representation O O
of O O
the O O
various O O
thymocyte O O
sub O O
populations O O
appears O O
normal O O
. O O

Furthermore O O
, O O
thymocytes O O
and O O
splenic O O
T O O
cells O O
from O O
lck-Mad1 O O
transgenic O O
mice O O
display O O
a O O
profound O O
proliferative O O
defect O O
in O O
response O O
to O O
activation O O
with O O
either O O
PMA/Ionomycin O O
or O O
immobilized B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
anti-CD3/CD28 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

This O O
proliferative O O
defect O O
is O O
not O O
reversed O O
by O O
addition O O
of O O
exogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
IL-2 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
is O O
p53-independent O O
. O O

Differential O O
requirement O O
for O O
the O O
transcription B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
factor I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
PU.1 I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
generation O O
of O O
natural O O
killer O O
cells O O
versus O O
B O O
and O O
T O O
cells O O
. O O

PU.1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
member O O
of O O
the O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
required O O
for O O
the O O
development O O
of O O
various O O
lymphoid O O
and O O
myeloid O O
cell O O
lineages O O
, O O
but O O
its O O
role O O
in O O
natural O O
killer O O
( O O
NK O O
) O O
cell O O
development O O
is O O
not O O
known O O
. O O

The O O
study O O
shows O O
that O O
PU.1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
expressed O O
in O O
NK O O
cells O O
and O O
that O O
, O O
on O O
cell O O
transfer O O
into O O
alymphoid O O
Rag2/gammac O O
( O O
-/- O O
) O O
mice O O
, O O
hematopoietic O O
progenitors O O
of O O
PU.1 O O
( O O
-/- O O
) O O
fetal O O
liver O O
cells O O
could O O
generate O O
functional O O
NK O O
cells O O
but O O
not O O
B O O
or O O
T O O
cells O O
. O O

Nevertheless O O
, O O
the O O
numbers O O
of O O
bone O O
marrow O O
NK O O
cell O O
precursors O O
and O O
splenic O O
mature O O
NK O O
cells O O
were O O
reduced O O
compared O O
to O O
controls O O
. O O

Moreover O O
, O O
PU.1 O O
( O O
-/- O O
) O O
NK O O
cells O O
displayed O O
reduced O O
expression O O
of O O
the O O
receptors O O
for O O
stem B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
interleukin B B_GENE
( I I_GENE
IL I I_GENE
) I I_GENE
-7 I I_GENE
, O O
suggesting O O
a O O
nonredundant O O
role O O
for O O
PU.1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
regulating O O
the O O
expression O O
of O O
these O O
cytokine B B_GENE
receptor I I_GENE
genes I I_GENE
during O O
NK O O
cell O O
development O O
. O O

PU.1 O O
( O O
-/- O O
) O O
NK O O
cells O O
also O O
showed O O
defective O O
expression O O
of O O
inhibitory O O
and O O
activating O O
members O O
of O O
the O O
Ly49 B B_GENE/B_PERSON
family I I_GENE/I_PERSON
and O O
failed O O
to O O
proliferate O O
in O O
response O O
to O O
IL-2 B B_GENE
and O O
IL-12 B B_GENE
. O O

Thus O O
, O O
despite O O
the O O
less O O
stringent O O
requirement O O
for O O
PU.1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
NK O O
cell O O
development O O
compared O O
to O O
B O O
and O O
T O O
cells O O
, O O
PU.1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulates O O
NK O O
cell O O
differentiation O O
and O O
homeostasis O O
. O O

Benzene-extracted O O
components O O
are O O
important O O
for O O
the O O
major O O
activity O O
of O O
diesel O O
exhaust O O
particles O O
: O O
effect O O
on O O
interleukin-8 B B_GENE
gene I I_GENE
expression O O
in O O
human O O
bronchial O O
epithelial O O
cells O O
. O O

Epidemiologic O O
and O O
experimental O O
studies O O
suggest O O
that O O
diesel O O
exhaust O O
particles O O
( O O
DEPs O O
) O O
may O O
be O O
related O O
to O O
increasing O O
respiratory O O
mortality O O
and O O
morbidity O O
. O O

We O O
have O O
shown O O
that O O
DEPs O O
augmented O O
the O O
production O O
of O O
inflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
human O O
airway O O
epithelial O O
cells O O
in O O
vitro O O
. O O

We O O
used O O
several O O
agents O O
active O O
on O O
signal O O
transduction O O
pathways O O
in O O
cytokine O O
expression O O
, O O
such O O
as O O
the O O
protein O O
kinase O O
C O O
inhibitor O O
staurosporin O O
, O O
antioxidant O O
agents O O
including O O
N-acetyl O O
cysteine O O
( O O
NAC O O
) O O
and O O
pyrrolidine O O
dithiocarbamate O O
( O O
PDTC O O
) O O
, O O
and O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE/B_LOCATION
) O O
inhibitor O O
SB203580 O O
. O O

Benzene-extracted O O
components O O
showed O O
effects O O
mimicking O O
DEPs O O
on O O
IL-8 O O
gene O O
expression O O
, O O
release O O
of O O
several O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
IL-8 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
; O O
granulocyte B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
macrophage I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
and O O
regulated O O
on O O
activation O O
, O O
normal O O
T O O
cells O O
expressed O O
and O O
secreted O O
) O O
and O O
nuclear O O
factor O O
( O O
NF O O
) O O
-kappa O O
B O O
activation O O
. O O

We O O
also O O
found O O
that O O
NAC O O
, O O
PDTC O O
, O O
and O O
SB203580 O O
suppressed O O
the O O
activities O O
of O O
DEPs O O
and O O
their O O
benzene O O
extracts O O
, O O
suggesting O O
the O O
roles O O
of O O
oxidants-mediated O O
NF-kappa O O
B O O
activation O O
and O O
p38MAPK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathways O O
. O O

Finally O O
, O O
benzo O O
[ O O
a O O
] O O
pyrene O O
, O O
one O O
of O O
the O O
important O O
compounds O O
included O O
in O O
the O O
benzene O O
component O O
, O O
replicated O O
the O O
activities O O
shown O O
by O O
DEPs O O
. O O

The O O
nuclear B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
PPAR I I_GENE/I_LOCATION
gamma I I_GENE/I_LOCATION
is O O
expressed O O
by O O
mouse O O
T O O
lymphocytes O O
and O O
PPAR O O
gamma O O
agonists O O
induce O O
apoptosis O O
. O O

Peroxisome B B_GENE/B_LOCATION
proliferator-activated I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
PPAR I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
-gamma I I_GENE/I_LOCATION
is O O
a O O
nuclear B B_GENE
hormone I I_GENE
receptor I I_GENE
that O O
serves O O
as O O
a O O
trans O O
factor O O
to O O
regulate O O
lipid O O
metabolism O O
. O O

Intense O O
interest O O
is O O
focused O O
on O O
PPAR-gamma B B_GENE
and O O
its O O
ligands O O
owing O O
to O O
its O O
putative O O
role O O
in O O
adipocyte O O
differentiation O O
. O O

Little O O
is O O
known O O
, O O
however O O
, O O
about O O
the O O
functions O O
of O O
PPAR-gamma B B_GENE
in O O
the O O
immune O O
system O O
, O O
especially O O
in O O
T O O
lymphocytes O O
. O O

We O O
demonstrate O O
that O O
both O O
naive O O
and O O
activated O O
ovalbumin-specific O O
T O O
cells O O
from O O
DO11.10-transgenic O O
mice O O
express O O
PPAR-gamma B B_GENE
mRNA O O
and O O
protein O O
. O O

In O O
order O O
to O O
determine O O
the O O
function O O
of O O
PPAR-gamma B B_GENE
, O O
T O O
cells O O
were O O
stimulated O O
with O O
phorbol O O
12-myristate O O
13-acetate O O
and O O
ionomycin O O
or O O
antigen O O
and O O
antigen-presenting O O
cells O O
. O O

The O O
decrease O O
in O O
cell O O
viability O O
was O O
due O O
to O O
apoptosis O O
of O O
the O O
T O O
lymphocytes O O
, O O
and O O
occurred O O
only O O
when O O
cells O O
were O O
treated O O
with O O
PPAR-gamma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
not O O
PPAR-alpha O O
agonists O O
, O O
revealing O O
specificity O O
of O O
this O O
response O O
for O O
PPAR-gamma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Suppression O O
of O O
lung O O
inflammation O O
in O O
rats O O
by O O
prevention O O
of O O
NF-kappaB O O
activation O O
in O O
the O O
liver O O
. O O

Activation O O
of O O
NF-kappaB B B_GENE
and O O
production O O
of O O
NF-kappaB B B_GENE
-dependent O O
chemokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
thought O O
to O O
be O O
involved O O
in O O
the O O
pathogenesis O O
of O O
neutrophilic O O
lung O O
inflammation O O
. O O

Calpain-1 O O
inhibitor O O
( O O
CI-1 O O
) O O
blocks O O
activation O O
of O O
NF-kappaB B B_GENE
by O O
preventing O O
proteolysis O O
of O O
the O O
inhibitory O O
protein O O
IkappaB-alpha B B_GENE
by O O
the O O
ubiquitin/proteasome O O
pathway O O
. O O

We O O
treated O O
rats O O
with O O
a O O
single O O
i.p. O O
injection O O
of O O
CI-1 O O
( O O
10 O O
mg/kg O O
) O O
two O O
hours O O
prior O O
to O O
i.p. O O
LPS O O
( O O
7 O O
mg/kg O O
) O O
. O O

Treatment O O
with O O
Cl-1 O O
prevented O O
degradation O O
of O O
IkappaB-alpha B B_GENE
and O O
activation O O
of O O
NF-kappaB B B_GENE
in O O
the O O
liver O O
in O O
response O O
to O O
LPS O O
; O O
however O O
, O O
Cl-1 O O
treatment O O
had O O
no O O
detected O O
effect O O
on O O
NF-kappaB O O
activation O O
in O O
lung O O
tissue O O
. O O

CI-1 O O
treatment O O
prior O O
to O O
LPS O O
resulted O O
in O O
40 O O
% O O
lower O O
MIP-2 O O
concentration O O
in O O
lung O O
lavage O O
fluid O O
compared O O
to O O
rats O O
treated O O
with O O
vehicle O O
prior O O
to O O
LPS O O
( O O
502 O O
+/- O O
112 O O
pg/ml O O
vs. O O
859 O O
+/-144 O O
pg/ml O O
, O O
P O O
< O O
0.05 O O
) O O
. O O

In O O
addition O O
, O O
CI-1 O O
treatment O O
substantially O O
inhibited O O
LPS-induced O O
neutrophilic O O
alveolitis O O
( O O
2.7+ O O
/- O O
1.2 O O
x O O
10 O O
( O O
5 O O
) O O
vs. O O
43.7 O O
+/- O O
12.2 O O
x O O
10 O O
( O O
5 O O
) O O
lung O O
lavage O O
neutrophils O O
, O O
P O O
< O O
0.01 O O
) O O
. O O

These O O
data O O
indicate O O
that O O
NF-kappaB O O
inhibition O O
in O O
the O O
liver O O
can O O
alter O O
lung O O
inflammation O O
induced O O
by O O
systemic O O
LPS O O
treatment O O
and O O
suggest O O
that O O
a O O
liver-lung O O
interaction O O
contributes O O
to O O
the O O
inflammatory O O
response O O
of O O
the O O
lung O O
. O O

Notch1 B B_GENE
regulates O O
maturation O O
of O O
CD4+ O O
and O O
CD8+ O O
thymocytes O O
by O O
modulating O O
TCR O O
signal O O
strength O O
. O O

We O O
demonstrate O O
in O O
this O O
report O O
that O O
retroviral O O
expression O O
of O O
activated O O
Notch1 B B_GENE
in O O
mouse O O
thymocytes O O
abrogates O O
differentiation O O
of O O
immature O O
CD4+CD8+ O O
thymocytes O O
into O O
both O O
CD4 O O
and O O
CD8 O O
mature O O
single-positive O O
T O O
cells O O
. O O

The O O
ability O O
of O O
Notch1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
inhibit O O
T O O
cell O O
development O O
was O O
observed O O
in O O
vitro O O
and O O
in O O
vivo O O
with O O
both O O
normal O O
and O O
TCR O O
transgenic O O
thymocytes O O
. O O

Notch1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-mediated O O
developmental O O
arrest O O
was O O
dose O O
dependent O O
and O O
was O O
associated O O
with O O
impaired O O
thymocyte O O
responses O O
to O O
TCR O O
stimulation O O
. O O

Notch1 B B_PERSON/B_PROTEIN[GENE]
also O O
inhibited O O
TCR-mediated O O
signaling O O
in O O
Jurkat O O
T O O
cells O O
. O O

These O O
data O O
indicate O O
that O O
constitutively O O
active O O
Notch1 B B_GENE/B_LOCATION
abrogates O O
CD4+ O O
and O O
CD8+ O O
maturation O O
by O O
interfering O O
with O O
TCR O O
signal O O
strength O O
and O O
provide O O
an O O
explanation O O
for O O
the O O
physiological O O
regulation O O
of O O
Notch O O
expression O O
during O O
thymocyte O O
development O O
. O O

Expression O O
of O O
SART3 B B_GENE
antigen I I_GENE
and O O
induction O O
of O O
CTLs O O
by O O
SART3-derived O O
peptides O O
in O O
breast O O
cancer O O
patients O O
. O O

This O O
study O O
investigated O O
expression O O
of O O
the O O
SART3 B B_GENE
antigen I I_GENE
in O O
breast O O
cancer O O
to O O
explore O O
an O O
appropriate O O
molecule O O
for O O
use O O
in O O
specific O O
immunotherapy O O
of O O
breast O O
cancer O O
patients O O
. O O

The O O
SART3 B B_GENE
antigen I I_GENE
was O O
detected O O
in O O
all O O
of O O
the O O
breast O O
cancer O O
cell O O
lines O O
tested O O
, O O
30 O O
of O O
40 O O
( O O
75 O O
% O O
) O O
breast O O
cancer O O
tissue O O
samples O O
, O O
and O O
0 O O
of O O
3 O O
non-tumourous O O
breast O O
tissue O O
samples O O
. O O

SART3 O O
derived O O
peptides O O
at O O
positions B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
109-118 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
315-323 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
HLA-A24 O O
restricted O O
CTLs O O
that O O
reacted O O
to O O
breast O O
cancer O O
cells O O
from O O
the O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMCs O O
) O O
of O O
breast O O
cancer O O
patients O O
. O O

Therefore O O
, O O
the O O
SART3 B B_GENE
antigen I I_GENE
and O O
its O O
peptides O O
could O O
be O O
an O O
appropriate O O
molecule O O
for O O
use O O
in O O
specific O O
immunotherapy O O
of O O
the O O
majority O O
of O O
HLA-A24-positive O O
breast O O
cancer O O
patients O O

Autostimulation O O
of O O
the O O
Epstein-Barr O O
virus O O
BRLF1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
mediated O O
through O O
consensus O O
Sp1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Sp3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Consistent O O
with O O
this O O
biologic O O
function O O
, O O
the O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
Rta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
powerfully O O
stimulates O O
the O O
promoter B B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
its O O
own O O
gene O O
, O O
Rp B B_GENE/B_DISEASE
, O O
in O O
EBV-positive O O
B O O
cells O O
in O O
transient-transfection O O
reporter-based O O
assays O O
. O O

Previously O O
described O O
binding O O
sites O O
for O O
the O O
cellular O O
transcription B B_GENE/B_BIO
factor I I_GENE/I_BIO
Zif268 I I_GENE/I_BIO
and O O
the O O
viral B B_GENE/B_BIO
transactivator I I_GENE/I_BIO
ZEBRA I I_GENE/I_BIO
were O O
found O O
to O O
be O O
dispensable O O
for O O
activation O O
of O O
RpCAT B B_GENE/B_BACTERIUM[BIO]
by O O
Rta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Gel O O
shift O O
analysis O O
, O O
using O O
extracts O O
of O O
B O O
cells O O
in O O
latency O O
or O O
induced O O
into O O
the O O
lytic O O
cycle O O
, O O
identified O O
Sp1 B B_GENE/B_LOCATION
and O O
Sp3 B B_GENE
as O O
the O O
predominant O O
cellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bound O O
to O O
Rp B B_PROTEIN[GENE]/B_DISEASE
near O O
-45 O O
. O O

The O O
binding O O
of O O
Sp1 B B_GENE/B_LOCATION
and O O
Sp3 B B_GENE/B_DISEASE
to O O
Rp B B_GENE/B_DISEASE
correlated O O
with O O
the O O
reporter O O
activities O O
in O O
the O O
mutagenesis O O
study O O
, O O
establishing O O
a O O
direct O O
link O O
between O O
transcriptional O O
activation O O
of O O
Rp B B_GENE/B_DISEASE
by O O
Rta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
DNA O O
binding O O
by O O
Sp1 B B_GENE/B_LOCATION
and/or O O
Sp3 B B_GENE/B_LOCATION
. O O

The O O
relative O O
abundance O O
or O O
functional O O
state O O
of O O
the O O
cellular O O
Sp1 B B_GENE/B_LOCATION
and O O
Sp3 B B_GENE
transcription B I_GENE
factors I I_GENE
may O O
be O O
altered O O
in O O
response O O
to O O
stimuli O O
that O O
induce O O
the O O
BRLF1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
thereby O O
contribute O O
to O O
the O O
activation O O
of O O
the O O
viral O O
lytic O O
cycle O O
. O O

Gene O O
transfer O O
of O O
antisense O O
hypoxia B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inducible I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhances O O
the O O
therapeutic O O
efficacy O O
of O O
cancer O O
immunotherapy O O
. O O

Hypoxia B B_GENE/B_MEASURE
inducible I I_GENE/I_MEASURE
factor-1 I I_GENE/I_MEASURE
( O O
HIF-1 B B_GENE/B_DISEASE
) O O
is O O
a O O
constitutively O O
expressed O O
basic O O
helix-loop-helix B B_GENE
transcription I I_GENE
factor I I_GENE
, O O
formed O O
by O O
the O O
assembly O O
of O O
HIF-1alpha B B_GENE
and O O
HIF-1beta B B_GENE
( O O
Arnt B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
, O O
that O O
is O O
stablized O O
in O O
response O O
to O O
hypoxia O O
, O O
and O O
rapidly O O
degraded O O
under O O
normoxic O O
conditions O O
. O O

Here O O
, O O
we O O
demonstrate O O
that O O
engineered O O
down-regulation O O
of O O
HIF-1alpha B B_GENE
by O O
intratumoral O O
gene O O
transfer O O
of O O
an O O
antisense B B_GENE
HIF-1alpha I I_GENE
plasmid I I_GENE
leads O O
to O O
the O O
down-regulation O O
of O O
VEGF B B_GENE/B_DISEASE
, O O
and O O
decreased O O
tumor O O
microvessel O O
density O O
. O O

Antisense O O
HIF-1alpha O O
monotherapy O O
resulted O O
in O O
the O O
complete O O
and O O
permanent O O
rejection O O
of O O
small O O
( O O
0.1 O O
cm O O
in O O
diameter O O
) O O
EL-4 O O
tumors O O
, O O
which O O
is O O
unusual O O
for O O
an O O
anti-angiogenic O O
agent O O
where O O
transient O O
suppression O O
of O O
tumor O O
growth O O
is O O
the O O
norm O O
. O O

It O O
induced O O
NK O O
cell O O
-dependent O O
rejection O O
of O O
tumors O O
, O O
but O O
failed O O
to O O
stimulate O O
systemic O O
T O O
cell O O
-mediated O O
anti-tumor O O
immunity O O
, O O
and O O
synergized O O
with O O
B7-1-mediated O O
immunotherapy O O
to O O
cause O O
the O O
NK O O
cell O O
and O O
CD8 O O
T O O
cell O O
-dependent O O
rejection O O
of O O
larger O O
EL-4 O O
tumors O O
( O O
0.4 O O
cm O O
in O O
diameter O O
) O O
that O O
were O O
refractory O O
to O O
monotherapies O O
. O O

Mice O O
cured O O
of O O
their O O
tumors O O
by O O
combination O O
therapy O O
resisted O O
a O O
rechallenge O O
with O O
parental O O
tumor O O
cells O O
, O O
indicating O O
systemic O O
antitumor O O
immunity O O
had O O
been O O
achieved O O
. O O

In O O
summary O O
, O O
whilst O O
intensive O O
investigations O O
are O O
in O O
progress O O
to O O
target O O
the O O
many O O
HIF-1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
effectors O O
, O O
the O O
results O O
herein O O
indicate O O
that O O
blocking O O
hypoxia-inducible O O
pathways O O
and O O
enhancing O O
NK-mediated O O
antitumor O O
immunity O O
by O O
targeting O O
HIF-1 B B_GENE/B_DISEASE
itself O O
may O O
be O O
advantageous O O
, O O
especially O O
when O O
combined O O
with O O
cancer O O
immunotherapy O O
. O O

Runx2 B B_GENE
: O O
a O O
novel O O
oncogenic O O
effector O O
revealed O O
by O O
in O O
vivo O O
complementation O O
and O O
retroviral O O
tagging O O
. O O

The O O
Runx2 B B_GENE
( O O
Cbfa1 B B_GENE
, O O
Pebp2alphaA B B_GENE/B_DISEASE
, O O
Aml3 B B_GENE
) O O
gene O O
was O O
previously O O
identified O O
as O O
a O O
frequent O O
target O O
for O O
transcriptional O O
activation O O
by O O
proviral O O
insertion O O
in O O
T-cell O O
lymphomas O O
of O O
CD2-MYC O O
transgenic O O
mice O O
. O O

To O O
gain O O
further O O
insight O O
into O O
the O O
relationship O O
of O O
Runx2 B B_GENE
to O O
other O O
lymphomagenic O O
pathways O O
, O O
we O O
tested O O
the O O
effect O O
of O O
combining O O
the O O
CD2-Runx2 B B_GENE
transgene I I_GENE
either O O
with O O
a O O
Pim1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transgene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
E B B_GENE
( I I_GENE
mu I I_GENE
) I I_GENE
-Pim1 I I_GENE
) O O
or O O
with O O
the O O
p53 B B_GENE/B_MEASURE
null O O
genotype O O
, O O
as O O
each O O
of O O
these O O
displays O O
independent O O
synergy O O
with O O
Myc B B_GENE/B_SPECIES[BIO]
. O O

In O O
both O O
cases O O
we O O
observed O O
synergistic O O
tumour O O
development O O
. O O

However O O
, O O
Runx2 B B_GENE/B_MEASURE
appeared O O
to O O
have O O
a O O
dominant O O
effect O O
on O O
the O O
tumour O O
phenotype O O
in O O
each O O
case O O
, O O
with O O
most O O
tumours O O
conforming O O
to O O
the O O
CD3 O O
( O O
+ O O
) O O
, O O
CD8 O O
( O O
+ O O
) O O
, O O
CD4 O O
( O O
+/- O O
) O O
phenotype O O
seen O O
in O O
CD2-Runx2 O O
mice O O
. O O

Neonatal O O
infection O O
of O O
CD2-Runx2 O O
mice O O
with O O
Moloney O O
murine O O
leukaemia O O
virus O O
( O O
Moloney O O
MLV O O
) O O
also O O
led O O
to O O
a O O
dramatic O O
acceleration O O
of O O
tumour O O
onset O O
. O O

Analysis O O
of O O
known O O
Moloney B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
MLV I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
target I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
these O O
lymphomas O O
showed O O
a O O
high O O
frequency O O
of O O
rearrangement O O
at O O
c-Myc B B_GENE/B_DISEASE
or O O
N-Myc B B_GENE
( O O
82 O O
% O O
) O O
, O O
and O O
a O O
significant O O
number O O
at O O
Pim1 B B_GENE
or O O
Pim2 B B_GENE
( O O
23 O O
% O O
) O O
, O O
and O O
at O O
Pal1/Gfi1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
18 O O
% O O
) O O
. O O

These O O
results O O
indicate O O
that O O
Runx2 B B_GENE
makes O O
a O O
distinct O O
contribution O O
to O O
T-cell O O
lymphoma O O
development O O
which O O
does O O
not O O
coincide O O
with O O
any O O
of O O
the O O
oncogene O O
complementation O O
groups O O
previously O O
identified O O
by O O
retroviral O O
tagging O O
. O O

The O O
involvement O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-related O O
apoptosis-inducing O O
ligand O O
in O O
the O O
enhanced O O
cytotoxicity O O
of O O
IFN-beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-stimulated O O
human O O
dendritic O O
cells O O
to O O
tumor O O
cells O O
. O O

TNF-alpha B B_DISEASE/B_GENE
-related O O
apoptosis-inducing O O
ligand O O
( O O
TRAIL O O
) O O
is O O
characterized O O
by O O
its O O
preferential O O
induction O O
of O O
apoptosis O O
of O O
tumor O O
cells O O
but O O
not O O
normal O O
cells O O
. O O

Dendritic O O
cells O O
( O O
DCs O O
) O O
, O O
besides O O
their O O
role O O
as O O
APCs O O
, O O
now O O
have O O
been O O
demonstrated O O
to O O
exert O O
cytotoxicity O O
or O O
cytostasis O O
on O O
some O O
tumor O O
cells O O
. O O

TRAIL O O
expression O O
on O O
immature O O
CD34DCs O O
or O O
MoDCs O O
was O O
greatly O O
up-regulated O O
after O O
IFN-beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O O
. O O

Moreover O O
, O O
IFN-beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
could O O
strikingly O O
enhance O O
the O O
ability O O
of O O
CD34DCs O O
or O O
MoDCs O O
to O O
kill O O
TRAIL-sensitive O O
tumor O O
cells O O
, O O
but O O
LPS O O
did O O
not O O
have O O
such O O
an O O
effect O O
. O O

The O O
up-regulation O O
of O O
TRAIL O O
on O O
IFN-beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-stimulated O O
DCs O O
partially O O
contributed O O
to O O
the O O
increased O O
cytotoxicity O O
of O O
DCS O O
: O O
Pretreatment O O
of O O
TRAIL-sensitive O O
tumor O O
cells O O
with O O
caspase-3 O O
inhibitor O O
could O O
significantly O O
increase O O
their O O
resistance O O
to O O
the O O
cytotoxicity O O
of O O
IFN-beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-stimulated O O
DCS O O
: O O
In O O
contrast O O
, O O
NF-kappaB O O
inhibitor O O
could O O
significantly O O
increase O O
the O O
sensitivity O O
of O O
tumor O O
cells O O
to O O
the O O
killing O O
by O O
nonstimulated O O
or O O
LPS-stimulated O O
DCS O O
: O O
Our O O
studies O O
demonstrate O O
that O O
IFN-beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-stimulated O O
DCs O O
are O O
functionally O O
cytotoxic O O
. O O

Subsequently O O
, O O
DCs O O
act O O
as O O
APCs O O
involved O O
in O O
the O O
uptake O O
, O O
processing O O
, O O
and O O
presentation O O
of O O
apoptotic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
tumor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
Ags I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
to O O
cross-prime O O
CD8 O O
( O O
+ O O
) O O
CTL O O
cells O O
. O O

Tumor-infiltrating O O
p58+ O O
T O O
cells O O
from O O
a O O
renal O O
tumor O O
were O O
specifically O O
expanded O O
in O O
response O O
to O O
tumor O O
cell O O
stimulation O O
and O O
cloned O O
. O O

Functionally O O
, O O
p58 O O
( O O
+ O O
) O O
CTLs O O
displayed O O
a O O
low O O
lytic O O
activity O O
for O O
HLA-A2 O O
tumor O O
and O O
normal O O
cells O O
. O O

Interestingly O O
, O O
we O O
demonstrated O O
that O O
stimulation O O
by O O
tumor O O
cells O O
was O O
required O O
to O O
trigger O O
the O O
inhibitory O O
effect O O
of O O
p58 B B_GENE
on O O
the O O
lytic O O
activity O O
of O O
antigen-specific O O
CTLs O O
and O O
that O O
stimulation O O
of O O
the O O
inhibitory O O
function O O
of O O
p58 B B_GENE
by O O
tumor O O
cells O O
correlated O O
with O O
an O O
inhibition O O
of O O
nuclear O O
factor-kappaB O O
activation O O
in O O
p58+ O O
tumor-specific O O
CTLS O O
. O O

T-cell B B_GENE
factor-1 I I_GENE
expression O O
during O O
human O O
natural O O
killer O O
cell O O
development O O
and O O
in O O
circulating O O
CD56 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
+ I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
bright O O
natural O O
killer O O
cells O O
. O O

Transcription B B_GENE/B_PERSON
factors I I_GENE/I_PERSON
are O O
essential O O
to O O
govern O O
differentiation O O
along O O
the O O
lymphoid O O
lineage O O
from O O
uncommitted O O
hematopoietic O O
stem O O
cells O O
. O O

Although O O
many O O
of O O
these O O
transcription B B_GENE/B_BIO
factors I I_GENE/I_BIO
have O O
putative O O
roles O O
based O O
on O O
murine O O
knockout O O
experiments O O
, O O
their O O
function O O
in O O
human O O
lymphoid O O
development O O
is O O
less O O
known O O
and O O
was O O
studied O O
further O O
. O O

Transcription O O
factor O O
expression O O
in O O
fresh O O
and O O
cultured O O
adult O O
human O O
bone O O
marrow O O
and O O
umbilical O O
cord O O
blood O O
progenitors O O
was O O
evaluated O O
. O O

We O O
found O O
that O O
fresh O O
CD34 O O
( O O
+ O O
) O O
Lin O O
( O O
- O O
) O O
cells O O
that O O
are O O
human O O
leukocyte O O
antigen O O
( O O
HLA O O
) O O
-DR O O
( O O
- O O
) O O
or O O
CD38 O O
( O O
- O O
) O O
constitutively O O
express O O
GATA-3 B B_GENE
but O O
not O O
T-cell B B_GENE/B_DISEASE
factor-1 I I_GENE/I_DISEASE
( O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
Id-3 B B_GENE
. O O

However O O
, O O
no O O
T-cell B B_GENE
receptor I I_GENE
gene I I_GENE
rearrangement O O
was O O
identified O O
in O O
cultured O O
progeny O O
. O O

Id-3 B B_GENE/B_LOCATION
, O O
a O O
basic B B_GENE/B_MEASURE
helix I I_GENE/I_MEASURE
loop I I_GENE/I_MEASURE
helix I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
with O O
dominant O O
negative O O
function O O
for O O
T-cell O O
differentiation O O
transcription B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
also O O
was O O
upregulated O O
and O O
may O O
explain O O
unsuccessful O O
T-cell O O
maturation O O
. O O

To O O
better O O
understand O O
the O O
developmental O O
link O O
between O O
natural O O
killer O O
( O O
NK O O
) O O
cells O O
derived O O
from O O
progenitors O O
, O O
we O O
studied O O
NK O O
cell O O
subsets O O
circulating O O
in O O
blood O O
. O O

CD56 O O
( O O
+bright O O
) O O
, O O
but O O
not O O
CD56 O O
( O O
+dim O O
) O O
, O O
NK O O
cells O O
constitutively O O
express O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
reverse O O
transcriptase O O
polymerase O O
chain O O
reaction O O
and O O
Western O O
blot O O
analysis O O
. O O

The O O
TCF-1 B B_GENE
isoform I I_GENE
found O O
in O O
CD56 O O
( O O
+bright O O
) O O
cells O O
, O O
which O O
express O O
lectin B B_GENE
but O O
not O O
immunoglobulin B B_GENE/B_LOCATION
class I I_GENE/I_LOCATION
I I I_GENE/I_LOCATION
recognizing O O
inhibitory B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
was O O
identical O O
to O O
that O O
induced O O
in O O
NK O O
cell O O
differentiation O O
culture O O
and O O
was O O
distinctly O O
different O O
from O O
isoforms O O
in O O
T O O
cells O O
. O O

Transcriptional O O
activation O O
by O O
a O O
matrix B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associating I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region-binding I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
B B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
regulator I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
IgH I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
a O O
B O O
cell O O
-specific O O
, O O
matrix B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
associating I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
transactivates O O
gene O O
expression O O
from O O
the O O
IgH B B_GENE
intronic I I_GENE
enhancer I I_GENE
( O O
E B B_PROTEIN[GENE]/B_PERSON
mu I I_PROTEIN[GENE]/I_PERSON
) O O
. O O

Transactivation O O
is O O
maximal O O
on O O
integrated O O
substrates O O
. O O

Two O O
of O O
the O O
three O O
previously O O
identified O O
binding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
E B B_GENE
mu I I_GENE
are O O
required O O
for O O
full O O
Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
transactivation O O
. O O

Similar O O
to O O
one O O
group O O
of O O
high B B_BIO/B_GENE
mobility I I_BIO/I_GENE
group I I_BIO/I_GENE
box I I_BIO/I_GENE
proteins I I_BIO/I_GENE
, O O
Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
distorts O O
E B B_GENE/B_LOCATION
mu I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
-containing O O
DNA O O
on O O
binding O O
, O O
supporting O O
the O O
concept O O
that O O
it O O
mediates O O
E B B_GENE
mu I I_GENE
remodeling O O
. O O

Transfection O O
studies O O
further O O
implicate O O
Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
facilitating O O
spatially O O
separated O O
promoter-enhancer O O
interactions O O
in O O
both O O
transient O O
and O O
stable O O
assays O O
. O O

Finally O O
, O O
we O O
show O O
that O O
overexpression O O
of O O
Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
leads O O
to O O
enhanced O O
DNase O O
I O O
sensitivity O O
of O O
the O O
endogenous O O
E B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
mu I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
matrix O O
associating O O
regions O O
. O O

These O O
data O O
further O O
suggest O O
that O O
Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
may O O
contribute O O
to O O
increased O O
gene O O
expression O O
by O O
remodeling O O
the O O
immunoglobulin B B_GENE
locus I I_GENE
during O O
B O O
cell O O
development O O
. O O

Analysis O O
of O O
BCL-6 O O
mutations O O
in O O
classic O O
Hodgkin O O
disease O O
of O O
the O O
B- O O
and O O
T-cell O O
type O O
. O O

The O O
5'-noncoding B B_GENE/B_LOCATION
region I I_GENE/I_LOCATION
of O O
the O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
even O O
a O O
target O O
for O O
the O O
mutation O O
machinery O O
. O O

Translocations O O
of O O
the O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
heterologous B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
mutations O O
of O O
its O O
5'-noncoding B B_GENE/B_MEASURE
regulatory I I_GENE/I_MEASURE
region I I_GENE/I_MEASURE
were O O
reported O O
to O O
be O O
potential O O
mechanisms O O
for O O
deregulating O O
BCL-6 B B_GENE
expression O O
and O O
for O O
playing O O
a O O
role O O
in O O
the O O
genesis O O
of O O
non-Hodgkin O O
lymphoma O O
. O O

In O O
line O O
with O O
this O O
hypothesis O O
is O O
the O O
observation O O
that O O
B-cell O O
lymphoma O O
with O O
somatic O O
mutations O O
, O O
such O O
as O O
diffuse O O
large O O
B-cell O O
lymphoma O O
and O O
follicular O O
lymphoma O O
, O O
also O O
carry O O
BCL-6 O O
mutations O O
, O O
some O O
of O O
which O O
are O O
recurrently O O
detectable O O
. O O

To O O
determine O O
the O O
presence O O
and O O
potential O O
role O O
of O O
BCL-6 O O
mutations O O
in O O
cHD O O
, O O
the O O
5'-noncoding B B_GENE/B_MEASURE
BCL-6 I B_GENE/I_MEASURE
proportion O O
of O O
single O O
Hodgkin O O
and O O
Reed-Sternberg O O
( O O
HRS O O
) O O
cells O O
from O O
6 O O
cases O O
of O O
cHD O O
and O O
6 O O
cases O O
of O O
HD-derived O O
cell O O
lines O O
was O O
analyzed O O
. O O

All O O
B-cell-derived O O
HD O O
cases O O
and O O
cell O O
lines O O
harbored O O
BCL-6 O O
mutations O O
. O O

In O O
contrast O O
, O O
both O O
T-cell-derived O O
HD O O
cases O O
and O O
cell O O
lines O O
were O O
devoid O O
of O O
BCL-6 O O
mutations O O
. O O

With O O
only O O
one O O
exception O O
, O O
there O O
were O O
no O O
lymphoma-specific O O
recurrent O O
BCL-6 O O
mutations O O
detected O O
, O O
and O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
absent O O
from O O
the O O
HRS O O
cells O O
of O O
most O O
cases O O
. O O

In O O
conclusion O O
, O O
( O O
1 O O
) O O
somatic O O
BCL-6 O O
mutations O O
are O O
restricted O O
to O O
cHD O O
cases O O
of O O
B-cell O O
origin O O
, O O
and O O
( O O
2 O O
) O O
the O O
BCL-6 O O
mutations O O
represent O O
mostly O O
irrelevant O O
somatic O O
base O O
substitutions O O
without O O
consequences O O
for O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
and O O
the O O
pathogenesis O O
of O O
cHD O O
. O O

Gadd45gamma B B_GENE
is O O
dispensable O O
for O O
normal O O
mouse O O
development O O
and O O
T-cell O O
proliferation O O
. O O

Gadd45gamma B B_GENE
, O O
a O O
family O O
member O O
of O O
the O O
growth B B_GENE/B_BIO
arrest I I_GENE/I_BIO
and I I_GENE/I_BIO
DNA I I_GENE/I_BIO
damage-inducible I I_GENE/I_BIO
gene I I_GENE/I_BIO
family I I_GENE/I_BIO
45 I I_GENE/I_BIO
( O O
Gadd45 B B_GENE
) O O
, O O
is O O
strongly O O
induced O O
by O O
interleukin-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IL-2 B B_GENE
) O O
in O O
peripheral O O
T O O
cells O O
. O O

Here O O
we O O
show O O
that O O
the O O
IL-2 B B_GENE
-induced O O
expression O O
of O O
Gadd45gamma B B_GENE
is O O
dependent O O
on O O
a O O
signaling O O
pathway O O
mediated O O
by O O
the O O
tyrosine B B_GENE
kinase I I_GENE
Jak3 I I_GENE
and O O
the O O
transcription B B_GENE
factors I I_GENE
Stat5a B I_GENE
and O O
Stat5b B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
signal B B_GENE/B_MEASURE
transducer I I_GENE/I_MEASURE
and I I_GENE/I_MEASURE
activator I I_GENE/I_MEASURE
of I I_GENE/I_MEASURE
transcription I I_GENE/I_MEASURE
) O O
. O O

Previous O O
studies O O
with O O
ectopically O O
overexpressed O O
Gadd45gamma B B_GENE
in O O
various O O
cell O O
lines O O
implicated O O
its O O
function O O
in O O
negative O O
growth O O
control O O
. O O

To O O
analyze O O
the O O
physiological O O
role O O
of O O
Gadd45gamma B B_GENE/B_BIO
we O O
used O O
homologous O O
recombination O O
to O O
generate O O
mice O O
lacking O O
Gadd45gamma B B_GENE
. O O

Gadd45gamma B B_GENE/B_DISEASE
-deficient O O
mice O O
develop O O
normally O O
, O O
are O O
indistinguishable O O
from O O
their O O
littermates O O
, O O
and O O
are O O
fertile O O
. O O

Furthermore O O
, O O
hematopoiesis O O
in O O
mice O O
lacking O O
Gadd45gamma B B_GENE
is O O
not O O
impaired O O
and O O
Gadd45gamma B B_GENE
-deficient O O
T O O
lymphocytes O O
show O O
normal O O
responses O O
to O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Gadd45gamma B B_GENE
is O O
also O O
dispensable O O
for O O
IL-2 B B_GENE
-induced O O
T-cell O O
proliferation O O
. O O

Decreased O O
expression O O
of O O
c-myc B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
thymuses O O
from O O
myasthenia O O
gravis O O
patients O O
. O O

The O O
thymus O O
is O O
a O O
critical O O
organ O O
for O O
the O O
elimination O O
of O O
autoreactive O O
T O O
cells O O
by O O
apoptosis O O
. O O

We O O
studied O O
the O O
expression O O
of O O
apoptosis-associated O O
genes O O
, O O
bcl-xL B B_GENE
, O O
bad B B_GENE/B_DISEASE
, O O
caspase-3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
c-myc B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
myasthenia O O
gravis O O
( O O
MG O O
) O O
thymuses O O
. O O

We O O
observed O O
that O O
the O O
mRNA O O
levels O O
of O O
myc B B_GENE
family I I_GENE
genes I I_GENE
, O O
c-myc B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
max B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
were O O
markedly O O
reduced O O
in O O
MG O O
thymuses O O
. O O

These O O
results O O
indicate O O
that O O
c-myc B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-mediated O O
signaling O O
is O O
abnormal O O
in O O
MG O O
thymuses O O
. O O

Immunohistochemical O O
detection O O
of O O
interferon-gamma-producing O O
cells O O
in O O
dermatophytosis O O
. O O

Considerable O O
numbers O O
of O O
CD1a-positive O O
cells O O
were O O
detected O O
in O O
the O O
upper O O
dermis O O
and O O
epidermis O O
. O O

A O O
marked O O
accumulation O O
of O O
CD68-positive O O
cells O O
was O O
found O O
in O O
the O O
upper O O
dermis O O
. O O

IFN-gamma-positive O O
cells O O
were O O
present O O
in O O
the O O
upper O O
dermis O O
of O O
the O O
lesions O O
. O O

The O O
staining O O
was O O
considered O O
to O O
be O O
highly O O
specific O O
because O O
it O O
could O O
be O O
completely O O
blocked O O
by O O
preabsorption O O
with O O
recombinant B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IFN-gamma I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
data O O
support O O
the O O
hypothesis O O
that O O
the O O
skin O O
lesions O O
of O O
dermatophytosis O O
may O O
be O O
associated O O
with O O
a O O
Th1 O O
response O O
. O O

Th1 O O
response O O
, O O
which O O
is O O
characterized O O
by O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
release O O
, O O
is O O
thought O O
to O O
be O O
involved O O
in O O
the O O
host O O
defense O O
against O O
dermatophytes O O
and O O
to O O
reflect O O
cutaneous O O
reaction O O
in O O
dermatophytosis O O
. O O

Regulation O O
of O O
the O O
helix-loop-helix B B_GENE/B_BIO
proteins I I_GENE/I_BIO
, O O
E2A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Id3 B B_GENE
, O O
by O O
the O O
Ras B B_GENE/B_DISEASE
- O O
ERK B B_GENE
MAPK B I_GENE
cascade O O
. O O

Activation O O
of O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE
) O O
pathways O O
leads O O
to O O
cellular O O
differentiation O O
and/or O O
proliferation O O
in O O
a O O
wide O O
variety O O
of O O
cell O O
types O O
, O O
including O O
developing O O
thymocytes O O
. O O

The O O
basic B B_PROTEIN[GENE]
helix-loop-helix I I_PROTEIN[GENE]
( I I_PROTEIN[GENE]
bHLH I I_PROTEIN[GENE]
) I I_PROTEIN[GENE]
proteins I I_PROTEIN[GENE]
E12 B I_PROTEIN[GENE]
and O O
E47 B B_PROTEIN[GENE]
and O O
an O O
inhibitor B B_PROTEIN[GENE]
HLH I I_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
, O O
Id3 B B_GENE
, O O
play O O
key O O
roles O O
in O O
thymocyte O O
differentiation O O
. O O

We O O
show O O
here O O
that O O
E2A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
DNA O O
binding O O
is O O
lowered O O
in O O
primary O O
immature O O
thymocytes O O
consequent O O
to O O
T O O
cell O O
receptor O O
( O O
TCR O O
) O O
-mediated O O
ligation O O
. O O

Whereas O O
expression O O
of O O
E2A O O
mRNA O O
and O O
protein O O
are O O
unaltered O O
, O O
Id3 B B_GENE/B_PERSON
transcripts I I_GENE/I_PERSON
are O O
rapidly O O
induced O O
upon O O
signaling O O
from O O
the O O
TCR B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Activation O O
of O O
Id3 O O
transcription O O
is O O
regulated O O
in O O
a O O
dose-dependent O O
manner O O
by O O
the O O
extracellular O O
signal-regulated O O
kinase O O
( O O
ERK B B_GENE
) O O
MAPK B B_GENE/B_LOCATION
module O O
. O O

These O O
observations O O
directly O O
connect O O
the O O
ERK B B_GENE
MAPK B I_GENE
cascade O O
and O O
HLH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
linear O O
pathway O O
. O O

Retinoic O O
acid O O
up-regulates O O
myeloid O O
ICAM-3 O O
expression O O
and O O
function O O
in O O
a O O
cell-specific O O
fashion O O
-- O O
evidence O O
for O O
retinoid O O
signaling O O
pathways O O
in O O
the O O
mast O O
cell O O
lineage O O
. O O

Investigation O O
of O O
mast O O
cell O O
responsiveness O O
toward O O
retinoic O O
acid O O
( O O
RA O O
) O O
revealed O O
selective O O
promotion O O
of O O
ICAM-3 B B_GENE
expression O O
in O O
the O O
human O O
mast O O
cell O O
line O O
HMC-1 O O
. O O

This O O
process O O
was O O
dose- O O
and O O
time-dependent O O
and O O
detectable O O
by O O
flow O O
cytometry O O
, O O
Western O O
blot O O
analysis O O
, O O
ELISA O O
, O O
and O O
Northern O O
blot O O
analysis O O
. O O

ICAM-3 B B_GENE/B_MEASURE
modulation O O
was O O
found O O
to O O
be O O
cell-type O O
dependent O O
, O O
detectable O O
also O O
for O O
HL-60 O O
cells O O
and O O
monocytes O O
but O O
not O O
U-937 O O
and O O
only O O
weakly O O
for O O
KU812 O O
cells O O
. O O

Terminally O O
differentiated O O
skin O O
mast O O
cells O O
also O O
failed O O
to O O
up-modulate O O
their O O
ICAM-3 B B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
suggesting O O
the O O
requirement O O
for O O
some O O
degree O O
of O O
immaturity O O
for O O
the O O
process O O
. O O

RA-mediated O O
effects O O
on O O
ICAM-1 B B_GENE
expression O O
, O O
studied O O
in O O
parallel O O
, O O
were O O
clearly O O
distinct O O
from O O
those O O
on O O
ICAM-3 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Investigation O O
of O O
retinoid B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
expression O O
, O O
known O O
to O O
mediate O O
intracellular O O
RA O O
signaling O O
, O O
revealed O O
presence O O
of O O
RAR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RAR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RXR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RXR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
all O O
cell O O
lines O O
studied O O
, O O
and O O
HMC-1 O O
cells O O
were O O
the O O
only O O
line O O
lacking O O
RXR B B_GENE/B_MEASURE
alpha I I_GENE/I_MEASURE
. O O

RAR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
not O O
expressed O O
at O O
baseline O O
, O O
was O O
induced O O
by O O
RA O O
in O O
a O O
fashion O O
obviously O O
correlating O O
with O O
ICAM-3 B B_GENE/B_LOCATION
up-regulation O O
. O O

Increased O O
ICAM-3 B B_GENE
expression O O
was O O
of O O
functional O O
significance O O
, O O
such O O
that O O
processes O O
stimulated O O
or O O
co-stimulated O O
via O O
ICAM-3 B B_GENE
( O O
homotypic O O
aggregation O O
, O O
IL-8 O O
secretion O O
) O O
were O O
clearly O O
enhanced O O
upon O O
RA O O
pretreatment O O
, O O
suggesting O O
that O O
RA O O
may O O
contribute O O
via O O
hitherto O O
unrecognized O O
pathways O O
to O O
immune O O
function O O
and O O
host O O
defense O O
. O O

CD28 B B_GENE
and O O
T O O
cell O O
co-stimulation O O
. O O

However O O
, O O
the O O
exact O O
definition O O
of O O
co-stimulation O O
is O O
still O O
unclear O O
. O O

In O O
this O O
review O O
, O O
we O O
re-examine O O
the O O
concept O O
of O O
co-stimulation O O
. O O

We O O
suggest O O
that O O
while O O
co-stimulation O O
is O O
important O O
, O O
there O O
is O O
little O O
evidence O O
to O O
link O O
co-stimulation O O
with O O
T O O
cell O O
anergy O O
. O O

We O O
then O O
suggest O O
a O O
framework O O
for O O
studying O O
co-stimulation O O
. O O

Focusing O O
on O O
recent O O
advances O O
in O O
our O O
understanding O O
of O O
CD28 B B_GENE/B_DISEASE
, O O
we O O
discuss O O
four O O
areas O O
of O O
T O O
cell O O
activation O O
where O O
co-stimulation O O
may O O
play O O
a O O
role O O
. O O

In O O
this O O
study O O
, O O
we O O
analyzed O O
the O O
regulation O O
of O O
AP-1 B B_GENE/B_LOCATION
- O O
and O O
NF-kappa B B_GENE
B I I_GENE
-mediated O O
transcription O O
during O O
in O O
vivo O O
induction O O
of O O
tolerance O O
to O O
a O O
self B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ag I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expressed O O
exclusively O O
on O O
hepatocytes O O
. O O

Naive O O
CD8 O O
( O O
+ O O
) O O
Desire O O
( O O
Des O O
) O O
( O O
+ O O
) O O
T O O
cells O O
isolated O O
from O O
the O O
Des O O
TCR-transgenic O O
mice O O
that O O
are O O
specific O O
for O O
the O O
H-2K B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
b I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ag I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
transferred O O
into O O
Alb-K O O
( O O
b O O
) O O
-transgenic O O
mice O O
that O O
express O O
the O O
H-2K B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
b I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
Ag I I_GENE/I_LOCATION
on O O
hepatocytes O O
only O O
. O O

Tolerance O O
develops O O
in O O
these O O
mice O O
. O O

In O O
contrast O O
to O O
CD8 O O
( O O
+ O O
) O O
Des O O
( O O
+ O O
) O O
T O O
cells O O
activated O O
in O O
vivo O O
with O O
APCs O O
, O O
which O O
express O O
high O O
AP-1 B B_GENE
and O O
high O O
NF-kappa B B_GENE
B I I_GENE
transcriptional O O
activity O O
, O O
the O O
unresponsive O O
CD8 O O
( O O
+ O O
) O O
Des O O
( O O
+ O O
) O O
T O O
cells O O
expressed O O
no O O
AP-1 B B_GENE
and O O
only O O
weak O O
NF-kappa B B_GENE
B I I_GENE
transcriptional O O
activity O O
. O O

The O O
differences O O
in O O
NF-kappa B B_GENE/B_DISEASE
B I I_GENE/I_DISEASE
transcriptional O O
activity O O
correlated O O
with O O
the O O
generation O O
of O O
distinct O O
NF-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
observations O O
suggest O O
that O O
fine O O
regulation O O
of O O
NF-kappa B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complex I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
formation O O
may O O
determine O O
T O O
cell O O
fate O O
. O O

The O O
transcription B B_GENE
factors I I_GENE
that O O
mediate O O
these O O
processes O O
are O O
often O O
expressed O O
broadly O O
in O O
many O O
cell O O
types O O
. O O

The O O
emerging O O
theme O O
is O O
one O O
of O O
cell-type-specific O O
regulation O O
, O O
affecting O O
not O O
only O O
the O O
functional O O
activation O O
of O O
transcription B B_GENE
factors I I_GENE
but O O
also O O
their O O
access O O
to O O
appropriate O O
regions O O
of O O
DNA O O
. O O

Existence O O
of O O
retinoic B B_GENE
acid-receptor I I_GENE
-independent O O
retinoid B B_GENE
X-receptor I I_GENE
-dependent O O
pathway O O
in O O
myeloid O O
cell O O
function O O
. O O

We O O
previously O O
reported O O
that O O
ER-27191 O O
( O O
4- O O
[ O O
4 O O
, O O
5 O O
, O O
7 O O
, O O
8 O O
, O O
9 O O
, O O
10-hexahydro-7 O O
, O O
7 O O
, O O
10 O O
, O O
10-tetramethyl-1- O O
( O O
3-pyridylmethyl O O
) O O
anthra O O
[ O O
1 O O
, O O
2-b O O
] O O
pyrrol-3-yl O O
] O O
benzoic O O
acid O O
) O O
is O O
a O O
potent O O
antagonist O O
of O O
retinoic B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RAR B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
ER-35795 O O
( O O
( O O
2E O O
, O O
4E O O
, O O
6E O O
) O O
-7- O O
[ O O
1- O O
( O O
1-methylethyl O O
) O O
-8-chloro-1 O O
, O O
2 O O
, O O
3 O O
, O O
4-tetrahydroquinolin-6-yl O O
] O O
-6-fluoro-3-methyl-2 O O
, O O
4 O O
, O O
6-nonatrienoic O O
acid O O
) O O
is O O
a O O
novel O O
retinoid B B_GENE/B_MEASURE
X I B_GENE/I_MEASURE
receptor I B_GENE/I_MEASURE
( O O
RXR B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
-specific O O
agonist O O
. O O

By O O
using O O
these O O
compounds O O
, O O
we O O
investigated O O
whether O O
distinct O O
RAR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O O
and O O
RXR B B_PROTEIN[GENE]/B_LOCATION
-dependent O O
pathways O O
operate O O
to O O
mediate O O
the O O
diverse O O
activities O O
of O O
retinoids O O
, O O
particularly O O
, O O
the O O
effects O O
of O O
the O O
RXR B B_GENE/B_LOCATION
pathway O O
on O O
cellular O O
function O O
. O O

ER-27191 O O
completely O O
antagonized O O
HL60 O O
cell O O
differentiation O O
induced O O
by O O
all-trans-retinoic O O
acid O O
( O O
atRA O O
) O O
. O O

However O O
, O O
the O O
differentiation O O
induced O O
by O O
the O O
ER-35795 O O
was O O
not O O
antagonized O O
at O O
all O O
by O O
the O O
RAR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O O
, O O
but O O
was O O
inhibited O O
by O O
an O O
RXR B B_GENE/B_LOCATION
homodimer I I_GENE/I_LOCATION
antagonist O O
( O O
LGD100754 O O
, O O
( O O
2E O O
, O O
4E O O
, O O
6Z O O
) O O
-7- O O
( O O
3-n-propoxy-5 O O
, O O
6 O O
, O O
7 O O
, O O
8-tetrahydro-5 O O
, O O
5 O O
, O O
8 O O
, O O
8-tetramethylnaphthalen-2-yl O O
) O O
-3-methylocta-2 O O
, O O
4 O O
, O O
6-trienoic O O
acid O O
) O O
. O O

Interestingly O O
, O O
a O O
functional O O
RXR B B_GENE/B_LOCATION
-pathway O O
was O O
also O O
seen O O
in O O
lipopolysaccharide-induced O O
inhibition O O
of O O
mouse O O
splenocyte O O
proliferation O O
. O O

These O O
results O O
strongly O O
suggest O O
the O O
existence O O
of O O
a O O
pharmacological O O
RXR B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-dependent O O
pathway O O
that O O
is O O
activated O O
by O O
a O O
ligand O O
that O O
can O O
bind O O
to O O
RXR B B_GENE/B_LOCATION
. O O

Targeting O O
Src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homology I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain-containing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SHP-1 B B_GENE/B_DISEASE
) O O
into O O
lipid O O
rafts O O
inhibits O O
CD3 B B_GENE
-induced O O
T O O
cell O O
activation O O
. O O

To O O
study O O
the O O
mechanism O O
by O O
which O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PTPs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
regulate O O
CD3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
tyrosine O O
phosphorylation O O
, O O
we O O
investigated O O
the O O
distribution O O
of O O
PTPs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
subdomains O O
of O O
plasma O O
membrane O O
. O O

We O O
report O O
here O O
that O O
the O O
bulk O O
PTP B B_ENZYME[GENE]
activity O O
associated O O
with O O
T O O
cell O O
membrane O O
is O O
present O O
outside O O
the O O
lipid O O
rafts O O
, O O
as O O
determined O O
by O O
sucrose O O
density O O
gradient O O
sedimentation O O
. O O

In O O
Jurkat O O
T O O
cells O O
, O O
approximately O O
5 O O
-- O O
10 O O
% O O
of O O
Src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homology I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain-containing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SHP-1 B B_GENE/B_DISEASE
) O O
is O O
constitutively O O
associated O O
with O O
plasma O O
membrane O O
, O O
and O O
nearly O O
50 O O
% O O
of O O
SHP-2 B B_GENE/B_BIO
is O O
translocated O O
to O O
plasma O O
membrane O O
after O O
vanadate O O
treatment O O
. O O

We O O
further O O
demonstrated O O
that O O
CD3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
tyrosine O O
phosphorylation O O
of O O
these O O
substrates O O
is O O
largely O O
restricted O O
to O O
lipid O O
rafts O O
, O O
unless O O
PTPs B B_GENE/B_PERSON
are O O
inhibited O O
. O O

To O O
test O O
this O O
hypothesis O O
, O O
we O O
targeted O O
SHP-1 B B_GENE
into O O
lipid O O
rafts O O
by O O
using O O
the O O
N-terminal B B_GENE
region I I_GENE
of I I_GENE
Lck I I_GENE
( O O
residues B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
14 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
results O O
indicate O O
that O O
the O O
expression O O
of O O
Lck/SHP-1 B B_GENE
chimera I I_GENE
inside O O
lipid O O
rafts O O
profoundly O O
inhibits O O
CD3 B B_GENE
-induced O O
tyrosine O O
phosphorylation O O
of O O
CD3 B B_GENE
zeta/epsilon I I_GENE
, O O
IL-2 O O
generation O O
, O O
and O O
nuclear O O
mobilization O O
of O O
NF-AT B B_GENE
. O O

Collectively O O
, O O
these O O
results O O
suggest O O
that O O
the O O
exclusion O O
of O O
PTPs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O O
lipid O O
rafts O O
may O O
be O O
a O O
mechanism O O
that O O
potentiates O O
TCR B B_GENE
/ O O
CD3 B B_GENE/B_LOCATION
activation O O

An O O
instructive O O
component O O
in O O
T O O
helper O O
cell O O
type O O
2 O O
( O O
Th2 O O
) O O
development O O
mediated O O
by O O
GATA-3 B B_GENE
. O O

We O O
observe O O
IL-4 B B_GENE/B_MEASURE
-dependent O O
redirection O O
of O O
phenotype O O
in O O
cells O O
that O O
have O O
already O O
committed O O
to O O
a O O
non-IL-4-producing O O
fate O O
, O O
inconsistent O O
with O O
predictions O O
of O O
the O O
selective O O
model O O
. O O

Further O O
, O O
retroviral O O
tagging O O
of O O
naive O O
progenitors O O
with O O
the O O
Th2-specific B B_GENE
transcription I I_GENE
factor I I_GENE
GATA-3 I I_GENE
provided O O
direct O O
evidence O O
for O O
instructive O O
differentiation O O
, O O
and O O
no O O
evidence O O
for O O
the O O
selective O O
outgrowth O O
of O O
cells O O
committed O O
to O O
either O O
the O O
Th1 O O
or O O
Th2 O O
fate O O
. O O

In O O
vitro-activated O O
human O O
lupus O O
T O O
cells O O
express O O
normal O O
estrogen B B_GENE
receptor I I_GENE
proteins I I_GENE
which O O
bind O O
to O O
the O O
estrogen B B_GENE/B_LOCATION
response I I_GENE/I_LOCATION
element I I_GENE/I_LOCATION
. O O

We O O
have O O
shown O O
that O O
estrogen B B_GENE/B_NUMBER[MEASURE]
receptor I I_GENE/I_NUMBER[MEASURE]
( O O
ERalpha B B_GENE/B_LOCATION
, O O
ERbeta B B_GENE/B_LOCATION
) O O
transcripts O O
are O O
expressed O O
in O O
SLE O O
and O O
normal O O
T O O
cells O O
. O O

T O O
cells O O
cultured O O
only O O
with O O
E2 O O
did O O
not O O
have O O
these O O
complexes O O
. O O

The O O
formation O O
of O O
the O O
complexes O O
was O O
inhibited O O
by O O
competition O O
with O O
the O O
hERE O O
cold O O
oligonucleotide O O
and O O
partially O O
with O O
anti-ERalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Together O O
, O O
these O O
results O O
suggest O O
that O O
activated O O
human O O
T O O
cells O O
, O O
whether O O
lupus-derived O O
or O O
normal-derived O O
, O O
contain O O
biologically O O
active O O
ERalpha B B_GENE
proteins I I_GENE
. O O

Other O O
factors O O
may O O
be O O
responsible O O
for O O
differential O O
sensitivity O O
of O O
lupus O O
T O O
cells O O
to O O
estrogen O O
. O O

If O O
the O O
inflammatory O O
response O O
becomes O O
excessive O O
or O O
uncontrolled O O
by O O
some O O
stimuli O O
, O O
inappropriate O O
inflammatory O O
responses O O
occur O O
. O O

In O O
this O O
study O O
we O O
investigated O O
the O O
mechanism O O
of O O
the O O
inhibitory O O
effect O O
of O O
protease O O
inhibitors O O
on O O
the O O
proinflammatory O O
cytokine O O
production O O
of O O
lipopolysaccharide- O O
( O O
LPS O O
) O O
stimulated O O
monocytes O O
. O O

LPS-stimulated O O
monocytes O O
were O O
treated O O
with O O
GM O O
or O O
UTI O O
. O O

The O O
value O O
of O O
TNFalpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL-10 B B_GENE
in O O
the O O
culture O O
medium O O
of O O
monocytes O O
was O O
measured O O
and O O
each O O
mRNA O O
expression O O
was O O
assayed O O
. O O

The O O
inhibitory O O
effect O O
of O O
protease O O
inhibitors O O
on O O
the O O
activity O O
of O O
intracellular O O
signal O O
transduction O O
pathways O O
such O O
as O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PKC B B_GENE
) O O
and O O
nuclear B B_GENE
factor I I_GENE
kappa I I_GENE
B I I_GENE
( O O
NFkappaB B B_GENE
) O O
were O O
also O O
evaluated O O
. O O

GM O O
decreased O O
the O O
TNFalpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
of O O
LPS-stimulated O O
monocytes O O
as O O
shown O O
by O O
the O O
inhibition O O
of O O
mRNA O O
expression O O
and O O
increased O O
the O O
IL-10 B B_GENE
production O O
of O O
LPS-stimulated O O
monocytes O O
. O O

GM O O
also O O
suppressed O O
the O O
NFkappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activity O O
of O O
LPS-stimulated O O
monocytes O O
. O O

UTI O O
decreased O O
the O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O O
of O O
LPS-stimulated O O
monocytes O O
, O O
but O O
did O O
not O O
inhibit O O
the O O
TNFalpha B B_GENE
mRNA I I_GENE
expression O O
. O O

The O O
present O O
study O O
shows O O
that O O
the O O
inhibitory O O
effect O O
of O O
GM O O
on O O
the O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O O
of O O
activated O O
human O O
monocytes O O
is O O
mediated O O
by O O
the O O
suppression O O
of O O
NFkappaB B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
, O O
while O O
the O O
mechanism O O
of O O
UTI O O
inhibiting O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O O
of O O
human O O
monocytes O O
may O O
be O O
due O O
to O O
the O O
inhibition O O
of O O
either O O
the O O
translation O O
or O O
secretion O O
of O O
TNFalpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Homocysteine O O
stimulates O O
the O O
expression O O
of O O
monocyte B B_GENE
chemoattractant I I_GENE
protein-1 I I_GENE
in O O
endothelial O O
cells O O
leading O O
to O O
enhanced O O
monocyte O O
chemotaxis O O
. O O

Hyperhomocysteinemia O O
has O O
been O O
identified O O
as O O
an O O
independent O O
risk O O
factor O O
for O O
atherosclerosis O O
. O O

The O O
infiltration O O
of O O
monocytes O O
into O O
the O O
arterial O O
wall O O
is O O
one O O
of O O
the O O
key O O
events O O
during O O
atherogenesis O O
. O O

Monocyte B B_GENE
chemoattractant I I_GENE
protein-1 I I_GENE
( O O
MCP-1 B B_GENE/B_DISEASE
) O O
is O O
a O O
potent O O
chemokine B B_GENE
that O O
stimulates O O
the O O
migration O O
of O O
monocytes O O
into O O
the O O
intima O O
of O O
the O O
arterial O O
wall O O
. O O

The O O
mechanism O O
by O O
which O O
increased O O
monocyte O O
infiltration O O
occurs O O
in O O
atherosclerotic O O
lesions O O
in O O
patients O O
with O O
hyperhomocysteinemia O O
has O O
not O O
been O O
delineated O O
. O O

The O O
objective O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
the O O
effect O O
of O O
homocysteine O O
on O O
MCP-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
in O O
endothelial O O
cells O O
. O O

Cells O O
were O O
incubated O O
with O O
homocysteine O O
. O O

The O O
secretion O O
of O O
MCP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
significantly O O
increased O O
( O O
195 O O
% O O
as O O
compared O O
to O O
the O O
control O O
) O O
in O O
cells O O
treated O O
with O O
pathological O O
concentrations O O
of O O
homocysteine O O
. O O

Such O O
effect O O
was O O
accompanied O O
by O O
an O O
increased O O
expression O O
of O O
MCP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
176 O O
% O O
as O O
compared O O
to O O
the O O
control O O
) O O
in O O
endothelial O O
cells O O
which O O
resulted O O
in O O
enhanced O O
monocyte O O
chemotaxis O O
. O O

The O O
p38 B B_GENE
MAP I I_GENE
kinase I I_GENE
as O O
well O O
as O O
other O O
members O O
of O O
the O O
p38 O O
MAP O O
kinase O O
pathway O O
, O O
including O O
MKK3 B B_GENE
, O O
MKK6 B B_GENE
, O O
ATF-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Elk-1 B B_GENE
, O O
were O O
activated O O
in O O
homocysteine-treated O O
cells O O
. O O

Homocysteine-induced O O
MCP-1 B B_GENE
expression O O
and O O
subsequent O O
monocyte O O
chemotaxis O O
were O O
blocked O O
by O O
a O O
p38 B B_GENE
MAP I I_GENE
kinase I I_GENE
inhibitor O O
( O O
SB203580 O O
) O O
suggesting O O
that O O
the O O
p38 B B_GENE
MAP I I_GENE
kinase I I_GENE
pathway O O
might O O
be O O
involved O O
in O O
homocysteine-induced O O
MCP-1 B B_GENE
expression O O
in O O
endothelial O O
cells O O
. O O

In O O
contrast O O
, O O
staurosporine O O
, O O
a O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
, O O
had O O
no O O
effect O O
on O O
homocysteine-induced O O
MCP-1 B B_GENE
expression O O
. O O

In O O
conclusion O O
, O O
our O O
results O O
indicate O O
that O O
homocysteine O O
stimulates O O
MCP-1 B B_GENE
expression O O
in O O
endothelial O O
cells O O
leading O O
to O O
enhanced O O
monocyte O O
chemotaxis O O
. O O

Inducible O O
resistance O O
to O O
Fas-mediated O O
apoptosis O O
in O O
B O O
cells O O
. O O

Apoptosis O O
produced O O
in O O
B O O
cells O O
through O O
Fas B B_GENE/B_DISEASE
( O O
APO-1 B B_GENE/B_LOCATION
, O O
CD95 B B_PROTEIN[GENE]/B_LOCATION
) O O
triggering O O
is O O
regulated O O
by O O
signals O O
derived O O
from O O
other O O
surface O O
receptors O O
: O O
CD40 O O
engagement O O
produces O O
upregulation O O
of O O
Fas B B_GENE
expression O O
and O O
marked O O
susceptibility O O
to O O
Fas B B_GENE/B_DISEASE
-induced O O
cell O O
death O O
, O O
whereas O O
antigen O O
receptor O O
engagement O O
, O O
or O O
IL-4R O O
engagement O O
, O O
inhibits O O
Fas B B_GENE/B_PERSON
killing O O
and O O
in O O
so O O
doing O O
induces O O
a O O
state O O
of O O
Fas B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-resistance O O
, O O
even O O
in O O
otherwise O O
sensitive O O
, O O
CD40 B B_GENE
-stimulated O O
targets O O
. O O

Surface B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunoglobulin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IL-4R B B_GENE
utilize O O
at O O
least O O
partially O O
distinct O O
pathways O O
to O O
produce O O
Fas B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-resistance O O
that O O
differentially O O
depend O O
on O O
PKC B B_GENE
and O O
STAT6 B B_GENE
, O O
respectively O O
. O O

Further O O
, O O
surface O O
immunoglobulin O O
signaling O O
for O O
inducible O O
Fas B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-resistance O O
bypasses O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
requires O O
NF-kappaB B B_GENE
, O O
and O O
entails O O
new O O
macromolecular O O
synthesis O O
. O O

Terminal O O
effectors O O
of O O
B O O
cell O O
Fas B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-resistance O O
include O O
the O O
known O O
anti-apoptotic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
products I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
Bcl-xL B B_GENE/B_LOCATION
and O O
FLIP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
a O O
novel O O
anti-apoptotic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
encodes O O
FAIM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fas B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Apoptosis I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Inhibitory I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Molecule I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

faim B B_PERSON/B_GENE
was O O
identified O O
by O O
differential O O
display O O
and O O
exists O O
in O O
two O O
alternatively O O
spliced O O
forms O O
; O O
faim-S B B_PERSON/B_PROTEIN[GENE]
is O O
broadly O O
expressed O O
, O O
but O O
faim-L O O
expression O O
is O O
tissue-specific O O
. O O

The O O
FAIM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
highly O O
evolu- O O
tionarily O O
conserved O O
, O O
suggesting O O
an O O
important O O
role O O
for O O
this O O
molecule O O
throughout O O
phylogeny O O
. O O

Inducible O O
resistance O O
to O O
Fas B B_GENE/B_PERSON
killing O O
is O O
hypothesized O O
to O O
protect O O
foreign O O
antigen-specific O O
B O O
cells O O
during O O
potentially O O
hazardous O O
interactions O O
with O O
FasL-bearing O O
T O O
cells O O
, O O
whereas O O
autoreactive O O
B O O
cells O O
fail O O
to O O
become O O
Fas B B_GENE/B_DISEASE
-resistant O O
and O O
are O O
deleted O O
via O O
Fas B B_GENE
-dependent O O
cytotoxicity O O
. O O

Inadvertent O O
or O O
aberrant O O
acquisition O O
of O O
Fas B B_GENE/B_DISEASE
-resistance O O
may O O
permit O O
autoreactive O O
B O O
cells O O
to O O
escape O O
Fas B B_GENE/B_LOCATION
deletion O O
, O O
and O O
malignant O O
lymphocytes O O
to O O
impede O O
anti-tumor O O
immunity O O
. O O

Stromal B B_GENE
cell-derived I I_GENE
factor I I_GENE
1 I I_GENE
alpha I I_GENE
-induced O O
chemotaxis O O
in O O
T O O
cells O O
is O O
mediated O O
by O O
nitric O O
oxide O O
signaling O O
pathways O O
. O O

Stromal B B_GENE
cell-derived I I_GENE
factor I I_GENE
1 I I_GENE
alpha I I_GENE
( O O
SDF1 B B_GENE
alpha I I_GENE
) O O
and O O
its O O
cognate O O
chemokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CXCR4 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
act O O
as O O
potent O O
chemoattractants O O
and O O
regulate O O
trafficking O O
and O O
homing O O
of O O
hematopoietic O O
progenitor O O
cells O O
and O O
lymphocytes O O
. O O

However O O
, O O
the O O
molecular O O
mechanisms O O
regulating O O
SDF1 B B_GENE
alpha I I_GENE
-driven O O
cell O O
migration O O
are O O
not O O
well O O
defined O O
. O O

In O O
this O O
study O O
, O O
we O O
have O O
explored O O
the O O
roles O O
of O O
the O O
second O O
messenger O O
NO O O
and O O
the O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
SDF1 B B_GENE
alpha I I_GENE
-induced O O
T O O
cell O O
migration O O
. O O

We O O
observed O O
that O O
pretreatment O O
of O O
Jurkat O O
cells O O
or O O
activated O O
PBLs O O
with O O
several O O
NO O O
donors O O
significantly O O
enhanced O O
the O O
SDF1 B B_GENE
alpha I I_GENE
-induced O O
migration O O
, O O
whereas O O
various O O
inhibitors O O
of O O
NO B B_GENE
synthase I I_GENE
markedly O O
abrogated O O
the O O
chemotactic O O
response O O
in O O
a O O
concentration-dependent O O
manner O O
. O O

Furthermore O O
, O O
we O O
observed O O
that O O
inhibitors O O
of O O
the O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
is O O
linked O O
to O O
NO O O
signaling O O
pathways O O
, O O
also O O
significantly O O
blocked O O
the O O
SDF1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
chemotactic O O
response O O
. O O

However O O
, O O
these O O
compounds O O
did O O
not O O
have O O
a O O
significant O O
effect O O
on O O
SDF1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-induced O O
mitogen-activated O O
protein O O
kinase O O
activity O O
. O O

In O O
addition O O
, O O
the O O
MAP/Erk O O
kinase O O
kinase O O
inhibitor O O
PD98059 O O
did O O
not O O
abrogate O O
SDF1 B B_GENE
alpha I I_GENE
-induced O O
chemotaxis O O
. O O

AKT B B_GENE
, O O
which O O
has O O
been O O
shown O O
to O O
mediate O O
NO O O
production O O
, O O
was O O
also O O
phosphorylated O O
upon O O
SDF1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O O
. O O

Using O O
triple O O
transgenic O O
mice O O
expressing O O
a O O
TCR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transgene I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
dominant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
negative I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ras/Mek I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
reporter B B_GENE
gene I I_GENE
construct I I_GENE
with O O
AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
showed O O
a O O
complete O O
lack O O
of O O
transcriptional O O
activity O O
of O O
NF-kappa B B_GENE
B I I_GENE
but O O
not O O
AP-1 B B_GENE
in O O
DP O O
thymocytes O O
, O O
whereas O O
both O O
were O O
transcriptionally O O
active O O
in O O
mature O O
T O O
cells O O
after O O
antigenic O O
stimulation O O
. O O

AP-1 B B_GENE/B_DISEASE
induction O O
was O O
dependent O O
on O O
the O O
integrity O O
of O O
the O O
ras/Mek O O
pathway O O
indicating O O
that O O
this O O
pathway O O
was O O
activated O O
in O O
the O O
DP O O
thymocytes O O
. O O

In O O
contrast O O
, O O
we O O
found O O
a O O
complete O O
lack O O
of O O
constitutive O O
expression O O
of O O
the O O
epsilon B B_PROTEIN[GENE]
isoform I I_PROTEIN[GENE]
of I I_PROTEIN[GENE]
Protein I I_PROTEIN[GENE]
Kinase I I_PROTEIN[GENE]
C I I_PROTEIN[GENE]
( O O
PKC B B_GENE
) O O
in O O
DP O O
thymocytes O O
, O O
although O O
it O O
was O O
present O O
in O O
mature O O
thymocytes O O
and O O
peripheral O O
T O O
cells O O
. O O

Taken O O
together O O
the O O
results O O
suggest O O
that O O
the O O
lack O O
of O O
PKC B B_GENE
epsilon I I_GENE
in O O
DP O O
thymocytes O O
could O O
lead O O
to O O
the O O
absence O O
of O O
NF-kappa B B_GENE
B I I_GENE
activity O O
after O O
antigenic O O
stimulation O O
contributing O O
to O O
negative O O
selection O O
. O O

Cell O O
Death O O
and O O
Differentiation O O
( O O
2000 O O
) O O
7 O O
, O O
1253 O O
- O O
1262 O O
. O O

CD2 O O
stimulation O O
leads O O
to O O
the O O
delayed O O
and O O
prolonged O O
activation O O
of O O
STAT1 B B_GENE
in O O
T O O
cells O O
but O O
not O O
NK O O
cells O O
. O O

OBJECTIVE O O
: O O
T O O
lymphocytes O O
can O O
be O O
activated O O
by O O
soluble O O
factors O O
such O O
as O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
through O O
direct O O
cell-cell O O
interactions O O
. O O

Although O O
cytokine B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
are O O
known O O
to O O
signal O O
through O O
STAT B B_GENE
family I I_GENE
transcription I I_GENE
factors I I_GENE
, O O
the O O
mechanisms O O
by O O
which O O
other O O
cell-surface B B_GENE/B_BIO
molecules I I_GENE/I_BIO
, O O
such O O
as O O
CD2 B B_GENE
, O O
transduce O O
signals O O
is O O
unclear O O
. O O

The O O
goal O O
of O O
this O O
study O O
was O O
to O O
determine O O
whether O O
stimulation O O
of O O
T O O
cells O O
through O O
CD2 B B_GENE
recapitulates O O
aspects O O
of O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
T-cell O O
activation O O
by O O
use O O
of O O
STAT B B_GENE
transcription I I_GENE
factors I I_GENE
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
T O O
cells O O
were O O
treated O O
with O O
anti-CD2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
cells O O
bearing O O
the O O
natural O O
CD2 B B_GENE
ligand I I_GENE
CD58 I I_GENE
, O O
after O O
which O O
signaling O O
through O O
STAT B B_GENE
transcription I I_GENE
factors I I_GENE
was O O
assessed O O
. O O

RESULTS O O
: O O
Stimulation O O
of O O
CD2 B B_GENE
on O O
primary O O
T O O
lymphocytes O O
leads O O
to O O
the O O
tyrosine O O
phosphorylation O O
, O O
nuclear O O
translocation O O
, O O
and O O
DNA O O
binding O O
of O O
STAT1 B B_GENE
. O O

In O O
contrast O O
to O O
stimulation O O
by O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
activation O O
of O O
STAT1 B B_GENE
in O O
response O O
to O O
CD2 O O
ligation O O
is O O
delayed O O
and O O
does O O
not O O
involve O O
Jak B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
while O O
STAT O O
phosphorylation O O
induced O O
by O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
generally O O
transient O O
, O O
STAT1 O O
phosphorylation O O
following O O
CD2 O O
stimulation O O
persists O O
for O O
a O O
period O O
of O O
days O O
. O O

Transcription O O
of O O
key O O
target O O
genes O O
such O O
as O O
IRF1 B B_GENE
and O O
c-fos B B_GENE
proceeds O O
with O O
delayed O O
kinetics O O
following O O
CD2 O O
stimulation O O
, O O
suggesting O O
that O O
this O O
unique O O
pattern O O
of O O
STAT O O
activation O O
may O O
lead O O
to O O
a O O
distinct O O
cellular O O
response O O
following O O
CD2 O O
ligation O O
. O O

This O O
pathway O O
appears O O
to O O
be O O
restricted O O
to O O
T O O
cells O O
, O O
as O O
stimulation O O
of O O
CD2 B B_GENE
on O O
NK O O
cells O O
does O O
not O O
lead O O
to O O
STAT1 O O
activation O O
. O O

CONCLUSION O O
: O O
Stimulation O O
of O O
T O O
cells O O
through O O
cell-surface B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
such O O
as O O
CD2 B B_GENE
involves O O
activation O O
of O O
STAT B B_GENE
transcription I I_GENE
factors I I_GENE
, O O
thus O O
recapitulating O O
elements O O
of O O
cytokine O O
signaling O O
. O O

NFATc1 B B_GENE
and O O
NFATc2 B B_GENE
together O O
control O O
both O O
T O O
and O O
B O O
cell O O
activation O O
and O O
differentiation O O
. O O

NFAT B B_GENE/B_PERSON
transcription I I_GENE/I_PERSON
factors I I_GENE/I_PERSON
play O O
critical O O
roles O O
in O O
gene O O
transcription O O
during O O
immune O O
responses O O
. O O

To O O
investigate O O
further O O
the O O
two O O
most O O
prominent O O
NFAT B B_GENE/B_PERSON
family I I_GENE/I_PERSON
members I I_GENE/I_PERSON
, O O
NFATc1 B B_GENE
and O O
NFATc2 B B_GENE
, O O
we O O
generated O O
mice O O
bearing O O
lymphoid O O
systems O O
devoid O O
of O O
both O O
. O O

Doubly O O
deficient O O
T O O
cells O O
displayed O O
cell O O
surface O O
markers O O
of O O
activation O O
yet O O
were O O
significantly O O
deficient O O
in O O
the O O
development O O
of O O
multiple O O
effector O O
functions O O
, O O
including O O
Th B B_GENE
cytokine I I_GENE
production O O
, O O
surface B B_GENE
effector I I_GENE
molecule I I_GENE
expression O O
, O O
and O O
cytolytic O O
activity O O
. O O

Nevertheless O O
, O O
doubly O O
deficient O O
B O O
cells O O
were O O
hyperactivated O O
, O O
as O O
evidenced O O
by O O
extremely O O
elevated O O
serum O O
IgG1 B B_GENE
and O O
IgE B B_GENE/B_DISEASE
, O O
as O O
well O O
as O O
plasma O O
cell O O
expansion O O
and O O
infiltration O O
of O O
end O O
organs O O
. O O

Thus O O
, O O
in O O
T O O
cells O O
, O O
NFATc1 B B_GENE
and O O
NFATc2 B B_GENE
are O O
dispensable O O
for O O
inflammatory O O
reactivity O O
but O O
are O O
required O O
for O O
effector O O
differentiation O O
, O O
while O O
in O O
B O O
cells O O
, O O
NFATs B B_GENE/B_PERSON
regulate O O
both O O
normal O O
homeostasis O O
and O O
differentiation O O
. O O

Epstein-barr O O
virus O O
immediate-early B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BZLF1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
SUMO-1 O O
modified O O
and O O
disrupts O O
promyelocytic O O
leukemia O O
bodies O O
. O O

Although O O
the O O
immediate-early B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
both O O
herpes O O
simplex O O
virus O O
( O O
HSV O O
) O O
and O O
cytomegalovirus O O
( O O
CMV O O
) O O
are O O
known O O
to O O
modify O O
promyelocytic O O
leukemia O O
( O O
PML O O
) O O
( O O
ND10 O O
) O O
bodies O O
in O O
the O O
nucleus O O
of O O
the O O
host O O
cell O O
, O O
it O O
has O O
been O O
unclear O O
whether O O
lytic O O
infection O O
with O O
gamma O O
herpesviruses O O
induces O O
a O O
similar O O
effect O O
. O O

Therefore O O
, O O
it O O
is O O
likely O O
that O O
PML O O
bodies O O
function O O
in O O
an O O
antiviral O O
capacity O O
. O O

SUMO-1 O O
modification O O
of O O
PML B B_GENE/B_DISEASE
is O O
known O O
to O O
be O O
required O O
for O O
the O O
formation O O
of O O
PML O O
bodies O O
. O O

We O O
also O O
found O O
that O O
Z B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O O
is O O
SUMO-1 O O
modified O O
( O O
through O O
amino O O
acid O O
12 O O
) O O
and O O
that O O
Z B B_OTHER/B_PROTEIN[GENE]
competes O O
with O O
PML B B_GENE/B_DISEASE
for O O
limiting O O
amounts O O
of O O
SUMO-1 B B_GENE
. O O

Furthermore O O
, O O
Z B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
potentially O O
alter O O
the O O
function O O
of O O
a O O
variety O O
of O O
cellular O O
proteins O O
by O O
inhibiting O O
SUMO-1 O O
modification O O

Suppression O O
of O O
nuclear B B_GENE/B_DISEASE
factor-kappaB I I_GENE/I_DISEASE
and O O
stimulation O O
of O O
inhibitor B B_GENE
kappaB I I_GENE
by O O
troglitazone O O
: O O
evidence O O
for O O
an O O
anti-inflammatory O O
effect O O
and O O
a O O
potential O O
antiatherosclerotic O O
effect O O
in O O
the O O
obese O O
. O O

To O O
elucidate O O
whether O O
troglitazone O O
exerts O O
an O O
antiinflammatory O O
effect O O
in O O
humans O O
, O O
in O O
vivo O O
, O O
we O O
investigated O O
the O O
suppression O O
of O O
nuclear B B_GENE
factor I I_GENE
kappaB I I_GENE
( O O
NFkappaB B B_GENE
) O O
in O O
mononuclear O O
cells O O
( O O
MNC O O
) O O
by O O
this O O
drug O O
. O O

We O O
measured O O
intranuclear B B_GENE/B_DISEASE
NFkappaB I I_GENE/I_DISEASE
, O O
total O O
cellular B B_GENE
NFkappaB I I_GENE
, O O
inhibitor B B_GENE
kappaB I I_GENE
( I I_GENE
IkappaB I I_GENE
) I I_GENE
alpha I I_GENE
, O O
reactive O O
oxygen O O
species O O
( O O
ROS O O
) O O
generation O O
, O O
and O O
p47 B B_GENE
( I I_GENE
phox I I_GENE
) I I_GENE
subunit I I_GENE
( O O
a O O
key O O
component O O
protein O O
of O O
nicotinamide B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adenine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dinucleotide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
MNC O O
. O O

Seven O O
nondiabetic O O
obese O O
patients O O
were O O
given O O
400 O O
mg O O
troglitazone O O
daily O O
for O O
4 O O
weeks O O
. O O

Blood O O
samples O O
were O O
collected O O
before O O
and O O
at O O
weekly O O
intervals O O
thereafter O O
. O O

MNC O O
were O O
separated O O
; O O
and O O
the O O
levels O O
of O O
intranuclear B B_GENE
NFkappaB I I_GENE
, O O
total O O
cellular B B_GENE
NFkappaB I I_GENE
, O O
IkappaBalpha B B_GENE
, O O
and O O
p47 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
phox I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
subunit I I_GENE/I_LOCATION
and O O
ROS O O
generation O O
were O O
determined O O
. O O

Plasma O O
was O O
used O O
to O O
measure O O
insulin O O
glucose O O
, O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
sICAM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
MCP-1 B B_GENE
, O O
PAI-1 B B_GENE
, O O
CRP B B_GENE
, O O
and O O
IL-10 B B_GENE
. O O

Plasma O O
glucose O O
concentrations O O
did O O
not O O
alter O O
significantly O O
. O O

There O O
was O O
a O O
fall O O
in O O
intranuclear B B_GENE
NFkappaB I I_GENE
, O O
total O O
cellular B B_GENE
NFkappaB I I_GENE
, O O
and O O
p47 B B_GENE
( I I_GENE
phox I I_GENE
) I I_GENE
subunit I I_GENE
, O O
with O O
an O O
increase O O
in O O
cellular O O
IkappaBalpha B B_GENE
at O O
week O O
2 O O
, O O
which O O
persisted O O
until O O
week O O
4 O O
. O O

There O O
was O O
a O O
parallel O O
fall O O
in O O
ROS O O
generation O O
by O O
MNC O O
at O O
week O O
1 O O
; O O
this O O
progressed O O
and O O
persisted O O
until O O
week O O
4 O O
( O O
P O O
< O O
0.001 O O
) O O
. O O

Plasma O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
sICAM-1 B B_GENE
, O O
MCP-1 B B_GENE
, O O
and O O
PAI-1 B B_GENE
concentrations O O
fell O O
significantly O O
at O O
week O O
4 O O
. O O

Plasma O O
IL-10 B B_GENE
concentration O O
increased O O
significantly O O
, O O
whereas O O
plasma B B_GENE
CRP I I_GENE
concentrations O O
decreased O O
. O O

We O O
conclude O O
that O O
troglitazone O O
has O O
an O O
antiinflammatory O O
action O O
that O O
may O O
contribute O O
to O O
its O O
putative O O
antiatherosclerotic O O
effects O O
. O O

Tyrosine O O
phosphorylation-dependent O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
. O O

Phosphorylation O O
of O O
the O O
N-terminal B B_GENE/B_MEASURE
domain I I_GENE/I_MEASURE
of O O
I B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
activation O O
of O O
the O O
transcription B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
B I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
serine O O
phosphorylation O O
has O O
been O O
shown O O
to O O
induce O O
ubiquitination O O
and O O
subsequent O O
proteasome-mediated O O
degradation O O
of O O
I B B_GENE
kappa I I_GENE
B-alpha I I_GENE
, O O
little O O
is O O
known O O
about O O
the O O
mechanisms O O
that O O
lead O O
to O O
release O O
of O O
active O O
NF-kappa B B_GENE
B I I_GENE
in O O
T O O
cells O O
as O O
a O O
consequence O O
of O O
tyrosine O O
phosphorylation O O
of O O
I B B_GENE
kappa I I_GENE
B-alpha I I_GENE
[ O O
Imbert O O
, O O
V. O O
, O O
Rupec O O
, O O
R.A. O O
, O O
Livolsi O O
, O O
A. O O
, O O
Pahl O O
, O O
H.L. O O
, O O
Traenckner O O
, O O
B.M. O O
, O O
Mueller-Dieckmann O O
, O O
C. O O
, O O
Farahifar O O
, O O
D. O O
, O O
Rossi O O
, O O
B. O O
, O O
Auberger O O
, O O
P. O O
, O O
Baeuerle O O
, O O
P. O O
& O O
Peyron O O
, O O
J.F. O O
( O O
1996 O O
) O O
Cell O O
86 O O
, O O
787 O O
-- O O
798 O O
] O O
. O O

The O O
involvement O O
of O O
the O O
tyrosine B B_GENE
kinases I I_GENE
p56 B I_GENE
( I I_GENE
lck I I_GENE
) I I_GENE
and O O
ZAP-70 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
reaction O O
is O O
demonstrated O O
here O O
using O O
specific O O
pharmacological O O
inhibitors O O
and O O
Jurkat O O
mutants O O
unable O O
to O O
express O O
these O O
kinases B B_ENZYME[GENE]
. O O

Although O O
the O O
inhibitors O O
prevented O O
both O O
pervanadate-induced O O
phosphorylation O O
of O O
I B B_GENE
kappa I I_GENE
B-alpha I I_GENE
on O O
Tyr42 O O
and O O
NF-kappa B B_GENE
B I I_GENE
activation O O
, O O
we O O
observed O O
that O O
, O O
in O O
p56 O O
( O O
lck O O
) O O
-deficient O O
Jurkat O O
mutants O O
, O O
NF-kappa B B_GENE
B I I_GENE
could O O
still O O
associate O O
with O O
I B B_GENE
kappa I I_GENE
B-alpha I I_GENE
despite O O
phosphorylation O O
on O O
Tyr42 O O
. O O

Furthermore O O
, O O
the O O
SH2 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
p56 B B_GENE
( I I_GENE
lck I I_GENE
) I I_GENE
appeared O O
to O O
be O O
required O O
for O O
pervanadate-induced O O
NF-kappa B B_GENE
B I I_GENE
activation O O
but O O
not O O
for O O
Tyr42 O O
phosphorylation O O
. O O

These O O
results O O
show O O
that O O
p56 B B_GENE
( I I_GENE
lck I I_GENE
) I I_GENE
and O O
ZAP-70 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
key O O
components O O
of O O
the O O
signaling O O
pathway O O
that O O
leads O O
to O O
phosphotyrosine-dependent O O
NF-kappa B B_GENE
B I I_GENE
activation O O
in O O
T O O
cells O O
and O O
confirm O O
that O O
tyrosine B B_GENE
kinases I I_GENE
must O O
control O O
at O O
least O O
two O O
different O O
steps O O
to O O
induce O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
. O O

Finally O O
, O O
we O O
show O O
that O O
H O O
( O O
2 O O
) O O
O O O
( O O
2 O O
) O O
, O O
which O O
stimulates O O
p56 B B_GENE
( I I_GENE
lck I I_GENE
) I I_GENE
and O O
ZAP-70 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
T O O
cells O O
, O O
is O O
an O O
activator O O
of O O
NF-kappa B B_GENE/B_DISEASE
B I I_GENE/I_DISEASE
through O O
tyrosine O O
phosphorylation O O
of O O
I B B_GENE
kappa I I_GENE
B-alpha I I_GENE
. O O

Specific O O
missense O O
mutations O O
in O O
NEMO B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
result O O
in O O
hyper-IgM O O
syndrome O O
with O O
hypohydrotic O O
ectodermal O O
dysplasia O O
. O O

The O O
gene O O
that O O
encodes O O
nuclear B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
kappaB I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
NF-kappaB I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
essential I I_GENE/I_LOCATION
modulator I I_GENE/I_LOCATION
( O O
or O O
NEMO B B_ENZYME[GENE]/B_PERSON
, O O
also O O
known O O
as O O
IKKgamma B B_GENE/B_LOCATION
) O O
is O O
required O O
for O O
activation O O
of O O
the O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
NF-kappaB I I_GENE/I_LOCATION
. O O

We O O
describe O O
mutations O O
in O O
the O O
putative B B_GENE/B_LOCATION
zinc-finger I I_GENE/I_LOCATION
domain I I_GENE/I_LOCATION
of O O
NEMO B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
result O O
in O O
an O O
X-linked O O
primary O O
immunodeficiency O O
characterized O O
by O O
hyper-IgM O O
syndrome O O
and O O
hypohydrotic O O
ectodermal O O
dysplasia O O
( O O
XHM-ED O O
) O O
. O O

These O O
mutations O O
prevent O O
CD40 B B_GENE
ligand I I_GENE
( O O
CD40L B B_GENE
) O O
-mediated O O
degradation O O
of O O
inhibitor O O
of O O
NF-kappaB B B_GENE
alpha I I_GENE
( O O
IkappaB-alpha B B_GENE/B_DISEASE
) O O
and O O
account O O
for O O
the O O
following O O
observations O O
: O O
B O O
cells O O
from O O
XHM-ED O O
patients O O
are O O
unable O O
to O O
undergo O O
immunoglobulin O O
class-switch O O
recombination O O
and O O
antigen-presenting O O
cells O O
( O O
APCs O O
) O O
are O O
unable O O
to O O
synthesize O O
the O O
NF-kappaB-regulated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
interleukin B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
12 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-12 B B_GENE/B_MEASURE
) O O
or O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
when O O
stimulated O O
with O O
CD40L B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Overall O O
, O O
the O O
phenotype O O
observed O O
in O O
XHM-ED O O
patients O O
shows O O
that O O
the O O
putative B B_GENE_EXPRESSION_ADJECTIVE[GENE]
zinc-finger I I_GENE_EXPRESSION_ADJECTIVE[GENE]
domain I I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
NEMO B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
a O O
regulatory O O
function O O
and O O
demonstrates O O
the O O
definite O O
requirement O O
of O O
CD40 B B_GENE
-mediated O O
NF-kappaB O O
activation O O
for O O
B O O
cell O O
immunoglobulin O O
class-switching O O
. O O

Granulocytic O O
differentiation O O
of O O
human O O
NB4 O O
promyelocytic O O
leukemia O O
cells O O
induced O O
by O O
all-trans O O
retinoic O O
acid O O
metabolites O O
. O O

The O O
metabolism O O
of O O
all-trans O O
retinoic O O
acid O O
( O O
ATRA O O
) O O
has O O
been O O
reported O O
to O O
be O O
partly O O
responsible O O
for O O
the O O
in O O
vivo O O
resistance O O
to O O
ATRA O O
seen O O
in O O
the O O
treatment O O
of O O
human O O
acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
evaluate O O
the O O
in O O
vitro O O
activity O O
of O O
the O O
principal O O
metabolites O O
of O O
ATRA O O
[ O O
4-hydroxy-retinoic O O
acid O O
( O O
4-OH-RA O O
) O O
, O O
18-hydroxy-retinoic O O
acid O O
( O O
18-OH-RA O O
) O O
, O O
4-oxo-retinoic O O
acid O O
( O O
4-oxo-RA O O
) O O
, O O
and O O
5 O O
, O O
6-epoxy-retinoic O O
acid O O
( O O
5 O O
, O O
6-epoxy-RA O O
) O O
] O O
in O O
NB4 O O
, O O
a O O
human O O
promyelocytic O O
leukemia O O
cell O O
line O O
that O O
exhibits O O
the O O
APL O O
diagnostic O O
t O O
( O O
15 O O
; O O
17 O O
) O O
chromosomal O O
translocation O O
and O O
expresses O O
the O O
PML-RAR B B_GENE/B_DISEASE
alpha I I_GENE/I_DISEASE
fusion I I_GENE/I_DISEASE
protein I I_GENE/I_DISEASE
. O O

We O O
established O O
that O O
the O O
four O O
ATRA O O
metabolites O O
were O O
indeed O O
formed O O
by O O
the O O
NB4 O O
cells O O
in O O
vitro O O
. O O

NB4 O O
cell O O
growth O O
was O O
inhibited O O
( O O
69-78 O O
% O O
at O O
120 O O
h O O
) O O
and O O
cell O O
cycle O O
progression O O
in O O
the O O
G1 O O
phase O O
( O O
82-85 O O
% O O
at O O
120 O O
h O O
) O O
was O O
blocked O O
by O O
ATRA O O
and O O
all O O
of O O
the O O
metabolites O O
at O O
1 O O
microM O O
concentration O O
. O O

ATRA O O
and O O
its O O
metabolites O O
could O O
induce O O
NB4 O O
cells O O
differentiation O O
with O O
similar O O
activity O O
, O O
as O O
evaluated O O
by O O
cell O O
morphology O O
, O O
by O O
the O O
nitroblue O O
tetrazolium O O
reduction O O
test O O
( O O
82-88 O O
% O O
at O O
120 O O
h O O
) O O
or O O
by O O
the O O
expression O O
of O O
the O O
maturation B B_GENE
specific I I_GENE
cell I I_GENE
surface I I_GENE
marker I I_GENE
CD11c I I_GENE
. O O

In O O
addition O O
, O O
nuclear O O
body O O
reorganization O O
to O O
macropunctated O O
structures O O
, O O
as O O
well O O
as O O
the O O
degradation O O
of O O
PML-RAR B B_GENE
alpha I I_GENE
, O O
was O O
found O O
to O O
be O O
similar O O
for O O
ATRA O O
and O O
all O O
of O O
its O O
metabolites O O
. O O

Comparison O O
of O O
the O O
relative O O
potency O O
of O O
the O O
retinoids O O
using O O
the O O
nitroblue O O
tetrazolium O O
reduction O O
test O O
showed O O
effective O O
concentrations O O
required O O
to O O
differentiate O O
50 O O
% O O
of O O
cells O O
in O O
72 O O
h O O
as O O
follows O O
: O O
ATRA O O
, O O
15.8 O O
+/- O O
1.7 O O
nM O O
; O O
4-oxo-RA O O
, O O
38.3 O O
+/- O O
1.3 O O
nM O O
; O O
18-OH-RA O O
, O O
55.5 O O
+/- O O
1.8 O O
nM O O
; O O
4-OH-RA O O
, O O
79.8 O O
+/- O O
1.8 O O
nM O O
; O O
and O O
5 O O
, O O
6-epoxy-RA O O
, O O
99.5 O O
+/- O O
1.5 O O
nM O O
. O O

The O O
ATRA O O
metabolites O O
were O O
found O O
to O O
exert O O
their O O
differentiation O O
effects O O
via O O
the O O
RAR B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
nuclear I I_GENE/I_LOCATION
receptors I I_GENE/I_LOCATION
, O O
because O O
the O O
RAR O O
alpha-specific O O
antagonist O O
BMS614 O O
blocked O O
metabolite-induced O O
CD11c O O
expression O O
in O O
NB4 O O
cells O O
. O O

Expression O O
of O O
oestrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
progesterone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
mast O O
cells O O
alone O O
, O O
but O O
not O O
lymphocytes O O
, O O
macrophages O O
or O O
other O O
immune O O
cells O O
in O O
human O O
upper O O
airways O O
. O O

BACKGROUND O O
: O O
Nasal O O
polyposis O O
often O O
coexists O O
with O O
asthma O O
in O O
airway O O
inflammatory O O
conditions O O
characterised O O
by O O
the O O
infiltration O O
of O O
a O O
range O O
of O O
immune O O
cells O O
. O O

A O O
potentially O O
important O O
role O O
for O O
ovarian O O
hormones O O
has O O
been O O
implicated O O
in O O
airway O O
inflammation O O
but O O
the O O
cellular O O
target O O
for O O
such O O
action O O
is O O
not O O
known O O
. O O

Numerous O O
ER/PR O O
positive O O
mast O O
cells O O
exist O O
in O O
nasal O O
polyps O O
, O O
indicating O O
that O O
this O O
may O O
be O O
a O O
major O O
route O O
for O O
the O O
involvement O O
of O O
sex O O
hormones O O
in O O
airway O O
inflammation O O
when O O
exposed O O
to O O
the O O
higher O O
and O O
varying O O
concentration O O
of O O
oestrogen O O
and O O
progesterone O O
characteristic O O
of O O
females O O
. O O

Our O O
previous O O
studies O O
have O O
implicated O O
the O O
nuclear O O
transcription O O
factor O O
kappa O O
B O O
( O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
) O O
in O O
the O O
regulation O O
of O O
adhesion B B_GENE
molecule I I_GENE
expression O O
in O O
endothelial O O
cells O O
exposed O O
to O O
anoxia-reoxygenation O O
( O O
A/R O O
) O O
or O O
a O O
redox O O
imbalance O O
. O O

The O O
objectives O O
of O O
this O O
study O O
were O O
( O O
1 O O
) O O
to O O
define O O
the O O
kinetics O O
of O O
NF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kappa I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
by O O
examining O O
I O O
kappa O O
B O O
alpha O O
degradation O O
and O O
the O O
nuclear O O
translocation O O
of O O
p65 B B_GENE
in O O
response O O
to O O
A/R O O
or O O
redox O O
imbalance O O
( O O
induced O O
by O O
treatment O O
of O O
cells O O
with O O
diamide O O
and O O
buthionine O O
sulfoximine O O
) O O
and O O
( O O
2 O O
) O O
to O O
determine O O
whether O O
the O O
signal O O
for O O
I O O
kappa O O
B O O
alpha O O
degradation O O
, O O
nuclear O O
translocation O O
of O O
p65 B B_GENE
, O O
and O O
E-selectin B B_GENE
-mediated O O
neutrophil O O
adhesion O O
is O O
related O O
to O O
the O O
activity O O
of O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PTK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
, O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PTPase B B_GENE/B_LOCATION
) O O
and/or O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
C I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PKC B B_GENE/B_DISEASE
) O O
. O O

The O O
results O O
demonstrate O O
that O O
both O O
A/R O O
and O O
redox O O
imbalance O O
led O O
to O O
I O O
kappa O O
B O O
alpha O O
degradation O O
within O O
30 O O
min O O
and O O
the O O
concomitant O O
appearance O O
of O O
p65 B B_GENE
in O O
the O O
nucleus O O
, O O
consistent O O
with O O
rapid O O
cytosolic O O
activation O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
and O O
subsequent O O
nuclear O O
translocation O O
of O O
the O O
activated B B_GENE
p65 I I_GENE
subunit I I_GENE
. O O

Inhibition O O
of O O
PKC B B_GENE
blocked O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degradation O O
and O O
p65 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
translocation O O
in O O
A/R-challenged O O
, O O
but O O
not O O
redox-altered O O
, O O
endothelial O O
cells O O
. O O

However O O
, O O
both O O
A/R- O O
and O O
redox-induced O O
NF O O
kappa O O
B O O
activation O O
was O O
blocked O O
by O O
inhibition O O
of O O
PTK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Similarly O O
, O O
A/R-induced O O
E-selectin O O
expression O O
and O O
neutrophil-endothelial O O
cell O O
adhesion O O
were O O
blocked O O
by O O
inhibition O O
of O O
PKC B B_GENE/B_LOCATION
or O O
PTK B B_LOCATION/B_GENE
, O O
while O O
only O O
PTK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O O
the O O
redox-induced O O
adhesion O O
response O O
. O O

Pretreatment O O
of O O
cells O O
with O O
N-acetyl O O
cysteine O O
effectively O O
blocked O O
A/R- O O
or O O
redox-induced O O
I O O
kappa O O
B O O
degradation O O
and O O
significantly O O
attenuated O O
the O O
respective O O
neutrophil O O
adhesion O O
responses O O
. O O

Collectively O O
, O O
these O O
findings O O
indicate O O
that O O
A/R-induced O O
E-selectin O O
expression O O
and O O
neutrophil-endothelial O O
cell O O
adhesion O O
are O O
mediated O O
by O O
both O O
PKC B B_GENE
and O O
PTK B B_GENE/B_LOCATION
, O O
which O O
signal O O
rapid O O
activation O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
. O O

This O O
A/R-induced O O
NF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
response O O
appears O O
to O O
be O O
mediated O O
, O O
at O O
least O O
in O O
part O O
, O O
by O O
intracellular O O
redox O O
imbalance O O
. O O

Copyright O O
2001 O O
S. O O
Karger O O
AG O O
, O O
Basel O O

Induction O O
of O O
apoptosis O O
in O O
human O O
lymphocytes O O
by O O
the O O
herbicide O O
2 O O
, O O
4-dichlorophenoxyacetic O O
acid O O
. O O

Dimethylammonium O O
salt O O
of O O
2 O O
, O O
4-dichlorophenoxyacetic O O
acid O O
( O O
DMA-2 O O
, O O
4-D O O
) O O
is O O
a O O
widely O O
used O O
herbicide O O
that O O
is O O
considered O O
moderately O O
toxic O O
. O O

Apoptosis O O
induced O O
by O O
DMA-2 O O
, O O
4-D O O
was O O
dose O O
and O O
time O O
dependent O O
, O O
independent O O
of O O
Fas B B_GENE
, O O
TNF B B_GENE
receptor I I_GENE
1 I I_GENE
or O O
the O O
aromatic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hydrocarbon I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
involved O O
disruption O O
of O O
the O O
mitochondrial O O
transmembrane O O
potential O O
and O O
activation O O
of O O
caspase-9 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

ZVAD-FMK O O
, O O
a O O
broad-spectrum O O
inhibitor O O
of O O
caspases B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
blocked O O
DMA-2 O O
, O O
4-D-induced O O
apoptosis O O
completely O O
. O O

While O O
an O O
inhibitor O O
of O O
caspase-9 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
well O O
as O O
caspase-9 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
caspase-3 O O
inhibitors O O
in O O
combination O O
, O O
strongly O O
blocked O O
DMA-2 O O
, O O
4-D-induced O O
apoptosis O O
, O O
an O O
inhibitor O O
of O O
caspase-3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
had O O
a O O
moderate O O
inhibitory O O
effect O O
. O O

Unlike O O
Fas B B_GENE
-mediated O O
apoptosis O O
, O O
the O O
initiator B B_PERSON/B_ENZYME[GENE]
caspase I I_PERSON/I_ENZYME[GENE]
, O O
caspase-8 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
not O O
involved O O
in O O
DMA-2 O O
, O O
4-D-induced O O
apoptosis O O
. O O

Transfection O O
of O O
Jurkat O O
cells O O
with O O
Bcl-2 B B_GENE
prevented O O
DMA-2 O O
, O O
4-D-induced O O
disruption O O
of O O
the O O
mitochondrial O O
transmembrane O O
potential O O
and O O
led O O
to O O
a O O
complete O O
blockage O O
of O O
apoptosis O O
. O O

The O O
activation O O
of O O
caspases B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
occurs O O
downstream O O
of O O
mitochondrial O O
damage O O
, O O
and O O
the O O
dysfunction O O
of O O
mitochondria O O
appears O O
to O O
be O O
sufficient O O
for O O
triggering O O
all O O
downstream O O
events O O
leading O O
to O O
apoptosis O O
. O O

Interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
a O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
by O O
immune O O
and O O
nonimmune O O
cells O O
and O O
exhibits O O
functional O O
pleiotropy O O
and O O
redundancy O O
. O O

IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plays O O
an O O
important O O
role O O
in O O
the O O
differentiation O O
of O O
several O O
cell O O
types O O
. O O

Here O O
, O O
we O O
describe O O
a O O
novel O O
function O O
of O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
: O O
the O O
negative O O
regulation O O
of O O
CD4 B B_GENE
+ O O
Th1 O O
cell O O
differentiation O O
. O O

Thus O O
, O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promotes O O
CD4 B B_GENE/B_LOCATION
+ O O
Th2 O O
differentiation O O
and O O
inhibits O O
Th1 O O
differentiation O O
by O O
two O O
independent O O
molecular O O
mechanisms O O
. O O

Interaction O O
between O O
CCAAT/enhancer B B_GENE
binding I I_GENE
protein I I_GENE
and O O
cyclic B B_GENE
AMP I I_GENE
response I I_GENE
element I I_GENE
binding I I_GENE
protein I I_GENE
1 I I_GENE
regulates O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
transcription O O
in O O
cells O O
of O O
the O O
monocyte/macrophage O O
lineage O O
. O O

Recent O O
observations O O
have O O
shown O O
two O O
CCAAT/enhancer B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
C/EBP I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
to O O
be O O
critically O O
important O O
for O O
efficient O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
replication O O
within O O
cells O O
of O O
the O O
monocyte/macrophage O O
lineage O O
, O O
a O O
cell O O
type O O
likely O O
involved O O
in O O
transport O O
of O O
the O O
virus O O
to O O
the O O
brain O O
. O O

Additionally O O
, O O
sequence O O
variation O O
at O O
C/EBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
lies O O
immediately O O
upstream O O
of O O
the O O
distal B B_GENE/B_DISEASE
nuclear I I_GENE/I_DISEASE
factor I I_GENE/I_DISEASE
kappa I I_GENE/I_DISEASE
B I I_GENE/I_DISEASE
site I I_GENE/I_DISEASE
and O O
immediately O O
downstream O O
of O O
a O O
binding O O
site O O
for O O
activating B B_GENE
transcription I I_GENE
factor I I_GENE
( O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
/ O O
cyclic B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
AMP I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
response I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
element I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CREB B B_GENE/B_LOCATION
) O O
, O O
has O O
been O O
shown O O
to O O
affect O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
long I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeat I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LTR B B_GENE/B_DISEASE
) O O
activity O O
. O O

Given O O
that O O
C/EBP B B_GENE/B_PERSON
proteins I I_GENE/I_PERSON
have O O
been O O
shown O O
to O O
interact O O
with O O
many O O
other O O
transcription B B_GENE/B_BIO
factors I I_GENE/I_BIO
including O O
members O O
of O O
the O O
ATF/CREB B B_GENE/B_MEASURE
family I I_GENE/I_MEASURE
, O O
we O O
proceeded O O
to O O
determine O O
whether O O
an O O
adjacent O O
ATF/CREB B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
could O O
affect O O
C/EBP B B_GENE
protein I I_GENE
binding O O
to O O
C/EBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
biophysical O O
interaction O O
appears O O
to O O
occur O O
via O O
at O O
least O O
two O O
mechanisms O O
. O O

First O O
, O O
low O O
amounts O O
of O O
CREB-1 B B_GENE
and O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
appear O O
to O O
heterodimerize O O
and O O
bind O O
to O O
a O O
site O O
consisting O O
of O O
a O O
half O O
site O O
from O O
both O O
the O O
ATF/CREB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C/EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O O
, O O
CREB-1 B B_GENE/B_BIO
homodimers I I_GENE/I_BIO
bind O O
to O O
the O O
ATF/CREB B B_GENE
site I I_GENE
and O O
recruit O O
C/EBP B B_GENE/B_BIO
dimers I I_GENE/I_BIO
to O O
their O O
cognate O O
weak B B_LOCATION/B_GENE
binding I I_LOCATION/I_GENE
sites I I_LOCATION/I_GENE
. O O

This O O
interaction O O
is O O
reciprocal O O
, O O
since O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dimer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding O O
to O O
a O O
strong O O
C/EBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leads O O
to O O
enhanced O O
CREB-1 B B_GENE
recruitment O O
to O O
ATF/CREB B B_GENE/B_LOCATION
sites I I_GENE/I_LOCATION
that O O
are O O
weakly O O
bound O O
by O O
CREB B B_GENE
. O O

Sequence O O
variation O O
at O O
both O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ATF/CREB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
affects O O
the O O
molecular O O
interactions O O
involved O O
in O O
mediating O O
both O O
of O O
these O O
mechanisms O O
. O O

Thus O O
, O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ATF/CREB B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence O O
variation O O
may O O
modulate O O
cellular O O
signaling O O
at O O
the O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
through O O
the O O
C/EBP O O
pathway O O

This O O
study O O
is O O
the O O
first O O
in O O
which O O
concentrations O O
of O O
ASA O O
in O O
the O O
therapeutic O O
range O O
were O O
found O O
to O O
significantly O O
reduce O O
interleukin B B_GENE
( I I_GENE
IL I I_GENE
) I I_GENE
-4 I I_GENE
secretion O O
and O O
RNA O O
expression O O
in O O
freshly O O
isolated O O
and O O
mitogen-primed O O
human O O
CD4+ O O
T O O
cells O O
. O O

In O O
contrast O O
, O O
ASA O O
did O O
not O O
affect O O
IL-13 B B_GENE
, O O
interferon-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
IL-2 B B_GENE
expression O O
. O O

ASA O O
inhibited O O
IL-4 B B_GENE
, O O
but O O
not O O
IL-2 B B_GENE
, O O
promoter-driven O O
chloramphenicol O O
acetyltransferase O O
expression O O
in O O
transiently O O
transfected O O
Jurkat O O
T O O
cells O O
. O O

The O O
structurally O O
unrelated O O
nonsteroidal O O
anti-inflammatory O O
drugs O O
indomethacin O O
and O O
flurbiprofen O O
did O O
not O O
affect O O
cytokine O O
gene O O
expression O O
in O O
T O O
cells O O
, O O
whereas O O
the O O
weak O O
cyclo-oxygenase O O
inhibitor O O
salicylic O O
acid O O
was O O
at O O
least O O
as O O
effective O O
as O O
ASA O O
in O O
inhibiting O O
IL-4 B B_GENE/B_PERSON
expression O O
and O O
promoter O O
activity O O
. O O

The O O
inhibitory O O
effect O O
of O O
ASA O O
on O O
IL-4 O O
transcription O O
was O O
not O O
mediated O O
by O O
decreased O O
nuclear O O
expression O O
of O O
the O O
known O O
salicylate B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
target I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-kappaB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
was O O
accompanied O O
by O O
reduced O O
binding O O
of O O
an O O
inducible O O
factor O O
to O O
an O O
IL-4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
upstream O O
of O O
, O O
but O O
not O O
overlapping O O
, O O
the O O
NF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappaB-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
is O O
concluded O O
that O O
anti-inflammatory O O
salicylates O O
, O O
by O O
means O O
of O O
a O O
previously O O
unrecognized O O
mechanism O O
of O O
action O O
, O O
can O O
influence O O
the O O
nature O O
of O O
adaptive O O
immune O O
responses O O
by O O
selectively O O
inhibiting O O
the O O
expression O O
of O O
IL-4 B B_GENE
, O O
a O O
critical O O
effector O O
of O O
these O O
responses O O
, O O
in O O
CD4+ O O
T O O
cells O O
. O O

Molecular O O
and O O
cellular O O
mediators O O
of O O
interleukin-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-dependent O O
acute O O
inflammatory O O
arthritis O O
. O O

At O O
day O O
7 O O
, O O
knee O O
joints O O
were O O
removed O O
and O O
assessed O O
histologically O O
. O O

Flow O O
cytometry O O
and O O
RNase O O
protection O O
were O O
used O O
to O O
analyze O O
IL-1 B B_GENE/B_MEASURE
-dependent O O
events O O
. O O

In O O
B6 O O
mice O O
, O O
flow O O
cytometry O O
demonstrated O O
an O O
IL-1-dependent O O
leukocyte O O
infiltration O O
into O O
the O O
synovial O O
compartment O O
and O O
RNase O O
protection O O
assays O O
revealed O O
induction O O
of O O
messenger B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
mRNA B B_GENE
) O O
for O O
the O O
chemokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
monocyte B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chemoattractant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
macrophage B B_PROTEIN[GENE]/B_MEASURE
inhibitory I I_PROTEIN[GENE]/I_MEASURE
protein I I_PROTEIN[GENE]/I_MEASURE
2 I I_PROTEIN[GENE]/I_MEASURE
( O O
MIP-2 B B_GENE/B_DISEASE
) O O
, O O
RANTES B B_GENE
, O O
MIP-1alpha B B_GENE
, O O
and O O
MIP-1beta B B_GENE
, O O
in O O
vivo O O
and O O
in O O
vitro O O
. O O

IL-1 B B_GENE/B_LOCATION
contributes O O
to O O
leukocyte O O
recruitment O O
to O O
the O O
synovium O O
and O O
directly O O
induces O O
chemokine O O
mRNA O O
production O O
by O O
synovial O O
cells O O
. O O

This O O
model O O
of O O
acute O O
monarticular O O
arthritis O O
is O O
particularly O O
suitable O O
for O O
further O O
investigations O O
into O O
cell-mediated O O
immunity O O
in O O
arthritis O O
and O O
the O O
role O O
of O O
IL-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Positive O O
and O O
negative O O
regulation O O
of O O
granulopoiesis O O
by O O
endogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RARalpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
is O O
always O O
associated O O
with O O
chromosomal O O
translocations O O
that O O
disrupt O O
the O O
retinoic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RARalpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Whether O O
these O O
translocations O O
relate O O
to O O
a O O
role O O
for O O
endogenous B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RARalpha I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
normal O O
granulopoiesis O O
remains O O
uncertain O O
because O O
most O O
studies O O
addressing O O
this O O
question O O
have O O
used O O
non-physiological O O
overexpression O O
systems O O
. O O

Granulocyte O O
differentiation O O
in O O
cells O O
derived O O
from O O
RARalpha-deficient O O
( O O
RARalpha O O
( O O
-/- O O
) O O
) O O
mice O O
was O O
studied O O
and O O
evaluated O O
in O O
the O O
context O O
of O O
agonist-bound B B_DISEASE/B_GENE
and I I_DISEASE/I_GENE
ligand-free I I_DISEASE/I_GENE
RARalpha I I_DISEASE/I_GENE
. O O

Our O O
results O O
demonstrate O O
that O O
RARalpha B B_GENE
is O O
dispensable O O
for O O
granulopoiesis O O
, O O
as O O
RARalpha O O
( O O
-/- O O
) O O
mice O O
have O O
a O O
normal O O
granulocyte O O
population O O
despite O O
an O O
impaired O O
ability O O
to O O
respond O O
to O O
retinoids O O
. O O

However O O
, O O
although O O
it O O
is O O
not O O
absolutely O O
required O O
, O O
RARalpha B B_GENE
can O O
bidirectionally O O
modulate O O
granulopoiesis O O
. O O

RARalpha B B_GENE
stimulates O O
differentiation O O
in O O
response O O
to O O
exogenous O O
retinoic O O
acid O O
. O O

Furthermore O O
, O O
endogenous O O
retinoids O O
control O O
granulopoiesis O O
in O O
vivo O O
, O O
as O O
either O O
vitamin O O
A-deficient O O
mice O O
or O O
animals O O
treated O O
with O O
an O O
RAR O O
antagonist O O
accumulate O O
more O O
immature O O
granulocytes O O
in O O
their O O
bone O O
marrow O O
. O O

Conversely O O
, O O
RARalpha B B_GENE
acts O O
to O O
limit O O
differentiation O O
in O O
the O O
absence O O
of O O
ligand B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
because O O
granulocyte O O
precursors O O
from O O
RARalpha O O
( O O
-/- O O
) O O
mice O O
differentiate O O
earlier O O
in O O
culture O O
. O O

Thus O O
, O O
the O O
block O O
in O O
granulopoiesis O O
exerted O O
by O O
RARalpha B B_GENE/B_LOCATION
fusion B I_GENE/I_LOCATION
proteins I I_GENE/I_LOCATION
expressed O O
in O O
APL O O
cells O O
may O O
correspond O O
to O O
an O O
amplification O O
of O O
a O O
normal O O
function O O
of O O
unliganded B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
RARalpha I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Expression O O
and O O
function O O
of O O
a O O
stem B B_GENE/B_PERSON
cell I I_GENE/I_PERSON
promoter I I_GENE/I_PERSON
for O O
the O O
murine B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
CBFalpha2 I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
: O O
distinct O O
roles O O
and O O
regulation O O
in O O
natural O O
killer O O
and O O
T O O
cell O O
development O O
. O O

The O O
Runt B B_GENE/B_MEASURE
family I I_GENE/I_MEASURE
transcription I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
CBFalpha2 B I_GENE/I_MEASURE
( O O
AML1 B B_GENE/B_DISEASE
, O O
PEBP2alphaB B B_GENE/B_DISEASE
, O O
or O O
Runx1 B B_GENE/B_DISEASE
) O O
is O O
required O O
by O O
hematopoietic O O
stem O O
cells O O
and O O
expressed O O
at O O
high O O
levels O O
in O O
T-lineage O O
cells O O
. O O

The O O
distal B B_PROTEIN[GENE]
N-terminal I I_PROTEIN[GENE]
isoform I I_PROTEIN[GENE]
binds O O
to O O
functionally O O
important O O
regulatory B B_GENE/B_LOCATION
sites I I_GENE/I_LOCATION
from O O
known O O
target B B_GENE
genes I I_GENE
with O O
two- O O
to O O
threefold O O
higher O O
affinity O O
than O O
the O O
proximal B B_LOCATION/B_GENE
N-terminal I I_LOCATION/I_GENE
isoform I I_LOCATION/I_GENE
. O O

Neither O O
full-length B B_GENE
isoform I I_GENE
alters O O
growth O O
of O O
a O O
myeloid O O
cell O O
line O O
under O O
nondifferentiating O O
conditions O O
, O O
but O O
the O O
proximal B B_GENE
isoform I I_GENE
selectively O O
delays O O
mitotic O O
arrest O O
of O O
the O O
cell O O
line O O
under O O
differentiating O O
conditions O O
, O O
resulting O O
in O O
the O O
generation O O
of O O
greater O O
numbers O O
of O O
neutrophils O O
. O O

Theileria O O
is O O
an O O
intracellular O O
parasite O O
that O O
causes O O
lymphoproliferative O O
disorders O O
in O O
cattle O O
, O O
and O O
infection O O
of O O
leucocytes O O
induces O O
a O O
transformed O O
phenotype O O
similar O O
to O O
tumour O O
cells O O
, O O
but O O
the O O
mechanisms O O
by O O
which O O
the O O
parasite O O
induces O O
this O O
phenotype O O
are O O
not O O
understood O O
. O O

Taken O O
together O O
, O O
our O O
results O O
highlight O O
a O O
novel O O
strategy O O
exploited O O
by O O
the O O
intracellular O O
parasite O O
Theileria O O
to O O
induce O O
continued O O
proliferation O O
of O O
its O O
host O O
leucocyte O O
. O O

Lymphokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dependence O O
of O O
STAT3 O O
activation O O
produced O O
by O O
surface O O
immunoglobulin O O
cross-linking O O
and O O
by O O
phorbol O O
ester O O
plus O O
calcium O O
ionophore O O
treatment O O
in O O
B O O
cells O O
. O O

Stimulation O O
of O O
B O O
cells O O
by O O
surface B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoglobulin I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
sIg B B_PROTEIN[GENE]/B_LOCATION
) O O
triggering O O
, O O
or O O
through O O
the O O
mitogenic O O
combination O O
of O O
phorbol O O
ester O O
and O O
calcium O O
ionophore O O
, O O
is O O
accompanied O O
by O O
activation O O
of O O
STAT B B_GENE
transcription I I_GENE
factors I I_GENE
. O O

The O O
mechanism O O
responsible O O
for O O
the O O
delayed O O
nuclear O O
accumulation O O
of O O
phosphorylated B B_GENE/B_DISEASE
STAT3 I I_GENE/I_DISEASE
was O O
examined O O
in O O
detail O O
, O O
focusing O O
on O O
the O O
role O O
of O O
B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell-derived I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lymphokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

sIg B B_GENE
-induced O O
activation O O
of O O
STAT3 B B_GENE
was O O
partially O O
inhibited O O
in O O
B O O
cells O O
obtained O O
from O O
IL-6- O O
or O O
IL-10-deficient O O
mice O O
, O O
and O O
was O O
partially O O
blocked O O
by O O
neutralizing B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
directed O O
against O O
either O O
of O O
these O O
lymphokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O O
, O O
IL-10 B B_GENE
alone O O
appeared O O
to O O
account O O
for O O
STAT3 O O
activation O O
resulting O O
from O O
B O O
cell O O
stimulation O O
with O O
phorbol O O
ester O O
and O O
calcium O O
ionophore O O
. O O

In O O
keeping O O
with O O
these O O
results O O
, O O
soluble O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
IL-10 B B_GENE
were O O
found O O
in O O
supernatant O O
fluid O O
obtained O O
from O O
stimulated O O
B O O
cells O O
. O O

This O O
work O O
indicates O O
that O O
a O O
lymphokine O O
pathway O O
is O O
responsible O O
for O O
STAT3 O O
activation O O
that O O
occurs O O
late O O
after O O
B O O
cell O O
stimulation O O
, O O
and O O
points O O
out O O
differences O O
in O O
B O O
cell O O
activation O O
that O O
result O O
from O O
stimulation O O
through O O
the O O
antigen B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
receptor I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
through O O
pharmacological O O
mimicry O O
of O O
signaling B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mediators I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
other O O
conserved B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
that O O
differ O O
between O O
Ig B B_GENE/B_BIO
variable I I_GENE/I_BIO
gene I I_GENE/I_BIO
families I I_GENE/I_BIO
, O O
are O O
required O O
for O O
normal O O
promoter O O
function O O
. O O

One O O
example O O
is O O
an O O
E-box B B_GENE
of O O
the O O
E47/E12 B B_GENE/B_MEASURE
type I I_GENE/I_MEASURE
( I I_GENE/I_MEASURE
5'-CAGCTG-3 I I_GENE/I_MEASURE
' I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
, O O
which O O
is O O
found O O
in O O
all O O
promoters O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
murine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ig-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subgroups/families I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
the O O
exception O O
of O O
subgroups O O
II O O
and O O
VI O O
and O O
their O O
related O O
murine B B_LOCATION/B_GENE
families I I_LOCATION/I_GENE
. O O

In O O
the O O
present O O
study O O
we O O
show O O
that O O
the O O
ubiquitously O O
expressed O O
transcription B B_GENE
factor I I_GENE
AP-4 I I_GENE
, O O
and O O
not O O
E47 B B_GENE
, O O
interacts O O
specifically O O
with O O
the O O
kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E-boxes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
when O O
tested O O
in O O
electrophoretic O O
mobility-shift O O
assays O O
using O O
nuclear O O
extracts O O
derived O O
from O O
human O O
and O O
murine O O
B-cell O O
lines O O
. O O

Furthermore O O
, O O
AP-4 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
unlike O O
E47 B B_GENE
, O O
did O O
not O O
act O O
as O O
a O O
transactivator B B_GENE
, O O
which O O
is O O
in O O
agreement O O
with O O
previous O O
studies O O
on O O
intact O O
kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
showing O O
that O O
transcription O O
is O O
absent O O
when O O
the O O
octamer B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
has O O
been O O
mutated O O
. O O

The O O
DNA B B_GENE/B_MEASURE
binding I I_GENE/I_MEASURE
domain I I_GENE/I_MEASURE
of O O
the O O
Drosophila B B_GENE
transcription I I_GENE
factor I I_GENE
( O O
Antennapedia B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
a O O
60 B B_GENE
amino I I_GENE
acid I I_GENE
protein I I_GENE
, O O
is O O
rapidly O O
taken O O
up O O
by O O
cells O O
and O O
has O O
been O O
fused O O
to O O
selected O O
antigens B B_GENE/B_DISEASE
to O O
enhance O O
their O O
immunogenicity O O
. O O

Synthetic O O
peptides O O
were O O
made O O
containing O O
the O O
16-mer O O
antennapedia O O
peptide O O
linked O O
in O O
tandem O O
to O O
the O O
ovalbumin O O
SIINFEKL O O
CTL O O
peptide O O
. O O

The O O
peptide O O
complex O O
was O O
shown O O
to O O
rapidly O O
internalise O O
into O O
APCs O O
by O O
confocal O O
microscopy O O
. O O

This O O
peptide O O
induced O O
CTL O O
in O O
C57BL/6 O O
mice O O
and O O
protected O O
them O O
against O O
growth O O
of O O
an O O
ovalbumin O O
expressing O O
tumour O O
cell O O
line O O
( O O
E.G7-OVA O O
) O O
. O O

Bone O O
marrow O O
cells O O
promote O O
TH2 O O
polarization O O
and O O
inhibit O O
virus-specific O O
CTL O O
generation O O
. O O

This O O
laboratory O O
recently O O
reported O O
that O O
human O O
bone O O
marrow O O
cells O O
( O O
BMC O O
) O O
inhibit O O
the O O
generation O O
of O O
virus-specific O O
CTL O O
in O O
culture O O
. O O

The O O
culture O O
supernatants O O
contained O O
increased O O
levels O O
of O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PGE I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
shown O O
to O O
favor O O
TH2 O O
cell O O
development O O
) O O
and O O
also O O
inhibited O O
EBV-CTL O O
effector O O
cell O O
development O O
. O O

In O O
this O O
study O O
, O O
we O O
obtained O O
PBL O O
from O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
IgG B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive O O
kidney O O
transplant O O
recipients O O
( O O
R O O
) O O
and O O
their O O
living-related O O
donors O O
( O O
LRD O O
) O O
one O O
year O O
after O O
renal O O
transplantation O O
. O O

EBV-specific O O
CTL O O
were O O
then O O
generated O O
in O O
vitro O O
by O O
stimulating O O
PBL O O
with O O
autologous O O
EBV-transformed O O
B O O
cells O O
( O O
EBV-B O O
) O O
in O O
the O O
presence O O
or O O
absence O O
of O O
autologous O O
BMC O O
. O O

The O O
addition O O
of O O
BMC O O
to O O
the O O
EBV-CTL O O
generation O O
cultures O O
increased O O
the O O
intracellular O O
expression O O
in O O
CD3+ O O
cells O O
of O O
IL-4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-10 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-13 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
CD3+ O O
cells O O
also O O
expressed O O
increased O O
levels O O
of O O
the O O
TH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
associated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CCR3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
was O O
then O O
observed O O
that O O
CD3+ O O
cells O O
obtained O O
after O O
7 O O
days O O
of O O
culture O O
in O O
the O O
presence O O
of O O
autologous O O
BMC O O
could O O
be O O
used O O
as O O
inhibitors O O
of O O
EBV-CTL O O
generation O O
. O O

Protein B B_GENE
Kinase I I_GENE
A I I_GENE
( O O
PKA B B_GENE/B_LOCATION
) O O
, O O
a O O
cAMP B B_ENZYME[GENE]/B_LOCATION
kinase I I_ENZYME[GENE]/I_LOCATION
that O O
is O O
involved O O
in O O
the O O
upregulation O O
of O O
TH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
, O O
was O O
increased O O
in O O
EBV-CTL O O
cultures O O
by O O
the O O
presence O O
of O O
BMC O O
. O O

Additionally O O
, O O
IL-4-mediated O O
signal O O
transduction O O
and O O
activation O O
of O O
transcription O O
( O O
STAT-6 B B_GENE/B_LOCATION
) O O
phosphorylation O O
was O O
slightly O O
increased O O
. O O

Reduction O O
in O O
DNA O O
binding O O
activity O O
of O O
the O O
transcription B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Pax-5a B I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
B O O
lymphocytes O O
of O O
aged O O
mice O O
. O O

Aging O O
has O O
been O O
associated O O
with O O
intrinsic O O
changes O O
of O O
the O O
humoral O O
immune O O
response O O
, O O
which O O
may O O
lead O O
to O O
an O O
increased O O
occurrence O O
of O O
autoimmune O O
disorders O O
and O O
pathogenic O O
susceptibility O O
. O O

The O O
transcription B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
factor I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
Pax-5 B I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
is O O
a O O
key O O
regulator O O
of O O
B O O
cell O O
development O O
. O O

Pax-5a/B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell-specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
an O O
alternatively B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
spliced I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoform I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Pax-5d I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
may O O
have O O
opposing O O
functions O O
in O O
transcriptional O O
regulation O O
due O O
to O O
the O O
lack O O
of O O
a O O
transactivation B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
in O O
Pax-5d B B_GENE/B_SPECIES[BIO]
. O O

To O O
study O O
B O O
cell O O
-specific O O
changes O O
that O O
occur O O
during O O
the O O
aging O O
process O O
, O O
we O O
investigated O O
expression O O
patterns O O
of O O
Pax-5a B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5d I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mature O O
B O O
cells O O
of O O
young O O
and O O
aged O O
mice O O
. O O

RNase O O
protection O O
assays O O
showed O O
a O O
similar O O
transcriptional O O
pattern O O
for O O
both O O
age O O
groups O O
that O O
indicates O O
that O O
aging O O
has O O
no O O
affect O O
on O O
transcription O O
initiation O O
or O O
alternative O O
splicing O O
for O O
either O O
isoform B B_GENE/B_LOCATION
. O O

The O O
observed O O
decrease O O
in O O
Pax-5a B B_GENE
binding O O
activity O O
correlated O O
with O O
changes O O
in O O
expression O O
of O O
two O O
Pax-5 B B_GENE/B_LOCATION
target I I_GENE/I_LOCATION
genes I I_GENE/I_LOCATION
in O O
aged O O
B O O
cells O O
. O O

Expression O O
of O O
the O O
Ig B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
secreted O O
form O O
of O O
Ig B B_GENE
mu I I_GENE
, O O
which O O
are O O
both O O
known O O
to O O
be O O
suppressed O O
by O O
Pax-5a B B_GENE
in O O
mature O O
B O O
cells O O
, O O
were O O
increased O O
in O O
B O O
cells O O
of O O
aged O O
mice O O
. O O

Together O O
, O O
our O O
studies O O
suggest O O
that O O
changes O O
associated O O
with O O
the O O
aging O O
phenotype O O
cause O O
posttranslational O O
modification O O
( O O
s O O
) O O
of O O
Pax-5a B B_GENE
but O O
not O O
Pax-5d B B_GENE
, O O
which O O
may O O
lead O O
to O O
an O O
abnormal O O
B O O
cell O O
phenotype O O
in O O
aged O O
mice O O
, O O
associated O O
with O O
elevated O O
levels O O
of O O
J B B_GENE
chain I I_GENE
, O O
and O O
secretion O O
of O O
IgM B B_GENE

The O O
NF-kappaB/Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
represents O O
one O O
signal O O
transduction O O
pathway O O
induced O O
during O O
such O O
activation O O
. O O

We O O
show O O
in O O
this O O
study O O
that O O
inhibition O O
of O O
NF-kappaB B B_GENE
through O O
the O O
expression O O
of O O
an O O
IkappaBalpha B B_GENE/B_DISEASE
( O O
inhibitory B B_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
that O O
dissociates O O
from O O
NF-kappaB B B_GENE
) O O
mutant O O
refractory O O
to O O
signal-induced O O
degradation O O
( O O
IkappaBalpha B B_GENE/B_DISEASE
( I I_GENE/I_DISEASE
DeltaN I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
) O O
interfered O O
with O O
the O O
acquisition O O
of O O
competence O O
to O O
proliferate O O
in O O
response O O
to O O
IL-4 B B_GENE
as O O
well O O
as O O
IL-2 B B_GENE
. O O

Thymocytes O O
and O O
T O O
cells O O
from O O
IkappaBalpha B B_GENE/B_PERSON
( I I_GENE/I_PERSON
DeltaN I I_GENE/I_PERSON
) I I_GENE/I_PERSON
transgenic O O
mice O O
expressed O O
normal O O
levels O O
of O O
IL-2R B B_GENE
subunits I I_GENE
. O O

However O O
, O O
transgenic O O
cells O O
exhibited O O
a O O
dramatic O O
defect O O
in O O
Stat5A O O
activation O O
treatment O O
with O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
a O O
similar O O
defect O O
was O O
observed O O
for O O
IL-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
Stat5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
contrast O O
, O O
T O O
lymphoid O O
cells O O
with O O
inhibition O O
of O O
NF-kappaB B B_GENE
showed O O
normal O O
insulin O O
receptor O O
substrate-2 O O
phosphorylation O O
and O O
only O O
a O O
modest O O
decrease O O
in O O
Stat6 O O
activation O O
and O O
insulin O O
receptor O O
substrate-1 O O
phosphorylation O O
after O O
IL-4 O O
stimulation O O
. O O

BMS-189453 O O
, O O
a O O
novel O O
retinoid O O
receptor O O
antagonist O O
, O O
is O O
a O O
potent O O
testicular O O
toxin O O
. O O

BMS-189453 O O
is O O
a O O
synthetic O O
retinoid O O
that O O
acts O O
as O O
an O O
antagonist O O
at O O
retinoic B B_GENE/B_DISEASE
acid I I_GENE/I_DISEASE
receptors I I_GENE/I_DISEASE
alpha I I_GENE/I_DISEASE
, I I_GENE/I_DISEASE
beta I I_GENE/I_DISEASE
, I I_GENE/I_DISEASE
and I I_GENE/I_DISEASE
gamma I I_GENE/I_DISEASE
. O O

In O O
Sprague O O
Dawley O O
rats O O
at O O
daily O O
oral O O
doses O O
of O O
15 O O
, O O
60 O O
, O O
or O O
240 O O
mg/kg O O
for O O
1 O O
month O O
, O O
BMS-189453 O O
produced O O
increases O O
in O O
leukocyte O O
counts O O
, O O
alkaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
phosphatase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
and O O
alanine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
aminotransferase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
levels O O
, O O
and O O
marked O O
testicular O O
degeneration O O
and O O
atrophy O O
at O O
all O O
doses O O
. O O

Significant O O
overt O O
signs O O
of O O
toxicity O O
and O O
deaths O O
occurred O O
at O O
240 O O
mg/kg O O
, O O
whereas O O
body-weight O O
and O O
food-consumption O O
decreases O O
occurred O O
at O O
60 O O
and O O
240 O O
mg/kg O O
. O O

When O O
BMS-189453 O O
was O O
administered O O
to O O
male O O
rats O O
at O O
daily O O
doses O O
ranging O O
from O O
12.5 O O
to O O
100 O O
mg/kg O O
for O O
1 O O
week O O
, O O
only O O
minimal O O
testicular O O
changes O O
occurred O O
at O O
all O O
doses O O
, O O
shortly O O
after O O
the O O
dosing O O
period O O
. O O

However O O
, O O
after O O
a O O
1-month O O
drug-free O O
observation O O
period O O
, O O
marked O O
testicular O O
atrophy O O
was O O
evident O O
at O O
all O O
doses O O
. O O

BMS-189453 O O
was O O
then O O
administered O O
at O O
doses O O
of O O
2 O O
, O O
10 O O
, O O
or O O
50 O O
mg/kg O O
to O O
male O O
rats O O
for O O
1 O O
, O O
3 O O
, O O
or O O
7 O O
consecutive O O
days O O
. O O

Dose- O O
and O O
duration-dependent O O
testicular O O
toxicity O O
that O O
occurred O O
after O O
a O O
1-month O O
observation O O
period O O
did O O
not O O
recover O O
, O O
and O O
, O O
in O O
some O O
cases O O
, O O
was O O
more O O
severe O O
4 O O
months O O
after O O
the O O
last O O
dose O O
. O O

In O O
rabbits O O
administered O O
BMS-189453 O O
at O O
oral O O
doses O O
of O O
2 O O
, O O
10 O O
, O O
or O O
50 O O
mg/kg O O
for O O
1 O O
week O O
, O O
testicular O O
degeneration O O
and O O
atrophy O O
were O O
evident O O
in O O
the O O
high-dose O O
group O O
at O O
1 O O
month O O
following O O
treatment O O
. O O

These O O
studies O O
indicate O O
that O O
retinoid O O
antagonists O O
can O O
selectively O O
produce O O
progressive O O
and O O
prolonged O O
testicular O O
toxicity O O
after O O
single O O
or O O
repeated O O
oral O O
doses O O
that O O
are O O
otherwise O O
well O O
tolerated O O
. O O

Sequential O O
involvement O O
of O O
NFAT B B_GENE
and O O
Egr B B_GENE
transcription B I_GENE
factors I I_GENE
in O O
FasL O O
regulation O O
. O O

The O O
critical O O
function O O
of O O
NFAT B B_GENE
proteins I I_GENE
in O O
maintaining O O
lymphoid O O
homeostasis O O
was O O
revealed O O
in O O
mice O O
lacking O O
both O O
NFATp B B_GENE
and O O
NFAT4 B B_GENE
( O O
DKO O O
) O O
. O O

DKO O O
mice O O
exhibit O O
increased O O
lymphoproliferation O O
, O O
decreased O O
activation-induced O O
cell O O
death O O
, O O
and O O
impaired O O
induction O O
of O O
FasL B B_GENE
. O O

The O O
transcription B B_GENE
factors I I_GENE
Egr2 B I_GENE
and O O
Egr3 B B_GENE
are O O
potent O O
activators O O
of O O
FasL O O
expression O O
. O O

Activation O O
of O O
FasL B B_GENE
occurs O O
via O O
the O O
NFAT B B_GENE
-dependent O O
induction O O
of O O
Egr3 B B_GENE
, O O
as O O
demonstrated O O
by O O
the O O
ability O O
of O O
exogenously O O
provided O O
NFATp B B_GENE
to O O
restore O O
Egr B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-dependent O O
FasL O O
promoter O O
activity O O
in O O
DKO O O
lymph O O
node O O
cells O O
. O O

Further O O
, O O
Egr3 B B_GENE
expression O O
is O O
enriched O O
in O O
Th1 O O
cells O O
, O O
suggesting O O
a O O
molecular O O
basis O O
for O O
the O O
known O O
preferential O O
expression O O
of O O
FasL B B_GENE
in O O
the O O
Th1 O O
versus O O
Th2 O O
subset O O
. O O

Mechanisms O O
and O O
clinical O O
relevance O O
of O O
nongenomic O O
glucocorticoid O O
actions O O
. O O

Glucocorticoids O O
have O O
profound O O
anti-inflammatory O O
and O O
immunosuppressive O O
actions O O
when O O
used O O
therapeutically O O
. O O

The O O
therapeutic O O
dose O O
is O O
quite O O
variable O O
and O O
depends O O
on O O
the O O
disease O O
, O O
but O O
ranges O O
from O O
very O O
low O O
to O O
extremely O O
high O O
. O O

The O O
rationale O O
for O O
the O O
use O O
of O O
various O O
dosage O O
regimens O O
for O O
specific O O
clinical O O
indications O O
is O O
the O O
existence O O
of O O
three O O
distinct O O
, O O
therapeutically O O
relevant O O
effects O O
: O O
genomic O O
, O O
specific O O
nongenomic O O
and O O
unspecific O O
nongenomic O O
. O O

Genomic O O
effects O O
are O O
mediated O O
by O O
cytosolic B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O O
alter O O
expression O O
of O O
specific O O
genes O O
. O O

Unspecific O O
nongenomic O O
effects O O
occur O O
within O O
seconds O O
, O O
but O O
only O O
at O O
high O O
glucocorticoid O O
dosages O O
, O O
and O O
seem O O
to O O
result O O
from O O
direct O O
interactions O O
with O O
biological O O
membranes O O
. O O

For O O
unspecific O O
nongenomic O O
effects O O
, O O
methylprednisolone O O
and O O
other O O
glucocorticoids O O
have O O
been O O
shown O O
to O O
inhibit O O
cation O O
cycling O O
across O O
the O O
plasma O O
membrane O O
, O O
but O O
to O O
have O O
little O O
effect O O
on O O
protein O O
synthesis O O
. O O

Thus O O
, O O
glucocorticoids O O
could O O
diminish O O
or O O
prevent O O
the O O
acute O O
immune O O
response O O
by O O
interfering O O
with O O
processes O O
such O O
as O O
the O O
rise O O
in O O
intracellular O O
Ca2+ O O
concentration O O
. O O

It O O
is O O
proposed O O
that O O
the O O
additional O O
therapeutic O O
benefit O O
of O O
higher O O
doses O O
is O O
obtained O O
via O O
these O O
nongenomic O O
effects O O
. O O

High O O
glucose-induced O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
( O O
ICAM-1 B B_GENE/B_DISEASE
) O O
expression O O
through O O
an O O
osmotic O O
effect O O
in O O
rat O O
mesangial O O
cells O O
is O O
PKC-NF-kappa O O
B-dependent O O
. O O

AIMS/HYPOTHESIS O O
: O O
Infiltration O O
of O O
mononuclear O O
cells O O
and O O
glomerular O O
enlargement O O
accompanied O O
by O O
glomerular O O
cell O O
proliferation O O
are O O
very O O
early O O
characteristics O O
of O O
the O O
pathophysiology O O
of O O
diabetes O O
. O O

To O O
clarify O O
the O O
mechanism O O
of O O
early O O
diabetic O O
nephropathy O O
, O O
we O O
measured O O
[ O O
3H O O
] O O
-thymidine O O
incorporation O O
and O O
cell O O
numbers O O
to O O
show O O
the O O
influence O O
of O O
a O O
high O O
ambient O O
glucose O O
concentration O O
and O O
the O O
osmotic O O
effect O O
on O O
rat O O
mesangial O O
cell O O
proliferation O O
. O O

We O O
also O O
measured O O
the O O
effect O O
of O O
high O O
glucose O O
on O O
the O O
expression O O
of O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
and O O
vascular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
by O O
flow O O
cytometry O O
and O O
semiquantitative O O
RT-PCR O O
in O O
mesangial O O
cells O O
and O O
the O O
adhesion O O
of O O
leukocytes O O
to O O
mesangial O O
cells O O
. O O

METHODS/RESULTS O O
: O O
Cells O O
exposed O O
to O O
high O O
D-glucose O O
( O O
30 O O
mmol/l O O
) O O
caused O O
an O O
increase O O
in O O
[ O O
3H O O
] O O
-thymidine O O
incorporation O O
and O O
cell O O
numbers O O
at O O
24 O O
and O O
48 O O
h O O
and O O
normalized O O
at O O
72 O O
h O O
( O O
p O O
< O O
0.05 O O
) O O
, O O
whereas O O
these O O
changes O O
were O O
not O O
found O O
in O O
high O O
mannitol O O
( O O
30 O O
mmol/l O O
) O O
, O O
IL-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
or O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-stimulated O O
mesangial O O
cells O O
. O O

Cells O O
exposed O O
to O O
high-glucose O O
( O O
15 O O
, O O
30 O O
, O O
or O O
60 O O
mmol/l O O
) O O
or O O
osmotic O O
agents O O
( O O
L-glucose O O
, O O
raffinose O O
and O O
mannitol O O
) O O
showed O O
that O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
expression O O
began O O
to O O
increase O O
after O O
24 O O
h O O
, O O
reached O O
its O O
maximum O O
at O O
24 O O
and O O
48 O O
h O O
and O O
gradually O O
decreased O O
afterwards O O
. O O

The O O
stimulatory O O
effects O O
of O O
high O O
glucose O O
and O O
high O O
mannitol O O
on O O
mRNA O O
expression O O
were O O
observed O O
as O O
early O O
as O O
6 O O
h O O
and O O
reached O O
its O O
maximum O O
at O O
12 O O
h O O
. O O

Neither O O
vascular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
protein O O
nor O O
mRNA O O
expression O O
was O O
, O O
however O O
, O O
affected O O
by O O
high O O
glucose O O
and O O
high O O
mannitol O O
. O O

Notably O O
, O O
the O O
protein O O
kinase O O
C O O
inhibitors O O
calphostin O O
C O O
and O O
staurosporine O O
reduced O O
high O O
glucose- O O
or O O
high O O
mannitol-induced O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
mRNA O O
expression O O
and O O
high O O
glucose-induced O O
proliferation O O
. O O

Furthermore O O
, O O
the O O
NF-kappa O O
B O O
inhibitor O O
N-tosyl-L-phenylalanine O O
chloromethyl O O
ketone O O
reduced O O
high O O
glucose- O O
or O O
high O O
mannitol-induced O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
mRNA O O
expression O O
and O O
high O O
glucose-induced O O
proliferation O O
. O O

Results O O
showed O O
that O O
high O O
glucose O O
( O O
15 O O
, O O
30 O O
mmol/l O O
) O O
or O O
high O O
concentrations O O
of O O
osmotic O O
agents O O
remarkably O O
increased O O
the O O
number O O
of O O
adherent O O
leukocytes O O
to O O
mesangial O O
cells O O
( O O
p O O
< O O
0.01 O O
) O O
compared O O
with O O
control O O
cells O O
( O O
5 O O
mmol/l O O
D-glucose O O
) O O
. O O

CONCLUSION/INTERPRETATION O O
: O O
These O O
results O O
suggest O O
that O O
high O O
glucose O O
can O O
upregulate O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
protein O O
and O O
mRNA O O
expression O O
but O O
not O O
vascular O O
adhesion O O
molecule-1 O O
expression O O
in O O
mesangial O O
cells O O
and O O
promote O O
leukocyte O O
adhesion O O
through O O
up-regulation O O
of O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
through O O
osmotic O O
effect O O
, O O
possibly O O
depending O O
on O O
the O O
protein B B_GENE/B_LOCATION
kinase I I_GENE/I_LOCATION
C I I_GENE/I_LOCATION
nuclear B I_GENE/I_LOCATION
factor-kappa I I_GENE/I_LOCATION
B I I_GENE/I_LOCATION
( O O
PKC B B_GENE
- O O
NF-kappa B B_PROTEIN[GENE]/B_LOCATION
B I I_PROTEIN[GENE]/I_LOCATION
) O O
pathway O O
. O O

High O O
glucose O O
itself O O
can O O
also O O
promote O O
mesangial O O
cell O O
proliferation O O
through O O
the O O
PKC-NF-kappa O O
B O O
pathways O O
. O O

We O O
conclude O O
that O O
hyperglycaemia O O
in O O
itself O O
seems O O
to O O
be O O
an O O
important O O
factor O O
in O O
the O O
development O O
of O O
early O O
diabetic O O
nephropathy O O
. O O

The O O
basis O O
for O O
the O O
refractory O O
state O O
in O O
the O O
remaining O O
patients O O
is O O
unknown O O
. O O

Nonadherent O O
cells O O
were O O
harvested O O
and O O
assayed O O
in O O
clonogenic O O
assays O O
for O O
granulocytic O O
colony O O
production O O
. O O

The O O
in O O
vitro O O
effect O O
of O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
corticosteroids O O
on O O
granulopoiesis O O
was O O
evaluated O O
in O O
clonogenic O O
assays O O
of O O
marrow O O
mononuclear O O
cells O O
, O O
by O O
proliferation O O
studies O O
of O O
the O O
murine O O
myeloid O O
cell O O
line O O
32D O O
expressing O O
the O O
patient O O
's O O
mutated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
G-CSFR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
by O O
measuring O O
STAT5 O O
activation O O
in O O
nuclear O O
extracts O O
from O O
stimulated O O
cells O O
. O O

Human O O
renal O O
mesangial O O
cells O O
are O O
a O O
target O O
for O O
the O O
anti-inflammatory O O
action O O
of O O
9-cis O O
retinoic O O
acid O O
. O O

Mesangial O O
cells O O
play O O
an O O
active O O
role O O
in O O
the O O
inflammatory O O
response O O
to O O
glomerular O O
injury O O
. O O

9-cRA O O
inhibited O O
foetal O O
calf O O
serum-induced O O
CHMC O O
proliferation O O
. O O

Interestingly O O
, O O
the O O
retinoid O O
also O O
inhibited O O
in O O
FCS-stimulated O O
cells O O
the O O
protein O O
expression O O
of O O
two O O
mesangial B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adhesion I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
fibronectin B B_GENE
and O O
osteopontin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
it O O
did O O
not O O
modify O O
the O O
protein O O
expression O O
of O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
and O O
vascular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
. O O

All O O
major O O
RARs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RXRs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isotypes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
expressed O O
in O O
CHMC O O
regardless O O
of O O
the O O
presence O O
or O O
absence O O
of O O
9-cRA O O
. O O

Transcripts O O
to O O
RAR-alpha B B_GENE
, O O
RAR-beta B B_GENE
and O O
RXR-alpha B B_GENE/B_LOCATION
increased O O
after O O
incubation O O
with O O
9-cRA O O
whereas O O
RXR-gamma B B_GENE
was O O
inhibited O O
, O O
suggesting O O
a O O
major O O
role O O
for O O
RARs B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
RXRs B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
9-cRA-anti-inflammatory O O
effects O O
. O O

9-cRA O O
was O O
toxic O O
only O O
at O O
50 O O
microM O O
( O O
a O O
concentration O O
50 O O
- O O
5000 O O
times O O
higher O O
than O O
required O O
for O O
the O O
effects O O
above O O
) O O
. O O

Cell O O
death O O
occurred O O
by O O
apoptosis O O
, O O
whose O O
onset O O
was O O
associated O O
with O O
a O O
pronounced O O
increase O O
in O O
catalase O O
activity O O
and O O
reduced O O
glutathione O O
content O O
, O O
being O O
more O O
effectively O O
induced O O
by O O
all-trans O O
retinoic O O
acid O O
. O O

Expression O O
of O O
mammalian B B_GENE
defensin I I_GENE
genes I I_GENE
. O O

Antimicrobial O O
peptides O O
are O O
a O O
prevalent O O
mechanism O O
of O O
host O O
defense O O
found O O
throughout O O
nature O O
. O O

In O O
epithelial O O
cells O O
, O O
defensin B B_GENE/B_BIO
genes I I_GENE/I_BIO
are O O
found O O
as O O
both O O
constitutively O O
expressed O O
and O O
inducible O O
. O O

Induction O O
has O O
been O O
observed O O
in O O
vitro O O
by O O
stimulation O O
with O O
bacterial O O
lipopolysaccharide O O
as O O
well O O
as O O
inflammatory O O
mediators O O
. O O

In O O
vivo O O
, O O
up-regulation O O
of O O
several O O
defensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
occurs O O
in O O
both O O
infectious O O
and O O
inflammatory O O
states O O
. O O

Gene O O
regulation O O
occurs O O
via O O
signal O O
transduction O O
pathways O O
common O O
to O O
other O O
innate O O
immune O O
responses O O
, O O
utilizing O O
transcription B B_GENE
factors I I_GENE
such O O
as O O
nuclear B B_GENE
factor I I_GENE
( I I_GENE
NF I I_GENE
) I I_GENE
-kappaB I I_GENE
and O O
NF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interleukin-6 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Together O O
, O O
the O O
data O O
suggest O O
a O O
broad-based O O
innate O O
host O O
defense O O
whereby O O
potent O O
antimicrobial O O
peptides O O
are O O
present O O
to O O
prevent O O
initial O O
colonization O O
by O O
pathogenic O O
microorganisms O O
. O O

In O O
addition O O
, O O
the O O
recognition O O
of O O
bacteria O O
coupled O O
with O O
a O O
nascent O O
inflammatory O O
response O O
can O O
bolster O O
this O O
defense O O
by O O
a O O
coordinated O O
up-regulation O O
of O O
the O O
peptides O O
. O O

Multiple O O
signals O O
required O O
for O O
cyclic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AMP-responsive I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CREB B B_GENE/B_LOCATION
) O O
binding O O
protein O O
interaction O O
induced O O
by O O
CD3/CD28 O O
costimulation O O
. O O

The O O
optimal O O
activation O O
of O O
cAMP-responsive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CREB B B_GENE/B_LOCATION
) O O
, O O
similar O O
to O O
the O O
full O O
activation O O
of O O
T O O
lymphocytes O O
, O O
requires O O
the O O
stimulation O O
of O O
both O O
CD3 B B_GENE
and O O
CD28 B B_GENE
. O O

Using O O
a O O
reporter O O
system O O
to O O
detect O O
interaction O O
of O O
CREB B B_GENE
and O O
CREB-binding B B_GENE
protein I I_GENE
( O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
in O O
this O O
study O O
we O O
found O O
that O O
CREB B B_GENE
binds O O
to O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
by O O
engagement O O
of O O
both O O
CD3 B B_GENE
and O O
CD28 B B_GENE
. O O

CD3/CD28 B B_GENE
-promoted O O
CREB B B_GENE/B_LOCATION
- O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O O
was O O
dependent O O
on O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE/B_LOCATION
) O O
and O O
calcium/calmodulin-dependent B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CaMK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
addition O O
to O O
the O O
previously O O
identified O O
extracellular O O
signal-regulated O O
kinase O O
pathway O O
. O O

Extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CaMKIV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
p38 B B_GENE
MAPK I I_GENE
were O O
also O O
the O O
kinases O O
involved O O
in O O
CREB B B_GENE
Ser O O
( O O
133 O O
) O O
phosphorylation O O
induced O O
by O O
CD3/CD28 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
reconstitution O O
experiment O O
illustrated O O
that O O
optimum O O
CREB B B_GENE
- O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O O
and O O
CREB B B_GENE
trans-activation O O
were O O
attained O O
when O O
these O O
three O O
kinase O O
pathways O O
were O O
simultaneously O O
activated O O
in O O
T O O
cells O O
. O O

Our O O
results O O
demonstrate O O
that O O
coordinated O O
activation O O
of O O
different O O
kinases B B_GENE/B_LOCATION
leads O O
to O O
full O O
activation O O
of O O
CREB B B_GENE
. O O

Notably O O
, O O
CD28 O O
ligation O O
activated O O
p38 B B_GENE
MAPK I I_GENE
and O O
CaMKIV B B_GENE
, O O
the O O
kinases B B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
by O O
CD3 O O
engagement O O
, O O
suggesting O O
that O O
CD28 B B_GENE
acts O O
by O O
increasing O O
the O O
activation O O
extent O O
of O O
p38 B B_GENE
MAPK I I_GENE
and O O
CaMKIV B B_GENE
. O O

These O O
results O O
support O O
the O O
model O O
of O O
a O O
minimum O O
activation O O
threshold O O
for O O
CREB B B_GENE
- O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O O
that O O
can O O
be O O
reached O O
only O O
when O O
both O O
CD3 B B_GENE
and O O
CD28 B B_GENE
are O O
stimulated O O
. O O

The O O
murine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL-2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
distal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
responsive O O
to O O
the O O
Ah B B_GENE
receptor I I_GENE
, O O
a O O
member O O
of O O
the O O
evolutionarily O O
conserved O O
bHLH-PAS B B_GENE/B_LOCATION
transcription I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
family I I_GENE/I_LOCATION
. O O

Signaling O O
through O O
the O O
TCR B B_GENE
and O O
costimulatory O O
signals O O
primarily O O
control O O
transcription O O
of O O
the O O
IL-2 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
in O O
naive O O
T O O
cells O O
. O O

The O O
minimal B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
necessary O O
for O O
this O O
expression O O
lies O O
proximal O O
, O O
between O O
-300 O O
and O O
the O O
transcription B B_GENE/B_LOCATION
start I B_GENE/I_LOCATION
site I B_GENE/I_LOCATION
. O O

The O O
AHR B B_GENE/B_DISEASE
is O O
abundant O O
in O O
the O O
thymus O O
and O O
may O O
play O O
a O O
role O O
for O O
the O O
development O O
of O O
the O O
immune O O
system O O
. O O

Moreover O O
, O O
its O O
overactivation O O
by O O
chemicals O O
such O O
as O O
dioxins O O
leads O O
to O O
immunosuppression O O
and O O
thymic O O
involution O O
. O O

We O O
show O O
here O O
that O O
these O O
DNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
motifs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
so-called O O
dioxin B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elements I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
after O O
binding O O
to O O
the O O
liganded B B_GENE/B_BACTERIUM[BIO]
AHR I I_GENE/I_BACTERIUM[BIO]
are O O
sufficient O O
to O O
transactivate O O
luciferase O O
expression O O
in O O
a O O
reporter O O
gene O O
system O O
. O O

The O O
IL-2 B B_GENE/B_DISEASE
gene I I_GENE/I_DISEASE
can O O
be O O
induced O O
by O O
the O O
AHR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O O
in O O
thymocytes O O
in O O
vivo O O
after O O
injection O O
of O O
2 O O
, O O
3 O O
, O O
7 O O
, O O
8-tetrachlorodibenzo-p-dioxin O O
, O O
a O O
potent O O
ligand O O
of O O
the O O
AHR B B_GENE/B_DISEASE
. O O

The O O
AHR B B_GENE/B_DISEASE
mediates O O
the O O
IL-2 O O
induction O O
as O O
shown O O
with O O
AHR B B_GENE/B_DISEASE
-deficient O O
mice O O
. O O

However O O
, O O
in O O
spleen O O
cells O O
in O O
vitro O O
costimulation O O
via O O
the O O
TCR B B_GENE
is O O
necessary O O
for O O
optimal O O
IL-2 B B_GENE
gene I I_GENE
induction O O
. O O

To O O
monitor O O
changes O O
in O O
the O O
subcellular O O
distribution O O
of O O
Syk B B_GENE/B_BACTERIUM[BIO]
in O O
B O O
cells O O
responding O O
to O O
BCR B B_GENE
cross-linking O O
, O O
we O O
expressed O O
in O O
Syk B B_GENE/B_BACTERIUM[BIO]
-deficient O O
DT40 O O
B O O
cells O O
a O O
fusion B B_GENE
protein I I_GENE
consisting O O
of O O
Syk B B_GENE/B_BACTERIUM[BIO]
coupled O O
to O O
green B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Syk B B_GENE/B_BACTERIUM[BIO]
is O O
not O O
demonstrably O O
associated O O
with O O
the O O
internalized B B_DISEASE/B_GENE
receptor I I_DISEASE/I_GENE
. O O

Lyn B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
not O O
required O O
for O O
the O O
recruitment O O
of O O
Syk B B_GENE/B_BACTERIUM[BIO]
to O O
the O O
cross-linked B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
is O O
required O O
for O O
the O O
internalization O O
of O O
the O O
clustered O O
BCR B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Thus O O
, O O
Lyn B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appears O O
to O O
function O O
to O O
negatively O O
regulate O O
aspects O O
of O O
BCR B B_GENE
-dependent O O
signaling O O
by O O
stimulating O O
receptor O O
internalization O O
and O O
down-regulation O O
. O O

Renal O O
interstitial O O
fibrosis O O
is O O
reduced O O
in O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1a I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-deficient O O
mice O O
. O O

Unilateral O O
ureteral O O
obstruction O O
( O O
UUO O O
) O O
results O O
in O O
tubulointerstitial O O
fibrosis O O
of O O
the O O
affected O O
kidney O O
by O O
stimulating O O
the O O
renin-angiotensin O O
system O O
. O O

This O O
study O O
established O O
a O O
UUO O O
model O O
in O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1a I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AT1a B B_PROTEIN[GENE]/B_LOCATION
) O O
deficient O O
( O O
mutant O O
) O O
mice O O
to O O
elucidate O O
the O O
role O O
of O O
angiotensin B B_DISEASE/B_GENE
II I B_DISEASE/I_GENE
through O O
AT1a B B_GENE
on O O
the O O
fibrosis O O
of O O
the O O
obstructed O O
kidney O O
( O O
OBK O O
) O O
. O O

The O O
relative O O
volume O O
of O O
the O O
tubulointerstitium O O
was O O
measured O O
by O O
an O O
image O O
analyzer O O
; O O
deposition O O
of O O
collagen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
types I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
III I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
monocyte O O
/ O O
macrophage O O
infiltration O O
were O O
histologically O O
examined O O
using O O
specific B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Also O O
determined O O
were O O
the O O
mRNA O O
levels O O
of O O
transforming B B_GENE
growth I I_GENE
factor-beta I I_GENE
by O O
Northern O O
blot O O
analysis O O
. O O

Nuclear B B_GENE
factor-kappaB I I_GENE
activity O O
was O O
assessed O O
by O O
gel O O
shift O O
assay O O
. O O

UUO O O
in O O
wild O O
mice O O
resulted O O
in O O
a O O
marked O O
expansion O O
of O O
relative O O
volume O O
of O O
the O O
tubulointerstitium O O
, O O
together O O
with O O
increased O O
deposition O O
of O O
collagen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
types I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
III I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
number O O
of O O
infiltrated O O
monocytes O O
/ O O
macrophages O O
in O O
the O O
interstitium O O
, O O
relative O O
to O O
sham-operated O O
mice O O
. O O

In O O
comparison O O
, O O
these O O
changes O O
were O O
significantly O O
lower O O
in O O
mutant O O
mice O O
with O O
UUO O O
. O O

The O O
mRNA O O
level O O
of O O
transforming B B_GENE
growth I I_GENE
factor-beta I I_GENE
was O O
significantly O O
higher O O
in O O
the O O
OBK O O
of O O
wild O O
mice O O
with O O
UUO O O
compared O O
with O O
sham-operated O O
mice O O
. O O

In O O
contrast O O
, O O
the O O
increase O O
in O O
mRNA O O
level O O
in O O
the O O
OBK O O
of O O
mutant O O
mice O O
was O O
significantly O O
less O O
than O O
in O O
wild O O
mice O O
. O O

Finally O O
, O O
UUO O O
resulted O O
in O O
activation O O
of O O
nuclear B B_GENE
factor-kappaB I I_GENE
in O O
wild O O
mice O O
but O O
was O O
inhibited O O
in O O
the O O
OBK O O
of O O
mutant O O
mice O O
. O O

The O O
results O O
provide O O
direct O O
evidence O O
that O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acting O O
via O O
the O O
AT1a B B_PROTEIN[GENE]/B_LOCATION
plays O O
a O O
pivotal O O
role O O
in O O
the O O
development O O
of O O
tubulointerstitial O O
fibrosis O O
in O O
UUO O O
. O O

Ag-specific O O
CD4+ O O
T O O
cells O O
are O O
present O O
in O O
peripheral O O
blood O O
in O O
low O O
frequency O O
, O O
where O O
they O O
undergo O O
recruitment O O
and O O
expansion O O
during O O
immune O O
responses O O
and O O
in O O
the O O
pathogenesis O O
of O O
numerous O O
autoimmune O O
diseases O O
. O O

In O O
this O O
study O O
, O O
we O O
utilized O O
this O O
technology O O
to O O
identify O O
HLA B B_GENE
DQ I I_GENE
-restricted O O
Ag-specific O O
T O O
cells O O
in O O
the O O
peripheral O O
blood O O
of O O
human O O
subjects O O
and O O
to O O
identify O O
immunodominant O O
epitopes O O
associated O O
with O O
viral O O
infection O O
. O O

Although O O
the O O
VP16 O O
369-380 O O
peptide O O
has O O
a O O
lower O O
binding O O
affinity O O
for O O
DQ0602 B B_GENE
molecules I I_GENE
than O O
the O O
VP16 O O
33-52 O O
peptide O O
, O O
T O O
cells O O
that O O
recognized O O
the O O
VP16 O O
369-380 O O
peptide O O
occurred O O
at O O
a O O
much O O
higher O O
frequency O O
than O O
those O O
that O O
were O O
specific O O
for O O
the O O
VP16 O O
33-52 O O
peptide O O
. O O

Down-regulation O O
of O O
BOB.1/OBF.1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Oct2 B B_GENE
in O O
classical O O
Hodgkin O O
disease O O
but O O
not O O
in O O
lymphocyte O O
predominant O O
Hodgkin O O
disease O O
correlates O O
with O O
immunoglobulin O O
transcription O O
. O O

In O O
contrast O O
to O O
the O O
tumor O O
cells O O
( O O
L O O
& O O
H O O
cells O O
) O O
of O O
lymphocyte O O
predominant O O
Hodgkin O O
disease O O
( O O
LPHD O O
) O O
, O O
Hodgkin O O
and O O
Reed-Sternberg O O
( O O
HRS O O
) O O
cells O O
of O O
classical O O
Hodgkin O O
disease O O
( O O
cHD O O
) O O
are O O
unable O O
to O O
transcribe O O
immunoglobulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
despite O O
the O O
presence O O
of O O
rearranged B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
immunoglobulin I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Although O O
initial O O
studies O O
have O O
suggested O O
crippling O O
immunoglobulin O O
gene O O
mutations O O
to O O
be O O
the O O
cause O O
of O O
absent O O
immunoglobulin O O
expression O O
in O O
cHD O O
, O O
recent O O
work O O
of O O
our O O
group O O
has O O
demonstrated O O
an O O
impaired O O
activation O O
of O O
the O O
immunoglobulin B B_GENE
promoter I I_GENE
as O O
a O O
superior O O
mechanism O O
. O O

As O O
immunoglobulin O O
transcription O O
is O O
mainly O O
regulated O O
by O O
the O O
B-cell B B_GENE
transcription I I_GENE
factors I I_GENE
Oct2 B I_GENE
and O O
BOB.1/OBF.1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
analyzed O O
35 O O
cases O O
of O O
LPHD O O
, O O
32 O O
cases O O
of O O
cHD O O
, O O
and O O
2 O O
Hodgkin O O
disease O O
cell O O
lines O O
for O O
the O O
expression O O
of O O
these O O
transcription B B_GENE
factors I I_GENE
and O O
also O O
in O O
parallel O O
for O O
immunoglobulin O O
expression O O
. O O

Our O O
results O O
demonstrate O O
an O O
absence O O
of O O
Oct2 B B_GENE/B_DISEASE
and/or O O
BOB.1/OBF.1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cHD O O
and O O
a O O
striking O O
overexpression O O
of O O
Oct2 B B_GENE
in O O
LPHD O O
. O O

Furthermore O O
, O O
the O O
reintroduction O O
of O O
BOB.1/OBF.1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Oct2 B B_GENE
into O O
cultured O O
HRS O O
cells O O
restored O O
the O O
activity O O
of O O
cotransduced O O
immunoglobulin B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
constructs I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Our O O
findings O O
dismiss O O
the O O
concept O O
that O O
the O O
different O O
immunoglobulin O O
expression O O
in O O
cHD O O
and O O
LPHD O O
is O O
due O O
to O O
disrupting O O
mutations O O
of O O
immunoglobulin B B_GENE
V I I_GENE
genes I I_GENE
in O O
cHD O O
but O O
is O O
most O O
likely O O
due O O
to O O
a O O
down-regulation O O
of O O
Oct2 B B_GENE
and/or O O
BOB.1/OBF.1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
study O O
further O O
revealed O O
Oct2 B B_GENE
as O O
a O O
new O O
and O O
valuable O O
marker O O
for O O
the O O
identification O O
of O O
L O O
& O O
H O O
cells O O
and O O
their O O
distinction O O
from O O
HRS O O
cells O O
. O O

The O O
impairment O O
of O O
immunoglobulin O O
transcription O O
with O O
a O O
down-regulated O O
synthesis O O
of O O
Oct2 B B_GENE
and O O
BOB.1/OBF.1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
first O O
established O O
general O O
recurrent O O
defect O O
found O O
in O O
HRS O O
cells O O
. O O

Constitutive O O
expression O O
of O O
NF-kappa B B_GENE
B I I_GENE
is O O
a O O
characteristic O O
feature O O
of O O
mycosis O O
fungoides O O
: O O
implications O O
for O O
apoptosis O O
resistance O O
and O O
pathogenesis O O
. O O

The O O
NF-kappa B B_GENE
B I I_GENE
family I I_GENE
of I I_GENE
transcription I I_GENE
factors I I_GENE
is O O
an O O
important O O
regulator O O
of O O
genes O O
expressed O O
during O O
inflammatory O O
responses O O
, O O
immunoglobulin O O
( O O
Ig O O
) O O
class O O
switching O O
, O O
cellular O O
differentiation O O
, O O
and O O
apoptosis O O
. O O

Recently O O
, O O
members O O
of O O
the O O
NF-kappaB B B_GENE/B_BIO
family I I_GENE/I_BIO
, O O
including O O
p65 B B_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
, O O
have O O
been O O
implicated O O
in O O
promoting O O
survival O O
of O O
various O O
hematopoeitic O O
neoplasms O O
, O O
including O O
T O O
cell O O
malignancies O O
such O O
as O O
adult O O
T O O
cell O O
leukemia-lymphoma O O
. O O

We O O
investigated O O
the O O
expression O O
of O O
active B B_GENE
NF-kappa I I_GENE
B I I_GENE
p65 I I_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
in O O
cases O O
of O O
mycosis O O
fungoides O O
( O O
MF O O
) O O
and O O
the O O
effect O O
of O O
chemical O O
inhibitors O O
of O O
NF-kappa B B_GENE
B I I_GENE
on O O
apoptosis O O
in O O
cutaneous O O
T O O
cell O O
lymphoma O O
( O O
CTCL O O
) O O
cell O O
lines O O
. O O

Nuclear O O
expression O O
of O O
p65 B B_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
before O O
and O O
after O O
treatment O O
with O O
the O O
various O O
inhibitory O O
compounds O O
was O O
measured O O
by O O
immunofluorescence O O
staining O O
in O O
each O O
CTCL O O
cell O O
line O O
. O O

Neoplastic O O
T O O
lymphocytes O O
from O O
22 O O
of O O
24 O O
cases O O
of O O
MF O O
showed O O
strong O O
nuclear O O
and O O
cytoplasmic O O
expression O O
of O O
active B B_GENE
p65 I I_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
. O O

These O O
data O O
show O O
that O O
the O O
active O O
form O O
of O O
NF-kappa B B_GENE
B I I_GENE
p65 I I_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
is O O
commonly O O
expressed O O
in O O
neoplastic O O
T O O
lymphocytes O O
in O O
patients O O
with O O
MF O O
. O O

In O O
CTCL O O
cell O O
lines O O
, O O
the O O
significant O O
decrease O O
in O O
nuclear O O
NF-kappa O O
B O O
expression O O
and O O
the O O
marked O O
increase O O
in O O
spontaneous O O
apoptosis O O
caused O O
by O O
chemical O O
NF-kappa O O
B O O
inhibition O O
suggest O O
a O O
critical O O
role O O
for O O
NF-kappa B B_GENE
B I I_GENE
in O O
the O O
pathogenesis O O
and O O
tumor O O
cell O O
maintenance O O
of O O
CTCLs O O
. O O

HUM O O
PATHOL O O
31 O O
: O O
1482-1490 O O
. O O

Human O O
T-cell O O
leukemia O O
virus O O
type O O
1 O O
tax B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activates O O
transcription O O
through O O
AP-1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O O
inducing O O
DNA O O
binding O O
activity O O
in O O
T O O
cells O O
. O O

Human O O
T-cell O O
leukemia O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
Tax B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
the O O
expression O O
of O O
various O O
family O O
members O O
of O O
the O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
AP-1 I I_GENE/I_LOCATION
, O O
such O O
as O O
c-Jun B B_GENE
, O O
JunD B B_GENE/B_DISEASE
, O O
c-Fos B B_GENE
, O O
and O O
Fra-1 B B_GENE
, O O
at O O
the O O
level O O
of O O
RNA O O
expression O O
in O O
T O O
cells O O
. O O

We O O
examined O O
the O O
activity O O
of O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
transcription O O
through O O
AP-1-binding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
T O O
cells O O
. O O

Transient O O
transfection O O
studies O O
showed O O
that O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activated O O
the O O
expression O O
of O O
a O O
luciferase B B_GENE/B_MEASURE
gene I I_GENE/I_MEASURE
regulated O O
by O O
two O O
copies O O
of O O
an O O
AP-1 B B_GENE/B_MEASURE
site I I_GENE/I_MEASURE
in O O
the O O
human O O
Jurkat O O
T-cell O O
line O O
. O O

Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activates O O
the O O
expression O O
of O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cellular I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
through O O
two O O
different O O
enhancers O O
: O O
a O O
cAMP-responsive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CRE I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
kappaB B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
. O O

In O O
addition O O
, O O
Tax703 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
TaxM22 B B_GENE
, O O
converted O O
cell O O
growth O O
of O O
a O O
mouse O O
T-cell O O
line O O
from O O
being O O
interleukin O O
( O O
IL O O
) O O
-2-dependent O O
to O O
being O O
IL-2-independent O O
. O O

Thus O O
, O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
seems O O
to O O
activate O O
the O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O O
mechanisms O O
distinct O O
from O O
those O O
of O O
kappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CRE-like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
the O O
activation O O
of O O
the O O
AP-1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
dispensable O O
for O O
IL-2-independent O O
growth O O
of O O
CTLL-2 O O
. O O

The O O
binding B B_GENE/B_LOCATION
complex I I_GENE/I_LOCATION
induced O O
by O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
CTLL-2 O O
contained O O
JunD B B_GENE/B_DISEASE
and O O
Fra-2 B B_GENE/B_LOCATION
. O O

Activation O O
of O O
transcription O O
through O O
the O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Jurkat O O
cells O O
by O O
JunD B B_GENE/B_DISEASE
and/or O O
Fra-2 B B_GENE
was O O
weak O O
. O O

c-Jun B B_GENE
, O O
JunB B B_GENE/B_BACTERIUM[BIO]
, O O
and O O
c-Fos B B_GENE
activation O O
was O O
greater O O
, O O
although O O
the O O
level O O
was O O
still O O
less O O
than O O
that O O
with O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Thus O O
, O O
the O O
induction O O
of O O
AP-1 B B_GENE
mRNA I I_GENE
by O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
not O O
be O O
sufficient O O
for O O
a O O
complete O O
activation O O
of O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
results O O
suggest O O
that O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activates O O
the O O
transcription O O
of O O
cellular B B_GENE/B_LOCATION
genes I I_GENE/I_LOCATION
with O O
AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
inducing O O
the O O
DNA-binding O O
activity O O
of O O
AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
T O O
cells O O
, O O
a O O
mechanism O O
distinct O O
from O O
those O O
of O O
CRE-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappaB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

Live-attenuated O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
variants O O
have O O
shown O O
great O O
promise O O
as O O
AIDS O O
vaccines O O
, O O
but O O
continued O O
replication O O
can O O
lead O O
to O O
the O O
selection O O
of O O
faster-replicating O O
variants O O
that O O
are O O
pathogenic O O
. O O

This O O
was O O
achieved O O
by O O
replacement O O
of O O
the O O
viral O O
TAR-Tat O O
system O O
for O O
transcriptional O O
activation O O
by O O
the O O
Escherichia O O
coli-derived O O
Tet O O
system O O
for O O
inducible O O
gene O O
expression O O
. O O

These O O
designer O O
`` O O
HIV-rtTA O O
'' O O
viruses O O
replicate O O
in O O
a O O
strictly O O
dox-dependent O O
manner O O
both O O
in O O
a O O
T-cell O O
line O O
and O O
in O O
primary O O
blood O O
cells O O
, O O
and O O
the O O
rate O O
of O O
replication O O
can O O
be O O
fine-tuned O O
by O O
simple O O
variation O O
of O O
the O O
dox O O
concentration O O

These O O
HIV-rtTA O O
viruses O O
provide O O
a O O
tool O O
to O O
perform O O
genetics O O
, O O
e.g. O O
, O O
selection O O
and O O
optimization O O
experiments O O
, O O
with O O
the O O
E. O O
coli-derived O O
Tet O O
reagents O O
in O O
a O O
eukaryotic O O
background O O
. O O

Synovial O O
fluid O O
induced O O
nuclear B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
factor-kappaB I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DNA O O
binding O O
in O O
a O O
monocytic O O
cell O O
line O O
. O O

OBJECTIVE O O
: O O
To O O
determine O O
the O O
effects O O
of O O
synovial O O
fluids O O
( O O
SF O O
) O O
on O O
DNA O O
binding O O
activity O O
of O O
transcription B B_GENE
factor I I_GENE
nuclear B I_GENE
factor-kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
in O O
the O O
Mono O O
Mac O O
6 O O
monocytic/macrophage O O
cell O O
line O O
as O O
a O O
model O O
for O O
the O O
interaction O O
between O O
SF O O
and O O
synovial O O
tissue O O
macrophages O O
in O O
arthritis O O
. O O

METHODS O O
: O O
Mono O O
Mac O O
6 O O
cells O O
were O O
incubated O O
with O O
SF O O
from O O
the O O
knee O O
joints O O
of O O
human O O
subjects O O
with O O
rheumatoid O O
arthritis O O
( O O
RA O O
) O O
, O O
undifferentiated O O
seronegative O O
oligoarthritis O O
, O O
and O O
osteoarthritis O O
( O O
OA O O
) O O
. O O

Nuclear O O
extracts O O
prepared O O
from O O
the O O
Mono O O
Mac O O
6 O O
cells O O
and O O
RA O O
synovial O O
tissue O O
were O O
analyzed O O
by O O
electrophoretic O O
mobility O O
shift O O
analysis O O
( O O
EMSA O O
) O O
for O O
NF-kappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O O
: O O
Induction O O
of O O
NF-kappaB B B_GENE
DNA O O
binding O O
by O O
the O O
p65 B B_GENE
( I I_GENE
RelA I I_GENE
) I I_GENE
/p50 I I_GENE
heterodimer I I_GENE
was O O
observed O O
in O O
response O O
to O O
incubation O O
of O O
Mono O O
Mac O O
6 O O
cells O O
with O O
SF O O
( O O
20 O O
% O O
in O O
culture O O
medium O O
) O O
from O O
5 O O
of O O
8 O O
subjects O O
with O O
RA O O
, O O
4 O O
of O O
5 O O
with O O
OA O O
, O O
and O O
none O O
of O O
3 O O
with O O
undifferentiated O O
seronegative O O
oligoarthritis O O
. O O

Unexpectedly O O
, O O
a O O
slowly O O
migrating O O
SF O O
inducible O O
NF-kappaB B B_GENE
-binding O O
complex O O
was O O
observed O O
in O O
EMSA O O
of O O
Mono O O
Mac O O
6 O O
cells O O
after O O
incubation O O
with O O
SF O O
from O O
5 O O
of O O
8 O O
RA O O
and O O
2 O O
of O O
5 O O
OA O O
subjects O O
. O O

A O O
NF-kappaB-binding B B_PROTEIN[GENE]/B_MEASURE
complex I I_PROTEIN[GENE]/I_MEASURE
with O O
similar O O
slow O O
mobility O O
was O O
observed O O
in O O
nuclear O O
extracts O O
prepared O O
from O O
fresh O O
human O O
RA O O
synovial O O
tissue O O
. O O

CONCLUSION O O
: O O
Biological O O
activity O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
SF O O
from O O
RA O O
and O O
OA O O
subjects O O
is O O
capable O O
of O O
inducing O O
p65/p50 B B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
NF-kappaB I I_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
DNA O O
binding O O
activity O O
in O O
macrophages O O
. O O

Soluble O O
mediators O O
in O O
SF O O
of O O
subjects O O
with O O
RA O O
and O O
OA O O
can O O
therefore O O
modulate O O
binding O O
of O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
NF-kappaB B B_GENE
binding I I_GENE
site I I_GENE
in O O
macrophages O O
and O O
may O O
play O O
a O O
role O O
in O O
inflammatory O O
gene O O
expression O O
in O O
arthritis O O
. O O

Peroxisome B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor-gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
agonists O O
and O O
15-deoxy-Delta O O
( O O
12 O O
, O O
14 O O
) O O
( O O
12 O O
, O O
14 O O
) O O
-PGJ O O
( O O
2 O O
) O O
induce O O
apoptosis O O
in O O
normal O O
and O O
malignant O O
B-lineage O O
cells O O
. O O

The O O
research O O
described O O
herein O O
evaluates O O
the O O
expression O O
and O O
functional O O
significance O O
of O O
peroxisome B B_GENE
proliferator I I_GENE
activator I I_GENE
receptor-gamma I I_GENE
( I I_GENE
PPAR-gamma I I_GENE
) I I_GENE
on O O
B-lineage O O
cells O O
. O O

Normal O O
mouse O O
B O O
cells O O
and O O
a O O
variety O O
of O O
B O O
lymphoma O O
cells O O
reflective O O
of O O
stages O O
of O O
B O O
cell O O
differentiation O O
( O O
e.g. O O
, O O
70Z/3 O O
, O O
CH31 O O
, O O
WEHI-231 O O
, O O
CH12 O O
, O O
and O O
J558 O O
) O O
express O O
PPAR-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
, O O
by O O
Western O O
blot O O
analysis O O
, O O
the O O
67-kDa B B_GENE
PPAR-gamma I I_GENE
protein I I_GENE
. O O

15-Deoxy-Delta O O
( O O
12 O O
, O O
14 O O
) O O
-PGJ O O
( O O
2 O O
) O O
( O O
15d-PGJ O O
( O O
2 O O
) O O
) O O
, O O
a O O
PPAR-gamma O O
agonist O O
, O O
has O O
a O O
dose-dependent O O
antiproliferative O O
and O O
cytotoxic O O
effect O O
on O O
normal O O
and O O
malignant O O
B O O
cells O O
as O O
shown O O
by O O
[ O O
( O O
3 O O
) O O
H O O
] O O
thymidine O O
and O O
3- O O
[ O O
4 O O
, O O
5-dimethylthiazol-2-yl O O
] O O
-2 O O
, O O
5-diphenyltetrazolium O O
bromide O O
assays O O
. O O

Only O O
PPAR-gamma O O
agonists O O
( O O
thiazolidinediones O O
) O O
, O O
and O O
not O O
PPAR-alpha O O
agonists O O
, O O
mimicked O O
the O O
effect O O
of O O
15d-PGJ O O
( O O
2 O O
) O O
on O O
B-lineage O O
cells O O
, O O
indicating O O
that O O
the O O
mechanism O O
by O O
which O O
15d-PGJ O O
( O O
2 O O
) O O
negatively O O
affects O O
B-lineage O O
cells O O
involves O O
in O O
part O O
PPAR-gamma B B_GENE
. O O

PPAR-gamma O O
agonists O O
may O O
serve O O
as O O
a O O
counterbalance O O
to O O
the O O
stimulating O O
effects O O
of O O
other O O
PGs O O
, O O
namely O O
PGE O O
( O O
2 O O
) O O
, O O
which O O
promotes O O
B O O
cell O O
differentiation O O
. O O

Finally O O
, O O
the O O
use O O
of O O
PGs O O
, O O
such O O
as O O
15d-PGJ O O
( O O
2 O O
) O O
, O O
and O O
synthetic O O
PPAR-gamma O O
agonists O O
to O O
induce O O
apoptosis O O
in O O
B-lineage O O
cells O O
may O O
lead O O
to O O
the O O
development O O
of O O
novel O O
therapies O O
for O O
fatal O O
B O O
lymphomas O O

These O O
leukemic O O
cells O O
are O O
resistant O O
to O O
Fas-mediated O O
apoptosis O O
despite O O
expressing O O
high O O
levels O O
of O O
Fas B B_GENE
. O O

We O O
found O O
that O O
leukemic O O
LGL O O
from O O
19 O O
patients O O
displayed O O
high O O
levels O O
of O O
activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
STAT3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Treatment O O
of O O
leukemic O O
LGL O O
with O O
the O O
JAK-selective O O
tyrosine O O
kinase O O
inhibitor O O
AG-490 O O
induced O O
apoptosis O O
with O O
a O O
corresponding O O
decrease O O
in O O
STAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-DNA O O
binding O O
activity O O
. O O

Activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
STAT3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
shown O O
to O O
bind O O
an O O
SIE-related B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
murine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mcl-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Using O O
a O O
luciferase O O
reporter O O
assay O O
, O O
we O O
demonstrated O O
that O O
v-src O O
overexpression O O
in O O
NIH3T3 O O
induced O O
STAT3 B B_GENE
-dependent O O
transcriptional O O
activity O O
from O O
the O O
mcl-1 B B_GENE
promoter I I_GENE
and O O
increased O O
endogenous O O
Mcl-1 O O
protein O O
levels O O
. O O

We O O
conclude O O
that O O
STAT3 B B_GENE
activation O O
contributed O O
to O O
accumulation O O
of O O
the O O
leukemic O O
LGL O O
clones O O
. O O

These O O
findings O O
suggest O O
that O O
investigation O O
should O O
focus O O
on O O
novel O O
strategies O O
targeting O O
STAT3 B B_GENE
in O O
the O O
treatment O O
of O O
LGL O O
leukemia O O
. O O

Decreased O O
immediate O O
inflammatory B B_GENE/B_DISEASE
gene I I_GENE/I_DISEASE
induction O O
in O O
activating B B_GENE/B_PERSON
transcription I I_GENE/I_PERSON
factor-2 I I_GENE/I_PERSON
mutant O O
mice O O
. O O

Transcription B B_GENE
factor I I_GENE
activating I I_GENE
transcription I I_GENE
factor I I_GENE
( I I_GENE
ATF I I_GENE
) I I_GENE
-2 I I_GENE
is O O
activated O O
by O O
inflammatory O O
signals O O
transduced O O
by O O
the O O
JNK O O
and O O
p38 O O
MAP O O
kinase O O
pathways O O
. O O

Within O O
3 O O
h O O
of O O
challenge O O
by O O
LPS O O
, O O
ATF-2 O O
mutant O O
mice O O
had O O
decreased O O
induction O O
of O O
the O O
adhesion B B_GENE
molecules I I_GENE
E-selectin B I_GENE
, O O
P-selectin B B_GENE
and O O
VCAM-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
as O O
well O O
as O O
the O O
cytokines B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumor B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necrosis I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor-alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL-1beta B B_GENE
and O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
compared O O
with O O
control O O
mice O O
. O O

Stimulation O O
of O O
T O O
lymphocytes O O
by O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O O
showed O O
less O O
induction O O
of O O
IL-1 B B_GENE
and O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
ATF-2 O O
mutant O O
tissues O O
. O O

ATF-2 O O
mutant O O
thymocytes O O
treated O O
with O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
vitro O O
demonstrated O O
reduced O O
induction O O
of O O
c-Jun B B_GENE
, O O
JunB B B_GENE/B_BACTERIUM[BIO]
, O O
JunD B B_GENE/B_DISEASE
and O O
Fra-2 B B_GENE
. O O

However O O
, O O
similar O O
to O O
what O O
was O O
observed O O
after O O
p38 O O
kinase O O
inhibition O O
in O O
normal O O
mice O O
, O O
relative O O
ATF-2 O O
deficiency O O
did O O
not O O
prevent O O
the O O
development O O
of O O
a O O
mononuclear O O
cell O O
infiltrate O O
in O O
the O O
week O O
following O O
an O O
inflammatory O O
stimulus O O
. O O

ATF-2 O O
mutant O O
mice O O
proved O O
more O O
susceptible O O
to O O
death O O
than O O
control O O
mice O O
from O O
LPS O O
plus O O
D-galactosamine O O
injection O O
or O O
Coxsackievirus O O
B3 O O
infection O O
and O O
had O O
a O O
higher O O
incidence O O
of O O
mononuclear O O
pulmonary O O
infiltrates O O
after O O
exposure O O
to O O
Herpes O O
simplex O O
virus-1 O O
. O O

ATF-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
essential O O
for O O
maximal O O
immediate O O
induction O O
of O O
adhesion B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cytokine B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
, O O
but O O
at O O
later O O
time O O
points O O
may O O
even O O
protect O O
against O O
overactive O O
immune O O
responses O O
. O O

LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
TNF-like B B_GENE
molecule I I_GENE
, O O
costimulates O O
T O O
cell O O
proliferation O O
and O O
is O O
required O O
for O O
dendritic O O
cell O O
-mediated O O
allogeneic O O
T O O
cell O O
response O O
. O O

LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
recently O O
identified O O
member O O
of O O
the O O
TNF B B_GENE/B_BIO
superfamily I I_GENE/I_BIO
and O O
its O O
receptors O O
, O O
herpesvirus B B_GENE
entry I I_GENE
mediator I I_GENE
and O O
lymphotoxin B B_GENE
beta I I_GENE
receptor I I_GENE
, O O
are O O
found O O
in O O
T O O
cells O O
and O O
stromal O O
cells O O
. O O

In O O
this O O
study O O
, O O
we O O
demonstrate O O
that O O
LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
selectively O O
expressed O O
on O O
immature O O
dendritic O O
cells O O
( O O
DCs O O
) O O
generated O O
from O O
human O O
PBMCs O O
. O O

In O O
contrast O O
, O O
LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
detectable O O
in O O
DCs O O
either O O
freshly O O
isolated O O
from O O
PBMCs O O
or O O
rendered O O
mature O O
in O O
vitro O O
by O O
LPS O O
treatment O O
. O O

Furthermore O O
, O O
engagement O O
of O O
LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
costimulates O O
human O O
T O O
cell O O
proliferation O O
, O O
amplifies O O
the O O
NF-kappaB O O
signaling O O
pathway O O
, O O
and O O
preferentially O O
induces O O
the O O
production O O
of O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
IL-4 B B_GENE
, O O
in O O
the O O
presence O O
of O O
an O O
antigenic O O
signal O O
. O O

Our O O
results O O
suggest O O
that O O
LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
costimulatory B B_GENE/B_LOCATION
molecule I I_GENE/I_LOCATION
involved O O
in O O
DC O O
-mediated O O
cellular O O
immune O O
responses O O
. O O

Activity O O
of O O
the O O
distal B B_GENE/B_BIO
region I I_GENE/I_BIO
of O O
the O O
human O O
immunodeficiency O O
virus O O
( O O
HIV-1 O O
) O O
long B B_GENE
terminal I I_GENE
repeat I I_GENE
( O O
LTR B B_GENE/B_DISEASE
) O O
, O O
which O O
contains O O
binding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
Ets-1 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
USF-1 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
integral O O
for O O
HIV-1 O O
replication O O
. O O

The O O
Ets-1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
USF-1 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
play O O
a O O
critical O O
role O O
in O O
the O O
activity O O
of O O
the O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
distal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
indicated O O
by O O
the O O
potent O O
dominant O O
negative O O
effect O O
of O O
a O O
mutant B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Ets-1 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
lacking I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
trans-activation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
domains I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
on O O
the O O
transcriptional O O
activity O O
of O O
the O O
LTR B B_GENE/B_DISEASE
. O O

To O O
determine O O
the O O
biological O O
relevance O O
of O O
the O O
Ets-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
USF-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
HIV-1 O O
replication O O
, O O
we O O
examined O O
the O O
effect O O
of O O
expression O O
of O O
the O O
dominant-negative O O
mutant O O
of O O
Ets-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
dnEts-1 B B_PROTEIN[GENE]
) O O
on O O
HIV-1 O O
infection O O
of O O
T O O
cells O O
. O O

We O O
demonstrated O O
that O O
expression O O
of O O
dnEts B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markedly O O
suppressed O O
HIV-1 O O
infection O O
of O O
a O O
T O O
cell O O
line O O
. O O

This O O
finding O O
indicates O O
that O O
formation O O
of O O
a O O
transcriptionaly B B_GENE/B_LOCATION
active I B_GENE/I_LOCATION
USF-1/Ets-1 I B_GENE/I_LOCATION
complex I B_GENE/I_LOCATION
is O O
important O O
in O O
the O O
productive O O
infection O O
of O O
cells O O
by O O
HIV-1 O O
, O O
and O O
suggests O O
that O O
inhibition O O
of O O
the O O
interaction O O
between O O
USF-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Ets-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
provide O O
a O O
new O O
target O O
for O O
anti-HIV-1 O O
gene O O
therapy O O
. O O

Human O O
eosinophils O O
constitutively O O
express O O
nuclear B B_GENE
factor I I_GENE
of I I_GENE
activated I I_GENE
T I I_GENE
cells I I_GENE
p I I_GENE
and I I_GENE
c I I_GENE
. O O

The O O
expression O O
of O O
almost O O
all O O
of O O
the O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
produced O O
by O O
eosinophils O O
, O O
including O O
the O O
proallergic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
now O O
known O O
to O O
be O O
regulated O O
at O O
the O O
level O O
of O O
transcription O O
by O O
members O O
of O O
the O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NFAT B B_GENE/B_LOCATION
) O O
family O O
of O O
transcription O O
factors O O
. O O

OBJECTIVE O O
: O O
We O O
sought O O
to O O
characterize O O
the O O
expression O O
of O O
different O O
NFAT B B_GENE
proteins I I_GENE
in O O
resting O O
and O O
activated O O
eosinophils O O
. O O

METHODS O O
: O O
Nuclear O O
and O O
whole O O
cell O O
extracts O O
were O O
obtained O O
from O O
both O O
peripheral O O
blood O O
eosinophils O O
and O O
those O O
obtained O O
from O O
bronchoalveolar O O
lavage O O
fluid O O
of O O
asthmatic O O
subjects O O
after O O
endobronchial O O
allergen O O
challenge O O
. O O

NFAT B B_GENE
expression O O
was O O
determined O O
by O O
using O O
immunoprecipitation O O
and O O
Western O O
blot O O
analysis O O
, O O
DNA-binding O O
assays O O
, O O
and O O
RT-PCR O O
analysis O O
of O O
eosinophil B B_GENE
mRNA I I_GENE
. O O

RESULTS O O
: O O
Both O O
peripheral O O
blood O O
and O O
bronchoalveolar O O
lavage O O
fluid O O
eosinophils O O
expressed O O
NFATp B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NFATc I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O O
, O O
eosinophils O O
were O O
found O O
to O O
constitutively O O
express O O
NFATc B B_GENE
mRNA I I_GENE
. O O

A O O
brief O O
incubation O O
with O O
the O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
H I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-4 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IL-5 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
sufficient O O
to O O
induce O O
the O O
nuclear O O
translocation O O
of O O
NFATc B B_GENE
. O O

Eosinophil O O
nuclear O O
extracts O O
contain O O
multiple O O
factors O O
that O O
can O O
specifically O O
recognize O O
the O O
IL-4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NFAT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
DNA-binding O O
assays O O
, O O
including O O
NFATp B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSION O O
: O O
NFATp B B_GENE
and O O
NFATc B B_GENE
can O O
regulate O O
the O O
expression O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
other O O
genes O O
in O O
eosinophils O O
but O O
appear O O
to O O
be O O
regulated O O
by O O
a O O
novel O O
signal O O
transduction O O
mechanism O O
in O O
these O O
cells O O
. O O

BLyS B B_GENE/B_DISEASE
BINDS O O
TO O O
B O O
CELLS O O
WITH O O
HIGH O O
AFFINITY O O
AND O O
INDUCES O O
ACTIVATION O O
OF O O
THE O O
TRANSCRIPTION B B_LOCATION/B_GENE
FACTORS I I_LOCATION/I_GENE
NF-kappaB B I_LOCATION/I_GENE
AND O O
ELF-1 B B_GENE
. O O

BLyS B B_GENE/B_DISEASE
was O O
shown O O
to O O
act O O
specifically O O
on O O
B O O
cells O O
, O O
inducing O O
proliferation O O
and O O
immunoglobulin O O
production O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

Analysis O O
of O O
equilibrium O O
binding O O
of O O
( B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
125 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
I-labeled I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
BLyS I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
purified O O
human O O
tonsillar O O
B O O
cells O O
demonstrated O O
saturable O O
binding O O
. O O

In O O
addition O O
we O O
report O O
that O O
BLyS B B_GENE/B_DISEASE
binding O O
to O O
B O O
cells O O
results O O
in O O
the O O
activation O O
of O O
NF-kappaB B B_GENE
and O O
the O O
Ets B B_GENE/B_PERSON
family I I_GENE/I_PERSON
transcription I I_GENE/I_PERSON
factor I I_GENE/I_PERSON
, O O
ELF-1 B B_GENE
, O O
and O O
in O O
the O O
induction O O
of O O
mRNA O O
for O O
Polo-like B B_GENE
kinase I I_GENE
( O O
PLK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

Design O O
and O O
use O O
of O O
an O O
inducibly O O
activated O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
Nef B B_BIO/B_GENE
to O O
study O O
immune O O
modulation O O
. O O

The O O
Nef B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
has O O
been O O
shown O O
to O O
enhance O O
the O O
infectivity O O
of O O
virus O O
particles O O
, O O
downmodulate O O
cell B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
surface I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
and O O
associate O O
with O O
many O O
intracellular B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
are O O
thought O O
to O O
facilitate O O
HIV O O
infection O O
. O O

One O O
of O O
the O O
challenges O O
in O O
defining O O
the O O
molecular O O
events O O
regulated O O
by O O
Nef B B_GENE/B_BACTERIUM[BIO]
has O O
been O O
obtaining O O
good O O
expression O O
of O O
Nef B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
T O O
cells O O
. O O

We O O
have O O
designed O O
a O O
Nef B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
is O O
readily O O
expressed O O
in O O
T-cell O O
lines O O
and O O
whose O O
function O O
is O O
inducibly O O
activated O O
. O O

It O O
is O O
composed O O
of O O
a O O
fusion O O
between O O
full-length B B_GENE
Nef I I_GENE
and O O
the O O
estrogen B B_PROTEIN[GENE]/B_LOCATION
receptor I I_PROTEIN[GENE]/I_LOCATION
hormone-binding I I_PROTEIN[GENE]/I_LOCATION
domain I I_PROTEIN[GENE]/I_LOCATION
( O O
Nef-ER B B_GENE/B_DISEASE
) O O
. O O

The O O
Nef-ER B B_ENZYME[GENE]/B_LOCATION
is O O
kept O O
in O O
an O O
inactive O O
state O O
due O O
to O O
steric O O
hindrance O O
, O O
and O O
addition O O
of O O
the O O
membrane-permeable O O
drug O O
4-hydroxytamoxifen O O
( O O
4-HT O O
) O O
, O O
which O O
binds O O
to O O
the O O
ER B B_GENE
domain I I_GENE
, O O
leads O O
to O O
inducible O O
activation O O
of O O
Nef-ER B B_GENE/B_LOCATION
within O O
cells O O
. O O

We O O
demonstrate O O
that O O
Nef-ER B B_GENE
inducibly O O
associates O O
with O O
the O O
62-kDa B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
Ser/Thr I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
kinase I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
is O O
localized O O
to O O
specific O O
membrane O O
microdomains O O
( O O
lipid O O
rafts O O
) O O
only O O
after O O
activation O O
. O O

Half-maximal O O
downmodulation O O
of O O
cell B B_GENE
surface I I_GENE
CD4 I I_GENE
required O O
very O O
little O O
active O O
Nef-ER B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
occurred O O
as O O
early O O
as O O
4 O O
h O O
after O O
addition O O
of O O
4-HT O O
. O O

The O O
differential O O
timing O O
of O O
CD4 B B_GENE/B_DISEASE
and O O
HLA-A2 B B_GENE
downmodulation O O
may O O
have O O
implications O O
for O O
HIV O O
pathogenesis O O
and O O
immune O O
evasion O O
. O O

Environmental O O
and O O
occupational O O
exposure O O
to O O
vanadium O O
dusts O O
results O O
in O O
toxic O O
effects O O
mainly O O
confined O O
to O O
the O O
respiratory O O
system O O
. O O

Using O O
a O O
rat O O
model O O
of O O
acute O O
lung O O
inflammation O O
induced O O
by O O
intratracheal O O
instillation O O
of O O
sodium O O
metavanadate O O
( O O
NaVO3 O O
) O O
at O O
the O O
dose O O
of O O
200 O O
microg O O
V/kg O O
, O O
we O O
investigated O O
the O O
relationship O O
between O O
the O O
cytologic O O
characterization O O
of O O
pulmonary O O
inflammation O O
and O O
the O O
expression O O
of O O
chemokine B B_GENE
mRNA I I_GENE
. O O

In O O
contrast O O
, O O
neither O O
PMNs O O
nor O O
AMs O O
changed O O
substantially O O
1 O O
h O O
after O O
NaVO3 O O
instillation O O
. O O

By O O
Northern O O
analysis O O
, O O
macrophage B B_GENE
inflammatory I I_GENE
protein I I_GENE
( I I_GENE
MIP I I_GENE
) I I_GENE
-2 I I_GENE
mRNA I I_GENE
in O O
BAL O O
cells O O
increased O O
markedly O O
1 O O
h O O
after O O
NaVO3 O O
instillation O O
and O O
reduced O O
a O O
little O O
bit O O
at O O
4 O O
h O O
, O O
whereas O O
MIP-1alpha B B_GENE/B_LOCATION
mRNA I I_GENE/I_LOCATION
in O O
BAL O O
cells O O
was O O
expressed O O
relatively O O
high O O
1 O O
h O O
after O O
NaVO3 O O
instillation O O
, O O
although O O
a O O
basal O O
expression O O
was O O
detected O O
in O O
control O O
group O O
, O O
and O O
returned O O
rapidly O O
nearly O O
to O O
control O O
level O O
at O O
4 O O
h O O
. O O

Since O O
MIP-2 B B_GENE
is O O
a O O
potent O O
PMN O O
chemoattractant O O
and O O
MIP-1alpha B B_GENE
is O O
a O O
potent O O
macrophage/monocyte O O
chemoattractant O O
has O O
been O O
well O O
known O O
. O O

To O O
delineate O O
the O O
mechanisms O O
of O O
transcriptional O O
activation O O
, O O
we O O
recently O O
cloned O O
the O O
5'-flanking B B_GENE/B_LOCATION
region I I_GENE/I_LOCATION
of O O
the O O
MIP-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
promotor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
consensus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
transcription B B_GENE
factor I I_GENE
nuclear I I_GENE
factor I I_GENE
kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
and O O
activator B B_GENE
protein-1 I I_GENE
( O O
AP-1 B B_GENE/B_DISEASE
) O O
. O O

Using O O
electrophoretic O O
mobility O O
shift O O
assay O O
, O O
increased O O
nuclear O O
NF-kappaB B B_GENE
, O O
not O O
AP-1 B B_GENE
, O O
binding O O
activity O O
was O O
detected O O
1 O O
h O O
after O O
NaVO3 O O
instillation O O
, O O
which O O
correlated O O
with O O
the O O
induction O O
of O O
MIP-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

p65 B B_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
and O O
p50 B B_GENE/B_BIO
protein I I_GENE/I_BIO
appears O O
to O O
be O O
involved O O
in O O
MIP-2 O O
NF-kappaB B B_GENE
binding O O
. O O

Taken O O
together O O
, O O
our O O
studies O O
suggest O O
that O O
MIP-2 B B_GENE
is O O
an O O
important O O
mediator O O
of O O
NaVO3-induced O O
pulmonary O O
inflammation O O
in O O
the O O
rat O O
model O O
. O O

In O O
addition O O
, O O
elevated O O
MIP-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
are O O
accompanied O O
by O O
increased O O
NF-kappaB B B_GENE
binding O O
activity O O
in O O
BAL O O
cells O O
, O O
suggesting O O
possible O O
MIP-2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcriptional O O
regulation O O
through O O
NF-kappaB B B_GENE
. O O

Persistent O O
activation O O
of O O
the O O
immune O O
system O O
is O O
one O O
of O O
the O O
hallmarks O O
of O O
HIV-1 O O
infection O O
. O O

In O O
this O O
study O O
we O O
analysed O O
the O O
induction O O
of O O
factors O O
involved O O
in O O
cytokine O O
signal O O
transduction O O
, O O
such O O
as O O
STAT B B_GENE
1 I I_GENE
proteins I I_GENE
and O O
IRF-1 B B_GENE
mRNA I I_GENE
, O O
in O O
normal O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMC O O
) O O
exposed O O
to O O
HIV-infected O O
cells O O
, O O
and O O
the O O
induction O O
of O O
apoptosis O O
. O O

Western O O
blot O O
analyses O O
and O O
reverse O O
transcriptase-polymerase O O
chain O O
reaction O O
results O O
indicate O O
that O O
both O O
cells O O
infected O O
with O O
a O O
X4 O O
strain O O
and O O
cells O O
infected O O
with O O
a O O
R5 O O
strain O O
are O O
able O O
to O O
increase O O
intracellular O O
levels O O
of O O
STAT B B_GENE/B_PERSON
1alpha I I_GENE/I_PERSON
and I I_GENE/I_PERSON
beta I I_GENE/I_PERSON
proteins O O
as O O
well O O
as O O
IRF-1 B B_GENE
mRNA I I_GENE
. O O

This O O
effect O O
was O O
prevented O O
by O O
neutralizing O O
antibodies O O
against O O
interferon-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IFN-alpha B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

HIV-1-infected O O
cells O O
dose-dependently O O
induced O O
apoptotic O O
commitment O O
in O O
normal O O
PBMC O O
, O O
as O O
revealed O O
by O O
DNA O O
fragmentation O O
analysis O O
, O O
but O O
this O O
was O O
not O O
accompanied O O
by O O
an O O
increase O O
of O O
caspase-3 O O
activity O O
, O O
even O O
if O O
a O O
slight O O
up-regulation O O
of O O
IL-1beta-converting B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
detected O O
. O O

All O O
these O O
findings O O
suggest O O
that O O
uninfected O O
PBMC O O
can O O
undergo O O
activation O O
of O O
signal O O
transduction O O
and O O
apoptosis O O
after O O
exposure O O
to O O
bystander O O
HIV-infected O O
cells O O
, O O
subsequent O O
to O O
the O O
induction O O
of O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
such O O
as O O
IFNs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
physical O O
association O O
of O O
protein B B_GENE
kinase I I_GENE
C I I_GENE
theta I I_GENE
with O O
a O O
lipid O O
raft-associated O O
inhibitor O O
of O O
kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IKK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plays O O
a O O
role O O
in O O
the O O
activation O O
of O O
the O O
NF-kappa O O
B O O
cascade O O
by O O
TCR B B_GENE
and O O
CD28 B B_GENE
. O O

We O O
investigated O O
the O O
role O O
of O O
protein B B_GENE
kinase I I_GENE
C I I_GENE
theta I I_GENE
( O O
PKCtheta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
the O O
activation O O
of O O
the O O
NF-kappaB B B_GENE/B_DISEASE
cascade O O
in O O
primary O O
human O O
CD4 O O
( O O
+ O O
) O O
lymphocytes O O
. O O

Signaling O O
via O O
both O O
the O O
TCR B B_GENE
and O O
CD28 B B_GENE
is O O
required O O
for O O
optimal O O
activation O O
of O O
the O O
multisubunit B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IkappaB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IKK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
primary O O
human O O
T O O
lymphocytes O O
; O O
this O O
activation O O
could O O
be O O
inhibited O O
by O O
a O O
Ca O O
( O O
2+ O O
) O O
-independent O O
PKC O O
isoform O O
inhibitor O O
, O O
rottlerin O O
. O O

Moreover O O
, O O
endogenous O O
PKCtheta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
physically O O
associates O O
with O O
activated O O
IKK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
CD3/CD28-costimulated O O
primary O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
. O O

The O O
same O O
set O O
of O O
stimuli O O
also O O
induced O O
relocation O O
of O O
endogenous O O
PKCtheta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IKKs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
a O O
GM1 O O
ganglioside-enriched O O
, O O
detergent-insoluble O O
membrane O O
compartment O O
in O O
primary O O
T O O
cells O O
. O O

Confocal O O
microscopy O O
further O O
demonstrated O O
that O O
exogenously O O
expressed O O
PKCtheta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IKKss B B_GENE
colocalize O O
in O O
the O O
membrane O O
of O O
CD3/CD28-costimulated O O
Jurkat O O
T O O
cells O O
. O O

Constitutively O O
active O O
but O O
not O O
kinase-inactive B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
PKCtheta I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activated O O
IKKbeta B B_GENE
in O O
Jurkat O O
T O O
cells O O
. O O

Expression O O
of O O
dominant-active B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PKCtheta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O O
had O O
stimulatory O O
effects O O
on O O
the O O
CD28 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
IL-2 B B_GENE
promoter I I_GENE
. O O

Taken O O
together O O
, O O
these O O
data O O
show O O
that O O
the O O
activation O O
of O O
PKCtheta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
the O O
TCR B B_GENE
and O O
CD28 B B_GENE
plays O O
an O O
important O O
role O O
in O O
the O O
assembly O O
and O O
activation O O
of O O
IKK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
T O O
cell O O
membrane O O

T-cell O O
-mediated O O
regulation O O
of O O
osteoclastogenesis O O
by O O
signalling O O
cross-talk O O
between O O
RANKL B B_GENE
and O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Bone O O
resorption O O
is O O
regulated O O
by O O
the O O
immune O O
system O O
, O O
where O O
T-cell O O
expression O O
of O O
RANKL B B_GENE
( O O
receptor B B_GENE/B_DISEASE
activator I I_GENE/I_DISEASE
of I I_GENE/I_DISEASE
nuclear I I_GENE/I_DISEASE
factor I I_GENE/I_DISEASE
( I I_GENE/I_DISEASE
NF I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
-kappaB I I_GENE/I_DISEASE
ligand I I_GENE/I_DISEASE
) O O
, O O
a O O
member O O
of O O
the O O
tumour-necrosis B B_GENE/B_BIO
factor I I_GENE/I_BIO
family I I_GENE/I_BIO
that O O
is O O
essential O O
for O O
osteoclastogenesis O O
, O O
may O O
contribute O O
to O O
pathological O O
conditions O O
, O O
such O O
as O O
autoimmune O O
arthritis O O
. O O

However O O
, O O
whether O O
activated O O
T O O
cells O O
maintain O O
bone O O
homeostasis O O
by O O
counterbalancing O O
the O O
action O O
of O O
RANKL B B_GENE
remains O O
unknown O O
. O O

Here O O
we O O
show O O
that O O
T-cell O O
production O O
of O O
interferon B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IFN I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
strongly O O
suppresses O O
osteoclastogenesis O O
by O O
interfering O O
with O O
the O O
RANKL B B_GENE
-RANK O O
signalling O O
pathway O O
. O O

IFN-gamma B B_DISEASE/B_GENE
induces O O
rapid O O
degradation O O
of O O
the O O
RANK B B_ENZYME[GENE]/B_PERSON
adapter I I_ENZYME[GENE]/I_PERSON
protein I I_ENZYME[GENE]/I_PERSON
, O O
TRAF6 B B_GENE
( O O
tumour B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor-associated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
which O O
results O O
in O O
strong O O
inhibition O O
of O O
the O O
RANKL B B_GENE
-induced O O
activation O O
of O O
the O O
transcription B B_GENE
factor I I_GENE
NF-kappaB B I_GENE
and O O
JNK B B_GENE
. O O

Furthermore O O
, O O
we O O
provide O O
evidence O O
that O O
the O O
accelerated O O
degradation O O
of O O
TRAF6 B B_GENE
requires O O
both O O
its O O
ubiquitination O O
, O O
which O O
is O O
initiated O O
by O O
RANKL B B_GENE
, O O
and O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-induced O O
activation O O
of O O
the O O
ubiquitin-proteasome O O
system O O
. O O

Our O O
results O O
may O O
offer O O
a O O
therapeutic O O
approach O O
to O O
treat O O
the O O
inflammation-induced O O
tissue O O
breakdown O O
. O O

Stromal-derived B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
thrombopoietin B B_GENE
regulate O O
distinct O O
aspects O O
of O O
human O O
megakaryopoiesis O O
. O O

The O O
role O O
of O O
the O O
chemokine B B_GENE
binding O O
stromal-derived B B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I I_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I I_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
SDF-1 B B_GENE
) O O
in O O
normal O O
human O O
megakaryopoiesis O O
at O O
the O O
cellular O O
and O O
molecular O O
levels O O
and O O
its O O
comparison O O
with O O
that O O
of O O
thrombopoietin B B_GENE
( O O
TPO B B_PROTEIN[GENE]
) O O
have O O
not O O
been O O
determined O O
. O O

In O O
this O O
study O O
it O O
was O O
found O O
that O O
SDF-1 B B_GENE/B_LOCATION
, O O
unlike O O
TPO B B_GENE
, O O
does O O
not O O
stimulate O O
alpha O O
( O O
IIb O O
) O O
beta O O
( O O
3 O O
) O O
( O O
+ O O
) O O
cell O O
proliferation O O
or O O
differentiation O O
or O O
have O O
an O O
antiapoptotic O O
effect O O
. O O

However O O
, O O
it O O
does O O
induce O O
chemotaxis O O
, O O
trans-Matrigel O O
migration O O
, O O
and O O
secretion O O
of O O
matrix O O
metalloproteinase B B_ENZYME[GENE]
9 I I_ENZYME[GENE]
( O O
MMP-9 B B_TIME[MEASURE]/B_GENE
) O O
and O O
vascular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
endothelial I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
VEGF B B_GENE
) O O
by O O
these O O
cells O O
, O O
and O O
both O O
SDF-1 B B_GENE
and O O
TPO B B_GENE
increase O O
the O O
adhesion O O
of O O
alpha O O
( O O
IIb O O
) O O
beta O O
( O O
3 O O
) O O
( O O
+ O O
) O O
cells O O
to O O
fibrinogen B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
vitronectin B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Investigating O O
the O O
intracellular O O
signaling O O
pathways O O
induced O O
by O O
SDF-1 B B_GENE
and O O
TPO B B_GENE/B_DISEASE
revealed O O
some O O
overlapping O O
patterns O O
of O O
protein O O
phosphorylation/activation O O
( O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MAPK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p42/44 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
MAPK B B_GENE
p38 I I_GENE
, O O
and O O
AKT B B_GENE
[ I I_GENE
protein I I_GENE
kinase I I_GENE
B I I_GENE
] I I_GENE
) O O
and O O
some O O
that O O
were O O
distinct O O
for O O
TPO B B_GENE/B_DISEASE
( O O
eg O O
, O O
JAK-STAT B B_GENE
) O O
and O O
for O O
SDF-1 B B_GENE
( O O
eg O O
, O O
NF-kappa B B_GENE
B I I_GENE
) O O
. O O

It O O
was O O
also O O
found O O
that O O
though O O
inhibition O O
of O O
phosphatidyl-inositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3-kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI-3K B B_GENE
) O O
by O O
LY294002 O O
in O O
alpha O O
( O O
IIb O O
) O O
beta O O
( O O
3 O O
) O O
( O O
+ O O
) O O
cells O O
induced O O
apoptosis O O
and O O
inhibited O O
chemotaxis O O
adhesion O O
and O O
the O O
secretion O O
of O O
MMP-9 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
VEGF B B_GENE
, O O
the O O
inhibition O O
of O O
MAPK B B_GENE
p42/44 I I_GENE
( O O
by O O
the O O
MEK O O
inhibitor O O
U0126 O O
) O O
had O O
no O O
effect O O
on O O
the O O
survival O O
, O O
proliferation O O
, O O
and O O
migration O O
of O O
these O O
cells O O
. O O

Hence O O
, O O
it O O
is O O
suggested O O
that O O
the O O
proliferative O O
effect O O
of O O
TPO B B_GENE
is O O
more O O
related O O
to O O
activation O O
of O O
the O O
JAK-STAT O O
pathway O O
( O O
unique O O
to O O
TPO B B_GENE
) O O
, O O
and O O
the O O
PI-3K-AKT O O
axis O O
is O O
differentially O O
involved O O
in O O
TPO- O O
and O O
SDF-1-dependent O O
signaling O O
. O O

Accordingly O O
, O O
PI-3K B B_GENE
is O O
involved O O
in O O
TPO B B_GENE
-mediated O O
inhibition O O
of O O
apoptosis O O
, O O
TPO- O O
and O O
SDF-1-regulated O O
adhesion O O
to O O
fibrinogen B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
vitronectin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
SDF-1 B B_GENE
-mediated O O
migration O O
. O O

This O O
study O O
expands O O
the O O
understanding O O
of O O
the O O
role O O
of O O
SDF-1 B B_GENE/B_LOCATION
and O O
TPO B B_GENE/B_LOCATION
in O O
normal O O
human O O
megakaryopoiesis O O
and O O
indicates O O
the O O
molecular O O
basis O O
of O O
the O O
observed O O
differences O O
in O O
cellular O O
responses O O
. O O

( O O
Blood. O O
2000 O O
; O O
96 O O
: O O
4142-4151 O O
) O O

Adhesion O O
of O O
immature O O
and O O
mature O O
T O O
cells O O
induces O O
in O O
human O O
thymic O O
epithelial O O
cells O O
( O O
TEC O O
) O O
activation O O
of O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
trascription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NF-kappaB B B_GENE
and O O
NF-IL6 B B_GENE
) O O
and O O
IL-6 O O
gene O O
expression O O
: O O
role O O
of O O
alpha3beta1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha6beta4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
integrins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

T O O
cell O O
precursors O O
homed O O
to O O
thymus O O
develop O O
in O O
close O O
contact O O
with O O
stromal O O
cells O O
. O O

Among O O
them O O
, O O
thymic O O
epithelial O O
cells O O
( O O
TEC O O
) O O
are O O
known O O
to O O
exert O O
dominant O O
roles O O
in O O
their O O
survival O O
and O O
functional O O
shaping O O
. O O

Key O O
molecules O O
mediating O O
TEC O O
/ O O
thymocytes O O
interactions O O
include O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
growth B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
secreted O O
by O O
the O O
two O O
cell O O
types O O
and O O
adhesion B B_GENE/B_BIO
receptors I I_GENE/I_BIO
mediating O O
cell O O
contact O O
. O O

Signaling O O
events O O
triggered O O
in O O
thymocytes O O
by O O
adhesion O O
to O O
epithelial O O
cells O O
have O O
been O O
extensively O O
investigated O O
, O O
whereas O O
little O O
is O O
known O O
on O O
the O O
opposite O O
phenomenon O O
. O O

We O O
have O O
previously O O
investigated O O
this O O
issue O O
in O O
a O O
co-culture O O
system O O
composed O O
of O O
TEC O O
cultures O O
derived O O
from O O
human O O
normal O O
thymus O O
and O O
heterologous O O
thymocytes O O
. O O

We O O
demonstrated O O
that O O
thymocytes O O
adhere O O
to O O
TEC O O
involving O O
beta1 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
beta4 I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
integrins I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
induce O O
the O O
clustering O O
of O O
alpha3beta1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha6beta4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
at O O
the O O
TEC O O
surface O O
. O O

In O O
addition O O
thymocyte O O
adhesion O O
was O O
followed O O
by O O
activation O O
of O O
NF-kappaB B B_GENE
and O O
NF-IL6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
enhanced O O
IL-6 O O
production O O
. O O

The O O
two O O
latter O O
phenomena O O
were O O
reproduced O O
by O O
the O O
cross-linking O O
of O O
the O O
alpha3 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
alpha6 B B_PROTEIN[GENE]/B_MEASURE
, O O
beta1 B B_GENE
and I I_GENE
beta4 I I_GENE
integrins I I_GENE
, O O
thus O O
implying O O
that O O
the O O
alpha3beta1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha6beta4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
signal O O
during O O
thymocyte O O
adhesion O O
. O O

We O O
have O O
extended O O
our O O
previous O O
work O O
investigating O O
in O O
the O O
same O O
experimental O O
setting O O
the O O
inducing O O
activity O O
of O O
non O O
stimulated O O
or O O
activated O O
policlonal O O
or O O
clonal O O
mature O O
T O O
cells O O
as O O
representative O O
of O O
the O O
more O O
mature O O
thymocyte O O
subset O O
. O O

We O O
found O O
that O O
adhesion O O
of O O
unstimulated O O
T O O
cell O O
i O O
) O O
involved O O
beta1 O O
, O O
but O O
not O O
beta4 O O
integrin O O
functions O O
at O O
the O O
surface O O
ii O O
) O O
induced O O
the O O
clustering O O
of O O
alpha3beta1 B B_GENE
, O O
but O O
not O O
alpha2beta1 B B_GENE
heterodimers I I_GENE
at O O
the O O
TEC O O
surface O O
and O O
iii O O
) O O
up-regulated O O
the O O
nuclear O O
binding O O
activity O O
of O O
NF-kappaB B B_GENE
transcription I I_GENE
factor I I_GENE
and O O
the O O
IL-6 O O
secretion O O
. O O

Identification O O
and O O
characterization O O
of O O
SKAT-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
novel O O
Th2-specific B B_GENE/B_PERSON
zinc I I_GENE/I_PERSON
finger I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
. O O

We O O
have O O
identified O O
a O O
novel O O
Kruppel-type B B_GENE/B_PERSON
zinc I I_GENE/I_PERSON
finger I I_GENE/I_PERSON
( I I_GENE/I_PERSON
ZF I I_GENE/I_PERSON
) I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
, O O
SKAT-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
selectively O O
expressed O O
by O O
murine O O
Th2 O O
cells O O
. O O

The O O
protein O O
encoded O O
by O O
this O O
gene O O
has O O
14 O O
C2H2-type O O
ZF O O
tandemly O O
arrayed O O
at O O
its O O
C B B_PROTEIN[GENE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
terminus I B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
N-terminal B B_PROTEIN[GENE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SCAN B I_PROTEIN[GENE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
box I I_PROTEIN[GENE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
KRAB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

SKAT-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
tissue O O
restricted O O
in O O
expression O O
at O O
the O O
RNA O O
level O O
, O O
detectable O O
only O O
in O O
brain O O
and O O
at O O
low O O
levels O O
in O O
kidney O O
and O O
spleen O O
and O O
few O O
hematopoietic O O
cell O O
lines O O
. O O

By O O
in O O
situ O O
hybridization O O
, O O
SKAT-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
was O O
found O O
to O O
peak O O
in O O
antigen-stimulated O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
after O O
2-3 O O
days O O
of O O
culture O O
under O O
Th2 O O
but O O
not O O
Th1 O O
biasing O O
conditions O O
. O O

This O O
pattern O O
of O O
expression O O
closely O O
mirrored O O
that O O
of O O
GATA-3 B B_GENE
in O O
the O O
same O O
cells O O
. O O

In O O
transient O O
transfection O O
experiments O O
in O O
phorbol O O
12-myristate O O
13-acetate/ionomycin-stimulated O O
EL4 O O
cells O O
, O O
SKAT-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
to O O
up-regulate O O
the O O
activity O O
of O O
the O O
IL-4 B B_GENE
but I I_GENE
not I I_GENE
the I I_GENE
IL-5 I I_GENE
promoter I I_GENE
, O O
contrasting O O
with O O
the O O
ability O O
of O O
GATA-3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
activate O O
both O O
promoters B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

hsp70 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interacting I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Hip I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
not O O
affect O O
glucocorticoid B B_GENE
receptor I I_GENE
folding O O
by O O
the O O
hsp90-based O O
chaperone O O
machinery O O
except O O
to O O
oppose O O
the O O
effect O O
of O O
BAG-1 B B_GENE
. O O

In O O
the O O
five-protein O O
system O O
, O O
Hip B B_GENE/B_DISEASE
prevents O O
inhibition O O
of O O
assembly O O
by O O
the O O
hsp70 B B_GENE
co-chaperone I I_GENE
BAG-1 I I_GENE
, O O
and O O
cotransfection O O
of O O
Hip B B_GENE/B_DISEASE
with O O
BAG-1 B B_GENE
opposes O O
BAG-1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
reduction O O
of O O
steroid O O
binding O O
activity O O
in O O
COS O O
cells O O
. O O

We O O
conclude O O
that O O
Hip B B_GENE/B_DISEASE
is O O
not O O
a O O
component O O
of O O
the O O
assembly O O
machinery O O
but O O
that O O
it O O
could O O
play O O
a O O
regulatory O O
role O O
in O O
opposition O O
to O O
BAG-1 B B_GENE/B_DISEASE
. O O

Cutting O O
edge O O
: O O
STAT6-deficient O O
mice O O
have O O
enhanced O O
tumor O O
immunity O O
to O O
primary O O
and O O
metastatic O O
mammary O O
carcinoma O O
. O O

STAT4 B B_GENE
and O O
STAT6 B B_GENE
are O O
essential O O
for O O
the O O
development O O
of O O
CD4 O O
( O O
+ O O
) O O
Th1 O O
and O O
Th2 O O
development O O
, O O
respectively O O
. O O

Therefore O O
, O O
deletion O O
of O O
the O O
STAT6 B B_GENE
gene I I_GENE
facilitates O O
development O O
of O O
potent O O
anti-tumor O O
immunity O O
via O O
a O O
CD4 O O
( O O
+ O O
) O O
-independent O O
pathway O O
. O O

Activation O O
of O O
oncogenic B B_GENE
transcription I I_GENE
factor I I_GENE
AP-1 I I_GENE
in O O
T O O
cells O O
infected O O
with O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
1 O O
. O O

Human O O
T O O
cell O O
leukemia O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
Tax B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
protein I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
transforms O O
primary O O
human O O
T O O
cells O O
in O O
vitro O O
. O O

We O O
previously O O
showed O O
that O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
the O O
expression O O
of O O
various O O
family O O
members O O
of O O
the O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
AP-1 I I_GENE/I_LOCATION
such O O
as O O
c-Jun B B_GENE
, O O
JunD B B_GENE/B_DISEASE
, O O
c-Fos B B_GENE
, O O
and O O
Fra-1 B B_GENE
at O O
the O O
mRNA O O
level O O
in O O
T O O
cells O O
. O O

In O O
this O O
study O O
, O O
we O O
have O O
examined O O
the O O
ability O O
of O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
activate O O
transcription O O
through O O
the O O
AP-1-binding B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
( O O
AP-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
site I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
. O O

Fresh O O
peripheral O O
blood O O
leukemia O O
cells O O
of O O
all O O
surveyed O O
ATL O O
patients O O
displayed O O
constitutive O O
AP-1 O O
DNA-binding O O
activity O O
, O O
whereas O O
no O O
normal O O
individuals O O
did O O
. O O

However O O
, O O
the O O
HTLV-1 B B_GENE/B_MEASURE
genes I I_GENE/I_MEASURE
, O O
including O O
tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
are O O
not O O
significantly O O
expressed O O
in O O
fresh O O
leukemia O O
cells O O
from O O
ATL O O
patients O O
. O O

Our O O
present O O
results O O
suggest O O
that O O
activation O O
of O O
AP-1 B B_GENE
occurs O O
through O O
Tax-dependent O O
and O O
-independent O O
mechanisms O O
in O O
HTLV-1-infected O O
T O O
cells O O
, O O
which O O
may O O
play O O
some O O
roles O O
in O O
dysregulated O O
phenotypes O O
of O O
HTLV-1-infected O O
cells O O
. O O

2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-pentachlorobiphenyl O O
induces O O
apoptosis O O
in O O
human O O
monocytic O O
cells O O
. O O

Polychlorinatedbiphenyls O O
( O O
PCBs O O
) O O
are O O
a O O
group O O
of O O
persistent O O
and O O
widely O O
dispersed O O
environmental O O
pollutants O O
, O O
some O O
of O O
which O O
may O O
be O O
immunotoxic O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
investigated O O
the O O
effect O O
of O O
PCBs O O
on O O
immune O O
system O O
by O O
assessing O O
apoptotic O O
cell O O
death O O
in O O
human O O
monocytic O O
U937 O O
cells O O
. O O

Among O O
the O O
various O O
congeners O O
tested O O
, O O
2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-pentachlorobiphenyl O O
( O O
PeCB O O
) O O
, O O
a O O
highly O O
ortho-substituted O O
congener O O
, O O
specifically O O
induced O O
DNA O O
fragmentation O O
, O O
a O O
hallmark O O
of O O
apoptosis O O
, O O
while O O
the O O
other O O
examined O O
di- O O
, O O
tri- O O
, O O
tetra- O O
, O O
and O O
pentachlorobiphenyls O O
did O O
not O O
. O O

To O O
further O O
study O O
the O O
2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-PeCB-induced O O
cell O O
death O O
, O O
various O O
features O O
of O O
apoptosis O O
were O O
examined O O
. O O

2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-PeCB O O
caused O O
a O O
decrease O O
in O O
cell O O
viability O O
and O O
induced O O
cellular O O
morphologic O O
features O O
characteristic O O
of O O
apoptosis O O
such O O
as O O
chromatin O O
aggregation O O
and O O
apoptotic O O
bodies O O
. O O

In O O
addition O O
, O O
caspase-3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
an O O
executioner O O
of O O
apoptosis O O
, O O
was O O
activated O O
and O O
its O O
substrate O O
, O O
poly B B_GENE
( I I_GENE
ADP-ribose I I_GENE
) I I_GENE
polymerase I I_GENE
( O O
PARP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
was O O
cleaved O O
during O O
2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-PeCB-induced O O
apoptosis O O
. O O

In O O
contrast O O
, O O
3 O O
, O O
3 O O
' O O
, O O
4 O O
, O O
4 O O
' O O
, O O
5-PeCB O O
, O O
a O O
congener O O
of O O
coplanar O O
structure O O
, O O
as O O
well O O
as O O
2 O O
, O O
3 O O
, O O
7 O O
, O O
8-TCDD O O
did O O
not O O
induce O O
apoptosis O O
in O O
these O O
human O O
monocytic O O
cells O O
, O O
although O O
they O O
potently O O
induced O O
CYP B B_DISEASE/B_GENE
1A1 I I_DISEASE/I_GENE
in O O
human O O
hepatoma O O
Hep O O
G2 O O
cells O O
. O O

Taken O O
together O O
, O O
the O O
data O O
indicate O O
that O O
2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-PeCB O O
induces O O
apoptosis O O
in O O
human O O
monocytic O O
cells O O
through O O
a O O
mechanism O O
that O O
is O O
independent O O
of O O
the O O
arylhydrocarbon B B_GENE
receptor I I_GENE
. O O

This O O
suggests O O
a O O
possibly O O
separate O O
mechanism O O
by O O
which O O
PCBs O O
cause O O
immunosuppression O O
. O O

Effects O O
of O O
deregulated O O
Raf O O
activation O O
on O O
integrin B B_GENE/B_DISEASE
, O O
cytokine-receptor O O
expression O O
and O O
the O O
induction O O
of O O
apoptosis O O
in O O
hematopoietic O O
cells O O
. O O

The O O
effects O O
of O O
deregulated O O
Raf O O
activation O O
on O O
the O O
growth O O
and O O
differentiation O O
of O O
hematopoietic O O
cells O O
were O O
investigated O O
. O O

The O O
cytokine-dependent O O
murine O O
myeloid O O
FDC-P1 O O
and O O
human O O
erythroleukemic O O
TF-1 O O
cell O O
lines O O
were O O
transformed O O
to O O
grow O O
in O O
response O O
to O O
deregulated O O
Raf O O
expression O O
in O O
the O O
absence O O
of O O
exogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokines I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
conditionally O O
active O O
Raf B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
regulated O O
by O O
beta-estradiol O O
as O O
cDNAs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
containing O O
the O O
Raf B B_GENE
catalytic I I_GENE
, O O
but O O
lacking O O
negative-regulatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
were O O
ligated O O
to O O
the O O
hormone B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
domain I I_GENE/I_LOCATION
of O O
the O O
estrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
deltaRaf B B_GENE/B_LOCATION
: I I_GENE/I_LOCATION
ER I I_GENE/I_LOCATION
) O O
. O O

Continuous O O
deltaRaf B B_GENE/B_LOCATION
expression O O
prevented O O
apoptosis O O
in O O
the O O
absence O O
of O O
exogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokines I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
altered O O
the O O
morphology O O
of O O
the O O
FD/deltaRaf O O
: O O
ER O O
cells O O
as O O
they O O
grew O O
in O O
large O O
aggregated O O
masses O O
( O O
> O O
100 O O
cells O O
) O O
whereas O O
the O O
parental O O
cytokine-dependent O O
FDC-P1 O O
cells O O
grew O O
in O O
smaller O O
grape-like O O
clusters O O
( O O
< O O
10 O O
cells O O
) O O
. O O

FD/deltaRaf-1 O O
: O O
ER O O
cells O O
growing O O
in O O
response O O
to O O
Raf O O
activation O O
displayed O O
decreased O O
levels O O
of O O
the O O
Mac-2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Mac-3 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
their O O
cell O O
surface O O
. O O

In O O
contrast O O
, O O
when O O
these O O
cells O O
were O O
cultured O O
in O O
IL-3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
higher O O
levels O O
of O O
these O O
adhesion B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
detected O O
. O O

Expression O O
of O O
activated O O
Raf B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oncoproteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O O
abrogated O O
cytokine O O
dependency O O
and O O
prevented O O
apoptosis O O
of O O
TF-1 O O
cells O O
. O O

Moreover O O
, O O
the O O
differentiation O O
status O O
of O O
these O O
Raf-responsive O O
cells O O
was O O
more O O
immature O O
upon O O
Raf O O
activation O O
as O O
culture O O
with O O
the O O
differentiation-inducing O O
agent O O
phorbol O O
12 O O
myristate O O
13-acetate O O
( O O
PMA O O
) O O
and O O
beta-estradiol O O
resulted O O
in O O
decreased O O
levels O O
of O O
the O O
CD11b B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
CD18 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
integrin I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
cell O O
surface O O
. O O

Retinoic O O
acid O O
( O O
RA O O
) O O
inhibited O O
3H-thymidine O O
incorporation O O
in O O
response O O
to O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Interestingly O O
, O O
Raf O O
activation O O
counterbalanced O O
the O O
inhibition O O
of O O
DNA O O
synthesis O O
caused O O
by O O
RA O O
but O O
not O O
PMA O O
. O O

Cyclic O O
AMP O O
activates O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Th2 O O
cells O O
: O O
phosphorylation O O
of O O
GATA-3 B B_GENE
and O O
stimulation O O
of O O
Th2 O O
cytokine O O
gene O O
expression O O
. O O

In O O
effector O O
T O O
cells O O
, O O
an O O
increase O O
in O O
the O O
level O O
of O O
intracellular O O
cAMP O O
inhibits O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
in O O
Th1 O O
cells O O
but O O
stimulates O O
cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O O
in O O
Th2 O O
cells O O
. O O

Here O O
we O O
report O O
that O O
cAMP-induced O O
effects O O
in O O
Th2 O O
cells O O
occur O O
independently O O
of O O
the O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
pathway O O
, O O
which O O
is O O
the O O
major O O
mediator O O
of O O
cAMP-induced O O
signaling O O
events O O
in O O
most O O
cell O O
types O O
. O O

Instead O O
, O O
cAMP O O
stimulates O O
activation O O
of O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Th2 O O
cells O O
. O O

This O O
appears O O
to O O
be O O
a O O
Th2 O O
-selective O O
event O O
because O O
cAMP O O
barely O O
increased O O
p38 B B_GENE
phosphorylation O O
in O O
Th1 O O
cells O O
. O O

We O O
show O O
that O O
in O O
Th2 O O
cells O O
, O O
cAMP O O
promotes O O
the O O
production O O
of O O
both O O
IL-5 B B_GENE
and O O
IL-13 B B_GENE
, O O
which O O
play O O
distinct O O
but O O
critical O O
roles O O
in O O
asthma O O
pathogenesis O O
. O O

Our O O
data O O
also O O
show O O
that O O
cAMP O O
causes O O
increased O O
phosphorylation O O
of O O
the O O
transcription B B_GENE
factor I I_GENE
GATA-3 I I_GENE
, O O
which O O
we O O
have O O
shown O O
is O O
a O O
critical O O
regulator O O
of O O
Th2 O O
cytokine O O
gene O O
expression O O
and O O
, O O
in O O
turn O O
, O O
of O O
airway O O
inflammation O O
in O O
mice O O
. O O

Thus O O
, O O
Th2 O O
-specific O O
GATA-3 B B_GENE
expression O O
and O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O O
together O O
provide O O
a O O
molecular O O
basis O O
for O O
the O O
differential O O
effects O O
of O O
cAMP O O
in O O
the O O
two O O
T O O
helper O O
cell O O
subsets O O
. O O

Characterization O O
of O O
IL-4 B B_GENE
and O O
IL-13 B B_GENE
signals O O
dependent O O
on O O
the O O
human B B_GENE/B_LOCATION
IL-13 I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
alpha I I_GENE/I_LOCATION
chain I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
: O O
redundancy O O
of O O
requirement O O
of O O
tyrosine O O
residue O O
for O O
STAT3 O O
activation O O
. O O

In O O
this O O
study O O
, O O
we O O
constructed O O
wild O O
and O O
mutated O O
types O O
of O O
human B B_GENE/B_BIO
IL-13R I I_GENE/I_BIO
alpha I I_GENE/I_BIO
1 I I_GENE/I_BIO
, O O
and O O
analyzed O O
IL-4 B B_GENE/B_DISEASE
and O O
IL-13 B B_GENE
signals O O
using O O
an O O
IL-13R B B_GENE
alpha I I_GENE
1 I I_GENE
-transfected O O
human O O
B O O
cell O O
line O O
. O O

Expression O O
of O O
IL-13R B B_GENE
alpha I I_GENE
1 I I_GENE
evoked O O
STAT3 B B_GENE/B_LOCATION
activation O O
by O O
IL-4 B B_GENE
and O O
IL-13 B B_GENE
, O O
and O O
in O O
stimulated O O
human O O
B O O
cells O O
, O O
on O O
which O O
IL-13R B B_GENE
alpha I I_GENE
1 I I_GENE
was O O
highly O O
expressed O O
, O O
IL-4 B B_GENE
and O O
IL-13 B B_GENE/B_MEASURE
induced O O
STAT3 B B_GENE
activation O O
. O O

Replacement O O
of O O
the O O
two O O
tyrosine O O
residues O O
completely O O
abolished O O
STAT3 B B_GENE
activation O O
, O O
although O O
replacing O O
either O O
tyrosine O O
residue O O
alone O O
retained O O
it O O
. O O

These O O
results O O
suggest O O
that O O
STAT3 B B_GENE
activation O O
is O O
involved O O
with O O
IL-4 B B_GENE
and O O
IL-13 B B_GENE
signals O O
in O O
human O O
B O O
cells O O
along O O
with O O
the O O
activation O O
of O O
STAT6 B B_GENE
, O O
and O O
that O O
there O O
is O O
a O O
unique O O
sequence O O
in O O
IL-13R B B_GENE/B_BIO
alpha I I_GENE/I_BIO
1 I I_GENE/I_BIO
to O O
activate O O
STAT3 B B_GENE
. O O

Human O O
T O O
cell O O
leukemia O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
transforms O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O O
T O O
lymphocytes O O
and O O
causes O O
adult O O
T O O
cell O O
leukemia O O
. O O

Janus B B_GENE
tyrosine I I_GENE
kinase I I_GENE
( I I_GENE
Jak I I_GENE
) I I_GENE
3 I I_GENE
and O O
transcription B B_PROTEIN[GENE]/B_MEASURE
factors I I_PROTEIN[GENE]/I_MEASURE
Stat5a B I_PROTEIN[GENE]/I_MEASURE
and O O
Stat5b B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
essential O O
for O O
the O O
proliferation O O
of O O
normal O O
T O O
cells O O
and O O
are O O
constitutively O O
hyperactivated O O
in O O
both O O
HTLV-1-transformed O O
human O O
T O O
cell O O
lines O O
and O O
lymphocytes O O
isolated O O
from O O
HTLV-1-infected O O
patients O O
; O O
therefore O O
, O O
a O O
critical O O
role O O
for O O
the O O
Jak3-Stat5 O O
pathway O O
in O O
the O O
progression O O
of O O
this O O
disease O O
has O O
been O O
postulated O O
. O O

We O O
recently O O
reported O O
that O O
tyrphostin O O
AG-490 O O
selectively O O
blocked O O
IL-2 O O
activation O O
of O O
Jak3/Stat5 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
growth O O
of O O
murine O O
T O O
cell O O
lines O O
. O O

Disruption O O
of O O
constitutive O O
Jak3/Stat5 O O
activation O O
by O O
AG-490 O O
was O O
demonstrated O O
by O O
inhibition O O
of O O
1 O O
) O O
tyrosine O O
phosphorylation O O
of O O
Jak3 B B_GENE
, O O
Stat5a B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Tyr O O
( O O
694 O O
) O O
) O O
, O O
and O O
Stat5b B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Tyr O O
( O O
699 O O
) O O
) O O
; O O
2 O O
) O O
serine O O
phosphorylation O O
of O O
Stat5a B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Ser O O
( O O
726 O O
) O O
) O O
as O O
determined O O
by O O
a O O
novel O O
phosphospecific B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Ab I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O O
and O O
3 O O
) O O
Stat5a/b O O
DNA O O
binding O O
to O O
the O O
Stat5-responsive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta-casein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Reversal O O
of O O
this O O
functional O O
uncoupling O O
may O O
be O O
required O O
before O O
Jak3/Stat5 O O
inhibitors O O
will O O
be O O
useful O O
in O O
the O O
treatment O O
of O O
this O O
malignancy O O
. O O

The O O
Epstein-Barr B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
initiating O O
B-cell O O
transformation O O
is O O
activated O O
by O O
RFX B B_GENE
proteins I I_GENE
and O O
the O O
B-cell-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BSAP/Pax5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
-induced O O
B-cell O O
growth O O
transformation O O
, O O
a O O
central O O
feature O O
of O O
the O O
virus O O
' O O
strategy O O
for O O
colonizing O O
the O O
human O O
B-cell O O
system O O
, O O
requires O O
full O O
virus O O
latent O O
gene O O
expression O O
and O O
is O O
initiated O O
by O O
transcription O O
from O O
the O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Wp I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Interestingly O O
, O O
when O O
EBV O O
accesses O O
other O O
cell O O
types O O
, O O
this O O
growth-transforming O O
program O O
is O O
not O O
activated O O
. O O

The O O
present O O
work O O
focuses O O
on O O
a O O
region O O
of O O
Wp B B_GENE/B_DISEASE
which O O
in O O
reporter O O
assays O O
confers O O
B-cell O O
-specific O O
activity O O
. O O

We O O
suggest O O
that O O
Wp B B_GENE/B_DISEASE
regulation O O
by O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
helps O O
to O O
ensure O O
the O O
B-cell O O
specificity O O
of O O
EBV O O
's O O
growth-transforming O O
function O O
. O O

Activation O O
of O O
the O O
Lck B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
Herpesvirus O O
saimiri O O
tip B B_GENE
protein I I_GENE
involves O O
two O O
binding O O
interactions O O
. O O

The O O
Tip B B_GENE
protein I I_GENE
of O O
Herpesvirus O O
saimiri O O
strain O O
484C O O
binds O O
to O O
and O O
activates O O
the O O
Lck B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O O
sequences O O
in O O
the O O
Tip B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
were O O
previously O O
shown O O
to O O
be O O
involved O O
in O O
binding O O
to O O
Lck B B_GENE/B_BACTERIUM[BIO]
. O O

Simultaneous O O
binding O O
of O O
both O O
domains O O
is O O
required O O
for O O
maximal O O
activation O O
of O O
Lck B B_GENE/B_BACTERIUM[BIO]
. O O

The O O
transient O O
expression O O
of O O
Tip B B_GENE
in O O
T O O
cells O O
was O O
found O O
to O O
stimulate O O
both O O
Stat3 B B_GENE
-dependent O O
and O O
NF-AT B B_GENE
-dependent O O
transcription O O
. O O

Mutant O O
forms O O
of O O
Tip B B_GENE
lacking O O
one O O
or O O
the O O
other O O
of O O
the O O
two O O
Lck-binding B B_GENE/B_LOCATION
domains I I_GENE/I_LOCATION
retained O O
the O O
ability O O
to O O
stimulate O O
Stat3 B B_GENE
-dependent O O
transcription O O
. O O

Tip B B_PROTEIN[GENE]/B_LOCATION
lacking O O
the O O
proline-rich O O
Lck-binding B B_LOCATION/B_GENE
domain I I_LOCATION/I_GENE
exhibited O O
almost O O
wild-type O O
activity O O
in O O
this O O
assay O O
. O O

In O O
contrast O O
, O O
ablation O O
of O O
either O O
Lck-binding B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
abolished O O
the O O
ability O O
of O O
Tip B B_GENE
to O O
stimulate O O
NF-AT B B_GENE
-dependent O O
transcription O O
. O O

Accumulation O O
of O O
RXR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
during O O
activation O O
of O O
cycling O O
human O O
T O O
lymphocytes O O
: O O
modulation O O
of O O
RXRE O O
transactivation O O
function O O
by O O
mitogen-activated O O
protein O O
kinase O O
pathways O O
. O O

We O O
have O O
previously O O
reported O O
that O O
the O O
activation O O
of O O
resting O O
human O O
immature O O
peripheral O O
blood O O
T O O
( O O
PBT O O
) O O
lymphocytes O O
is O O
associated O O
with O O
the O O
loss O O
of O O
retinoid B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RXRalpha B B_GENE
) O O
expression O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
have O O
demonstrated O O
that O O
, O O
unlike O O
resting O O
cells O O
, O O
activation O O
of O O
cycling O O
human O O
mature O O
PBT O O
lymphocytes O O
, O O
and O O
T O O
lymphocyte O O
leukemia O O
cell O O
lines O O
is O O
accompanied O O
by O O
the O O
accumulation O O
of O O
RXRalpha B B_GENE
mRNA O O
and O O
protein O O
. O O

Interestingly O O
, O O
cyclosporin O O
A O O
further O O
augmented O O
RXRalpha B B_GENE
expression O O
, O O
indicating O O
the O O
involvement O O
of O O
calcineurin O O
pathways O O
in O O
the O O
process O O
. O O

9-cis O O
retinoic O O
acid O O
inhibited O O
the O O
accumulation O O
, O O
suggesting O O
that O O
retinoids O O
can O O
regulate O O
the O O
synthesis O O
of O O
their O O
own O O
receptors O O
during O O
T O O
cell O O
activation O O
. O O

Transfection O O
analysis O O
in O O
Jurkat O O
cells O O
, O O
using O O
RXRE-dependent O O
reporter O O
assays O O
, O O
showed O O
that O O
RXRalpha B B_GENE/B_LOCATION
accumulated O O
during O O
T O O
cell O O
activation O O
was O O
transcriptionally O O
inactive O O
. O O

To O O
investigate O O
the O O
mechanism O O
of O O
such O O
inhibition O O
, O O
the O O
role O O
of O O
two O O
mitogen-activated O O
protein O O
kinase O O
pathways O O
, O O
c-Jun B B_GENE
N-terminal I I_GENE
kinase I I_GENE
( O O
JNK B B_GENE/B_LOCATION
) O O
and O O
extracellular B B_GENE
signal-regulated I I_GENE
kinase I I_GENE
( O O
ERK B B_GENE/B_LOCATION
) O O
, O O
in O O
modulating O O
RXRE-dependent O O
transcription O O
, O O
was O O
explored O O
. O O

The O O
expression O O
of O O
constitutively O O
active O O
MAP/ERK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MEKK1 B B_GENE
) O O
inhibited O O
RXRE-dependent O O
transcription O O
, O O
whereas O O
dominant B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
negative I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MEKK1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
the O O
transcription O O
, O O
indicating O O
the O O
involvement O O
of O O
JNK B B_GENE/B_PERSON
signaling O O
pathways O O
in O O
the O O
process O O
. O O

In O O
contrast O O
, O O
expression O O
of O O
constitutively B B_GENE
active I I_GENE
MEK1 I I_GENE
, O O
which O O
activates O O
ERK B B_GENE
pathway O O
, O O
enhanced O O
RXRE-dependent O O
activation O O
. O O

When O O
both O O
were O O
activated O O
simultaneously O O
, O O
JNK B B_GENE
pathway O O
was O O
dominant O O
over O O
ERK B B_GENE
pathway O O
and O O
resulted O O
in O O
inhibition O O
of O O
RXRE-mediated O O
transcription O O
. O O

These O O
data O O
demonstrate O O
a O O
dual O O
regulatory O O
control O O
of O O
RXRalpha B B_GENE
expression O O
during O O
the O O
activation O O
of O O
resting O O
and O O
cycling O O
T O O
lymphocytes O O
and O O
indicate O O
a O O
dynamic O O
balance O O
between O O
JNK O O
and O O
ERK O O
pathways O O
in O O
modulating O O
RXRE-mediated O O
transactivation O O
. O O

The O O
proteasome B B_ENZYME[GENE]/B_LOCATION
regulates O O
receptor-mediated O O
endocytosis O O
of O O
interleukin-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Recent O O
studies O O
have O O
increasingly O O
implicated O O
the O O
proteasome B B_GENE
in O O
the O O
regulation O O
of O O
cell B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
surface I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
receptors I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

In O O
the O O
present O O
study O O
, O O
we O O
investigated O O
the O O
role O O
of O O
the O O
proteasome B B_GENE
for O O
ligand-dependent O O
endocytosis O O
and O O
degradation O O
of O O
the O O
interleukin-2 B B_GENE
( I I_GENE
IL-2 I I_GENE
) I I_GENE
-interleukin-2 I I_GENE
receptor I I_GENE
( I I_GENE
IL-2R I I_GENE
) I I_GENE
complex I I_GENE
. O O

Proteasome O O
inhibitors O O
impaired O O
internalization O O
of O O
IL-2.IL-2R B B_GENE
and O O
prevented O O
the O O
lysosomal O O
degradation O O
of O O
this O O
cytokine B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Based O O
on O O
time-course O O
studies O O
, O O
proteasome B B_GENE
activity O O
is O O
primarily O O
required O O
after O O
initial O O
endocytosis O O
of O O
the O O
IL-2.IL-2R B B_GENE
. O O

Therefore O O
, O O
a O O
functional O O
proteasome B B_GENE/B_LOCATION
is O O
required O O
for O O
optimal O O
endocytosis O O
of O O
the O O
IL-2R/ligand B B_GENE
complex I I_GENE
and O O
is O O
essential O O
for O O
the O O
subsequent O O
lysosomal O O
degradation O O
of O O
IL-2 B B_GENE
, O O
possibly O O
by O O
regulating O O
trafficking O O
to O O
the O O
lysosome O O
. O O

Functional O O
characterization O O
of O O
the O O
two O O
alternative O O
promoters O O
of O O
human B B_GENE
p45 I I_GENE
NF-E2 I I_GENE
gene I I_GENE
. O O

OBJECTIVE O O
: O O
The O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-E2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
heterodimeric B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
complex I I_GENE/I_LOCATION
composed O O
of O O
p45 B B_GENE/B_MEASURE
and O O
small O O
Maf B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
family I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
considered O O
crucial O O
for O O
the O O
proper O O
differentiation O O
of O O
erythrocytes O O
and O O
megakaryocytes O O
in O O
vivo O O
. O O

We O O
report O O
the O O
results O O
of O O
studies O O
aimed O O
at O O
understanding O O
the O O
regulatory O O
mechanisms O O
controlling O O
p45 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
erythroid O O
cells O O
. O O

For O O
functional O O
characterization O O
of O O
both O O
promoters O O
, O O
plasmids O O
in O O
which O O
reporter B B_BIO/B_GENE
genes I I_BIO/I_GENE
were O O
placed O O
under O O
the O O
control O O
of O O
a O O
series O O
of O O
truncated O O
or O O
mutated O O
promoter B B_GENE/B_LOCATION
fragments I I_GENE/I_LOCATION
were O O
transfected O O
to O O
human O O
hematopoietic O O
cell O O
lines O O
. O O

fNF-E2 B B_GENE
mRNA I I_GENE
was O O
found O O
to O O
be O O
more O O
abundant O O
in O O
erythroid O O
cells O O
than O O
megakaryocytic O O
cells O O
at O O
day O O
7 O O
of O O
culture O O
. O O

Although O O
both O O
isomers O O
were O O
expressed O O
in O O
human O O
erythroid-megakaryocytic O O
cell O O
lines O O
, O O
megakaryocytic O O
maturation O O
with O O
loss O O
of O O
erythroid O O
phenotype O O
induced O O
by O O
phorbol O O
12-myristate O O
13-acetate O O
( O O
PMA O O
) O O
resulted O O
in O O
exclusive O O
downregulation O O
of O O
fNF-E2 B B_GENE
, O O
suggesting O O
that O O
fNF-E2 B B_GENE
promoter I I_GENE
is O O
more O O
erythroid O O
specific O O
. O O

Functional O O
analysis O O
of O O
fNF-E2 B B_GENE
promoter I I_GENE
showed O O
that O O
the O O
promoter O O
is O O
active O O
only O O
in O O
erythroid-megakaryocytic O O
cells O O
and O O
that O O
the O O
double B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
GATA I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sit I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
e O O
in O O
the O O
proximal O O
region O O
is O O
necessary O O
for O O
its O O
efficient O O
activity O O
. O O

CONCLUSION O O
: O O
These O O
results O O
suggest O O
that O O
GATA B B_GENE
proteins I I_GENE
, O O
which O O
govern O O
the O O
differentiation O O
of O O
erythroid O O
lineage O O
cells O O
, O O
are O O
required O O
for O O
full O O
promoter O O
activity O O
of O O
the O O
p45 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Transcriptional O O
activation O O
of O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
functional O O
significance O O
in O O
acetaminophen-induced O O
hepatitis O O
and O O
hepatocellular O O
injury O O
in O O
the O O
rat O O
. O O

BACKGROUND/AIM O O
: O O
Glutathione O O
depletion O O
contributes O O
to O O
acetaminophen O O
hepatotoxicity O O
and O O
is O O
known O O
to O O
induce O O
the O O
oxidative O O
stress O O
reactant O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
metabolites O O
of O O
the O O
heme O O
oxygenase O O
pathway O O
, O O
biliverdin O O
, O O
carbon O O
monoxide O O
, O O
and O O
iron O O
may O O
modulate O O
acetaminophen O O
toxicity O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
assess O O
cell-type O O
specific O O
expression O O
of O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
impact O O
on O O
liver O O
injury O O
and O O
microcirculatory O O
disturbances O O
in O O
a O O
model O O
of O O
acetaminophen-induced O O
hepatitis O O
. O O

METHODS O O
: O O
Gene O O
expression O O
of O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
studied O O
by O O
Northern- O O
and O O
Western O O
analysis O O
as O O
well O O
as O O
immunohistochemistry O O
. O O

The O O
time O O
course O O
of O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
cytokine-induced B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
neutrophil I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chemoattractant-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
was O O
studied O O
by O O
Northern O O
analysis O O
. O O

DNA-binding O O
activity O O
of O O
nuclear B B_GENE
factor-kappaB I I_GENE
was O O
determined O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

Sinusoidal O O
perfusion O O
and O O
leukocyte-endothelial O O
interactions O O
were O O
assessed O O
by O O
intravital O O
microscopy O O
. O O

RESULTS O O
: O O
Acetaminophen O O
caused O O
a O O
moderate O O
sinusoidal O O
perfusion O O
failure O O
( O O
-15 O O
% O O
) O O
and O O
infiltration O O
of O O
neutrophils O O
along O O
with O O
activation O O
of O O
nuclear B B_GENE
factor-kappaB I I_GENE
and O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
and O O
cytokine-induced B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
neutrophil I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chemoattractant-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs O O
. O O

Induction O O
of O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA O O
and O O
protein O O
( O O
approximately O O
30-fold O O
) O O
in O O
hepatocytes O O
and O O
non-parenchymal O O
cells O O
paralleled O O
the O O
inflammatory O O
response O O
. O O

Blockade O O
of O O
heme O O
oxygenase O O
activity O O
with O O
tin-protoporphyrin-IX O O
abrogated O O
acetaminophen-induced O O
hepatic O O
neutrophil O O
accumulation O O
and O O
nuclear B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor-kappaB I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
, O O
but O O
failed O O
to O O
affect O O
sinusoidal O O
perfusion O O
and O O
liver O O
injury O O
. O O

CONCLUSIONS O O
: O O
The O O
inflammatory O O
response O O
associated O O
with O O
acetaminophen O O
hepatotoxicity O O
is O O
modulated O O
by O O
the O O
parallel O O
induction O O
of O O
the O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
data O O
argue O O
against O O
a O O
central O O
role O O
of O O
nuclear B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
factor-kappaB I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
activation O O
and O O
neutrophil O O
infiltration O O
as O O
perpetuating O O
factors O O
of O O
liver O O
injury O O
in O O
acetaminophen O O
toxicity O O
. O O

Tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-induced O O
proliferation O O
requires O O
synthesis O O
of O O
granulocyte-macrophage B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVE O O
: O O
Tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
necrosis I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
induces O O
a O O
variety O O
of O O
cellular O O
responses O O
, O O
some O O
of O O
them O O
being O O
at O O
least O O
seemingly O O
contradictory O O
. O O

Direct O O
and O O
indirect O O
signaling O O
mechanisms O O
, O O
including O O
NF-kappaB B B_GENE
activation O O
and O O
cytokine O O
synthesis O O
, O O
were O O
analyzed O O
. O O

Nevertheless O O
, O O
inhibitors O O
of O O
these O O
pathways O O
clearly O O
reduced O O
the O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-induced O O
cell O O
growth O O
, O O
indicating O O
that O O
TNF- O O
alpha-proliferative O O
cells O O
produced O O
a O O
growth O O
factor O O
that O O
induced O O
proliferation O O
upon O O
stimulation O O
of O O
the O O
above O O
pathways O O
. O O

Anti-GM-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibited O O
the O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-induced O O
growth O O
, O O
suggesting O O
the O O
presence O O
of O O
an O O
autocrine O O
loop O O
for O O
cell O O
proliferation O O
mediated O O
by O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
show O O
for O O
the O O
first O O
time O O
that O O
TNF-alpha-treated O O
cell O O
lines O O
producing O O
no O O
or O O
only O O
minimal O O
amounts O O
of O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
demonstrate O O
an O O
apoptotic O O
phenotype O O
, O O
while O O
cell O O
lines O O
with O O
high O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O O
rates O O
can O O
escape O O
from O O
growth O O
arrest O O
or O O
even O O
apoptosis O O
. O O

In O O
this O O
context O O
, O O
we O O
discuss O O
arguments O O
pointing O O
at O O
NF-kappaB B B_GENE
as O O
regulator O O
of O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synthesis O O
and O O
thus O O
indirectly O O
as O O
regulator O O
for O O
the O O
escape O O
of O O
TNF-alpha B B_DISEASE/B_GENE
-induced O O
apoptosis O O

Glucocorticoid B B_GENE/B_MEASURE
receptor I I_GENE/I_MEASURE
content O O
of O O
T O O
lymphocytes O O
: O O
evidence O O
for O O
heterogeneity O O
. O O

T O O
cells O O
isolated O O
by O O
nylon O O
wool O O
filtration O O
specifically O O
bind O O
6.7 O O
+/- O O
0.2 O O
fmol O O
of O O
dexamethasone O O
per O O
million O O
cells O O
( O O
equivalent O O
to O O
4000 O O
+/- O O
200 O O
receptors O O
per O O
cell O O
) O O
, O O
whereas O O
T O O
cells O O
isolated O O
by O O
E-rosette O O
sedimentation O O
bind O O
12.0 O O
+/- O O
0.7 O O
fmol O O
of O O
dexamethasone O O
per O O
million O O
cells O O
( O O
equivalent O O
to O O
7200 O O
+/- O O
400 O O
receptors O O
per O O
cell O O
) O O
. O O

The O O
binding O O
affinities O O
of O O
the O O
different O O
T O O
cell O O
preparations O O
for O O
dexamethasone O O
were O O
similar O O
. O O

T O O
cells O O
that O O
are O O
isolated O O
by O O
a O O
combination O O
of O O
nylon O O
wool O O
filtration O O
followed O O
by O O
E-rosette O O
sedimentation O O
bind O O
the O O
same O O
amount O O
of O O
dexamethasone O O
as O O
T O O
cells O O
isolated O O
by O O
nylon O O
wool O O
filtration O O
alone O O
. O O

T O O
cells O O
isolated O O
by O O
a O O
combination O O
of O O
E-rosette O O
sedimentation O O
following O O
by O O
nylon O O
wool O O
filtration O O
bind O O
less O O
dexamethasone O O
than O O
do O O
T O O
cells O O
isolated O O
by O O
E-rosette O O
sedimentation O O
alone O O
. O O

These O O
findings O O
suggest O O
that O O
T O O
cells O O
are O O
heterogeneous O O
with O O
respect O O
to O O
their O O
quantity O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Isolation O O
of O O
T O O
cells O O
by O O
E-rosette O O
sedimentation O O
enriches O O
for O O
T O O
cells O O
that O O
have O O
a O O
greater O O
number O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
isolation O O
of O O
T O O
cells O O
by O O
nylon O O
wool O O
filtration O O
enriches O O
for O O
T O O
cells O O
that O O
have O O
a O O
lesser O O
number O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O O

A O O
number O O
of O O
leukemia O O
cell O O
lines O O
in O O
continuous O O
culture O O
were O O
also O O
subjected O O
to O O
the O O
GR B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assay O O
, O O
and O O
the O O
results O O
were O O
correlated O O
with O O
the O O
sensitivity O O
of O O
these O O
cell O O
lines O O
to O O
glucocorticoid O O
steroids O O
in O O
vitro O O
. O O

The O O
GR B B_PROTEIN[GENE]/B_DISEASE
content O O
of O O
normal O O
human O O
lymphocytes O O
amounted O O
to O O
4 O O
, O O
850 O O
+/- O O
1 O O
, O O
340 O O
( O O
mean O O
+/- O O
SD O O
) O O
receptors/cell O O
. O O

The O O
mean O O
equilibrium O O
dissociation O O
constant O O
( O O
KD O O
) O O
of O O
the O O
interaction O O
of O O
[ O O
3H O O
] O O
dexamethasone O O
with O O
the O O
GR B B_PROTEIN[GENE]/B_DISEASE
was O O
1.2 O O
x O O
10 O O
( O O
-8 O O
) O O
M O O
. O O

The O O
GR B B_PROTEIN[GENE]/B_DISEASE
content O O
of O O
the O O
blast O O
cells O O
obtained O O
from O O
eight O O
patients O O
suffering O O
from O O
acute O O
leukemia O O
and O O
four O O
patients O O
with O O
a O O
blast O O
crisis O O
of O O
chronic O O
myelocytic O O
leukemia O O
was O O
found O O
to O O
be O O
highly O O
variable O O
( O O
3 O O
, O O
230-29 O O
, O O
900 O O
receptors/cell O O
) O O
, O O
while O O
the O O
lymphocytes O O
of O O
six O O
patients O O
with O O
chronic O O
lymphatic O O
leukemia O O
contained O O
a O O
rather O O
stable O O
GR B B_PROTEIN[GENE]/B_DISEASE
content O O
( O O
2 O O
, O O
930-5 O O
, O O
120 O O
receptors/cell O O
) O O
, O O
which O O
was O O
comparable O O
with O O
that O O
of O O
normal O O
lymphocytes O O
. O O

GR B B_GENE/B_DISEASE
was O O
identified O O
in O O
all O O
the O O
12 O O
malignant O O
continuous O O
white O O
cell O O
lines O O
studied O O
. O O

Large O O
cells O O
contained O O
more O O
GR B B_GENE/B_DISEASE
than O O
the O O
smaller O O
ones O O
. O O

We O O
conclude O O
that O O
the O O
presence O O
of O O
GR B B_GENE/B_DISEASE
is O O
probably O O
a O O
universal O O
feature O O
of O O
the O O
leukemic O O
cells O O
, O O
and O O
, O O
from O O
a O O
clinical O O
standpoint O O
, O O
probably O O
does O O
not O O
alone O O
imply O O
steroid O O
responsiveness O O
. O O

Evidence O O
for O O
a O O
steroid B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
receptor I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
rheumatoid O O
synovial O O
tissue O O
cells O O
. O O

This O O
report O O
is O O
of O O
an O O
investigation O O
into O O
such O O
a O O
possibility O O
in O O
synovial O O
cells O O
. O O

These O O
, O O
together O O
with O O
cells O O
obtained O O
from O O
synovial O O
fluid O O
aspirated O O
from O O
patients O O
with O O
rheumatoid O O
arthritis O O
, O O
were O O
identified O O
by O O
electron O O
microscopy O O
. O O

Duplicate O O
samples O O
of O O
these O O
cell O O
suspensions O O
were O O
incubated O O
with O O
increasing O O
concentrations O O
of O O
H3Dexamethasone O O
( O O
1 O O
x O O
10 O O
( O O
-10 O O
) O O
M-1 O O
x O O
10 O O
( O O
-9 O O
) O O
M O O
) O O
for O O
30 O O
minutes O O
at O O
37 O O
degrees O O
C O O
. O O

Analysis O O
of O O
the O O
proportion O O
of O O
steroid O O
bound O O
to O O
whole O O
cells O O
showed O O
evidence O O
for O O
specific O O
, O O
rapidly O O
saturable O O
, O O
receptors O O
in O O
the O O
cells O O
obtained O O
from O O
synovial O O
tissue O O
, O O
but O O
this O O
was O O
not O O
found O O
in O O
synovial O O
fluid O O
cells O O
. O O

Electron O O
micrographs O O
showed O O
that O O
cells O O
obtained O O
from O O
synovial O O
tissue O O
consisted O O
of O O
synovial O O
fibroblast O O
- O O
and O O
macrophage-types O O
, O O
lymphocytes O O
, O O
monocytes O O
and O O
macrophages O O
. O O

Polymorphonuclear O O
leucocytes O O
appeared O O
to O O
be O O
absent O O
. O O

However O O
, O O
in O O
synovial O O
fluid O O
cell O O
type O O
polymorphonuclear O O
leucocytes O O
were O O
the O O
predominant O O
cell O O
type O O
. O O

We O O
concluded O O
from O O
this O O
, O O
that O O
one O O
or O O
more O O
of O O
the O O
cell O O
types O O
present O O
in O O
synovial O O
tissue O O
contain O O
a O O
specific B B_GENE
steroid I I_GENE
receptor I I_GENE
, O O
but O O
that O O
this O O
is O O
lacking O O
in O O
synovial O O
fluid O O
polymorphonuclear O O
leucocytes O O
. O O

Clinical O O
implications O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O O
leukemia O O
. O O

Normal O O
lymphocytes O O
contain O O
low O O
levels O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
( O O
approximately O O
2 O O
, O O
500 O O
sites/cell O O
) O O
which O O
are O O
identical O O
in O O
T- O O
and O O
non-T-fractions O O
. O O

Leukemic O O
lymphoblasts O O
contain O O
larger O O
numbers O O
of O O
receptor O O
sites O O
. O O

Quantitative O O
determination O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
levels O O
in O O
acute O O
lymphoblastic O O
leukemia O O
may O O
be O O
of O O
value O O
both O O
as O O
an O O
independent O O
prognostic O O
variable O O
and O O
in O O
suggesting O O
which O O
patients O O
should O O
receive O O
glucocorticoid O O
therapy O O
. O O

Functional O O
and O O
physical O O
interaction O O
of O O
protein-tyrosine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Fyn I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Csk I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
T-cell O O
signaling O O
system O O
. O O

The O O
Src-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein-tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Fyn B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
associated O O
with O O
T-cell B B_DISEASE/B_GENE
antigen I I_DISEASE/I_GENE
receptor I I_DISEASE/I_GENE
. O O

Transient O O
expression O O
of O O
actively O O
mutated O O
Fyn B B_GENE
, O O
having O O
Phe-528 O O
instead O O
of O O
Tyr-528 O O
or O O
Thr-338 O O
instead O O
of O O
Ile-338 O O
, O O
in O O
Jurkat O O
T-cells O O
stimulated B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SRE B B_GENE/B_DISEASE
) O O
, O O
12-O-tetradecanoyl-phorbol-13-acetate B B_GENE/B_LOCATION
response I I_GENE/I_LOCATION
element I I_GENE/I_LOCATION
, O O
cyclic B B_GENE
AMP I I_GENE
response I I_GENE
element I I_GENE
, O O
and O O
c-fos B B_GENE
promoter I I_GENE
. O O

The O O
stimulation O O
of O O
SRE B B_DISEASE/B_GENE
was O O
particularly O O
prominent O O
not O O
only O O
with O O
active O O
Fyn B B_GENE/B_DISEASE
but O O
also O O
with O O
normal B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wild-type I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fyn I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Under O O
the O O
same O O
conditions O O
, O O
Lck B B_GENE/B_BACTERIUM[BIO]
did O O
not O O
stimulate O O
IL-2 B B_GENE
promoter I I_GENE
unless O O
it O O
was O O
activated O O
by O O
mutation O O
. O O

Interestingly O O
, O O
a O O
mutant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Fyn I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
has O O
deletions O O
within O O
the O O
SH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
so O O
is O O
able O O
to O O
transform O O
chicken O O
embryo O O
fibroblasts O O
, O O
did O O
not O O
stimulate O O
either O O
the O O
c-fos B B_GENE
or I I_GENE
IL-2 I I_GENE
promoter I I_GENE
, O O
suggesting O O
the O O
importance O O
of O O
this O O
region O O
in O O
T-cell O O
signaling O O
. O O

Csk B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
phosphorylates O O
tyrosine O O
residues O O
in O O
the O O
negative O O
regulatory O O
sites O O
of O O
Src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
down-regulated O O
Fyn- O O
and O O
Lck-mediated O O
stimulation O O
of O O
the O O
serum B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Fyn-mediated O O
enhancement O O
of O O
IL-2 B B_GENE
promoter I I_GENE
activity O O
. O O

These O O
data O O
suggest O O
that O O
Fyn B B_GENE/B_LOCATION
and O O
Lck B B_GENE/B_BACTERIUM[BIO]
, O O
whose O O
activities O O
are O O
regulated O O
by O O
Csk B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
are O O
involved O O
in O O
different O O
phases O O
of O O
T-cell O O
activation O O
. O O

A O O
novel O O
NF-kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
complex I I_GENE/I_LOCATION
containing O O
p65 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
implications O O
for O O
transcriptional O O
control O O
at O O
the O O
level O O
of O O
subunit O O
dimerization O O
. O O

We O O
now O O
provide O O
direct O O
biochemical O O
evidence O O
for O O
the O O
presence O O
of O O
an O O
endogenous O O
pool O O
of O O
inducible O O
p65 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
intact O O
human O O
T O O
cells O O
. O O

Site-directed O O
mutagenesis O O
studies O O
indicate O O
that O O
the O O
homodimerization O O
function O O
of O O
p65 B B_GENE
is O O
dependent O O
upon O O
the O O
presence O O
of O O
cysteine O O
216 O O
and O O
a O O
conserved O O
recognition O O
motif O O
for O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
( O O
RRPS B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O
amino O O
acids O O
273 O O
to O O
276 O O
) O O
, O O
both O O
of O O
which O O
reside O O
within O O
a O O
91-amino-acid O O
segment O O
of O O
the O O
Rel B B_GENE
homology I I_GENE
domain I I_GENE
that O O
mediates O O
self-association O O
. O O

In O O
contrast O O
, O O
mutations O O
at O O
these O O
two O O
sites O O
do O O
not O O
affect O O
heterodimerization O O
of O O
p65 B B_GENE
with O O
p50 B B_GENE
or O O
its O O
functional O O
interaction O O
with O O
I O O
kappa O O
B O O
alpha O O
. O O

Taken O O
together O O
with O O
prior O O
in O O
vivo O O
transcription O O
studies O O
, O O
these O O
results O O
suggest O O
that O O
the O O
biological O O
activities O O
of O O
p65 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p50 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
independently O O
regulated O O
, O O
thereby O O
providing O O
an O O
integrated O O
and O O
flexible O O
control O O
mechanism O O
for O O
the O O
rapid O O
activation O O
and O O
repression O O
of O O
NF-kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
/ O O
Rel B B_GENE/B_DISEASE
-directed O O
gene O O
expression O O
. O O

We O O
report O O
the O O
development O O
of O O
a O O
relatively O O
quick O O
and O O
simple O O
method O O
for O O
the O O
assessment O O
of O O
X O O
inactivation O O
status O O
for O O
carrier O O
determination O O
in O O
families O O
affected O O
by O O
X-linked O O
agammaglobulinemia O O
( O O
XLA O O
) O O
. O O

This O O
method O O
utilises O O
an O O
immunomagnetic O O
separation O O
technique O O
for O O
B O O
cell O O
purification O O
and O O
a O O
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
based O O
assay O O
for O O
the O O
determination O O
of O O
methylation O O
status O O
at O O
the O O
androgen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
assess O O
whether O O
X O O
inactivation O O
is O O
random O O
or O O
non-random O O
at O O
this O O
locus O O
. O O

We O O
report O O
the O O
results O O
we O O
have O O
obtained O O
using O O
this O O
assay O O
to O O
investigate O O
females O O
known O O
to O O
be O O
carriers O O
of O O
various O O
X-linked O O
immunodeficiency O O
disorders O O
. O O

In O O
addition O O
, O O
we O O
investigated O O
four O O
females O O
from O O
different O O
families O O
affected O O
by O O
XLA O O
, O O
two O O
of O O
whom O O
were O O
of O O
unknown O O
carrier O O
status O O
, O O
and O O
we O O
discuss O O
the O O
results O O
obtained O O
with O O
this O O
and O O
other O O
X-inactivation O O
assays O O
. O O

A O O
similar O O
assay O O
has O O
recently O O
been O O
described O O
by O O
Allen O O
et O O
al. O O
( O O
1992 O O
) O O
and O O
applied O O
to O O
members O O
of O O
one O O
family O O
affected O O
by O O
XLA O O
. O O

Effects O O
of O O
IL-4 B B_GENE
and O O
Fc B B_GENE/B_LOCATION
gamma I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
II I I_GENE/I_LOCATION
engagement O O
on O O
Egr-1 B B_GENE
expression O O
during O O
stimulation O O
of O O
B O O
lymphocytes O O
by O O
membrane O O
immunoglobulin O O
crosslinking O O
. O O

Egr-1 B B_GENE
is O O
an O O
immediate B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
early I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
is O O
rapidly O O
upregulated O O
in O O
response O O
to O O
mitogenic O O
signals O O
induced O O
by O O
antigen O O
receptor O O
crosslinking O O
on O O
murine O O
B O O
lymphocytes O O
. O O

It O O
has O O
been O O
shown O O
that O O
levels O O
of O O
Egr-1 B B_GENE
expression O O
are O O
closely O O
correlated O O
with O O
B O O
cell O O
proliferation O O
in O O
several O O
models O O
of O O
B O O
cell O O
activation O O
and O O
tolerance O O
. O O

We O O
compared O O
the O O
expression O O
of O O
Egr-1 B B_GENE
during O O
B O O
cell O O
stimulation O O
with O O
Fab'2 B B_GENE
and O O
IgG B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
anti-immunoglobulin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
anti-Ig B B_GENE/B_LOCATION
) O O
, O O
since O O
it O O
is O O
known O O
that O O
Fab'2 B B_GENE
anti-Ig I I_GENE
is O O
mitogenic O O
while O O
IgG B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
anti-Ig I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
, O O
owing O O
to O O
a O O
dominant O O
inhibitory O O
effect O O
of O O
crosslinking O O
the O O
B B B_GENE
cell I I_GENE
Fc I I_GENE
gamma I I_GENE
RII I I_GENE
to O O
membrane B B_GENE
Ig I I_GENE
. O O

No O O
corresponding O O
increases O O
in O O
Egr-1 B B_GENE
mRNA I I_GENE
levels O O
are O O
observed O O
when O O
IL-4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
added O O
. O O

Identification O O
of O O
a O O
novel O O
cyclosporin-sensitive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
tumor I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
necrosis I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factor I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
alpha I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
promoter I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF-alpha B B_GENE/B_LOCATION
) O O
, O O
a O O
cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
with O O
pleiotropic O O
biological O O
effects O O
, O O
is O O
produced O O
by O O
a O O
variety O O
of O O
cell O O
types O O
in O O
response O O
to O O
induction O O
by O O
diverse O O
stimuli O O
. O O

In O O
this O O
paper O O
, O O
TNF-alpha B B_GENE/B_LOCATION
mRNA I I_GENE/I_LOCATION
is O O
shown O O
to O O
be O O
highly O O
induced O O
in O O
a O O
murine O O
T O O
cell O O
clone O O
by O O
stimulation O O
with O O
T B B_GENE
cell I I_GENE
receptor I I_GENE
( O O
TCR B B_PROTEIN[GENE]/B_LOCATION
) O O
ligands O O
or O O
by O O
calcium O O
ionophores O O
alone O O
. O O

Induction O O
is O O
rapid O O
, O O
does O O
not O O
require O O
de O O
novo O O
protein O O
synthesis O O
, O O
and O O
is O O
completely O O
blocked O O
by O O
the O O
immunosuppressant O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
. O O

We O O
have O O
identified O O
a O O
human B B_GENE/B_PERSON
TNF-alpha I I_GENE/I_PERSON
promoter I I_GENE/I_PERSON
element I I_GENE/I_PERSON
, O O
kappa B B_PROTEIN[GENE]/B_LOCATION
3 I I_PROTEIN[GENE]/I_LOCATION
, O O
which O O
plays O O
a O O
key O O
role O O
in O O
the O O
calcium-mediated O O
inducibility O O
and O O
CsA O O
sensitivity O O
of O O
the O O
gene O O
. O O

In O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
an O O
oligonucleotide O O
containing O O
kappa B B_GENE
3 I I_GENE
forms O O
two O O
DNA O O
protein O O
complexes O O
with O O
proteins O O
that O O
are O O
present O O
in O O
extracts O O
from O O
unstimulated O O
T O O
cells O O
. O O

These O O
complexes O O
appear O O
in O O
nuclear O O
extracts O O
only O O
after O O
T O O
cell O O
stimulation O O
. O O

Induction O O
of O O
the O O
inducible O O
nuclear B B_GENE
complexes I I_GENE
is O O
rapid O O
, O O
independent O O
of O O
protein O O
synthesis O O
, O O
and O O
blocked O O
by O O
CsA O O
, O O
and O O
thus O O
, O O
exactly O O
parallels O O
the O O
induction O O
of O O
TNF-alpha B B_GENE
mRNA I I_GENE
by O O
TCR O O
ligands O O
or O O
by O O
calcium O O
ionophore O O
. O O

Our O O
studies O O
indicate O O
that O O
the O O
kappa B B_PROTEIN[GENE]/B_MEASURE
3 I I_PROTEIN[GENE]/I_MEASURE
binding I I_PROTEIN[GENE]/I_MEASURE
factor I I_PROTEIN[GENE]/I_MEASURE
resembles O O
the O O
preexisting O O
component O O
of O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
activated O O
T O O
cells O O
. O O

Thus O O
, O O
the O O
TNF-alpha B B_GENE
gene I I_GENE
is O O
an O O
immediate O O
early O O
gene O O
in O O
activated O O
T O O
cells O O
and O O
provides O O
a O O
new O O
model O O
system O O
in O O
which O O
to O O
study O O
CsA-sensitive B B_GENE/B_DISEASE
gene I I_GENE/I_DISEASE
induction O O
in O O
activated O O
T O O
cells O O
. O O

Differences O O
in O O
expression O O
of O O
transcription B B_GENE
factor I I_GENE
AP-1 I I_GENE
in O O
human O O
promyelocytic O O
HL-60 O O
cells O O
during O O
differentiation O O
towards O O
macrophages O O
versus O O
granulocytes O O
. O O

Commitment O O
of O O
HL-60 O O
cells O O
to O O
macrophage O O
or O O
granulocytic O O
differentiation O O
was O O
achieved O O
by O O
incubation O O
with O O
4 O O
beta-phorbol O O
12-myristate O O
13-acetate O O
( O O
PMA O O
) O O
for O O
30-60 O O
min O O
or O O
with O O
dimethyl O O
sulphoxide O O
( O O
DMSO O O
) O O
for O O
24 O O
h O O
respectively O O
. O O

The O O
commitment O O
stage O O
towards O O
PMA-induced O O
macrophage O O
differentiation O O
was O O
associated O O
with O O
increases O O
in O O
jun O O
B O O
and O O
c-fos O O
mRNA O O
levels O O
, O O
as O O
well O O
as O O
with O O
an O O
increase O O
in O O
the O O
binding O O
activity O O
of O O
transcription B B_GENE
factor I I_GENE
AP-1 I I_GENE
. O O

Nevertheless O O
, O O
gel O O
retardation O O
analysis O O
indicated O O
that O O
the O O
AP-1 B B_GENE
activity O O
detected O O
in O O
untreated O O
cells O O
was O O
drastically O O
reduced O O
during O O
the O O
commitment O O
stage O O
of O O
DMSO-induced O O
HL-60 O O
differentiation O O
towards O O
granulocytes O O
. O O

Treatment O O
of O O
HL-60 O O
cells O O
with O O
1 O O
alpha O O
, O O
25-dihydroxyvitamin O O
D3 O O
, O O
another O O
monocytic O O
differentiation O O
agent O O
, O O
induced O O
a O O
weak O O
, O O
but O O
appreciable O O
, O O
increase O O
in O O
AP-1 B B_GENE
activity O O
. O O

Furthermore O O
, O O
addition O O
of O O
sodium O O
butyrate O O
or O O
1 O O
alpha O O
, O O
25-dihydroxyvitamin O O
D3 O O
to O O
HL-60 O O
cells O O
induced O O
the O O
expression O O
of O O
c-fos B B_GENE
, I I_GENE
c-jun I I_GENE
, I I_GENE
jun I I_GENE
B I I_GENE
and I I_GENE
jun I I_GENE
D I I_GENE
proto-oncogenes I I_GENE
. O O

In O O
contrast O O
, O O
when O O
HL-60 O O
cells O O
were O O
treated O O
with O O
retinoic O O
acid O O
, O O
a O O
granulocytic O O
differentiation O O
inducer O O
, O O
no O O
enhanced O O
AP-1 O O
binding O O
activity O O
was O O
observed O O
, O O
and O O
only O O
a O O
weak O O
increase O O
in O O
jun B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
D I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
level O O
was O O
detected O O
. O O

These O O
data O O
indicate O O
that O O
formation O O
of O O
AP-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
required O O
for O O
the O O
induction O O
of O O
HL-60 O O
differentiation O O
towards O O
granulocytes O O
, O O
whereas O O
induction O O
of O O
monocytic O O
differentiation O O
is O O
correlated O O
with O O
an O O
increase O O
in O O
AP-1 B B_GENE
activity O O
. O O

The O O
differential O O
expression O O
of O O
AP-1 B B_GENE
activity O O
may O O
be O O
critical O O
in O O
the O O
differentiation O O
of O O
HL-60 O O
cells O O
towards O O
monocytic O O
or O O
granulocytic O O
lineages O O

In O O
the O O
normal O O
lymphocytes O O
there O O
were O O
3 O O
, O O
875 O O
( O O
Median O O
) O O
specific O O
binding O O
sites O O
per O O
cell O O
. O O

The O O
blasts O O
from O O
17 O O
patients O O
with O O
ANLL O O
had O O
on O O
average O O
higher O O
levels O O
of O O
binding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
per O O
cell O O
( O O
Median O O
= O O
7 O O
, O O
250 O O
, O O
range O O
: O O
0 O O
to O O
15 O O
, O O
295 O O
) O O
than O O
the O O
other O O
leukemias O O
. O O

Of O O
the O O
15 O O
patients O O
with O O
CLL O O
, O O
six O O
had O O
received O O
glucocorticoid O O
treatment O O
for O O
3 O O
to O O
5 O O
years O O
. O O

Their O O
lymphocytes O O
had O O
lower O O
number O O
of O O
receptors O O
( O O
Median O O
= O O
2 O O
, O O
000 O O
) O O
than O O
the O O
other O O
cases O O
which O O
were O O
newly O O
diagnosed O O
( O O
Median O O
= O O
4 O O
, O O
500 O O
) O O
. O O

Four O O
patients O O
had O O
ALL/AUL O O
, O O
three O O
patients O O
had O O
blast O O
crisis O O
as O O
terminal O O
phase O O
of O O
CML O O
, O O
and O O
seven O O
had O O
leukemic O O
Non-Hodgkin O O
lymphomas O O
( O O
Median O O
= O O
3 O O
, O O
500 O O
sites/cell O O
) O O
. O O

In O O
24 O O
patients O O
we O O
have O O
also O O
studied O O
the O O
in O O
vitro O O
sensitivity O O
of O O
the O O
leukemic O O
cells O O
to O O
dexamethasone O O
. O O

There O O
was O O
no O O
marked O O
correlation O O
between O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
and O O
in O O
vitro O O
sensitivity O O
. O O

An O O
attempt O O
to O O
correlate O O
receptor O O
levels O O
with O O
clinical O O
responsiveness O O
demonstrated O O
that O O
glucocorticoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
determination O O
might O O
be O O
of O O
value O O
in O O
patients O O
with O O
lymphoid O O
malignancies O O
but O O
probably O O
not O O
in O O
patients O O
with O O
other O O
leukemias O O
. O O

For O O
cytoplasmic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid-receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
enter O O
and O O
accumulate O O
in O O
the O O
nucleus O O
a O O
temperature-dependent O O
event O O
, O O
'activation O O
' O O
is O O
required O O
. O O

Granulocytes O O
in O O
the O O
endometrium O O
of O O
post-partum O O
women O O
. O O

Endometrial O O
samples O O
of O O
women O O
at O O
various O O
stages O O
of O O
gonadal O O
activity O O
after O O
parturition O O
were O O
examined O O
for O O
the O O
presence O O
and O O
numbers O O
of O O
endometrial O O
granulocytes O O
. O O

Although O O
samples O O
at O O
all O O
the O O
stages O O
contained O O
significant O O
numbers O O
of O O
the O O
granulocytes O O
( O O
i.e. O O
greater O O
than O O
7/high-power O O
field O O
) O O
, O O
the O O
100 O O
% O O
values O O
for O O
late-proliferative O O
and O O
adaptation O O
hyperplasia O O
were O O
significantly O O
higher O O
than O O
the O O
values O O
for O O
the O O
resting O O
( O O
81.8 O O
% O O
) O O
, O O
early O O
( O O
82.4 O O
% O O
) O O
and O O
mid- O O
( O O
87.9 O O
% O O
) O O
proliferative O O
and O O
secretory O O
( O O
83.3 O O
% O O
) O O
phases O O
. O O

Interaction O O
of O O
glucocorticoids O O
with O O
macrophages O O
. O O

Identification O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
monocytes O O
and O O
macrophages O O
. O O

Two O O
assays O O
of O O
binding O O
were O O
used O O
-- O O
an O O
assay O O
with O O
intact O O
cells O O
in O O
suspension O O
or O O
monolayers O O
, O O
and O O
an O O
assay O O
of O O
cytosol O O
and O O
nuclear O O
forms O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cortisol O O
, O O
corticosterone O O
, O O
and O O
progesterone O O
competed O O
with O O
dexamethasone O O
for O O
binding O O
, O O
whereas O O
estradiol O O
, O O
dihydrotestosterone O O
, O O
and O O
11-epicortisol O O
competed O O
very O O
little O O
. O O

Binding O O
of O O
dexamethasone O O
to O O
cytosol O O
and O O
nuclear O O
forms O O
of O O
the O O
receptor B B_GENE
complex I I_GENE
and O O
temperature-sensitive O O
translocation O O
of O O
cytosol O O
forms O O
to O O
nuclear O O
forms O O
were O O
shown O O
. O O

At O O
37 O O
degrees O O
C O O
the O O
predominant O O
form O O
of O O
the O O
hormone-receptor B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
nuclear O O
. O O

Nitric O O
oxide O O
signaling O O
: O O
a O O
possible O O
role O O
for O O
G B B_GENE/B_DISEASE
proteins I I_GENE/I_DISEASE
. O O

We O O
have O O
previously O O
reported O O
various O O
inductive O O
effects O O
of O O
nitric O O
oxide O O
on O O
human O O
PBMC O O
. O O

We O O
describe O O
a O O
novel O O
and O O
potentially O O
important O O
mechanism O O
of O O
nitric O O
oxide O O
signaling-through O O
direct O O
activation O O
of O O
guanine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
G B B_GENE/B_DISEASE
proteins I I_GENE/I_DISEASE
) O O
. O O

We O O
have O O
found O O
that O O
nitric O O
oxide O O
treatment O O
of O O
membranes O O
isolated O O
from O O
fresh O O
human O O
PBMC O O
enhances O O
the O O
ability O O
of O O
these O O
membranes O O
to O O
hydrolyze O O
[ O O
gamma-32P O O
] O O
GTP O O
and O O
bind O O
[ O O
gamma-35S O O
] O O
GTP O O
. O O

In O O
addition O O
, O O
treatment O O
of O O
whole O O
cells O O
with O O
nitric O O
oxide O O
yielded O O
membranes O O
with O O
enhanced O O
GTPase O O
activity O O
. O O

Furthermore O O
, O O
the O O
GTPase O O
activity O O
of O O
pure O O
, O O
recombinant O O
Gs B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Gi B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
p21ras B B_GENE
was O O
greatly O O
enhanced O O
by O O
nitric O O
oxide O O
. O O

In O O
support O O
of O O
the O O
existence O O
of O O
this O O
pathway O O
in O O
whole O O
cells O O
, O O
we O O
found O O
that O O
the O O
G O O
protein O O
inhibitor O O
, O O
GDP-beta-S O O
, O O
blocked O O
NF-kappa B B_GENE
B I I_GENE
translocation O O
induced O O
by O O
nitric O O
oxide O O
or O O
LPS O O
in O O
permeabilized O O
cells O O
. O O

In O O
addition O O
, O O
nitric O O
oxide O O
greatly O O
reduced O O
the O O
pertussis O O
toxin-mediated O O
ADP-ribosylation O O
of O O
45- B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
41-kDa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
membranes O O
of O O
these O O
cells O O
. O O

Because O O
G B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
play O O
a O O
central O O
role O O
in O O
many O O
diverse O O
signaling O O
systems O O
, O O
activation O O
by O O
an O O
endogenous O O
and O O
inducible O O
oxidant O O
may O O
represent O O
a O O
novel O O
signaling O O
pathway O O
. O O

The O O
granulocyte-macrophage B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cis-acting I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CLE0 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mediates O O
induction O O
signals O O
in O O
T O O
cells O O
and O O
is O O
recognized O O
by O O
factors O O
related O O
to O O
AP1 B B_GENE
and O O
NFAT B B_GENE
. O O

Expression O O
of O O
the O O
granulocyte-macrophage B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GM-CSF I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
T O O
cells O O
is O O
activated O O
by O O
the O O
combination O O
of O O
phorbol O O
ester O O
( O O
phorbol O O
myristate O O
acetate O O
) O O
and O O
calcium O O
ionophore O O
( O O
A23187 O O
) O O
, O O
which O O
mimic O O
antigen O O
stimulation O O
through O O
the O O
T-cell B B_GENE
receptor I I_GENE
. O O

We O O
have O O
previously O O
shown O O
that O O
a O O
fragment O O
containing O O
bp B B_GENE/B_LOCATION
-95 I B_GENE/I_LOCATION
to I B_GENE/I_LOCATION
+27 I B_GENE/I_LOCATION
of O O
the O O
mouse B B_GENE/B_LOCATION
GM-CSF I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
can O O
confer O O
inducibility O O
to O O
reporter B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
human O O
Jurkat O O
T-cell O O
line O O
. O O

Here O O
we O O
use O O
an O O
in O O
vitro O O
transcription O O
system O O
to O O
demonstrate O O
that O O
a O O
cis-acting B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
positions B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
-54 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
to I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
-40 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
, O O
referred O O
to O O
as O O
CLE0 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
a O O
target O O
for O O
the O O
induction O O
signals O O
. O O

We O O
observed O O
induction O O
with O O
templates O O
containing O O
intact O O
CLE0 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
not O O
with O O
templates O O
with O O
deleted B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CLE0 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
also O O
observed O O
that O O
two O O
distinct O O
signals O O
were O O
required O O
for O O
the O O
stimulation O O
through O O
CLE0 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
since O O
only O O
extracts O O
from O O
cells O O
treated O O
with O O
both O O
phorbol O O
myristate O O
acetate O O
and O O
A23187 O O
supported O O
optimal O O
induction O O
. O O

Stimulation O O
probably O O
was O O
mediated O O
by O O
CLE0-binding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
because O O
depletion O O
of O O
these O O
proteins O O
specifically O O
reduced O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transcription O O
. O O

Another O O
factor O O
resembled O O
the O O
T-cell-specific B B_GENE/B_PERSON
factor I I_GENE/I_PERSON
NFAT I I_GENE/I_PERSON
. O O

The O O
characteristics O O
of O O
these O O
two O O
factors O O
are O O
consistent O O
with O O
their O O
involvement O O
in O O
GM-CSF O O
induction O O
. O O

Identification O O
and O O
characterization O O
of O O
an O O
Alu-containing B B_GENE
, I I_GENE
T-cell-specific I I_GENE
enhancer I I_GENE
located O O
in O O
the O O
last O O
intron B B_GENE/B_LOCATION
of O O
the O O
human B B_GENE
CD8 I I_GENE
alpha I I_GENE
gene I I_GENE
. O O

Expression O O
of O O
the O O
human B B_GENE
CD8 I I_GENE
alpha I I_GENE
gene I I_GENE
is O O
restricted O O
to O O
cells O O
of O O
the O O
lymphoid O O
lineage O O
and O O
developmentally O O
regulated O O
during O O
thymopoiesis O O
. O O

By O O
using O O
a O O
reporter-based O O
expression O O
approach O O
, O O
a O O
T-cell-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
identified O O
by O O
its O O
close O O
association O O
with O O
a O O
prominent O O
T-cell-restricted B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
hypersensitive I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sites I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
last O O
intron O O
of O O
the O O
CD8 B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
. O O

DNA O O
sequence O O
analysis O O
of O O
the O O
minimal B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancer I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
a O O
striking O O
cluster O O
of O O
consensus B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
binding I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sites I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
for O O
Ets-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TCF-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CRE I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GATA-3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LyF-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
were O O
verified O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
. O O

Site-directed O O
mutation O O
of O O
the O O
Ets-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GATA-3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dramatically O O
reduced O O
enhancer O O
activity O O
. O O

The O O
functional O O
importance O O
of O O
the O O
other O O
binding O O
sites O O
only O O
became O O
apparent O O
when O O
combinations O O
of O O
mutations O O
were O O
analyzed O O
. O O

Taken O O
together O O
, O O
these O O
results O O
suggest O O
that O O
the O O
human B B_GENE
CD8 I I_GENE
alpha I I_GENE
gene I I_GENE
is O O
regulated O O
by O O
the O O
interaction O O
of O O
multiple O O
T-cell B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
transcriptional O O
enhancer O O
located O O
in O O
the O O
last O O
intron B B_GENE/B_LOCATION
of O O
the O O
gene O O
. O O

Comparison O O
of O O
the O O
CD8 B B_GENE
alpha I I_GENE
enhancer I I_GENE
with O O
other O O
recently O O
identified O O
T-cell-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
suggests O O
that O O
a O O
common O O
set O O
of O O
transcription B B_GENE/B_LOCATION
factors I I_GENE/I_LOCATION
regulates O O
several O O
T-cell B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Molecular O O
regulation O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL-3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
inducible O O
T O O
cell-restricted O O
expression O O
requires O O
intact O O
AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Elf-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-3 B B_GENE
) O O
is O O
a O O
hematopoietic B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem-cell I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentiation I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
is O O
expressed O O
solely O O
in O O
activated O O
T O O
and O O
NK O O
cells O O
. O O

Studies O O
to O O
date O O
have O O
identified O O
elements O O
5 O O
' O O
to O O
the O O
IL-3 B B_GENE
coding I I_GENE
sequences I I_GENE
that O O
regulate O O
its O O
transcription O O
, O O
but O O
the O O
sequences O O
that O O
confer O O
T O O
cell-specific O O
expression O O
remain O O
to O O
be O O
clearly O O
defined O O
. O O

We O O
have O O
now O O
identified O O
DNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
are O O
required O O
for O O
T O O
cell-restricted O O
IL-3 B B_GENE
gene I I_GENE
transcription O O
. O O

A O O
series O O
of O O
transient O O
transfections O O
performed O O
with O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL-3-chloramphenicol I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acetyltransferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CAT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmids I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
T O O
and O O
non-T O O
cells O O
revealed O O
that O O
a O O
plasmid B B_GENE/B_LOCATION
containing O O
319 O O
bp O O
of O O
5 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
' I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
flanking I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
active O O
exclusively O O
in O O
T O O
cells O O
. O O

DNaseI B B_GENE
footprint O O
and O O
electrophoretic O O
mobility O O
shift O O
assay O O
analyses O O
performed O O
with O O
MLA-144 O O
T O O
cell O O
nuclear O O
extracts O O
demonstrated O O
that O O
this O O
49-bp B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
a O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
includes O O
consensus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Elf-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O O
, O O
extracts O O
prepared O O
from O O
purified O O
human O O
T O O
cells O O
contained O O
proteins O O
that O O
bound O O
to O O
synthetic O O
oligonucleotides O O
corresponding O O
to O O
the O O
AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Elf-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Transient O O
transfection O O
studies O O
in O O
MLA-144 O O
T O O
cells O O
revealed O O
that O O
constructs O O
containing O O
mutations O O
in O O
the O O
AP-1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
almost O O
completely O O
abolished O O
CAT O O
activity O O
while O O
mutation O O
of O O
the O O
Elf-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
the O O
NF-IL-3 B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
, O O
a O O
previously O O
described O O
nuclear B B_GENE/B_LOCATION
protein I B_GENE/I_LOCATION
binding I B_GENE/I_LOCATION
site I B_GENE/I_LOCATION
( O O
bp. B B_GENE/B_DISEASE
-155 I I_GENE/I_DISEASE
to I I_GENE/I_DISEASE
-148 I I_GENE/I_DISEASE
) O O
in O O
the O O
IL-3 B B_GENE
promoter I I_GENE
, O O
reduced O O
CAT O O
activity O O
to O O
< O O
25 O O
% O O
of O O
the O O
activity O O
given O O
by O O
wild-type O O
constructs O O
. O O

We O O
conclude O O
that O O
expression O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL-3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
requires O O
the O O
AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Elf-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
however O O
, O O
unlike O O
other O O
previously O O
characterized O O
cytokine B B_GENE/B_BIO
genes I I_GENE/I_BIO
such O O
as O O
IL-2 B B_GENE
, O O
the O O
AP-1 B B_MEASURE/B_GENE
and I I_MEASURE/I_GENE
Elf-1 I I_MEASURE/I_GENE
factors I I_MEASURE/I_GENE
can O O
bind O O
independently O O
in O O
the O O
IL-3 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
gene I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

Combination O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
IL-4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduces O O
glucocorticoid O O
receptor-binding O O
affinity O O
and O O
T O O
cell O O
response O O
to O O
glucocorticoids O O
. O O

We O O
examined O O
the O O
possibility O O
that O O
certain O O
cytokines O O
, O O
specifically O O
IL-2 B B_GENE
and O O
IL-4 B B_GENE
, O O
could O O
affect O O
T O O
cell O O
response O O
to O O
glucocorticoids O O
. O O

PBMC O O
from O O
normal O O
donors O O
incubated O O
for O O
48 O O
h O O
in O O
the O O
presence O O
of O O
combination O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O O
IL-4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O O
nuclear O O
GR O O
with O O
significantly O O
reduced O O
binding O O
affinity O O
( O O
GR O O
Kd O O
= O O
36.1 O O
+/- O O
1.63 O O
nM O O
, O O
mean O O
+/- O O
SEM O O
; O O
p O O
= O O
0.0001 O O
) O O
as O O
compared O O
with O O
PBMC O O
incubated O O
with O O
medium O O
alone O O
( O O
GR O O
Kd O O
= O O
6.74 O O
+/- O O
0.46 O O
nM O O
) O O
. O O

The O O
cytosolic O O
GR O O
Kd O O
remained O O
unchanged O O
. O O

However O O
, O O
when O O
PBMC O O
were O O
incubated O O
with O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
or O O
IL-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
, O O
no O O
change O O
in O O
GR-binding O O
affinity O O
was O O
observed O O
. O O

More O O
importantly O O
, O O
the O O
alteration O O
in O O
PBMC O O
GR-binding O O
affinity O O
with O O
IL-2 B B_GENE
+ O O
IL-4 B B_GENE
was O O
associated O O
with O O
a O O
functional O O
change O O
in O O
T O O
cell O O
response O O
to O O
methylprednisolone O O
MPN O O
, O O
i.e. O O
, O O
a O O
reduced O O
inhibitory O O
effect O O
of O O
MPN O O
on O O
PMA/ionomycin-induced O O
T O O
cell O O
proliferation O O
. O O

These O O
observations O O
suggest O O
that O O
with O O
persistent O O
inflammation O O
certain O O
cytokines B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
may O O
contribute O O
to O O
an O O
impaired O O
response O O
to O O
glucocorticoids O O
. O O

We O O
analyzed O O
the O O
5 B B_GENE/B_LOCATION
' I I_GENE/I_LOCATION
transcription I I_GENE/I_LOCATION
control I I_GENE/I_LOCATION
sequences I I_GENE/I_LOCATION
of O O
the O O
human B B_GENE/B_BIO
CD4 I I_GENE/I_BIO
gene I I_GENE/I_BIO
. O O

The O O
transcriptional O O
activity O O
of O O
the O O
CD4 B B_GENE
gene I I_GENE
promoter I I_GENE
correlated O O
with O O
CD4 O O
expression O O
in O O
various O O
cell O O
types O O
. O O

Interestingly O O
, O O
the O O
CD4 B B_GENE
core I I_GENE
promoter I I_GENE
also O O
displayed O O
a O O
tissue-specific O O
transcriptional O O
activity O O
. O O

Within O O
this O O
fragment O O
, O O
three O O
nucleic O O
acid O O
sequences O O
are O O
completely O O
conserved O O
in O O
the O O
murine B B_GENE/B_BIO
CD4 I I_GENE/I_BIO
gene I I_GENE/I_BIO
. O O

One O O
of O O
these O O
sequences O O
contains O O
a O O
perfect B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ETS I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
consensus I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequence I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Electrophoretic-mobility-shift O O
assays O O
showed O O
that O O
the O O
core O O
promoter O O
ETS O O
motif O O
binds O O
an O O
Ets-related B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
specifically O O
expressed O O
at O O
high O O
levels O O
in O O
CD4+ O O
cells O O
. O O

Moreover O O
, O O
in O O
CD4- O O
cells O O
, O O
overexpression O O
of O O
Ets-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
Ets-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efficiently O O
and O O
specifically O O
activated O O
transcription O O
from O O
the O O
CD4 B B_GENE
promoter I I_GENE
and O O
core B B_GENE
promoter I I_GENE
. O O

These O O
data O O
indicate O O
that O O
Ets B B_GENE
transcription I I_GENE
factors I I_GENE
play O O
a O O
central O O
role O O
in O O
controlling O O
CD4 O O
gene O O
expression O O
, O O
by O O
binding O O
to O O
both O O
a O O
classical B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remote I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
an O O
unusual O O
proximal B B_GENE/B_LOCATION
activator I I_GENE/I_LOCATION
sequence I I_GENE/I_LOCATION

Glucocorticoid O O
receptor O O
activation O O
and O O
inactivation O O
in O O
c O O
ultured O O
human O O
lymphocytes O O
. O O

Although O O
glucocorticoids O O
are O O
not O O
cytolytic O O
for O O
and O O
do O O
not O O
inhibit O O
the O O
growth O O
of O O
the O O
IM-9 O O
line O O
of O O
cultured O O
human O O
lymphoblasts O O
, O O
these O O
cells O O
have O O
a O O
high O O
steroid-binding O O
capacity O O
. O O

We O O
have O O
used O O
IM-9 O O
cells O O
in O O
order O O
to O O
examine O O
whether O O
unoccupied B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
inactivated O O
and O O
activated O O
in O O
intact O O
cells O O
. O O

when O O
IM-9 O O
cells O O
are O O
incubated O O
in O O
glucose-free O O
medium O O
in O O
a O O
nitrogen O O
atmosphere O O
, O O
both O O
their O O
ability O O
to O O
bind O O
triamcinolone O O
acetonide O O
and O O
their O O
ATP O O
levels O O
decline O O
and O O
, O O
when O O
glucose O O
and O O
oxygen O O
are O O
reintroduced O O
, O O
ATP O O
levels O O
and O O
receptor O O
activity O O
return O O
. O O

The O O
specific O O
glucocorticoid-binding O O
activity O O
of O O
cytosol O O
prepared O O
from O O
cells O O
exposed O O
to O O
various O O
degrees O O
of O O
energy O O
limitation O O
is O O
directly O O
correlated O O
with O O
the O O
ATP O O
content O O
. O O

Receptor O O
activation O O
in O O
intact O O
cells O O
is O O
rapid O O
and O O
independent O O
of O O
protein O O
synthesis O O
. O O

Cytosol O O
prepared O O
from O O
inactivated O O
cells O O
can O O
not O O
be O O
activated O O
by O O
addition O O
of O O
ATP O O
. O O

The O O
inactivation O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
occurs O O
when O O
cytosol O O
from O O
normal O O
IM-9 O O
cells O O
is O O
incubated O O
at O O
25 O O
degrees O O
C O O
is O O
inhibited O O
by O O
molybdate O O
, O O
vanadate O O
, O O
fluoride O O
, O O
ATP O O
, O O
and O O
several O O
other O O
nucleotides O O
. O O

The O O
experiments O O
with O O
intact O O
human O O
lymphoblasts O O
suggest O O
that O O
assays O O
of O O
specific O O
glucocorticoid-binding O O
capacity O O
do O O
not O O
necessarily O O
reflect O O
the O O
cellular O O
content O O
of O O
receptor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Glucocorticoids O O
and O O
lymphocytes O O
. O O

II O O
. O O

Cell O O
cycle-dependent O O
changes O O
in O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O O
. O O

To O O
study O O
variations O O
in O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O O
during O O
the O O
cell O O
cycle O O
, O O
we O O
have O O
separated O O
mitogen-stimulated O O
human O O
peripheral O O
lymphocytes O O
and O O
rat O O
lymph O O
node O O
cells O O
by O O
unit O O
gravity O O
sedimentation O O
and O O
measured O O
glucocorticoid O O
binding O O
in O O
the O O
resultant O O
fractions O O
. O O

Certain O O
oncogenic O O
viruses O O
have O O
been O O
implicated O O
in O O
human O O
breast O O
cancer O O
, O O
including O O
the O O
murine O O
mammary O O
tumor O O
virus O O
( O O
MuMTV O O
) O O
and O O
the O O
Mason-Pfizer O O
monkey O O
virus O O
( O O
MPMV O O
) O O
. O O

We O O
have O O
used O O
the O O
leukocyte O O
migration O O
inhibition O O
( O O
LMI O O
) O O
response O O
to O O
assay O O
the O O
response O O
to O O
several O O
potential O O
breast O O
cancer-related O O
antigens O O
, O O
including O O
MuMTV B B_VIRUS[BIO]/B_GENE
, O O
MPMV B B_GENE/B_BIO
, O O
and O O
a O O
breast O O
cancer O O
cultured O O
cell O O
line O O
, O O
MCF-7 O O
, O O
in O O
96 O O
breast O O
cancer O O
patients O O
, O O
in O O
32 O O
women O O
with O O
benign O O
breast O O
disease O O
, O O
and O O
in O O
67 O O
normal O O
women O O
. O O

The O O
lowest O O
tenth O O
percentile O O
of O O
control O O
( O O
LMI O O
) O O
responses O O
was O O
used O O
as O O
the O O
cutoff O O
point O O
to O O
designate O O
responders O O
. O O

The O O
potential O O
for O O
this O O
assay O O
to O O
distinguish O O
`` O O
normal O O
'' O O
from O O
`` O O
breast O O
cancer O O
'' O O
was O O
analyzed O O
using O O
a O O
migration O O
index O O
derived O O
from O O
discriminant O O

The O O
ability O O
of O O
the O O
assay O O
to O O
discriminate O O
`` O O
normal O O
'' O O
from O O
`` O O
cancer O O
'' O O
was O O
significant O O
( O O
P O O
less O O
than O O
0.001 O O
) O O
and O O
showed O O
a O O
sensitivity O O
of O O
detecting O O
`` O O
cancer O O
'' O O
of O O

These O O
responses O O
appear O O
to O O
be O O
independent O O
of O O
major O O
prognostic O O
variables O O
. O O

Further O O
refinement O O
of O O
this O O
assay O O
may O O
yield O O
one O O
which O O
is O O
more O O
highly O O
discriminating O O
for O O
breast O O
cancer O O
. O O

Chronic O O
lymphatic O O
leukaemia O O
: O O
cellular O O
effects O O
of O O
glucocorticoids O O
in O O
vitro O O
. O O

Glucocorticoid B B_GENE
receptor I I_GENE
levels O O
and O O
steroid O O
induced O O
inhibition O O
of O O
nucleic O O
acid O O
precursors O O
have O O
been O O
examined O O
in O O
lymphocytes O O
from O O
27 O O
patients O O
at O O
different O O
stages O O
of O O
chronic O O
lymphatic O O
leukaemia O O
. O O

No O O
correlation O O
can O O
be O O
found O O
between O O
the O O
level O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
stage O O
of O O
the O O
disease O O
. O O

Pyrrolidine O O
dithiocarbamate O O
inhibits O O
NF-kappa B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mobilization O O
and O O
TNF O O
production O O
in O O
human O O
monocytes O O
. O O

Nuclear O O
extracts O O
from O O
unstimulated O O
cells O O
of O O
the O O
human O O
monocytic O O
cell O O
line O O
, O O
Mono O O
Mac O O
6 O O
, O O
contain O O
one O O
specific B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
complex B B_GENE/B_DISEASE
II I I_GENE/I_DISEASE
) O O
, O O
consistent O O
with O O
a O O
constitutive B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p50 I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homodimer I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Northern O O
blot O O
analysis O O
demonstrates O O
that O O
PDTC O O
treatment O O
will O O
strongly O O
reduce O O
LPS-induced B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
TNF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Kinetic O O
analyses O O
show O O
that O O
after O O
LPS O O
stimulation O O
, O O
NF-kappa B B_GENE
B I I_GENE
will O O
peak O O
at O O
1 O O
h O O
, O O
TNF O O
transcript O O
prevalence O O
at O O
2 O O
h O O
, O O
and O O
TNF B B_GENE/B_MEASURE
protein I B_GENE/I_MEASURE
at O O
4 O O
h O O
. O O

PDTC O O
did O O
not O O
shift O O
this O O
response O O
to O O
LPS O O
to O O
a O O
later O O
time O O
, O O
but O O
suppressed O O
NF-kappa O O
B O O
mobilization O O
, O O
TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
over O O
the O O
entire O O
8-h O O
observation O O
period O O
. O O

Analysis O O
of O O
freshly O O
isolated O O
, O O
LPS-stimulated O O
blood O O
monocytes O O
showed O O
a O O
similar O O
blockade O O
of O O
NF-kappa B B_GENE
B I I_GENE
. O O

Furthermore O O
, O O
in O O
these O O
primary O O
cells O O
, O O
induction O O
of O O
TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
determined O O
by O O
Northern O O
blot O O
analysis O O
and O O
by O O
quantitative O O
polymerase O O
chain O O
reaction O O
, O O
was O O
prevented O O
by O O
PDTC O O
as O O
was O O
TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
production O O
. O O

These O O
data O O
show O O
that O O
dithiocarbamates O O
can O O
profoundly O O
affect O O
cytokine O O
expression O O
and O O
suggest O O
that O O
NF-kappa B B_GENE
B I I_GENE
is O O
involved O O
in O O
LPS-induced O O
TNF O O
gene O O
expression O O
in O O
human O O
monocytes O O
. O O

Comparing O O
regions O O
of O O
the O O
Epstein-Barr B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ZEBRA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
function O O
as O O
transcriptional B B_GENE/B_MEASURE
activating I I_GENE/I_MEASURE
sequences I I_GENE/I_MEASURE
in O O
Saccharomyces O O
cerevisiae O O
and O O
in O O
B O O
cells O O
. O O

The O O
ZEBRA B B_GENE
protein I I_GENE
activates O O
expression O O
of O O
Epstein-Barr O O
virus O O
early-lytic-cycle B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
B O O
lymphocytes O O
. O O

Here O O
it O O
is O O
shown O O
that O O
ZEBRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
behaves O O
as O O
a O O
sequence-specific B B_GENE/B_PERSON
transcriptional I I_GENE/I_PERSON
activator I I_GENE/I_PERSON
in O O
Saccharomyces O O
cerevisiae O O
. O O

Deletional O O
mutagenesis O O
defined O O
three O O
regions O O
of O O
ZEBRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
participate O O
in O O
activation O O
in O O
S. O O
cerevisiae O O
. O O

Regions O O
of O O
ZEBRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
affected O O
activation O O
in O O
S. O O
cerevisiae O O
were O O
also O O
required O O
in O O
human O O
B O O
lymphocytes O O
. O O

However O O
, O O
certain O O
deletion B B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
mutants I I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
of O O
ZEBRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
mutations O O
in O O
the O O
N-terminal B B_GENE/B_LOCATION
region I I_GENE/I_LOCATION
exhibited O O
discordant O O
behaviors O O
in O O
S. O O
cerevisiae O O
and O O
in O O
B O O
cells O O
. O O

For O O
example O O
, O O
deletion O O
of O O
ZEBRA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
aa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
26 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
51 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
impaired O O
activation O O
to O O
a O O
great O O
extent O O
in O O
B O O
cells O O
but O O
had O O
little O O
or O O
no O O
effect O O
in O O
S. O O
cerevisiae O O
. O O

Functional O O
interaction O O
of O O
the O O
v-Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Rel I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncoproteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
TATA-binding B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
association O O
with O O
transcription B B_GENE
factor I I_GENE
IIB I I_GENE
. O O

Rel B B_PERSON/B_GENE
family I I_PERSON/I_GENE
proteins I I_PERSON/I_GENE
regulate O O
the O O
expression O O
of O O
genes O O
linked O O
to O O
kappa O O
B-binding O O
motifs O O
. O O

Little O O
is O O
known O O
, O O
however O O
, O O
of O O
the O O
mechanism O O
by O O
which O O
they O O
enhance O O
transcription O O
. O O

We O O
have O O
investigated O O
the O O
ability O O
of O O
the O O
v-Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Rel I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncoproteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
interact O O
with O O
components O O
of O O
the O O
basal O O
transcription O O
machinery O O
. O O

One O O
immediate O O
consequence O O
of O O
T O O
cell O O
activation O O
via O O
the O O
TCR B B_GENE
is O O
an O O
increase O O
in O O
cytosolic O O
calcium O O
. O O

Calcium O O
signals O O
are O O
important O O
for O O
NFAT O O
induction O O
, O O
and O O
recent O O
studies O O
have O O
identified O O
calcineurin B B_GENE
, O O
a O O
calcium-calmodulin B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serine-threonine I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphatase I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
a O O
prominent O O
component O O
of O O
the O O
calcium O O
signaling O O
pathway O O
in O O
T O O
cells O O
. O O

A O O
second O O
important O O
molecule O O
in O O
TCR O O
signal O O
transduction O O
is O O
the O O
guanine B B_GENE
nucleotide I I_GENE
binding I I_GENE
protein I I_GENE
, O O
p21ras B B_GENE
, O O
which O O
is O O
coupled O O
to O O
the O O
TCR B B_GENE
by O O
a O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent O O
mechanism O O
. O O

The O O
experiments O O
presented O O
here O O
show O O
that O O
expression O O
by O O
transfection O O
of O O
mutationally O O
activated O O
calcineurin B B_GENE/B_DISEASE
or O O
activated O O
p21ras B B_GENE
alone O O
is O O
insufficient O O
for O O
NFAT O O
transactivation O O
. O O

These O O
data O O
identify O O
calcineurin B B_GENE
and O O
p21ras B B_GENE
as O O
cooperative O O
partners O O
in O O
T O O
cell O O
activation O O
. O O

Expression O O
of O O
the O O
chicken B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GATA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
early O O
erythroid O O
development O O
and O O
differentiation O O
. O O

The O O
DNA O O
motif O O
WGATAR O O
has O O
been O O
identified O O
within O O
transcriptional B B_LOCATION/B_GENE
regulatory I I_LOCATION/I_GENE
domains I I_LOCATION/I_GENE
of O O
globin B B_GENE
and O O
other O O
erythroid-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
activator B B_GENE/B_BIO
proteins I I_GENE/I_BIO
that O O
bind O O
to O O
this O O
regulatory B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
, O O
the O O
GATA B B_GENE/B_BIO
factors I I_GENE/I_BIO
, O O
belong O O
to O O
a O O
multi-gene B B_GENE/B_LOCATION
family I I_GENE/I_LOCATION
that O O
is O O
expressed O O
in O O
chicken O O
erythroid O O
cells O O
. O O

Here O O
we O O
show O O
that O O
, O O
as O O
in O O
chickens O O
, O O
multiple O O
members O O
of O O
the O O
GATA B B_GENE/B_BIO
factor I I_GENE/I_BIO
family I I_GENE/I_BIO
are O O
expressed O O
in O O
human O O
and O O
murine O O
erythroid O O
cells O O
. O O

During O O
the O O
early O O
stages O O
of O O
chicken O O
embryogenesis O O
( O O
well O O
before O O
blood O O
island O O
formation O O
) O O
, O O
each O O
of O O
the O O
GATA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
members I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
transcribed O O
with O O
a O O
unique O O
temporal O O
and O O
spatial O O
pattern O O
. O O

In O O
the O O
primitive O O
erythroid O O
lineage O O
, O O
transcription O O
of O O
the O O
embryonic B B_GENE/B_MEASURE
epsilon-globin I I_GENE/I_MEASURE
gene I I_GENE/I_MEASURE
parallels O O
GATA-1 O O
expression O O
while O O
the O O
switch O O
to O O
beta-globin O O
transcription O O
in O O
definitive O O
erythroid O O
cells O O
is O O
directly O O
preceded O O
by O O
a O O
pronounced O O
increase O O
in O O
GATA-3 B B_GENE
accumulation O O
. O O

The O O
timing O O
and O O
pattern O O
of O O
expression O O
of O O
these O O
different O O
mRNAs B B_GENE/B_BIO
during O O
avian O O
erythroid O O
development O O
and O O
differentiation O O
suggests O O
that O O
temporally O O
regulated O O
changes O O
in O O
GATA B B_GENE/B_BIO
factor I I_GENE/I_BIO
expression O O
are O O
required O O
for O O
vertebrate O O
hematopoiesis O O
. O O

Molecular O O
regulation O O
of O O
human B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
interleukin I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
2 I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
T-cell O O
function O O
by O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Distinct O O
functional O O
T-cell O O
subsets O O
, O O
differing O O
in O O
the O O
patterns O O
of O O
lymphokines B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
, O O
regulate O O
cell-mediated O O
and O O
humoral O O
immune O O
responses O O
. O O

To O O
analyze O O
the O O
molecular O O
mechanism O O
of O O
IL-4-mediated O O
suppression O O
of O O
cell-mediated O O
immunity O O
we O O
studied O O
its O O
effects O O
on O O
expression O O
of O O
interleukin B B_GENE
2 I I_GENE
( O O
IL-2 B B_GENE/B_MEASURE
) O O
and O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

IL-4 B B_PERSON/B_GENE
suppressed O O
IL-2 O O
and O O
IFN-gamma O O
mRNA O O
levels O O
in O O
primary O O
human O O
T O O
cells O O
, O O
and O O
addition O O
of O O
anti-CD28 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
relieved O O
this O O
suppression O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
using O O
a O O
DNA O O
oligomer O O
containing O O
the O O
NFIL-2B B B_GENE
binding I I_GENE
site I I_GENE
indicated O O
that O O
IL-4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O O
the O O
NFIL-2B B B_GENE
complex I I_GENE
and O O
that O O
the O O
NFIL-2B B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
distinct O O
from O O
AP- B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
. O O

Immunochemical O O
differences O O
between O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
corticoid-sensitive O O
and O O
-resistant O O
malignant O O
lymphocytes O O
. O O

We O O
then O O
examined O O
the O O
ability O O
of O O
the O O
affinity O O
gel O O
to O O
recognize O O
cytosolic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
[ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3H I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
triamcinolone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acetonide-receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
corticoid-sensitive O O
( O O
CS O O
) O O
and O O
-resistant O O
strains O O
of O O
mouse O O
lymphoma O O
P1798 O O
, O O
from O O
CS O O
lymphocytes O O
of O O
patients O O
with O O
chronic O O
lymphatic O O
leukemia O O
, O O
and O O
from O O
a O O
CS O O
clone O O
of O O
human O O
leukemic O O
lymphoblasts O O
in O O
tissue O O
culture O O
( O O
CH6 O O
) O O
. O O

Mouse O O
thymus O O
was O O
used O O
as O O
a O O
source O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
from O O
normal O O
CS O O
lymphocytes O O
. O O

Therefore O O
, O O
under O O
appropriate O O
experimental O O
conditions O O
, O O
it O O
was O O
possible O O
to O O
demonstrate O O
cross-reactivity O O
between O O
the O O
antiserum O O
against O O
rat B B_GENE
liver I I_GENE
glucocorticoid I I_GENE
receptor I I_GENE
and O O
the O O
58- O O
to O O
62-A O O
( O O
Stokes O O
radius O O
) O O
glucocorticoid B B_PROTEIN[GENE]/B_LOCATION
receptor I I_PROTEIN[GENE]/I_LOCATION
from O O
species O O
as O O
diverse O O
as O O
mouse O O
and O O
humans O O
. O O

Heterogeneity O O
of O O
the O O
in O O
vitro O O
responses O O
to O O
glucocorticoids O O
in O O
acute O O
leukemia O O
. O O

In O O
addition O O
, O O
in O O
some O O
cases O O
, O O
the O O
short-term O O
response O O
to O O
steroid O O
therapy O O
was O O
determined O O
. O O

Although O O
, O O
in O O
all O O
the O O
patients O O
studied O O
, O O
leukocytes O O
were O O
found O O
to O O
contain O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
failed O O
to O O
demonstrate O O
any O O
correlation O O
between O O
the O O
level O O
of O O
binding O O
sites O O
and O O
the O O
in O O
vitro O O
or O O
in O O
vivo O O
response O O
to O O
glucocorticoids O O
. O O

This O O
absence O O
of O O
correlation O O
could O O
be O O
in O O
part O O
explained O O
by O O
the O O
marked O O
heterogeneity O O
of O O
the O O
steroid O O
response O O
demonstrated O O
in O O
leukocyte O O
subpopulations O O
. O O

It O O
appears O O
, O O
however O O
, O O
that O O
the O O
degree O O
of O O
steroid O O
action O O
in O O
vitro O O
as O O
well O O
as O O
the O O
extent O O
of O O
spontaneous O O
and O O
dexamethasone-induced O O
cell O O
death O O
may O O
be O O
related O O
to O O
the O O
number O O
of O O
cells O O
in O O
the O O
S O O
phase O O
of O O
the O O
cell O O
cycle O O
. O O

Glucocorticoid B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
cytosol O O
and O O
nuclear O O
extract O O
of O O
human O O
leukocytes O O
. O O

Cortisol O O
binding O O
by O O
cytosol O O
and O O
0.4 O O
M O O
KCl O O
extract O O
of O O
the O O
nuclear O O
fraction O O
of O O
human O O
leukocytes O O
were O O
studied O O
by O O
gel O O
chromatography O O
and O O
ion O O
exchange O O
filtration O O
on O O
DEAE O O
cellulose O O
. O O

The O O
cytoplasmic B B_PROTEIN[GENE]
cortisol I I_PROTEIN[GENE]
binding I I_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
has O O
a O O
molecular O O
weight O O
95 O O
000 O O
and O O
the O O
soluble B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
nuclear I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
binding I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
protein I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
50 O O
000 O O
. O O

The O O
absence O O
of O O
the O O
uptake O O
of O O
radioactive O O
cortisol O O
by O O
isolated O O
nuclei O O
and O O
the O O
apparent O O
requirement O O
of O O
the O O
cytosol O O
for O O
glucocorticoid O O
specific O O
binding O O
in O O
nuclear O O
receptor O O
sites O O
was O O
observed O O
. O O

Corticosteroid-induced O O
lymphopenia O O
, O O
immunosuppression O O
, O O
and O O
body O O
defense O O
. O O

The O O
question O O
is O O
asked O O
how O O
this O O
lowered O O
defensive O O
capability O O
, O O
which O O
occurs O O
in O O
the O O
face O O
of O O
a O O
threat O O
to O O
body O O
integrity O O
, O O
is O O
consistent O O
with O O
Cannon O O
's O O
principals O O
of O O
the O O
`` O O
wisdom O O
of O O
the O O
body. O O
'' O O

Protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O O
is O O
required O O
for O O
lipopolysaccharide O O
induction O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
blood O O
monocytes O O
. O O

However O O
, O O
the O O
mechanisms O O
by O O
which O O
LPS O O
activates O O
these O O
cells O O
to O O
express O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O O
not O O
completely O O
characterized O O
. O O

The O O
present O O
study O O
addressed O O
the O O
role O O
of O O
different O O
protein B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
kinases I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
LPS O O
induction O O
of O O
cytokines B B_DISEASE/B_GENE
. O O

Protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibition O O
by O O
staurosporine O O
reduced O O
LPS O O
induction O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
it O O
had O O
no O O
effects O O
on O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
IL-1 O O
beta O O
. O O

Inhibition O O
of O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
by O O
H89 O O
reduced O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
but O O
did O O
not O O
detectably O O
change O O
IL-1 O O
beta O O
or O O
TNF-alpha O O
mRNA O O
levels O O
. O O

In O O
contrast O O
, O O
LPS O O
did O O
not O O
increase O O
leukemia B B_GENE
inhibitory I I_GENE
factor I I_GENE
mRNA I I_GENE
, O O
which O O
was O O
constitutively O O
expressed O O
and O O
not O O
significantly O O
reduced O O
by O O
these O O
inhibitors O O
. O O

In O O
addition O O
to O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
, O O
LPS-induced O O
IL-6 O O
protein O O
synthesis O O
and O O
IL-6 O O
bioactivity O O
were O O
also O O
reduced O O
to O O
baseline O O
levels O O
by O O
the O O
PTK O O
inhibitors O O
herbimycin O O
A O O
and O O
genistein O O
. O O

Both O O
PTK O O
inhibitors O O
also O O
reduced O O
the O O
LPS O O
activation O O
of O O
nuclear B B_GENE
factor-kappa I I_GENE
B I I_GENE
( O O
NF-kappa B B_GENE
B I I_GENE
) O O
, O O
which O O
is O O
a O O
transcription B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
involved O O
in O O
the O O
expression O O
of O O
cytokine B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
such O O
as O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
was O O
also O O
reduced O O
by O O
H89 O O
, O O
whereas O O
staurosporine O O
had O O
no O O
effect O O
on O O
this O O
response O O
. O O

In O O
summary O O
, O O
these O O
findings O O
suggest O O
that O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
appear O O
to O O
have O O
selective O O
effects O O
in O O
the O O
LPS O O
induction O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
PTK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
required O O
for O O
LPS O O
induction O O
of O O
a O O
broad O O
spectrum O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
NF-kappa B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
in O O
monocytes O O
. O O

In O O
vivo O O
control O O
of O O
NF-kappa B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
by O O
I B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kappa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
transcription B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa B I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
B I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
stored O O
in O O
the O O
cytoplasm O O
in O O
complexes O O
with O O
the O O
inhibitor B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
I I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
kappa I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
alpha I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

It O O
has O O
been O O
shown O O
in O O
vitro O O
that O O
dissociation O O
of O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
these O O
complexes O O
results O O
in O O
active B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NF-kappa I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Many O O
liberated O O
NF-kappa B B_GENE
B I I_GENE
dimers I I_GENE
reached O O
the O O
nucleus O O
, O O
where O O
increased O O
c-rel B B_GENE
, O O
p65 O O
and O O
p50 O O
were O O
detected O O
by O O
immunoblotting O O
and O O
by O O
DNA O O
binding O O
assays O O
. O O

No O O
effect O O
of O O
LPS O O
treatment O O
was O O
detected O O
on O O
p105 B B_GENE
or O O
p100 B B_GENE
, O O
which O O
also O O
retain O O
rel B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
family I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
members I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
cytoplasm O O
. O O

Quite O O
unexpectedly O O
, O O
we O O
also O O
found O O
that O O
in O O
unstimulated O O
cells O O
there O O
is O O
a O O
constant O O
ongoing O O
process O O
of O O
degradation O O
and O O
replacement O O
of O O
complexed B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kappa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

We O O
propose O O
that O O
this O O
turnover O O
results O O
in O O
the O O
low O O
level O O
of O O
active B B_GENE
NF-kappa I I_GENE
B I I_GENE
presumably O O
necessary O O
even O O
in O O
the O O
unstimulated O O
cell O O
, O O
and O O
that O O
the O O
high O O
rate O O
of O O
synthesis O O
of O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O O
the O O
ability O O
to O O
turn O O
off O O
NF-kappa B B_GENE
B I I_GENE
activity O O
rapidly O O
as O O
soon O O
as O O
the O O
activating O O
signal O O
ceases O O
. O O

Identification O O
of O O
a O O
killer B B_GENE/B_PERSON
cell-specific I I_GENE/I_PERSON
regulatory I I_GENE/I_PERSON
element I I_GENE/I_PERSON
of O O
the O O
mouse B B_GENE
perforin I I_GENE
gene I I_GENE
: O O
an O O
Ets-binding O O
site-homologous O O
motif O O
that O O
interacts O O
with O O
Ets-related B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
gene O O
encoding O O
the O O
cytolytic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
perforin B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
selectively O O
expressed O O
by O O
activated O O
killer O O
lymphocytes O O
. O O

To O O
understand O O
the O O
mechanisms O O
underlying O O
the O O
cell-type-specific O O
expression O O
of O O
this O O
gene O O
, O O
we O O
have O O
characterized O O
the O O
regulatory O O
functions O O
and O O
the O O
DNA-protein O O
interactions O O
of O O
the O O
5'-flanking B B_GENE/B_MEASURE
region I I_GENE/I_MEASURE
of O O
the O O
mouse B B_GENE
perforin I I_GENE
gene I I_GENE
( O O
Pfp B B_PROTEIN[GENE]/B_SPECIES[BIO]
) O O
. O O

A O O
region O O
extending O O
from O O
residues B B_LOCATION/B_GENE
+62 I I_LOCATION/I_GENE
through I I_LOCATION/I_GENE
-141 I I_LOCATION/I_GENE
, O O
which O O
possesses O O
the O O
essential O O
promoter O O
activity O O
, O O
and O O
regions O O
further O O
upstream O O
, O O
which O O
are O O
able O O
to O O
either O O
enhance O O
or O O
suppress O O
gene O O
expression O O
, O O
were O O
identified O O
. O O

The O O
region O O
between O O
residues B B_LOCATION/B_GENE
-411 I I_LOCATION/I_GENE
and I I_LOCATION/I_GENE
-566 I I_LOCATION/I_GENE
was O O
chosen O O
for O O
further O O
characterization O O
, O O
since O O
it O O
contains O O
an O O
enhancer-like O O
activity O O
. O O

We O O
have O O
identified O O
a O O
32-mer O O
sequence O O
( O O
residues B B_PROTEIN[GENE]/B_MEASURE
-491 I I_PROTEIN[GENE]/I_MEASURE
to I I_PROTEIN[GENE]/I_MEASURE
-522 I I_PROTEIN[GENE]/I_MEASURE
) O O
which O O
appeared O O
to O O
be O O
capable O O
of O O
enhancing O O
gene O O
expression O O
in O O
a O O
killer O O
cell-specific O O
manner O O
. O O

Within O O
this O O
segment O O
, O O
a O O
9-mer O O
motif O O
( O O
5'-ACAGGAAGT-3 O O
' O O
, O O
residues B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-505 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-497 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
designated O O
NF-P O O
motif O O
) O O
, O O
which O O
is O O
highly O O
homologous O O
to O O
the O O
Ets B B_GENE/B_TIME[MEASURE]
proto-oncoprotein-binding I I_GENE/I_TIME[MEASURE]
site I I_GENE/I_TIME[MEASURE]
, O O
was O O
found O O
to O O
interact O O
with O O
two O O
proteins O O
, O O
NF-P1 B B_GENE
and O O
NF-P2 B B_GENE
. O O

NF-P2 B B_GENE/B_DISEASE
appears O O
to O O
be O O
induced O O
by O O
reagents O O
known O O
to O O
up-regulate O O
the O O
perforin O O
message O O
level O O
and O O
is O O
present O O
exclusively O O
in O O
killer O O
cells O O
. O O

Electrophoretic O O
mobility O O
shift O O
assay O O
and O O
UV O O
cross-linking O O
experiments O O
revealed O O
that O O
NF-P1 B B_GENE
and O O
NF-P2 B B_GENE
may O O
possess O O
common O O
DNA-binding B B_GENE/B_LOCATION
subunits I B_GENE/I_LOCATION
. O O

However O O
, O O
the O O
larger O O
native O O
molecular O O
mass O O
of O O
NF-P1 B B_GENE
suggests O O
that O O
NF-P1 B B_GENE/B_PERSON
contains O O
an O O
additional O O
non-DNA-binding B B_GENE
subunit I I_GENE
( O O
s O O
) O O
. O O

Results O O
obtained O O
from O O
the O O
binding O O
competition O O
assay O O
, O O
nevertheless O O
, O O
suggest O O
that O O
NF-P1 B B_GENE
and O O
NF-P2 B B_GENE
are O O
related O O
to O O
but O O
distinct O O
from O O
Ets B B_GENE/B_PERSON
proteins I I_GENE/I_PERSON
, O O
e.g. O O
, O O
Ets-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Ets-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
NF-AT/Elf-1 B B_GENE
, O O
known O O
to O O
be O O
expressed O O
in O O
T O O
cells O O
. O O

Stimulation O O
of O O
primary O O
human O O
T-lymphocytes O O
via O O
CD2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CD28 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
a O O
long-lasting O O
proliferation O O
( O O
> O O
3 O O
weeks O O
) O O
. O O

This O O
potent O O
activation O O
does O O
not O O
require O O
accessory O O
cells O O
, O O
such O O
as O O
monocytes O O
, O O
but O O
depends O O
on O O
persistent O O
interleukin B B_GENE
2 I I_GENE
( O O
IL-2 B B_GENE/B_MEASURE
) O O
secretion O O
and O O
receptivity O O
, O O
which O O
is O O
associated O O
with O O
high O O
and O O
prolonged O O
expression O O
of O O
the O O
inducible O O
CD25/IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-2R I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
evaluate O O
the O O
role O O
of O O
NF-kappa B B_GENE
B I I_GENE
in O O
human O O
peripheral O O
blood O O
T-lymphocytes O O
, O O
we O O
previously O O
analyzed O O
the O O
activation O O
of O O
NF-kappa B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B-related I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complexes I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
response O O
to O O
CD2+CD28 O O
costimulation O O
. O O

We O O
demonstrated O O
a O O
long-term O O
induction O O
of O O
p50/p65 B B_GENE
heterodimer I I_GENE
, O O
a O O
putative B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p65/c-Rel I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
a O O
constitutive O O
nuclear O O
expression O O
of O O
KBF1/p50 B B_GENE
homodimers I I_GENE
. I I_GENE

As O O
the O O
role O O
of O O
p50 B B_GENE
remains O O
unclear O O
, O O
we O O
focused O O
our O O
present O O
study O O
on O O
NF-kappa B B_GENE
B1 I I_GENE
( O O
p50/p105 B B_GENE/B_DISEASE
) O O
gene O O
regulation O O
. O O

Using O O
electrophoretic O O
mobility O O
shift O O
assays O O
and O O
Western O O
and O O
Northern O O
blot O O
analyses O O
, O O
we O O
studied O O
NF-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
during O O
T-cell O O
stimulation O O
via O O
CD2+CD28 B B_GENE
. O O

Partial O O
inhibition O O
of O O
p50 O O
and O O
p105 O O
expression O O
by O O
NF-kappa B B_GENE/B_NUMBER[MEASURE]
B1 I I_GENE/I_NUMBER[MEASURE]
antisense O O
oligonucleotides O O
significantly O O
reduced O O
T-cell O O
proliferation O O
and O O
CD25/IL-2R B B_GENE
alpha I I_GENE
cell O O
surface O O
expression O O
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Vitamin B B_GENE/B_PERSON
D I I_GENE/I_PERSON
receptor I I_GENE/I_PERSON
quantitation O O
in O O
human O O
blood O O
mononuclear O O
cells O O
in O O
health O O
and O O
disease O O
. O O

Vitamin B B_PROTEIN[GENE]
D I I_PROTEIN[GENE]
receptor I I_PROTEIN[GENE]
( O O
VDR O O
) O O
concentration O O
was O O
quantitated O O
in O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMC O O
) O O
from O O
patients O O
with O O
absorptive O O
hypercalciuria O O
( O O
AH O O
) O O
and O O
patients O O
with O O
high O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
due O O
to O O
acquired O O
or O O
transient O O
disease O O
states O O
and O O
the O O
results O O
compared O O
to O O
those O O
in O O
normal O O
subjects O O
. O O

Following O O
activation O O
with O O
phytohemagglutinin B B_BIO/B_GENE
, O O
patients O O
with O O
hypercalcitriolemia O O
demonstrated O O
significantly O O
greater O O
VDR O O
concentrations O O
. O O

Patients O O
with O O
AH O O
demonstrated O O
a O O
normal O O
value O O
for O O
the O O
group O O
, O O
but O O
6 O O
patients O O
had O O
significantly O O
greater O O
concentrations O O
of O O
VDR B B_GENE
despite O O
normal O O
plasma O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
in O O
four O O
of O O
the O O
patients O O
. O O

Taken O O
together O O
, O O
the O O
results O O
suggest O O
that O O
PBMC O O
provide O O
a O O
useful O O
system O O
for O O
studying O O
VDR B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
status O O
in O O
transient O O
or O O
acquired O O
states O O
of O O
hypercalcitriolemia O O
. O O

Furthermore O O
, O O
the O O
studies O O
in O O
patients O O
with O O
absorptive O O
hypercalciuria O O
disclosed O O
it O O
to O O
be O O
a O O
heterogeneous O O
disorder O O
, O O
characterized O O
by O O
both O O
vitamin O O
D-dependent O O
and O O
D-independent O O
forms O O
of O O
receptor O O
up-regulation O O
. O O

Reactive O O
oxygen O O
intermediates O O
activate O O
NF-kappa B B_GENE
B I I_GENE
in O O
a O O
tyrosine O O
kinase-dependent O O
mechanism O O
and O O
in O O
combination O O
with O O
vanadate O O
activate O O
the O O
p56lck B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p59fyn I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
lymphocytes O O
. O O

We O O
have O O
previously O O
observed O O
that O O
ionizing O O
radiation O O
induces O O
tyrosine O O
phosphorylation O O
in O O
human O O
B-lymphocyte O O
precursors O O
by O O
stimulation O O
of O O
unidentified O O
tyrosine B B_ENZYME[GENE]
kinases I I_ENZYME[GENE]
and O O
this O O
phosphorylation O O
is O O
substantially O O
augmented O O
by O O
vanadate O O
. O O

Ionizing O O
radiation O O
generates O O
reactive O O
oxygen O O
intermediates O O
( O O
ROI O O
) O O
. O O

Because O O
H2O2 O O
is O O
a O O
potent O O
ROI O O
generator O O
that O O
readily O O
crosses O O
the O O
plasma O O
membrane O O
, O O
we O O
used O O
H2O2 O O
to O O
examine O O
the O O
effects O O
of O O
ROI O O
on O O
signal O O
transduction O O
. O O

We O O
now O O
provide O O
evidence O O
that O O
the O O
tyrosine O O
kinase O O
inhibitor O O
herbimycin O O
A O O
and O O
the O O
free O O
radical O O
scavenger O O
N-acetyl-cysteine O O
inhibit O O
both O O
radiation-induced O O
and O O
H2O2-induced O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
, O O
indicating O O
that O O
activation O O
triggered O O
by O O
ROI O O
is O O
dependent O O
on O O
tyrosine O O
kinase O O
activity O O
. O O

H2O2 O O
was O O
found O O
to O O
stimulate O O
Ins-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5-P3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
production O O
in O O
a O O
tyrosine O O
kinase-dependent O O
manner O O
and O O
to O O
induce O O
calcium O O
signals O O
that O O
were O O
greatly O O
augmented O O
by O O
vanadate O O
. O O

The O O
synergistic O O
induction O O
of O O
tyrosine O O
phosphorylation O O
by O O
H2O2 O O
plus O O
vanadate O O
included O O
physiologically O O
relevant O O
proteins O O
such O O
as O O
PLC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
treatment O O
of O O
cells O O
with O O
H2O2 O O
alone O O
did O O
not O O
affect O O
the O O
activity O O
of O O
src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
treatment O O
with O O
H2O2 O O
plus O O
vanadate O O
led O O
to O O
activation O O
of O O
the O O
p56lck B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
p59fyn I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
combined O O
inhibition O O
of O O
phosphatases B B_GENE
and O O
activation O O
of O O
kinases B B_GENE
provides O O
a O O
potent O O
mechanism O O
for O O
the O O
synergistic O O
effects O O
of O O
H2O2 O O
plus O O
vanadate O O
. O O

Induction O O
of O O
tyrosine O O
phosphorylation O O
by O O
ROI O O
may O O
thus O O
lead O O
to O O
many O O
of O O
the O O
pleiotropic O O
effects O O
of O O
ROI O O
in O O
lymphoid O O
cells O O
, O O
including O O
downstream O O
activation O O
of O O
PLC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
NF-kappa B B_GENE
B I I_GENE

Total O O
plasma O O
and O O
albumin B B_GENE
delayed O O
the O O
conversion O O
rate O O
of O O
androstenedione O O
, O O
while O O
SHBG B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
it O O
markedly O O
. O O

The O O
effect O O
of O O
SHBG B B_GENE
was O O
largely O O
abolished O O
by O O
heating O O
to O O
60 O O
degrees O O
C O O
for O O
1 O O
h O O
and O O
by O O
saturating O O
its O O
binding O O
sites O O
by O O
DHT O O
. O O

The O O
effect O O
of O O
both O O
proteins O O
was O O
found O O
to O O
be O O
related O O
to O O
their O O
concentration O O
. O O

It O O
appears O O
that O O
the O O
binding O O
sites O O
of O O
albumin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O O
a O O
mechanism O O
for O O
retarding O O
androstenedione O O
uptake O O
by O O
the O O
erythrocytes O O
and O O
that O O
the O O
high O O
binding O O
affinity O O
of O O
SHBG B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
for O O
testosterone O O
facilitates O O
the O O
diffusion O O
of O O
this O O
steroid O O
out O O
of O O
the O O
cell O O
and O O
thus O O
, O O
displaces O O
the O O
chemical O O
equilibrium O O
within O O
the O O
cell O O
. O O

Glucocorticoids O O
and O O
lymphocytes O O
. O O

I O O
. O O

Increased O O
glucocorticoid B B_GENE
receptor I I_GENE
levels O O
in O O
antigen-stimulated O O
lymphocytes O O
. O O

Here O O
, O O
we O O
extend O O
these O O
observations O O
to O O
in O O
vivo O O
immunization O O
. O O

After O O
unilateral O O
immunization O O
of O O
adrenalectomized O O
male O O
rats O O
, O O
a O O
50 O O
% O O
increase O O
in O O
glucocorticoid O O
receptor O O
sites O O
per O O
cell O O
, O O
determined O O
by O O
binding O O
of O O
dexamethasone O O
, O O
was O O
observed O O
in O O
cell O O
suspensions O O
of O O
homolateral O O
lymph O O
nodes O O
over O O
those O O
from O O
the O O
contralateral O O
nonimmunized O O
side O O
of O O
the O O
same O O
animal O O
. O O

The O O
association O O
constant O O
for O O
dexamethasone O O
was O O
similar O O
in O O
both O O
groups O O
, O O
as O O
was O O
the O O
stereospecificity O O
for O O
various O O
steroids O O
, O O
the O O
time O O
course O O
of O O
cytoplasmic O O
and O O
nuclear O O
association O O
, O O
and O O
cytoplasmic-to-nuclear O O
translocation O O
. O O

Glucocorticoid O O
receptors O O
and O O
actions O O
in O O
rat O O
thymocytes O O
and O O
immunologically O O
stimulated O O
human O O
peripheral O O
lymphocytes O O
. O O

After O O
reviewing O O
briefly O O
our O O
earlier O O
studies O O
on O O
glucocorticoid O O
receptors O O
and O O
mechanisms O O
in O O
thymus O O
cells O O
, O O
we O O
have O O
outlined O O
results O O
from O O
the O O
following O O
two O O
areas O O
of O O
current O O
interest O O
in O O
our O O
laboratories O O
: O O
the O O
`` O O
life-cycle O O
'' O O
of O O
glucocorticoid O O
receptors O O
and O O
complexes O O
in O O
thymus O O
cells O O
, O O
and O O
the O O
levels O O
of O O
glucocorticoid O O
receptors O O
and O O
sensitivity O O
in O O
immunologically O O
stimulated O O
human O O
peripheral O O
lymphocytes O O

Several O O
of O O
our O O
results O O
on O O
energetics O O
and O O
kinetics O O
of O O
hormone O O
binding O O
to O O
glucocorticoid B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rat O O
thymus O O
cells O O
seem O O
to O O
require O O
extension O O
of O O
the O O
simplest O O
model O O
of O O
hormone-receptor O O
transformations O O
in O O
intact O O
cells O O
. O O

ATP-depletion O O
experiments O O
suggest O O
the O O
existence O O
of O O
a O O
nonbinding O O
form O O
of O O
the O O
receptor O O
; O O
`` O O
chase O O
'' O O
experiments O O
suggest O O
reaction O O
of O O
hormone O O
directly O O
with O O
nuclear-bound O O
receptor O O
; O O
experiments O O
on O O
depletion O O
and O O
replenishment O O
of O O
cytoplasmic B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
using O O
cortisol O O
and O O
dexamethasone O O
suggest O O
the O O
existence O O
of O O
at O O
least O O
two O O
subpopulations O O
of O O
nuclear-bound B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hormone-receptor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complex I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
have O O
found O O
that O O
mitogen O O
or O O
immunologic O O
stimulation O O
of O O
human O O
peripheral O O
lymphocytes O O
in O O
culture O O
leads O O
within O O
24 O O
h O O
or O O
so O O
to O O
a O O
striking O O
increase O O
in O O
the O O
number O O
of O O
glucocorticoid B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O O
per O O
cell O O
. O O

We O O
believe O O
this O O
increase O O
may O O
be O O
due O O
to O O
partial O O
synchronization O O
of O O
the O O
cell O O
population O O
in O O
a O O
phase O O
of O O
the O O
cell O O
cycle O O
in O O
which O O
receptor O O
content O O
is O O
high O O
. O O

Nuclear O O
glucocorticoid O O
binding O O
in O O
chronic O O
lymphatic O O
leukemia O O
lymphocytes O O
. O O

Using O O
this O O
method O O
, O O
specific O O
nuclear O O
glucocorticoid O O
binding O O
was O O
demonstrated O O
in O O
14/14 O O
patients O O
with O O
untreated O O
CLL O O
. O O

Multiple O O
closely-linked O O
NFAT/octamer B B_GENE/B_LOCATION
and O O
HMG B B_GENE
I I I_GENE
( I I_GENE
Y I I_GENE
) I I_GENE
binding I I_GENE
sites I I_GENE
are O O
part O O
of O O
the O O
interleukin-4 O O
promoter O O
. O O

We O O
show O O
here O O
that O O
the O O
immediate B B_GENE/B_LOCATION
upstream I B_GENE/I_LOCATION
region I B_GENE/I_LOCATION
( O O
from O O
position O O
-12 O O
to O O
-270 O O
) O O
of O O
the O O
murine B B_GENE/B_LOCATION
interleukin I I_GENE/I_LOCATION
4 I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
Il-4 I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
harbors O O
a O O
strong O O
cell-type O O
specific O O
transcriptional B B_GENE
enhancer I I_GENE
. O O

In O O
T O O
lymphoma O O
cells O O
, O O
the O O
activity O O
of O O
the O O
Il-4 B B_GENE
promoter/enhancer I I_GENE
is O O
stimulated O O
by O O
phorbol O O
esters O O
, O O
Ca++ O O
ionophores O O
and O O
agonists O O
of O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
and O O
inhibited O O
by O O
low O O
doses O O
of O O
the O O
immunosuppressant O O
cyclosporin O O
A O O
. O O

The O O
Il-4 B B_GENE
promoter/enhancer I I_GENE
is O O
transcriptionally O O
inactive O O
in O O
B O O
lymphoma O O
cells O O
and O O
HeLa O O
cells O O
. O O

DNase O O
I O O
footprint O O
protection O O
experiments O O
revealed O O
six O O
sites O O
of O O
the O O
Il-4 B B_GENE
promoter/enhancer I I_GENE
to O O
be O O
bound O O
by O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
lymphoid O O
and O O
myeloid O O
cells O O
. O O

Among O O
them O O
are O O
four O O
purine O O
boxes O O
which O O
have O O
been O O
described O O
to O O
be O O
important O O
sequence O O
motifs O O
of O O
the O O
Il-2 B B_GENE
promoter I I_GENE
. O O

They O O
contain O O
the O O
motif O O
GGAAA O O
and O O
are O O
recognized O O
by O O
the O O
inducible B B_GENE/B_ORGANIZATION
and I I_GENE/I_ORGANIZATION
cyclosporin I I_GENE/I_ORGANIZATION
A-sensitive I I_GENE/I_ORGANIZATION
transcription I I_GENE/I_ORGANIZATION
factor I I_GENE/I_ORGANIZATION
NFAT-1 I I_GENE/I_ORGANIZATION
. O O

Three O O
of O O
the O O
Il-4 B B_GENE/B_LOCATION
NFAT-1 I B_GENE/I_LOCATION
sites I B_GENE/I_LOCATION
are O O
closely O O
linked O O
to O O
weak O O
binding O O
sites O O
of O O
Octamer B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Several O O
purine O O
boxes O O
and O O
an O O
AT-rich B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
Il-4 O O
promoter O O
are O O
also O O
recognized O O
by O O
the O O
high B B_GENE/B_LOCATION
mobility I I_GENE/I_LOCATION
group I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
HMG B I_GENE/I_LOCATION
I I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
Y I I_GENE/I_LOCATION
) O O
. O O

Whereas O O
the O O
binding O O
of O O
NFAT-1 B B_GENE/B_LOCATION
and O O
Octamer B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhance O O
the O O
activity O O
of O O
the O O
Il-4 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
the O O
binding O O
of O O
HMG O O
I O O
( O O
Y O O
) O O
suppresses O O
its O O
activity O O
and O O
, O O
therefore O O
, O O
appears O O
to O O
be O O
involved O O
in O O
the O O
suppression O O
of O O
Il-4 B B_GENE/B_DISEASE
transcription O O
in O O
resting O O
T O O
lymphocytes O O
. O O

Reversibility O O
of O O
the O O
differentiated O O
state O O
in O O
somatic O O
cells O O
. O O

These O O
properties O O
have O O
been O O
exploited O O
to O O
design O O
strategies O O
for O O
identifying O O
novel O O
regulators O O
of O O
cellular O O
differentiation O O
. O O

Phosphatidylcholine O O
hydrolysis O O
activates O O
NF-kappa B B_GENE
B I I_GENE
and O O
increases O O
human O O
immunodeficiency O O
virus O O
replication O O
in O O
human O O
monocytes O O
and O O
T O O
lymphocytes O O
. O O

PC-PLC-activated O O
hydrolysis O O
of O O
PC O O
was O O
found O O
to O O
induce O O
bona O O
fide O O
p50/p65 B B_GENE
NF-kappa I I_GENE
B I I_GENE
binding O O
activity O O
in O O
three O O
different O O
cell O O
lines O O
of O O
human O O
or O O
murine O O
origin O O
. O O

No O O
significant O O
changes O O
in O O
the O O
turnover O O
of O O
other O O
cellular O O
phospholipids O O
were O O
detected O O
in O O
PC-PLC-treated O O
cells O O
. O O

NF-kappa O O
B O O
activation O O
promoted O O
by O O
addition O O
of O O
exogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PC-PLC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
correlated O O
with O O
an O O
intense O O
production O O
of O O
diacylglycerol O O
. O O

However O O
, O O
addition O O
of O O
a O O
phosphatidylinositol-specific B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PLC I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
B.cereus O O
also O O
induced O O
diacylglycerol O O
but O O
did O O
not O O
activate O O
kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer-directed I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
vectors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

PC-PLC-induced O O
NF-kappa O O
B O O
activation O O
could O O
not O O
be O O
blocked O O
by O O
a O O
specific O O
inhibitor O O
of O O
phorbol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ester-inducible I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O O
indicate O O
that O O
a O O
cellular O O
transduction O O
pathway O O
, O O
dependent O O
on O O
specific O O
PC O O
breakdown O O
, O O
is O O
functional O O
in O O
T O O
lymphocytes O O
and O O
monocytes O O
and O O
may O O
be O O
used O O
by O O
various O O
transmembrane O O
receptors O O
to O O
activate O O
HIV O O
transcription O O
through O O
NF-kappa O O
B-dependent O O
induction O O
of O O
the O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Novel O O
mechanism O O
for O O
inhibition O O
of O O
human O O
T O O
cells O O
by O O
glucocorticoids O O
. O O

Glucocorticoids O O
inhibit O O
signal O O
transduction O O
through O O
IL-2 B B_GENE
receptor I I_GENE
. O O

Glucocorticoids O O
inhibit O O
IL-2 B B_GENE
production O O
by O O
inhibiting O O
TCR-mediated O O
signal O O
transduction O O
. O O

We O O
asked O O
whether O O
they O O
also O O
inhibit O O
the O O
action O O
of O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
inhibiting O O
signal O O
transduction O O
through O O
IL-2R B B_GENE
. O O

Human O O
peripheral O O
blood O O
T O O
cells O O
, O O
stimulated O O
with O O
PMA O O
for O O
48 O O
h O O
( O O
PMA O O
blasts O O
) O O
, O O
were O O
incubated O O
with O O
IL-2 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
presence O O
of O O
incremental O O
dosages O O
of O O
dexamethasone O O
( O O
Dex O O
; O O
10 O O
( O O
-5 O O
) O O
-10 O O
( O O
-9 O O
) O O
M O O
) O O
. O O

Dex O O
inhibited O O
the O O
IL-2-dependent O O
proliferation O O
of O O
PMA O O
blasts O O
in O O
a O O
dose-dependent O O
fashion O O
( O O
IC50 O O
, O O
5 O O
x O O
10 O O
( O O
-8 O O
) O O
M O O
) O O
. O O

Cell O O
surface O O
expression O O
of O O
IL-2R B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta-chains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
determined O O
by O O
immunofluorescence O O
analysis O O
was O O
not O O
affected O O
by O O
Dex O O
. O O

Inhibition O O
of O O
T O O
cell O O
proliferation O O
by O O
Dex O O
was O O
associated O O
with O O
decreased O O
IL-2-dependent O O
tyrosine O O
phosphorylation O O
of O O
several O O
intracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
decreased O O
phosphorylation O O
of O O
the O O
retinoblastoma B B_GENE
gene I I_GENE
product I I_GENE
Rb I I_GENE
, O O
a O O
protein O O
essential O O
for O O
controlling O O
the O O
progression O O
of O O
cells O O
through O O
the O O
cell O O
cycle O O
. O O

IL-2-dependent O O
IL-2R O O
alpha O O
expression O O
in O O
PMA O O
blasts O O
and O O
NF-kB B B_GENE
induction O O
in O O
resting O O
human O O
T O O
cells O O
were O O
also O O
inhibited O O
by O O
Dex O O
. O O

These O O
results O O
demonstrate O O
that O O
glucocorticoids O O
inhibit O O
preactivated O O
T O O
cells O O
by O O
down-regulating O O
signal O O
transduction O O
through O O
IL-2R B B_GENE
. O O

Chronic O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
infection O O
stimulates O O
distinct O O
NF-kappa O O
B/rel O O
DNA O O
binding O O
activities O O
in O O
myelomonoblastic O O
cells O O
. O O

In O O
this O O
report O O
, O O
we O O
characterize O O
the O O
nature O O
of O O
these O O
proteins O O
and O O
demonstrate O O
that O O
binding O O
of O O
these O O
proteins O O
is O O
also O O
induced O O
following O O
Sendai O O
paramyxovirus O O
infection O O
. O O

The O O
70-kDa B B_PROTEIN[GENE]/B_MEASURE
protein I I_PROTEIN[GENE]/I_MEASURE
corresponds O O
to O O
the O O
NF-kappa B B_GENE
B I I_GENE
RelA I I_GENE
( I I_GENE
p65 I I_GENE
) I I_GENE
subunit I I_GENE
, O O
which O O
is O O
activated O O
in O O
response O O
to O O
an O O
acute O O
paramyxovirus O O
infection O O
or O O
a O O
chronic O O
HIV-1 O O
infection O O
. O O

DNA O O
binding O O
of O O
the O O
90- B B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to I B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100-kDa I B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
inhibited O O
by O O
recombinant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kappa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha/MAD-3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
was O O
resistant O O
to O O
tryptic O O
digestion O O
, O O
suggesting O O
that O O
these O O
proteins O O
may O O
not O O
be O O
NF-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Transient O O
cotransfection O O
experiments O O
demonstrated O O
that O O
RelA O O
and O O
NFKB1 O O
expression O O
maximally O O
stimulated O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B-dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
differences O O
in O O
NF-kappa O O
B-like O O
binding O O
activity O O
were O O
also O O
reflected O O
in O O
higher O O
constitutive O O
levels O O
of O O
NF-kappa O O
B-regulated O O
gene O O
expression O O
in O O
HIV-1-infected O O
myeloid O O
cells O O
. O O

OBJECTIVE O O
. O O

METHODS O O
. O O

RESULTS O O
. O O

Higher O O
affinity O O
EBS O O
were O O
found O O
mostly O O
in O O
nuclear O O
cell O O
fractions O O
of O O
either O O
RA O O
or O O
control O O
synovial O O
tissues O O
( O O
28 O O
of O O
the O O
33 O O
) O O
. O O

These O O
EBS O O
were O O
present O O
to O O
a O O
lesser O O
extent O O
in O O
soluble O O
cell O O
fractions O O
( O O
11 O O
of O O
the O O
33 O O
) O O
. O O

CONCLUSION O O
. O O

